PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hankey, GJ				Hankey, Graeme J.			Statins after transient ischaemic attack and ischaemic stroke	LANCET NEUROLOGY			English	Editorial Material							CHOLESTEROL; PEOPLE; SIMVASTATIN; DISEASE; RISK		Royal Perth Hosp, Dept Neurol, Perth, WA, Australia	Royal Perth Hospital; University of Western Australia	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, Perth, WA, Australia.	gjhankey@cyllene.uwa.edu.au	Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				Amarenco P, 2006, NEW ENGL J MED, V355, P549; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Collins R, 2004, LANCET, V363, P757; Ebrahim S, 2006, BMJ-BRIT MED J, V333, P22, DOI 10.1136/bmj.38855.610324.80; Mihaylova B, 2005, LANCET, V365, P1779, DOI 10.1016/S0140-6736(05)63014-0; Ovbiagele B, 2006, NEUROLOGY, V66, P1164, DOI 10.1212/01.wnl.0000208403.18885.0e; Qizilbash N, 1995, LANCET, V346, P1647; Wardlaw JM, 2005, J NEUROL NEUROSUR PS, V76, P617, DOI 10.1136/jnnp.2004.039982	8	11	14	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2006	5	10					810	812		10.1016/S1474-4422(06)70559-2	http://dx.doi.org/10.1016/S1474-4422(06)70559-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	087YD	16987726				2022-12-18	WOS:000240777800006
J	Siva, N				Siva, N			Can ketogenic diet slow progression of ALS?	LANCET NEUROLOGY			English	News Item																			0	11	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					476	476		10.1016/S1474-4422(06)70462-8	http://dx.doi.org/10.1016/S1474-4422(06)70462-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16739298				2022-12-18	WOS:000237906000012
J	Sisodiya, SM; Bates, SE				Sisodiya, SM; Bates, SE			Treatment of drug resistance in epilepsy: one step at a time	LANCET NEUROLOGY			English	Editorial Material							P-GLYCOPROTEIN; INHIBITION		UCL, Neurol Inst, Dept Clin & Expt Epilepsy, London, England; NCI, Med Oncol Branch, Mol Therapeur Sect, Bethesda, MD 20892 USA	University of London; University College London; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sisodiya, SM (corresponding author), UCL, Neurol Inst, Dept Clin & Expt Epilepsy, London, England.	sisodiya@ion.ucl.ac.uk	Bates, Susan/AFP-9514-2022		NATIONAL CANCER INSTITUTE [Z01BC010620] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates Susan F, 2002, Novartis Found Symp, V243, P83; Brandt C, 2005, EPILEPSIA, V46, P60; Schmidt D, 2005, EPILEPSIA, V46, P858, DOI 10.1111/j.1528-1167.2005.54904.x; Tan NCK, 2004, NEUROLOGY, V63, P1090, DOI 10.1212/01.WNL.0000137051.33486.C7; Van Vliet EA, 2005, EPILEPSIA, V46, P376	5	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2006	5	5					380	381		10.1016/S1474-4422(06)70422-7	http://dx.doi.org/10.1016/S1474-4422(06)70422-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	037LF	16632304				2022-12-18	WOS:000237147600006
J	Rothwell, PM				Rothwell, PM			Lack of epidemiological data on secondary stroke prevention	LANCET NEUROLOGY			English	Editorial Material							TRANSIENT ISCHEMIC ATTACK; EARLY RISK; MINOR STROKE; PROGNOSIS; MORTALITY; DISEASE; NEED; TIA		Univ Oxford, Radcliffe Infirm, Stroke Prevent Res Unit, Dept Clin Neurol, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Rothwell, PM (corresponding author), Univ Oxford, Radcliffe Infirm, Stroke Prevent Res Unit, Dept Clin Neurol, Woodstock Rd, Oxford OX2 6HE, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				BHATIA M, IN PRESS CEREBROVASC; Clark TG, 2003, J NEUROL NEUROSUR PS, V74, P577, DOI 10.1136/jnnp.74.5.577; Coull AJ, 2004, STROKE, V35, P1925, DOI 10.1161/01.STR.0000133129.58126.67; Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44; FAIRHEAD JF, 2005, NEUROLOGY       0714; Flossmann E, 2003, BRAIN, V126, P1940, DOI 10.1093/brain/awg197; Imray CHE, 2005, LANCET NEUROL, V4, P580, DOI 10.1016/S1474-4422(05)70169-1; Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2005, LANCET, V366, P29, DOI 10.1016/S0140-6736(05)66702-5; Rothwell PM, 2001, LANCET, V357, P1612, DOI 10.1016/S0140-6736(00)04730-9; Rothwell PM, 2003, CEREBROVASC DIS, V16, P2, DOI 10.1159/000070271; Rothwell PM, 2005, LANCET, V365, P256; Rothwell PM, 2004, LANCET, V363, P1925, DOI 10.1016/S0140-6736(04)16405-2; van Wijk I, 2005, LANCET, V365, P2098, DOI 10.1016/S0140-6736(05)66734-7	16	11	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2005	4	9					518	519		10.1016/S1474-4422(05)70148-4	http://dx.doi.org/10.1016/S1474-4422(05)70148-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	958VK	16109356				2022-12-18	WOS:000231476100002
J	Chio, A				Chio, A			Mortality trends in ALS: an increasingly intricate puzzle	LANCET NEUROLOGY			English	Letter							UNITED-STATES		Univ Turin, Dept Neurosci, I-10126 Turin, Italy	University of Turin	Chio, A (corresponding author), Univ Turin, Dept Neurosci, Via Cherasco 15, I-10126 Turin, Italy.	achio@usa.net	Chio, Adriano/K-3425-2016	Chio, Adriano/0000-0001-9579-5341				Chio A, 2001, NEUROLOGY, V56, P239; Forbes RB, 2004, J NEUROL NEUROSUR PS, V75, P1753, DOI 10.1136/jnnp.2003.024364; NEILSON S, 1993, MECH AGEING DEV, V66, P223, DOI 10.1016/0047-6374(93)90010-O; Noonan CW, 2005, NEUROLOGY, V64, P1215, DOI 10.1212/01.WNL.0000156518.22559.7F; Ragonese P, 2004, NEUROEPIDEMIOLOGY, V23, P73, DOI 10.1159/000073978; RIGGS JE, 1990, MECH AGEING DEV, V55, P207, DOI 10.1016/0047-6374(90)90149-A	6	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2005	4	8					453	454		10.1016/S1474-4422(05)70125-3	http://dx.doi.org/10.1016/S1474-4422(05)70125-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	951EX	16033687				2022-12-18	WOS:000230913000003
J	Beghi, E				Beghi, E			Injuries in patients with epilepsy	LANCET NEUROLOGY			English	Editorial Material									Univ Milano Bicocca, Epilepsy Ctr, Monza, Italy; Mario Negri Inst Pharmacol Res, Lab Neurol Disorders, Milan, Italy	University of Milano-Bicocca; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Beghi, E (corresponding author), Univ Milano Bicocca, Epilepsy Ctr, Monza, Italy.	beghi@marionegri.it	Beghi, Ettore/AAA-7426-2020	Beghi, Ettore/0000-0003-2542-0469				Beghi E, 2002, EPILEPSIA, V43, P1076, DOI 10.1046/j.1528-1157.2002.18701.x; Beghi E, 1997, NEUROEPIDEMIOLOGY, V16, P207, DOI 10.1159/000109689; Begley CE, 2002, EPILEPSIA, V43, P3, DOI 10.1046/j.1528-1157.43.s.4.2.x; Berg AT, 2004, NEUROLOGY, V63, P1549; Buck D, 1997, EPILEPSIA, V38, P439, DOI 10.1111/j.1528-1157.1997.tb01733.x; Lawn ND, 2004, NEUROLOGY, V63, P1565, DOI 10.1212/01.WNL.0000142991.14507.B5; NAKKEN KO, 1993, EPILEPSIA, V34, P836, DOI 10.1111/j.1528-1157.1993.tb02099.x	7	11	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					71	72		10.1016/S1474-4422(05)00971-3	http://dx.doi.org/10.1016/S1474-4422(05)00971-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15664535				2022-12-18	WOS:000226712300003
J	Schols, L; Bauer, P; Schmidt, T; Schulte, T; Riess, O				Schols, L; Bauer, P; Schmidt, T; Schulte, T; Riess, O			Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. (vol 3, pg 291, 2004)	LANCET NEUROLOGY			English	Correction													Schöls, Ludger/ABB-2482-2021; Schmidt, Thorsten/AAR-6486-2021	Schöls, Ludger/0000-0001-7774-5025; Schmidt, Thorsten/0000-0002-1862-655X				Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9	1	11	12	2	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2004	3	7					443	443		10.1016/S1474-4422(04)00816-6	http://dx.doi.org/10.1016/S1474-4422(04)00816-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832ZQ					2022-12-18	WOS:000222306600025
J	Gorelick, PB; Ruland, S				Gorelick, PB; Ruland, S			IMAGES and FAST-MAG: magnesium for acute ischaemic stroke	LANCET NEUROLOGY			English	Editorial Material									Univ Illinois, Coll Med, Dept Neurol & Rehabil, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gorelick, PB (corresponding author), Univ Illinois, Coll Med, Dept Neurol & Rehabil, Chicago, IL 60680 USA.	pgorelic@uic.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033430] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS33430] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers GW, 2001, STROKE, V32, P1598, DOI 10.1161/01.STR.32.7.1598; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53; Gorelick PB, 2000, LANCET, V355, P1925, DOI 10.1016/S0140-6736(00)02318-7; Lees KR, 2004, LANCET, V363, P439, DOI 10.1016/S0140-6736(04)15490-1; Ovbiagele Bruce, 2003, Curr Neurol Neurosci Rep, V3, P9, DOI 10.1007/s11910-003-0031-z; Saver JL, 2004, STROKE, V35, pE106, DOI 10.1161/01.STR.0000124458.98123.52	7	11	11	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					330	330		10.1016/S1474-4422(04)00762-8	http://dx.doi.org/10.1016/S1474-4422(04)00762-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15157845				2022-12-18	WOS:000221663000011
J	Rascol, O				Rascol, O			Monoamine oxidase inhibitors - is it time to up the TEMPO?	LANCET NEUROLOGY			English	Editorial Material							PARKINSONS-DISEASE		Toulouse Univ Hosp, Clin Invest Ctr, Dept Clin Pharmacol, INSERM,U455, Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rascol, O (corresponding author), Toulouse Univ Hosp, Clin Invest Ctr, Dept Clin Pharmacol, INSERM,U455, Toulouse, France.							Lees AJ, 1995, BRIT MED J, V311, P1602, DOI 10.1136/bmj.311.7020.1602; *PARK STUD GROUP, 1993, ANN NEUROL, V33, P350; Rascol O, 2002, LANCET, V359, P1589, DOI 10.1016/S0140-6736(02)08520-3; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Siderowf A, 2002, ARCH NEUROL-CHICAGO, V59, P1937	5	11	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2003	2	3					142	143		10.1016/S1474-4422(03)00318-1	http://dx.doi.org/10.1016/S1474-4422(03)00318-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	648NV	12849233				2022-12-18	WOS:000181158200011
J	Krolak-Salmon, P; Androdias, G; Honnorat, J; Caudie, C; Bret, P; Hernette, D; Vighetto, A				Krolak-Salmon, P; Androdias, G; Honnorat, J; Caudie, C; Bret, P; Hernette, D; Vighetto, A			Beware of optic neuritis!	LANCET NEUROLOGY			English	Editorial Material							IGG		Hosp Neurol, Dept Neurol C, F-69003 Lyon, France; Hosp Neurol, Dept Neurol B, F-69003 Lyon, France; Hosp Neurol, Dept Biol, F-69003 Lyon, France; Hosp Neurol, Dept Neurosurg, F-69003 Lyon, France	CHU Lyon; CHU Lyon; CHU Lyon; CHU Lyon	Krolak-Salmon, P (corresponding author), Hosp Neurol, Dept Neurol C, 59 Bd Pinel, F-69003 Lyon, France.		Honnorat, jerome/G-6394-2017; krolak-salmon, pierre/AAV-2152-2020	Honnorat, jerome/0000-0002-4721-5952; 				BECK RW, 1995, OPHTHALMOLOGY, V102, P1504; Cohen O, 2000, ARCH NEUROL-CHICAGO, V57, P553, DOI 10.1001/archneur.57.4.553; KASPER CS, 1983, AM J MED, V75, P705, DOI 10.1016/0002-9343(83)90461-8; Matsutani M, 1997, J NEUROSURG, V86, P446, DOI 10.3171/jns.1997.86.3.0446; SCHIPPER HI, 1988, NEUROLOGY, V38, P413, DOI 10.1212/WNL.38.3.413	5	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2002	1	8					516	517		10.1016/S1474-4422(02)00225-9	http://dx.doi.org/10.1016/S1474-4422(02)00225-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	618PP	12849337				2022-12-18	WOS:000179426700027
J	McCarron, MO; McKinstry, CS; Gibson, JM				McCarron, MO; McKinstry, CS; Gibson, JM			Superficial siderosis 20 years after brain tumour	LANCET NEUROLOGY			English	Review							CENTRAL-NERVOUS-SYSTEM		Royal Victoria Hosp, Dept Neurol, Belfast BT12 6BA, Antrim, North Ireland; Royal Victoria Hosp, Dept Neuroradiol, Belfast BT12 6BA, Antrim, North Ireland		McCarron, MO (corresponding author), Royal Victoria Hosp, Dept Neurol, Belfast BT12 6BA, Antrim, North Ireland.							Anderson NE, 1999, NEUROLOGY, V52, P163, DOI 10.1212/WNL.52.1.163; FEARNLEY JM, 1995, BRAIN, V118, P1051, DOI 10.1093/brain/118.4.1051; KOEPPEN AH, 1993, ANN NEUROL, V34, P646, DOI 10.1002/ana.410340505; KOEPPEN AH, 1988, J NEUROPATH EXP NEUR, V47, P249, DOI 10.1097/00005072-198805000-00005; RIVER Y, 1994, MOVEMENT DISORD, V9, P559, DOI 10.1002/mds.870090509	5	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2002	1	5					326	326		10.1016/S1474-4422(02)00138-2	http://dx.doi.org/10.1016/S1474-4422(02)00138-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588LB	12849430				2022-12-18	WOS:000177702000020
J	Peschanski, M; Dunnett, SB				Peschanski, M; Dunnett, SB			Cell therapy for Huntington's disease, the next step forward	LANCET NEUROLOGY			English	Letter									Fac Med, INSERM U421, IM3, Creteil, France; Cardiff Univ, Sch Biosci, Brain Repair Grp, Cardiff, S Glam, Wales	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Cardiff University	Peschanski, M (corresponding author), Fac Med, INSERM U421, IM3, Creteil, France.	peschanski@im3.inserm.fr	Peschanski, Marc/N-5769-2017; Dunnett, Stephen B/A-5869-2010	Dunnett, Stephen B/0000-0003-1826-1578				Bachoud-Levi A, 2000, LANCET, V356, P1975, DOI 10.1016/S0140-6736(00)03310-9; Dekkers W, 2001, J MED ETHICS, V27, P151, DOI 10.1136/jme.27.3.151; Greenamyre JT, 2002, NEUROLOGY, V58, P675, DOI 10.1212/WNL.58.5.675; Hauser RA, 2002, NEUROLOGY, V58, P687, DOI 10.1212/WNL.58.5.687; ROSSER AE, 2001, SURG PARKINSONS DIS, P353	5	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2002	1	2					81	81		10.1016/S1474-4422(02)00034-0	http://dx.doi.org/10.1016/S1474-4422(02)00034-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HA	12849508				2022-12-18	WOS:000177695000013
J	Langhorne, P; Cadilhac, D; Feigin, V; Grieve, R; Liu, M				Langhorne, P; Cadilhac, D; Feigin, V; Grieve, R; Liu, M			How should stroke services be organised?	LANCET NEUROLOGY			English	Editorial Material							COST-EFFECTIVENESS ANALYSIS; CARE; MANAGEMENT; UNIT		Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland; Austin & Repatriation Med Ctr, Natl Stroke Res Inst, Melbourne, Vic, Australia; Univ Auckland, Dept Med, Clin Trials Res Unit, Auckland, New Zealand; Sichuan Univ, W China Hosp, Dept Neurol, Chengdu, Peoples R China	University of Glasgow; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Auckland; Sichuan University	Langhorne, P (corresponding author), Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland.		Feigin, Valery/AAF-2313-2019; Cadilhac, D A/I-1912-2014	Cadilhac, D A/0000-0001-8162-682X; Feigin, Valery L./0000-0002-6372-1740; Grieve, Richard/0000-0001-8899-1301				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 2001, IMPR STROK SERV PAT; Asplund K, 1997, STROKE, V28, P2139, DOI 10.1161/01.STR.28.11.2139; *AUSTR I HLTH WELF, 2001, NAT HLTH LAB FORC SE, V20; Beech R, 1996, STROKE, V27, P1958, DOI 10.1161/01.STR.27.11.1958; Chambers M, 1999, PHARMACOECONOMICS, V16, P577, DOI 10.2165/00019053-199916050-00013; Chen Z, 1997, J Stroke Cerebrovasc Dis, V6, P361, DOI 10.1016/S1052-3057(97)80219-4; Department of Health, 2001, NAT SERV FRAM OLD PE; Dowswell G, 2000, CLIN REHABIL, V14, P160, DOI 10.1191/026921500672130349; *EARL SUPP DISCH T, 2002, COCHRANE DATABASE SY, V1; Early Supported Discharge Trialists, 2002, COCHRANE LIB; Evans A, 2001, LANCET, V358, P1586, DOI 10.1016/S0140-6736(01)06652-1; FEIGIN VL, 1995, STROKE, V26, P924, DOI 10.1161/01.STR.26.6.924; Feigin VL, 2001, ZH NEVROPATOL PSIKH, V101, P52; Grieve R, 2001, STROKE, V32, P1684, DOI 10.1161/01.STR.32.7.1684; Gubitz G, 2000, BMJ-BRIT MED J, V320, P692, DOI 10.1136/bmj.320.7236.692; Hacke W, 2000, EUR J NEUROL, V7, P607, DOI 10.1046/j.1468-1331.2000.00137.x; Hutton J, 2000, HEALTH ECON, V9, P89, DOI 10.1002/(SICI)1099-1050(200003)9:2<89::AID-HEC504>3.0.CO;2-G; ISARD PA, 1992, CEREBROVASC DIS, V2, P47, DOI 10.1159/000108988; Kalra L, 2000, LANCET, V356, P894, DOI 10.1016/S0140-6736(00)02679-9; KREGER A, 1991, NATL NURSING CONSULT; LIU M, 1995, CEREBROVASC DIS, V5, P362; LIU M, 2002, IN PRESS PRACTICAL N, V2; LIU M, 1996, FOREIGN MED SCI CERE, V4, P352; Matchar D. B., 1994, STROKE CLIN UPDATES, V5, P9; McNamee P, 1998, AGE AGEING, V27, P345, DOI 10.1093/ageing/27.3.345; *NAT STROK FDN, 2001, VICT STROK STRAT IMP; *NAT STROK FDN, 2001, SCOPES STUD GROUP ST; *NAT STROK FDN, 1997, VICT STROK STRAT; *NAT STROK FDN, 1997, NAT STROK STRAT; Nolan M, 1998, Br J Nurs, V7, P388; OGDEN K, 2001, CEREBROVASC DIS S4, V11; Pound P, 1999, AGE AGEING, V28, P433, DOI 10.1093/ageing/28.5.433; Pound P, 2000, SOC SCI MED, V51, P1437, DOI 10.1016/S0277-9536(00)00040-X; Samsa GP, 1999, J CLIN EPIDEMIOL, V52, P259, DOI 10.1016/S0895-4356(98)00151-6; *STROK ASS STROK C, 1999, NAT SURV STROK SERV; *STROK UN TRIAL CO, 2002, ORG IMP STROK UN CAR; *VICT GOV DEP HUM, 2001, POL DEV PLANN DIV VI; Warlow CP., 2001, STROKE PRACTICAL GUI; WARLOW CP, 2001, STROKE PRACTICAL GUI, P723; Warner R, 2000, Nurs Stand, V14, P32	41	11	12	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2002	1	1					62	68		10.1016/S1474-4422(02)00011-X	http://dx.doi.org/10.1016/S1474-4422(02)00011-X			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588GQ	12849547				2022-12-18	WOS:000177694100022
J	Kvistad, CE; Naess, H; Helleberg, BH; Idicula, T; Hagberg, G; Nordby, LM; Jenssen, KN; Tobro, H; Rorholt, DM; Kaur, K; Eltoft, A; Evensen, K; Haasz, J; Singaravel, G; Fromm, A; Thomassen, L				Kvistad, Christopher Elnan; Naess, Halvor; Helleberg, Bernt H.; Idicula, Titto; Hagberg, Guri; Nordby, Linn Marie; Jenssen, Kristian N.; Tobro, Hakon; Rorholt, Dag M.; Kaur, Kamaljit; Eltoft, Agnethe; Evensen, Kristin; Haasz, Judit; Singaravel, Guruparan; Fromm, Annette; Thomassen, Lars			Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial	LANCET NEUROLOGY			English	Article							PLASMINOGEN-ACTIVATOR; THROMBOLYSIS	Background Tenecteplase is a modified tissue plasminogen activator with pharmacological and practical advantages over alteplase-which is currently the only approved thrombolytic drug for ischaemic stroke. The NOR-TEST trial showed that 0.4 mg/kg tenecteplase had an efficacy and safety profile similar to that of a standard dose (0.9 mg/kg) of alteplase, albeit in a patient population with a high prevalence of minor stroke. The aim of NOR-TEST 2 was to establish the non-inferiority of tenecteplase 0.4 mg/kg to alteplase 0.9 mg/kg for patients with moderate or severe ischaemic stroke. Methods This phase 3, randomised, open-label, blinded endpoint, non-inferiority trial was performed at 11 hospitals with stroke units in Norway. Patients with suspected acute ischaemic stroke with a National Institutes of Health Stroke Scale score of 6 or more who were eligible for thrombolysis and admitted within 4.5 h of symptom onset were consecutively included. Random assignment, done by a computer with a block size of 4 and with allocations placed into opaque envelopes to be opened consecutively, was 1:1 between intravenous tenecteplase (0.4 mg/kg) or standard dose alteplase (0.9 mg/kg). Doctors and nurses providing acute care were not masked to treatment, but primary outcome assessment at 3 months was masked. The primary outcome was favourable functional outcome defined as a modified Rankin Scale score of 0-1 at 3 months, assessed in the modified intention-to-treat analysis (excluding patients who did not qualify for thrombolysis after randomisation or who withdrew informed consent). The noninferiority margin was 3%. This trial (NOR-TEST 2) is registered with EudraCT (number 2018-003090-95) and ClinicalTrials.gov (NCT03854500). The trial was stopped early for safety reasons and is designated part A for analysis. Part B is ongoing with a lower dose of tenecteplase (0.25 mg/kg). Findings Between Oct 28, 2019, and Sept 26, 2021, 216 patients were enrolled. Patient enrolment was stopped after a per-protocol safety review showed an imbalance in the rates of symptomatic intracranial haemorrhage between the treatment groups, which surpassed the prespecified criteria for stopping the trial. Of 204 patients entering the modified intention-to-treat analysis, 100 were randomly allocated tenecteplase and 104 were allocated alteplase. All patients were followed up within 14 days of the end of the 3-months' follow-up period. A favourable functional outcome was reported less frequently in patients receiving tenecteplase (31 [32%] of 96 patients) compared with alteplase (52 [51%] of 101 patients; unadjusted OR 0.45 [95% CI 0.25-0.80]; p=0.0064). Any intracranial haemorrhage was significantly more frequent with tenecteplase (21 [21%] of 100 patients) than with alteplase (seven [7%] of 104 patients; unadjusted OR 3.68 [95% CI 1.49-9.11]; p=0.0031). Mortality at 3 months was also significantly higher with tenecteplase (15 [16%] of 96 patients) than with alteplase (five [5%] of 101 patients; unadjusted OR 3.56 [95% CI 1.24-10.21]; p=0.013). Numerically more cases of symptomatic intracranial haemorrhage were reported with tenecteplase (six [6%] of 100 patients) than with alteplase (one [1%] of 104 patients; unadjusted OR 6.57 [95% CI 0.78-55.62]; p=0.061). Interpretation In this prematurely terminated study (terminated to fulfil the prespecified safety criteria), tenecteplase at a dose of 0.4 mg/kg yielded worse safety and functional outcomes compared with alteplase. Our study consequently could not show that 0.4 mg/kg tenecteplase is non-inferior to alteplase in moderate and severe ischaemic stroke. Future stroke trials should assess a lower dose of tenecteplase versus alteplase in patients with moderate or severe stroke. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[Kvistad, Christopher Elnan; Naess, Halvor; Fromm, Annette; Thomassen, Lars] Haukeland Hosp, Dept Neurol, N-5053 Bergen, Norway; [Haasz, Judit; Singaravel, Guruparan] Haukeland Hosp, Dept Radiol, Bergen, Norway; [Kvistad, Christopher Elnan; Thomassen, Lars] Univ Bergen, Dept Clin Med, Bergen, Norway; [Helleberg, Bernt H.] St Olavs Univ Hosp, Stroke Unit, Dept Internal Med, Trondheim, Norway; [Idicula, Titto] St Olavs Univ Hosp, Dept Neurol, Trondheim, Norway; [Hagberg, Guri] Oslo Univ Hosp, Dept Neurol, Ulleval, Norway; [Nordby, Linn Marie] Akershus Univ Hosp, Dept Neurol, Lorenskog, Norway; [Jenssen, Kristian N.] Vestfold Hosp, Dept Neurol, Tonsberg, Norway; [Tobro, Hakon] Telemark Hosp, Dept Neurol, Skien, Norway; [Rorholt, Dag M.] Molde Hosp, Dept Neurol, Molde, Norway; [Kaur, Kamaljit] Haugesund Hosp, Dept Neurol, Haugesund, Norway; [Eltoft, Agnethe] Univ Hosp Northern Norway, Dept Neurol, Tromso, Norway; [Evensen, Kristin] Vestre Viken Hosp, Dept Neurol, Drammen, Norway; [Naess, Halvor] Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway	University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); University of Oslo; University of Oslo; Telemark Hospital Trust; UiT The Arctic University of Tromso; University Hospital of North Norway; Stavanger University Hospital	Kvistad, CE (corresponding author), Haukeland Hosp, Dept Neurol, N-5053 Bergen, Norway.	echr@helse-bergen.no			Norwegian National Programme for Clinical Therapy Research	Norwegian National Programme for Clinical Therapy Research	The Norwegian National Programme for Clinical Therapy Research.	Berge E, 2021, EUR STROKE J, V6, pI, DOI 10.1177/2396987321989865; Burgos AM, 2019, STROKE, V50, P2156, DOI 10.1161/STROKEAHA.119.025080; Campbell BCV, 2018, NEW ENGL J MED, V378, P1573, DOI 10.1056/NEJMoa1716405; Campbell BCV, 2020, JAMA-J AM MED ASSOC, V323, P1257, DOI 10.1001/jama.2020.1511; Coutts SB, 2015, STROKE, V46, P769, DOI 10.1161/STROKEAHA.114.008504; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Haley EC, 2010, STROKE, V41, P707, DOI 10.1161/STROKEAHA.109.572040; Haley EC, 2005, STROKE, V36, P607, DOI 10.1161/01.STR.0000154872.73240.e9; Huang XY, 2015, LANCET NEUROL, V14, P368, DOI 10.1016/S1474-4422(15)70017-7; Kvistad CE, 2019, STROKE, V50, P1279, DOI 10.1161/STROKEAHA.119.025041; Kvistad CE, 2019, INT J STROKE, V14, P508, DOI 10.1177/1747493018790015; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; Logallo N, 2017, LANCET NEUROL, V16, P781, DOI 10.1016/S1474-4422(17)30253-3; Logallo N, 2015, CNS DRUGS, V29, P811, DOI 10.1007/s40263-015-0280-9; Parsons M, 2012, NEW ENGL J MED, V366, P1099, DOI 10.1056/NEJMoa1109842; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Van de Werf F, 1999, AM HEART J, V137, P786, DOI 10.1016/S0002-8703(99)70400-X; Warach SJ, 2020, STROKE, V51, P3440, DOI 10.1161/STROKEAHA.120.029749; Whiteley WN, 2016, LANCET NEUROL, V15, P925, DOI [10.1016/s1474-4422(16)30076-X, 10.1016/S1474-4422(16)30076-X]; Yogendrakumar V, 2022, NEUROLOGY, V98, pE1292, DOI 10.1212/WNL.0000000000013302	22	10	10	7	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2022	21	6					511	519		10.1016/S1474-4422(22)00124-7	http://dx.doi.org/10.1016/S1474-4422(22)00124-7			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3Z0EK	35525250				2022-12-18	WOS:000844093900006
J	Gutierrez, J; Turan, TN; Hoh, BL; Chimowitz, MI				Gutierrez, J.; Turan, T. N.; Hoh, B. L.; Chimowitz, M., I			Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment (vol 21, pg 355, 2022)	LANCET NEUROLOGY			English	Correction																		Gutierrez J, 2022, LANCET NEUROL, V21, P4, DOI 10.1016/S1474-4422(21)00376-8	1	10	10	3	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2022	21	4					4	4		10.1016/S1474-4422(21)00376-8	http://dx.doi.org/10.1016/S1474-4422(21)00376-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	1Y0JM	35143758				2022-12-18	WOS:000807832700018
J	Boeve, BF; Boxer, AL; Kumfor, F; Pijnenburg, Y; Rohrer, JD				Boeve, Bradley F.; Boxer, Adam L.; Kumfor, Fiona; Pijnenburg, Yolande; Rohrer, Jonathan			Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	LANCET NEUROLOGY			English	Review							PRIMARY PROGRESSIVE APHASIA; NEUROFILAMENT LIGHT-CHAIN; BEHAVIORAL-VARIANT; LOBAR DEGENERATION; DISEASE PROGRESSION; ALZHEIMERS-DISEASE; C9ORF72; TAU; MEMORY; NONFLUENT	Frontotemporal dementia comprises a group of clinical syndromes that are characterised by progressive changes in behaviour, executive function, or language. The term frontotemporal lobar degeneration encompasses the neurodegenerative diseases that give rise to these clinical syndromes and involve proteinopathies associated with frontotemporal network dysfunction. Improvements in clinical, genetic, and molecular characterisation have provided new insights into frontotemporal dementia and frontotemporal lobar degeneration, with a much broader range of signs and symptoms at presentation than has been previously considered. Accurate and early diagnosis of frontotemporal dementia is now a possibility due to development of neuropsychological measures with a special focus on social cognition. Advances in plasma and CSF biomarkers, and innovations in structural and functional imaging, will prove useful for future clinical trials in people with frontotemporal dementia.	[Boeve, Bradley F.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Boxer, Adam L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Kumfor, Fiona] Univ Sydney, Sch Psychol, Sydney, NSW, Australia; [Kumfor, Fiona] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia; [Pijnenburg, Yolande] Vrije Univ Amsterdam, Amsterdam UMC, Alzheimer Ctr Amsterdam, Dept Neurol,Amsterdam Neurosci, Amsterdam, Netherlands; [Rohrer, Jonathan] Univ Coll London Queen Sq, Dementia Res Ctr, Inst Neurol, London, England	Mayo Clinic; University of California System; University of California San Francisco; University of Sydney; University of Sydney; University of Amsterdam; Vrije Universiteit Amsterdam; University of London; University College London	Boeve, BF (corresponding author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.	bboeve@mayo.edu	Kumfor, Fiona/AAK-9997-2020		NIH [AG063911, AG045390, NS092089, AG038791, AG062677, AG052943, U24AG057437]; Rainwater Charitable Foundation; Bluefield Project to Cure FTD; Association for Frontotemporal Degeneration; University of California Cures AD Program; Australian National Health and Medical Research Council Career Development Fellowship [GNT1158762]; UK Medical Research Council [MR/M008525/1, MR/M023664/1]; UK National Institute for Health Research [BRC149/NS/MH]; EU Joint Programme-Neurodegenerative Disease Research [2019-02248]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rainwater Charitable Foundation; Bluefield Project to Cure FTD; Association for Frontotemporal Degeneration; University of California Cures AD Program; Australian National Health and Medical Research Council Career Development Fellowship(National Health and Medical Research Council (NHMRC) of Australia); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute for Health Research(National Institute for Health Research (NIHR)); EU Joint Programme-Neurodegenerative Disease Research	The authors were supported by NIH grants AG063911 (BFB, ALB), AG045390 (BFB, ALB), NS092089 (BFB, ALB), AG038791 (BFB, ALB), AG062677 (BFB), AG052943 (BFB), U24AG057437 (ALB), and grants from the Rainwater Charitable Foundation (ALB), Bluefield Project to Cure FTD (ALB), Association for Frontotemporal Degeneration (ALB), University of California Cures AD Program (ALB), Australian National Health and Medical Research Council Career Development Fellowship GNT1158762 (FK), UK Medical Research Council MR/M008525/1 and MR/M023664/1 (JDR), UK National Institute for Health Research BRC149/NS/MH (JDR), and EU Joint Programme-Neurodegenerative Disease Research 2019-02248 (JDR). We thank our many colleagues with whom we collaborate on clinical and research activities in frontotemporal dementia and frontotemporal lobar degeneration. We particularly thank our patients and their families for participating in frontotemporal dementia and frontotemporal lobar degeneration research.	Abramzon YA, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00042; Bang J, 2015, LANCET, V386, P1672, DOI 10.1016/S0140-6736(15)00461-4; Bejanin A, 2020, NEUROLOGY, V95, pE140, DOI 10.1212/WNL.0000000000009760; Boeve B, 2020, ALZHEIMERS DEMENT, V16, P22, DOI 10.1016/j.jalz.2019.06.4947; Botha Hugo, 2019, Continuum (Minneap Minn), V25, P101, DOI 10.1212/CON.0000000000000699; Boxer AL, 2020, ALZHEIMERS DEMENT, V16, P131, DOI 10.1016/j.jalz.2019.06.4956; Boxer AL, 2017, LANCET NEUROL, V16, P552, DOI 10.1016/S1474-4422(17)30157-6; Bridel C, 2019, JAMA NEUROL, V76, P1035, DOI 10.1001/jamaneurol.2019.1534; Casaletto KB, 2020, ALZHEIMERS DEMENT, V16, P91, DOI 10.1002/alz.12001; Chen Q, 2019, ALZH DEMENT-TRCI, V5, P338, DOI 10.1016/j.trci.2019.05.010; Cotelli M, 2020, NEUROSCI BIOBEHAV R, V108, P498, DOI 10.1016/j.neubiorev.2019.12.003; Denali Therapeutics, OUR PIP; Ducharme S, 2020, BRAIN, V143, P1632, DOI 10.1093/brain/awaa018; Eratne D, 2020, AUST NZ J PSYCHIAT, V54, P57, DOI 10.1177/0004867419857811; Erkoyun HU, 2020, BRAIN, V143, P2831, DOI 10.1093/brain/awaa225; Erkoyun HU, 2021, J ALZHEIMERS DIS, V79, P1195, DOI 10.3233/JAD-201191; Estevez-Fraga C, 2021, NEUROL-GENET, V7, DOI 10.1212/NXG.0000000000000575; Falgas N, 2019, NEUROIMAGE-CLIN, V23, DOI 10.1016/j.nicl.2019.101927; Fittipaldi S, 2019, NEUROSCI BIOBEHAV R, V100, P263, DOI 10.1016/j.neubiorev.2019.02.020; Ghirelli A, 2020, ANN NEUROL, V88, P1009, DOI 10.1002/ana.25893; Giannini LAA, 2019, ANN NEUROL, V85, P630, DOI 10.1002/ana.25465; Gorno-Tempini M L, 2011, Neurology, V76, P1006, DOI 10.1212/WNL.0b013e31821103e6; Harris JM, 2019, J NEUROPSYCHOL, V13, P214, DOI 10.1111/jnp.12149; Heller C, 2021, J NEUROL NEUROSUR PS, V92, P455, DOI 10.1136/jnnp-2020-325085; Henry ML, 2019, J SPEECH LANG HEAR R, V62, P2723, DOI 10.1044/2018_JSLHR-L-18-0144; Henry ML, 2018, SEMIN SPEECH LANG, V39, P231, DOI 10.1055/s-0038-1660782; Henry ML, 2018, BRAIN, V141, P1799, DOI 10.1093/brain/awy101; Heuer HW, 2020, ALZHEIMERS DEMENT, V16, P60, DOI 10.1002/alz.12046; Hughes LE, 2018, BRAIN, V141, P2486, DOI 10.1093/brain/awy176; Ida CM, 2018, NEURODEGENER DIS, V18, P239, DOI 10.1159/000492499; Illan-Gaia I, 2021, NEUROLOGY, V96, pE671, DOI 10.1212/WNL.0000000000011226; Jiang J, 2016, NEURON, V90, P535, DOI 10.1016/j.neuron.2016.04.006; Johnen Andreas, 2018, Alzheimers Dement (Amst), V10, P363, DOI 10.1016/j.dadm.2018.04.002; Jones DT, 2018, NEUROLOGY, V90, pE947, DOI 10.1212/WNL.0000000000005117; Josephs KA, 2019, BRAIN, V142, DOI 10.1093/brain/awz224; Kamath V, 2020, J INT NEUROPSYCH SOC, V26, P322, DOI 10.1017/S1355617719001115; Katisko K, 2020, J NEUROL, V267, P162, DOI 10.1007/s00415-019-09567-8; Khan BK, 2012, J NEUROL NEUROSUR PS, V83, P358, DOI 10.1136/jnnp-2011-301883; Kumfor F, 2017, CORTEX, V93, P166, DOI 10.1016/j.cortex.2017.05.022; Kumfor F, 2016, BRAIN, V139, P986, DOI 10.1093/brain/awv387; Ljubenkov PA, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.25584; Louwersheimer E, 2016, J ALZHEIMERS DIS, V51, P581, DOI 10.3233/JAD-150812; Makaretz SJ, 2018, J NEUROL NEUROSUR PS, V89, P1024, DOI 10.1136/jnnp-2017-316409; Matias-Guiu JA, 2020, CORTEX, V132, P63, DOI 10.1016/j.cortex.2020.08.013; Meeter LH, 2016, ANN CLIN TRANSL NEUR, V3, P623, DOI 10.1002/acn3.325; Mesulam MM, 2014, BRAIN, V137, P1176, DOI 10.1093/brain/awu024; Moore KM, 2020, LANCET NEUROL, V19, P145, DOI 10.1016/S1474-4422(19)30394-1; Mummery C, 2021, ALZHEIMERS DEMENT, DOI [10.1002/alz.051871, DOI 10.1002/ALZ.051871]; Murley AG, 2020, BRAIN, V143, P1555, DOI 10.1093/brain/awaa097; Nelson PT, 2019, BRAIN, V142, P1503, DOI 10.1093/brain/awz099; Neumann M, 2019, NEUROPATH APPL NEURO, V45, P19, DOI 10.1111/nan.12526; Novak P, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0436-1; O'Connor CMC, 2021, NEUROPSYCHOL REHABIL, V31, P507, DOI 10.1080/09602011.2019.1707099; Oliver LD, 2020, NEUROLOGY, V95, pE2635, DOI 10.1212/WNL.0000000000010933; Olney NT, 2020, ALZHEIMERS DEMENT, V16, P49, DOI 10.1016/j.jalz.2019.08.196; Palmqvist S, 2020, JAMA-J AM MED ASSOC, V324, P772, DOI 10.1001/jama.2020.12134; Poos JM, 2018, J INT NEUROPSYCH SOC, V24, P593, DOI 10.1017/S1355617718000115; Pressman PS, 2021, J NEUROPSYCH CLIN N, V33, P152, DOI 10.1176/appi.neuropsych.20090238; Prudencio M, 2020, J CLIN INVEST, V130, P6080, DOI 10.1172/JCI139741; Ramanan S, 2017, J INT NEUROPSYCH SOC, V23, P34, DOI 10.1017/S1355617716000837; Ramos EM, 2020, ALZHEIMERS DEMENT, V16, P118, DOI 10.1002/alz.12011; Ranasinghe KG, 2016, NEUROLOGY, V86, P600, DOI 10.1212/WNL.0000000000002373; Rascovsky K, 2011, BRAIN, V134, P2456, DOI 10.1093/brain/awr179; Rogalski EJ, 2018, SEMIN SPEECH LANG, V39, P284, DOI 10.1055/s-0038-1660786; Rohrer JD, 2015, LANCET NEUROL, V14, P253, DOI 10.1016/S1474-4422(14)70324-2; Rojas JC, 2021, NEUROLOGY, V96, pE2296, DOI 10.1212/WNL.0000000000011848; Rosen HJ, 2020, ALZHEIMERS DEMENT, V16, P71, DOI 10.1002/alz.12004; Salimi S, 2019, J NEUROL SCI, V402, P74, DOI 10.1016/j.jns.2019.04.019; Sandusky-Beltran LA, 2020, NEUROPHARMACOLOGY, V175, DOI 10.1016/j.neuropharm.2020.108104; Schievink WI, 2018, OPER NEUROSURG, V15, P505, DOI 10.1093/ons/opy029; Scialo C, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa142; Seckin ZI, 2020, PARKINSONISM RELAT D, V81, P34, DOI 10.1016/j.parkreldis.2020.09.039; Sha Sharon J, 2017, Alzheimers Dement (N Y), V3, P507, DOI 10.1016/j.trci.2017.08.002; Snowden JS, 2012, BRAIN, V135, P693, DOI 10.1093/brain/awr355; Spina S, 2021, BRAIN, V144, P2186, DOI 10.1093/brain/awab099; Staffaroni AM, 2021, ALZH DEMENT-DADM, V13, DOI 10.1002/dad2.12148; Staffaroni AM, 2020, ALZHEIMERS DEMENT, V16, P37, DOI 10.1016/j.jalz.2019.04.007; Suarez-Gonzalez A, 2018, NEUROPSYCHOL REHABIL, V28, P1095, DOI 10.1080/09602011.2016.1234399; Swift IJ, 2021, J NEUROL NEUROSUR PS, V92, P204, DOI 10.1136/jnnp-2020-323520; Tennant JM, 2020, PRION, V14, P249, DOI 10.1080/19336896.2020.1832946; Tetzloff KA, 2019, BRAIN, V142, P2466, DOI 10.1093/brain/awz157; Thijssen EH, 2021, LANCET NEUROL, V20, P739, DOI 10.1016/S1474-4422(21)00214-3; Thijssen EH, 2020, NAT MED, V26, P387, DOI 10.1038/s41591-020-0762-2; Todd TW, 2016, J NEUROCHEM, V138, P145, DOI 10.1111/jnc.13623; Townley RA, 2020, BRAIN COMMUN, V2, DOI 10.1093/braincomms/fcaa068; Tran H, 2022, NAT MED, V28, P117, DOI 10.1038/s41591-021-01557-6; Tsai RM, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0470-7; Tu SC, 2017, J ALZHEIMERS DIS, V59, P883, DOI 10.3233/JAD-160592; Valente ES, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0483-2; van der Ende EL, 2019, LANCET NEUROL, V18, P1103, DOI 10.1016/S1474-4422(19)30354-0; VandeVrede L, 2020, NEUROSCI LETT, V731, DOI 10.1016/j.neulet.2020.134919; Vijverberg EGB, 2016, J ALZHEIMERS DIS, V53, P1287, DOI 10.3233/JAD-160285; Volkmer A, 2020, PRACT NEUROL, V20, P154, DOI 10.1136/practneurol-2018-001921; Wong S, 2017, NEUROPSYCHOLOGIA, V104, P157, DOI 10.1016/j.neuropsychologia.2017.08.016	94	10	10	6	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					258	272		10.1016/S1474-4422(21)00341-0	http://dx.doi.org/10.1016/S1474-4422(21)00341-0			15	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	ZF7BZ	35182511	Green Accepted			2022-12-18	WOS:000759721800022
J	Espay, AJ				Espay, Alberto J.			Movement disorders research in 2021: cracking the paradigm	LANCET NEUROLOGY			English	Editorial Material							SYNUCLEIN; BEHAVIOR		[Espay, Alberto J.] Univ Cincinnati, James J & Joan A Gardner Family Ctr Parkinsons Di, Dept Neurol, Cincinnati, OH 45219 USA	University System of Ohio; University of Cincinnati	Espay, AJ (corresponding author), Univ Cincinnati, James J & Joan A Gardner Family Ctr Parkinsons Di, Dept Neurol, Cincinnati, OH 45219 USA.	alberto.espay@uc.edu						Bargar C, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-021-01175-w; Dam T, 2021, NAT MED, V27, P1451, DOI 10.1038/s41591-021-01455-x; Espay AJ, 2021, PARKINSONISM RELAT D, V92, P15, DOI 10.1016/j.parkreldis.2021.10.010; Hebron ML, 2013, HUM MOL GENET, V22, P3315, DOI 10.1093/hmg/ddt192; Hoglinger GU, 2021, LANCET NEUROL, V20, P182, DOI 10.1016/S1474-4422(20)30489-0; Iranzo A, 2021, LANCET NEUROL, V20, P203, DOI 10.1016/S1474-4422(20)30449-X; Irwin DJ, 2020, ANN NEUROL, V88, P574, DOI 10.1002/ana.25811; Kwon SH, 2021, J MED CHEM, V64, P15091, DOI 10.1021/acs.jmedchem.1c01022; LANG A, 2021, INT PARKINSON MOVEME, P408; Simuni T, 2021, JAMA NEUROL, V78, P312, DOI 10.1001/jamaneurol.2020.4725	10	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					10	11		10.1016/S1474-4422(21)00413-0	http://dx.doi.org/10.1016/S1474-4422(21)00413-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XV0SP	34942122				2022-12-18	WOS:000734663200008
J	Diaz-Manera, J; Kishnani, PS; Kushlaf, H; Ladha, S; Mozaffar, T; Straub, V; Toscano, A; Van der Ploeg, AT; Berger, KI; Clemens, PR; Chien, YH; Day, JW; Illarioshkin, S; Roberts, M; Attarian, S; Borges, JL; Bouhour, F; Choi, YC; Erdem-Ozdamar, S; Goker-Alpan, O; Kostera-Pruszczyk, A; Haack, KA; Hug, C; Huynh-Ba, O; Johnson, J; Thibault, N; Zhou, TY; Dimachkie, MM; Schoser, B				Diaz-Manera, Jordi; Kishnani, Priya S.; Kushlaf, Hani; Ladha, Shafeeq; Mozaffar, Tahseen; Straub, Volker; Toscano, Antonio; Van der Ploeg, Ans T.; Berger, Kenneth I.; Clemens, Paula R.; Chien, Yin-Hsiu; Day, John W.; Illarioshkin, Sergey; Roberts, Mark; Attarian, Shahram; Borges, Joao Lindolfo; Bouhour, Francoise; Choi, Young Chul; Erdem-Ozdamar, Sevim; Goker-Alpan, Ozlem; Kostera-Pruszczyk, Anna; Haack, Kristina An; Hug, Christopher; Huynh-Ba, Olivier; Johnson, Judith; Thibault, Nathan; Zhou, Tianyue; Dimachkie, Mazen M.; Schoser, Benedikt		The Comet	Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	LANCET NEUROLOGY			English	Article							MOTOR FUNCTION; NATURAL COURSE; WALK TEST; GLUCOSIDASE; SPECTRUM; MODEL	Background Pompe disease is a rare, progressive neuromuscular disorder caused by deficiency of acid ti-glucosidase (GAA) and accumulation of lysosomal glycogen. We assessed the safety and efficacy of avalglucosidase alfa, a recombinant human GAA enzyme replacement therapy specifically designed for enhanced mannose-6-phosphatereceptor targeting and enzyme uptake aimed at increased glycogen clearance, compared with the current approved standard of care, alglucosidase alfa, in patients with late -onset Pompe disease. Methods We did a randomised, double-blind, phase 3 trial at 55 sites in 20 countries. We enrolled individuals (aged years) with enzymatically confirmed late-onset Pompe disease who had never received treatment. We used a centralised treatment allocation system to randomly allocate participants to either avalglucosidase alfa or alglucosidase alfa. Participants and investigators were unaware of their treatment allocation. The primary outcome measure was change from baseline to week 49 in upright forced vital capacity percent (FVC%) predicted. We used a hierarchical fixed sequential testing strategy, whereby non -inferiority of avalglucosidase alfa compared with alglucosidase alfa was assessed first, with a non-inferiority margin of 1.1. If non-inferiority was seen, then superiority was tested with a 5% significance level. The key secondary objective was effect on functional endurance, measured by the 6-minute walk test (6MWT). Safety was assessed, including treatment-emergent adverse events and infusion-associated reactions. The modified intent-to -treat population was the primary analysis population for all efficacy analyses. The safety population was the analysis population for safety analyses. This trial is registered with ClinicalTrials.gov, NCT02782741. We report results of the 49 -week primary analysis period. Findings Between Nov 2, 2016, and March 29, 2019, 100 participants were randomly allocated avalglucosidase alfa (n=51) or alglucosidase alfa (n=49). Treatment with avalglucosidase alfa resulted in a least-squares mean improvement in upright FVC% predicted of 2.89% (S E 0.88) compared with 0.46% (0.93) with alglucosidase alfa at week 49 (difference 2.43% [95% CI 0.13 to 4.99]). Non-inferiority was shown because the lower bound of the 95% CI for the difference far exceeded the predefined non -inferiority margin but did not exclude 0 (p=0. 0074). Superiority was not reached (p=0. 063), so formal testing was stopped, as per the testing hierarchy. Improvements were also seen in the 6MWT with avalglucosidase alfa compared with alglucosidase alfa, with greater increases in distance covered (difference 3001 in [95% CI 1.33 to 58.69]) and percent predicted (4.71% [0. 25 to 9.17]). Treatment-emergent adverse events potentially related to treatment were reported in 23 (45%) of 51 participants in the avalglucosidase alfa group and in 24 (49%) of 49 in the alglucosidase alfa group, and infusion-associated reactions were reported in 13 (26%) participants in the avalglucosidase alfa group and 16 (33%) in the alglucosidase alfa group. Of the five trial withdrawals, all in the alglucosidase alfa group, four were due to adverse events, including two infusion-associated reactions. Serious treatment-emergent adverse events were reported in eight (16%) participants who received avalglucosidase alfa and in 12 (25%) who received alglucosidase alfa. One participant treated with alglucosidase alfa died because of acute myocardial infarction determined to be unrelated to treatment. Antidrug antibody responses were similar in both groups. High and persistent titres W.2 800) and neutralising antibodies were more common with alglucosidase alfa (in 16 [33%] participants) than with avalglucosidase alfa (ten [20%]). Interpretation We consider that this study provides evidence ofclinically meaningful improvement with avalglucosida se alfa therapy over alglucosidase alfa in respiratory function, ambulation, and functional endurance, with no new safety signals reported. An open-label extended -treatment period is ongoing to confirm the long-term safety and efficacy of avalglucosidase alfa, with the aim for this therapy to become the new standard treatment in late-onset Pompe disease.	[Diaz-Manera, Jordi; Straub, Volker] Newcastle Univ, John Walton Muscular Dystrophy Res Ctr, Ctr Life, Newcastle Upon Tyne, Tyne & Wear, England; [Diaz-Manera, Jordi] Hosp Santa Creu & Sant Pau, Dept Neurol, Neuromuscular Dis Unit, Barcelona, Spain; [Diaz-Manera, Jordi] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Barcelona, Spain; [Kishnani, Priya S.] Duke Univ, Div Med Genet, Dept Pediat, Med Ctr, Durham, NC USA; [Kushlaf, Hani] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH USA; [Kushlaf, Hani] Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH USA; [Ladha, Shafeeq] Barrow Neurol Inst, Gregory Fulton ALS & Neuromuscular Ctr, Phoenix, AZ 85013 USA; [Mozaffar, Tahseen] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA; [Toscano, Antonio] Univ Messina, Dept Clin & Expt Med, Reference Ctr Rare Neuromuscular Disorders, Messina, Italy; [Van der Ploeg, Ans T.] Erasmus MC, Univ Med Ctr, Ctr Lysosomal & Metab Dis, Rotterdam, Netherlands; [Berger, Kenneth I.] NYU, Grossman Sch Med, Div Pulm Crit Care & Sleep Med, New York, NY USA; [Berger, Kenneth I.] Bellevue Hosp, Andre Cournand Pulm Physiol Lab, New York, NY USA; [Clemens, Paula R.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Clemens, Paula R.] Dept Vet Affairs Med Ctr, Pittsburgh, PA USA; [Chien, Yin-Hsiu] Natl Taiwan Univ Hosp, Dept Med Genet & Pediat, Taipei, Taiwan; [Day, John W.] Stanford Univ, Dept Neurol, Stanford, CA 94305 USA; [Day, John W.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Illarioshkin, Sergey] Res Ctr Neurol, Moscow, Russia; [Roberts, Mark] Salford Royal NHS Fdn Trust, Salford, Lancs, England; [Attarian, Shahram] Hop La Timone, Referral Ctr Neuromuscular Dis & ALS, Marseille, France; [Borges, Joao Lindolfo] Clin Res Ctr Brazil, Brasilia, DF, Brazil; [Bouhour, Francoise] Hop Neurol, Referral Ctr Neuromuscular Dis, Lyon, France; [Choi, Young Chul] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Seoul, South Korea; [Erdem-Ozdamar, Sevim] Hacettepe Univ, Dept Neurol, Ankara, Turkey; [Goker-Alpan, Ozlem] Lysosomal & Rare Disorders Res & Treatment Ctr LD, Fairfax, VA USA; [Kostera-Pruszczyk, Anna] Med Univ Warsaw, Dept Neurol, Warsaw, Poland; [Haack, Kristina An] Sanofi Genzyme, Shanghai, Peoples R China; [Hug, Christopher; Johnson, Judith; Thibault, Nathan; Zhou, Tianyue] Sanofi Genzyme, Cambridge, MA USA; [Huynh-Ba, Olivier] Sanofi Genzyme, Chilly Mazarin, France; [Dimachkie, Mazen M.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA; [Schoser, Benedikt] LMU Klinikum Munchen, Friedrich Baur Inst, Dept Neurol, Munich, Germany	Newcastle University - UK; Hospital of Santa Creu i Sant Pau; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Duke University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Barrow Neurological Institute; University of California System; University of California Irvine; University of Messina; Erasmus University Rotterdam; Erasmus MC; New York University; Bellevue Hospital Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Taiwan University; National Taiwan University Hospital; Stanford University; Stanford University; Research Center of Neurology; Salford Royal NHS Foundation Trust; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Lyon; Yonsei University; Yonsei University Health System; Hacettepe University; Medical University of Warsaw; Sanofi-Aventis; Genzyme Corporation; Sanofi-Aventis; Genzyme Corporation; Sanofi-Aventis; Genzyme Corporation; University of Kansas; University of Kansas Medical Center; University of Munich	Diaz-Manera, J (corresponding author), Newcastle Univ, John Walton Muscular Dystrophy Res Ctr, Ctr Life, Newcastle Upon Tyne, Tyne & Wear, England.; Diaz-Manera, J (corresponding author), Hosp Santa Creu & Sant Pau, Dept Neurol, Neuromuscular Dis Unit, Barcelona, Spain.; Diaz-Manera, J (corresponding author), Ctr Invest Biomed Red Enfermedades Raras CIBERER, Barcelona, Spain.		Toscano, Antonio/AHE-4657-2022; Kushlaf, Hani/E-9912-2018; Natera-de Benito, Daniel/AAC-9892-2021	Kushlaf, Hani/0000-0002-3786-1133; Natera-de Benito, Daniel/0000-0001-7764-2085; Alonso-Perez, Jorge/0000-0001-8866-5186; Schoser, Benedikt/0000-0002-2757-8131; BOSCHI, SILVIA/0000-0003-1610-1917; Straub, Volker/0000-0001-9046-3540; Hatcher, Erin/0000-0002-3638-4742; Franco, Hamilton/0000-0002-7965-4802; Fedotova, Ekaterina/0000-0001-8070-7644; Day, John/0000-0002-0086-9529; Statland, Jeffrey/0000-0003-0790-5315	Sanofi Genzyme	Sanofi Genzyme(Sanofi-AventisGenzyme Corporation)	Sanofi Genzyme.	Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518; Angelini C, 2012, MUSCLE NERVE, V45, P831, DOI 10.1002/mus.23340; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 2014, LUMIZYME ALGL ALF IN; [Anonymous], 2014, MYOZYME ALGL ALF INJ; Berger KI, 2019, J NEUROL, V266, P2312, DOI 10.1007/s00415-019-09401-1; Berger KI, 2016, NEUROMUSCULAR DISORD, V26, P481, DOI 10.1016/j.nmd.2016.05.018; Braulke T, 2009, BBA-MOL CELL RES, V1793, P605, DOI 10.1016/j.bbamcr.2008.10.016; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Dimachkie MM, 2020, MOL GENET METAB, V129, pS49, DOI 10.1016/j.ymgme.2019.11.107; Geiger R, 2007, J PEDIATR-US, V150, P395, DOI 10.1016/j.jpeds.2006.12.052; Gibbons W J, 2001, J Cardiopulm Rehabil, V21, P87, DOI 10.1097/00008483-200103000-00005; Gungor D, 2013, AM J MED GENET A, V161A, P399, DOI 10.1002/ajmg.a.35662; Hagemans MLC, 2005, BRAIN, V128, P671, DOI 10.1093/brain/awh384; Johnson EM, 2016, NEUROMUSCULAR DISORD, V26, P136, DOI 10.1016/j.nmd.2015.11.009; Kishnani PS, 2012, AM J MED GENET C, V160C, P1, DOI [10.1002/ajmc.31324, 10.1002/ajmg.c.31324]; Lachmann R, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-160; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Montagnese F, 2016, J NEUROL, V263, P631, DOI 10.1007/s00415-015-7926-x; Nie L, 2010, STAT MED, V29, P1107, DOI 10.1002/sim.3871; Pena LDM, 2019, NEUROMUSCULAR DISORD, V29, P167, DOI 10.1016/j.nmd.2018.12.004; Perrot S, 2019, EUR J PAIN, V23, P1117, DOI 10.1002/ejp.1378; Redelmeier DA, 1997, AM J RESP CRIT CARE, V155, P1278, DOI 10.1164/ajrccm.155.4.9105067; Reuser AJ., 2018, ONLINE METABOLIC MOL; Stockton DW, 2020, J NEUROL, V267, P3038, DOI 10.1007/s00415-020-09936-8; Toscano A, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.24; van Capelle CI, 2012, J INHERIT METAB DIS, V35, P317, DOI 10.1007/s10545-011-9388-3; van der Beek NAME, 2013, NEUROMUSCULAR DISORD, V23, P256, DOI 10.1016/j.nmd.2012.10.024; van der Ploeg A, 2016, MOL GENET METAB, V119, P115, DOI 10.1016/j.ymgme.2016.05.013; van der Ploeg AT, 2008, LANCET, V372, P1342, DOI 10.1016/S0140-6736(08)61555-X; van der Ploeg AT, 2012, MOL GENET METAB, V107, P456, DOI 10.1016/j.ymgme.2012.09.015; van der Ploeg AT, 2010, NEW ENGL J MED, V362, P1396, DOI 10.1056/NEJMoa0909859; Winkel LPF, 2005, J NEUROL, V252, P875, DOI 10.1007/s00415-005-0922-9; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Zhou Q, 2013, BIOCONJUGATE CHEM, V24, P2025, DOI 10.1021/bc400365a; Zhu YX, 2009, MOL THER, V17, P954, DOI 10.1038/mt.2009.37	36	10	10	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2021	20	12					1012	1026		10.1016/S1474-4422(21)00241-6	http://dx.doi.org/10.1016/S1474-4422(21)00241-6			15	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YZ6RX	34800399				2022-12-18	WOS:000755602800026
J	Todisco, M; Alfonsi, E; Arceri, S; Bertino, G; Robotti, C; Albergati, M; Gastaldi, M; Tassorelli, C; Cosentino, G				Todisco, Massimiliano; Alfonsi, Enrico; Arceri, Sebastiano; Bertino, Giulia; Robotti, Carlo; Albergati, Michele; Gastaldi, Matteo; Tassorelli, Cristina; Cosentino, Giuseppe			Isolated bulbar palsy after SARS-CoV-2 infection	LANCET NEUROLOGY			English	Letter							COVID-19		[Todisco, Massimiliano; Alfonsi, Enrico; Arceri, Sebastiano; Cosentino, Giuseppe] IRCCS Mondino Fdn, Clin Neurophysiol Unit, I-27100 Pavia, Italy; [Todisco, Massimiliano; Tassorelli, Cristina; Cosentino, Giuseppe] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy; [Bertino, Giulia; Robotti, Carlo] Univ Pavia, Dept Otolaryngol Head & Neck Surg, IRCCS Policlin San Matteo Fdn, Pavia, Italy; [Robotti, Carlo] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Pavia, Italy; [Albergati, Michele] ASST Bergamo Ovest, Rehabil Unit, Romano Di Lombardia, Italy; [Tassorelli, Cristina] IRCCS Mondino Fdn, Neurorehabil Unit, Pavia, Italy; [Gastaldi, Matteo] IRCCS Mondino Fdn, Neuroimmunol Lab, Pavia, Italy	IRCCS Fondazione Casimiro Mondino; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia; University of Pavia; IRCCS Fondazione Casimiro Mondino; IRCCS Fondazione Casimiro Mondino	Alfonsi, E (corresponding author), IRCCS Mondino Fdn, Clin Neurophysiol Unit, I-27100 Pavia, Italy.	enrico.alfonsi@mondino.it	Todisco, Massimiliano/AAA-5934-2022	Todisco, Massimiliano/0000-0002-6527-3558; Bertino, Giulia/0000-0003-2840-5184				Decavel P, 2020, NEUROLOGY, V95, P312, DOI 10.1212/WNL.0000000000010011; Dinkin M, 2020, NEUROLOGY, V95, P221, DOI 10.1212/WNL.0000000000009700; Pellitero SE, 2020, NEUROLOGIA, V35, P271, DOI 10.1016/j.nrl.2020.04.010; Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619; Matschke J, 2020, LANCET NEUROL, V19, P919, DOI 10.1016/S1474-4422(20)30308-2	5	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2021	20	3					169	170		10.1016/S1474-4422(21)00025-9	http://dx.doi.org/10.1016/S1474-4422(21)00025-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QK3CL	33609467	Bronze, Green Published			2022-12-18	WOS:000620258400006
J	Dawson, WD; Bobrow, K; Ibanez, A; Booi, L; Pintado-Caipa, M; Yamamoto, S; Tarnanas, I; Evans, T; Comas-Herrera, A; Cummings, J; Kaye, J; Yaffe, K; Miller, BL; Eyre, HA				Dawson, Walter D.; Bobrow, Kirsten; Ibanez, Agustin; Booi, Laura; Pintado-Caipa, Maritza; Yamamoto, Stacey; Tarnanas, Ioannis; Evans, Timothy; Comas-Herrera, Adelina; Cummings, Jeffrey; Kaye, Jeffrey; Yaffe, Kristine; Miller, Bruce L.; Eyre, Harris A.			The necessity of diplomacy in brain health	LANCET NEUROLOGY			English	Letter									[Dawson, Walter D.; Kaye, Jeffrey] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97239 USA; [Dawson, Walter D.] Portland State Univ, Inst Aging, Coll Urban & Publ Affairs, Portland, OR 97201 USA; [Dawson, Walter D.; Bobrow, Kirsten; Ibanez, Agustin; Booi, Laura; Pintado-Caipa, Maritza; Yamamoto, Stacey; Tarnanas, Ioannis; Evans, Timothy; Miller, Bruce L.; Eyre, Harris A.] Univ Calif San Francisco, Global Brain Hlth Inst, San Francisco, CA 94143 USA; [Dawson, Walter D.; Bobrow, Kirsten; Ibanez, Agustin; Booi, Laura; Pintado-Caipa, Maritza; Yamamoto, Stacey; Tarnanas, Ioannis; Yaffe, Kristine; Miller, Bruce L.; Eyre, Harris A.] Trinity Coll Dublin, Trinity Coll Inst Neurosci, Global Brain Hlth Inst, Dublin 2, Ireland; [Ibanez, Agustin] Univ San Andres, Natl Sci & Tech Res Council, Buenos Aires, DF, Argentina; [Ibanez, Agustin] Univ Adolfo Ibanez, Ctr Social & Cognit Neurosci CSCN, Sch Psychol, Santiago, Chile; [Ibanez, Agustin] Univ Autonoma Caribe, Barranquilla, Atlantico, Colombia; [Booi, Laura] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Pintado-Caipa, Maritza] Peruvian Inst Neurosci, Dept Neurol, Res Unit, Lince, Peru; [Pintado-Caipa, Maritza; Yamamoto, Stacey; Yaffe, Kristine; Miller, Bruce L.] Univ Calif San Francisco, Sch Med, Memory & Aging Ctr, San Francisco, CA USA; [Tarnanas, Ioannis] Johns Hopkins Precis Med Ctr, Hellen Initiat Alzheimers Dis, Baltimore, MD USA; [Tarnanas, Ioannis] Ionian Univ, BiHeLab, Kerkira, Greece; [Tarnanas, Ioannis] Swiss Natl Dementia Task Force, Fed Off Publ Hlth, Luzern, Switzerland; [Tarnanas, Ioannis] Swiss Conf Cantonal Ministers Publ Hlth, Luzern, Switzerland; [Tarnanas, Ioannis] Altoida, Texas Med Ctr Houston, Houston, TX USA; [Evans, Timothy] McGill Univ, Fac Med, Sch Populat & Global Hlth, Montreal, PQ, Canada; [Comas-Herrera, Adelina] London Sch Econ & Polit Sci, Dept Hlth Policy, London, England; [Cummings, Jeffrey] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV USA; [Cummings, Jeffrey] Univ Nevada, Dept Brain Hlth, Las Vegas, NV 89154 USA; [Eyre, Harris A.] Univ Melbourne, Royal Melbourne Hosp, Dept Psychiat, Melbourne, Vic, Australia; [Eyre, Harris A.] Deakin Univ, IMPACT SRC, Sch Med, Geelong, Vic, Australia; [Eyre, Harris A.] Stanford Univ, Sch Med, Dept Psychiat, Brainstorm Lab Mental Hlth Innovat, Palo Alto, CA 94304 USA; [Eyre, Harris A.] Univ Adelaide, Sch Med, Discipline Psychiat, Adelaide, SA, Australia	Oregon Health & Science University; Portland State University; University of California System; University of California San Francisco; Trinity College Dublin; Universidad de San Andres Argentina; Universidad Adolfo Ibanez; Newcastle University - UK; University of California System; University of California San Francisco; McGill University; University of London; London School Economics & Political Science; Cleveland Clinic Foundation; Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Royal Melbourne Hospital; University of Melbourne; Deakin University; Stanford University; University of Adelaide	Dawson, WD (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97239 USA.; Dawson, WD (corresponding author), Portland State Univ, Inst Aging, Coll Urban & Publ Affairs, Portland, OR 97201 USA.; Dawson, WD (corresponding author), Univ Calif San Francisco, Global Brain Hlth Inst, San Francisco, CA 94143 USA.; Dawson, WD (corresponding author), Trinity Coll Dublin, Trinity Coll Inst Neurosci, Global Brain Hlth Inst, Dublin 2, Ireland.	dawsonw@ohsu.edu	Eyre, Harris/AAT-2457-2021; Comas-Herrera, Adelina/Q-7107-2019; Ibanez, Agustin/H-7976-2015	Comas-Herrera, Adelina/0000-0002-9860-9062; Ibanez, Agustin/0000-0001-6758-5101; Dawson, Walter/0000-0002-1172-0471; Miller, Bruce/0000-0002-2152-4220	NIH-NIGMS; NIH; NIH-NINDS; National Institute on Aging; ESRC [ES/P010938/1] Funding Source: UKRI	NIH-NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	WDD reports personal fees from AARP, Commonwealth Fund, Insights to Illuminate, Cognitive Solutions, Oregon Health Care Association, Splaine Consulting, and Mather, outside the submitted work; AI reports grants from FONCyT-PICT 2017-1818 & 2017-1820, FONDAP 15150012, Interamerican Development Bank (IDB), Alzheimer's Association GBHI ALZ UK-20-639295, and the Multi-Partner Consortium to Expand Dementia Research in Latin America, supported by NIH NIA R01 AG057234, Alzheimer's Association (SG-20-725707), Tau Consortium, and Global Brain Health Institute, outside the submitted work; JC reports grants from NIH-NIGMS, NIH, and NIH-NINDS; personal fees from Keep Memory Alive, during the conduct of the study; personal fees from Acadia, Actinogen, AgeneBio, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Cassava, Cerecin, Cerevel, Cognoptix, Cortexyme, EIP Pharma, Eisai, Foresight, Green Valley, Grifols, Karuna, Nutricia, Orion, Otsuka, Probiodrug, ReMYND, Resverlogix, Roche, Samumed, SamusTherapeutics, Third Rock, Signant Health, Sunovion, Suven, and United Neuroscience pharmaceutical and assessment companies, and the Alzheimer Drug Discovery Foundation; and other from ADAMAS, BioAsis, MedAvante, QR Pharma, and United Neuroscience, outside the submitted work. In addition, JC has a patent Neuropsychiatric Inventory (NPI) with royalties paid and is the Chief Scientific Advisor of CNS Innovations and a Board member of Keep Memory Alive; KY serves on DSMBs for Eli Lilly and a National Institute on Aging-sponsored study, is a board member of Alector, and is also a member of the Beeson Scientific Advisory Board and the Global Council on Brain Health; HAE reports personal fees from CNSdose, Scioto Biosciences, Prodeo, and Altoida, outside the submitted work; KB, LB, MP-C, SY, IT, AC-H, TE, JK, and BLM declare no competing interests.	Khor SK, 2020, S CHINA MORNING POST; Smith D., 2017, LANCET NEUROL, V17, P29; Ternes K, 2020, INT PSYCHOGERIATR, V32, P955, DOI 10.1017/S1041610219002266; WHO, GLOB HLTH DIPL TRAD	4	10	10	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2020	19	12					972	+		10.1016/S1474-4422(20)30358-6	http://dx.doi.org/10.1016/S1474-4422(20)30358-6			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PG3EL	33212057	Bronze, Green Accepted			2022-12-18	WOS:000599622000009
J	Nisar, T; Sutherland-Foggio, H; Husar, W				Nisar, Taha; Sutherland-Foggio, Harry; Husar, Walter			Antiviral amantadine	LANCET NEUROLOGY			English	Editorial Material														Husar, Walter/0000-0003-1385-8412; Sutherland, Harry/0000-0001-8654-1737				Galvao MGA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002745.pub4; COHEN RA, 1989, ARCH NEUROL-CHICAGO, V46, P676, DOI 10.1001/archneur.1989.00520420096030; Hubsher G, 2012, NEUROLOGY, V78, P1096, DOI 10.1212/WNL.0b013e31824e8f0d; MAUGH TH, 1979, SCIENCE, V206, P1058, DOI 10.1126/science.386515; POSKANZER DAVID C., 1961, TRANS AMER NEUROL ASSOC, V86, P234; SCHWAB R S, 1969, Transactions of the American Neurological Association, V94, P85; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168	7	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1080	1080		10.1016/S1474-4422(19)30361-8	http://dx.doi.org/10.1016/S1474-4422(19)30361-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	31973807				2022-12-18	WOS:000495892200013
J	[Anonymous]				[Anonymous]			A focus on patient outcomes in cervical myelopathy	LANCET NEUROLOGY			English	Editorial Material																			0	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2019	18	7					615	615		10.1016/S1474-4422(19)30168-1	http://dx.doi.org/10.1016/S1474-4422(19)30168-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IC7SE	31202463	Bronze			2022-12-18	WOS:000471176500002
J	Albers, GW				Albers, Gregory W.			Endovascular thrombectomy in patients with large infarctions: reasons for restraint	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; CONTROLLED-TRIAL		[Albers, Gregory W.] Stanford Univ, Stanford Stroke Ctr, Dept Neurol & Neurol Sci, Palo Alto, CA 94305 USA	Stanford University	Albers, GW (corresponding author), Stanford Univ, Stanford Stroke Ctr, Dept Neurol & Neurol Sci, Palo Alto, CA 94305 USA.	albers@stanford.edu		Albers, Gregory/0000-0003-0263-4632				Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Bracard S, 2016, LANCET NEUROL, V15, P1138, DOI 10.1016/S1474-4422(16)30177-6; McTaggart RA, 2015, STROKE, V46, P407, DOI 10.1161/STROKEAHA.114.006564; Muir KW, 2017, J NEUROL NEUROSUR PS, V88, P38, DOI 10.1136/jnnp-2016-314117; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Roman LS, 2018, LANCET NEUROL, V17, P895, DOI 10.1016/S1474-4422(18)30242-4; Singer OC, 2008, ANN NEUROL, V63, P52, DOI 10.1002/ana.21222	7	10	11	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2018	17	10					836	837		10.1016/S1474-4422(18)30273-4	http://dx.doi.org/10.1016/S1474-4422(18)30273-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GT9LD	30264719				2022-12-18	WOS:000444862200006
J	Mora, JS				Mora, Jesus S.			Edaravone for treatment of early-stage ALS	LANCET NEUROLOGY			English	Letter									[Mora, Jesus S.] Hosp San Rafael, ALS Unit, Madrid 28016, Spain		Mora, JS (corresponding author), Hosp San Rafael, ALS Unit, Madrid 28016, Spain.	neurologia.sanrafael@hsjd.es						Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1	1	10	10	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2017	16	10					772	772		10.1016/S1474-4422(17)30289-2	http://dx.doi.org/10.1016/S1474-4422(17)30289-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5PI	28920880				2022-12-18	WOS:000410379900009
J	[Anonymous]				[Anonymous]			Treating rare disorders: time to act on unfair prices	LANCET NEUROLOGY			English	Editorial Material																			0	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2017	16	10					761	761		10.1016/S1474-4422(17)30295-8	http://dx.doi.org/10.1016/S1474-4422(17)30295-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5PI	28920873	Bronze			2022-12-18	WOS:000410379900001
J	Yassine, HN; Schneider, LS				Yassine, Hussein N.; Schneider, Lon S.			Lessons from the Multidomain Alzheimer Preventive Trial	LANCET NEUROLOGY			English	Letter							DOCOSAHEXAENOIC ACID SUPPLEMENTATION; DISEASE		[Yassine, Hussein N.; Schneider, Lon S.] USC, Keck Sch Med, Los Angeles, CA 90007 USA	University of Southern California; University of Southern California Keck Hospital	Yassine, HN (corresponding author), USC, Keck Sch Med, Los Angeles, CA 90007 USA.	hyassine@usc.edu			National Institute of Heart, Lung and Blood; Alzheimer's Association; National Institute on Aging; State of California; University of Southern California; Eli Lilly; Lundbeck; Novartis; Biogen; Merck; Roche/Genentech; TauRx; AC Immune; Avraham; Boehringer Ingelheim; Cerespir; Cognition; Neurim; Stemedica; Takeda; vTv; Toyama/FujiFilm; Nestle; Heptares; Allergan; Axovant; Impel NeuroPharma; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL107389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG055770, R01AG054434] Funding Source: NIH RePORTER	National Institute of Heart, Lung and Blood(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Alzheimer's Association(Alzheimer's Association); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); State of California; University of Southern California; Eli Lilly(Eli Lilly); Lundbeck(Lundbeck Corporation); Novartis(Novartis); Biogen(Biogen); Merck(Merck & Company); Roche/Genentech(Roche HoldingGenentech); TauRx; AC Immune; Avraham; Boehringer Ingelheim(Boehringer Ingelheim); Cerespir; Cognition; Neurim; Stemedica; Takeda(Takeda Pharmaceutical Company Ltd); vTv; Toyama/FujiFilm; Nestle(Nestle SA); Heptares; Allergan(AbbVieAllergan); Axovant; Impel NeuroPharma; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	HNY reports grants from the National Institute of Heart, Lung and Blood and the Alzheimer's Association. LSS reports grants from the National Institute on Aging and the State of California, and other from University of Southern California; grants from Eli Lilly, Lundbeck, Novartis, and Biogen; grants and personal fees from, Merck, Roche/Genentech, and TauRx; and personal fees from AC Immune, Avraham, Boehringer Ingelheim, Cerespir, Cognition, Neurim, Stemedica, Takeda, vTv, Toyama/FujiFilm, Nestle, Heptares, Allergan, Axovant, and Impel NeuroPharma.	Andrieu S, 2017, LANCET NEUROL, V16, P377, DOI 10.1016/S1474-4422(17)30040-6; Hooijmans CR, 2012, J ALZHEIMERS DIS, V28, P191, DOI 10.3233/JAD-2011-111217; Kivipelto M, 2017, LANCET NEUROL, V16, P338, DOI 10.1016/S1474-4422(17)30080-7; Laitinen MH, 2006, DEMENT GERIATR COGN, V22, P99, DOI 10.1159/000093478; Quinn JF, 2010, JAMA-J AM MED ASSOC, V304, P1903, DOI 10.1001/jama.2010.1510; Umhau JC, 2009, J LIPID RES, V50, P1259, DOI 10.1194/jlr.M800530-JLR200; van de Rest O., 2008, NEUROLOGY, V71, P430, DOI DOI 10.1212/01.WNL.0000324268.45138.86; Yassine HN, 2017, JAMA NEUROL, V74, P337, DOI 10.1001/jamaneurol.2016.4899; Yassine HN, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0194-x	9	10	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2017	16	8					585	586		10.1016/S1474-4422(17)30227-2	http://dx.doi.org/10.1016/S1474-4422(17)30227-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FA1LP	28721922	Green Accepted, Bronze			2022-12-18	WOS:000405201300014
J	[Anonymous]				[Anonymous]			Integrating palliative care into neurological practice	LANCET NEUROLOGY			English	Editorial Material																			0	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2017	16	7					489	489		10.1016/S1474-4422(17)30176-X	http://dx.doi.org/10.1016/S1474-4422(17)30176-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX4MH	28653639	Bronze			2022-12-18	WOS:000403208400001
J	Giamberardino, MA; Costantini, R				Giamberardino, Maria Adele; Costantini, Raffaele			Challenging chronic migraine: targeting the CGRP receptor	LANCET NEUROLOGY			English	Editorial Material							DOUBLE-BLIND; EFFICACY; SAFETY		[Giamberardino, Maria Adele] Univ G dAnnunzio, Dept Med & Sci Aging, Headache Ctr, I-66100 Chieti, Italy; [Giamberardino, Maria Adele] Univ G dAnnunzio, Ctr Aging Sci & Translat Med, I-66100 Chieti, Italy; [Costantini, Raffaele] Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, Inst Surg Pathol, I-66100 Chieti, Italy	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara	Giamberardino, MA (corresponding author), Univ G dAnnunzio, Dept Med & Sci Aging, Headache Ctr, I-66100 Chieti, Italy.; Giamberardino, MA (corresponding author), Univ G dAnnunzio, Ctr Aging Sci & Translat Med, I-66100 Chieti, Italy.	mag@unich.it						Bigal ME, 2015, LANCET NEUROL, V14, P1091, DOI 10.1016/S1474-4422(15)00245-8; Bigal ME, 2015, BRIT J CLIN PHARMACO, V79, P886, DOI 10.1111/bcp.12591; de Tommaso M, 2016, CURR RHEUMATOL REV, V12, P113, DOI 10.2174/1573397112666151231110813; Giamberardino MA, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0619-8; Giamberardino MA, 2016, INTERN EMERG MED, V11, P1045, DOI 10.1007/s11739-016-1489-4; Lipton RB, 2011, HEADACHE, V51, P77, DOI 10.1111/j.1526-4610.2011.01954.x; May A, 2016, NAT REV NEUROL, V12, P455, DOI 10.1038/nrneurol.2016.93; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; Schou WS, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0741-2; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Sun H, 2016, LANCET NEUROL, V15, P382, DOI 10.1016/S1474-4422(16)00019-3; Sun-Edelstein C, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-015-0533-9; Tepper S, 2017, LANCET NEUROL; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4	14	10	10	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2017	16	6					410	411		10.1016/S1474-4422(17)30126-6	http://dx.doi.org/10.1016/S1474-4422(17)30126-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EU1WD	28460891				2022-12-18	WOS:000400815800002
J	Aartsma-Rus, A; Balabanov, P; Binetti, L				Aartsma-Rus, A.; Balabanov, P.; Binetti, L.			Stakeholder collaboration for spinal muscular atrophy therapy development (vol 16, pg 264, 2017)	LANCET NEUROLOGY			English	Correction													; Mercuri, Eugenio/G-1351-2015	Aartsma-Rus, Annemieke/0000-0003-1565-654X; Mercuri, Eugenio/0000-0002-9851-5365	National Institute for Health Research [NF-SI-0515-10022] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Aartsma-Rus A, 2017, LANCET NEUROL, V16, P341, DOI 10.1016/S1474-4422(17)30041-8	1	10	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2017	16	5					341	341		10.1016/S1474-4422(17)30041-8	http://dx.doi.org/10.1016/S1474-4422(17)30041-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ER4PH	28327335	Bronze			2022-12-18	WOS:000398782100007
J	Hardy, J				Hardy, John			Membrane damage is at the core of Alzheimer's disease	LANCET NEUROLOGY			English	Letter									[Hardy, John] UCL, Inst Neurol, Reta Lila Res Labs, London WC1N 3BG, England; [Hardy, John] UCL, Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Hardy, J (corresponding author), UCL, Inst Neurol, Reta Lila Res Labs, London WC1N 3BG, England.; Hardy, J (corresponding author), UCL, Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England.	J.hardy@ucl.ac.uk	Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423	MRC [G0701075, MR/K01417X/1, MR/J004758/1, G1001253, G0901254] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Jones L, 2010, PLOS ONE, V5; Mahley RW, 2016, J MOL MED, V94, P739, DOI 10.1007/s00109-016-1427-y; Matarin M, 2015, CELL REP, V10, P633, DOI 10.1016/j.celrep.2014.12.041; Quazi F, 2013, J BIOL CHEM, V288, P34414, DOI 10.1074/jbc.M113.508812; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Zhou Q, 2012, AM J HUM GENET, V91, P713, DOI 10.1016/j.ajhg.2012.08.006	8	10	10	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2017	16	5					342	342		10.1016/S1474-4422(17)30091-1	http://dx.doi.org/10.1016/S1474-4422(17)30091-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ER4PH	28414646	Bronze			2022-12-18	WOS:000398782100008
J	Aartsma-Rus, A; Balabanov, P; Binetti, L; Haas, M; Haberkamp, M; Mitchell, J; Rosa, MM; Muntoni, F; Finkel, R; Mercuri, E				Aartsma-Rus, Annemieke; Balabanov, Pavel; Binetti, Luca; Haas, Manuel; Haberkamp, Marion; Mitchell, Joanna; Rosa, Mario Miguel; Muntoni, Francesco; Finkel, Richard; Mercuri, Eugenio			Stakeholder collaboration for spinal muscular atrophy therapy development	LANCET NEUROLOGY			English	Letter									[Aartsma-Rus, Annemieke] Leiden Univ, Med Ctr, Leiden, Netherlands; [Balabanov, Pavel] European Med Assoc, Human Med Evaluat Div, Sci & Regulatory Dept, Cent Nervous Syst & Ophthalmol Off, London, England; [Binetti, Luca] Famiglie Sma, Milan, Italy; Bundesinst Arzneimittel & Med Prod, D-53175 Bonn, Germany; [Mitchell, Joanna] SMA Trust, Stratford Upon Avon, England; [Rosa, Mario Miguel] Univ Lisbon, Fac Med, Lab Farmacol Clin & Terapeut, Lisbon, Portugal; [Muntoni, Francesco] UCL, Dubowitz Neuromuscular Ctr, Great Ormond St Inst Child Hlth, London, England; [Muntoni, Francesco] Great Ormond St Hosp Sick Children, London, England; [Finkel, Richard] Nemours Childrens Hosp, Orlando, FL USA; [Finkel, Richard] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA; [Mercuri, Eugenio] Univ Cattolica Sacro Cuore, Rome, Italy	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Universidade de Lisboa; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; State University System of Florida; University of Central Florida; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Aartsma-Rus, A (corresponding author), Leiden Univ, Med Ctr, Leiden, Netherlands.	a.m.rus@lumc.nl	; Mercuri, Eugenio/G-1351-2015	Aartsma-Rus, Annemieke/0000-0003-1565-654X; Mercuri, Eugenio/0000-0002-9851-5365	ZonMw; Duchenne Parent Project Netherlands; Prinses Beatrix Spierfonds; European Union; Parent Project Muscular Dystrophy; Roche; Isis/Biogen; GOSH Charity; Spinal Muscular Atrophy Trust; Wellcome Trust; Biogen; AveXis; Pfizer; Ionis; National Institute for Health Research [NF-SI-0515-10022] Funding Source: researchfish	ZonMw(Netherlands Organization for Health Research and Development); Duchenne Parent Project Netherlands(Netherlands Government); Prinses Beatrix Spierfonds; European Union(European Commission); Parent Project Muscular Dystrophy; Roche(Roche Holding); Isis/Biogen; GOSH Charity; Spinal Muscular Atrophy Trust; Wellcome Trust(Wellcome TrustEuropean Commission); Biogen(Biogen); AveXis; Pfizer(Pfizer); Ionis; National Institute for Health Research(National Institute for Health Research (NIHR))	AA-R is employed by Leiden University Medical Center, which has patents on exon skipping technology; as co-inventor of some of these patents, AA-R is entitled to a share of royalties. AA-R also reports grants from ZonMw, Duchenne Parent Project Netherlands, Prinses Beatrix Spierfonds, European Union 7th Framework Programme, and Parent Project Muscular Dystrophy. FM is a member of a scientific advisory board for Pfizer; reports grants from Roche, Isis/Biogen, GOSH Charity, Spinal Muscular Atrophy Trust, and Wellcome Trust; and has received personal fees from Roche, Biogen, AveXis, and Pfizer. RF is a member of a scientific advisory board for AveXis and Roche; is a consulant for Biogen, Ionis, AveXis, Roche, and Novartis; and reports grants from Biogen and Ionis. All other authors declare no competing interests.	Mercuri E, 2016, NEUROMUSCULAR DISORD, V26, P126, DOI 10.1016/j.nmd.2015.10.006; Straub V, 2016, LANCET NEUROL, V15, P882, DOI 10.1016/S1474-4422(16)30035-7	2	10	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2017	16	4					264	264		10.1016/S1474-4422(17)30041-8	http://dx.doi.org/10.1016/S1474-4422(17)30041-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EN9RF	28327335	Bronze			2022-12-18	WOS:000396336600015
J	Sorensen, PS				Sorensen, Per Soelberg			Ozanimod: a better or just another S1P receptor modulator?	LANCET NEUROLOGY			English	Editorial Material							REMITTING MULTIPLE-SCLEROSIS; ORAL FINGOLIMOD; TRIAL; EFFICACY		[Sorensen, Per Soelberg] Copenhagen Univ Hosp, Danish Multiple Sclerosis Ctr, Dept Neurol, Rigshosp, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Sorensen, PS (corresponding author), Copenhagen Univ Hosp, Danish Multiple Sclerosis Ctr, Dept Neurol, Rigshosp, DK-2100 Copenhagen, Denmark.	pss@rh.dk		Sorensen, Per Soelberg/0000-0002-2818-3780				Calabresi PA, 2014, LANCET NEUROL, V13, P545, DOI 10.1016/S1474-4422(14)70049-3; Cohen JA, 2016, LANCET NEUROL; Cohen JA, 2011, ANN NEUROL, V69, P759, DOI 10.1002/ana.22426; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Francis G, 2014, MULT SCLER J, V20, P471, DOI 10.1177/1352458513500551; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Olsson T, 2014, J NEUROL NEUROSUR PS, V85, P1198, DOI 10.1136/jnnp-2013-307282; Selmaj K, 2013, LANCET NEUROL, V12, P756, DOI 10.1016/S1474-4422(13)70102-9	8	10	10	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					345	347		10.1016/S1474-4422(16)00041-7	http://dx.doi.org/10.1016/S1474-4422(16)00041-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP	26879277				2022-12-18	WOS:000371974000003
J	Gunn, AJ; Bennet, L				Gunn, Alistair J.; Bennet, Laura			Timing still key to treating hypoxic ischaemic brain injury	LANCET NEUROLOGY			English	Editorial Material							ASPHYXIA		[Gunn, Alistair J.; Bennet, Laura] Univ Auckland, Dept Physiol, Auckland 1023, New Zealand	University of Auckland	Gunn, AJ (corresponding author), Univ Auckland, Dept Physiol, Private Bag 92019, Auckland 1023, New Zealand.	aj.gunn@auckland.ac.nz		Bennet, Laura/0000-0002-4336-7596; Gunn, Alistair/0000-0003-0656-7035				Azzopardi D, 2015, LANCET NEUROL; Chakkarapani E, 2010, ANN NEUROL, V68, P330, DOI 10.1002/ana.22016; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Gunn AJ, 2015, RESUSCITATION, V97, P88, DOI 10.1016/j.resuscitation.2015.03.026; Iwata O, 2008, BRAIN, V131, P2220, DOI 10.1093/brain/awn150; Jacobs S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub2; Robertson NJ, 2012, J PEDIATR-US, V160, P544, DOI 10.1016/j.jpeds.2011.12.052; ROTH SC, 1992, DEV MED CHILD NEUROL, V34, P285; Sabir H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109845	9	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2016	15	2					126	127		10.1016/S1474-4422(15)00386-5	http://dx.doi.org/10.1016/S1474-4422(15)00386-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DA9GC	26708678	hybrid			2022-12-18	WOS:000368116000002
J	Pascual, J				Pascual, Julio			CGRP antibodies: the Holy Grail for migraine prevention?	LANCET NEUROLOGY			English	Editorial Material							GENE-RELATED PEPTIDE; PERIPHERAL-BLOOD; DOUBLE-BLIND; BIOMARKER; LY2951742; EFFICACY; PHASE-2; SAFETY		[Pascual, Julio] Univ Hosp Marques de Valdecilla, Santander 39011, Spain; [Pascual, Julio] IDIVAL, Santander 39011, Spain	Hospital Universitario Marques de Valdecilla (HUMV)	Pascual, J (corresponding author), Univ Hosp Marques de Valdecilla, Santander 39011, Spain.	juliopascual@telefonica.net						Aurora SK, 2011, HEADACHE, V51, P1358, DOI 10.1111/j.1526-4610.2011.01990.x; Bigal ME, 2015, LANCET NEUROL; Cernuda-Morollon E, 2015, CEPHALALGIA, V35, P310, DOI 10.1177/0333102414535111; Cernuda-Morollon E, 2013, NEUROLOGY, V81, P1191, DOI 10.1212/WNL.0b013e3182a6cb72; Dodick DW, 2014, LANCET NEUROL, V13, P1100, DOI 10.1016/S1474-4422(14)70209-1; Dodick DW, 2014, LANCET NEUROL, V13, P885, DOI 10.1016/S1474-4422(14)70128-0; Tfelt-Hansen P, 2015, LANCET NEUROL, V14, P31, DOI 10.1016/S1474-4422(14)70306-0; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2	8	10	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2015	14	11					1066	1067		10.1016/S1474-4422(15)00244-6	http://dx.doi.org/10.1016/S1474-4422(15)00244-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT7DY	26432183				2022-12-18	WOS:000362975200002
J	Puschmann, A; Dickson, DW; Englund, E; Wszolek, ZK; Ross, OA				Puschmann, Andreas; Dickson, Dennis W.; Englund, Elisabet; Wszolek, Zbigniew K.; Ross, Owen A.			CHCHD2 and Parkinson's disease	LANCET NEUROLOGY			English	Letter									[Puschmann, Andreas; Englund, Elisabet] Lund Univ, Dept Clin Sci, Lund, Sweden; [Puschmann, Andreas] Skane Univ Hosp, Neurol, S-22185 Lund, Sweden; [Puschmann, Andreas] Skane Univ Hosp, Dept Neurol, S-22185 Lund, Sweden; [Ross, Owen A.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Dickson, Dennis W.] Mayo Clin, Dept Neurosci Neuropathol, Jacksonville, FL 32224 USA; [Englund, Elisabet] Skane Univ Hosp, Oncol & Pathol, S-22185 Lund, Sweden; [Englund, Elisabet] Skane Univ Hosp, Dept Clin Pathol, S-22185 Lund, Sweden; [Wszolek, Zbigniew K.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA	Lund University; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Mayo Clinic; Mayo Clinic; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Mayo Clinic	Puschmann, A (corresponding author), Lund Univ, Dept Clin Sci, Lund, Sweden.	andreas.puschmann@med.lu.se	Wszolek, Zbigniew K./AAB-1431-2019	Puschmann, Andreas/0000-0002-3201-8198; Ross, Owen/0000-0003-4813-756X; Englund, Elisabet/0000-0002-2708-2443	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS078086, P50NS072187] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2; Puschmann A, 2011, NEUROLOGY, V76, P1623, DOI 10.1212/WNL.0b013e318219fb42; Puschmann AJ, 2010, MOVEMENT DISORD, V25, pIX; Puschmann A, 2013, PARKINSONISM RELAT D, V19, P407, DOI 10.1016/j.parkreldis.2013.01.020; Singleton A, 2015, LANCET NEUROL, V14, P239, DOI 10.1016/S1474-4422(14)70270-4	5	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					679	679		10.1016/S1474-4422(15)00095-2	http://dx.doi.org/10.1016/S1474-4422(15)00095-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26067111	Green Published			2022-12-18	WOS:000356195900009
J	Reuter, U				Reuter, Uwe			Anti-CGRP antibodies: a new approach to migraine prevention	LANCET NEUROLOGY			English	Editorial Material							GENE-RELATED PEPTIDE		Charite, Dept Neurol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Reuter, U (corresponding author), Charite, Dept Neurol, Charitepl 1, D-10117 Berlin, Germany.	uwe.reuter@charite.de		Reuter, Uwe/0000-0002-8527-0725				Ayata C, 2006, ANN NEUROL, V59, P652, DOI 10.1002/ana.20778; Benschop RJ, 2014, OSTEOARTHR CARTILAGE, V22, P578, DOI 10.1016/j.joca.2014.01.009; Bigal ME, 2014, CNS DRUGS, V28, P389, DOI 10.1007/s40263-014-0156-4; Dodick DW, 2014, LANCET NEUROL; Eberhardt M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5381; GOADSBY PJ, 1988, ANN NEUROL, V23, P193, DOI 10.1002/ana.410230214; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505; UDDMAN R, 1986, REGUL PEPTIDES, V15, P1, DOI 10.1016/0167-0115(86)90071-6	8	10	22	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2014	13	9					857	859		10.1016/S1474-4422(14)70126-7	http://dx.doi.org/10.1016/S1474-4422(14)70126-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO5SK	25127171				2022-12-18	WOS:000341405400003
J	McKeon, A; Lennon, VA				McKeon, Andrew; Lennon, Vanda A.			NMDAR encephalitis: which specimens, and the value of values	LANCET NEUROLOGY			English	Editorial Material							RECEPTOR ENCEPHALITIS; ANTIBODIES; MECHANISMS; CHANNEL; MARKER; IGG		[McKeon, Andrew; Lennon, Vanda A.] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [McKeon, Andrew; Lennon, Vanda A.] Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55905 USA; [Lennon, Vanda A.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	McKeon, A (corresponding author), Mayo Clin, Coll Med, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	mckeon.andrew@mayo.edu	McKeon, Andrew/AAY-9214-2021	McKeon, Andrew/0000-0001-6856-8143				Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Gresa-Arribas N, 2013, LANCET NEUROL; Hughes EG, 2010, J NEUROSCI, V30, P5866, DOI 10.1523/JNEUROSCI.0167-10.2010; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; McKeon A, 2013, CURR TREAT OPTION NE, V15, P723, DOI 10.1007/s11940-013-0251-8; McKeon A, 2011, ACTA NEUROPATHOL, V122, P381, DOI [10.1007/s00401-011-0876-1, 10.10007/s00401-011-0876-1]; McKeon A, 2011, NEUROLOGY, V76, P1108, DOI 10.1212/WNL.0b013e318211c379; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Yu ZY, 2001, ANN NEUROL, V49, P146	10	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2014	13	2					133	135		10.1016/S1474-4422(13)70277-1	http://dx.doi.org/10.1016/S1474-4422(13)70277-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	301QE	24360483				2022-12-18	WOS:000330546200005
J	Hariz, M				Hariz, Marwan			Early surgery for Parkinson's disease? Maybe, but not just yet	LANCET NEUROLOGY			English	Editorial Material							SUBTHALAMIC STIMULATION		[Hariz, Marwan] UCL Inst Neurol, Unit Funct Neurosurg, London WC1N 3BG, England; [Hariz, Marwan] Umea Univ, Dept Clin Neurosci, Umea, Sweden	University of London; University College London; Umea University	Hariz, M (corresponding author), UCL Inst Neurol, Unit Funct Neurosurg, Queen Sq, London WC1N 3BG, England.	m.hariz@ucl.ac.uk						Angeli A, 2013, MOVEMENT DISORD, V28, P1370, DOI 10.1002/mds.25535; Bejjani BPW, 2008, NEUROLOGY, V70, pA179; Deuschl G, 2013, LANCET NEUROL, V12, P1025, DOI 10.1016/S1474-4422(13)70151-0; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; Schuepbach WMM, 2013, NEW ENGL J MED, V368, P610, DOI 10.1056/NEJMoa1205158; Schwab J., 1968, 3 S PARK DIS, P152; Vitek JL, 2003, ANN NEUROL; Voon V, 2008, BRAIN, V131, P2720, DOI 10.1093/brain/awn214	9	10	11	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2013	12	10					938	939		10.1016/S1474-4422(13)70191-1	http://dx.doi.org/10.1016/S1474-4422(13)70191-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	237XV	24050730				2022-12-18	WOS:000325905800006
J	Kaste, M				Kaste, Markku			Is the door open again for neuroprotection trials in stroke?	LANCET NEUROLOGY			English	Editorial Material									Univ Helsinki, Cent Hosp, FI-00029 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Kaste, M (corresponding author), Univ Helsinki, Cent Hosp, POB 340, FI-00029 Helsinki, Finland.	markku.kaste@hus.fi		Kaste, Markku/0000-0001-6557-6412				Hill MD, 2012, LANCET NEUROL, V2012, DOI DOI 10.1016/51474-4422(12)70225-9; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Liman TG, 2012, STROKE, V43, P2086, DOI 10.1161/STROKEAHA.112.657270; Liu X, 2012, EUR J NEUROL, V19, P855, DOI 10.1111/j.1468-1331.2011.03634.x; Otomo E, 2003, CEREBROVASC DIS, V15, P222, DOI 10.1159/000069318	5	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2012	11	11					930	931		10.1016/S1474-4422(12)70229-6	http://dx.doi.org/10.1016/S1474-4422(12)70229-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	028KW	23051990				2022-12-18	WOS:000310422200002
J	Winkler, AS				Winkler, Andrea S.			Measuring the epilepsy treatment gap in sub-Saharan Africa	LANCET NEUROLOGY			English	Editorial Material							NORTHERN TANZANIA; RURAL-COMMUNITY; PREVALENCE; ATTITUDES; ZAMBIA; PEOPLE; CARE		Tech Univ Munich, Dept Neurol, D-81675 Munich, Germany	Technical University of Munich	Winkler, AS (corresponding author), Tech Univ Munich, Dept Neurol, Ismaninger Str 22, D-81675 Munich, Germany.	drawinkler@yahoo.com.au						Birbeck GL, 2000, ARCH NEUROL-CHICAGO, V57, P414, DOI 10.1001/archneur.57.3.414; Birbeck G, 2007, LANCET NEUROL, V6, P39, DOI 10.1016/S1474-4422(06)70629-9; Coleman R, 2002, B WORLD HEALTH ORGAN, V80, P378; Diop AG, 2005, EPILEPSIA, V46, P33, DOI 10.1111/j.1528-1167.2005.00405.x; Mbuba CK, 2012, LANCET NEUROL; Meinardi H, 2001, EPILEPSIA, V42, P136, DOI 10.1046/j.1528-1157.2001.32800.x; Meyer AC, 2010, B WORLD HEALTH ORGAN, V88, P260, DOI 10.2471/BLT.09.064147; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Ndoye NF, 2005, SEIZURE-EUR J EPILEP, V14, P106, DOI 10.1016/j.seizure.2004.11.003; Patsalos PN, 2008, EPILEPSIA, V49, P1239, DOI 10.1111/j.1528-1167.2008.01561.x; Winkler AS, 2009, EPILEPSIA, V50, P2310, DOI 10.1111/j.1528-1167.2009.02184.x; Winkler AS, 2010, EPILEPSY BEHAV, V19, P596, DOI 10.1016/j.yebeh.2010.09.023; Winkler AS, 2010, AFR J TRADIT COMPLEM, V7, P162	13	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2012	11	8					655	657		10.1016/S1474-4422(12)70160-6	http://dx.doi.org/10.1016/S1474-4422(12)70160-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	983AX	22770913				2022-12-18	WOS:000307089700004
J	[Anonymous]				[Anonymous]			A united approach to vascular disease and neurodegeneration	LANCET NEUROLOGY			English	Editorial Material															Medical Research Council [MR/J006971/1] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)			0	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2012	11	4					293	293		10.1016/S1474-4422(12)70050-9	http://dx.doi.org/10.1016/S1474-4422(12)70050-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	915CD	22441191	Bronze			2022-12-18	WOS:000301999600001
J	Duyckaerts, C				Duyckaerts, Charles			Disentangling Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							POSTERIOR CORTICAL ATROPHY		[Duyckaerts, Charles] Univ Paris 06, AP HP, Lab Neuropathol Escourolle, Paris, France; [Duyckaerts, Charles] Grp Hosp Pitie Salpetriere, Inst Cerveau & Moelle, F-75634 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Duyckaerts, C (corresponding author), Univ Paris 06, AP HP, Lab Neuropathol Escourolle, Paris, France.							BENSON DF, 1988, ARCH NEUROL-CHICAGO, V45, P789, DOI 10.1001/archneur.1988.00520310107024; Cataldo A, 2001, ANN NEUROL, V50, P661, DOI 10.1002/ana.1254.abs; Didic M, 1998, ANN NEUROL, V43, P526, DOI 10.1002/ana.410430418; Johnson JK, 1999, ARCH NEUROL-CHICAGO, V56, P1233, DOI 10.1001/archneur.56.10.1233; Kas A, 2011, BRAIN, V134, P1464, DOI 10.1093/brain/awr055; Le TV, 2001, J NEUROPATH EXP NEUR, V60, P1051, DOI 10.1093/jnen/60.11.1051; Mesulam M, 2008, ANN NEUROL, V63, P709, DOI 10.1002/ana.21388; Murray ME, 2011, LANCET NEUROL, V10, P785, DOI 10.1016/S1474-4422(11)70156-9	8	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2011	10	9					774	775		10.1016/S1474-4422(11)70171-5	http://dx.doi.org/10.1016/S1474-4422(11)70171-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	815NM	21802368				2022-12-18	WOS:000294532300002
J	Montaner, J				Montaner, Joan			Genetics of intracerebral haemorrhage: a tsunami effect of APOE epsilon 2 genotype on brain bleeding size?	LANCET NEUROLOGY			English	Editorial Material							ASSOCIATION		[Montaner, Joan] Univ Autonoma Barcelona, VHIR & Hosp, Neurovasc Res Lab, E-08193 Barcelona, Spain; [Montaner, Joan] Univ Autonoma Barcelona, VHIR & Hosp, Neurovasc Unit, E-08193 Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Montaner, J (corresponding author), Univ Autonoma Barcelona, VHIR & Hosp, Neurovasc Res Lab, E-08193 Barcelona, Spain.	31862jmv@comb.cat	Montaner, Joan/D-3063-2015	Montaner, Joan/0000-0003-4845-2279				Biffi A, 2011, LANCET NEUROL, V10, P702, DOI 10.1016/S1474-4422(11)70148-X; Biffi A, 2010, ANN NEUROL, V68, P934, DOI 10.1002/ana.22134; Brown WM, 2011, STROKE, V42, pE218; Clark JF, 2002, FRONT BIOSCI-LANDMRK, V7, pA163, DOI 10.2741/clark; Greenberg SM, 1998, NEUROLOGY, V50, P961, DOI 10.1212/WNL.50.4.961; Hernandez-Guillamon M, 2012, BRAIN PATHOL, V22, P133, DOI 10.1111/j.1750-3639.2011.00512.x; Mayer SA, 2009, STROKE, V40, P833, DOI 10.1161/STROKEAHA.108.524470; Rost NS, 2008, STROKE, V39, P2166, DOI 10.1161/STROKEAHA.107.501650; Steiner T, CEREBROVASC IN PRESS; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3; Zhao LZ, 2009, J NEUROSCI, V29, P3603, DOI 10.1523/JNEUROSCI.5302-08.2009	11	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2011	10	8					673	675		10.1016/S1474-4422(11)70157-0	http://dx.doi.org/10.1016/S1474-4422(11)70157-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	803WJ	21741315				2022-12-18	WOS:000293612600003
J	Ransohoff, RM				Ransohoff, Richard M.			PML risk and natalizumab: more questions than answers	LANCET NEUROLOGY			English	Editorial Material							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; MULTIPLE-SCLEROSIS; JC VIRUS; DISEASE		[Ransohoff, Richard M.] Cleveland Clin, Neurol Inst, Neuroinflammat Res Ctr, Lerner Res Inst,Mellen Ctr MS Treatment & Res, Cleveland, OH 44195 USA; [Ransohoff, Richard M.] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation	Ransohoff, RM (corresponding author), Cleveland Clin, Neurol Inst, Neuroinflammat Res Ctr, Lerner Res Inst,Mellen Ctr MS Treatment & Res, Mail Code NC30,9500 Euclid Ave, Cleveland, OH 44195 USA.	ransohr@ccf.org						Calabrese LH, 2007, ARTHRITIS RHEUM-US, V56, P2116, DOI 10.1002/art.22657; Carson KR, 2009, LANCET ONCOL, V10, P816, DOI 10.1016/S1470-2045(09)70161-5; Chen YP, 2009, NEW ENGL J MED, V361, P1067, DOI 10.1056/NEJMoa0904267; DeLorenze GN, 2006, ARCH NEUROL-CHICAGO, V63, P839, DOI 10.1001/archneur.63.6.noc50328; Jilek S, 2010, LANCET NEUROL, V9, P264, DOI 10.1016/S1474-4422(10)70006-5; Khatri BO, 2009, NEUROLOGY, V72, P402, DOI 10.1212/01.wnl.0000341766.59028.9d; Kivisakk P, 2009, NEUROLOGY, V72, P1922, DOI 10.1212/WNL.0b013e3181a8266f; Knowles WA, 2006, ADV EXP MED BIOL, V577, P19; Koralnik IJ, 2006, ANN NEUROL, V60, P162, DOI 10.1002/ana.20933; Linda H, 2009, NEW ENGL J MED, V361, P1081, DOI 10.1056/NEJMoa0810316; Ransohoff RM, 2007, NEW ENGL J MED, V356, P2622, DOI 10.1056/NEJMct071462; Thompson JP, 2008, NEUROLOGY, V71, P357, DOI 10.1212/01.wnl.0000319648.65173.7a; Wenning W, 2009, NEW ENGL J MED, V361, P1075, DOI 10.1056/NEJMoa0810257	13	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2010	9	3					231	233		10.1016/S1474-4422(10)70025-9	http://dx.doi.org/10.1016/S1474-4422(10)70025-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	565BL	20117056				2022-12-18	WOS:000275263400004
J	Pareyson, D; Solari, A				Pareyson, Davide; Solari, Alessandra			Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective?	LANCET NEUROLOGY			English	Editorial Material							RELIABILITY; HISTORY		[Pareyson, Davide] C Besta Neurol Inst, IRCCS Fdn, Dept Clin Neurosci, Unit Neurol 8,Clin Cent & Peripheral Degenerat Ne, I-20133 Milan, Italy; [Solari, Alessandra] C Besta Neurol Inst, IRCCS Fdn, Unit Neuroepidemiol, I-20133 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico	Pareyson, D (corresponding author), C Besta Neurol Inst, IRCCS Fdn, Dept Clin Neurosci, Unit Neurol 8,Clin Cent & Peripheral Degenerat Ne, I-20133 Milan, Italy.	dpareys@istituto-besta.it	Pareyson, Davide/K-5890-2016; Solari, Alessandra/AAO-1741-2021	Pareyson, Davide/0000-0001-6854-765X; Solari, Alessandra/0000-0001-9930-7579				Burns J, 2009, LANCET NEUROL, V8, P537, DOI 10.1016/S1474-4422(09)70108-5; Chalmers I, 2002, EVAL HEALTH PROF, V25, P12, DOI 10.1177/0163278702025001003; Micallef J, 2009, LANCET NEUROL, V8, P1103, DOI 10.1016/S1474-4422(09)70260-1; Pareyson D, 2006, PHARMACOL RES, V54, P436, DOI 10.1016/j.phrs.2006.09.001; Pareyson D, 2009, LANCET NEUROL, V8, P654, DOI 10.1016/S1474-4422(09)70110-3; Passage E, 2004, NAT MED, V10, P396, DOI 10.1038/nm1023; Reilly M M, 2006, Neuromuscul Disord, V16, P396, DOI 10.1016/j.nmd.2006.03.008; Shy ME, 2008, NEUROLOGY, V70, P378, DOI 10.1212/01.wnl.0000297553.36441.ce; Shy ME, 2005, NEUROLOGY, V64, P1209, DOI 10.1212/01.WNL.0000156517.00615.A3; Solari A, 2008, NEUROMUSCULAR DISORD, V18, P19, DOI 10.1016/j.nmd.2007.09.006; Toth C, 2009, ACTA NEUROL SCAND, V120, P134, DOI 10.1111/j.1600-0404.2008.01134.x; Verhamme C, 2009, J PERIPHER NERV SYST, V14, P152	12	10	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2009	8	12					1075	1077		10.1016/S1474-4422(09)70270-4	http://dx.doi.org/10.1016/S1474-4422(09)70270-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	523WS	19818689				2022-12-18	WOS:000272106100003
J	Ratan, RR				Ratan, Rajiv R.			Epigenetics and the nervous system: epiphenomenon or missing piece of the neurotherapeutic puzzle?	LANCET NEUROLOGY			English	Editorial Material							PLASTICITY		[Ratan, Rajiv R.] Burke Med Res Inst, Dept Neurol & Neurosci, White Plains, NY 10605 USA; [Ratan, Rajiv R.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Cornell University	Ratan, RR (corresponding author), Burke Med Res Inst, Dept Neurol & Neurosci, White Plains, NY 10605 USA.	rratan@burke.org			NATIONAL INSTITUTE ON AGING [P01AG014930] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG014930] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Borrelli E, 2008, NEURON, V60, P961, DOI 10.1016/j.neuron.2008.10.012; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Guan JS, 2009, NATURE, V459, P55, DOI 10.1038/nature07925; Langley B, 2009, STROKE, V40, P2899, DOI 10.1161/STROKEAHA.108.540229; Mehler MF, 2008, ANN NEUROL, V64, P602, DOI 10.1002/ana.21595; Parmigiani RB, 2008, P NATL ACAD SCI USA, V105, P9633, DOI 10.1073/pnas.0803749105; Sleiman SF, 2009, EXPERT OPIN INV DRUG, V18, P573, DOI [10.1517/13543780902810345, 10.1517/13543780902810345 ]; Urdinguio RG, 2009, LANCET NEUROL, V8, P1056, DOI 10.1016/S1474-4422(09)70262-5	9	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2009	8	11					975	977		10.1016/S1474-4422(09)70276-5	http://dx.doi.org/10.1016/S1474-4422(09)70276-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	513GC	19833291	Green Accepted			2022-12-18	WOS:000271309600005
J	Eckstein, HH; Ringleb, P; Allenberg, JR				Eckstein, H-H; Ringleb, P.; Allenberg, J-R			Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial (vol 7, pg 893, 2008)	LANCET NEUROLOGY			English	Correction													Eckstein, Hans-Henning/AAF-9200-2022; Eckstein, Hans-Henning/AFK-1881-2022					Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0	1	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2009	8	2					135	135		10.1016/S1474-4422(08)70196-0	http://dx.doi.org/10.1016/S1474-4422(08)70196-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	398SO					2022-12-18	WOS:000262752000009
J	[Anonymous]				[Anonymous]			China's battle with stroke	LANCET NEUROLOGY			English	Editorial Material																			0	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2008	7	12					1073	1073		10.1016/S1474-4422(08)70245-X	http://dx.doi.org/10.1016/S1474-4422(08)70245-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	379KV	19007728	Bronze			2022-12-18	WOS:000261396000001
J	Wormser, GP; Halperin, JJ				Wormser, Gary P.; Halperin, John J.			Oral doxycycline for neuroborreliosis	LANCET NEUROLOGY			English	Editorial Material							LYME BORRELIOSIS; DISEASE; DIAGNOSIS		[Wormser, Gary P.] New York Med Coll, Dept Med, Div Infect Dis, Valhalla, NY 10595 USA; [Halperin, John J.] Atlantic Neurosci Inst, Summit, NJ USA	New York Medical College	Wormser, GP (corresponding author), New York Med Coll, Dept Med, Div Infect Dis, Valhalla, NY 10595 USA.	gary_wormser@nymc.edu	halperin, john/X-6433-2019	halperin, john/0000-0003-1170-1710				Aguero-Rosenfeld ME, 2005, CLIN MICROBIOL REV, V18, P484, DOI 10.1128/CMR.18.3.484-509.2005; DATTWYLER RJ, 1988, LANCET, V1, P1191; Halperin JJ, 2007, NEUROLOGY, V69, P91, DOI 10.1212/01.wnl.0000265517.66976.28; Halperin JJ, 1996, NEUROLOGY, V46, P619, DOI 10.1212/WNL.46.3.619; KRUGER H, 1990, ACTA NEUROL SCAND, V82, P59; Ljostad U, 2008, LANCET NEUROL, V7, P690, DOI 10.1016/S1474-4422(08)70119-4; Oksi J, 2007, EUR J CLIN MICROBIOL, V26, P571, DOI 10.1007/s10096-007-0340-2; SAIVIN S, 1988, CLIN PHARMACOKINET, V15, P355, DOI 10.2165/00003088-198815060-00001; STEER AC, 1983, ANN INTERN MED, V99, P767, DOI 10.7326/0003-4819-99-6-767; Wormser GP, 2006, CLIN INFECT DIS, V43, P1089, DOI 10.1086/508667	10	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2008	7	8					665	666		10.1016/S1474-4422(08)70120-0	http://dx.doi.org/10.1016/S1474-4422(08)70120-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	330VA	18567540				2022-12-18	WOS:000257969700003
J	Forsgren, L				Forsgren, Lars			Estimations of the prevalence of epilepsy in sub-Saharan Africa	LANCET NEUROLOGY			English	Editorial Material									Umea Univ Hosp, Dept Neurol, S-90185 Umea, Sweden	Umea University	Forsgren, L (corresponding author), Umea Univ Hosp, Dept Neurol, S-90185 Umea, Sweden.	lars.forsgren@neuro.umu.se						Edwards T, 2008, LANCET NEUROL, V7, P50, DOI 10.1016/S1474-4422(07)70292-2; Forsgren L., 2004, TREATM EP 2 ED, P21; Preux PM, 2005, LANCET NEUROL, V4, P21, DOI 10.1016/S1474-4422(04)00963-9; Scott RA, 2001, B WORLD HEALTH ORGAN, V79, P344; TEKLEHAIMANOT R, 1990, EPILEPSY RES, V7, P230, DOI 10.1016/0920-1211(90)90020-V; World Health Organization, 2001, WORLD HLTH REPORT 20	6	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2008	7	1					21	22		10.1016/S1474-4422(07)70295-8	http://dx.doi.org/10.1016/S1474-4422(07)70295-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	247FO	18068521				2022-12-18	WOS:000252063300013
J	Hankey, GJ				Hankey, GJ			Neuroprotection for acute ischaemic stroke: hope reignited	LANCET NEUROLOGY			English	Editorial Material							TRIALS; RECOMMENDATIONS		Royal Perth Hosp, Dept Neurol, Perth, WA, Australia	Royal Perth Hospital; University of Western Australia	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, Perth, WA, Australia.	gjhankey@cyllene.uwa.edu.au	Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				Davalos A, 2002, STROKE, V33, P2850, DOI 10.1161/01.STR.0000038691.03334.71; Donnan GA, 2003, STROKE, V34, P1041, DOI 10.1161/01.STR.0000063142.39828.67; Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; HANKEY GJ, 2005, STROKE TREATMENT PRE; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213	7	10	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2006	5	4					287	288		10.1016/S1474-4422(06)70387-8	http://dx.doi.org/10.1016/S1474-4422(06)70387-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	029CI	16545741				2022-12-18	WOS:000236535200004
J	de Leon, M; Klunk, W				de Leon, M; Klunk, W			Biomarkers for the early diagnosis of Alzheimer' disease	LANCET NEUROLOGY			English	Editorial Material							COGNITIVE DECLINE; FDG-PET; DEMENTIA; TOMOGRAPHY; PREDICTION; ATROPHY		NYU, Sch Med, New York, NY 10011 USA; Univ Pittsburgh, Pittsburgh, PA USA	New York University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	de Leon, M (corresponding author), NYU, Sch Med, New York, NY 10011 USA.	mony.deleon@med.nyu.edu	de Leon, Mony/AAP-7890-2021	Klunk, William/0000-0001-5512-0251; de Leon, Mony/0000-0003-2245-4380	NIA NIH HHS [R01 AG022374] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG022374] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Buerger K, 2002, ARCH NEUROL-CHICAGO, V59, P1267, DOI 10.1001/archneur.59.8.1267; Chetelat G, 2003, NEUROLOGY, V60, P1374, DOI 10.1212/01.WNL.0000055847.17752.E6; de Leon MJ, 2001, P NATL ACAD SCI USA, V98, P10966, DOI 10.1073/pnas.191044198; DELEON MJ, 1989, LANCET, V2, P672; DELEON MJ, 2005, NEUROBIOL AGING 0825; den Heijer T, 2006, ARCH GEN PSYCHIAT, V63, P57, DOI 10.1001/archpsyc.63.1.57; FAGAN AM, 2005, ANN NEUROL      1221; Fox NC, 2004, LANCET, V363, P392, DOI 10.1016/S0140-6736(04)15441-X; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Mosconi L, 2004, NEUROLOGY, V63, P2332, DOI 10.1212/01.WNL.0000147469.18313.3B; Rusinek H, 2003, RADIOLOGY, V229, P691, DOI 10.1148/radiol.2293021299; Shoghi-Jadid K, 2002, AM J GERIAT PSYCHIAT, V10, P24, DOI 10.1176/appi.ajgp.10.1.24; Silverman DHS, 2001, JAMA-J AM MED ASSOC, V286, P2120, DOI 10.1001/jama.286.17.2120; Verhoeff NPLG, 2004, AM J GERIAT PSYCHIAT, V12, P584, DOI 10.1176/appi.ajgp.12.6.584	15	10	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2006	5	3					198	199		10.1016/S1474-4422(06)70357-X	http://dx.doi.org/10.1016/S1474-4422(06)70357-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	016PS	16488371				2022-12-18	WOS:000235632900002
J	Pilcher, H				Pilcher, H			Parkin implicated in sporadic Parkinson's disease	LANCET NEUROLOGY			English	News Item																			0	10	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2005	4	12					798	798		10.1016/S1474-4422(05)70237-4	http://dx.doi.org/10.1016/S1474-4422(05)70237-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	989SG	16323352				2022-12-18	WOS:000233693500009
J	Manno, EM				Manno, EM			Magnesium sulphate and cerebral vasospasm	LANCET NEUROLOGY			English	Editorial Material									Mayo Clin & Mayo Fdn, Sch Med, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic	Manno, EM (corresponding author), Mayo Clin & Mayo Fdn, Sch Med, Dept Neurol, Rochester, MN 55905 USA.	Manno.Edward@mayo.edu						Lees KR, 2004, LANCET, V363, P439, DOI 10.1016/S0140-6736(04)15490-1; Macdonald RL, 2004, J NEUROSURG, V100, P106, DOI 10.3171/jns.2004.100.1.0106; McKee JA, 2005, CRIT CARE MED, V33, P661, DOI 10.1097/01.ccm.0000156293.35868.b2; RINKEL GJ, 2005, COCHRANE DB SYST REV, V1; van den Bergh WM, 2005, STROKE, V36, P1011, DOI 10.1161/01.STR.0000160801.96998.57	5	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2005	4	6					329	330		10.1016/S1474-4422(05)70080-6	http://dx.doi.org/10.1016/S1474-4422(05)70080-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	931EQ	15907735				2022-12-18	WOS:000229469000004
J	Facheris, M; Mancuso, M; Scaravilli, T; Bonifati, DM				Facheris, M; Mancuso, M; Scaravilli, T; Bonifati, DM			Neurology residency training in Europe: an Italian perspective	LANCET NEUROLOGY			English	Editorial Material							PROGRAMS; QUALITY	Education is the most important part of medical-science training. Assessment of training programmes and examination of trainees' skills are necessary to guarantee that trainees develop competence. Training programmes vary between and within countries. The impending integration of the medical-job market among European countries highlights the need for people training to be specialists to achieve a certain standard. Here, we review the neurological training programmes in Europe, principally those in Italy, and discuss the standardisation of the training of residents in Italy and the quality control of current residency training, or its absence, in Europe.	Univ Milan, Dept Neurosci & Biomed Technol, I-20052 Monza, Italy; Univ Pisa, Dept Neurosci, Neurol Clin, I-56100 Pisa, Italy; Univ Padua, Dept Neurosci, I-35100 Padua, Italy	University of Milan; University of Pisa; University of Padua	Facheris, M (corresponding author), Univ Milan, Dept Neurosci & Biomed Technol, Via Donizetti 106, I-20052 Monza, Italy.	maurizio.facheris@unimib.it	Mancuso, Michelangelo/K-4170-2016	Mancuso, Michelangelo/0000-0003-2738-8562				Bakshi R, 2003, J NEUROIMAGING, V13, P215, DOI 10.1177/1051228403013003002; Bartos A, 2001, EUR J NEUROL, V8, P551, DOI 10.1046/j.1468-1331.2001.00288.x; Bonifati DM, 2003, EUR J NEUROL, V10, P301, DOI 10.1046/j.1468-1331.2003.00596.x; Bradley WG, 1997, NEUROLOGY, V49, P1205, DOI 10.1212/WNL.49.5.1205; Capobianco M, 2003, LANCET NEUROL, V2, P594, DOI 10.1016/S1474-4422(03)00526-X; Corboy JR, 2002, NEUROLOGY, V58, P1454, DOI 10.1212/WNL.58.10.1454; Hooker J, 2003, LANCET NEUROL, V2, P572, DOI 10.1016/S1474-4422(03)00507-6; Keyser A, 2003, EUR J NEUROL, V10, P343, DOI 10.1046/j.1468-1331.2003.00602.x; Pontes C, 2001, EUR J NEUROL, V8, P381, DOI 10.1046/j.1468-1331.2001.00248.x	9	10	10	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2005	4	4					258	262		10.1016/S1474-4422(05)70046-6	http://dx.doi.org/10.1016/S1474-4422(05)70046-6			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	910ID	15778106				2022-12-18	WOS:000227923600018
J	Schellinger, PD; Hacke, W				Schellinger, PD; Hacke, W			Stroke: advances in therapy	LANCET NEUROLOGY			English	Editorial Material							HIGH-RISK PATIENTS; CONTROLLED-TRIAL; ENDARTERECTOMY		Univ Heidelberg, Dept Neurol, Kopfklin, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Schellinger, PD (corresponding author), Univ Heidelberg, Dept Neurol, Kopfklin, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Werner_Hacke@med.uni-heidelberg.de	Hacke, Werner/ABE-8661-2020					Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Hacke W, 2004, LANCET, V363, P768; HACKE W, 2004, STROKE; Halliday A, 2004, LANCET, V363, P1491; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	5	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2005	4	1					2	2		10.1016/S1474-4422(04)00942-1	http://dx.doi.org/10.1016/S1474-4422(04)00942-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886SZ	15620844				2022-12-18	WOS:000226250200002
J	Cantu, R				Cantu, R			Concussion severity should not be determined until all postconcussion symptoms have abated	LANCET NEUROLOGY			English	Editorial Material									Emerson Hosp, Concord, MA USA		Cantu, R (corresponding author), Emerson Hosp, Concord, MA USA.								0	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2004	3	7					437	438						2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832ZQ					2022-12-18	WOS:000222306600022
J	Cummings, JL				Cummings, JL			Fluctuations in cognitive function in dementia with Lewy bodies	LANCET NEUROLOGY			English	Editorial Material							DIAGNOSIS; CRITERIA; VALIDITY; DLB		Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cummings, JL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA.	jcummings@mednet.ucla.edu			NATIONAL INSTITUTE ON AGING [P50AG016570] Funding Source: NIH RePORTER; NIA NIH HHS [AG16570] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cummings JL, 2003, ANN NEUROL, V54, P147, DOI 10.1002/ana.10616; Ferman TJ, 2004, NEUROLOGY, V62, P181, DOI 10.1212/WNL.62.2.181; Hohl U, 2000, ARCH NEUROL-CHICAGO, V57, P347, DOI 10.1001/archneur.57.3.347; McKeith IG, 2000, NEUROLOGY, V54, P1050, DOI 10.1212/WNL.54.5.1050; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; Mega MS, 1996, NEUROLOGY, V47, P1403, DOI 10.1212/WNL.47.6.1403; Verghese J, 1999, NEUROLOGY, V53, P1974, DOI 10.1212/WNL.53.9.1974; Walker MP, 2000, NEUROLOGY, V54, P1616, DOI 10.1212/WNL.54.8.1616; Walker MP, 2000, BRIT J PSYCHIAT, V177, P252, DOI 10.1192/bjp.177.3.252	9	10	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2004	3	5					266	266		10.1016/S1474-4422(04)00728-8	http://dx.doi.org/10.1016/S1474-4422(04)00728-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817EL	15099536				2022-12-18	WOS:000221160700014
J	Love, R				Love, R			GM-CSF induced arteriogenesis: a potential treatment for stroke?	LANCET NEUROLOGY			English	News Item																			0	10	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2003	2	8					458	458		10.1016/S1474-4422(03)00478-2	http://dx.doi.org/10.1016/S1474-4422(03)00478-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	704AC	15320353				2022-12-18	WOS:000184314700011
J	Messing, A; Brenner, M				Messing, A; Brenner, M			Alexander disease: GFAP mutations unify young and old	LANCET NEUROLOGY			English	Letter									Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Univ Alabama, Dept Neurobiol, Birmingham, AL USA	University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham	Messing, A (corresponding author), Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA.							Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; Li R, 2002, INT J DEV NEUROSCI, V20, P259, DOI 10.1016/S0736-5748(02)00019-9; Namekawa M, 2002, ANN NEUROL, V52, P779, DOI 10.1002/ana.10375; Okamoto Y, 2002, J NEUROL SCI, V195, P71, DOI 10.1016/S0022-510X(01)00687-6	4	10	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2003	2	2					75	75		10.1016/S1474-4422(03)00301-6	http://dx.doi.org/10.1016/S1474-4422(03)00301-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	638BY	12849260				2022-12-18	WOS:000180550600012
J	Sharma, T				Sharma, T			Characterisation of cognitive impairment in schizophrenia	LANCET NEUROLOGY			English	Editorial Material									Clin Neurosci Res Ctr, Dartford DA1 2EN, Kent, England		Sharma, T (corresponding author), Clin Neurosci Res Ctr, 7 Twisleton Court,Priory Hill, Dartford DA1 2EN, Kent, England.	t.sharma@psychmed.org.uk						Green MF, 1996, AM J PSYCHIAT, V153, P321; Hughes C, 2003, SCHIZOPHR RES, V59, P137, DOI 10.1016/S0920-9964(01)00393-0; Riley EM, 2000, SCHIZOPHR RES, V43, P47, DOI 10.1016/S0920-9964(99)00177-2; SHARMA T, 2001, SCHIZOPHRENIA COGNIT; Turetsky BI, 2002, NEUROPSYCHOLOGY, V16, P481, DOI 10.1037//0894-4105.16.4.481	5	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2003	2	1					10	10		10.1016/S1474-4422(03)00257-6	http://dx.doi.org/10.1016/S1474-4422(03)00257-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	629DU	12849291				2022-12-18	WOS:000180035800014
J	Fins, JJ				Fins, JJ			The ethical limits of neuroscience	LANCET NEUROLOGY			English	Editorial Material							BRAIN		New York Weill Cornell Med Ctr, Div Med Eth, New York, NY 10021 USA	Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar	Fins, JJ (corresponding author), New York Weill Cornell Med Ctr, Div Med Eth, 525 E 68th St,F-173, New York, NY 10021 USA.			Fins, Joseph/0000-0002-7221-0053				CARMICHAEL M, 2002, NEWSWEEK        0624; Diefenbach G J, 1999, J Hist Neurosci, V8, P60, DOI 10.1076/jhin.8.1.60.1766; Diethelm O, 1939, AM J PSYCHIAT, V95, P1165, DOI 10.1176/ajp.95.5.1165; Fins JJ, 2000, NEUROL RES, V22, P273; Fins JJ, 2000, JAMA-J AM MED ASSOC, V283, P2392, DOI 10.1001/jama.283.18.2392; Goodman S, 2002, NATURE, V417, P677, DOI 10.1038/417677a; Michels R, 1999, NEW ENGL J MED, V340, P1427, DOI 10.1056/NEJM199905063401811; Miller FG, 1999, ARCH GEN PSYCHIAT, V56, P701, DOI 10.1001/archpsyc.56.8.701; National Bioethics Advisory Committee, 1998, RES INV PERS MENT DI; Valenstein E. S., 1986, GREAT DESPERATE CURE; 2002, ECONOMIST       0525; 2002, LANCET NEUROLOGY, V1, P137; 1972, LANCET, V7767, P69	13	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2002	1	4					213	213		10.1016/S1474-4422(02)00099-6	http://dx.doi.org/10.1016/S1474-4422(02)00099-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588KZ	12849453				2022-12-18	WOS:000177701800017
J	Bivard, A; Zhao, H; Churilov, L; Campbell, BCV; Coote, S; Yassi, N; Yan, B; Valente, M; Sharobeam, A; Balabanski, AH; Dos Santos, A; Ng, JL; Yogendrakumar, V; Ng, F; Langenberg, F; Easton, D; Warwick, A; Mackey, E; MacDonald, A; Sharma, G; Stephenson, M; Smith, K; Anderson, D; Choi, P; Thijs, V; Ma, H; Cloud, GC; Wijeratne, T; Olenko, L; Italiano, D; Davis, SM; Donnan, GA; Parsons, MW				Bivard, Andrew; Zhao, Henry; Churilov, Leonid; Campbell, Bruce C., V; Coote, Skye; Yassi, Nawaf; Yan, Bernard; Valente, Michael; Sharobeam, Angelos; Balabanski, Anna H.; Dos Santos, Angela; Ng, Jo Lyn; Yogendrakumar, Vignan; Ng, Felix; Langenberg, Francesca; Easton, Damien; Warwick, Alex; Mackey, Elizabeth; MacDonald, Amy; Sharma, Gagan; Stephenson, Michael; Smith, Karen; Anderson, David; Choi, Philip; Thijs, Vincent; Ma, Henry; Cloud, Geoffrey C.; Wijeratne, Tissa; Olenko, Liudmyla; Italiano, Dominic; Davis, Stephen M.; Donnan, Geoffrey A.; Parsons, Mark W.		TASTE-A Collaborators	Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial	LANCET NEUROLOGY			English	Article							PERFUSION COMPUTED-TOMOGRAPHY; THROMBOLYSIS; THROMBECTOMY; IMPACT	Background Mobile stroke units (MSUs) equipped with a CT scanner reduce time to thrombolytic treatment and improve patient outcomes. We tested the hypothesis that tenecteplase administered in an MSU would result in superior reperfusion at hospital arrival, when compared with alteplase. Methods The TASTE-A trial is a phase 2, randomised, open-label trial at the Melbourne MSU and five tertiary hospitals in Melbourne, VIC, Australia. Patients (aged >= 18 years) with ischaemic stroke who were eligible for thrombolytic treatment were randomly allocated in the MSU to receive, within 4.5 h of symptom onset, either standard-of-care alteplase (0.9 mg/kg [maximum 90 mg], administered intravenously with 10% as a bolus over 1 min and 90% as an infusion over 1 h), or the investigational product tenecteplase (0.25 mg/kg [maximum 25 mg], administered as an intravenous bolus over 10 s), before being transported to hospital for ongoing care. The primary outcome was the volume of the perfusion lesion on arrival at hospital, assessed by CT-perfusion imaging. Secondary safety outcomes were modified Rankin Scale (mRS) score of 5 or 6 at 90 days, symptomatic intracerebral haemorrhage and any haemorrhage within 36 h, and death at 90 days. Assessors were masked to treatment allocation. Analysis was by intention-to-treat. The trial was registered with ClinicalTrials.gov, NCT04071613, and is completed. Findings Between June 20, 2019, and Nov 16, 2021, 104 patients were enrolled and randomly allocated to receive either tenecteplase (n=55) or alteplase (n=49). The median age of patients was 73 years (IQR 61-83), and the median NIHSS at baseline was 8 (5-14). On arrival at the hospital, the perfusion lesion volume was significantly smaller with tenecteplase (median 12 mL [IQR 3-28]) than with alteplase (35 mL [18-76]; adjusted incidence rate ratio 0.55, 95% CI 0.37-0.81; p=0.0030). At 90 days, an mRS of 5 or 6 was reported in eight (15%) patients allocated to tenecteplase and ten (20%) patients allocated to alteplase (adjusted odds ratio [aOR] 0.70, 95% CI 0.23-2.16; p=0.54). Five (9%) patients allocated to tenecteplase and five (10%) patients allocated to alteplase died from any cause at 90 days (aOR 1.12, 95% CI 0.26-4.90; p=0.88). No cases of symptomatic intracerebral haemorrhage were reported within 36 h with either treatment. Up to day 90, 13 serious adverse events were noted: five (5%) in patients treated with tenecteplase, and eight (8%) in patients treated with alteplase. Interpretation Treatment with tenecteplase on the MSU in Melbourne resulted in a superior rate of early reperfusion compared with alteplase, and no safety concerns were noted. This trial provides evidence to support the use of tenecteplase and MSUs in an optimal model of stroke care. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[Bivard, Andrew; Zhao, Henry; Churilov, Leonid; Campbell, Bruce C., V; Coote, Skye; Yassi, Nawaf; Yan, Bernard; Valente, Michael; Sharobeam, Angelos; Balabanski, Anna H.; Dos Santos, Angela; Ng, Jo Lyn; Yogendrakumar, Vignan; Ng, Felix; Langenberg, Francesca; Easton, Damien; Warwick, Alex; Mackey, Elizabeth; MacDonald, Amy; Sharma, Gagan; Olenko, Liudmyla; Italiano, Dominic; Davis, Stephen M.; Donnan, Geoffrey A.; Parsons, Mark W.] Univ Melbourne, Royal Melbourne Hosp, Melbourne Brain Ctr, Dept Med & Neurol, Parkville, Vic, Australia; [Bivard, Andrew; Zhao, Henry; Campbell, Bruce C., V; Coote, Skye; Yassi, Nawaf; Yan, Bernard; Valente, Michael; Sharobeam, Angelos; Balabanski, Anna H.; Dos Santos, Angela; Ng, Jo Lyn; Stephenson, Michael; Smith, Karen; Anderson, David] Ambulance Victoria, Melbourne, Vic, Australia; [Yassi, Nawaf] Walter & Eliza Hall Inst Med Res, Populat Hlth & Immun Div, Parkville, Vic, Australia; [Balabanski, Anna H.; Dos Santos, Angela; Cloud, Geoffrey C.] Alfred Hlth, Dept Neurol, Melbourne, Vic, Australia; [Choi, Philip] Box Hill Hosp, Dept Neurol, Melbourne, Vic, Australia; [Thijs, Vincent] Austin Hlth, Dept Neurol, Heidelberg, Vic, Australia; [Ma, Henry] Monash Univ, Sch Clin Sci Monash Hlth, Dept Med, Melbourne, Vic, Australia; [Smith, Karen; Cloud, Geoffrey C.] Monash Univ, Cent Clin Sch, Dept Neurosci, Melbourne, Vic, Australia; [Wijeratne, Tissa] Western Hlth, Dept Neurol, Melbourne, Vic, Australia; [Parsons, Mark W.] Ingham Inst Appl Med Res, Liverpool Hosp, South Western Sydney Clin Sch, Dept Neurol, Liverpool, NSW 2170, Australia	Royal Melbourne Hospital; University of Melbourne; Walter & Eliza Hall Institute; Box Hill Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; Ingham Institute for Applied Medical Research; Liverpool Hospital	Parsons, MW (corresponding author), Ingham Inst Appl Med Res, Liverpool Hosp, South Western Sydney Clin Sch, Dept Neurol, Liverpool, NSW 2170, Australia.	abivard@unimelb.edu.au; mark.parsons@unsw.edu.au	Davis, Stephen/L-5260-2013	Davis, Stephen/0000-0003-0962-2300; Ng, Felix/0000-0001-6973-8677; Balabanski, Anna/0000-0003-3209-3101	Melbourne Academic Centre for Health	Melbourne Academic Centre for Health	Melbourne Academic Centre for Health.	Bivard A, 2017, CIRCULATION, V135, P440, DOI 10.1161/CIRCULATIONAHA.116.022582; Bivard A, 2015, BRAIN, V138, P1919, DOI 10.1093/brain/awv071; Bivard A, 2013, J STROKE, V15, P90, DOI 10.5853/jos.2013.15.2.90; Campbell BCV, 2018, NEW ENGL J MED, V378, P1573, DOI 10.1056/NEJMoa1716405; Ebinger M, 2021, JAMA-J AM MED ASSOC, V325, P454, DOI 10.1001/jama.2020.26345; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Grotta JC, 2021, NEW ENGL J MED, V385, P971, DOI 10.1056/NEJMoa2103879; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Kawano H, 2017, BRAIN, V140, P684, DOI 10.1093/brain/aww338; Mehta CR, 2011, STAT MED, V30, P3267, DOI 10.1002/sim.4102; Meretoja A, 2014, STROKE, V45, P1053, DOI 10.1161/STROKEAHA.113.002910; Parsons M, 2012, NEW ENGL J MED, V366, P1099, DOI 10.1056/NEJMoa1109842; Stroke Foundation, 2019, CLIN GUID STROK MAN; Tung EL, 2017, STROKE, V48, P2488, DOI 10.1161/STROKEAHA.117.017182; Turc G, 2022, JAMA NEUROL, V79, P281, DOI 10.1001/jamaneurol.2021.5321; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; Yang PF, 2020, NEW ENGL J MED, V382, P1981, DOI 10.1056/NEJMoa2001123; Zhao H, 2020, STROKE, V51, P922, DOI 10.1161/STROKEAHA.119.027843	19	9	9	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2022	21	6					520	527		10.1016/S1474-4422(22)00171-5	http://dx.doi.org/10.1016/S1474-4422(22)00171-5			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3Z0EK	35525251				2022-12-18	WOS:000844093900015
J	Punga, AR; Maddison, P; Heckmann, JM; Guptill, JT; Evoli, A				Punga, Anna Rostedt; Maddison, Paul; Heckmann, Jeannine M.; Guptill, Jeffrey; Evoli, Amelia			Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders	LANCET NEUROLOGY			English	Article							POSITIVE MYASTHENIA-GRAVIS; REPETITIVE NERVE-STIMULATION; LATE-ONSET MYASTHENIA; SINGLE-FIBER EMG; QUALITY-OF-LIFE; CLINICAL CHARACTERISTICS; FOLLOW-UP; PROTEIN 4; MUSK; AUTOANTIBODIES	Autoimmune neuromuscular junction disorders are rare. However, myasthenia gravis is being increasingly recognised in people older than 50 years. In the past 5-10 years, epidemiological studies worldwide suggest an incidence of acetylcholine receptor antibody-positive myasthenia gravis of up to 29 cases per 1 million people per year. Muscle-specific tyrosine kinase antibody-positive myasthenia gravis and Lambert-Eaton myasthenic syndrome are about 20 times less common. Several diagnostic methods are available for autoimmune neuromuscular junction disorders, including serological antibody, electrophysiological, imaging, and pharmacological tests. The course of disease can be followed up with internationally accepted clinical scores or patient-reported outcome measures. For prognostic purposes, determining whether the disease is paraneoplastic is of great importance, as myasthenia gravis can be associated with thymoma and Lambert-Eaton myasthenic syndrome with small-cell lung cancer. However, despite well defined diagnostic parameters to classify patients into subgroups, objective biomarkers for use in the clinic or in clinical trials to predict the course of myasthenia gravis and Lambert-Eaton myasthenic syndrome are needed.	[Punga, Anna Rostedt] Uppsala Univ, Dept Med Sci, Clin Neurophysiol, S-75185 Uppsala, Sweden; [Maddison, Paul] Queens Med Ctr, Dept Neurol, Nottingham, England; [Heckmann, Jeannine M.] Univ Cape Town, Dept Med, Div Neurol, Cape Town, South Africa; [Guptill, Jeffrey] Duke Univ, Dept Neurol, Neuromuscular Med, Med Ctr, Durham, NC USA; [Evoli, Amelia] Catholic Univ, Dept Neurol, Rome, Italy	Uppsala University; University of Nottingham; University of Cape Town; Duke University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Punga, AR (corresponding author), Uppsala Univ, Dept Med Sci, Clin Neurophysiol, S-75185 Uppsala, Sweden.	annarostedtpunga@gmail.Com		Heckmann, Jeannine/0000-0002-8999-718X				Amandusson A, 2017, J CLIN NEUROPHYSIOL, V34, P400, DOI 10.1097/WNP.0000000000000398; Barnett C, 2018, NEUROL CLIN, V36, P339, DOI 10.1016/j.ncl.2018.01.006; Baruca M, 2016, MUSCLE NERVE, V54, P1034, DOI 10.1002/mus.25174; Basta I, 2018, MUSCLE NERVE, V58, P708, DOI 10.1002/mus.26132; Boldingh MI, 2015, NEUROEPIDEMIOLOGY, V44, P221, DOI 10.1159/000431036; Breiner A, 2016, NEUROMUSCULAR DISORD, V26, P41, DOI 10.1016/j.nmd.2015.10.009; Burns TM, 2016, MUSCLE NERVE, V53, P3, DOI 10.1002/mus.24953; Chatzistefanou KI, 2009, OPHTHALMOLOGY, V116, P2236, DOI 10.1016/j.ophtha.2009.04.039; CHEN WH, 1993, J NEUROL NEUROSUR PS, V56, P382, DOI 10.1136/jnnp.56.4.382; Chuang WY, 2014, J AUTOIMMUN, V52, P122, DOI 10.1016/j.jaut.2013.12.006; Cortes-Vicente E, 2020, NEUROLOGY, V94, pE1171, DOI 10.1212/WNL.0000000000008903; Cortes-Vicente E, 2016, JAMA NEUROL, V73, P1099, DOI 10.1001/jamaneurol.2016.2032; Cron MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00539; Cruz PMR, 2015, JAMA NEUROL, V72, P642, DOI 10.1001/jamaneurol.2015.0203; de Meel RHP, 2019, EUR J NEUROL, V26, P947, DOI 10.1111/ene.13867; de Meel RHP, 2020, NEUROLOGY, V94, pE1693, DOI 10.1212/WNL.0000000000009306; de Meel RHP, 2019, NEUROMUSCULAR DISORD, V29, P664, DOI 10.1016/j.nmd.2019.07.006; Ding JQ, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01805-1; Dragin N, 2016, J CLIN INVEST, V126, P1525, DOI 10.1172/JCI81894; Dubey D, 2020, ANN NEUROL, V87, P659, DOI 10.1002/ana.25708; Europa TA, 2019, NEUROMUSCULAR DISORD, V29, P381, DOI 10.1016/j.nmd.2019.03.009; Fang F, 2015, J INTERN MED, V277, P594, DOI 10.1111/joim.12310; Farrugia ME, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00604; Feng XL, 2020, EUR NEUROL, V83, P182, DOI 10.1159/000507853; Gasperi C, 2014, NEUROLOGY, V82, P1976, DOI 10.1212/WNL.0000000000000478; Gattellari M, 2012, EUR J NEUROL, V19, P1413, DOI 10.1111/j.1468-1331.2012.03698.x; Giannoccaro MP, 2020, NEUROLOGY, V95, pE1800, DOI 10.1212/WNL.0000000000010619; Giannoccaro MP, 2020, J NEUROL, V267, P739, DOI 10.1007/s00415-019-09631-3; Gilhus NE, 2015, LANCET NEUROL, V14, P1023, DOI 10.1016/S1474-4422(15)00145-3; Gregersen PK, 2012, ANN NEUROL, V72, P927, DOI 10.1002/ana.23691; Guptill JT, 2011, MUSCLE NERVE, V44, P36, DOI 10.1002/mus.22006; Hacohen Y, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000057; Hansen JS, 2016, MUSCLE NERVE, V53, P73, DOI 10.1002/mus.24697; Heckmann JM, 2018, ANN NY ACAD SCI, V1412, P14, DOI 10.1111/nyas.13471; Hendricks TM, 2019, AM J OPHTHALMOL, V205, P99, DOI 10.1016/j.ajo.2019.04.017; Higuchi O, 2011, ANN NEUROL, V69, P418, DOI 10.1002/ana.22312; Huda S, 2016, MUSCLE NERVE, V54, P1023, DOI 10.1002/mus.25154; Huijbers MG, 2022, LANCET NEUROL, V21, P163, DOI 10.1016/S1474-4422(21)00357-4; Jeong A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206754; Jovandaric MZ, 2016, FETAL PEDIATR PATHOL, V35, P167, DOI 10.3109/15513815.2016.1164773; Katarzyna MZ, 2015, J NEUROL SCI, V348, P241, DOI 10.1016/j.jns.2014.12.015; Keene KR, 2021, NMR BIOMED, V34, DOI 10.1002/nbm.4407; Klimiec E, 2018, MUSCLE NERVE, V58, P153, DOI 10.1002/mus.26096; Li F, 2018, J NEUROL, V265, P2773, DOI 10.1007/s00415-018-9056-8; Li MQ, 2018, CLIN NEUROL NEUROSUR, V172, P69, DOI 10.1016/j.clineuro.2018.06.041; Liik M, 2016, CLIN NEUROPHYSIOL, V127, P3480, DOI 10.1016/j.clinph.2016.09.012; Lipka AF, 2020, NEUROLOGY, V94, pE511, DOI 10.1212/WNL.0000000000008747; Liu F, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1384-5; Lotan I, 2020, ACTA NEUROL SCAND, V142, P66, DOI 10.1111/ane.13239; Lu YR, 2020, NEUROMUSCULAR DISORD, V30, P534, DOI 10.1016/j.nmd.2020.03.012; Maddison P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67571-9; Maddison P, 2020, J NEUROIMMUNOL, V340, DOI 10.1016/j.jneuroim.2020.577149; Maddison P, 2019, NEUROEPIDEMIOLOGY, V53, P93, DOI 10.1159/000500268; Maddison P, 2017, NEUROLOGY, V88, P1334, DOI 10.1212/WNL.0000000000003794; Maggi L, 2008, J NEUROIMMUNOL, V201, P237, DOI 10.1016/j.jneuroim.2008.07.012; Makarious D, 2017, EUR J CANCER, V82, P128, DOI 10.1016/j.ejca.2017.05.041; Maniaol AH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036603; Martinka I, 2018, NEUROEPIDEMIOLOGY, V50, P153, DOI 10.1159/000487886; MATSUKI K, 1990, J CLIN INVEST, V86, P392, DOI 10.1172/JCI114724; Mombaur B, 2015, MUSCLE NERVE, V51, P533, DOI 10.1002/mus.24348; Muppidi S, 2020, LANCET NEUROL, V19, P970, DOI 10.1016/S1474-4422(20)30413-0; Muppidi Srikanth, 2017, J Clin Neuromuscul Dis, V18, P135, DOI 10.1097/CND.0000000000000156; Neumann B, 2020, NEUROLOGY, V94, pE299, DOI 10.1212/WNL.0000000000008688; Nicholson G A, 1983, Clin Exp Neurol, V19, P45; Niks EH, 2006, NEUROLOGY, V66, P1772, DOI 10.1212/01.wnl.0000218159.79769.5c; Padda SK, 2018, J THORAC ONCOL, V13, P436, DOI 10.1016/j.jtho.2017.11.118; Padua L, 2014, CLIN NEUROPHYSIOL, V125, P1270, DOI 10.1016/j.clinph.2013.11.005; Park KH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193723; Park SY, 2016, J CLIN NEUROL, V12, P340, DOI 10.3988/jcn.2016.12.3.340; Pedersen EG, 2013, EUR J NEUROL, V20, P309, DOI 10.1111/j.1468-1331.2012.03850.x; Pevzner A, 2012, J NEUROL, V259, P427, DOI 10.1007/s00415-011-6194-7; Popperud TH, 2017, EUR J PAEDIATR NEURO, V21, P312, DOI 10.1016/j.ejpn.2016.09.001; Priola AM, 2014, CLIN RADIOL, V69, pE230, DOI 10.1016/j.crad.2014.01.005; Punga AR, 2020, CLIN NEUROPHYS PRACT, V5, P46, DOI 10.1016/j.cnp.2020.01.002; Punga AR, 2015, J NEUROL SCI, V356, P90, DOI 10.1016/j.jns.2015.06.019; Punga T, 2016, J NEUROIMMUNOL, V292, P21, DOI 10.1016/j.jneuroim.2016.01.003; Punga T, 2014, ANN CLIN TRANSL NEUR, V1, P49, DOI 10.1002/acn3.24; Rakocevic G, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0891-5; Rautenbach RM, 2017, J NEURO-OPHTHALMOL, V37, P414, DOI 10.1097/WNO.0000000000000534; Renton AE, 2015, JAMA NEUROL, V72, P396, DOI 10.1001/jamaneurol.2014.4103; Richards J, 2017, NEUROMUSCULAR DISORD, V27, P417, DOI 10.1016/j.nmd.2017.01.023; Rivner MH, 2018, NEUROL CLIN, V36, P293, DOI 10.1016/j.ncl.2018.01.004; Rodolico Carmelo, 2016, J Neuromuscul Dis, V3, P413; Romi F, 2000, ARCH NEUROL-CHICAGO, V57, P1596, DOI 10.1001/archneur.57.11.1596; Roper J, 2017, J EMERG MED, V53, P843, DOI 10.1016/j.jemermed.2017.06.009; Ruiter AM, 2020, NEUROMUSCULAR DISORD, V30, P631, DOI 10.1016/j.nmd.2020.06.010; Sabater L, 2008, NEUROLOGY, V70, P924, DOI 10.1212/01.wnl.0000281663.81079.24; Sabre L, 2019, ANN CLIN TRANSL NEUR, V6, P243, DOI 10.1002/acn3.692; Sabre L, 2018, J NEUROIMMUNOL, V321, P164, DOI 10.1016/j.jneuroim.2018.05.003; Sanders DB, 2021, MUSCLE NERVE, V63, P209, DOI 10.1002/mus.27120; Santos E, 2018, NEUROMUSCULAR DISORD, V28, P150, DOI 10.1016/j.nmd.2017.11.014; Santos E, 2016, MUSCLE NERVE, V54, P413, DOI 10.1002/mus.25068; Sipila JOT, 2019, J NEUROL SCI, V407, DOI 10.1016/j.jns.2019.116520; Sivadasan A, 2019, ANN INDIAN ACAD NEUR, V22, P464, DOI 10.4103/aian.AIAN_197_19; Sussman Jon, 2015, Pract Neurol, V15, P199, DOI 10.1136/practneurol-2015-001126; Szczudlik P, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.553626; Thomsen JLS, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.596382; Titulaer MJ, 2008, J CLIN ONCOL, V26, P4276, DOI 10.1200/JCO.2008.17.5133; Titulaer MJ, 2011, J CLIN ONCOL, V29, P902, DOI 10.1200/JCO.2010.32.0440; Townsel C, 2016, AJP REP, V6, pE133, DOI 10.1055/s-0036-1579624; Valko Y, 2016, NEUROLOGY, V86, P660, DOI 10.1212/WNL.0000000000002383; Verschuuren JJ, 2022, LANCET NEUROL, V21, P189, DOI 10.1016/S1474-4422(21)00463-4; Verschuuren JJGM, 2010, AUTOIMMUNITY, V43, P344, DOI 10.3109/08916931003602130; Verwijst J, 2021, EUR J NEUROL, V28, P1706, DOI 10.1111/ene.14730; Westerberg E, 2020, NEUROMUSCULAR DISORD, V30, P815, DOI 10.1016/j.nmd.2020.08.355; Westerberg E, 2020, BRAIN BEHAV, V10, DOI 10.1002/brb3.1819; Wirtz PW, 2004, J NEUROL, V251, P1255, DOI 10.1007/s00415-004-0528-7; Wirtz PW, 2004, NEUROLOGY, V63, P397, DOI 10.1212/01.WNL.0000130254.27019.14; Wong SH, 2016, J NEURO-OPHTHALMOL, V36, P252, DOI 10.1097/WNO.0000000000000350; Xu L, 2020, MUSCLE NERVE, V61, P226, DOI 10.1002/mus.26745; Yang XL, 2019, AM J OTOLARYNG, V40, P292, DOI 10.1016/j.amjoto.2018.11.002; Zhang B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091816; Zhang B, 2012, ARCH NEUROL-CHICAGO, V69, P445, DOI 10.1001/archneurol.2011.2393; Zhong HH, 2020, J NEUROIMMUNOL, V348, DOI 10.1016/j.jneuroim.2020.577383; Zieda A, 2018, EUR J NEUROL, V25, P519, DOI 10.1111/ene.13535; Zisimopoulou P, 2014, J AUTOIMMUN, V52, P139, DOI 10.1016/j.jaut.2013.12.004	116	9	9	24	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2022	21	2					176	188		10.1016/S1474-4422(21)00297-0	http://dx.doi.org/10.1016/S1474-4422(21)00297-0			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZT4ER	35065040				2022-12-18	WOS:000769111800018
J	Laumann, TO; Ortega, M; Hoyt, CR; Seider, NA; Snyder, AZ; Dosenbach, NUF				Laumann, Timothy O.; Ortega, Mario; Hoyt, Catherine R.; Seider, Nicole A.; Snyder, Abraham Z.; Dosenbach, Nico U. F.		Brain Network Plasticity Grp	Brain network reorganisation in an adolescent after bilateral perinatal strokes	LANCET NEUROLOGY			English	Letter									[Laumann, Timothy O.; Ortega, Mario; Hoyt, Catherine R.; Seider, Nicole A.; Snyder, Abraham Z.; Dosenbach, Nico U. F.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Snyder, Abraham Z.; Dosenbach, Nico U. F.] Washington Univ, Dept Radiol, St Louis, MO 63110 USA; [Laumann, Timothy O.] Washington Univ, Dept Psychiat, St Louis, MO 63110 USA; [Dosenbach, Nico U. F.] Washington Univ, Dept Biomed Engn, St Louis, MO 63110 USA; [Dosenbach, Nico U. F.] Washington Univ, Dept Pediat, St Louis, MO 63110 USA; [Hoyt, Catherine R.; Dosenbach, Nico U. F.] Washington Univ, Program Occupat Therapy, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Laumann, TO (corresponding author), Washington Univ, Dept Neurol, St Louis, MO 63110 USA.	laumannt@wustl.edu	Hoyt, Catherine/AAV-6193-2021	Hoyt, Catherine/0000-0002-3398-9439; Laumann, Timothy/0000-0002-0428-427X; Gilmore, Adrian/0000-0001-8910-5009				Benton A., 2000, HIST NOTES REORGANIZ, P3; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Gordon EM, 2017, NEURON, V95, P791, DOI 10.1016/j.neuron.2017.07.011; Gottesman RF, 2006, STROKE, V37, P2306, DOI 10.1161/01.STR.0000236024.68020.3a; Laumann TO, FUNCTIONAL SYSTEM AR; Lee J, 2005, ANN NEUROL, V58, P303, DOI 10.1002/ana.20557; Newbold DJ, 2020, NEURON, V107, P580, DOI 10.1016/j.neuron.2020.05.007; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Smyser CD, 2010, CEREB CORTEX, V20, P2852, DOI 10.1093/cercor/bhq035	10	9	9	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					255	256		10.1016/S1474-4422(21)00062-4	http://dx.doi.org/10.1016/S1474-4422(21)00062-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33743230	Bronze			2022-12-18	WOS:000630325700008
J	Walgaard, C; Jacobs, BC; Lingsma, HF; Steyerberg, EW; van den Berg, B; Doets, AY; Leonhard, SE; Verboon, C; Huizinga, R; Drenthen, J; Arends, S; Budde, IK; Kleyweg, RP; Kuitwaard, K; van der Meulen, MFG; Samijn, JPA; Vermeij, FH; Kuks, JBM; van Dijk, GW; Wirtz, PW; Eftimov, F; van der Kooi, AJ; Garssen, MPJ; Gijsbers, CJ; de Rijk, MC; Visser, LH; Blom, RJ; Linssen, WHJP; van der Kooi, EL; Verschuuren, JJGM; van Koningsveld, R; Dieks, RJG; Gilhuis, HJ; Jellema, K; van der Ree, TC; Bienfait, HME; Faber, CG; Lovenich, H; van Engelen, BGM; Groen, RJ; Merkies, ISJ; van Oosten, BW; van der Pol, WL; van der Meulen, WDM; Badrising, UA; Stevens, M; Breukelman, AJJ; Zwetsloot, CP; van der Graaff, MM; Wohlgemuth, M; Hughes, RAC; Cornblath, DR; van Doorn, PA				Walgaard, Christa; Jacobs, Bart C.; Lingsma, Hester F.; Steyerberg, Ewout W.; van den Berg, Bianca; Doets, Alexandra Y.; Leonhard, Sonja E.; Verboon, Christine; Huizinga, Ruth; Drenthen, Judith; Arends, Samuel; Budde, Ilona Kleine; Kleyweg, Ruud P.; Kuitwaard, Krista; van der Meulen, Marjon F. G.; Samijn, Johnny P. A.; Vermeij, Frederique H.; Kuks, Jan B. M.; van Dijk, Gert W.; Wirtz, Paul W.; Eftimov, Filip; van der Kooi, Anneke J.; Garssen, Marcel P. J.; Gijsbers, Cees J.; de Rijk, Maarten C.; Visser, Leo H.; Blom, Roderik J.; Linssen, Wim H. J. P.; van der Kooi, Elly L.; Verschuuren, Jan J. G. M.; van Koningsveld, Rinske; Dieks, Rita J. G.; Gilhuis, H. Job; Jellema, Korne; van der Ree, Taco C.; Bienfait, Henriette M. E.; Faber, Catharina G.; Lovenich, Harry; van Engelen, Baziel G. M.; Groen, Rutger J.; Merkies, Ingemar S. J.; van Oosten, Bob W.; van der Pol, W. Ludo; van der Meulen, Willem D. M.; Badrising, Umesh A.; Stevens, Martijn; Breukelman, Albert-Jan J.; Zwetsloot, Casper P.; van der Graaff, Maaike M.; Wohlgemuth, Marielle; Hughes, Richard A. C.; Cornblath, David R.; van Doorn, Pieter A.		Dutch GBS Study Grp	Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial	LANCET NEUROLOGY			English	Article							PLASMA-EXCHANGE; INFECTIONS; VALIDATION; DIAGNOSIS	Background Treatment with one standard dose (2 g/kg) of intravenous immunoglobulin is insufficient in a proportion of patients with severe Guillain-Barre syndrome. Worldwide, around 25% of patients severely affected with the syndrome are given a second intravenous immunoglobulin dose (SID), although it has not been proven effective. We aimed to investigate whether a SID is effective in patients with Guillain-Barre syndrome with a predicted poor outcome. Methods In this randomised, double-blind, placebo-controlled trial (SID-GBS), we included patients (>= 12 years) with Guillain-Barre syndrome admitted to one of 59 participating hospitals in the Netherlands. Patients were included on the first day of standard intravenous immunoglobulin treatment (2 g/kg over 5 days). Only patients with a poor prognosis (score of >= 6) according to the modified Erasmus Guillain-Barre syndrome Outcome Score were randomly assigned, via block randomisation stratified by centre, to SID (2 g/kg over 5 days) or to placebo, 7-9 days after inclusion. Patients, outcome adjudicators, monitors, and the steering committee were masked to treatment allocation. The primary outcome measure was the Guillain-Barre syndrome disability score 4 weeks after inclusion. All patients in whom allocated trial medication was started were included in the modified intention-to-treat analysis. Findings Between Feb 16, 2010, and June 5, 2018, 327 of 339 patients assessed for eligibility were included. 112 had a poor prognosis. Of those, 93 patients with a poor prognosis were included in the modified intention-to-treat analysis: 49 (53%) received SID and 44 (47%) received placebo. The adjusted common odds ratio for improvement on the Guillain-Barre syndrome disability score at 4 weeks was 1.4 (95% CI 0.6-3.3; p=0.45). Patients given SID had more serious adverse events (35% vs 16% in the first 30 days), including thromboembolic events, than those in the placebo group. Four patients died in the intervention group (13-24 weeks after randomisation). Interpretation Our study does not provide evidence that patients with Guillain-Barre syndrome with a poor prognosis benefit from a second intravenous immunoglobulin course; moreover, it entails a risk of serious adverse events. Therefore, a second intravenous immunoglobulin course should not be considered for treatment of Guillain-Barre syndrome because of a poor prognosis. The results indicate the need for treatment trials with other immune modulators in patients severely affected by Guillain-Barre syndrome. Funding Prinses Beatrix Spierfonds and Sanquin Plasma Products. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Walgaard, Christa; Jacobs, Bart C.; van den Berg, Bianca; Doets, Alexandra Y.; Leonhard, Sonja E.; Verboon, Christine; Drenthen, Judith; Arends, Samuel; Kuitwaard, Krista; van Doorn, Pieter A.] Erasmus MC Univ Med Ctr, Dept Neurol, NL-3015 GD Rotterdam, Netherlands; [Jacobs, Bart C.; Huizinga, Ruth] Erasmus MC Univ Med Ctr, Dept Immunol, Rotterdam, Netherlands; [Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Steyerberg, Ewout W.] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands; [Verschuuren, Jan J. G. M.; Badrising, Umesh A.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands; [van den Berg, Bianca; Visser, Leo H.; Wohlgemuth, Marielle] Elisabeth TweeSteden Hosp, Dept Neurol, Tilburg, Netherlands; [Budde, Ilona Kleine] Sanquin Plasma Prod, Med Dept, Amsterdam, Netherlands; [Kleyweg, Ruud P.; Kuitwaard, Krista] Albert Schweitzer Hosp, Dept Neurol, Dordrecht, Netherlands; [van der Meulen, Marjon F. G.] St Antonius Hosp, Dept Neurol, Nieuwegein, Netherlands; [Samijn, Johnny P. A.] Maasstad Hosp, Dept Neurol, Rotterdam, Netherlands; [Vermeij, Frederique H.; Gijsbers, Cees J.] Franciscus & Vlietland Hosp, Dept Neurol, Rotterdam, Netherlands; [Kuks, Jan B. M.] Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [van Dijk, Gert W.] Canisius Wilhelmina Hosp, Dept Neurol, Nijmegen, Netherlands; [Wirtz, Paul W.] Haga Hosp, Dept Neurol, The Hague, Netherlands; [Eftimov, Filip; van der Kooi, Anneke J.] Univ Amsterdam, Dept Neurol, Amsterdam UMC, Amsterdam, Netherlands; [Garssen, Marcel P. J.] Jeroen Bosch Hosp, Dept Neurol, Den Bosch, Netherlands; [de Rijk, Maarten C.] Catharina Hosp, Dept Neurol, Eindhoven, Netherlands; [Blom, Roderik J.] Diakonessen Hosp, Dept Neurol, Utrecht, Netherlands; [Linssen, Wim H. J. P.] Onze Lieve Vrouwen Gasthuis West, Dept Neurol, Amsterdam, Netherlands; [Linssen, Wim H. J. P.] Zaans Med Ctr, Zaandam, Netherlands; [van der Kooi, Elly L.] Leeuwarden Med Ctr, Dept Neurol, Leeuwarden, Netherlands; [van Koningsveld, Rinske] Elkerliek Hosp, Dept Neurol, Helmond, Netherlands; [Dieks, Rita J. G.] Ropke Zweers Hosp, Dept Neurol, Hardenberg, Netherlands; [Gilhuis, H. Job] Reinier de Graaf Hosp, Dept Neurol, Delft, Netherlands; [Jellema, Korne; Groen, Rutger J.] Haaglanden Med Ctr, Dept Neurol, The Hague, Netherlands; [van der Ree, Taco C.] Dijklander Hosp, Dept Neurol, Hoorn, Netherlands; [Bienfait, Henriette M. E.; Merkies, Ingemar S. J.] Spaarne Gasthuis, Dept Neurol, Haarlem, Netherlands; [Faber, Catharina G.; Merkies, Ingemar S. J.] Maastricht Univ, Dept Neurol, Med Ctr, Maastricht, Netherlands; [Lovenich, Harry] St Jans Hosp, Dept Neurol, Weert, Netherlands; [van Engelen, Baziel G. M.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, Nijmegen, Netherlands; [van Oosten, Bob W.] Amsterdam Univ Med Ctr, Dept Neurol, VUmc, Amsterdam, Netherlands; [van der Pol, W. Ludo] Univ Med Ctr Utrecht, Dept Neurol, Utrecht, Netherlands; [van der Meulen, Willem D. M.] Rode Kruis Hosp, Dept Neurol, Beverwijk, Netherlands; [Badrising, Umesh A.] van Weei Bethesda Hosp, Dept Neurol, Dirksland, Netherlands; [Stevens, Martijn] Tergooi Hosp, Dept Neurol, Blaricum, Netherlands; [Breukelman, Albert-Jan J.] ZorgSaam Hosp, Dept Neurol, Terneuzen, Netherlands; [Zwetsloot, Casper P.] Dijklander Hosp, Dept Neurol, Purmerend, Netherlands; [van der Graaff, Maaike M.] Bovenlj Hosp, Dept Neurol, Amsterdam, Netherlands; [Hughes, Richard A. C.] Natl Hosp Neurol & Neurosurg, MRC Ctr Neuromuscular Dis, London, England; [Cornblath, David R.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Elisabeth-TweeSteden Ziekenhuis (ETZ); Albert Schweitzer Ziekenhuis; St. Antonius Hospital Utrecht; Maasstad Hospital; Franciscus Gasthuis; University of Groningen; Canisius-Wilhelmina Hospital; Haga Hospital; University of Amsterdam; Vrije Universiteit Amsterdam; Jeroen Bosch Ziekenhuis; Catharina Hospital; Diakonessenhuis; Medical Center Leeuwarden; Reinier de Graaf Hospital; Haaglanden Medical Center; Spaarne Hospital; Maastricht University; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Tergooi Blaricum; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Johns Hopkins University	van Doorn, PA (corresponding author), Erasmus MC Univ Med Ctr, Dept Neurol, NL-3015 GD Rotterdam, Netherlands.	p.a.vandoorn@erasmusmc.nl	Jacobs, Bart/ABE-2210-2021; van Engelen, Baziel/H-8027-2014; van Oosten, Bob/I-7152-2012	van Engelen, Baziel/0000-0001-9867-9047; van Oosten, Bob/0000-0003-4536-6201; Eftimov, Filip/0000-0002-0146-0776; van der Kooi, Anneke/0000-0002-5261-5512; Arends, Samuel/0000-0003-4279-4657	Prinses Beatrix Spierfonds; Sanquin Plasma Products	Prinses Beatrix Spierfonds; Sanquin Plasma Products	Prinses Beatrix Spierfonds and Sanquin Plasma Products.	Godoy DA, 2015, ARQ NEURO-PSIQUIAT, V73, P848, DOI 10.1590/0004-282X20150136; Ang CW, 2007, CLIN MICROBIOL INFEC, V13, P915, DOI 10.1111/j.1469-0691.2007.01765.x; Annane D, 1997, ANN NEUROL, V41, P298; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; Chevret S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001798.pub3; Farcas P, 1997, LANCET, V350, P1747, DOI 10.1016/S0140-6736(97)24050-X; Graham RC, 2006, J NEUROL NEUROSUR PS, V77, P973, DOI 10.1136/jnnp.2005.081547; Hadden RDM, 1998, ANN NEUROL, V44, P780, DOI 10.1002/ana.410440512; Hughes RAC, 1997, LANCET, V349, P225; HUGHES RAC, 1978, LANCET, V2, P750, DOI 10.1016/s0140-6736(78)92644-2; Hughes RAC, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002063.pub6; Jacobs BC, 1996, ANN NEUROL, V40, P181, DOI 10.1002/ana.410400209; Kapoor M, 2020, NEUROLOGY, V94, pE635, DOI 10.1212/WNL.0000000000008742; KLEYWEG RP, 1991, MUSCLE NERVE, V14, P1103, DOI 10.1002/mus.880141111; Kuijf ML, 2005, J NEUROL SCI, V239, P37, DOI 10.1016/j.jns.2005.07.009; Kuitwaard K, 2009, ANN NEUROL, V66, P597, DOI 10.1002/ana.21737; Leonhard SE, 2019, NAT REV NEUROL, V15, P671, DOI 10.1038/s41582-019-0250-9; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Nguyen TP, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000050; Raphael JC, 2001, J NEUROL NEUROSUR PS, V71, P235, DOI 10.1136/jnnp.71.2.235; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Ruts L, 2010, NEUROLOGY, V74, P1680, DOI 10.1212/WNL.0b013e3181e07d14; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; van den Berg B, 2014, NAT REV NEUROL, V10, P469, DOI 10.1038/nrneurol.2014.121; van den Berg B, 2014, NEUROLOGY, V82, P491, DOI 10.1212/WNL.0000000000000111; VAN KR, 2004, LANCET, V363, P192; van Leeuwen N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211404; Verboon C, 2020, J NEUROL NEUROSUR PS, V91, P113, DOI 10.1136/jnnp-2019-321496; Verboon C, 2019, NEUROLOGY, V93, pE59, DOI 10.1212/WNL.0000000000007719; Walgaard C, 2011, Neurology, V76, P968, DOI 10.1212/WNL.0b013e3182104407; Walgaard C, 2018, J PERIPHER NERV SYST, V23, P210, DOI 10.1111/jns.12286; Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1	32	9	10	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					275	283		10.1016/S1474-4422(20)30494-4	http://dx.doi.org/10.1016/S1474-4422(20)30494-4			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	33743237	Green Published			2022-12-18	WOS:000630325700018
J	Li, S; Le, WD				Li, Song; Le, Weidong			Parkinson's disease in traditional Chinese medicine	LANCET NEUROLOGY			English	Editorial Material													Li, Song/C-6701-2014	Li, Song/0000-0003-2713-9136					0	9	9	2	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2021	20	4					262	262		10.1016/S1474-4422(19)30224-8	http://dx.doi.org/10.1016/S1474-4422(19)30224-8		MAR 2021	1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY8ZN	31182383				2022-12-18	WOS:000630325700023
J	Masters, CL				Masters, Colin L.			Major risk factors for Alzheimer's disease: age and genetics	LANCET NEUROLOGY			English	Editorial Material									[Masters, Colin L.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne	Masters, CL (corresponding author), Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia.	c.masters@unimelb.edu.au						Buckley RF, 2019, AM J EPIDEMIOL, V188, P1213, DOI 10.1093/aje/kwz048; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Lim YY, 2015, MOL PSYCHIATR, V20, P1322, DOI 10.1038/mp.2014.123; Mattsson N, 2019, JAMA NEUROL, V76, P791, DOI 10.1001/jamaneurol.2019.0765; Nakamura A, 2018, NATURE, V554, P249, DOI 10.1038/nature25456; Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3; Quiroz YT, 2020, LANCET NEUROL, V19, P513, DOI 10.1016/S1474-4422(20)30137-X; Schindler SE, 2019, NEUROLOGY, V93, pE1647, DOI 10.1212/WNL.0000000000008081; Sperling RA, 2020, JAMA NEUROL, DOI [10.1001//jamaneurol.2020.0387, DOI 10.1001//JAMANEUROL.2020.0387]; Teunissen CE, 2018, J ALZHEIMERS DIS, V62, P1857, DOI 10.3233/JAD-170784	10	9	9	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2020	19	6					475	476		10.1016/S1474-4422(20)30155-1	http://dx.doi.org/10.1016/S1474-4422(20)30155-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6CK	32470411				2022-12-18	WOS:000544059200004
J	Jack, CR				Jack, Clifford R., Jr.			The transformative potential of plasma phosphorylated tau	LANCET NEUROLOGY			English	Editorial Material									[Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA	Mayo Clinic	Jack, CR (corresponding author), Mayo Clin, Dept Radiol, Rochester, MN 55905 USA.	jack.clifford@mayo.edu	Jack, Clifford R/F-2508-2010	Jack, Clifford R/0000-0001-7916-622X	US National Institutes of Health; Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic	CRJ serves on an independent data monitoring board for Roche and has consulted for Eisai, but he receives no personal compensation from any commercial entity. He receives research support from the US National Institutes of Health and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.	Barthelemy NR, 2020, NAT MED, V26, P398, DOI 10.1038/s41591-020-0781-z; Jack CR, 2019, BRAIN, V142, P3230, DOI 10.1093/brain/awz268; Karikari TK, 2020, LANCET NEUROL, V19, P422, DOI 10.1016/S1474-4422(20)30071-5; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; Mielke MM, 2018, ALZHEIMERS DEMENT, V14, P989, DOI 10.1016/j.jalz.2018.02.013; Park JC, 2019, BRAIN, V142, P771, DOI 10.1093/brain/awy347; Sato C, 2018, NEURON, V97, P1284, DOI 10.1016/j.neuron.2018.02.015; Shaw LM, 2018, ALZHEIMERS DEMENT, V14, P1505, DOI 10.1016/j.jalz.2018.07.220; Sperling RA, JAMA NEUROL; Thijssen EH, 2020, NAT MED, V26, P387, DOI 10.1038/s41591-020-0762-2	10	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					373	374		10.1016/S1474-4422(20)30112-5	http://dx.doi.org/10.1016/S1474-4422(20)30112-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32333888				2022-12-18	WOS:000573045100005
J	Hartung, HP; Aktas, O				Hartung, Hans-Peter; Aktas, Orhan			Old and new breakthroughs in neuromyelitis optica	LANCET NEUROLOGY			English	Editorial Material									[Hartung, Hans-Peter; Aktas, Orhan] Heinrich Heine Univ, Dept Neurol, Fac Med, D-40225 Dusseldorf, Germany; [Hartung, Hans-Peter; Aktas, Orhan] Heinrich Heine Univ, Ctr Neurol & Neuropsychiat, LVR Klinikum, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Hartung, HP (corresponding author), Heinrich Heine Univ, Dept Neurol, Fac Med, D-40225 Dusseldorf, Germany.; Hartung, HP (corresponding author), Heinrich Heine Univ, Ctr Neurol & Neuropsychiat, LVR Klinikum, D-40225 Dusseldorf, Germany.	hans-peter.hartung@uni-duesseldorf.de	Aktas, Orhan/B-7623-2009	Aktas, Orhan/0000-0002-2020-9210				Bennett JL, 2009, ANN NEUROL, V66, P617, DOI 10.1002/ana.21802; Ciron J, 2018, REV NEUROL-FRANCE, V174, P255, DOI 10.1016/j.neurol.2017.11.005; Cree BAC, 2019, LANCET, V394, P1352, DOI 10.1016/S0140-6736(19)31817-3; Cree BAC, 2016, MULT SCLER J, V22, P862, DOI 10.1177/1352458515620934; Jarius S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-14; Kim SH, 2018, NEUROLOGY, V91, pE2089, DOI 10.1212/WNL.0000000000006574; Pittock SJ, 2019, NEW ENGL J MED, V381, P614, DOI 10.1056/NEJMoa1900866; Tahara M, 2020, LANCET NEUROL, V19, P298, DOI 10.1016/S1474-4422(20)30066-1; Trebst C, 2014, J NEUROL, V261, P1, DOI 10.1007/s00415-013-7169-7; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729; Yamamura T, 2019, NEW ENGL J MED, V381, P2114, DOI 10.1056/NEJMoa1901747	11	9	9	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2020	19	4					280	281		10.1016/S1474-4422(20)30062-4	http://dx.doi.org/10.1016/S1474-4422(20)30062-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KW1GS	32199085				2022-12-18	WOS:000520920500004
J	Mercuri, E; Sansone, V				Mercuri, Eugenio; Sansone, Valeria			Nusinersen in adults with spinal muscular atrophy: new challenges	LANCET NEUROLOGY			English	Editorial Material							SHAM CONTROL		[Mercuri, Eugenio] Univ Cattolica Sacro Cuore, Pediat Neurol, I-00168 Rome, Italy; [Mercuri, Eugenio] Fdn Policlin Univ Agostino Gemelli IRCCS, Nemo Clin Ctr, Rome, Italy; [Sansone, Valeria] Univ Milan, Neurorehabil Unit, NEMO Clin Ctr Milan, Milan, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Milan	Mercuri, E (corresponding author), Univ Cattolica Sacro Cuore, Pediat Neurol, I-00168 Rome, Italy.; Mercuri, E (corresponding author), Fdn Policlin Univ Agostino Gemelli IRCCS, Nemo Clin Ctr, Rome, Italy.	eugeniomaria.mercuri@unicatt.it						Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752; Hagenacker T, 2020, LANCET NEUROL, V19, P317, DOI 10.1016/S1474-4422(20)30037-5; McMillan HJ, 2020, MUSCLE NERVE, V61, P1, DOI 10.1002/mus.26735; Mercuri E, 2018, NEW ENGL J MED, V378, P625, DOI 10.1056/NEJMoa1710504; Mercuri E, 2016, NEUROMUSCULAR DISORD, V26, P126, DOI 10.1016/j.nmd.2015.10.006; Montes J, 2019, MUSCLE NERVE, V60, P409, DOI 10.1002/mus.26633; Veerapandiyan A, 2020, MUSCLE NERVE, V61, P222, DOI 10.1002/mus.26769; Walter MC, 2019, J NEUROMUSCULAR DIS, V6, P453, DOI 10.3233/JND-190416	8	9	9	3	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2020	19	4					283	+		10.1016/S1474-4422(20)30068-5	http://dx.doi.org/10.1016/S1474-4422(20)30068-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KW1GS	32199087				2022-12-18	WOS:000520920500006
J	Howard, R				Howard, Robert			Subjective cognitive decline: what is it good for?	LANCET NEUROLOGY			English	Editorial Material							FRAMEWORK		[Howard, Robert] UCL, Div Psychiat, London W1T 7NF, England	University of London; University College London	Howard, R (corresponding author), UCL, Div Psychiat, London W1T 7NF, England.	robert.howard@ucl.ac.uk		Howard, Robert/0000-0002-3071-2338				Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Jessen F, 2020, LANCET NEUROL, V19, P271, DOI 10.1016/S1474-4422(19)30368-0; Jessen F, 2014, ALZHEIMERS DEMENT, V10, P844, DOI 10.1016/j.jalz.2014.01.001; McWhirter L, 2020, LANCET PSYCHIAT, V7, P191, DOI 10.1016/S2215-0366(19)30405-5; Mitchell AJ, 2014, ACTA PSYCHIAT SCAND, V130, P439, DOI 10.1111/acps.12336; van Harten AC, 2018, NEUROLOGY, V91, pE300, DOI 10.1212/WNL.0000000000005863	6	9	9	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					203	204		10.1016/S1474-4422(20)30002-8	http://dx.doi.org/10.1016/S1474-4422(20)30002-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	31958405				2022-12-18	WOS:000514832700009
J	Arnold, S				Arnold, Stephan			Cenobamate: new hope for treatment-resistant epilepsy	LANCET NEUROLOGY			English	Editorial Material							OUTCOMES		[Arnold, Stephan] Schon Klin Vogtareuth, Dept Neurosurg, Epilepsy Unit, D-83569 Vogtareuth, Germany; [Arnold, Stephan] Neurozentrum Nymphenburg, Epileptol, Munich, Germany		Arnold, S (corresponding author), Schon Klin Vogtareuth, Dept Neurosurg, Epilepsy Unit, D-83569 Vogtareuth, Germany.; Arnold, S (corresponding author), Neurozentrum Nymphenburg, Epileptol, Munich, Germany.	sarnold@schoen-klinik.de						Chen ZB, 2018, JAMA NEUROL, V75, P279, DOI 10.1001/jamaneurol.2017.3949; Josephson CB, 2017, EPILEPSIA, V58, P764, DOI 10.1111/epi.13723; Krauss GL, 2020, LANCET NEUROL, V19, P38, DOI 10.1016/S1474-4422(19)30399-0; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Sperling M, 2018, AM EP SOC ANN M NEW	5	9	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					23	24		10.1016/S1474-4422(19)30434-X	http://dx.doi.org/10.1016/S1474-4422(19)30434-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM	31734104				2022-12-18	WOS:000502286000016
J	Jack, CR				Jack, Clifford R., Jr.			Preclinical Alzheimer's disease: a valid concept	LANCET NEUROLOGY			English	Letter									[Jack, Clifford R., Jr.] Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Jack, CR (corresponding author), Mayo Clin, Rochester, MN 55905 USA.	jack.clifford@mayo.edu	Jack, Clifford R/F-2508-2010	Jack, Clifford R/0000-0001-7916-622X				Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Frisoni GB, 2019, LANCET NEUROL, V18, P918, DOI 10.1016/S1474-4422(19)30323-0; Jack CR, 2019, JAMA NEUROL, V76, P1174, DOI 10.1001/jamaneurol.2019.1971; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3	5	9	9	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					31	31		10.1016/S1474-4422(19)30440-5	http://dx.doi.org/10.1016/S1474-4422(19)30440-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM	31839247	Bronze			2022-12-18	WOS:000502286000021
J	Knauss, S; Stelzl, D; Emmrich, JV; Korsnes, MS; Sejvar, JJ; Winkler, AS				Knauss, Samuel; Stelzl, Dominik; Emmrich, Julius Valentin; Korsnes, Maria Stylianou; Sejvar, James J.; Winkler, Andrea Sylvia			An emphasis on neurology in low and middle-income countries	LANCET NEUROLOGY			English	Editorial Material														Emmrich, Julius/0000-0002-3393-0840					0	9	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1078	1079		10.1016/S1474-4422(19)30392-8	http://dx.doi.org/10.1016/S1474-4422(19)30392-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	31973806				2022-12-18	WOS:000495892200011
J	Wijeratne, T; Grisold, W; Dodick, D; Carroll, W				Wijeratne, Tissa; Grisold, Wolfgang; Dodick, David; Carroll, William			World Brain Day 2019: migraine, the painful truth	LANCET NEUROLOGY			English	Letter							HEADACHE; BURDEN		[Wijeratne, Tissa] Sunshine Hosp, Melbourne Med Sch & Western Hlth, Dept Neurol, St Albans, Vic 3021, Australia; [Grisold, Wolfgang] Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria; [Dodick, David] Mayo Clin, Dept Neurol, Scottsdale, AZ USA; [Carroll, William] Sir Charles Gairdner Hosp, Dept Neurol, Nedlands, WA, Australia; [Carroll, William] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perron Inst, Perth, WA, Australia	Ludwig Boltzmann Institute; Mayo Clinic; Mayo Clinic Phoenix; University of Western Australia; University of Western Australia	Wijeratne, T (corresponding author), Sunshine Hosp, Melbourne Med Sch & Western Hlth, Dept Neurol, St Albans, Vic 3021, Australia.	twi@unimelb.edu.au	FRACP, Tissa Wijeratne MD PhD/I-2086-2019	FRACP, Tissa Wijeratne MD PhD/0000-0002-1701-7111				Dodick D, 2018, CEPHALALGIA, V38, P1899, DOI 10.1177/0333102418781644; Grisold W, 2019, ADVOCACY NEUROLOGY, P400; Mateen FJ, 2008, CEPHALALGIA, V28, P1107, DOI 10.1111/j.1468-2982.2008.01681.x; Reuter U, 2018, LANCET NEUROL, V17, P929, DOI 10.1016/S1474-4422(18)30360-0; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Wijeratne T., OUT SIGHT OUT MIND H; Wijeratne T, 2019, NEUROEPIDEMIOLOGY, V52, P104, DOI 10.1159/000494758	7	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2019	18	10					914	914		10.1016/S1474-4422(19)30281-9	http://dx.doi.org/10.1016/S1474-4422(19)30281-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IX6HN	31345666	Bronze			2022-12-18	WOS:000485784000010
J	Guerreiro, R; Orme, T; Neto, JL; Bras, J				Guerreiro, Rita; Orme, Tatiana; Neto, Joao Luis; Bras, Jose		Int DLB Genetics Consortium	LRP10 in alpha-synucleinopathies	LANCET NEUROLOGY			English	Letter							PARKINSONS-DISEASE; GENE		[Guerreiro, Rita; Orme, Tatiana; Neto, Joao Luis] UCL, Inst Neurol, Dept Neurodegenerat Dis, London, England; [Guerreiro, Rita; Orme, Tatiana; Neto, Joao Luis; Bras, Jose] UCL, UK Dementia Res Inst, London, England	University of London; University College London; University of London; University College London	Bras, J (corresponding author), UCL, UK Dementia Res Inst, London, England.	j.bras@ucl.ac.uk	Singleton, Andrew B/C-3010-2009; Oinas, Minna/X-2511-2019; Shepherd, Claire E/C-9807-2011; Pastor, Pau/C-9834-2009; Neto, João/K-8243-2019; Lashley, Tammaryn/D-2583-2009; Revesz, Tamas/A-8732-2010; Hardy, John/C-2451-2009	Oinas, Minna/0000-0002-6150-091X; Shepherd, Claire E/0000-0002-0399-3218; Pastor, Pau/0000-0002-7493-8777; Neto, João/0000-0003-0863-158X; Revesz, Tamas/0000-0003-2501-0259; Guerreiro, Rita/0000-0001-5879-3486; Diez-Fairen, Monica/0000-0003-1882-0309; Hardy, John/0000-0002-3122-0423; Lashley, Tammaryn/0000-0001-7389-0348	Medical Research Council [MR/L016397/1] Funding Source: Medline; Wellcome Trust [203249/Z/16/Z] Funding Source: Medline; MRC [UKDRI-1003, MR/L016397/1] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Guerreiro R., 2018, BIORXIV; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Polymeropoulos MH, 1996, SCIENCE, V274, P1197, DOI 10.1126/science.274.5290.1197; Power C, 2006, INT J EPIDEMIOL, V35, P34, DOI 10.1093/ije/dyi183; Quadri M, 2018, LANCET NEUROL, V17, P597, DOI 10.1016/S1474-4422(18)30179-0	7	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2018	17	12					1032	1033		10.1016/S1474-4422(18)30399-5	http://dx.doi.org/10.1016/S1474-4422(18)30399-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HA3AA	30507384	Bronze			2022-12-18	WOS:000450119300009
J	Pihlstrom, L; Schottlaender, L; Chelban, V; Houlden, H				Pihlstrom, Lasse; Schottlaender, Lucia; Chelban, Viorica; Houlden, Henry		MSA Exome Consortium	LRP10 in alpha-synucleinopathies	LANCET NEUROLOGY			English	Letter									[Pihlstrom, Lasse; Schottlaender, Lucia; Chelban, Viorica; Houlden, Henry] UCL, Inst Neurol, Dept Mol Neurosci, London, England; [Pihlstrom, Lasse; Schottlaender, Lucia; Chelban, Viorica; Houlden, Henry] Natl Hosp Neurol & Neurosurg, Queen Sq, London, England; [Pihlstrom, Lasse] Oslo Univ Hosp, Dept Neurol, Oslo, Norway	University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Oslo	Pihlstrom, L (corresponding author), UCL, Inst Neurol, Dept Mol Neurosci, London, England.; Pihlstrom, L (corresponding author), Natl Hosp Neurol & Neurosurg, Queen Sq, London, England.; Pihlstrom, L (corresponding author), Oslo Univ Hosp, Dept Neurol, Oslo, Norway.	lasse.pihlstrom@medisin.uio.no	Morris, Huw R/B-8527-2008; Singleton, Andrew B/C-3010-2009; Houlden, Henry J/C-1532-2008; Wood, Nicholas/C-2505-2009; Meissner, Wassilios/C-7817-2015; Hardy, John/C-2451-2009	Morris, Huw R/0000-0002-5473-3774; Houlden, Henry J/0000-0002-2866-7777; Wood, Nicholas/0000-0002-9500-3348; Chelban, Viorica/0000-0002-5817-6290; Morris, Christopher/0000-0002-3749-0993; Meissner, Wassilios/0000-0003-2172-7527; Ross, Owen/0000-0003-4813-756X; Hardy, John/0000-0002-3122-0423; Bettencourt, Conceicao/0000-0001-9090-7690				Gilman S, 2008, NEUROLOGY, V71, P670, DOI 10.1212/01.wnl.0000324625.00404.15; Guerreiro R., 2018, BIORXIV270686, DOI [10.1101/270686, DOI 10.1101/270686]; Klely AP, 2013, ACTA NEUROPATHOL, V125, P753; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Quadri M, 2018, LANCET NEUROL, V17, P597, DOI 10.1016/S1474-4422(18)30179-0	5	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2018	17	12					1033	1034		10.1016/S1474-4422(18)30407-1	http://dx.doi.org/10.1016/S1474-4422(18)30407-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HA3AA	30507385	Bronze			2022-12-18	WOS:000450119300010
J	Petzold, A				Petzold, Axel			Applying the 2017 McDonald diagnostic criteria for multiple sclerosis	LANCET NEUROLOGY			English	Letter							CEREBROSPINAL-FLUID ANALYSIS		[Petzold, Axel] Vrije Univ Amsterdam Med Ctr, MS Ctr Amsterdam, Dept Neurol, Amsterdam, Netherlands; [Petzold, Axel] UCL, UCL Inst Neurol, Neuroimmunol & CSF Lab, London WC1N 3BG, England	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of London; University College London	Petzold, A (corresponding author), Vrije Univ Amsterdam Med Ctr, MS Ctr Amsterdam, Dept Neurol, Amsterdam, Netherlands.; Petzold, A (corresponding author), UCL, UCL Inst Neurol, Neuroimmunol & CSF Lab, London WC1N 3BG, England.	a.petzold@ucl.ac.uk	Petzold, Axel/C-1090-2009	Petzold, Axel/0000-0002-0344-9749	steering committee of the OCTiMS; Novartis; National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital National Health Service (NHS) Foundation Trust and University College London Institute of Ophthalmology	steering committee of the OCTiMS; Novartis(Novartis); National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital National Health Service (NHS) Foundation Trust and University College London Institute of Ophthalmology	I am grateful to Bill Egner, Director of the UK NEQAS Immunology, Immunochemistry and Allergy, and to Dina Patel, Director of the UK NEQAS CSF programme, for giving me permission to review the UK NEQAS data for CSF oligoclonal bands. I reports personal fees and grants paid to my instution from being part of the steering committee of the OCTiMS, study, which is sponsored by Novartis, but have not received honoraria for this activity. I am supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital National Health Service (NHS) Foundation Trust and University College London Institute of Ophthalmology.	Filippi M, 2018, LANCET NEUROL, V17, P133, DOI 10.1016/S1474-4422(17)30469-6; Freedman MS, 2005, ARCH NEUROL-CHICAGO, V62, P865, DOI 10.1001/archneur.62.6.865; Petzold A, 2013, J NEUROIMMUNOL, V262, P1, DOI 10.1016/j.jneuroim.2013.06.014; Stangel M, 2013, NAT REV NEUROL, V9, P267, DOI 10.1038/nrneurol.2013.41; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2	5	9	9	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2018	17	6					496	497		10.1016/S1474-4422(18)30159-5	http://dx.doi.org/10.1016/S1474-4422(18)30159-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GG1RD	29778355	Bronze, Green Submitted			2022-12-18	WOS:000432463400014
J	de Meel, RHP; Verschuuren, JJGM; Tannemaat, MR				de Meel, Robert Henri Pasquale; Verschuuren, Jan J. G. M.; Tannemaat, Martijn R.			Distinct representation of muscle weakness in QMG and MG-ADL	LANCET NEUROLOGY			English	Letter							MYASTHENIA-GRAVIS; ECULIZUMAB		[de Meel, Robert Henri Pasquale; Verschuuren, Jan J. G. M.; Tannemaat, Martijn R.] Leiden Univ, Dept Neurol, Med Ctr, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	de Meel, RHP (corresponding author), Leiden Univ, Dept Neurol, Med Ctr, NL-2333 ZA Leiden, Netherlands.	rhpdemeel@lumc.nl	de Meel, Robert/AAX-2463-2021; Tannemaat, Martijn/S-3445-2016	Tannemaat, Martijn/0000-0003-2929-0390; Verschuuren, Jan/0000-0002-4572-1501; de Meel, Robert/0000-0002-4374-3715	National Institutes of Health [NCT00294658]; European MG grant [602420]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European MG grant	JJGMV reports involvement in a National Institutes of Health-sponsored thymectomy trial (ClinicalTrials.gov, number NCT00294658); reports a FP7 European MG grant (602420); and is a consultant for Alexion Pharmaceuticals and arGEN-X. MRT is a member of the scientific advisory board of Araim Pharmaceuticals and reports stock options in this company. RHPdM declares no competing interests.	Barnett C, 2017, NEUROLOGY, V89, P2357, DOI 10.1212/WNL.0000000000004676; Howard JF, 2017, LANCET NEUROL, V16, P976, DOI 10.1016/S1474-4422(17)30369-1; Howard JF, 2017, MUSCLE NERVE, V56, P328, DOI 10.1002/mus.25529; Wolfe GI, 2008, MUSCLE NERVE, V38, P1429, DOI 10.1002/mus.21142	4	9	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2018	17	3					204	205		10.1016/S1474-4422(18)30037-1	http://dx.doi.org/10.1016/S1474-4422(18)30037-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FW1WE	29452679	Bronze			2022-12-18	WOS:000425090000010
J	Schneider, LS				Schneider, Lon S.			Pimavanserin for patients with Alzheimer's disease psychosis	LANCET NEUROLOGY			English	Editorial Material							DEMENTIAS		[Schneider, Lon S.] Univ Southern Calif, Dept Psychiat & Behav Sci, Keck Sch Med, Los Angeles, CA 90033 USA; [Schneider, Lon S.] Univ Southern Calif, Dept Neurol, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Schneider, LS (corresponding author), Univ Southern Calif, Dept Psychiat & Behav Sci, Keck Sch Med, Los Angeles, CA 90033 USA.; Schneider, LS (corresponding author), Univ Southern Calif, Dept Neurol, Keck Sch Med, Los Angeles, CA 90033 USA.	lschneid@usc.edu			National Institute on Aging; State of California; University of Southern California; Eli Lilly; Lundbeck; Novartis; Biogen; Merck; Roche/Genentech; TauRx; AC Immune; Boehringer Ingelheim; Cerespir; Cognition; Neurim; Stemedica; Takeda; vTv; Toyama/FujiFilm; Heptares; Allergan; Axovant; Impel NeuroPharma	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); State of California; University of Southern California; Eli Lilly(Eli Lilly); Lundbeck(Lundbeck Corporation); Novartis(Novartis); Biogen(Biogen); Merck(Merck & Company); Roche/Genentech(Roche HoldingGenentech); TauRx; AC Immune; Boehringer Ingelheim(Boehringer Ingelheim); Cerespir; Cognition; Neurim; Stemedica; Takeda(Takeda Pharmaceutical Company Ltd); vTv; Toyama/FujiFilm; Heptares; Allergan(AbbVieAllergan); Axovant; Impel NeuroPharma	LSS reports grants from the National Institute on Aging and the State of California, and other from University of Southern California; grants from Eli Lilly, Lundbeck, Novartis, and Biogen; grants and personal fees from, Merck, Roche/Genentech, and TauRx; and personal fees from AC Immune, Avraham, Boehringer Ingelheim, Cerespir, Cognition, Neurim, Stemedica, Takeda, vTv, Toyama/FujiFilm, Heptares, Allergan, Axovant, and Impel NeuroPharma.	Ballard C, 2018, LANCET NEUROL, V17, P213, DOI 10.1016/S1474-4422(18)30039-5; Cummings J, 2014, LANCET, V383, P533, DOI 10.1016/S0140-6736(13)62106-6; Jeste DV, 2000, AM J GERIAT PSYCHIAT, V8, P29, DOI 10.1097/00019442-200002000-00004; Laughren T, 2001, AM J GERIAT PSYCHIAT, V9, P340, DOI 10.1176/appi.ajgp.9.4.340; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Schneider JA, 2009, ANN NEUROL, V66, P200, DOI 10.1002/ana.21706; Schneider LS, 2003, AM J GERIAT PSYCHIAT, V11, P414, DOI 10.1176/appi.ajgp.11.4.414; Schneider LS, 2006, AM J GERIAT PSYCHIAT, V14, P191, DOI 10.1097/01.JGP.0000200589.01396.6d; US Food and Drug Administration, 2016, PIM PRESCR INF; Winblad B, 2016, LANCET NEUROL, V15, P455, DOI 10.1016/S1474-4422(16)00062-4	10	9	9	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2018	17	3					194	195		10.1016/S1474-4422(18)30052-8	http://dx.doi.org/10.1016/S1474-4422(18)30052-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FW1WE	29452674				2022-12-18	WOS:000425090000002
J	Yassine, HN				Yassine, Hussein N.			Targeting prodromal Alzheimer's disease: too late for prevention?	LANCET NEUROLOGY			English	Editorial Material							CONTROLLED-TRIAL; EFFICACY		[Yassine, Hussein N.] USC, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California Keck Hospital	Yassine, HN (corresponding author), USC, Keck Sch Med, Los Angeles, CA 90033 USA.	hyassine@usc.edu			National Institute of Aging [R01AG055770, R01AG054434]; Alzheimer's Association [NIRG-15-361854]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL107389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005142, R01AG054434, R01AG055770] Funding Source: NIH RePORTER	National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Alzheimer's Association(Alzheimer's Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	HNY reports grants from the National Institute of Aging (R01AG055770, R01AG054434), and the Alzheimer's Association (NIRG-15-361854).	Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Scheltens P, 2012, J ALZHEIMERS DIS, V31, P225, DOI 10.3233/JAD-2012-121189; Scheltens P, 2010, ALZHEIMERS DEMENT, V6, P1, DOI 10.1016/j.jalz.2009.10.003; Shah RC, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt224; Soininen H., 2017, LANCET NEUROL; Wurtman RJ, 2006, BRAIN RES, V1088, P83, DOI 10.1016/j.brainres.2006.03.019; Yassine HN, 2017, JAMA NEUROL, V74, P337, DOI 10.1001/jamaneurol.2016.4899	7	9	9	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2017	16	12					946	947		10.1016/S1474-4422(17)30372-1	http://dx.doi.org/10.1016/S1474-4422(17)30372-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FM8DJ	29097165	Green Accepted, hybrid			2022-12-18	WOS:000415315400002
J	[Anonymous]				[Anonymous]			Global analysis of neurological disease: burden and benefit	LANCET NEUROLOGY			English	Editorial Material																			0	9	9	2	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2017	16	11					857	857		10.1016/S1474-4422(17)30338-1	http://dx.doi.org/10.1016/S1474-4422(17)30338-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FJ3WM	29029838	Bronze			2022-12-18	WOS:000412663200001
J	Ben-Menachem, E				Ben-Menachem, Elinor			Epilepsy in 2015: the year of collaborations for big data	LANCET NEUROLOGY			English	Editorial Material							ANTIEPILEPTIC DRUGS; OUTCOMES; PREGNANCY; EXPOSURE; SEIZURES		[Ben-Menachem, Elinor] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden	University of Gothenburg	Ben-Menachem, E (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden.	ebm@neuro.gu.se						Baker GA, 2015, NEUROLOGY, V84, P382, DOI 10.1212/WNL.0000000000001182; Cleary RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057148; European Medicines Agency, 2014, VALPR REL SUBST CMDH; Glauser TA, 2013, EPILEPSIA, V54, P141, DOI 10.1111/epi.12028; Jehi L, 2015, LANCET NEUROL, V14, P283, DOI 10.1016/S1474-4422(14)70325-4; Meador KJ, 2013, LANCET NEUROL, V12, P244, DOI 10.1016/S1474-4422(12)70323-X; Pressler RM, 2015, LANCET NEUROL, V14, P469, DOI 10.1016/S1474-4422(14)70303-5; Shinnar S, 2015, NEUROLOGY, V85, P1108, DOI 10.1212/WNL.0000000000001971; Tomson T, 2011, LANCET NEUROL, V10, P609, DOI 10.1016/S1474-4422(11)70107-7; Viale L, 2015, LANCET, V386, P1845, DOI 10.1016/S0140-6736(15)00045-8	10	9	10	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					6	7		10.1016/S1474-4422(15)00356-7	http://dx.doi.org/10.1016/S1474-4422(15)00356-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700895				2022-12-18	WOS:000366313900004
J	[Anonymous]				[Anonymous]			A neurology revival in Latin America	LANCET NEUROLOGY			English	Editorial Material																			0	9	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2015	14	12					1143	1143		10.1016/S1474-4422(15)00307-5	http://dx.doi.org/10.1016/S1474-4422(15)00307-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW2WZ	26527174	Bronze			2022-12-18	WOS:000364855100001
J	Frisoni, GB; Visser, PJ				Frisoni, Giovanni B.; Visser, Pieter Jelle			Biomarkers for Alzheimer's disease: a controversial topic	LANCET NEUROLOGY			English	Editorial Material							DEMENTIA; METAANALYSIS; PREVALENCE		[Frisoni, Giovanni B.] Univ Hosp Geneva, Geneva, Switzerland; [Frisoni, Giovanni B.] Univ Geneva, Geneva, Switzerland; [Frisoni, Giovanni B.] IRCCS Fatebenefratelli, Brescia, Italy; [Visser, Pieter Jelle] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands; [Visser, Pieter Jelle] Maastricht Univ, Maastricht, Netherlands	University of Geneva; University of Geneva; IRCCS Fatebenefratelli; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Maastricht University	Frisoni, GB (corresponding author), Univ Hosp Geneva, Geneva, Switzerland.	giovanni.frisoni@hcuge.ch	Frisoni, Giovanni B./K-1360-2016; Visser, Pieter J/C-8541-2015; Visser, Pieter Jelle/S-5242-2019; Frisoni, Giovanni/K-1360-2016	Frisoni, Giovanni B./0000-0002-6419-1753; Visser, Pieter J/0000-0001-8008-9727; Visser, Pieter Jelle/0000-0001-8008-9727; Frisoni, Giovanni/0000-0001-7075-7082				Bertens D, 2015, ALZHEIMERS DEMENT, V11, P511, DOI 10.1016/j.jalz.2014.05.1754; Detsky AS, 2011, JAMA-J AM MED ASSOC, V306, P2500, DOI 10.1001/jama.2011.1819; Frisoni GB, 2011, LANCET NEUROL, V10, P598, DOI 10.1016/S1474-4422(11)70126-0; Herrup K, 2015, NAT NEUROSCI, V18, P794, DOI 10.1038/nn.4017; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Le Couteur DG, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5125; Ossenkoppele R, 2015, JAMA-J AM MED ASSOC, V313, P1939, DOI 10.1001/jama.2015.4669; Yau W-YW, 2015, LANCET NEUROL	9	9	9	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2015	14	8					781	783		10.1016/S1474-4422(15)00150-7	http://dx.doi.org/10.1016/S1474-4422(15)00150-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CM7MZ	26139024				2022-12-18	WOS:000357879200003
J	Iqbal, Z; Toft, M				Iqbal, Zafar; Toft, Mathias			CHCHD2 and Parkinson's disease	LANCET NEUROLOGY			English	Letter									[Iqbal, Zafar; Toft, Mathias] Oslo Univ Hosp, Dept Neurol, Oslo, Norway	University of Oslo	Iqbal, Z (corresponding author), Oslo Univ Hosp, Dept Neurol, Oslo, Norway.	iqbal.z.phd@gmail.com	Toft, Mathias/AAY-5212-2021; Iqbal, Zafar/J-8700-2015	Iqbal, Zafar/0000-0002-6387-8019; Iqbal, Zafar/0000-0002-1334-6372; Toft, Mathias/0000-0002-6723-6865				Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2; Healy DG, 2008, LANCET NEUROL, V7, P583, DOI 10.1016/S1474-4422(08)70117-0; Kachergus J, 2005, AM J HUM GENET, V76, P672, DOI 10.1086/429256; Singleton A, 2015, LANCET NEUROL, V14, P239, DOI 10.1016/S1474-4422(14)70270-4	4	9	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					680	681		10.1016/S1474-4422(15)00096-4	http://dx.doi.org/10.1016/S1474-4422(15)00096-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26067113				2022-12-18	WOS:000356195900011
J	Woolf, CJ				Woolf, Clifford J.			Pain: morphine, metabolites, mambas, and mutations	LANCET NEUROLOGY			English	Editorial Material							NEUROPATHIC PAIN		[Woolf, Clifford J.] Boston Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Woolf, Clifford J.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Woolf, Clifford J.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Woolf, CJ (corresponding author), Boston Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA.	cliffford.woolf@childrens.harvard.edu	Woolf, Clifford/A-9784-2010					Baliki MN, 2012, NAT NEUROSCI, V15, P1117, DOI 10.1038/nn.3153; Bierhaus A, 2012, NAT MED, V18, P926, DOI 10.1038/nm.2750; Braz JM, 2012, NEURON, V74, P663, DOI 10.1016/j.neuron.2012.02.033; Chambers SM, 2012, NAT BIOTECHNOL, V30, P715, DOI 10.1038/nbt.2249; Diochot S, 2012, NATURE, V490, P552, DOI 10.1038/nature11494; Faber CG, 2012, ANN NEUROL, V71, P26, DOI 10.1002/ana.22485; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0	8	9	12	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					18	20		10.1016/S1474-4422(12)70287-9	http://dx.doi.org/10.1016/S1474-4422(12)70287-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23237896				2022-12-18	WOS:000312429400011
J	Mateen, FJ; Dua, T; Shen, GC; Reed, GM; Shakir, R; Saxena, S				Mateen, Farrah J.; Dua, Torun; Shen, Gordon C.; Reed, Geoffrey M.; Shakir, Raad; Saxena, Shekhar			Neurological disorders in the 11th revision of the International Classification of Diseases: now open to public feedback	LANCET NEUROLOGY			English	Letter									[Mateen, Farrah J.; Dua, Torun; Reed, Geoffrey M.; Saxena, Shekhar] World Hlth Org, Dept Mental Hlth & Substance Abuse, Geneva, Switzerland; [Mateen, Farrah J.] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA; [Mateen, Farrah J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Shen, Gordon C.] Univ Calif Berkeley, Dept Hlth Policy, Berkeley, CA 94720 USA; [Shakir, Raad] Univ London Imperial Coll Sci Technol & Med, Dept Neurol, London, England	World Health Organization; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California Berkeley; Imperial College London	Mateen, FJ (corresponding author), World Hlth Org, Dept Mental Hlth & Substance Abuse, Geneva, Switzerland.	duat@who.int		Mateen, Farrah/0000-0002-4293-8115				[Anonymous], 2007, BAS DOC; Reed GM, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3830	2	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2012	11	6					484	485		10.1016/S1474-4422(12)70125-4	http://dx.doi.org/10.1016/S1474-4422(12)70125-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	952JW	22608660				2022-12-18	WOS:000304789800009
J	Gold, R; Montalban, X				Gold, Ralf; Montalban, Xavier			Multiple sclerosis: more pieces of the immunological puzzle	LANCET NEUROLOGY			English	Editorial Material									[Gold, Ralf] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany; [Montalban, Xavier] Vall dHebron Univ Hosp, Dept Neurosci, Barcelona, Spain; [Montalban, Xavier] Vall dHebron Univ Hosp, MS Ctr Catalonia CEM Cat, Barcelona, Spain	Ruhr University Bochum; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron	Gold, R (corresponding author), Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany.	ralf.gold@rub.de	Montalban, Xavier/J-5938-2016	Montalban, Xavier/0000-0002-0098-9918				Aly L, 2011, BRAIN, V134, P2687, DOI 10.1093/brain/awr206; Berer K, 2011, NATURE, V479, P538, DOI 10.1038/nature10554; *BIOG ID, TYS; Montalban X, 2010, NEUROLOGY, V74, P427, DOI 10.1212/WNL.0b013e3181cec45c; O'Connor P, 2011, NEW ENGL J MED, V365, P1293, DOI 10.1056/NEJMoa1014656; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251	7	9	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2012	11	1					9	10		10.1016/S1474-4422(11)70268-X	http://dx.doi.org/10.1016/S1474-4422(11)70268-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	868HG	22172612				2022-12-18	WOS:000298513700006
J	Zamvil, SS; Steinman, L				Zamvil, Scott S.; Steinman, Lawrence			Combining statins with interferon beta in multiple sclerosis: think twice, it might not be all right	LANCET NEUROLOGY			English	Editorial Material							SYSTEM AUTOIMMUNE-DISEASE; COMBINATION THERAPY; CONTROLLED-TRIAL; ATORVASTATIN; ENCEPHALOMYELITIS; EFFICACY		[Zamvil, Scott S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA; Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Interdept Program Immunol, Stanford, CA 94305 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Stanford University	Zamvil, SS (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.	zamvil@ucsf.neuroimmunol.org		Steinman, Lawrence/0000-0002-2437-2250	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059709, R01AI073737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS063008] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI059709, R01 AI073737] Funding Source: Medline; NINDS NIH HHS [R01 NS063008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Axtell RC, 2010, NAT MED, V16, P406, DOI 10.1038/nm.2110; Birnbaum G, 2008, NEUROLOGY, V71, P1390, DOI 10.1212/01.wnl.0000319698.40024.1c; Lanzillo R, 2010, MULT SCLER J, V16, P450, DOI 10.1177/1352458509358909; Paintlia AS, 2006, AM J PATHOL, V169, P1012, DOI 10.2353/ajpath.2006.051309; Paul F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001928; SORENSEN PS, 2011, LANCET NEUROL, DOI DOI 10.1016/51474-4422(11)70144-2; Stuve O, 2006, J CLIN INVEST, V116, P1037, DOI 10.1172/JCI25805; Togha M, 2010, MULT SCLER J, V16, P848, DOI 10.1177/1352458510369147; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	10	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2011	10	8					672	673		10.1016/S1474-4422(11)70153-3	http://dx.doi.org/10.1016/S1474-4422(11)70153-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	803WJ	21742557	Green Accepted			2022-12-18	WOS:000293612600002
J	Takeuchi, S; Nawashiro, H; Otani, N				Takeuchi, Satoru; Nawashiro, Hiroshi; Otani, Naoki			Hypothermia in patients with brain injury: the way forward?	LANCET NEUROLOGY			English	Letter									[Takeuchi, Satoru; Nawashiro, Hiroshi; Otani, Naoki] Natl Def Med Coll, Dept Neurosurg, Saitama 3598913, Japan	National Defense Medical College - Japan	Takeuchi, S (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Saitama 3598913, Japan.	s.takeuchi@room.ocn.ne.jp	Cooper, D. James/G-7961-2013; Ho, Kwok M./E-3546-2010	Cooper, D. James/0000-0002-5872-9051; Ho, Kwok M./0000-0002-6705-6004				Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Maas A, 2011, LANCET NEUROL, V10, P111, DOI 10.1016/S1474-4422(10)70312-4; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub3	5	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2011	10	5					404	404		10.1016/S1474-4422(11)70083-7	http://dx.doi.org/10.1016/S1474-4422(11)70083-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	761TV	21511191	Bronze			2022-12-18	WOS:000290424800006
J	Nollet, F				Nollet, Frans			Postpolio syndrome: unanswered questions regarding cause, course, risk factors, and therapies	LANCET NEUROLOGY			English	Editorial Material							LATE-ONSET SEQUELAE; POLIOMYELITIS; STRENGTH; AGE		Univ Amsterdam, Acad Med Ctr, Dept Rehabil, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Nollet, F (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Rehabil, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	f.nollet@amc.uva.nl						Berthelsen PG, 2003, ACTA ANAESTH SCAND, V47, P1190, DOI 10.1046/j.1399-6576.2003.00256.x; Elovaara I, 2008, EUR J NEUROL, V15, P893, DOI 10.1111/j.1468-1331.2008.02246.x; Farbu E, 2006, EUR J NEUROL, V13, P795, DOI 10.1111/j.1468-1331.2006.01385.x; Gonzalez H, 2010, LANCET NEUROL, V9, P634, DOI 10.1016/S1474-4422(10)70095-8; Horemans HL, 2004, ARCH PHYS MED REHAB, V85, P1273, DOI 10.1016/j.apmr.2003.10.026; Koopman FS, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-8; LASSEN HCA, 1953, LANCET, V264, P37; Nollet F, 2004, ARCH NEUROL-CHICAGO, V61, P1142, DOI 10.1001/archneur.61.7.1142; Nollet F, 2003, ARCH PHYS MED REHAB, V84, P1048, DOI 10.1016/S0003-9993(03)00108-4; Stolwijk-Swiiste JM, 2010, ARCH PHYS MED REHAB, V91, P523, DOI 10.1016/j.apmr.2009.10.034; Stolwijk-Swuste JM, 2005, ARCH PHYS MED REHAB, V86, P1693, DOI 10.1016/j.apmr.2004.12.022; WEINSTEIN L, 1957, NEW ENGL J MED, V257, P47, DOI 10.1056/NEJM195707112570201	12	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2010	9	6					561	563		10.1016/S1474-4422(10)70110-1	http://dx.doi.org/10.1016/S1474-4422(10)70110-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	607NY	20494317				2022-12-18	WOS:000278512000005
J	Wilcock, GK				Wilcock, Gordon K.			Bapineuzumab in Alzheimer's disease: where now?	LANCET NEUROLOGY			English	Editorial Material							TRIAL; IMMUNIZATION; TARENFLURBIL		Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	University of Oxford	Wilcock, GK (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.	gordon.wilcock@ndm.ox.ac.uk						Green RC, 2009, JAMA-J AM MED ASSOC, V302, P2557, DOI 10.1001/jama.2009.1866; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Wilcock GK, 2008, LANCET NEUROL, V7, P483, DOI 10.1016/S1474-4422(08)70090-5	5	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2010	9	2					134	136		10.1016/S1474-4422(09)70359-X	http://dx.doi.org/10.1016/S1474-4422(09)70359-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	547XB	20129159				2022-12-18	WOS:000273922000005
J	Schapira, AHV				Schapira, Anthony H. V.			Movement disorders: advances in cause and treatment	LANCET NEUROLOGY			English	Editorial Material							MUTATIONS		UCL, Dept Clin Neurosci, Inst Neurol, London, England	University of London; University College London	Schapira, AHV (corresponding author), UCL, Dept Clin Neurosci, Inst Neurol, London, England.	a.schapira@medsch.ucl.ac.uk	Schapira, Anthony H V/A-1245-2010	Schapira, Anthony H V/0000-0002-3018-3966				Bressman SB, 2009, LANCET NEUROL, V8, P441, DOI 10.1016/S1474-4422(09)70081-X; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Fuchs T, 2009, NAT GENET, V41, P286, DOI 10.1038/ng.304; Gandhi S, 2009, MOL CELL, V33, P627, DOI 10.1016/j.molcel.2009.02.013; Gegg ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004756; Grunewald A, 2009, EXP NEUROL, V219, P266, DOI 10.1016/j.expneurol.2009.05.027; Olanow CW, 2009, NEW ENGL J MED, V361, P1268, DOI 10.1056/NEJMoa0809335; Sha D, 2010, HUM MOL GENET, V19, P352, DOI 10.1093/hmg/ddp501; Sidransky E, 2009, NEW ENGL J MED, V361, P1651, DOI 10.1056/NEJMoa0901281; Tain LS, 2009, NAT NEUROSCI, V12, P1129, DOI 10.1038/nn.2372	10	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					6	7		10.1016/S1474-4422(09)70339-4	http://dx.doi.org/10.1016/S1474-4422(09)70339-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	20083023				2022-12-18	WOS:000273199700004
J	Tamiya, G				Tamiya, Gen			Transcriptional dysregulation: a cause of dystonia?	LANCET NEUROLOGY			English	Editorial Material							EXPANDED POLYGLUTAMINE; PROTEIN; DISEASE; GENE		Yamagata Univ, Sch Med, Adv Mol Epidemiol Res Inst, Yamagata 99023, Japan	Yamagata University	Tamiya, G (corresponding author), Yamagata Univ, Sch Med, Adv Mol Epidemiol Res Inst, Yamagata 99023, Japan.	gtamiya@genetix-h.com		Tamiya, Gen/0000-0002-0597-415X				Bressman SB, 2009, LANCET NEUROL, V8, P441, DOI 10.1016/S1474-4422(09)70081-X; Cayrol C, 2007, BLOOD, V109, P584, DOI 10.1182/blood-2006-03-012013; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Djarmati A, 2009, LANCET NEUROL, V8, P447, DOI 10.1016/S1474-4422(09)70083-3; Freiman RN, 2002, SCIENCE, V296, P2149, DOI 10.1126/science.1073845; Fuchs T, 2009, NAT GENET, V41, P286, DOI 10.1038/ng.304; Hoglinger GU, 2007, P NATL ACAD SCI USA, V104, P3585, DOI 10.1073/pnas.0611671104; Makino S, 2007, AM J HUM GENET, V80, P393, DOI 10.1086/512129; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139	10	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2009	8	5					416	418		10.1016/S1474-4422(09)70087-0	http://dx.doi.org/10.1016/S1474-4422(09)70087-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	435UE	19345149				2022-12-18	WOS:000265368000004
J	Relkin, NR				Relkin, Norman R.			Testing the mettle of PBT2 for Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							A-BETA		Coll Med, Memory Disorders Program, New York, NY USA		Relkin, NR (corresponding author), Coll Med, Memory Disorders Program, New York, NY USA.	nrelkin@med.cornell.edu						Adlard PA, 2008, NEURON, V59, P43, DOI 10.1016/j.neuron.2008.06.018; Lannfelt L, 2008, LANCET NEUROL, V7, P779, DOI 10.1016/S1474-4422(08)70167-4; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685	3	9	9	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2008	7	9					762	763		10.1016/S1474-4422(08)70168-6	http://dx.doi.org/10.1016/S1474-4422(08)70168-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345HZ	18672401				2022-12-18	WOS:000258988400002
J	Wiznitzer, M				Wiznitzer, Max			From observations to trials: the ketogenic diet and epilepsy	LANCET NEUROLOGY			English	Editorial Material									Rainbow Babies & Childrens Hosp, Dept Pediat Neurol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Wiznitzer, M (corresponding author), Rainbow Babies & Childrens Hosp, Dept Pediat Neurol, Cleveland, OH 44106 USA.	max.wiznitzer@case.edu						Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Bough KJ, 2007, EPILEPSIA, V48, P43, DOI 10.1111/j.1528-1167.2007.00915.x; Freeman JM, 2007, PEDIATRICS, V119, P535, DOI 10.1542/peds.2006-2447; Hartman AL, 2007, EPILEPSIA, V48, P31, DOI 10.1111/j.1528-1167.2007.00914.x; Keene DL, 2006, PEDIATR NEUROL, V35, P1, DOI 10.1016/j.pediatrneurol.2006.01.005; Levy R, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001903; Ligthelm RJ, 2007, CLIN THER, V29, P1284, DOI 10.1016/j.clinthera.2007.07.004; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Wilder Russel M., 1921, MAYO CLIN PROC, V2, P307, DOI DOI 10.1111/J.1469-8749.1989.TB03973.X	9	9	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2008	7	6					471	472		10.1016/S1474-4422(08)70093-0	http://dx.doi.org/10.1016/S1474-4422(08)70093-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	305WF	18456560				2022-12-18	WOS:000256207800004
J	Butcher, J				Butcher, James			The hunt for drugs to modify Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material																			0	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2007	6	12					1038	1039		10.1016/S1474-4422(07)70280-6	http://dx.doi.org/10.1016/S1474-4422(07)70280-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	239UI	18031701	Bronze			2022-12-18	WOS:000251543100007
J	Rossi, A; Giovenali, P; Benvenuti, M; Di Lorio, W; Calabresi, P				Rossi, Aroldo; Giovenali, Paolo; Benvenuti, Massimiliano; Di Lorio, Walter; Calabresi, Paolo			Skin biopsy: a new diagnostic tool for autonomic dysfunctions in Parkinson's disease?	LANCET NEUROLOGY			English	Letter							MANAGEMENT		Osped S Maria Misericordia, Neurol Clin, Perugia, Italy	Hospital Santa Maria della Misericordia	Rossi, A (corresponding author), Osped S Maria Misericordia, Neurol Clin, Perugia, Italy.	calabre@unipg.it	Calabresi, Paolo/G-8496-2011	Calabresi, Paolo/0000-0003-0326-5509				Chaudhuri KR, 2006, LANCET NEUROL, V5, P235, DOI 10.1016/S1474-4422(06)70373-8; McArthur JC, 1998, ARCH NEUROL-CHICAGO, V55, P1513, DOI 10.1001/archneur.55.12.1513; Muller T, 2004, ARCH NEUROL-CHICAGO, V61, P657, DOI 10.1001/archneur.61.5.657; Ohsawa Y, 2005, NEUROLOGY, V65, P459, DOI 10.1212/01.wnl.0000171859.85078.3d; Sommer C, 2007, LANCET NEUROL, V6, P632, DOI 10.1016/S1474-4422(07)70172-2	5	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2007	6	10					848	849		10.1016/S1474-4422(07)70231-4	http://dx.doi.org/10.1016/S1474-4422(07)70231-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218SQ	17884672				2022-12-18	WOS:000250035600009
J	Marrie, RA				Marrie, Ruth Ann			Autoimmune disease and multiple sclerosis: methods, methods, methods	LANCET NEUROLOGY			English	Editorial Material									Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Marrie, RA (corresponding author), Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, 9500 Euclid Ave, Cleveland, OH 44195 USA.	marrier@ccf.org		Marrie, Ruth Ann/0000-0002-1855-5595				Bernstein CN, 2005, GASTROENTEROLOGY, V129, P827, DOI 10.1053/j.gastro.2005.06.021; Granieri E, 1997, NEUROLOGY, V49, pS2, DOI 10.1212/WNL.49.2_Suppl_2.S2; Gupta G, 2005, GASTROENTEROLOGY, V129, P819, DOI 10.1053/j.gastro.2005.06.022; Nielsen NM, 2006, ARCH NEUROL-CHICAGO, V63, P1001, DOI 10.1001/archneur.63.7.1001; Okura Y, 2004, J CLIN EPIDEMIOL, V57, P1096, DOI 10.1016/j.jclinepi.2004.04.005; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; Ramagopolan SV, 2007, LANCET NEUROL, V6, P604, DOI 10.1016/S1474-4422(07)70132-1; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397	8	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2007	6	7					575	576		10.1016/S1474-4422(07)70157-6	http://dx.doi.org/10.1016/S1474-4422(07)70157-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	184WJ	17582353				2022-12-18	WOS:000247673000004
J	Lotufo, PA; Bensenor, IM				Lotufo, Paulo A.; Bensenor, Isabela M.			Improving WHOSTEPS Stroke in Brazil	LANCET NEUROLOGY			English	Editorial Material									Hosp Univ Sao Paulo, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Dept Internal Med, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Lotufo, PA (corresponding author), Hosp Univ Sao Paulo, BR-05508900 Sao Paulo, Brazil.	palotufo@hu.usp.br	Lotufo, Paulo/A-9843-2008; Bensenor, Isabela Judith Martins/L-3306-2017	Lotufo, Paulo/0000-0002-4856-8450; 				LOTOFO PA, 2005, SAO PAULO MED J, V123, P3; Lotufo PA, 2005, STROKE, V36, P505; *STEPS, 2007, LANCET NEUROL, V6, P93; Truelsen T, 2007, LANCET NEUROL, V6, P134, DOI 10.1016/S1474-4422(06)70686-X; World Health Organization, 2006, WHO STEPS STROK MAN	5	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2007	6	5					387	388		10.1016/S1474-4422(07)70091-1	http://dx.doi.org/10.1016/S1474-4422(07)70091-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161XO	17434087				2022-12-18	WOS:000246050600007
J	Rossi, S; Bartalini, S; Ulivelli, M				Rossi, S; Bartalini, S; Ulivelli, M			Antiparkinsonian drugs and visual hallucinations	LANCET NEUROLOGY			English	Editorial Material							PARKINSONS-DISEASE		Univ Siena, Dipartimento Neurosci, Sez Neurol, I-53100 Siena, Italy	University of Siena	Rossi, S (corresponding author), Univ Siena, Dipartimento Neurosci, Sez Neurol, Via Laterina 8, I-53100 Siena, Italy.	Rossisimo@unisi.it	Ulivelli, Monica/K-7270-2016; Rossi, Simone/AAC-6067-2022	Ulivelli, Monica/0000-0003-3463-6341; Rossi, Simone/0000-0001-6697-9459				Olanow CW, 2001, NEUROLOGY, V56, pS1, DOI 10.1212/WNL.56.suppl_5.S1; Papapetropoulos S, 2005, J NEUROL, V252, P753, DOI 10.1007/s00415-005-0918-5; SCHWAB RS, 1950, AM J PSYCHIAT, V107, P901; Williams DR, 2005, LANCET NEUROL, V4, P605, DOI 10.1016/S1474-4422(05)70146-0	4	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2006	5	1					18	19		10.1016/S1474-4422(05)70267-2	http://dx.doi.org/10.1016/S1474-4422(05)70267-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	998OI	16361017				2022-12-18	WOS:000234328100013
J	Becker-Barroso, E				Becker-Barroso, E			More support for vascular basis of Alzheimer's disease	LANCET NEUROLOGY			English	News Item																			0	9	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2005	4	10					598	599		10.1016/S1474-4422(05)70182-4	http://dx.doi.org/10.1016/S1474-4422(05)70182-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969PG	16208856				2022-12-18	WOS:000232245900009
J	Gandy, S; Heppner, FL				Gandy, S; Heppner, FL			Alzheimer's amyloid immunotherapy: quo vadis?	LANCET NEUROLOGY			English	Letter							BETA IMMUNIZATION AN1792; DISEASE; MENINGOENCEPHALITIS; BRAIN; AD		Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland	Jefferson University; University of Zurich; University Zurich Hospital	Gandy, S (corresponding author), Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA.	samgandy@earthlink.net; frank.heppner@usz.ch	Heppner, Frank/ABH-8393-2020	Heppner, Frank/0000-0001-9816-8917				Fox NC, 2005, NEUROLOGY, V64, P1563, DOI 10.1212/01.WNL.0000159743.08996.99; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Lee EB, 2005, FEBS LETT, V579, P2564, DOI 10.1016/j.febslet.2005.03.070; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Schenk D, 2004, CURR OPIN IMMUNOL, V16, P599, DOI 10.1016/j.coi.2004.07.012	10	9	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2005	4	8					452	453		10.1016/S1474-4422(05)70124-1	http://dx.doi.org/10.1016/S1474-4422(05)70124-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	951EX	16033686				2022-12-18	WOS:000230913000002
J	Hoffman, JR; Cooper, RJ				Hoffman, JR; Cooper, RJ			Stroke thrombolysis: we need new data, not more reviews	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; TPA		Univ Calif Los Angeles, Ctr Emergency Med, Div Emergency Med, Dept Med, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Hoffman, JR (corresponding author), Univ Calif Los Angeles, Ctr Emergency Med, Div Emergency Med, Dept Med, 924 Westwood Blvd,Suite 300, Los Angeles, CA 90024 USA.	jrh@ucla.edu						Bravata DM, 2002, ARCH INTERN MED, V162, P1994, DOI 10.1001/archinte.162.17.1994; CANDELISE L, 1995, LANCET, V346, P1509; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; FARKOUH ME, 1994, ANN INTERN MED, V120, P886, DOI 10.7326/0003-4819-120-10-199405150-00011; Hacke W, 2004, LANCET, V363, P768; Hoffman JR, 2003, MED J AUSTRALIA, V179, P333, DOI 10.5694/j.1326-5377.2003.tb05584.x; Hoffman JR, 2000, WESTERN J MED, V173, P149, DOI 10.1136/ewjm.173.3.149; Hommel M, 1996, NEW ENGL J MED, V335, P145; HUNT D, 1992, LANCET, V339, P753; Ingall TJ, 2004, STROKE, V35, P2418, DOI 10.1161/01.STR.0000140891.70547.56; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; Lindley RI, 2005, LANCET NEUROL, V4, P249, DOI 10.1016/S1474-4422(05)70044-2; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; RIDKER PM, 1994, ANN INTERN MED, V120, P882, DOI 10.7326/0003-4819-120-10-199405150-00010; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1990, LANCET, V336, P71	17	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2005	4	4					204	205		10.1016/S1474-4422(05)70025-9	http://dx.doi.org/10.1016/S1474-4422(05)70025-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	910ID	15778096				2022-12-18	WOS:000227923600002
J	Koch, M; den Dunnen, W; Sie, OG; De Keyser, J				Koch, M; den Dunnen, W; Sie, OG; De Keyser, J			A fatal demyelinating illness in a young woman 10 weeks post partum	LANCET NEUROLOGY			English	Editorial Material							ACUTE DISSEMINATED ENCEPHALOMYELITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ZOSTER-VIRUS VASCULOPATHY; MULTIPLE-SCLEROSIS; NERVOUS-SYSTEM; INTRAVASCULAR LYMPHOMATOSIS; NEUROLOGICAL INVOLVEMENT; BEHCETS-DISEASE; ADULT PATIENTS; MANIFESTATIONS		Acad Hosp Groningen, Dept Neurol, Groningen, Netherlands; Acad Hosp Groningen, Dept Pathol, Groningen, Netherlands	University of Groningen; University of Groningen	De Keyser, J (corresponding author), Univ Groningen Hosp, Dept Neurol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	j.h.a.de.keyser@neuro.azg.nl	Dunnen, Wilfred FA den/A-4034-2009; De Keyser, Jacques/D-3725-2013; Koch, Marcus/L-9346-2019	De Keyser, Jacques/0000-0002-3394-7757; Koch, Marcus/0000-0001-9972-5092; den Dunnen, Wilfred/0000-0002-4168-1207				Abe K, 2004, NEURORADIOLOGY, V46, P113, DOI 10.1007/s00234-003-1138-2; Akman-Demir G, 1999, BRAIN, V122, P2171, DOI 10.1093/brain/122.11.2171; Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; BERGER JR, 1992, ANN NEUROL, V31, P34, DOI 10.1002/ana.410310107; Beristain X, 2002, ARCH NEUROL-CHICAGO, V59, P439, DOI 10.1001/archneur.59.3.439; BURNS J, 1983, CELL IMMUNOL, V81, P435, DOI 10.1016/0008-8749(83)90250-2; Burns TM, 2003, ARCH NEUROL-CHICAGO, V60, P1166, DOI 10.1001/archneur.60.8.1166; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; CRYSTAL R, 2004, HARRISONS PRINCIPLES, P2017; Filley CM, 2001, NEW ENGL J MED, V345, P425, DOI 10.1056/NEJM200108093450606; Gilden DH, 2002, J NEUROVIROL, V8, P75, DOI 10.1080/13550280290167902; Gilden DH, 2002, J NEUROL SCI, V195, P99, DOI 10.1016/S0022-510X(02)00021-7; Gullapalli D, 2002, NEUROL CLIN, V20, P59, DOI 10.1016/S0733-8619(03)00054-9; Hartung HP, 2001, NEUROLOGY, V56, P1257, DOI 10.1212/WNL.56.10.1257; Hynson JL, 2001, NEUROLOGY, V56, P1308, DOI 10.1212/WNL.56.10.1308; Kadhim H, 2003, HUM PATHOL, V34, P293, DOI 10.1053/hupa.2003.34; KANTER DS, 1995, NEUROLOGY, V45, P824, DOI 10.1212/WNL.45.4.824; Koralnik IJ, 2004, CURR OPIN NEUROL, V17, P365, DOI 10.1097/00019052-200406000-00019; Kuperan S, 2003, NEUROLOGY, V60, P721, DOI 10.1212/01.WNL.0000048493.82053.4C; Marchioni E, 2002, J NEUROL, V249, P100, DOI 10.1007/PL00007836; Martin-Duverneuil N, 2002, NEURORADIOLOGY, V44, P749, DOI 10.1007/s00234-002-0808-9; Martino G, 1999, CURR OPIN NEUROL, V12, P309, DOI 10.1097/00019052-199906000-00010; Masuhr E, 2004, J NEUROL, V251, P11, DOI 10.1007/s00415-004-0321-7; MCLEAN BN, 1990, BRAIN, V113, P1269, DOI 10.1093/brain/113.5.1269; Moore PM, 1998, J NEUROL NEUROSUR PS, V65, P10, DOI 10.1136/jnnp.65.1.10; Murthy SNK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.2.e21; Nadelman RB, 1998, LANCET, V352, P557, DOI 10.1016/S0140-6736(98)01146-5; Noseworthy JH, 2003, CLIN NEUROPHARMACOL, V26, P28, DOI 10.1097/00002826-200301000-00007; Ozenci V, 2002, MULT SCLER J, V8, P396, DOI 10.1191/1352458502ms837rr; Sahlas DJ, 2000, NEUROLOGY, V54, P1370, DOI 10.1212/WNL.54.6.1370; Schwarz S, 2001, NEUROLOGY, V56, P1313, DOI 10.1212/WNL.56.10.1313; Simon DK, 1999, ANNU REV MED, V50, P111; Singhal AB, 2004, ARCH NEUROL-CHICAGO, V61, P411, DOI 10.1001/archneur.61.3.411; Siva A, 2004, CURR OPIN NEUROL, V17, P347, DOI 10.1097/00019052-200406000-00017; Siva A, 2001, J NEUROL, V248, P451, DOI 10.1007/s004150170154; Siva A, 2001, J NEUROL, V248, P95, DOI 10.1007/s004150170242; Stuve O, 1999, CURR OPIN NEUROL, V12, P395, DOI 10.1097/00019052-199908000-00005; Tenembaum S, 2002, NEUROLOGY, V59, P1224, DOI 10.1212/WNL.59.8.1224; WHITEMAN MLH, 1993, RADIOLOGY, V187, P233, DOI 10.1148/radiology.187.1.8451420; Williams RL, 1998, AM J NEURORADIOL, V19, P427; Yoshitomi T, 2000, J NEUROIMMUNOL, V111, P224, DOI 10.1016/S0165-5728(00)00358-1; Younger DS, 2004, CURR OPIN NEUROL, V17, P317, DOI 10.1097/00019052-200406000-00014	43	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					129	134		10.1016/S1474-4422(05)00994-4	http://dx.doi.org/10.1016/S1474-4422(05)00994-4			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15664545				2022-12-18	WOS:000226712300021
J	Meininger, V				Meininger, V			Treatment of emotional lability in ALS	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; NEURONS		Natl Referral ALS Ctr, Paris, France		Meininger, V (corresponding author), Natl Referral ALS Ctr, Paris, France.	vincent.meininger@psl.aphp.fr						Brooks BR, 2004, NEUROLOGY, V63, P1364; Fornal CA, 1996, BRAIN RES, V716, P123, DOI 10.1016/0006-8993(96)00006-6; Ishibashi H, 2000, NEUROPHARMACOLOGY, V39, P2302, DOI 10.1016/S0028-3908(00)00092-7; Kim HS, 1999, LIFE SCI, V64, P2463, DOI 10.1016/S0024-3205(99)00203-9; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Turner BJ, 2003, AMYOTROPH LATERAL SC, V4, P171, DOI 10.1080/14660820310009389	6	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					70	70		10.1016/S1474-4422(05)00970-1	http://dx.doi.org/10.1016/S1474-4422(05)00970-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15664534				2022-12-18	WOS:000226712300002
J	Brown, SW				Brown, SW			Will teleneurology hit the big time?	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; TELEMEDICINE; CARE		Peninsula Med Sch Dev, Disabil Res & Educ Grp, Unit 10, Bodmin Business Ctr, Bodmin PL31 1AH, Cornwall, England	University of Plymouth	Brown, SW (corresponding author), Peninsula Med Sch Dev, Disabil Res & Educ Grp, Unit 10, Bodmin Business Ctr, Harleigh Rd, Bodmin PL31 1AH, Cornwall, England.	stephen.brown@pms.ac.uk						Bergeron Bryan, 2003, MedGenMed, V5, P43; Chua R, 2002, J TELEMED TELECARE, V8, P270, DOI 10.1258/135763302760314234; Chua R, 2001, J TELEMED TELECARE, V7, pS62; Chua R, 2001, J NEUROL NEUROSUR PS, V71, P63, DOI 10.1136/jnnp.71.1.63; Craig J, 2004, J NEUROL NEUROSUR PS, V75, P1031, DOI 10.1136/jnnp.2002.001651; CURRELL R, 2004, COCHRANE LIB; Grigoriev AI, 2002, AVIAT SPACE ENVIR MD, V73, P688; Harrison R, 1999, J TELEMED TELECARE, V5, P126, DOI 10.1258/1357633991933440; Mielonen ML, 2000, J TELEMED TELECARE, V6, P152, DOI 10.1258/1357633001935248	9	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2004	3	9					517	518		10.1016/S1474-4422(04)00849-X	http://dx.doi.org/10.1016/S1474-4422(04)00849-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	849VD	15324718				2022-12-18	WOS:000223568300013
J	Gillum, LA; Johnston, SC				Gillum, LA; Johnston, SC			Oral contraceptives and stroke risk: the debate continues	LANCET NEUROLOGY			English	Editorial Material							WOMEN		Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Gillum, LA (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.	clay.johnston@ucsfmedctr.org						BLACKBURN R, 2000, POPULATION REPORTS S, V9; Chan WS, 2004, ARCH INTERN MED, V164, P741, DOI 10.1001/archinte.164.7.741; Gillum LA, 2000, JAMA-J AM MED ASSOC, V284, P72, DOI 10.1001/jama.284.1.72; Poulter NR, 1996, LANCET, V348, P505; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673	5	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2004	3	8					453	454		10.1016/S1474-4422(04)00819-1	http://dx.doi.org/10.1016/S1474-4422(04)00819-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	842OD	15261603				2022-12-18	WOS:000223012800014
J	Spinney, L				Spinney, L			Update on elan vaccine for Alzheimer's disease	LANCET NEUROLOGY			English	News Item																			0	9	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					5	5		10.1016/S1474-4422(03)00634-3	http://dx.doi.org/10.1016/S1474-4422(03)00634-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14703630				2022-12-18	WOS:000187447100004
J	Spinney, L				Spinney, L			Cocaine use may damage dopaminergic system	LANCET NEUROLOGY			English	News Item																			0	9	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					5	5		10.1016/S1474-4422(03)00635-5	http://dx.doi.org/10.1016/S1474-4422(03)00635-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14703630				2022-12-18	WOS:000187447100005
J	Simic, G				Simic, G			Pathological tau proteins in argyrophilic grain disease	LANCET NEUROLOGY			English	Editorial Material									Univ Zagreb, Croatian Inst Brain Res, Dept Neurosci, HR-10002 Zagreb, Croatia	University of Zagreb	Simic, G (corresponding author), Univ Zagreb, Croatian Inst Brain Res, Dept Neurosci, HR-10002 Zagreb, Croatia.	gsimic@hiim.hr	Šimić, Goran/GZA-9931-2022; Šimić, Goran/A-9262-2013	Šimić, Goran/0000-0002-6339-9261				BRAAK H, 1987, NEUROSCI LETT, V76, P124, DOI 10.1016/0304-3940(87)90204-7; Braak H, 1998, J NEURAL TRANSM, V105, P801, DOI 10.1007/s007020050096; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Ikeda K, 2000, CLIN NEUROPATHOL, V19, P278; Togo T, 2002, J NEUROPATH EXP NEUR, V61, P547, DOI 10.1093/jnen/61.6.547	5	9	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2002	1	5					276	276		10.1016/S1474-4422(02)00130-8	http://dx.doi.org/10.1016/S1474-4422(02)00130-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588LB	12849422				2022-12-18	WOS:000177702000013
J	Barber, M; Whitehouse, PJ				Barber, M; Whitehouse, PJ			Susceptibility testing for Alzheimer's disease: race for the future	LANCET NEUROLOGY			English	Editorial Material									Case Western Reserve Univ, Univ Memory & Aging Ctr, Cleveland, OH 44120 USA	Case Western Reserve University	Barber, M (corresponding author), Case Western Reserve Univ, Univ Memory & Aging Ctr, 12200 Fairhill Rd, Cleveland, OH 44120 USA.							Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Farrer LA, 2000, ARCH NEUROL-CHICAGO, V57, P28, DOI 10.1001/archneur.57.1.28; Green RC, 2002, JAMA-J AM MED ASSOC, V287, P329, DOI 10.1001/jama.287.3.329; POST SG, 1998, GENETIC TESTING ALZH; RELKIN NR, 1996, NEUROL ALERT, V14, P58	5	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2002	1	1					10	10		10.1016/S1474-4422(02)00009-1	http://dx.doi.org/10.1016/S1474-4422(02)00009-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588GQ	12849539				2022-12-18	WOS:000177694100014
J	Fabrigoule, C				Fabrigoule, C			Do leisure activities protect against Alzheimer's disease?	LANCET NEUROLOGY			English	Editorial Material									Univ Bordeaux 2, INSERM 330, F-33076 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Fabrigoule, C (corresponding author), Univ Bordeaux 2, INSERM 330, 146 Rue Leo Saignat, F-33076 Bordeaux, France.							FABRIGOULE C, 1995, J AM GERIATR SOC, V43, P485, DOI 10.1111/j.1532-5415.1995.tb06093.x; Grady CL, 2000, BIOL PSYCHOL, V54, P259, DOI 10.1016/S0301-0511(00)00059-4; MORTIMER JA, 1997, GERIATRICS, V52, P550; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742	5	9	9	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2002	1	1					11	11		10.1016/S1474-4422(02)00010-8	http://dx.doi.org/10.1016/S1474-4422(02)00010-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588GQ	12849540				2022-12-18	WOS:000177694100015
J	Foley, JF; Defer, G; Ryerson, LZ; Cohen, JA; Arnold, DL; Butzkueven, H; Cutter, G; Giovannoni, G; Killestein, J; Wiendl, H; Smirnakis, K; Xiao, S; Kong, G; Kuhelj, R; Campbell, N				Foley, John F.; Defer, Gilles; Ryerson, Lana Zhovtis; Cohen, Jeffrey A.; Arnold, Douglas L.; Butzkueven, Helmut; Cutter, Gary; Giovannoni, Gavin; Killestein, Joep; Wiendl, Heinz; Smirnakis, Karen; Xiao, Shan; Kong, George; Kuhelj, Robert; Campbell, Nolan		NOVA Study Investigators	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial	LANCET NEUROLOGY			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PLACEBO-CONTROLLED TRIAL; RETROSPECTIVE ANALYSIS; DISEASE-ACTIVITY; MRI; MS; EFFICACY; SAFETY; RISK	Background Treatment with natalizumab once every 4 weeks is approved for patients with relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal leukoencephalopathy. Switching to extended-interval dosing is associated with lower progressive multifocal leukoencephalopathy risk, but the efficacy of this approach is unclear. We aimed to assess the safety and efficacy of natalizumab once every 6 weeks compared with once every 4 weeks in patients with relapsing-remitting multiple sclerosis. Methods We did a randomised, controlled, open-label, phase 3b trial (NOVA) at 89 multiple sclerosis centres across 11 countries in the Americas, Europe, and Western Pacific. Included participants were aged 18-60 years with relapsing-remitting multiple sclerosis and had been treated with intravenous natalizumab 300 mg once every 4 weeks with no relapses for at least 12 months before randomisation, with no missed doses in the previous 3 months. Participants were randomly assigned (1:1), using a randomisation sequence generated by the study funder and contract personnel with interactive response technology, to switch to natalizumab once every 6 weeks or continue with once every 4 weeks. The centralised MRI reader, independent neurology evaluation committee, site examining neurologists, site backup examining neurologists, and site examining technicians were masked to study group assignments. The primary endpoint was the number of new or newly enlarging T2 hyperintense lesions at week 72, assessed in all participants who received at least one dose of assigned treatment and had at least one postbaseline MRI, relapse, or neurological examination or efficacy assessment. Missing primary endpoint data were handled under prespecified primary and secondary estimands: the primary estimand included all data, regardless of whether participants remained on the assigned treatment; the secondary estimand classed all data obtained after treatment discontinuation or study withdrawal as missing. Safety was assessed in all participants who received at least one dose of study treatment. Study enrolment is closed and an open-label extension study is ongoing. This study is registered with EudraCT, 2018-002145-11, and ClinicalTrials.gov, NCT03689972. Findings Between Dec 26, 2018, and Aug 30,2019,605 patients were assessed for eligibility and 499 were enrolled and assigned to receive natalizumab once every 6 weeks (n=251) or once every 4 weeks (n=248). After prespecified adjustments for missing data, mean numbers of new or newly enlarging T2 hyperintense lesions at week 72 were 0.20 (95% CI 0.07-0-63) in the once every 6 weeks group and 0.05 (0.01-0-22) in the once every 4 weeks group (mean lesion ratio 4.24 [95% CI 0.86-20-85]; p=0.076) under the primary estimand, and 0.31 (95% CI 0.12-0-82) and 0.06 (0.01-0-31; mean lesion ratio 4.93 [95% CI 1.05-23.20]; p=0.044) under the secondary estimand. Two participants in the once every 6 weeks group with extreme new or newly enlarging T2 hyperintense lesion numbers (>= 25) contributed most of the excess lesions. Adverse events occurred in 194 (78%) of 250 participants in the once every 6 weeks group and 190 (77%) of 247 in the once every 4 weeks group, and serious adverse events occurred in 17 (7%) and 17 (7%), respectively. No deaths were reported. There was one case of asymptomatic progressive multifocal leukoencephalopathy (without clinical signs) in the once every 6 weeks group, and no cases in the once every 4 weeks group; 6 months after diagnosis, the participant was without increased disability and remained classified as asymptomatic. Interpretation We found a numerical difference in the mean number of new or newly enlarging T2 hyperintense lesions at week 72 between the once every 6 weeks and once every 4 weeks groups, which reached significance under the secondary estimand, but interpretation of statistical differences (or absence thereof) is limited because disease activity in the once every 4 weeks group was lower than expected. The safety profiles of natalizumab once every 6 weeks and once every 4 weeks were similar. Although this trial was not powered to assess differences in risk of progressive multifocal leukoencephalopathy, the occurrence of the (asymptomatic) case underscores the importance of monitoring and risk factor consideration in all patients receiving natalizumab. Copyright (C) 2022 Elsevier Ltd. All rights reserved.	[Foley, John F.] Rocky Mt MS Clin, Salt Lake City, UT 84103 USA; [Defer, Gilles] CHU Caen, Dept Neurol, Caen, France; [Ryerson, Lana Zhovtis] NYU Langone Hlth, NYU Multiple Sclerosis Ctr, New York, NY USA; [Cohen, Jeffrey A.] Cleveland Clin, Neurol Inst, Mellen MS Ctr, Cleveland, OH 44106 USA; [Arnold, Douglas L.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Arnold, Douglas L.] NeuroRx Res, Montreal, PQ, Canada; [Butzkueven, Helmut] Monash Univ, Cent Clin Sch, Dept Neurosci, Melbourne, Vic, Australia; [Cutter, Gary] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA; [Giovannoni, Gavin] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, London, England; [Giovannoni, Gavin] Queen Mary Univ London, London, England; [Killestein, Joep] Vrije Univ, Amsterdam Univ Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Wiendl, Heinz] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany; [Smirnakis, Karen; Xiao, Shan; Kong, George; Campbell, Nolan] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA; [Kuhelj, Robert] Biogen, Baar, Switzerland	CHU de Caen NORMANDIE; Universite de Caen Normandie; NYU Langone Medical Center; Cleveland Clinic Foundation; McGill University; Monash University; University of Alabama System; University of Alabama Birmingham; University of London; Queen Mary University London; University of London; Queen Mary University London; Vrije Universiteit Amsterdam; University of Munster; Biogen	Foley, JF (corresponding author), Rocky Mt MS Clin, Salt Lake City, UT 84103 USA.	jfoley@rmmsc.com	Vargas, Wendy/ABC-5003-2020	Vargas, Wendy/0000-0001-8512-048X	Biogen	Biogen(Biogen)	Biogen.	Akacha M, 2021, CPT-PHARMACOMET SYST, V10, P279, DOI 10.1002/psp4.12617; Biogen, 2020, TYSABRI NATALIZUMAB; Bloomgren G, 2012, NEW ENGL J MED, V366, P1870, DOI 10.1056/NEJMoa1107829; Bomprezzi R, 2014, THER ADV NEUROL DISO, V7, P227, DOI 10.1177/1756285614540224; Butzkueven H, 2021, THER ADV NEUROL DISO, V14, DOI 10.1177/17562864211042458; Butzkueven H, 2020, J NEUROL NEUROSUR PS, V91, P660, DOI 10.1136/jnnp-2019-322326; Chang I, 2021, J CLIN PHARMACOL, V61, P339, DOI 10.1002/jcph.1737; Chisari CG, 2020, J NEUROL NEUROSUR PS, V91, P1297, DOI 10.1136/jnnp-2020-323472; Clerico M, 2020, NEUROTHERAPEUTICS, V17, P200, DOI 10.1007/s13311-019-00776-7; Dong-Si T, 2014, ANN CLIN TRANSL NEUR, V1, P755, DOI 10.1002/acn3.114; Fox RJ, 2014, NEUROLOGY, V82, P1491, DOI 10.1212/WNL.0000000000000355; Havrdova E, 2009, LANCET NEUROL, V8, P254, DOI 10.1016/S1474-4422(09)70021-3; Ho PR, 2017, LANCET NEUROL, V16, P925, DOI 10.1016/S1474-4422(17)30282-X; Horakova D, 2020, MULT SCLER RELAT DIS, V46, DOI 10.1016/j.msard.2020.102543; International Council for Harmonisation, 2019, ADD EST SENS AN CLIN; Little RJ, 2021, JAMA-J AM MED ASSOC, V326, P967, DOI 10.1001/jama.2021.2886; Miller DH, 2007, NEUROLOGY, V68, P1390, DOI 10.1212/01.wnl.0000260064.77700.fd; Muralidharan KK, 2017, J PHARMACOKINET PHAR, V44, P263, DOI 10.1007/s10928-017-9514-4; Perumal J, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1337-z; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Riancho J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.614715; Rudick Richard A, 2004, Expert Rev Neurother, V4, P571, DOI 10.1586/14737175.4.4.571; Ryerson LZ, 2016, J NEUROL NEUROSUR PS, V87, P885, DOI 10.1136/jnnp-2015-312940; Ryerson LZ, 2019, NEUROLOGY, V93, pE1452, DOI 10.1212/WNL.0000000000008243; Scarpazza C, 2019, NEUROL SCI, V40, P2119, DOI 10.1007/s10072-019-03959-4; Sormani MP, 2013, LANCET NEUROL, V12, P669, DOI 10.1016/S1474-4422(13)70103-0; Trojano M, 2021, MULT SCLER J, V27, P2240, DOI 10.1177/13524585211003020; van Kempen ZLE, 2020, NEUROLOGY, V95, pE745, DOI 10.1212/WNL.0000000000009995; van Kempen ZLE, 2017, MULT SCLER J, V23, P995, DOI 10.1177/1352458516684023; Wattjes MP, 2021, LANCET NEUROL, V20, P653, DOI 10.1016/S1474-4422(21)00095-8; Yamout BI, 2018, MULT SCLER RELAT DIS, V24, P113, DOI 10.1016/j.msard.2018.06.015	31	8	8	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2022	21	7					608	619		10.1016/S1474-4422(22)00143-0	http://dx.doi.org/10.1016/S1474-4422(22)00143-0			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3J4YF	35483387				2022-12-18	WOS:000833401200014
J	Chun, JY; Park, S; Jung, JH; Kim, SH; Kim, TS; Choi, YJ; Kim, HJ; Eom, HS; Hyun, JW				Chun, June Young; Park, Sohyun; Jung, Jongheon; Kim, Su-Hyun; Kim, Tae-Sung; Choi, Young Ju; Kim, Ho Jin; Eom, Hyeon-Seok; Hyun, Jae-Won			Guillain-Barre syndrome after vaccination against COVID-19	LANCET NEUROLOGY			English	Letter									[Chun, June Young; Choi, Young Ju] Natl Canc Ctr, Div Infect Dis, Dept Internal Med, Res Inst & Hosp, Goyang 10408, South Korea; [Park, Sohyun; Kim, Tae-Sung] Natl Canc Ctr, Dept Nucl Med, Res Inst & Hosp, Goyang 10408, South Korea; [Jung, Jongheon; Eom, Hyeon-Seok] Natl Canc Ctr, Dept Hemato Oncol, Res Inst & Hosp, Goyang 10408, South Korea; [Kim, Su-Hyun; Kim, Ho Jin; Hyun, Jae-Won] Natl Canc Ctr, Ctr Hematol Malignancy, Res Inst & Hosp, Goyang 10408, South Korea; [Kim, Su-Hyun; Kim, Ho Jin; Hyun, Jae-Won] Natl Canc Ctr, Dept Neurol, Res Inst & Hosp, Goyang 10408, South Korea	National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC)	Eom, HS (corresponding author), Natl Canc Ctr, Dept Hemato Oncol, Res Inst & Hosp, Goyang 10408, South Korea.; Hyun, JW (corresponding author), Natl Canc Ctr, Ctr Hematol Malignancy, Res Inst & Hosp, Goyang 10408, South Korea.; Hyun, JW (corresponding author), Natl Canc Ctr, Dept Neurol, Res Inst & Hosp, Goyang 10408, South Korea.	hseom@ncc.re.kr; jacksy12@naver.com		Chun, June Young/0000-0001-9345-6645				Allen CM, 2021, ANN NEUROL, V90, P315, DOI 10.1002/ana.26144; European Medicines Agency, 2021, M HIGHL PHARM RISK A; European Medicines Agency (EMA), 2021, COVID 19 VACC JANSS; Fokke C, 2014, BRAIN, V137, P33, DOI 10.1093/brain/awt285; Korea Centers for Disease Control and Prevention, 2021, TRENDS OCC ADV REACT; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Slart RHJA, 2018, EUR J NUCL MED MOL I, V45, P1250, DOI 10.1007/s00259-018-3973-8; Strobel K, 2007, CLIN NUCL MED, V32, P646, DOI 10.1097/RLU.0b013e3180a1ac74; US Food and Drug Administration, 2021, COR COVID 19 UPD; Yanagiya Ryo, 2019, Rinsho Ketsueki, V60, P761, DOI 10.11406/rinketsu.60.761	10	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2022	21	2					117	119		10.1016/S1474-4422(21)	http://dx.doi.org/10.1016/S1474-4422(21)			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZT4ER	34929194				2022-12-18	WOS:000769111800010
J	Doty, RL				Doty, Richard L.			The mechanisms of smell loss after SARS-CoV-2 infection	LANCET NEUROLOGY			English	Editorial Material									[Doty, Richard L.] Univ Penn, Perelman Sch Med, Smell & Taste Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Doty, RL (corresponding author), Univ Penn, Perelman Sch Med, Smell & Taste Ctr, Philadelphia, PA 19104 USA.	richard.doty@uphs.upenn.edu						Doty RL, 2017, LANCET NEUROL, V16, P478, DOI 10.1016/S1474-4422(17)30123-0; Doty RL, 2011, PSYCHOL AGING, V26, P864, DOI 10.1037/a0023263; Graves AB, 1999, NEUROLOGY, V53, P1480, DOI 10.1212/WNL.53.7.1480; Henry J, 2010, PARKINSONISM RELAT D, V16, P566, DOI 10.1016/j.parkreldis.2010.06.012; Huart C, 2020, RHINOLOGY, V58, P623, DOI 10.4193/Rhin20.251; Loo AT, 1996, INT J DEV NEUROSCI, V14, P881, DOI 10.1016/S0736-5748(96)00046-9; Moein ST, 2020, INT FORUM ALLERGY RH, V10, P1127, DOI 10.1002/alr.22680; Potter MR, 2020, INT FORUM ALLERGY RH, V10, P706, DOI 10.1002/alr.22551; Xydakis MS, 2021, LANCET NEUROL, V20, P753, DOI 10.1016/S1474-4422(21)00182-4; YAMAGISHI M, 1988, ARCH OTO-RHINO-LARYN, V245, P316, DOI 10.1007/BF00464640	10	8	8	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2021	20	9					693	695		10.1016/S1474-4422(21)00202-7	http://dx.doi.org/10.1016/S1474-4422(21)00202-7		AUG 2021	3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UK3MC	34339627	Green Published, Bronze			2022-12-18	WOS:000691876000005
J	Wilbrink, LA; De Coo, IF; Doesborg, PGG; Mulleners, WM; Teernstra, OPM; Bartels, EC; Burger, K; Wille, F; Van Dongen, RTM; Kurt, E; Spincemaille, GH; Haan, J; Van Zwet, EW; Huygen, FJPM; Ferrari, MD				Wilbrink, Leopoldine A.; de Coo, Ilse F.; Doesborg, Patty G. G.; Mulleners, Wim M.; Teernstra, Onno P. M.; Bartels, Eveline C.; Burger, Katja; Wille, Frank; van Dongen, Robert T. M.; Kurt, Erkan; Spincemaille, Geert H.; Haan, Joost; van Zwet, Erik W.; Huygen, FranK J. P. M.; Ferrari, Michel D.			Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-controlled trial	LANCET NEUROLOGY			English	Article							CHRONIC MIGRAINE; PLACEBO; PATHOPHYSIOLOGY; MANAGEMENT; NOCEBO; TENS; PAIN	Background Occipital nerve stimulation (ONS) has shown promising results in small uncontrolled trials in patients with medically intractable chronic cluster headache (MICCH). We aimed to establish whether ONS could serve as an effective treatment for patients with MICCH. Methods The ONS in MICCH (ICON) study is an investigator-initiated, international, multicentre, randomised, double-blind, phase 3, electrical dose-controlled clinical trial. The study took place at four hospitals in the Netherlands, one hospital in Belgium, one in Germany, and one in Hungary. After 12 weeks' baseline observation, patients with MICCH, at least four attacks per week, and history of being non-responsive to at least three standard preventive drugs, were randomly allocated (at a 1:1 ratio using a computer-generated permuted block) to 24 weeks of occipital nerve stimulation at either 100% or 30% of the individually determined range between paraesthesia threshold and neardiscomfort (double-blind study phase). Because ONS causes paraesthesia, preventing masked comparison versus placebo, we compared high-intensity versus low-intensity ONS, which are hypothesised to cause similar paraesthesia, but with different efficacy. In weeks 25-48, participants received individually optimised open-label ONS. The primary outcome was the weekly mean attack frequency in weeks 21-24 compared with baseline across all patients and, if a decrease was shown, to show a group-wise difference. The trial is closed to recruitment (ClinicalTrials.gov NCT01151631). Findings Patients were enrolled between Oct 12, 2010, and Dec 3, 2017. We enrolled 150 patients and randomly assigned 131 (87%) to treatment; 65 (50%) patients to 100% ONS and 66 (50%) to 30% ONS. One of the 66 patients assigned to 30% ONS was not implanted and was therefore excluded from the intention-to-treat analysis. Because the weekly mean attack frequencies at baseline were skewed (median 15.75; IQR 9.44 to 24.75) we used log transformation to analyse the data and medians to present the results. Median weekly mean attack frequencies in the total population decreased from baseline to 7.38 (2.50 to 18.50; p<0.0001) in weeks 21-24, a median change of -5.21 (-11.18 to -0.19; p<0.0001) attacks per week. In the 100% ONS stimulation group, mean attack frequency decreased from 17.58 (9.83 to 29.33) at baseline to 9.50 (3.00 to 21.25) at 21-24 weeks (median change from baseline -4.08, -11.92 to -0.25), and for the 30% ONS stimulation group, mean attack frequency decreased from 15.00 (9.25 to 22.33) to 6.75 (1.50 to 16.50; -6.50, -10.83 to -0.08). The difference in median weekly mean attack frequency between groups at the end of the masked phase in weeks 21-24 was -2.42 (95% CI -5.17 to 3.33). In the masked study phase, 129 adverse events occurred with 100% ONS and 95 occurred with 30% ONS. None of the adverse events was unexpected but 17 with 100% ONS and eight with 30% ONS were labelled as serious, given they required brief hospital admission for minor hardware-related issues. The most common adverse events were local pain, impaired wound healing, neck stiffness, and hardware damage. Interpretation In patients with MICCH, both 100% ONS intensity and 30% ONS intensity substantially reduced attack frequency and were safe and well tolerated. Future research should focus on optimising stimulation protocols and disentangling the underlying mechanism of action. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Wilbrink, Leopoldine A.; de Coo, Ilse F.; Doesborg, Patty G. G.; Haan, Joost; Ferrari, Michel D.] Leiden Univ Med Ctr, Dept Neurol, NL-2300 Leiden, Netherlands; [Wilbrink, Leopoldine A.] Zuyderland Med Ctr, Dept Neurol, Heerlen, Netherlands; [de Coo, Ilse F.] Basalt Rehabil Ctr, The Hague, Netherlands; [Mulleners, Wim M.] Canisius Wilhelmina Hosp, Dept Neurol, Nijmegen, Netherlands; [Teernstra, Onno P. M.; Spincemaille, Geert H.] Maastricht Univ Med Ctr, Dept Neurosurg, Maastricht, Netherlands; [Bartels, Eveline C.] Leiden Univ Med Ctr, Dept Anaesthesiol, Leiden, Netherlands; [Burger, Katja] Alrijne Hosp, Dept Anaesthesiol, Leiderdorp, Netherlands; [Wille, Frank] Diakonessenhuis Hosp, Dept Anaesthesiol, Zeist, Netherlands; [van Dongen, Robert T. M.] Radboud Univ Nijmegen Med Ctr, Dept Anaesthesiol, Nijmegen, Netherlands; [Kurt, Erkan] Radboud Univ Nijmegen Med Ctr, Dept Neurosurg, Nijmegen, Netherlands; [Haan, Joost] Alrijne Hosp, Dept Neurol, Leiderdorp, Netherlands; [van Zwet, Erik W.] Leiden Univ Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands; [Huygen, FranK J. P. M.] Erasmus MC, Dept Anaesthesiol, Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Canisius-Wilhelmina Hospital; Maastricht University; Maastricht University Medical Centre (MUMC); Leiden University; Leiden University Medical Center (LUMC); Diakonessenhuis; Radboud University Nijmegen; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Erasmus University Rotterdam; Erasmus MC	Ferrari, MD (corresponding author), Leiden Univ Med Ctr, Dept Neurol, NL-2300 Leiden, Netherlands.	m.d.ferrari@lumc.nl	Ferrari, Michel D./ABE-3758-2021; Mulleners, Wim/ABC-7853-2021	Ferrari, Michel D./0000-0001-9691-9449; Eross, Lorand/0000-0002-5796-5546	Netherlands Organisation for Scientific Research; Dutch Ministry of Health; NutsOhra Foundation from the Dutch Health Insurance Companies; Medtronic	Netherlands Organisation for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Ministry of Health; NutsOhra Foundation from the Dutch Health Insurance Companies; Medtronic(Medtronic)	The Netherlands Organisation for Scientific Research, the Dutch Ministry of Health, the NutsOhra Foundation from the Dutch Health Insurance Companies, and Medtronic.	Aibar-Duran JA, 2021, J NEUROSURG, V134, P393, DOI 10.3171/2019.11.JNS192042; Ambrosini A, 2005, PAIN, V118, P92, DOI 10.1016/j.pain.2005.07.015; Benedetti F, 2016, LANCET NEUROL, V15, P736, DOI [10.1016/S1474-4422(16)00066-1, 10.1016/s1474-4422(16)00066-1]; BENMENACHEM E, 1994, EPILEPSIA, V35, P616, DOI 10.1111/j.1528-1157.1994.tb02482.x; Burns B, 2007, LANCET, V369, P1099, DOI 10.1016/S0140-6736(07)60328-6; Burns B, 2009, NEUROLOGY, V72, P341, DOI 10.1212/01.wnl.0000341279.17344.c9; Charles A, 2019, LANCET, V394, P1765, DOI 10.1016/S0140-6736(19)32504-8; Colloca L, 2020, NEW ENGL J MED, V382, P554, DOI 10.1056/NEJMra1907805; de Coo IF, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0514-z; Dodick DW, 2020, CEPHALALGIA, V40, P935, DOI 10.1177/0333102420905321; Fontaine D, 2011, CEPHALALGIA, V31, P1101, DOI 10.1177/0333102411412086; Fontaine D, 2010, J HEADACHE PAIN, V11, P23, DOI 10.1007/s10194-009-0169-4; Garcia-Ortega R, 2019, NEUROMODULATION, V22, P638, DOI 10.1111/ner.12977; Gaul C, 2016, CEPHALALGIA, V36, P534, DOI 10.1177/0333102415607070; Gelfand AA, 2018, JAMA NEUROL, V75, P1179, DOI 10.1001/jamaneurol.2018.1428; Goadsby PJ, 2006, CEPHALALGIA, V26, P1168, DOI 10.1111/j.1468-2982.2006.01173.x; Goadsby PJ, 2019, LANCET NEUROL, V18, P1081, DOI 10.1016/S1474-4422(19)30322-9; Goadsby PJ, 2019, NEW ENGL J MED, V381, P132, DOI 10.1056/NEJMoa1813440; Hoffmann J, 2018, LANCET NEUROL, V17, P75, DOI 10.1016/S1474-4422(17)30405-2; Kaptchuk TJ, 2015, NEW ENGL J MED, V373, P8, DOI 10.1056/NEJMp1504023; Kapural L, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0406-7; Lazarou L, 2009, CLIN J PAIN, V25, P773, DOI 10.1097/AJP.0b013e3181a7ece3; Leplus A, 2021, NEUROSURGERY, V88, P375, DOI 10.1093/neuros/nyaa373; Leroux E, 2011, LANCET NEUROL, V10, P891, DOI 10.1016/S1474-4422(11)70186-7; Magis D, 2007, LANCET NEUROL, V6, P314, DOI 10.1016/S1474-4422(07)70058-3; Magis D, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0598-9; Magis D, 2011, HEADACHE, V51, P1191, DOI 10.1111/j.1526-4610.2011.01973.x; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; Matharu MS, 2004, BRAIN, V127, P220, DOI 10.1093/brain/awh022; Miller S, 2017, EUR J NEUROL, V24, P381, DOI 10.1111/ene.13215; Miller S, 2018, CEPHALALGIA, V38, P1267, DOI 10.1177/0333102417728747; Mitsikostas DD, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-79; Moran F, 2011, J PAIN, V12, P929, DOI 10.1016/j.jpain.2011.02.352; Nowacki A, 2020, ANN NEUROL, V88, P956, DOI 10.1002/ana.25887; Rozen TD, 2019, HEADACHE, V59, P56, DOI 10.1111/head.13394; Rozen TD, 2012, HEADACHE, V52, P99, DOI 10.1111/j.1526-4610.2011.02028.x; Schoenen J, 2005, BRAIN, V128, P940, DOI 10.1093/brain/awh411; Sharan A, 2015, NEUROMODULATION, V18, P305, DOI 10.1111/ner.12243; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Trentman TL, 2008, NEUROMODULATION, V11, P56, DOI 10.1111/j.1525-1403.2007.00143.x; Vyas DB, 2019, NEUROMODULATION, V22, P388, DOI 10.1111/ner.12869; Wartolowska KA, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1720-7; Wilbrink LA, 2013, CEPHALALGIA, V33, P1238, DOI 10.1177/0333102413490351; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x	45	8	8	15	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2021	20	7					515	525		10.1016/S1474-4422(21)00101-0	http://dx.doi.org/10.1016/S1474-4422(21)00101-0			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UD5TG	34146510	Green Published			2022-12-18	WOS:000687268300011
J	Hardiman, O				Hardiman, Orla			Major advances in amyotrophic lateral sclerosis in 2020	LANCET NEUROLOGY			English	Editorial Material									[Hardiman, Orla] Trinity Coll Dublin, Acad Unit Neurol, Trinity Biomed Sci Inst, Dublin 2, Ireland	Trinity College Dublin	Hardiman, O (corresponding author), Trinity Coll Dublin, Acad Unit Neurol, Trinity Biomed Sci Inst, Dublin 2, Ireland.	hardimao@tcd.ie						De Vocht J, 2020, JAMA NEUROL, V77, P1008, DOI 10.1001/jamaneurol.2020.1087; Dukic S, 2019, HUM BRAIN MAPP, V40, P4827, DOI 10.1002/hbm.24740; Dyer MS, 2021, J NEUROCHEM, V157, P1300, DOI 10.1111/jnc.15214; Meier JM, 2020, ANN NEUROL, V87, P725, DOI 10.1002/ana.25706; Menon P, 2020, ANN CLIN TRANSL NEUR, V7, P733, DOI 10.1002/acn3.51039; Miller T, 2020, NEW ENGL J MED, V383, P109, DOI 10.1056/NEJMoa2003715; Paganoni S, 2020, NEW ENGL J MED, V383, P919, DOI 10.1056/NEJMoa1916945; Shefner JM, 2020, CLIN NEUROPHYSIOL, V131, P1975, DOI 10.1016/j.clinph.2020.04.005; van Eijk RPA, 2020, AMYOTROPH LAT SCL FR, V21, P496, DOI 10.1080/21678421.2020.1788092; van Es MA, 2020, EXPERT REV NEUROTHER, V20, P895, DOI 10.1080/14737175.2020.1806061	10	8	9	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					14	15		10.1016/S1474-4422(20)30447-6	http://dx.doi.org/10.1016/S1474-4422(20)30447-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33340474				2022-12-18	WOS:000600831400010
J	Moro, E; Deuschl, G; de Visser, M; Muresanu, D; Soffietti, R; Marson, A; Vidailhet, M; Vodusek, DB; Bassetti, CLA				Moro, Elena; Deuschl, Gunther; de Visser, Marianne; Muresanu, Dafin; Soffietti, Riccardo; Marson, Anthony; Vidailhet, Marie; Vodusek, David B.; Bassetti, Claudio L. A.			A call from the European Academy of Neurology on COVID-19	LANCET NEUROLOGY			English	Letter									[Moro, Elena] Grenoble Alpes Univ, Div Neurol, CHU Grenoble, Grenoble, France; [Deuschl, Gunther] Univ Klinikum Schleswig Holstein, Klin Neurol, Campus Kiel, Kiel, Germany; [de Visser, Marianne] Acad Med Ctr Amsterdam, Dept Neurol, Amsterdam, Netherlands; [Muresanu, Dafin] Spitalul Clin Judetean Cluj, Dept Neurol, Cluj Napoca, Romania; [Soffietti, Riccardo] Univ Torino, Dept Neurooncol, Turin, Italy; [Soffietti, Riccardo] City Hlth & Sci Hosp, Turin, Italy; [Marson, Anthony] Univ Liverpool, Dept Neurol Sci, Unit Neurosci Res, Liverpool, Merseyside, England; [Vidailhet, Marie] Grp Hosp Pitie Salpetriere, Serv Neurol, Federat Neurol, Paris, France; [Vodusek, David B.] Univ Med Ctr Ljubljana, Div Neurol, Ljubljana, Slovenia; [Bassetti, Claudio L. A.] Univ Bern, Dept Neurol, Inselspital, Bern, Switzerland	CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Kiel; Schleswig Holstein University Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; University of Liverpool; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University Medical Centre Ljubljana; University of Bern	Bassetti, CLA (corresponding author), Univ Bern, Dept Neurol, Inselspital, Bern, Switzerland.	claudio.bassetti@insel.ch	Muresanu, Fior-Dafin/AAI-8120-2021; Soffietti, Riccardo/AAA-7965-2022; Deuschl, Gunther/A-7986-2010; Marson, Anthony/AAW-9776-2020	Soffietti, Riccardo/0000-0002-9204-7038; Deuschl, Gunther/0000-0002-4176-9196; Marson, Anthony/0000-0002-6861-8806; Bassetti, Claudio/0000-0002-4535-0245				Gutierrez C, 2020, NEUROLOGY, V94; He Q, 2020, NEUROLOGICAL MANIFES, DOI [DOI 10.2139/SSRN.3544840, 10. 1101/2020.02.22.20026500, DOI 10.1101/2020.02.22.20026500]; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728; Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191	5	8	9	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2020	19	6					482	482		10.1016/S1474-4422(20)30151-4	http://dx.doi.org/10.1016/S1474-4422(20)30151-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MD6CK	32470415	Green Published, Bronze			2022-12-18	WOS:000544059200019
J	Khalil, H; Chahine, L; Siddiqui, J; Aldaajani, Z; Bajwa, JA				Khalil, Hanan; Chahine, Lana; Siddiqui, Junaid; Aldaajani, Zakiyah; Bajwa, Jawad A.			Parkinson's disease in the MENASA countries	LANCET NEUROLOGY			English	Editorial Material									[Khalil, Hanan; Chahine, Lana; Siddiqui, Junaid; Aldaajani, Zakiyah; Bajwa, Jawad A.] King Fahad Med City, Natl Neurosci Inst, Riyadh, Saudi Arabia	King Fahad Medical City	Khalil, H (corresponding author), King Fahad Med City, Natl Neurosci Inst, Riyadh, Saudi Arabia.		Siddiqui, Junaid H/O-6648-2015	Siddiqui, Junaid H/0000-0003-3798-1036; Khalil, Hanan/0000-0001-7741-8892				[Anonymous], 2015, PLOS ONE, V10; [Anonymous], 2000, NEUROLOGY, V54, P1603; [Anonymous], 2012, NEUROEPIDEMIOLOGY, V38, P154; [Anonymous], 2001, ASS U B ENV RES, V4, P1; [Anonymous], 2005, MOV DISORD, V20, P1264; [Anonymous], 2015, NEUROL RES, V37, P607; [Anonymous], 2004, ASS U B ENV RES, V7, P105; [Anonymous], 2008, MOV DISORD, V23, P1205; [Anonymous], 2010, HUMAN MOL GENET, V19, P1998; [Anonymous], 2017, MOV DISORD S2, V32; [Anonymous], 2010, ANN NUTR METAB, V57, P193; [Anonymous], 2012, PARKINSONISM RELAT D, V18, pS63	12	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2020	19	4					293	294		10.1016/S1474-4422(20)30026-0	http://dx.doi.org/10.1016/S1474-4422(20)30026-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KW1GS	32169157	Bronze			2022-12-18	WOS:000520920500013
J	Ciccarelli, O				Ciccarelli, Olga			Multiple sclerosis in 2018: new therapies and biomarkers	LANCET NEUROLOGY			English	Editorial Material							NEUROFILAMENT LIGHT; FINGOLIMOD; TRIAL		[Ciccarelli, Olga] UCL Queen Sq Inst Neurol, London, England	University of London; University College London	Ciccarelli, O (corresponding author), UCL Queen Sq Inst Neurol, London, England.	o.ciccarelli@ucl.ac.uk	Ciccarelli, Olga/AAY-3328-2020	Ciccarelli, Olga/0000-0001-7485-1367	NIHR University College London Hospitals (UCLH) Biomedical Research Centre (BRC); UK MS Society; National MS Society; NIHR UCLH; BRC; Progressive MS Alliance; Bioclinica; GE Neuro; EU; Spinal Cord Research Foundation; Rosetrees Trust	NIHR University College London Hospitals (UCLH) Biomedical Research Centre (BRC); UK MS Society; National MS Society(National Multiple Sclerosis Society); NIHR UCLH; BRC; Progressive MS Alliance; Bioclinica; GE Neuro(General Electric); EU(European Commission); Spinal Cord Research Foundation; Rosetrees Trust(Rosetrees Trust)	OC is a National Institute for Health Research (NIHR) research professor; is supported by the NIHR University College London Hospitals (UCLH) Biomedical Research Centre (BRC); has received grants from the UK MS Society, National MS Society, NIHR UCLH, BRC, Progressive MS Alliance, Bioclinica, GE Neuro, the EU, Spinal Cord Research Foundation, and Rosetrees Trust; has received personal fees from Novartis, Teva, Roche, Biogen, and Merck; and has received an honorarium from the journal Neurology.	Barro C, 2018, BRAIN, V141, P2382, DOI 10.1093/brain/awy154; Chitnis T, 2018, NEW ENGL J MED, V379, P1017, DOI 10.1056/NEJMoa1800149; Eshaghi A, 2018, BRAIN, V141, P1665, DOI 10.1093/brain/awy088; Feneberg E, 2018, NEUROLOGY, V90, pE22, DOI 10.1212/WNL.0000000000004761; Fox RJ, 2018, NEW ENGL J MED, V379, P846, DOI 10.1056/NEJMoa1803583; Kappos L, 2018, LANCET, V391, P1263, DOI 10.1016/S0140-6736(18)30475-6; Kuhle J, 2015, NEUROLOGY, V84, P1639, DOI 10.1212/WNL.0000000000001491; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117	8	8	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2019	18	1					10	+		10.1016/S1474-4422(18)30455-1	http://dx.doi.org/10.1016/S1474-4422(18)30455-1			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HE1CJ	30563672	Green Submitted			2022-12-18	WOS:000453007700009
J	Nobile-Orazio, E				Nobile-Orazio, Eduardo			The complement story in Guillain-Barre syndrome: from pathogenesis to therapy	LANCET NEUROLOGY			English	Editorial Material							ANTIBODIES		[Nobile-Orazio, Eduardo] Univ Milan, Dept Med Biotechnol & Translat Med, Humanitas Clin & Res Ctr, Neuromuscular & Neuroimmunol Serv, I-20089 Milan, Italy	University of Milan	Nobile-Orazio, E (corresponding author), Univ Milan, Dept Med Biotechnol & Translat Med, Humanitas Clin & Res Ctr, Neuromuscular & Neuroimmunol Serv, I-20089 Milan, Italy.	eduardo.nobile@unimi.it	Nobile-Orazio, Eduardo/B-7915-2013	Nobile-Orazio, Eduardo/0000-0003-2624-8138	Baxter; CSL Behring; Kedrion Biopharma; LFB; Novartis; UCB; Astellas Biopharma	Baxter; CSL Behring; Kedrion Biopharma; LFB; Novartis(Novartis); UCB(UCB Pharma SA); Astellas Biopharma(Astellas Pharmaceuticals)	I have received personal fees for lecturing or for advisory, scientific, or safety board memberships from Baxter, CSL Behring, Kedrion Biopharma, LFB, Novartis, UCB, and Astellas Biopharma.	Chevret S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001798.pub3; HaferMacko CE, 1996, ANN NEUROL, V39, P627, DOI 10.1002/ana.410390512; Halstead SK, 2008, BRAIN, V131, P1197, DOI 10.1093/brain/awm316; Hughes RAC, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002063.pub5; MCKHANN, 1985, NEUROLOGY, V35, P1096; Misawa S, 2018, LANCET NEUROL, V17, P519, DOI 10.1016/S1474-4422(18)30114-5; Sekiguchi Y, 2012, J NEUROL NEUROSUR PS, V83, P23, DOI 10.1136/jnnp-2011-300309; Susuki K, 2007, J NEUROSCI, V27, P3956, DOI 10.1523/JNEUROSCI.4401-06.2007; Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1; Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525	10	8	8	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2018	17	6					483	485		10.1016/S1474-4422(18)30144-3	http://dx.doi.org/10.1016/S1474-4422(18)30144-3			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GG1RD	29685816	Green Submitted			2022-12-18	WOS:000432463400003
J	Dufouil, C; Glymour, MM				Dufouil, Carole; Glymour, M. Maria			Prediction to prevention in Alzheimer's disease and dementia	LANCET NEUROLOGY			English	Editorial Material									[Dufouil, Carole] Univ Bordeaux, CHU Bordeaux, Bordeaux Sch Publ Hlth, INSERM,U1219,Inst Sante Publ Epiderniol & Dev, F-33000 Bordeaux, France; [Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of California System; University of California San Francisco	Dufouil, C (corresponding author), Univ Bordeaux, CHU Bordeaux, Bordeaux Sch Publ Hlth, INSERM,U1219,Inst Sante Publ Epiderniol & Dev, F-33000 Bordeaux, France.	carole.dufouil@inserm.fr	Dufouil, Carole/J-4968-2012; Dufouil, Carole/F-5751-2014	Dufouil, Carole/0000-0003-2442-4476				Chapko D, 2018, AGING MENT HEALTH, V22, P915, DOI 10.1080/13607863.2017.1348471; Desikan RS, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002258; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Skoog I, 2016, NAT REV NEUROL, V12, P316, DOI 10.1038/nrneurol.2016.55; van der Lee SJ, 2018, LANCET NEUROL, V17, P434, DOI [10.1016/s1474-4422(18)30053-X, 10.1016/S1474-4422(18)30053-X]	5	8	8	1	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2018	17	5					388	389		10.1016/S1474-4422(18)30123-6	http://dx.doi.org/10.1016/S1474-4422(18)30123-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GC7JA	29656734				2022-12-18	WOS:000429968100005
J	Bove, RM; Hauser, SL				Bove, Riley M.; Hauser, Stephen L.			Diagnosing multiple sclerosis: art and science	LANCET NEUROLOGY			English	Editorial Material							BRAIN		[Bove, Riley M.; Hauser, Stephen L.] Univ Calif San Francisco, Dept Neurol, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Hauser, SL (corresponding author), Univ Calif San Francisco, Dept Neurol, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA.	stephen.hauser@ucsf.edu			Genzyme-Sanofi; Roche-Genentech; Novartis	Genzyme-Sanofi(Sanofi-AventisGenzyme Corporation); Roche-Genentech(Roche HoldingGenentech); Novartis(Novartis)	RMB reports personal fees from Genzyme-Sanofi, Roche-Genentech, and Novartis. SLH serves on the Board of Trustees for Neurona Therapeutics, and Scientific Advisory Board for Symbiotix, Annexon, Bionure, and Molecular Stethoscope. SLH also reports travel reimbursement and writing support from F Hoffmann La Roche.	Davis RL., 1991, TXB NEUROPATHOLOGY; Filippi M, 2017, LANCET NEUROL; Filippi M, 2016, LANCET NEUROL, V15, P292, DOI 10.1016/S1474-4422(15)00393-2; Kappos L, 2016, NEUROLOGY, V87, P978, DOI 10.1212/WNL.0000000000003078; Kocevar G, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00478; Lehmann-Werman R, 2016, P NATL ACAD SCI USA, V113, pE1826, DOI 10.1073/pnas.1519286113; Olsen JA, 2016, EBIOMEDICINE, V10, P227, DOI 10.1016/j.ebiom.2016.06.031; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Sati P, 2016, NAT REV NEUROL, V12, P714, DOI 10.1038/nrneurol.2016.166; Siva A, 2013, CLIN NEUROL NEUROSUR, V115, pS1, DOI 10.1016/j.clineuro.2013.09.012; Solomon AJ, 2017, NAT REV NEUROL, V13, P567, DOI 10.1038/nrneurol.2017.106; Thompson AJ, 2017, LANCET NEUROL; Vickrey BG, 2010, ANN NEUROL, V67, P425, DOI 10.1002/ana.21907; YOUNG IR, 1981, LANCET, V2, P1063, DOI 10.1016/S0140-6736(81)91273-3	14	8	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2018	17	2					109	111		10.1016/S1474-4422(17)30461-1	http://dx.doi.org/10.1016/S1474-4422(17)30461-1			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT0PA	29275980				2022-12-18	WOS:000422828500006
J	Zafonte, RD				Zafonte, Ross D.			Traumatic brain injury: an enduring challenge	LANCET NEUROLOGY			English	Editorial Material							PAROXYSMAL SYMPATHETIC HYPERACTIVITY; REHABILITATION; FOOTBALL; PLAYERS; MODEL; RISK		[Zafonte, Ross D.] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA 02129 USA; [Zafonte, Ross D.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital; Spaulding Rehabilitation Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Zafonte, RD (corresponding author), Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA 02129 USA.; Zafonte, RD (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02129 USA.	rzafonte@mgh.harvard.edu			National Institutes of Health, National Institute on Disability, Independent Living, and Rehabilitation Research; US Army Medical Research and Material Command for the Football Players Health Study at Harvard University, USA	National Institutes of Health, National Institute on Disability, Independent Living, and Rehabilitation Research; US Army Medical Research and Material Command for the Football Players Health Study at Harvard University, USA	I have received research funding from the National Institutes of Health, National Institute on Disability, Independent Living, and Rehabilitation Research, and the US Army Medical Research and Material Command for the Football Players Health Study at Harvard University, USA. I serve on the scientific advisory boards of Myomo, Oxeia Biopharma, and ElMindA, and I have received royalties for a textbook from Demos Medical Publishing and for an educational CD from Oakstone.	Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Deshpande SK, 2017, JAMA NEUROL, V74, P909, DOI 10.1001/jamaneurol.2017.1317; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Mathew MJ, 2016, ACTA NEUROCHIR, V158, P2047, DOI 10.1007/s00701-016-2934-x; McMillan TM, 2014, J NEUROL NEUROSUR PS, V85, P1214, DOI 10.1136/jnnp-2013-307279; Meyfroidt G, 2017, LANCET NEUROL, V16, P721, DOI 10.1016/S1474-4422(17)30259-4; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X	14	8	8	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2017	16	10					766	768		10.1016/S1474-4422(17)30300-9	http://dx.doi.org/10.1016/S1474-4422(17)30300-9			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5PI	28920875				2022-12-18	WOS:000410379900005
J	Isaac, MT; Vamvakas, S; Isaac, MB				Isaac, M. T.; Vamvakas, S.; Isaac, M. B.			Diagnostic biomarkers for Alzheimer's disease: a regulatory view	LANCET NEUROLOGY			English	Editorial Material									[Vamvakas, S.; Isaac, M. B.] European Med Agcy, London E14 5EU, England; [Isaac, M. T.] Inst Psychiat Neurol & Neurosci, London, England		Isaac, MB (corresponding author), European Med Agcy, London E14 5EU, England.	maria.isaac@ema.europa.eu						European Medicines Agency, 2017, HUM MED HIHGL 2016; European Medicines Agency, QUAL NOV METH MED DE; European Medicines Agency, 2016, DRAFT GUID CLIN INV; Food and Drug Administration, 2017, NEW DRUGS FDA CDER N; Frisoni GB, 2017, LANCET NEUROL, V16, P661, DOI 10.1016/S1474-4422(17)30159-X; Le Couteur David G, 2016, BMJ, V355, pi6771, DOI 10.1136/bmj.i6771; Ritchie CW, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001893; University of Tokyo Hospital, 2013, PROJ PROM DEV INN PH; US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2013, ALZH DIS DEV DRUG TR	9	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2017	16	8					580	581		10.1016/S1474-4422(17)30223-5	http://dx.doi.org/10.1016/S1474-4422(17)30223-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FA1LP	28721916				2022-12-18	WOS:000405201300007
J	Terashima, KH; Reich, DS				Terashima, Kevin H.; Reich, Daniel S.			Gadolinium deposition: practical guidelines in the face of uncertainty	LANCET NEUROLOGY			English	Editorial Material							CONTRAST; BRAIN		[Terashima, Kevin H.; Reich, Daniel S.] NIH, Translat Neuroradiol Sect, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Reich, DS (corresponding author), NIH, Translat Neuroradiol Sect, Bldg 10, Bethesda, MD 20892 USA.	reichds@ninds.nih.gov			Vertex Pharmaceuticals; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003119] Funding Source: NIH RePORTER	Vertex Pharmaceuticals(Vertex Pharmaceuticals); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	KHT declares no competing interests. DSR reports receiving grants from Vertex Pharmaceuticals.	Absinta M, 2016, NAT REV NEUROL, V12, P358, DOI 10.1038/nrneurol.2016.59; ASNR, 2017, ART SAF GAD CONTR AG; Blumfield E, 2017, PEDIATR RADIOL, V47, P665, DOI 10.1007/s00247-017-3807-z; FDA, 2017, FDA DRUG SAF COMM FD; Gulani V, 2017, LANCET NEUROL, V16, P564, DOI 10.1016/S1474-4422(17)30158-8; Kanda T, 2014, RADIOLOGY, V270, P834, DOI 10.1148/radiol.13131669; Malayeri AA, 2016, J AM COLL RADIOL, V13, P237, DOI 10.1016/j.jacr.2015.11.009; McDonald RJ, 2015, RADIOLOGY, V275, P772, DOI 10.1148/radiol.15150025; Murata N, 2016, INVEST RADIOL, V51, P447, DOI 10.1097/RLI.0000000000000252	9	8	8	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2017	16	7					495	497		10.1016/S1474-4422(17)30174-6	http://dx.doi.org/10.1016/S1474-4422(17)30174-6			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX4MH	28653641				2022-12-18	WOS:000403208400006
J	[Anonymous]				[Anonymous]			Vascular disease and neurodegeneration: advancing together	LANCET NEUROLOGY			English	Editorial Material																			0	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2017	16	5					333	333		10.1016/S1474-4422(17)30086-8	http://dx.doi.org/10.1016/S1474-4422(17)30086-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ER4PH	28414641	Bronze			2022-12-18	WOS:000398782100001
J	Smith, AD; Mangialasche, F; Kivipelto, M				Smith, A. David; Mangialasche, Francesca; Kivipelto, Miia			Dementia research priorities-2	LANCET NEUROLOGY			English	Letter							ALZHEIMERS-DISEASE		[Smith, A. David] Univ Oxford, Dept Pharmacol, Oxford Project Invest Memory & Ageing OPTIMA, Oxford OX1 2JD, England; [Mangialasche, Francesca] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden; [Mangialasche, Francesca] Stockholm Univ, Stockholm, Sweden; [Kivipelto, Miia] Karolinska Inst, Dept Clin Geriatr, S-14186 Huddinge, Sweden; [Kivipelto, Miia] Karolinska Univ Hosp, Stockholm, Sweden	University of Oxford; Karolinska Institutet; Stockholm University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Kivipelto, M (corresponding author), Karolinska Inst, Dept Clin Geriatr, S-14186 Huddinge, Sweden.; Kivipelto, M (corresponding author), Karolinska Univ Hosp, Stockholm, Sweden.	miia.kivipelto@ki.se	Smith, David/GQQ-8257-2022; Kivipelto, Miia/AAS-3557-2021; Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722; Mangialasche, Francesca/0000-0002-2686-3926	Nestle Health Sciences; E Merck	Nestle Health Sciences(Nestle SA); E Merck	ADS reports personal fees from Nestle Health Sciences and from E Merck; he has patents US6008221 and US6127370 licensed to Pamlab, a patent U59364497 issued, and a patent PCT/GB2015/050786 pending. FM and MK declare no competing interests.	Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Norton S, 2014, LANCET NEUROL, V13, P788, DOI 10.1016/S1474-4422(14)70136-X; Schneider LS, 2016, LANCET NEUROL, V15, P1202, DOI 10.1016/S1474-4422(16)30258-7; Shah H, 2016, LANCET NEUROL, V15, P1283, DOI 10.1016/S1474-4422(16)30235-6; van Charante EPM, 2016, LANCET, V388, P797, DOI 10.1016/S0140-6736(16)30950-3; Winblad B, 2016, LANCET NEUROL, V15, P455, DOI 10.1016/S1474-4422(16)00062-4	6	8	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2017	16	3					181	182		10.1016/S1474-4422(16)30401-X	http://dx.doi.org/10.1016/S1474-4422(16)30401-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EK4ZC	28229885				2022-12-18	WOS:000393935700011
J	Panza, F; Logroscino, G				Panza, Francesco; Logroscino, Giancarlo			Anti-tau vaccine in Alzheimer's disease: a tentative step	LANCET NEUROLOGY			English	Editorial Material									[Panza, Francesco; Logroscino, Giancarlo] Univ Bari Aldo Moro, Neurodegenerat Dis Unit, Dept Basic Med Neurosci & Sense Organs, I-70100 Bari, Italy; [Panza, Francesco; Logroscino, Giancarlo] Univ Bari Aldo Moro, Dept Clin Res Neurol, Pia Fdn Cardinale G Panico, Lecce, Italy; [Panza, Francesco] IRCCS Casa Sollievo Sofferenza, Geriatr Unit, Foggia, Italy; [Panza, Francesco] IRCCS Casa Sollievo Sofferenza, Lab Gerontol & Geriatr, Dept Med Sci, Foggia, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; IRCCS Casa Sollievo Della Sofferenza; IRCCS Casa Sollievo Della Sofferenza	Panza, F (corresponding author), Univ Bari Aldo Moro, Neurodegenerat Dis Unit, Dept Basic Med Neurosci & Sense Organs, I-70100 Bari, Italy.; Panza, F (corresponding author), Univ Bari Aldo Moro, Dept Clin Res Neurol, Pia Fdn Cardinale G Panico, Lecce, Italy.; Panza, F (corresponding author), IRCCS Casa Sollievo Sofferenza, Geriatr Unit, Foggia, Italy.; Panza, F (corresponding author), IRCCS Casa Sollievo Sofferenza, Lab Gerontol & Geriatr, Dept Med Sci, Foggia, Italy.	geriat.dot@geriatria.uniba.it	Panza, Francesco/M-6804-2017; Panza, Francesco/Y-2539-2019	Panza, Francesco/0000-0002-7220-0656; Panza, Francesco/0000-0002-7220-0656				Ahmed RM, 2014, J NEUROL NEUROSUR PS, V85, P1426, DOI 10.1136/jnnp-2014-307662; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Kontsekova E, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt278; Novak P, 2016, LANCET NEUROL; Paholikova K, 2015, J ALZHEIMERS DIS, V43, P915, DOI 10.3233/JAD-140996; Panza F, 2016, EXPERT OPIN EMERG DR, V21, P377, DOI 10.1080/14728214.2016.1241232; Panza F, 2016, IMMUNOTHERAPY-UK, V8, P1119, DOI 10.2217/imt-2016-0019	8	8	8	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2017	16	2					99	100		10.1016/S1474-4422(16)30340-4	http://dx.doi.org/10.1016/S1474-4422(16)30340-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EH6VA	27955996				2022-12-18	WOS:000391910800003
J	Riikonen, R				Riikonen, Raili			Combination therapy for treatment of infantile spasms	LANCET NEUROLOGY			English	Editorial Material							CORTICOTROPIN		[Riikonen, Raili] Univ Eastern Finland, Childrens Hosp, Kuopio, Finland; [Riikonen, Raili] Kuopio Univ Hosp, Kuopio, Finland	University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland	Riikonen, R (corresponding author), Univ Eastern Finland, Childrens Hosp, Kuopio, Finland.; Riikonen, R (corresponding author), Kuopio Univ Hosp, Kuopio, Finland.	raili.riikonen@kolumbus.fi						Go CY, 2012, NEUROLOGY, V78, P1974, DOI 10.1212/WNL.0b013e318259e2cf; Granstrom ML, 1999, EPILEPSIA, V40, P950, DOI 10.1111/j.1528-1157.1999.tb00802.x; Hancock EC, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001770.pub3; HRACHOVY RA, 1994, J PEDIATR-US, V124, P803, DOI 10.1016/S0022-3476(05)81379-4; Knupp KG, 2016, ANN NEUROL, V79, P475, DOI 10.1002/ana.24594; LOMBROSO CT, 1983, EPILEPSIA, V24, P135, DOI 10.1111/j.1528-1157.1983.tb04874.x; O'Callaghan FJK, 2016, LANCET NEUROL; Riikonen R, 2014, CNS DRUGS, V28, P279, DOI 10.1007/s40263-014-0139-5; Riikonen R, 2012, NAT REV NEUROL, V8, P480, DOI 10.1038/nrneurol.2012.157; Wanigasinghe J, 2015, PEDIATR NEUROL, V53, P193, DOI 10.1016/j.pediatrneurol.2015.05.004	10	8	8	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					19	20		10.1016/s1474-4422(16)30276-9	http://dx.doi.org/10.1016/s1474-4422(16)30276-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27838191				2022-12-18	WOS:000389869200012
J	[Anonymous]				[Anonymous]			Rare advances for rare diseases	LANCET NEUROLOGY			English	Editorial Material																			0	8	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					1	1		10.1016/S1474-4422(16)30352-0	http://dx.doi.org/10.1016/S1474-4422(16)30352-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27979337				2022-12-18	WOS:000389869200001
J	Ramos, ML; Pascual, J				Ramos, Marta L.; Pascual, Julio			AMG 334 CGRP antibody for migraine: time to celebrate?	LANCET NEUROLOGY			English	Editorial Material							GENE-RELATED PEPTIDE; DOUBLE-BLIND; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; PHASE 2B; EFFICACY; SAFETY; TOLERABILITY; CIRCULATION; MULTICENTER		[Ramos, Marta L.] Hosp Occidente Kennedy, Dept Neurol, Bogota, Colombia; [Ramos, Marta L.] Univ La Sabana, Bogota, Colombia; [Pascual, Julio] Univ Hosp Marques Valdecilla, Santander 39008, Spain; [Pascual, Julio] IDIVAL, Santander 39008, Spain	Universidad de La Sabana; Hospital Universitario Marques de Valdecilla (HUMV)	Pascual, J (corresponding author), Univ Hosp Marques Valdecilla, Santander 39008, Spain.; Pascual, J (corresponding author), IDIVAL, Santander 39008, Spain.	juliopascual@telefonica.net						Bigal ME, 2015, LANCET NEUROL, V14, P1081, DOI 10.1016/S1474-4422(15)00249-5; Bigal ME, 2015, LANCET NEUROL, V14, P1091, DOI 10.1016/S1474-4422(15)00245-8; Cernuda-Morollon E, 2014, HEADACHE, V54, P987, DOI 10.1111/head.12372; Cernuda-Morollon E, 2013, NEUROLOGY, V81, P1191, DOI 10.1212/WNL.0b013e3182a6cb72; de Hoon JN, 2015, HEADACHE, V55, P174; Dodick DW, 2014, LANCET NEUROL, V13, P1100, DOI 10.1016/S1474-4422(14)70209-1; Dodick DW, 2014, LANCET NEUROL, V13, P885, DOI 10.1016/S1474-4422(14)70128-0; EDVINSSON L, 1985, TRENDS NEUROSCI, V8, P126, DOI 10.1016/0166-2236(85)90050-5; GOADSBY PJ, 1990, ANN NEUROL, V28, P183, DOI 10.1002/ana.410280213; Lassen LH, 2002, CEPHALALGIA, V22, P54, DOI 10.1046/j.1468-2982.2002.00310.x; Pascual J, 2015, LANCET NEUROL, V14, P1066, DOI 10.1016/S1474-4422(15)00244-6; Sun H., 2016, LANCET NEUROL	12	8	17	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					347	349		10.1016/S1474-4422(16)00040-5	http://dx.doi.org/10.1016/S1474-4422(16)00040-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP	26879278				2022-12-18	WOS:000371974000004
J	Diener, HC; Dodick, DW				Diener, Hans-Christoph; Dodick, David W.			Headache research in 2015: progress in migraine treatment	LANCET NEUROLOGY			English	Editorial Material							GENE-RELATED PEPTIDE; DOUBLE-BLIND; PREVENTIVE TREATMENT; EPISODIC MIGRAINE; PHASE 2B; EFFICACY; SAFETY; TOLERABILITY; MULTICENTER; TEV-48125		[Diener, Hans-Christoph] Univ Hosp Essen, Dept Neurol, D-45122 Essen, Germany; [Diener, Hans-Christoph] Univ Hosp Essen, Headache Ctr, D-45122 Essen, Germany; [Dodick, David W.] Mayo Clin, Dept Neurol, Phoenix, AZ USA	University of Duisburg Essen; University of Duisburg Essen; Mayo Clinic; Mayo Clinic Phoenix	Diener, HC (corresponding author), Univ Hosp Essen, Dept Neurol, D-45122 Essen, Germany.	hans.diener@uk-essen.de	Diener, Hans-Christoph/AAF-7275-2019					Bigal ME, 2015, LANCET NEUROL, V14, P1081, DOI 10.1016/S1474-4422(15)00249-5; Bigal ME, 2015, LANCET NEUROL, V14, P1091, DOI 10.1016/S1474-4422(15)00245-8; Buettner C, 2015, ANN NEUROL, V78, P970, DOI 10.1002/ana.24534; Dodick DW, 2014, LANCET NEUROL, V13, P1100, DOI 10.1016/S1474-4422(14)70209-1; Dodick DW, 2014, LANCET NEUROL, V13, P885, DOI 10.1016/S1474-4422(14)70128-0; Jackson JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130733; Kroger IL, 2015, NEUROLOGY, V84, P2124, DOI 10.1212/WNL.0000000000001610; Schwedt TJ, 2015, HEADACHE, V55, P762, DOI 10.1111/head.12584	8	8	9	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					4	5		10.1016/S1474-4422(15)00341-5	http://dx.doi.org/10.1016/S1474-4422(15)00341-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700894				2022-12-18	WOS:000366313900003
J	Keezer, MR; Sisodiya, SM; Sander, JW				Keezer, M. R.; Sisodiya, S. M.; Sander, J. W.			Comorbidities of epilepsy: current concepts and future perspectives (vol 15, pg 106, 2015)	LANCET NEUROLOGY			English	Correction													Sander, Josemir/C-1576-2008	Sander, Josemir/0000-0001-6041-9661				Keezer MR, 2015, LANCET NEUROL, V14, P683, DOI 10.1016/S1474-4422(15)00100-3	1	8	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					28	28		10.1016/S1474-4422(15)00352-X	http://dx.doi.org/10.1016/S1474-4422(15)00352-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700905				2022-12-18	WOS:000366313900016
J	Wimo, A				Wimo, Anders			Long-term effects of Alzheimer's disease treatment	LANCET NEUROLOGY			English	Editorial Material							ECONOMIC-EVALUATION; CLINICAL-TRIALS; DOUBLE-BLIND; DONEPEZIL; MODERATE; MEMANTINE; POWER		[Wimo, Anders] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Ctr Alzheimer Res, Div Neurogeriatr, Huddinge, Sweden	Karolinska Institutet	Wimo, A (corresponding author), Karolinska Inst, Dept Neurobiol Care Sci & Soc, Ctr Alzheimer Res, Div Neurogeriatr, Huddinge, Sweden.	anders.wimo@ki.se	Wimo, Anders/ABA-2678-2021					Bentham P, 2004, LANCET, V363, P2105; Bond M, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16210; Briggs A, 2000, BRIT MED J, V321, P1362, DOI 10.1136/bmj.321.7273.1362; Feldman H, 2004, NEUROLOGY, V63, P644, DOI 10.1212/01.WNL.0000134663.79663.6E; Howard R, 2015, LANCET NEUROL; Howard R, 2012, NEW ENGL J MED, V366, P893, DOI 10.1056/NEJMoa1106668; Jones R, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-57; Nordberg G, 2005, INT J GERIATR PSYCH, V20, P862, DOI 10.1002/gps.1371; Sansoni J, 2013, Ann Ig, V25, P235, DOI 10.7416/ai.2013.1926; Vollmer SH, 2010, SCI ENG ETHICS, V16, P675, DOI 10.1007/s11948-010-9244-0; Wimo A, 2003, DEMENT GERIATR COGN, V15, P44, DOI 10.1159/000066669; Wimo A, 2003, PHARMACOECONOMICS, V21, P327, DOI 10.2165/00019053-200321050-00004	12	8	9	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2015	14	12					1145	1146		10.1016/S1474-4422(15)00302-6	http://dx.doi.org/10.1016/S1474-4422(15)00302-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW2WZ	26515659				2022-12-18	WOS:000364855100003
J	Berg, AT; Dobyns, WB				Berg, Anne T.; Dobyns, William B.			Progress in autism and related disorders of brain development	LANCET NEUROLOGY			English	Editorial Material									[Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Chicago, IL 60611 USA; [Dobyns, William B.] Univ Washington, Dept Pediat, Seattle, WA 98145 USA; [Dobyns, William B.] Univ Washington, Dept Neurol, Seattle, WA 98145 USA; [Dobyns, William B.] Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA 98145 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Berg, AT (corresponding author), Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Chicago, IL 60611 USA.	atberg@luriechildrens.org	Dobyns, William/AAI-2768-2020; Dobyns, William Brian/ABC-6525-2021	Dobyns, William/0000-0002-7681-2844; 				American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI 10.1176/appi.books.9780890425596; Bernasconi A, 2011, NAT REV NEUROL, V7, P99, DOI 10.1038/nrneurol.2010.199; Ecker C, 2015, LANCET NEUROL; Geschwind DH, 2015, LANCET NEUROL, V14, P1109, DOI 10.1016/S1474-4422(15)00044-7; Guerrini R, 2014, LANCET NEUROL, V13, P710, DOI 10.1016/S1474-4422(14)70040-7; Lemke JR, 2012, EPILEPSIA, V53, P1387, DOI 10.1111/j.1528-1167.2012.03516.x; Mefford HC, 2012, NEW ENGL J MED, V366, P733, DOI 10.1056/NEJMra1114194; Mirzaa GM, 2014, AM J MED GENET C, V166, P117, DOI 10.1002/ajmg.c.31404; Mirzaa GM, 2013, PEDIATR NEUROL, V48, P367, DOI 10.1016/j.pediatrneurol.2012.12.030; Paciorkowski AR, 2011, PEDIATR NEUROL, V45, P355, DOI 10.1016/j.pediatrneurol.2011.08.010	10	8	9	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2015	14	11					1069	1070		10.1016/S1474-4422(15)00048-4	http://dx.doi.org/10.1016/S1474-4422(15)00048-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT7DY	25891008				2022-12-18	WOS:000362975200004
J	Farrer, LA				Farrer, Lindsay A.			Expanding the genomic roadmap of Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							COMMON VARIANTS; ABCA7; CD2AP; EPHA1; CD33		[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Med Biomed Genet, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA; [Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Boston University	Farrer, LA (corresponding author), Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.	farrer@bu.edu	Farrer, Lindsay/AAS-1035-2020	Farrer, Lindsay/0000-0001-5533-4225				Cuyvers E, 2015, LANCET NEUROL; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Hollingworth P, 2011, NAT GENET, V43, P429, DOI 10.1038/ng.803; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kim WS, 2013, J NEUROSCI, V33, P4387, DOI 10.1523/JNEUROSCI.4165-12.2013; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Logue MW, 2014, ALZHEIMERS DEMENT, V10, P609, DOI 10.1016/j.jalz.2014.06.010; Naj AC, 2011, NAT GENET, V43, P436, DOI 10.1038/ng.801; Sherva R, 2011, CURR PSYCHIAT REP, V13, P138, DOI 10.1007/s11920-011-0184-4; Steinberg S, 2015, NAT GENET, V47, P445, DOI 10.1038/ng.3246; Wetzel-Smith MK, 2014, NAT MED, V20, P1452, DOI 10.1038/nm.3736	11	8	13	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2015	14	8					783	785		10.1016/S1474-4422(15)00146-5	http://dx.doi.org/10.1016/S1474-4422(15)00146-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CM7MZ	26141618				2022-12-18	WOS:000357879200004
J	Schulte, LH; May, A				Schulte, Laura H.; May, Arne			Headache research in 2014: advancing migraine therapy	LANCET NEUROLOGY			English	Editorial Material							VASOACTIVE-INTESTINAL-PEPTIDE; GENE-RELATED PEPTIDE; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; INHIBITION; PREVENTION; PARAMETERS; EFFICACY; LBR-101; PHASE-2		[Schulte, Laura H.; May, Arne] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, D-22046 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Schulte, LH (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, D-22046 Hamburg, Germany.	a.may@uke.de						Amin FM, 2014, BRAIN, V137, P779, DOI 10.1093/brain/awt369; Bigal ME, 2014, CEPHALALGIA, V34, P968, DOI 10.1177/0333102414527646; Burstein R, 2014, CEPHALALGIA, V34, P853, DOI 10.1177/0333102414527648; Dodick DW, 2014, LANCET NEUROL, V13, P1100, DOI 10.1016/S1474-4422(14)70209-1; Dodick DW, 2014, LANCET NEUROL, V13, P885, DOI 10.1016/S1474-4422(14)70128-0; Harmar AJ, 2012, BRIT J PHARMACOL, V166, P4, DOI 10.1111/j.1476-5381.2012.01871.x; Ho TW, 2014, NEUROLOGY, V83, P958, DOI 10.1212/WNL.0000000000000771; Kam-Hansen S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3006175; Oktay C, 2015, CEPHALALGIA, V35, P579, DOI 10.1177/0333102414553821; Rahmann A, 2008, CEPHALALGIA, V28, P226, DOI 10.1111/j.1468-2982.2007.01497.x; Schytz HW, 2009, BRAIN, V132, P16, DOI 10.1093/brain/awn307; Walter S, 2014, MABS-AUSTIN, V6, P871, DOI 10.4161/mabs.29242	12	8	9	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					6	7		10.1016/S1474-4422(14)70295-9	http://dx.doi.org/10.1016/S1474-4422(14)70295-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25496881				2022-12-18	WOS:000346885300004
J	Greying, JP; Wermer, MJH; Rinkel, GJE; Algra, A				Greying, Jacoba P.; Wermer, Mariekel J. H.; Rinkel, Gabriel J. E.; Algra, Ale			Unruptured intracranial aneurysms: why we must not perpetuate the impasse for another 25 years Reply	LANCET NEUROLOGY			English	Letter							ENDOVASCULAR TREATMENT; SAFETY; METAANALYSIS		[Greying, Jacoba P.; Algra, Ale] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Rinkel, Gabriel J. E.; Algra, Ale] Univ Med Ctr Utrecht, Dept Neurol & Neurosurg, Brain Ctr Rudolf Magnus, Utrecht, Netherlands; [Wermer, Mariekel J. H.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Greying, JP (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.	j.p.greving@umcutrecht.nl						Brinjikji W, 2011, AM J NEURORADIOL, V32, P1071, DOI 10.3174/ajnr.A2453; Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1; Greving JP, 2009, NEUROLOGY, V73, P258, DOI 10.1212/01.wnl.0b013e3181a2a4ea; Kotowski M, 2013, J NEUROL NEUROSUR PS, V84, P42, DOI 10.1136/jnnp-2011-302068; Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260; Naggara ON, 2012, RADIOLOGY, V263, P828, DOI 10.1148/radiol.12112114; Naggara ON, 2010, RADIOLOGY, V256, P887, DOI 10.1148/radiol.10091982; Raymond J, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-64; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401	9	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2014	13	6					538	538		10.1016/S1474-4422(14)70092-4	http://dx.doi.org/10.1016/S1474-4422(14)70092-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI8YK					2022-12-18	WOS:000337212700011
J	[Anonymous]				[Anonymous]			A rally for traumatic brain injury research	LANCET NEUROLOGY			English	Editorial Material																			0	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2013	12	12					1127	1127		10.1016/S1474-4422(13)70266-7	http://dx.doi.org/10.1016/S1474-4422(13)70266-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	265BG	24229612				2022-12-18	WOS:000327924100001
J	Hutchison, JS; Guerguerian, AM				Hutchison, James S.; Guerguerian, Anne-Marie			Cooling of children with severe traumatic brain injury	LANCET NEUROLOGY			English	Editorial Material							MODERATE HYPOTHERMIA		[Hutchison, James S.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Hutchison, JS (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jamie.hutchison@sickkids.ca; anne-marie.guerguerian@sickkids.ca						Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Adelson PD, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70077-2; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 2001, SYSTEMATIC REV HLTH; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Roozenbeek Bob, 2012, Clin Investig (Lond), V2, P153	8	8	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2013	12	6					527	529		10.1016/S1474-4422(13)70058-9	http://dx.doi.org/10.1016/S1474-4422(13)70058-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161SL	23664371				2022-12-18	WOS:000320213500003
J	Frisoni, GB; Blennow, K				Frisoni, Giovanni B.; Blennow, Kaj			Biomarkers for Alzheimer's: the sequel of an original model	LANCET NEUROLOGY			English	Editorial Material							HYPOTHETICAL MODEL; MARKERS; DEMENTIA; PREDICT; DISEASE		[Frisoni, Giovanni B.] IRCCS San Giovanni di Dio Fatebenefratelli, Lab Epidemiol Neuroimaging & Telemed, I-25125 Brescia, Italy; [Blennow, Kaj] Univ Gothenburg, Clin Neurochem Lab, Sahlgrenska Acad, Molndal, Sweden	IRCCS Fatebenefratelli; University of Gothenburg	Frisoni, GB (corresponding author), IRCCS San Giovanni di Dio Fatebenefratelli, Lab Epidemiol Neuroimaging & Telemed, I-25125 Brescia, Italy.	gfrisoni@fatebenefratelli.it	Frisoni, Giovanni B./K-1360-2016; Frisoni, Giovanni/K-1360-2016	Frisoni, Giovanni B./0000-0002-6419-1753; Frisoni, Giovanni/0000-0001-7075-7082				Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; Braak H, 2011, ACTA NEUROPATHOL, V121, P171, DOI 10.1007/s00401-010-0789-4; Cavedo E, 2012, J ALZHEIMERS DIS, V31, P623, DOI 10.3233/JAD-2012-111817; Committee for Medicinal Products for Human Use (CHMP), EMACHMPSAWP809208201; Committee for Medicinal Products for Human Use (CHMP), EMACHMPSAWP893622201; Fodero-Tavoletti MT, 2011, BRAIN, V134, P1089, DOI 10.1093/brain/awr038; Fox NC, 2000, ARCH NEUROL-CHICAGO, V57, P339, DOI 10.1001/archneur.57.3.339; Honer WG, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.38; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Lorenzi M, 2010, NEUROBIOL AGING, V31, P1443, DOI 10.1016/j.neurobiolaging.2010.04.036; Mattsson N, 2012, J ALZHEIMERS DIS, V30, P767, DOI 10.3233/JAD-2012-120019; van Rossum IA, 2012, NEUROLOGY, V79, P1809, DOI 10.1212/WNL.0b013e3182704056; Wallin AK, 2010, NEUROLOGY, V74, P1531, DOI 10.1212/WNL.0b013e3181dd4dd8	15	8	8	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2013	12	2					126	128		10.1016/S1474-4422(12)70305-8	http://dx.doi.org/10.1016/S1474-4422(12)70305-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	081NZ	23332358				2022-12-18	WOS:000314330200006
J	Hodges, JR				Hodges, John R.			Hope abandoned: memantine therapy in frontotemporal dementia	LANCET NEUROLOGY			English	Editorial Material									[Hodges, John R.] Neurosci Res Australia, Randwick, NSW 2031, Australia; [Hodges, John R.] Univ New S Wales, Randwick, NSW 2031, Australia	Neuroscience Research Australia; University of New South Wales Sydney	Hodges, JR (corresponding author), Neurosci Res Australia, Randwick, NSW 2031, Australia.	j.hodges@neura.edu.au						Boxer A, 2013, LANCET NEUROL; Boxer AL, 2009, ALZ DIS ASSOC DIS, V23, P211, DOI 10.1097/WAD.0b013e318197852f; Boxer AL, 2012, ALZHEIMERS DEMENT; Bozeat S, 2000, J NEUROL NEUROSUR PS, V69, P178, DOI 10.1136/jnnp.69.2.178; Cummings JL, 2006, NEUROLOGY, V67, P57, DOI 10.1212/01.wnl.0000223333.42368.f1; Hodges JR, 2007, LANCET NEUROL, V6, P1004, DOI 10.1016/S1474-4422(07)70266-1; Huey ED, 2006, NEUROLOGY, V66, P17, DOI 10.1212/01.wnl.0000191304.55196.4d; Josephs KA, 2011, ACTA NEUROPATHOL, V122, P137, DOI 10.1007/s00401-011-0839-6; Mioshi E, 2010, NEUROLOGY, V74, P1591, DOI 10.1212/WNL.0b013e3181e04070; Mioshi E, 2012, ALZHEIMER DIS ASS DI; Piguet O, 2011, LANCET NEUROL, V10, P162, DOI 10.1016/S1474-4422(10)70299-4; Swanberg MM, 2007, ALZ DIS ASSOC DIS, V21, P164, DOI 10.1097/WAD.0b013e318047df5d; Vercelletto M, 2011, J ALZHEIMERS DIS, V23, P749, DOI 10.3233/JAD-2010-101632	13	8	9	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2013	12	2					121	123		10.1016/S1474-4422(13)70001-2	http://dx.doi.org/10.1016/S1474-4422(13)70001-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	081NZ	23305744				2022-12-18	WOS:000314330200003
J	Fox, N				Fox, Nick			When, where, and how does Alzheimer's disease start?	LANCET NEUROLOGY			English	Editorial Material							PREVENTION; PROPOSAL		UCL, Dementia Res Ctr, Inst Neurol, London WC1N 3BG, England	University of London; University College London	Fox, N (corresponding author), UCL, Dementia Res Ctr, Inst Neurol, Queen Sq, London WC1N 3BG, England.	n.fox@ucl.ac.uk	Fox, Nick C/B-1319-2009	Fox, Nick C/0000-0002-6660-657X	Arthritis Research UK Funding Source: Medline; Medical Research Council Funding Source: Medline	Arthritis Research UK(Versus Arthritis); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alzheimer Research Forum, BAP PHAS 3 TARG ENG; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bateman RJ, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt59; Chavez-Gutierrez L, 2012, EMBO J, V31, P2261, DOI 10.1038/emboj.2012.79; Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4; Golde TE, 2011, NEURON, V69, P203, DOI 10.1016/j.neuron.2011.01.002; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Reiman EM, 2012, LANCET NEUROL; Reiman EM, 2010, BIOMARK MED, V4, P3, DOI [10.2217/bmm.09.91, 10.2217/BMM.09.91]; Ridha BH, 2006, LANCET NEUROL, V5, P828, DOI 10.1016/S1474-4422(06)70550-6	10	8	8	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2012	11	12					1017	1018		10.1016/S1474-4422(12)70256-9	http://dx.doi.org/10.1016/S1474-4422(12)70256-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044CX	23137950				2022-12-18	WOS:000311598100004
J	Kovacs, GG				Kovacs, Gabor G.			Clinical stratification of subtypes of Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							CLASSIFICATION; ATROPHY		Med Univ Vienna, Inst Neurol, A-1097 Vienna, Austria	Medical University of Vienna	Kovacs, GG (corresponding author), Med Univ Vienna, Inst Neurol, Waehringer Guertel 18-20, A-1097 Vienna, Austria.	gabor.kovacs@meduniwien.ac.at	Kovacs, Gabor/A-7468-2013	Kovacs, Gabor/0000-0003-3841-5511				Barkhof F, 2007, NEUROLOGY, V69, P1521, DOI 10.1212/01.wnl.0000277459.83543.99; Dawe RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026286; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P474, DOI 10.1016/j.jalz.2011.04.007; Kantarci K, 2012, NEUROLOGY, V79, P553, DOI 10.1212/WNL.0b013e31826357a5; Kloppel S, 2008, BRAIN, V131, P681, DOI 10.1093/brain/awm319; Kovacs GG, 2010, ACTA NEUROPATHOL, V119, P389, DOI 10.1007/s00401-010-0658-1; Murray ME, 2011, LANCET NEUROL, V10, P785, DOI 10.1016/S1474-4422(11)70156-9; Whitwell JL, 2012, LANCET NEUROL, V11, P868, DOI 10.1016/S1474-4422(12)70200-4; Whitwell JL, 2012, NAT REV NEUROL, V8, P131, DOI 10.1038/nrneurol.2012.7	10	8	8	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2012	11	10					839	841		10.1016/S1474-4422(12)70209-0	http://dx.doi.org/10.1016/S1474-4422(12)70209-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	018BG	22995685				2022-12-18	WOS:000309634300004
J	Schneider, LS				Schneider, Lon S.			Ginkgo and AD: key negatives and lessons from GuidAge	LANCET NEUROLOGY			English	Editorial Material							BILOBA; DEMENTIA; POPULATION; PREVENTION; TRIALS; DRUG		[Schneider, Lon S.] Univ So Calif, Keck Sch Med, Calif Alzheimers Dis Ctr, Dept Psychiat, Los Angeles, CA 90033 USA; [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Calif Alzheimers Dis Ctr, Dept Neurol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Schneider, LS (corresponding author), Univ So Calif, Keck Sch Med, Calif Alzheimers Dis Ctr, Dept Psychiat, Los Angeles, CA 90033 USA.	lschneid@usc.edu						Andrieu S, 2003, J GERONTOL A-BIOL, V58, P372; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; BIRKS J, 2009, COCHRANE DB SYST REV, V2; Canter PH, 2007, HUM PSYCHOPHARM CLIN, V22, P265, DOI 10.1002/hup.843; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; Kivipelto M, 2008, J CELL MOL MED, V12, P2762, DOI 10.1111/j.1582-4934.2008.00296.x; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; McCarney R, 2008, INT J GERIATR PSYCH, V23, P1222, DOI 10.1002/gps.2055; Meinert CL, 2008, ALZHEIMERS DEMENT, V4, pS7, DOI 10.1016/j.jalz.2007.10.007; Richard E, 2012, J NEUROL SCI; Schneider Lon S., 2005, Current Alzheimer Research, V2, P541, DOI 10.2174/156720505774932287; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Vellas B, 2012, LANCET NEUROL	14	8	8	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2012	11	10					836	837		10.1016/S1474-4422(12)70212-0	http://dx.doi.org/10.1016/S1474-4422(12)70212-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	018BG	22959218				2022-12-18	WOS:000309634300002
J	Biessels, GJ				Biessels, Geert Jan			Intensive glucose lowering and cognition in type 2 diabetes	LANCET NEUROLOGY			English	Editorial Material							OLDER-PEOPLE; DEMENTIA; MELLITUS; RISK		Univ Med Ctr, Dept Neurol, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Biessels, GJ (corresponding author), Univ Med Ctr, Dept Neurol, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands.	g.j.biessels@umcutrecht.nl						Biessels GJ, 2008, LANCET NEUROL, V7, P184, DOI 10.1016/S1474-4422(08)70021-8; Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2; Bruce DG, 2008, DIABETOLOGIA, V51, P241, DOI 10.1007/s00125-007-0894-7; Christman AL, 2011, DIABETOLOGIA, V54, P1645, DOI 10.1007/s00125-011-2095-7; de Bresser J, 2010, DIABETES CARE, V33, P1309, DOI 10.2337/dc09-1923; Euser SM, 2010, DIABETES, V59, P1601, DOI 10.2337/db09-0568; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; LAUNER LJ, 2011, LANCET NEUROL, DOI DOI 10.1016/51474-4422(11)70188-0; Reijmer YD, 2010, DIABETES-METAB RES, V26, P507, DOI 10.1002/dmrr.1112; van den Berg E, 2010, DIABETOLOGIA, V53, P58, DOI 10.1007/s00125-009-1571-9; Whitmer RA, 2009, JAMA-J AM MED ASSOC, V301, P1565, DOI 10.1001/jama.2009.460	11	8	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2011	10	11					949	950		10.1016/S1474-4422(11)70199-5	http://dx.doi.org/10.1016/S1474-4422(11)70199-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	839WJ	21958948				2022-12-18	WOS:000296399900003
J	Nichol, AD; Trapani, T; Murray, L; Vallance, S; Cooper, DJ				Nichol, Alistair D.; Trapani, Tony; Murray, Lynne; Vallance, Shirley; Cooper, David J.			Hypothermia in patients with brain injury: the way forward?	LANCET NEUROLOGY			English	Letter									[Nichol, Alistair D.; Trapani, Tony; Murray, Lynne] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia; [Nichol, Alistair D.; Vallance, Shirley] Alfred Hosp, Intens Care Med Dept, Melbourne, Vic, Australia; [Murray, Lynne] Epworth Richmond, Richmond, Vic, Australia	Monash University; Florey Institute of Neuroscience & Mental Health; Epworth Medical Foundation	Nichol, AD (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia.	alistair.nichol@med.monash.edu.au	Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051; Nichol, Alistair Dualta/0000-0002-4771-5615; Nichol, Alistair/0000-0002-4689-1238				Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8	1	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2011	10	5					405	405		10.1016/S1474-4422(11)70085-0	http://dx.doi.org/10.1016/S1474-4422(11)70085-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	761TV	21511193				2022-12-18	WOS:000290424800008
J	de Visser, M; Verhamme, C				de Visser, Marianne; Verhamme, Camiel			Ascorbic acid for treatment in CMT1A: what's next?	LANCET NEUROLOGY			English	Editorial Material							MARIE-TOOTH-DISEASE; 1A; PROGRESSION		[de Visser, Marianne; Verhamme, Camiel] Acad Med Ctr, Dept Neurol, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	de Visser, M (corresponding author), Acad Med Ctr, Dept Neurol, NL-1100 DD Amsterdam, Netherlands.	m.devisser@amc.nl						Berciano J, 2000, NEUROMUSCULAR DISORD, V10, P419, DOI 10.1016/S0960-8966(99)00114-5; Burns J, 2009, LANCET NEUROL, V8, P537, DOI 10.1016/S1474-4422(09)70108-5; Fornai F, 2008, P NATL ACAD SCI USA, V105, P2052, DOI 10.1073/pnas.0708022105; GABREELSFESTEN AAWM, 1995, ACTA NEUROPATHOL, V90, P645, DOI 10.1007/BF00318579; Micallef J, 2009, LANCET NEUROL, V8, P1103, DOI 10.1016/S1474-4422(09)70260-1; MILLER RG, 2010, AMYOTROPH LATERAL S1, V11, P63; Pareyson D, 2011, LANCET NEUROL, V10, P320, DOI 10.1016/S1474-4422(11)70025-4; Passage E, 2004, NAT MED, V10, P396, DOI 10.1038/nm1023; Ramdharry GM, 2010, NEUROMUSCULAR DISORD, V20, pS18, DOI 10.1016/j.nmd.2010.08.001; Reilly MM, 2009, J NEUROL NEUROSUR PS, V80, P1304, DOI 10.1136/jnnp.2008.158295; Robaglia-Schlupp A, 2002, BRAIN, V125, P2213, DOI 10.1093/brain/awf230; Saporta MA, 2009, BRAIN, V132, P3263, DOI 10.1093/brain/awp274; Shy ME, 2008, NEUROLOGY, V70, P378, DOI 10.1212/01.wnl.0000297553.36441.ce; Shy ME, 2005, NEUROLOGY, V64, P1209, DOI 10.1212/01.WNL.0000156517.00615.A3; TUGWELL P, 1993, J RHEUMATOL, V20, P528; Verhamme C, 2009, BRAIN, V132, P3252, DOI 10.1093/brain/awp251; Verhamme C, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-70; Young P, 2008, COCHRANE DB SYST REV, V1	18	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2011	10	4					291	293		10.1016/S1474-4422(11)70042-4	http://dx.doi.org/10.1016/S1474-4422(11)70042-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745SB	21393064				2022-12-18	WOS:000289185000003
J	Lane, DA; Lip, GYH				Lane, Deirdre A.; Lip, Gregory Y. H.			Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk	LANCET NEUROLOGY			English	Editorial Material							ANTICOAGULATION; WARFARIN		[Lane, Deirdre A.; Lip, Gregory Y. H.] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Lane, DA (corresponding author), Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Dudley Rd, Birmingham B18 7QH, W Midlands, England.		Lane, Deirdre/AAX-1866-2020	Lane, Deirdre/0000-0002-5604-9378				Akins PT, 2007, STROKE, V38, P874, DOI 10.1161/01.STR.0000258004.64840.0b; Camm AJ, 2010, EUROPACE, V12, P1360, DOI [10.1093/europace/euq350, 10.1093/eurheartj/ehq278]; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; DIENER HC, 2010, LANCET NEUROL, DOI DOI 10.1016/S14744422(10)70274X; Gorter JW, 1999, NEUROLOGY, V53, P1319, DOI 10.1212/WNL.53.6.1319; Hart RG, 2007, NEUROLOGY, V69, P546; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Palareti G, 2009, THROMB HAEMOSTASIS, V102, P268, DOI 10.1160/TH08-11-0730; PISTERS R, 2010, CHEST, DOI DOI 10.1378/CHEST100134	10	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2010	9	12					1140	1142		10.1016/S1474-4422(10)70275-1	http://dx.doi.org/10.1016/S1474-4422(10)70275-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	691KG	21059485				2022-12-18	WOS:000285078100002
J	Schneider, LS				Schneider, Lon S.			Organising the language of Alzheimer's disease in light of biomarkers	LANCET NEUROLOGY			English	Editorial Material							COGNITIVE IMPAIRMENT		[Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Psychiat, Los Angeles, CA 90033 USA; [Schneider, Lon S.] Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA; [Schneider, Lon S.] Univ So Calif, Alzheimers Dis Res Ctr, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Schneider, LS (corresponding author), Univ So Calif, Keck Sch Med, Dept Psychiat, Los Angeles, CA 90033 USA.	lschneid@usc.edu						Bennett DA, 2006, NEUROLOGY, V66, P1837, DOI 10.1212/01.wnl.0000219668.47116.e6; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; DELEON M, 1989, LANCET, V334, P672; Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4; FLICKER C, 1991, NEUROLOGY, V41, P1006, DOI 10.1212/WNL.41.7.1006; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; MORRIS JC, 1991, NEUROLOGY, V41, P469, DOI 10.1212/WNL.41.4.469	7	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2010	9	11					1044	1045		10.1016/S1474-4422(10)70246-5	http://dx.doi.org/10.1016/S1474-4422(10)70246-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	680PL	20934913				2022-12-18	WOS:000284246800006
J	Fernandez, HH; Merello, M				Fernandez, Hubert H.; Merello, Marcelo			Pramipexole for depression and motor symptoms in Parkinson's disease: can we kill two birds with one stone?	LANCET NEUROLOGY			English	Editorial Material							ANTIDEPRESSANTS		[Fernandez, Hubert H.] Univ Florida, Dept Neurol, Gainesville, FL 32610 USA; [Merello, Marcelo] Fdn Lucha Enfermedades Neurol Infancia, Dept Neurosci, Movement Disorders Sect, Buenos Aires, DF, Argentina	State University System of Florida; University of Florida	Fernandez, HH (corresponding author), Univ Florida, Dept Neurol, Gainesville, FL 32610 USA.	fernandez@neurology.ufl.edu		Afifa, Sayyidah/0000-0002-1151-9583				Barone P, 2010, LANCET NEUROL, V9, P573, DOI 10.1016/S1474-4422(10)70106-X; Devos D, 2008, MOVEMENT DISORD, V23, P850, DOI 10.1002/mds.21966; Marsh L, 2006, MOVEMENT DISORD, V21, P148, DOI 10.1002/mds.20723; Menza M, 2009, NEUROLOGY, V72, P886, DOI 10.1212/01.wnl.0000336340.89821.b3; Okun MS, 2009, NEUROLOGY, V72, P868, DOI 10.1212/01.wnl.0000338145.24512.02; Pahwa R, 2007, NEUROLOGY, V68, P1108, DOI 10.1212/01.wnl.0000258660.74391.c1; Rodriguez-Oroz MC, 2009, LANCET NEUROL, V8, P1128, DOI 10.1016/S1474-4422(09)70293-5; Schrag A, 2007, MOVEMENT DISORD, V22, P1077, DOI 10.1002/mds.21333; Starkstein SE, 2008, MOVEMENT DISORD, V23, P538, DOI 10.1002/mds.21866	9	8	9	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2010	9	6					556	557		10.1016/S1474-4422(10)70114-9	http://dx.doi.org/10.1016/S1474-4422(10)70114-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	607NY	20452824				2022-12-18	WOS:000278512000002
J	Tan, CS; Chen, YP; Viscidi, RP; Kinkel, RP; Stein, MC; Koralnik, IJ				Tan, Chen S.; Chen, Yiping; Viscidi, Raphael P.; Kinkel, R. Philip; Stein, Marion C.; Koralnik, Igor J.			Discrepant findings in immune responses to JC virus in patients receiving natalizumab	LANCET NEUROLOGY			English	Letter							CYTOTOXIC T-LYMPHOCYTES		[Tan, Chen S.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; [Tan, Chen S.; Chen, Yiping; Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA; [Tan, Chen S.; Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Dept Med, Div NeuroVirol, Boston, MA 02215 USA; [Kinkel, R. Philip; Stein, Marion C.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Viscidi, Raphael P.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University	Tan, CS (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.	ikoralni@bidmc.harvard.edu		Viscidi, Raphael/0000-0002-7906-8002	NIAID NIH HHS [T32 AI007061] Funding Source: Medline; NINDS NIH HHS [K08 NS064215] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS064215] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chen YP, 2009, NEW ENGL J MED, V361, P1067, DOI 10.1056/NEJMoa0904267; Du Pasquier RA, 2004, J VIROL, V78, P10206, DOI 10.1128/JVI.78.18.10206-10210.2004; Du Pasquier RA, 2004, BRAIN, V127, P1970, DOI 10.1093/brain/awh215; Gorelik L, 2010, NEUROLOGY, V74, pA390; Jilek S, 2010, LANCET NEUROL, V9, P264, DOI 10.1016/S1474-4422(10)70006-5; Ransohoff RM, 2010, LANCET NEUROL, V9, P231, DOI 10.1016/S1474-4422(10)70025-9	6	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2010	9	6					565	566		10.1016/S1474-4422(10)70124-1	http://dx.doi.org/10.1016/S1474-4422(10)70124-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	607NY	20494320	Green Accepted			2022-12-18	WOS:000278512000008
J	Bonati, LH; Jongen, LM; Haller, S				Bonati, L. H.; Jongen, L. M.; Haller, S.			New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS) (vol 9, pg 353, 2010)	LANCET NEUROLOGY			English	Correction													Bonati, Leo/G-4058-2012	Bonati, Leo/0000-0003-1163-8133				Bonati LH, 2010, LANCET NEUROL, V9, P353, DOI 10.1016/S1474-4422(10)70057-0	1	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2010	9	4					345	345		10.1016/S1474-4422(10)70057-0	http://dx.doi.org/10.1016/S1474-4422(10)70057-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	576KA		hybrid, Green Accepted			2022-12-18	WOS:000276142000012
J	Antonini, A				Antonini, Angelo			Imaging for early differential diagnosis of parkinsonism	LANCET NEUROLOGY			English	Editorial Material							CLINICAL-DIAGNOSIS; DISEASE; ACCURACY; SPECT		IRCCS San Camillo, Venice & Parkinson Inst, Milan, Italy	IRCCS Ospedale San Camillo	Antonini, A (corresponding author), IRCCS San Camillo, Venice & Parkinson Inst, Milan, Italy.	angelo3000@yahoo.com	Antonini, Angelo/H-9726-2019	Antonini, Angelo/0000-0003-1040-2807				Antonini Angelo, 2008, Expert Rev Neurother, V8, P1853, DOI 10.1586/14737175.8.12.1853; Antonini A, 2008, MOVEMENT DISORD, V23, P2202, DOI 10.1002/mds.22278; Eidelberg D, 2009, TRENDS NEUROSCI, V32, P548, DOI 10.1016/j.tins.2009.06.003; Fahn S, 2004, NEW ENGL J MED, V351, P2498; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; HUGHES AJ, 1993, ARCH NEUROL-CHICAGO, V50, P140, DOI 10.1001/archneur.1993.00540020018011; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Olanow CW, 2009, NEW ENGL J MED, V361, P1268, DOI 10.1056/NEJMoa0809335; RAJPUT AH, 1991, CAN J NEUROL SCI, V18, P275, DOI 10.1017/S0317167100031814; Scherfler C, 2007, MOVEMENT DISORD, V22, P1229, DOI 10.1002/mds.21505; Tang CC, 2010, LANCET NEUROL, V9, P149, DOI 10.1016/S1474-4422(10)70002-8; Tolosa E, 2006, LANCET NEUROL, V5, P75, DOI 10.1016/S1474-4422(05)70285-4	12	8	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2010	9	2					130	131		10.1016/S1474-4422(09)70360-6	http://dx.doi.org/10.1016/S1474-4422(09)70360-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	547XB	20061184				2022-12-18	WOS:000273922000002
J	Neil, J				Neil, Jeff			Is MRI still cool after hypothermia?	LANCET NEUROLOGY			English	Editorial Material							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; DIFFUSION; TERM		[Neil, Jeff] Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA; [Neil, Jeff] Washington Univ, Dept Pediat, Sch Med, St Louis, MO 63110 USA; [Neil, Jeff] Washington Univ, Dept Radiol, Sch Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Neil, J (corresponding author), Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA.	neil@wustl.edu						Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Inder TE, 2004, J PEDIATR-US, V145, P835, DOI 10.1016/j.jpeds.2004.07.034; Inder TE, 2005, PEDIATRICS, V115, P286, DOI 10.1542/peds.2004-0326; JACOBS S, 2007, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003311.PUB2; McKinstry RC, 2002, NEUROLOGY, V59, P824, DOI 10.1212/WNL.59.6.824; Rutherford MA, 2005, PEDIATRICS, V116, P1001, DOI 10.1542/peds.2005-0328; Rutherford M, 2010, LANCET NEUROL, V9, P39, DOI 10.1016/S1474-4422(09)70295-9; WELCH KMA, 1995, STROKE, V26, P1983, DOI 10.1161/01.STR.26.11.1983; ZHANG Y, 1992, INT J HYPERTHER, V8, P263, DOI 10.3109/02656739209021781	9	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					19	20		10.1016/S1474-4422(09)70302-3	http://dx.doi.org/10.1016/S1474-4422(09)70302-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	19896903				2022-12-18	WOS:000273199700011
J	Valente, EM; Ferraris, A; Dallapiccola, B				Valente, Enza Maria; Ferraris, Alessandro; Dallapiccola, Bruno			Genetic testing for paediatric neurological disorders	LANCET NEUROLOGY			English	Review							SPINAL MUSCULAR-ATROPHY; FRAGILE-X PREMUTATION; MITOCHONDRIAL DISORDERS; MYOCLONUS-DYSTONIA; PRENATAL-DIAGNOSIS; REPEAT EXPANSION; FRIEDREICHS-ATAXIA; MYOTONIC-DYSTROPHY; TORSION DYSTONIA; PARKIN MUTATIONS	Paediatric neurological disorders encompass a large group of clinically heterogeneous diseases, of which some are known to have a genetic cause. Over the past few years, advances in nosological classifications and in strategies for molecular testing have substantially improved the diagnosis, genetic counselling, and clinical management of many patients, and have facilitated the possibility of prenatal diagnoses for future pregnancies. However, the increasing availability of genetic tests for paediatric neurological disorders is raising important questions with regard to the appropriateness, choice of protocols, interpretation of results, and ethical and social concerns of these services. In this Review, we discuss these topics and how these concerns affect genetic counselling.	[Valente, Enza Maria; Ferraris, Alessandro; Dallapiccola, Bruno] Casa Sollievo Sofferenza Hosp, Mendel Inst, Rome, Italy; [Valente, Enza Maria] Univ Messina, Dept Med & Surg Paediat Sci, Messina, Italy; [Ferraris, Alessandro; Dallapiccola, Bruno] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy	IRCCS Casa Sollievo Della Sofferenza; Istituto CSS Mendel; University of Messina; Sapienza University Rome	Valente, EM (corresponding author), CSS Mendel Inst, Viale Regina Margherita 261, I-00198 Rome, Italy.	e.valente@css-mendel.it	Ferraris, Alessandro/E-4392-2013; Valente, Enza Maria/G-2942-2017; Ferraris, Alessandro/AHC-2875-2022; Dallapiccola, Bruno/K-8692-2016	Valente, Enza Maria/0000-0002-0600-6820; Ferraris, Alessandro/0000-0003-2947-9572; Dallapiccola, Bruno/0000-0002-5031-1013	Italian Ministry of Health; Italian Ministry of University and Research; Telethon-Italy; US National Institutes of Health	Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Telethon-Italy(Fondazione Telethon); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank E Bertini for his critical reading and helpful suggestions. The authors' research is funded by the Italian Ministry of Health, the Italian Ministry of University and Research, Telethon-Italy, and the US National Institutes of Health.	Ala A, 2007, LANCET, V369, P397, DOI 10.1016/S0140-6736(07)60196-2; [Anonymous], 2003, FED REGISTER, V68, P3639; Ayme S, 2000, EUR J PEDIATR, V159, pS183, DOI 10.1007/PL00014399; Badano JL, 2006, NATURE, V439, P326, DOI 10.1038/nature04370; Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Beck M, 2007, HUM GENET, V121, P1, DOI 10.1007/s00439-006-0280-4; BORRY P, GENETIC TESTING ASYM; BORRY P, 2007, EUROPEAN ETHICAL LEG, V3; Borry P, 2007, NAT REV GENET, V8, P828, DOI 10.1038/nrg2222; Bredenoord AL, 2008, HUM REPROD UPDATE, V14, P83, DOI 10.1093/humupd/dmm037; Bruinooge SS, 2003, J CLIN ONCOL, V21, P2397, DOI 10.1200/JCO.2003.03.189; Bunyan DJ, 2007, MOL BIOTECHNOL, V35, P135, DOI 10.1007/BF02686108; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; Castori M, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.027375; Cruz JB, 2007, ARQ BRAS ENDOCRINOL, V51, P1463, DOI 10.1590/S0004-27302007000900008; Dallapiccola B, 2006, EUR J HUM GENET, V14, P911, DOI 10.1038/sj.ejhg.5201653; Das S, 2008, GENET MED, V10, P332, DOI 10.1097/GIM.0b013e318172838d; Depienne C, 2007, CURR OPIN NEUROL, V20, P674, DOI 10.1097/WCO.0b013e3282f190ba; Depienne C, 2007, J MED GENET, V44, P281, DOI 10.1136/jmg.2006.046425; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Edwards M, 2003, MOVEMENT DISORD, V18, P706, DOI 10.1002/mds.10411; ELDRIDGE R, 1983, LANCET, V2, P838, DOI 10.1016/s0140-6736(83)90749-3; *EUR SOC HUM GEN, 2008, REC GEN COUNS REL GE; *EUR SOC HUM GEN, GEN TEST AS MIN PROP; Fackenthal DL, 2005, METH MOL B, V311, P73; Francke U, 2006, NAT CLIN PRACT NEURO, V2, P212, DOI 10.1038/ncpneuro0148; Gambarin M, 2006, MOVEMENT DISORD, V21, P1782, DOI 10.1002/mds.21056; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Gojova L, 2008, CLIN GENET, V73, P441, DOI 10.1111/j.1399-0004.2008.00989.x; Grabowski M, 2003, EUR J HUM GENET, V11, P138, DOI 10.1038/sj.ejhg.5200938; Grunewald A, 2008, HUM MUTAT, V29, P331, DOI 10.1002/humu.9521; Hagerman PJ, 2004, AM J HUM GENET, V74, P805, DOI 10.1086/386296; HARPER PS, 2004, PRACTICAL GENETIC CO, P21; HARPER PS, 2004, PRACTICAL GENETIC CO, P369; HARPER PS, 2004, PRACTICAL GENETIC CO, P381; Hedrich K, 2004, MOVEMENT DISORD, V19, P1146, DOI 10.1002/mds.20234; Horsthemke B, 2008, AM J MED GENET A, V146A, P2041, DOI 10.1002/ajmg.a.32364; Hudson K, 2007, AM J HUM GENET, V81, P635, DOI 10.1086/521634; Isken O, 2007, GENE DEV, V21, P1833, DOI 10.1101/gad.1566807; Jozwiak J, 2008, LANCET ONCOL, V9, P73, DOI 10.1016/S1470-2045(07)70411-4; Kalviainen R, 2008, EPILEPSIA, V49, P549, DOI 10.1111/j.1528-1167.2008.01546.x; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Korneluk RG, 1997, NAT GENET, V15, P119, DOI 10.1038/ng0297-119; Kostic VS, 2006, J NEUROL SCI, V250, P92, DOI 10.1016/j.jns.2006.07.010; Kozlowski P, 2007, HUM GENET, V121, P389, DOI 10.1007/s00439-006-0308-9; Leutenegger AL, 2006, ARCH NEUROL-CHICAGO, V63, P1257, DOI 10.1001/archneur.63.9.1257; Li W, 2004, MOL CELL BIOL, V24, P3295, DOI 10.1128/MCB.24.8.3295-3306.2004; Mavrou A, 2008, ANTICANCER RES, V28, P401; MCNALLY E, 2004, REPORT ETHICAL LEGAL, P15; MCNALLY E, 2004, REPORT ETHICAL LEGAL, P51; Morava E, 2006, NEUROLOGY, V67, P1823, DOI 10.1212/01.wnl.0000244435.27645.54; Moser HW, 2007, NAT CLIN PRACT NEURO, V3, P140, DOI 10.1038/ncpneuro0421; Moslemi AR, 2007, MITOCHONDRION, V7, P241, DOI 10.1016/j.mito.2007.02.002; Muller B, 2002, AM J HUM GENET, V71, P1303, DOI 10.1086/344531; Nave KA, 2007, NAT CLIN PRACT NEURO, V3, P453, DOI 10.1038/ncpneuro0583; NOVAK CB, 2007, SEMIN PEDIAT NEUROL, V14, P140; Ohya K, 1997, JPN J HUM GENET, V42, P169, DOI 10.1007/BF02766919; Opal P, 2002, MOVEMENT DISORD, V17, P339, DOI 10.1002/mds.10096; Organization for Economic Co-operation and Development, 2007, OECD GUID QUAL ASS M, P11; Prior TW, 2007, J CHILD NEUROL, V22, P952, DOI 10.1177/0883073807305668; Prior TW, 2005, J MOL DIAGN, V7, P317, DOI 10.1016/S1525-1578(10)60560-0; Rantanen E, 2008, EUR J HUM GENET, V16, P1208, DOI 10.1038/ejhg.2008.93; Rantanen E, 2008, EUR J HUM GENET, V16, P445, DOI 10.1038/sj.ejhg.5201983; REDMAN JB, 1993, JAMA-J AM MED ASSOC, V269, P1960, DOI 10.1001/jama.269.15.1960; Renwick P, 2007, EXPERT REV MOL DIAGN, V7, P33, DOI 10.1586/14737159.7.1.33; Ribai P, 2007, ARCH NEUROL-CHICAGO, V64, P813, DOI 10.1001/archneur.64.6.813; Risch NJ, 2007, AM J HUM GENET, V80, P1188, DOI 10.1086/518427; Schattman G, 2007, FERTIL STERIL, V88, P1497, DOI 10.1016/j.fertnstert.2007.10.010; Sellner LN, 2004, HUM MUTAT, V23, P413, DOI 10.1002/humu.20035; SEQUEIROS J, 2005, DEFINITIONS IN PRESS; Slater H, 2004, HUM MUTAT, V24, P164, DOI 10.1002/humu.20072; South ST, 2008, CLIN OBSTET GYNECOL, V51, P62, DOI 10.1097/GRF.0b013e3181616509; Stultiens L, 2007, EUR J HEALTH LAW, V14, P21, DOI 10.1163/092902707X182788; Tassin J, 2000, BRAIN, V123, P1112, DOI 10.1093/brain/123.6.1112; Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380; Uhlmann WR, 2008, JAMA-J AM MED ASSOC, V299, P1356, DOI 10.1001/jama.299.11.1356; Valente EM, 2008, EUR J MED GENET, V51, P1, DOI 10.1016/j.ejmg.2007.11.003; van der Knapp MS, 2006, LANCET NEUROL, V5, P413, DOI 10.1016/S1474-4422(06)70440-9; Van Esch H, 2006, EUR J MED GENET, V49, P1, DOI 10.1016/j.ejmg.2005.11.001; van Ommen GJ, 2008, CURR OPIN MOL THER, V10, P140; Viskochil D, 2005, MANAGEMENT GENETIC S, P369; Waisbren SE, 2008, AM FAM PHYSICIAN, V77, P987; Wang CH, 2007, J CHILD NEUROL, V22, P1027, DOI 10.1177/0883073807305788; WILFOND BS, 1995, AM J HUM GENET, V57, P1233; Williams RE, 2006, BBA-MOL BASIS DIS, V1762, P865, DOI 10.1016/j.bbadis.2006.07.001; Winship IM, 2008, LANCET ONCOL, V9, P462, DOI 10.1016/S1470-2045(08)70126-8; WISNIEWSKI KE, 2006, GENEREVIEWS; Zeng FY, 2008, HUM MUTAT, V29, P190, DOI 10.1002/humu.20613; Zeviani M, 2007, CURR OPIN NEUROL, V20, P564, DOI 10.1097/WCO.0b013e3282ef58cd	90	8	8	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2008	7	12					1113	1126		10.1016/S1474-4422(08)70257-6	http://dx.doi.org/10.1016/S1474-4422(08)70257-6			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	379KV	19007736				2022-12-18	WOS:000261396000017
J	Diener, HC; Sacco, RL; Yusuf, S				Diener, H-C; Sacco, R. L.; Yusuf, S.			Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study (vol 7, pg 875, 2008)	LANCET NEUROLOGY			English	Correction													Luisa, Sacchetti/F-2644-2011	Luisa, Sacchetti/0000-0002-2318-9868				Dienert HC, 2008, LANCET NEUROL, V7, P875, DOI 10.1016/S1474-4422(08)70198-4	1	8	9	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2008	7	11					985	985		10.1016/S1474-4422(08)70232-1	http://dx.doi.org/10.1016/S1474-4422(08)70232-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	370EP					2022-12-18	WOS:000260745800007
J	Treiman, DM				Treiman, David M.			Importance of early recognition and treatment of generalised convulsive status epilepticus	LANCET NEUROLOGY			English	Editorial Material							PHARMACORESISTANCE; PILOCARPINE; DIAZEPAM		Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA	Barrow Neurological Institute	Treiman, DM (corresponding author), Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA.	dtreiman@chw.edu						Alldredge BK, 2001, NEW ENGL J MED, V345, P631, DOI 10.1056/NEJMoa002141; Avanzini GG, 2008, EPILEPSY COMPREHENSI, P415; Chin RFM, 2008, LANCET NEUROL, V7, P696, DOI 10.1016/S1474-4422(08)70141-8; DELORENZO RJ, 1995, J CLIN NEUROPHYSIOL, V12, P316; Jones DM, 2002, EPILEPSY RES, V50, P301, DOI 10.1016/S0920-1211(02)00085-2; Logroscino G, 1997, EPILEPSIA, V38, P1344, DOI 10.1111/j.1528-1157.1997.tb00073.x; Mazarati AM, 1998, BRAIN RES, V814, P179, DOI 10.1016/S0006-8993(98)01080-4; Naylor DE, 2005, J NEUROSCI, V25, P7724, DOI 10.1523/JNEUROSCI.4944-04.2005; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Treiman DM, 2008, EPILEPSY COMPREHENSI, P665; WALTON NY, 1988, EXP NEUROL, V101, P267, DOI 10.1016/0014-4886(88)90010-6	11	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2008	7	8					667	668		10.1016/S1474-4422(08)70142-X	http://dx.doi.org/10.1016/S1474-4422(08)70142-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	330VA	18602344				2022-12-18	WOS:000257969700004
J	Brown, RD				Brown, Robert D., Jr.			Unruptured brain AVMs: to treat or not to treat	LANCET NEUROLOGY			English	Editorial Material							INTRACRANIAL VASCULAR MALFORMATIONS; ARTERIOVENOUS-MALFORMATIONS; NATURAL-HISTORY; OLMSTED COUNTY; MANAGEMENT		Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic	Brown, RD (corresponding author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.	brown.robert@mayo.edu						Al-Shahi R, 2003, STROKE, V34, P1156, DOI 10.1161/01.STR.0000069012.23858.69; Brown RD, 1996, J NEUROSURG, V85, P29, DOI 10.3171/jns.1996.85.1.0029; BROWN RD, 1988, J NEUROSURG, V68, P352, DOI 10.3171/jns.1988.68.3.0352; Brown RD, 2005, MAYO CLIN PROC, V80, P269, DOI 10.4065/80.2.269; Brown RD, 1996, NEUROLOGY, V46, P949, DOI 10.1212/WNL.46.4.949; Cockroft KM, 2007, STROKE, V38, P3310, DOI 10.1161/STROKEAHA.107.504613; Mohr JP, 2004, STROKE, V35, P328; Ogilvy CS, 2001, STROKE, V32, P1458, DOI 10.1161/01.STR.32.6.1458; Stapf C, 2003, STROKE, V34, pE29, DOI 10.1161/01.STR.0000068784.36838.19; Stapf C, 2007, STROKE, V38, P3308, DOI 10.1161/STROKEAHA.107.504605; Wedderburn CJ, 2008, LANCET NEUROL, V7, P223, DOI 10.1016/S1474-4422(08)70026-7	11	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2008	7	3					195	196		10.1016/S1474-4422(08)70027-9	http://dx.doi.org/10.1016/S1474-4422(08)70027-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	268KZ	18243055				2022-12-18	WOS:000253580000004
J	Illes, J				Illes, Judy			Brain screening and incidental findings: flocking to folly?	LANCET NEUROLOGY			English	Editorial Material							NEUROSCIENCE; MRI		Univ British Columbia, Vancouver, BC V6T 2B5, Canada	University of British Columbia	Illes, J (corresponding author), Univ British Columbia, 2211 Wesbrook Mall,Koerner Pavil S124, Vancouver, BC V6T 2B5, Canada.	jilles@interchange.ubc.ca	Kam, Grace/F-5364-2012					Hyman SE, 2003, BIOL PSYCHIAT, V54, P1310, DOI 10.1016/j.biopsych.2003.10.003; Illes J, 2004, NEUROLOGY, V62, P888, DOI 10.1212/01.WNL.0000118531.90418.89; Illes J, 2006, TRENDS NEUROSCI, V29, P511, DOI 10.1016/j.tins.2006.07.002; Khamsi R., 2007, NEW SCI; Kim BS, 2002, AM J NEURORADIOL, V23, P1674; Singh J, 2007, NAT REV NEUROSCI, V8, P153, DOI 10.1038/nrn2073; STOBBE M, 2007, DAILY HERALD    1104; Vernooij MW, 2007, NEW ENGL J MED, V357, P1821, DOI 10.1056/NEJMoa070972; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0	9	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2008	7	1					23	24		10.1016/S1474-4422(07)70308-3	http://dx.doi.org/10.1016/S1474-4422(07)70308-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	247FO	18093555				2022-12-18	WOS:000252063300014
J	Spinney, L				Spinney, Laura			Alzheimer's disease funding and the French health system	LANCET NEUROLOGY			English	Editorial Material												laura.spinney@orange.fr							0	8	8	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2008	7	1					26	27		10.1016/S1474-4422(07)70315-0	http://dx.doi.org/10.1016/S1474-4422(07)70315-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	247FO	18093559				2022-12-18	WOS:000252063300021
J	Teunissen, CE; Scheltens, P				Teunissen, Charlotte E.; Scheltens, Philip			Use of proteomic approaches to identify disease biomarkers	LANCET NEUROLOGY			English	Editorial Material							INCIPIENT ALZHEIMERS-DISEASE		Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, NeuroUnit Biomarkers Inflammat & Neurodegenerat, Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Dept Neurol & Alzheimer Ctr, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Teunissen, CE (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, NeuroUnit Biomarkers Inflammat & Neurodegenerat, Amsterdam, Netherlands.	p.scheltens@vumc.nl	Scheltens, Philip/E-1205-2012; Scheltens, Philip/AAL-9631-2020	Scheltens, Philip/0000-0002-1046-6408				Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; de la Torre JC, 2004, LANCET NEUROL, V3, P184, DOI 10.1016/S1474-4422(04)00683-0; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Mehta PD, 2007, CURR ALZHEIMER RES, V4, P359, DOI 10.2174/156720507781788891; RAY S, 2007, NAT MED; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484	6	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2007	6	12					1036	1037		10.1016/S1474-4422(07)70276-4	http://dx.doi.org/10.1016/S1474-4422(07)70276-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	239UI	18031700				2022-12-18	WOS:000251543100004
J	Topakian, R; Steilbauer, K; Aichner, FT				Topakian, Raffi; Steilbauer, Karl; Aichner, Franz T.			Unexplained cerebral vasculitis and stroke: keep Lyme neuroborreliosis in mind	LANCET NEUROLOGY			English	Editorial Material							HEMORRHAGE		Acad Teaching Hosp Wagner Jauregg, Dept Neurol, A-4020 Linz, Austria	Kepler University Hospital	Topakian, R (corresponding author), Acad Teaching Hosp Wagner Jauregg, Dept Neurol, Wagner Jauregg Weg 15, A-4020 Linz, Austria.	raffi.topakian@hotmail.com						Chehrenama M, 1997, NEUROLOGY, V48, P520, DOI 10.1212/WNL.48.2.520; HAMMERSBERGGREN S, 1993, STROKE, V24, P1393, DOI 10.1161/01.STR.24.9.1393; Martinez MS, 2001, NEUROLOGIA, V16, P43; MAY EF, 1990, STROKE, V21, P1232, DOI 10.1161/01.STR.21.8.1232; Pachner AR, 2007, LANCET NEUROL, V6, P544, DOI 10.1016/S1474-4422(07)70128-X	5	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2007	6	9					756	757		10.1016/S1474-4422(07)70203-X	http://dx.doi.org/10.1016/S1474-4422(07)70203-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	204SV	17706557				2022-12-18	WOS:000249065200007
J	[Anonymous]				[Anonymous]			Epilepsy and HIV-a dangerous combination	LANCET NEUROLOGY			English	Editorial Material																			0	8	8	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2007	6	9					747	747		10.1016/S1474-4422(07)70197-7	http://dx.doi.org/10.1016/S1474-4422(07)70197-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	204SV	17706551	Bronze			2022-12-18	WOS:000249065200001
J	Kleindorfer, D				Kleindorfer, Dawn			The bad news: stroke incidence is stable	LANCET NEUROLOGY			English	Editorial Material							INTRACEREBRAL HEMORRHAGE; WARFARIN		Univ Cincinnati, Coll Med, Dept Neurol, Greater Cincinnati & No Kentucky Stroke Team, Cincinnati, OH 45221 USA	University of Cincinnati	Kleindorfer, D (corresponding author), Univ Cincinnati, Coll Med, Dept Neurol, Greater Cincinnati & No Kentucky Stroke Team, Cincinnati, OH 45221 USA.	kleinddo@ucmail.uc.edu						Flaherty ML, 2007, NEUROLOGY, V68, P116, DOI 10.1212/01.wnl.0000250340.05202.8b; Flaherty ML, 2006, NEUROLOGY, V66, P1182, DOI 10.1212/01.wnl.0000208400.08722.7c; Flibotte JJ, 2004, NEUROLOGY, V63, P1059, DOI 10.1212/01.WNL.0000138428.40673.83; Kleindorfer D, 2006, STROKE, V37, P2473, DOI 10.1161/01.STR.0000242766.65550.92; Lovelock CE, 2007, LANCET NEUROL, V6, P487, DOI 10.1016/S1474-4422(07)70107-2; PERRET G, 1966, J NEUROSURG, V25, P467, DOI 10.3171/jns.1966.25.4.0467; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; Stapf C, 2002, CEREBROVASC DIS, V13, P43, DOI 10.1159/000047745	8	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2007	6	6					470	471		10.1016/S1474-4422(07)70111-4	http://dx.doi.org/10.1016/S1474-4422(07)70111-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	175WO	17509473				2022-12-18	WOS:000247044900002
J	O'Sullivan, SS				O'Sullivan, Sean S.			Pathological gambling in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							PERSONALITY		UCL, Reta Lila Inst Neurol Studies, Inst Neurol, London WC1N 1PJ, England	University of London; University College London	O'Sullivan, SS (corresponding author), UCL, Reta Lila Inst Neurol Studies, Inst Neurol, London WC1N 1PJ, England.	alees@ion.uci.ac.uk	O'Sullivan, Sean S/C-9333-2012	O'Sullivan, Sean S/0000-0002-0583-7956				Evans AH, 2005, NEUROLOGY, V65, P1570, DOI 10.1212/01.wnl.0000184487.72289.f0; Evans AH, 2007, MOVEMENT DISORD, V22, P590, DOI 10.1002/mds.21303; Giovannoni G, 2000, J NEUROL NEUROSUR PS, V68, P423, DOI 10.1136/jnnp.68.4.423; Grosset KA, 2006, MOVEMENT DISORD, V21, P2206, DOI 10.1002/mds.21110; Ishihara L, 2006, MOVEMENT DISORD, V21, P1066, DOI 10.1002/mds.20980; MENZA MA, 1994, J NEUROPSYCH CLIN N, V6, P165; Molina JA, 2000, MOVEMENT DISORD, V15, P869, DOI 10.1002/1531-8257(200009)15:5<869::AID-MDS1016>3.0.CO;2-I; Petry NM, 2005, J CLIN PSYCHIAT, V66, P564, DOI 10.4088/JCP.v66n0504; Voon V, 2006, NEUROLOGY, V66, P1750, DOI 10.1212/01.wnl.0000218206.20920.4d; Voon V, 2007, ARCH NEUROL-CHICAGO, V64, P212, DOI 10.1001/archneur.64.2.212	10	8	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2007	6	5					384	386		10.1016/S1474-4422(07)70089-3	http://dx.doi.org/10.1016/S1474-4422(07)70089-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	161XO	17434085				2022-12-18	WOS:000246050600005
J	van de Beek, D				van de Beek, Diederik			Brain teasing effect of dexamethasone	LANCET NEUROLOGY			English	Editorial Material							TUBERCULOUS MENINGITIS; BACTERIAL-MENINGITIS; ADULTS		Univ Amsterdam, Acad Med Ctr, Dept Neurol H2, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	van de Beek, D (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol H2, NL-1100 DD Amsterdam, Netherlands.	d.vandebeek@amc.uva.nl	van de Beek, Diederik/Y-2713-2019	van de Beek, Diederik/0000-0002-4571-044X				de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334; PRASAD K, 2000, COCHRANE DB SYST REV, V3; Simmons CP, 2005, J IMMUNOL, V175, P579, DOI 10.4049/jimmunol.175.1.579; Thwaites GE, 2004, NEW ENGL J MED, V351, P1741, DOI 10.1056/NEJMoa040573; Thwaites GE, 2005, LANCET NEUROL, V4, P160, DOI 10.1016/S1474-4422(05)01013-6; Thwaites GE, 2007, LANCET NEUROL, V6, P230, DOI 10.1016/S1474-4422(07)70034-0; van de Beek D, 2006, NEW ENGL J MED, V354, P44, DOI 10.1056/NEJMra052116; van de Beek D, 2004, ANN INTERN MED, V141, P327, DOI 10.7326/0003-4819-141-4-200408170-00028; World Health Organization, TUB	9	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2007	6	3					203	204		10.1016/S1474-4422(07)70041-8	http://dx.doi.org/10.1016/S1474-4422(07)70041-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138BU	17303522				2022-12-18	WOS:000244338400004
J	[Anonymous]				[Anonymous]			Neurology in sub-Saharan Africa - WHO cares?	LANCET NEUROLOGY			English	Editorial Material																			0	8	8	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2006	5	8					637	637		10.1016/S1474-4422(06)70502-6	http://dx.doi.org/10.1016/S1474-4422(06)70502-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	068ZV	16857564	Bronze			2022-12-18	WOS:000239415100001
J	Kukull, WA				Kukull, WA			The growing global burden of dementia	LANCET NEUROLOGY			English	Editorial Material							METABOLIC SYNDROME; PREVALENCE; DISEASE		Univ Washington, Dept Epidemiol, Natl Alzheimers Coordinating Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kukull, WA (corresponding author), Univ Washington, Dept Epidemiol, Natl Alzheimers Coordinating Ctr, Seattle, WA 98195 USA.	kukull@u.washington.edu		Kukull, Walter/0000-0001-8761-9014				Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Kwon HM, 2006, STROKE, V37, P466, DOI 10.1161/01.STR.0000199081.17935.81; Launer LJ, 2002, AGEING RES REV, V1, P61, DOI 10.1016/S0047-6374(01)00364-5; Yan Y, 2003, J CLIN EPIDEMIOL, V56, P546, DOI 10.1016/S0895-4356(03)00057-X	5	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2006	5	3					199	200		10.1016/S1474-4422(06)70358-1	http://dx.doi.org/10.1016/S1474-4422(06)70358-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	016PS	16488372				2022-12-18	WOS:000235632900003
J	Lehmann, HC; Hengge, UR; Alswede, L; Saleh, A; von Geldern, G; Hartung, HP; Ruzicka, T; Hemmer, R				Lehmann, HC; Hengge, UR; Alswede, L; Saleh, A; von Geldern, G; Hartung, HP; Ruzicka, T; Hemmer, R			A 32-year-old man with relapsing-progressive brainstem symptoms	LANCET NEUROLOGY			English	Article							ENZYME REPLACEMENT THERAPY; ANDERSON-FABRY-DISEASE; CEREBRAL HYPERPERFUSION; ATAXIA-TELANGIECTASIA; ALPHA-GALACTOSIDASE; MANIFESTATIONS; COMPLICATIONS; DIAGNOSIS; REVERSAL; STROKE		Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Ophthalmol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Diagnost Radiol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Hemmer, R (corresponding author), Univ Dusseldorf, Dept Neurol, Moorenstr 5, D-40225 Dusseldorf, Germany.	bernhard.hemmer@uni-duesseldorf.de	Lehmann, Helmar C/G-4998-2016	Lehmann, Helmar C/0000-0001-6205-2293				Altarescu G, 2001, STROKE, V32, P1559, DOI 10.1161/01.STR.32.7.1559; Brady RO, 2000, JAMA-J AM MED ASSOC, V284, P2771, DOI 10.1001/jama.284.21.2771; Bushara KO, 2005, GASTROENTEROLOGY, V128, pS92, DOI 10.1053/j.gastro.2005.02.018; CHUNG EO, 1994, J CHILD NEUROL, V9, P31, DOI 10.1177/088307389400900106; Desnick RJ, 2003, ANN INTERN MED, V138, P338, DOI 10.7326/0003-4819-138-4-200302180-00014; Dewar DH, 2005, GASTROENTEROLOGY, V128, pS19, DOI 10.1053/j.gastro.2005.02.010; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; FILLINGKATZ MR, 1989, NEUROLOGY, V39, P598, DOI 10.1212/WNL.39.4.598; Gerard A, 2002, MEDICINE, V81, P443, DOI 10.1097/00005792-200211000-00005; Germain DP, 2002, MOL MED, V8, P304, DOI 10.1007/BF03402156; GREWAL RP, 1994, J NEUROL, V241, P153; GREWAL RP, 1992, CLIN NEUROL NEUROSUR, V94, P177, DOI 10.1016/0303-8467(92)90079-I; Hill ID, 2005, GASTROENTEROLOGY, V128, pS25, DOI 10.1053/j.gastro.2005.02.012; Hilz MJ, 2004, NEUROLOGY, V62, P1066, DOI 10.1212/01.WNL.0000118207.84514.40; Hoffmann B, 2005, J MED GENET, V42, P247, DOI 10.1136/jmg.2004.025791; KINT J A, 1970, Science (Washington D C), V167, P1268, DOI 10.1126/science.167.3922.1268; KOEPP M, 1994, MOVEMENT DISORD, V9, P455, DOI 10.1002/mds.870090414; Larralde M, 2004, ARCH DERMATOL, V140, P1440, DOI 10.1001/archderm.140.12.1440; MacDermot KD, 2001, J MED GENET, V38, P750, DOI 10.1136/jmg.38.11.750; Marth T, 2003, LANCET, V361, P239, DOI 10.1016/S0140-6736(03)12274-X; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Mitsias P, 1996, ANN NEUROL, V40, P8, DOI 10.1002/ana.410400105; Moore DF, 2002, BMC NEUROL, V2, DOI 10.1186/1471-2377-2-4; Moore DF, 2002, STROKE, V33, P525, DOI 10.1161/hs0202.102601; Moore DF, 2003, AM J NEURORADIOL, V24, P1096; Moore DF, 2001, J NEUROIMAGING, V11, P303, DOI 10.1111/j.1552-6569.2001.tb00051.x; Moore DF, 2001, CIRCULATION, V104, P1506, DOI 10.1161/hc3801.096352; MORGAN SH, 1990, Q J MED, V75, P491; NAKAO S, 1995, NEW ENGL J MED, V333, P288, DOI 10.1056/NEJM199508033330504; Perlman Susan, 2003, Semin Pediatr Neurol, V10, P173, DOI 10.1016/S1071-9091(03)00026-3; Ries M, 2003, J INHERIT METAB DIS, V26, P413, DOI 10.1023/A:1025127723729; Schiffmann R, 2001, JAMA-J AM MED ASSOC, V285, P2743, DOI 10.1001/jama.285.21.2743; Sessa A, 2001, NEPHRON, V89, P469, DOI 10.1159/000046124; Tanaka N, 2005, EUR J NEUROL, V12, P486, DOI 10.1111/j.1468-1331.2005.01016.x; TAREYEVA IE, 1980, CLIN NEPHROL, V14, P233; Utsumi K, 1997, INTERNAL MED, V36, P327, DOI 10.2169/internalmedicine.36.327; Younger DS, 2004, CURR OPIN NEUROL, V17, P317, DOI 10.1097/00019052-200406000-00014	38	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2006	5	1					97	102		10.1016/S1474-4422(05)70287-8	http://dx.doi.org/10.1016/S1474-4422(05)70287-8			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	998OI	16361027				2022-12-18	WOS:000234328100032
J	Gold, R; Hartung, HP				Gold, R; Hartung, HP			Towards individualised multiple-sclerosis therapy	LANCET NEUROLOGY			English	Editorial Material							PLASMA-EXCHANGE		Univ Gottingen, Inst MS Res, Dusseldorf, Germany; Univ Dusseldorf, Dept Neurol, D-4000 Dusseldorf, Germany	University of Gottingen; Heinrich Heine University Dusseldorf	Gold, R (corresponding author), Univ Gottingen, Inst MS Res, Dusseldorf, Germany.	r.gold@med.uni-goettingen.de						Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; Chan A, 2005, CLIN EXP IMMUNOL, V139, P152, DOI 10.1111/j.1365-2249.2005.02653.x; Compston A.E.G., 1998, MCALPINES MULTIPLE S, V3rd; Cree BAC, 2005, NEUROLOGY, V64, P1270, DOI 10.1212/01.WNL.0000159399.81861.D5; Keegan M, 2005, LANCET, V366, P579, DOI 10.1016/S0140-6736(05)67102-4; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; Ruprecht K, 2004, NEUROLOGY, V63, P1081, DOI 10.1212/01.WNL.0000138437.99046.6B; STUEVE O, 2005, ARCH NEUROL-CHICAGO, V62, P1; Weinshenker BG, 1999, ANN NEUROL, V46, P878, DOI 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q	9	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2005	4	11					693	694		10.1016/S1474-4422(05)70205-2	http://dx.doi.org/10.1016/S1474-4422(05)70205-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980GK	16239174				2022-12-18	WOS:000233002400004
J	Amato, MP				Amato, MP			Donepezil for memory impairment in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							COGNITIVE DYSFUNCTION		Univ Florence, Dept Neurol, Florence, Italy	University of Florence	Amato, MP (corresponding author), Univ Florence, Dept Neurol, Florence, Italy.	mariapia.amato@unifi.it	Amato, Maria Pia/AAC-5940-2022; amato, Maria Pia/AAL-5998-2020	amato, Maria Pia/0000-0003-3325-3760				Amato MP, 2001, ARCH NEUROL-CHICAGO, V58, P1602, DOI 10.1001/archneur.58.10.1602; AMATO MP, 2003, INT MS J, V10, P70; Bobholz JA, 2003, CURR OPIN NEUROL, V16, P283, DOI 10.1097/00019052-200306000-00006; Fischer JS, 2000, ANN NEUROL, V48, P885, DOI 10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.3.CO;2-T; Krupp LB, 2004, NEUROLOGY, V63, P1579, DOI 10.1212/01.WNL.0000142989.09633.5A	5	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					72	73		10.1016/S1474-4422(05)00972-5	http://dx.doi.org/10.1016/S1474-4422(05)00972-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15664536				2022-12-18	WOS:000226712300004
J	Fillit, H				Fillit, H			Intravenous immunoglobulins for Alzheimer's disease	LANCET NEUROLOGY			English	Letter							ANTIBODIES		Inst Study Aging, New York, NY USA		Fillit, H (corresponding author), Inst Study Aging, New York, NY USA.	hfillit@aging-institute.org						Aisen PS, 2002, LANCET NEUROL, V1, P279, DOI 10.1016/S1474-4422(02)00133-3; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Dodel RC, 2004, J NEUROL NEUROSUR PS, V75, P1472, DOI 10.1136/jnnp.2003.033399; FOLEY P, 1988, J NEUROL, V235, P466, DOI 10.1007/BF00314249; Hack CE, 2004, J NEUROL NEUROSUR PS, V75, P1374, DOI 10.1136/jnnp.2004.043141; ISHII T, 1975, ACTA NEUROPATHOL, V32, P157, DOI 10.1007/BF00689569; Matsuoka Y, 2003, J NEUROSCI, V23, P29; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; MUTHINITI S, 2004, NEUROBIOL AGING, V25, P1023	9	8	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2004	3	12					704	704		10.1016/S1474-4422(04)00929-9	http://dx.doi.org/10.1016/S1474-4422(04)00929-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	873MD	15556799				2022-12-18	WOS:000225283500013
J	Larkin, M				Larkin, M			Warner-Lambert found guilty of promoting Neurontin off label	LANCET NEUROLOGY			English	News Item																			0	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2004	3	7					387	387		10.1016/S1474-4422(04)00792-6	http://dx.doi.org/10.1016/S1474-4422(04)00792-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832ZQ	15228033				2022-12-18	WOS:000222306600002
J	Yaffe, K				Yaffe, K			Testosterone and the brain: uncharted territory	LANCET NEUROLOGY			English	Editorial Material							OLDER MEN; ALZHEIMER; WOMEN		Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Yaffe, K (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	kyaffe@itsa.ucsf.edu						LIVERMAN CT, 2004, TESTOSTERONE AGING; Moffat SD, 2004, NEUROLOGY, V62, P188, DOI 10.1212/WNL.62.2.188; Okun MS, 2004, NEUROLOGY, V62, P411, DOI 10.1212/01.WNL.0000106840.72938.84; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Yaffe K, 2003, BIOL PSYCHIAT, V54, P943, DOI 10.1016/S0006-3223(03)00115-X; Yaffe K, 2000, LANCET, V356, P708, DOI 10.1016/S0140-6736(00)02628-3	6	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2004	3	5					270	270		10.1016/S1474-4422(04)00732-X	http://dx.doi.org/10.1016/S1474-4422(04)00732-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817EL	15099540				2022-12-18	WOS:000221160700018
J	Singh, G; Sander, JW				Singh, G; Sander, JW			Anticysticercal treatment and seizures in neurocysticercosis	LANCET NEUROLOGY			English	Letter							ALBENDAZOLE; LESIONS		UCL, Inst Neurol, Natl Hosp Neurol & Neurosurg, Dept Clin & Expt Epilepsy, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Sander, JW (corresponding author), UCL, Inst Neurol, Natl Hosp Neurol & Neurosurg, Dept Clin & Expt Epilepsy, Queen Sq, London WC1N 3BG, England.	jsander@ion.ucl.ac.uk	Sander, Josemir/C-1576-2008	Sander, Josemir/0000-0001-6041-9661				Baranwal AK, 1998, PEDIATR INFECT DIS J, V17, P696, DOI 10.1097/00006454-199808000-00007; CARPIO A, 1995, ARCH INTERN MED, V155, P1982, DOI 10.1001/archinte.155.18.1982; FAIRLEY H, 1934, TROP DIS B, V31, P784; Garcia HH, 2004, NEW ENGL J MED, V350, P249, DOI 10.1056/NEJMoa031294; Mall RK, 2003, EPILEPSIA, V44, P1397, DOI 10.1046/j.1528-1157.2003.08003.x; Ong S, 2002, EMERG INFECT DIS, V8, P608, DOI 10.3201/eid0806.010377; Padma M. V., 1995, National Medical Journal of India, V8, P255; PADMA MV, 1994, NEUROLOGY, V44, P1344, DOI 10.1212/WNL.44.7.1344; Pal DK, 2000, J NEUROL NEUROSUR PS, V68, P137, DOI 10.1136/jnnp.68.2.137; Schantz Peter M., 2002, P63, DOI 10.1079/9780851996288.0063	10	8	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2004	3	4					207	208		10.1016/S1474-4422(04)00705-7	http://dx.doi.org/10.1016/S1474-4422(04)00705-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	814QU	15039032				2022-12-18	WOS:000220990000014
J	Goodin, D				Goodin, D			Marijuana and multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							CANNABINOIDS; SPASTICITY		Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Goodin, D (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.	dsg@itsa.ucsf.edu						ASHWORTH B, 1964, PRACTITIONER, V192, P540; CHECK WA, 1979, JAMA-J AM MED ASSOC, V241, P2476; Iversen L, 2003, BRAIN, V126, P1252, DOI 10.1093/brain/awg143; Killestein J, 2002, NEUROLOGY, V58, P1404, DOI 10.1212/WNL.58.9.1404; MEINCK HM, 1989, J NEUROL, V236, P120, DOI 10.1007/BF00314410; Page SA, 2003, CAN J NEUROL SCI, V30, P201, DOI 10.1017/S0317167100002584; Pertwee RG, 2002, PHARMACOL THERAPEUT, V95, P165, DOI 10.1016/S0163-7258(02)00255-3; Ross S.A., 1995, ZAGAZIG J PHARM SCI, V4, P1, DOI [10.21608/zjps.1995.169714, DOI 10.21608/ZJPS.1995.169714]; Smith Paul F, 2002, Curr Opin Investig Drugs, V3, P859; UNGERLEIDER J T, 1987, Advances in Alcohol and Substance Abuse, V7, P39; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1	11	8	8	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2004	3	2					79	80		10.1016/S1474-4422(03)00655-0	http://dx.doi.org/10.1016/S1474-4422(03)00655-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	772AQ	14746994				2022-12-18	WOS:000188818500012
J	Schachter, SC				Schachter, SC			Epilepsy: major advances in treatment	LANCET NEUROLOGY			English	Editorial Material									Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Schachter, SC (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Attarian H, 2003, EPILEPSY BEHAV, V4, P298, DOI 10.1016/S1525-5050(03)00083-0; Lada C, 2003, EPILEPSIA, V44, P81, DOI 10.1046/j.1528-1157.2003.32602.x; Tergau F, 2003, EPILEPSY RES, V56, P67, DOI 10.1016/j.eplepsyres.2003.08.006; Yoon HH, 2003, NEUROLOGY, V61, P445, DOI 10.1212/01.WNL.0000081226.51886.5B	4	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					11	11		10.1016/S1474-4422(03)00611-2	http://dx.doi.org/10.1016/S1474-4422(03)00611-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14693100				2022-12-18	WOS:000187447100014
J	Seeck, M				Seeck, M			Surgical treatment of tumoral temporal-lobe epilepsy	LANCET NEUROLOGY			English	Editorial Material							SEIZURE		Univ Hosp Geneva, Geneva, Switzerland; Univ Lausanne Hosp, Lausanne, Switzerland	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Seeck, M (corresponding author), Univ Hosp Geneva, Geneva, Switzerland.	margitta.seeck@hcuge.ch						Beaumont A, 2000, ACTA NEUROCHIR, V142, P1, DOI 10.1007/s007010050001; Engel Jerome Jr, 2003, Epilepsy Curr, V3, P37, DOI 10.1046/j.1535-7597.2003.03201.x; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Luyken C, 2003, EPILEPSIA, V44, P822, DOI 10.1046/j.1528-1157.2003.56102.x; Nakamura M, 2000, ONCOLOGY-BASEL, V58, P108, DOI 10.1159/000012087; Spencer SS, 2002, LANCET NEUROL, V1, P375, DOI 10.1016/S1474-4422(02)00163-1; Sperling MR, 1999, ANN NEUROL, V46, P45, DOI 10.1002/1531-8249(199907)46:1<45::AID-ANA8>3.0.CO;2-I; Stephen LJ, 2001, EPILEPSIA, V42, P357, DOI 10.1046/j.1528-1157.2001.29000.x; Zaatreh MM, 2003, NEUROLOGY, V61, P636, DOI 10.1212/01.WNL.0000079374.78589.1B	9	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2003	2	12					722	723		10.1016/S1474-4422(03)00592-1	http://dx.doi.org/10.1016/S1474-4422(03)00592-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745AV	14636774				2022-12-18	WOS:000186665800013
J	Reagan, P; Hurst, R; Cook, L; Zylicz, Z; Otlowski, M; Veldink, JH; van den Berg, LH; Wokke, JHJ				Reagan, P; Hurst, R; Cook, L; Zylicz, Z; Otlowski, M; Veldink, JH; van den Berg, LH; Wokke, JHJ			Physician-assisted death: dying with dignity?	LANCET NEUROLOGY			English	Editorial Material							SUICIDE; EUTHANASIA		Hospice Rozenheuvel, Rozendaal, Netherlands; Univ Tasmania, Hobart, Tas 7001, Australia	University of Tasmania			Otlowski, Margaret/J-7279-2014	Otlowski, Margaret/0000-0003-4707-4325; Veldink, Jan/0000-0001-5572-9657				Bannink M, 2000, LANCET, V356, P2067, DOI 10.1016/S0140-6736(00)03407-3; Dyer C, 2002, BRIT MED J, V324, P1055, DOI 10.1136/bmj.324.7345.1055; Ganzini L, 2002, J PAIN SYMPTOM MANAG, V24, P312, DOI 10.1016/S0885-3924(02)00496-7; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GUNNING KF, EUTHANASIA NETHERLAN; Hedberg K, 2003, NEW ENGL J MED, V348, P961, DOI 10.1056/NEJM200303063481022; Hurst SA, 2003, BRIT MED J, V326, P271, DOI 10.1136/bmj.326.7383.271; Kissane DW, 1998, LANCET, V352, P1097, DOI 10.1016/S0140-6736(98)05406-3; OOSTVEEN M, 2001, SPIJT; *OR DEP HUM SERV, 2002, PHYS ASS SUIC DEATH; Otlowski M, 1997, VOLUNTARY EUTHANASIA; Otlowski Margaret, 2002, Monash Bioeth Rev, V21, P10; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; Reagan P, 1999, LANCET, V353, P1265, DOI 10.1016/S0140-6736(98)12219-5; VANDERWAL G, 2003, MED BESLUITVORMING A; Veldink JH, 2002, NEW ENGL J MED, V346, P1638, DOI 10.1056/NEJMsa012739; ZYLICZ Z, 1998, CANC PAIN, P121	17	8	8	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2003	2	10					637	643		10.1016/S1474-4422(03)00536-2	http://dx.doi.org/10.1016/S1474-4422(03)00536-2			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	723KR	14505588				2022-12-18	WOS:000185432000023
J	Meschia, JF				Meschia, JF			Ischaemic stroke: one or several complex genetic disorders?	LANCET NEUROLOGY			English	Editorial Material							CLASSIFICATION; SUBTYPES; HISTORY		Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA	Mayo Clinic	Meschia, JF (corresponding author), Mayo Clin, Dept Neurol, Davis 8B,4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Meschia, James/GPP-1636-2022	Meschia, James/0000-0002-4475-8142				ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Gretarsdottir S, 2002, AM J HUM GENET, V70, P593, DOI 10.1086/339252; Jerrard-Dunne P, 2003, STROKE, V34, P1364, DOI 10.1161/01.STR.0000069723.17984.FD; Meschia JF, 2002, STROKE, V33, P2770, DOI 10.1161/01.STR.0000035261.28528.C8	5	8	8	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2003	2	8					459	459		10.1016/S1474-4422(03)00479-4	http://dx.doi.org/10.1016/S1474-4422(03)00479-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	704AC	12878431				2022-12-18	WOS:000184314700012
J	Sisodiya, S				Sisodiya, S			Drug resistance in epilepsy: not futile, but complex?	LANCET NEUROLOGY			English	Editorial Material									Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England	University of London; University College London	Sisodiya, S (corresponding author), Inst Neurol, Dept Clin & Expt Epilepsy, Queen Sq, London WC1N 3BG, England.							Mulley JC, 2003, CURR OPIN NEUROL, V16, P171, DOI 10.1097/00019052-200304000-00009; Remy S, 2003, ANN NEUROL, V53, P469, DOI 10.1002/ana.10473; Siddiqui A, 2003, NEW ENGL J MED, V348, P1442, DOI 10.1056/NEJMoa021986; Sisodiya SM, 2003, CURR OPIN NEUROL, V16, P197, DOI 10.1097/00019052-200304000-00013	4	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2003	2	6					331	331		10.1016/S1474-4422(03)00402-2	http://dx.doi.org/10.1016/S1474-4422(03)00402-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	682WH	12849144				2022-12-18	WOS:000183115000011
J	Roesler, R; Quevedo, J; Schroder, N				Roesler, R; Quevedo, J; Schroder, N			Is it time to conclude that NMDA antagonists have failed?	LANCET NEUROLOGY			English	Letter									Univ Fed Rio Grande Sul, Ctr Biotechnol, GENOTOX Lab, BR-90046900 Porto Alegre, RS, Brazil; Univ So Santa Catarina, Dept Med, Criciuma, Brazil; Catholic Univ, Dept Physiol Sci, Porto Alegre, RS, Brazil	Universidade Federal do Rio Grande do Sul; Universidade do Sul de Santa Catarina	Roesler, R (corresponding author), Univ Fed Rio Grande Sul, Ctr Biotechnol, GENOTOX Lab, BR-90046900 Porto Alegre, RS, Brazil.		de Quevedo, João Luciano/N-1407-2019; de Quevedo, João Luciano/E-5491-2013; Roesler, Rafael/U-9261-2019; Schroder, Nadja/AAE-9376-2019	de Quevedo, João Luciano/0000-0003-3114-6611; de Quevedo, João Luciano/0000-0003-3114-6611; Schroder, Nadja/0000-0002-4227-5702; Roesler, Rafael/0000-0001-6016-2261				BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Evins AE, 2002, SCHIZOPHR RES, V56, P19, DOI 10.1016/S0920-9964(01)00220-1; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Kemp JA, 2002, NAT NEUROSCI, V5, P1039, DOI 10.1038/nn936; Schwartz BL, 1996, NEUROLOGY, V46, P420, DOI 10.1212/WNL.46.2.420	5	8	10	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2003	2	1					13	13		10.1016/S1474-4422(03)00260-6	http://dx.doi.org/10.1016/S1474-4422(03)00260-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	629DU	12849294				2022-12-18	WOS:000180035800017
J	Lewis, V; Boyd, A; Masters, CL; Collins, SJ				Lewis, V; Boyd, A; Masters, CL; Collins, SJ			Apparently sporadic CJD and covert health-care transmissions	LANCET NEUROLOGY			English	Editorial Material							CREUTZFELDT-JAKOB-DISEASE; RISK		Univ Melbourne, Australian Natl Creutzfeldt Jakob Dis Registry, Dept Pathol, Melbourne, Vic 3010, Australia	University of Melbourne	Lewis, V (corresponding author), Univ Melbourne, Australian Natl Creutzfeldt Jakob Dis Registry, Dept Pathol, Melbourne, Vic 3010, Australia.			Lewis, Victoria/0000-0003-2936-6308				Collins S, 1999, LANCET, V353, P693, DOI 10.1016/S0140-6736(98)08138-0; Hill AF, 2000, P NATL ACAD SCI USA, V97, P10248, DOI 10.1073/pnas.97.18.10248; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Ward HJT, 2002, NEUROLOGY, V59, P543, DOI 10.1212/WNL.59.4.543; Zerr I, 2000, J CLIN EPIDEMIOL, V53, P747, DOI 10.1016/S0895-4356(99)00207-3	5	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2002	1	8					470	471		10.1016/S1474-4422(02)00233-8	http://dx.doi.org/10.1016/S1474-4422(02)00233-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	618PP	12849325				2022-12-18	WOS:000179426700016
J	Bonifati, V				Bonifati, V			Deciphering Parkinson's disease - PARK8	LANCET NEUROLOGY			English	Letter									Univ Roma La Sapienza, Dept Neurol Sci, Rome, Italy; Erasmus Univ, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands	Sapienza University Rome; Erasmus University Rotterdam	Bonifati, V (corresponding author), Univ Roma La Sapienza, Dept Neurol Sci, Rome, Italy.							Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Scott WK, 2000, AM J HUM GENET, V66, P922, DOI 10.1086/302828; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627	5	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2002	1	2					83	83		10.1016/S1474-4422(02)00036-4	http://dx.doi.org/10.1016/S1474-4422(02)00036-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HA	12849510				2022-12-18	WOS:000177695000015
J	Rapoport, SI				Rapoport, SI			Hydrogen magnetic resonance spectroscopy in Alzheimer's disease	LANCET NEUROLOGY			English	Letter							H-1 MRS		NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Rapoport, SI (corresponding author), NIA, Brain Physiol & Metab Sect, NIH, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE ON AGING [ZIAAG000148, Z01AG000148] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Huang W, 2001, NEUROLOGY, V57, P626, DOI 10.1212/WNL.57.4.626; Huang W, 1999, AM J PSYCHIAT, V156, P1879; Kantarci K, 2000, NEUROLOGY, V55, P210, DOI 10.1212/WNL.55.2.210; Rapoport S I, 1997, Int Psychogeriatr, V9 Suppl 1, P229, DOI 10.1017/S1041610297004936; Schuff N, 2002, NEUROLOGY, V58, P928, DOI 10.1212/WNL.58.6.928	5	8	9	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2002	1	2					82	82		10.1016/S1474-4422(02)00035-2	http://dx.doi.org/10.1016/S1474-4422(02)00035-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HA	12849509				2022-12-18	WOS:000177695000014
J	Charidimou, A; Boulouis, G; Frosch, MP; Baron, JC; Pasi, M; Albucher, JF; Banerjee, G; Barbato, C; Bonneville, F; Brandner, S; Calviere, L; Caparros, F; Casolla, B; Cordonnier, C; Delisle, MB; Deramecourt, V; Dichgans, M; Gokcal, E; Herms, J; Hernandez-Guillamon, M; Jager, HR; Jaunmuktane, Z; Linn, J; Martinez-Ramirez, S; Martinez-Saez, E; Mawrin, C; Montaner, J; Moulin, S; Olivot, JM; Piazza, F; Puy, L; Raposo, N; Rodrigues, MA; Roeber, S; Romero, JR; Samarasekera, N; Schneider, JA; Schreiber, S; Schreiber, F; Schwall, C; Smith, C; Szalardy, L; Varlet, P; Viguier, A; Wardlaw, JM; Warren, A; Wollenweber, FA; Zedde, M; van Buchem, MA; Gurol, ME; Viswanathan, A; Salman, RAS; Smith, EE; Werring, DJ; Greenberg, SM				Charidimou, Andreas; Boulouis, Gregoire; Frosch, Matthew P.; Baron, Jean-Claude; Pasi, Marco; Albucher, Jean Francois; Banerjee, Gargi; Barbato, Carmen; Bonneville, Fabrice; Brandner, Sebastian; Calviere, Lionel; Caparros, Francois; Casolla, Barbara; Cordonnier, Charlotte; Delisle, Marie-Bernadette; Deramecourt, Vincent; Dichgans, Martin; Gokcal, Elif; Herms, Jochen; Hernandez-Guillamon, Mar; Jager, Hans Rolf; Jaunmuktane, Zane; Linn, Jennifer; Martinez-Ramirez, Sergi; Martinez-Saez, Elena; Mawrin, Christian; Montaner, Joan; Moulin, Solene; Olivot, Jean-Marc; Piazza, Fabrizio; Puy, Laurent; Raposo, Nicolas; Rodrigues, Mark A.; Roeber, Sigrun; Romero, Jose Rafael; Samarasekera, Neshika; Schneider, Julie A.; Schreiber, Stefanie; Schreiber, Frank; Schwall, Corentin; Smith, Colin; Szalardy, Levente; Varlet, Pascale; Viguier, Alain; Wardlaw, Joanna M.; Warren, Andrew; Wollenweber, Frank A.; Zedde, Marialuisa; van Buchem, Mark A.; Gurol, M. Edip; Viswanathan, Anand; Salman, Rustam Al-Shahi; Smith, Eric E.; Werring, David J.; Greenberg, Steven M.			The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study	LANCET NEUROLOGY			English	Article							INTRACEREBRAL HEMORRHAGE; SUPERFICIAL SIDEROSIS; PERIVASCULAR SPACES; DISEASE; MICROBLEEDS; VALIDATION; HEREDITARY; MARKERS	Background Cerebral amyloid angiopathy (CAA) is an age-related small vessel disease, characterised pathologically by progressive deposition of amyloid beta in the cerebrovascular wall. The Boston criteria are used worldwide for the in-vivo diagnosis of CAA but have not been updated since 2010, before the emergence of additional MRI markers. We report an international collaborative study aiming to update and externally validate the Boston diagnostic criteria across the full spectrum of clinical CAA presentations. Methods In this multicentre, hospital-based, retrospective, MRI and neuropathology diagnostic accuracy study, we did a retrospective analysis of clinical, radiological, and histopathological data available to sites participating in the International CAA Association to formulate updated Boston criteria and establish their diagnostic accuracy across different populations and clinical presentations. Ten North American and European academic medical centres identified patients aged 50 years and older with potential CAA-related clinical presentations (ie, spontaneous intracerebral haemorrhage, cognitive impairment, or transient focal neurological episodes), available brain MRI, and histopathological assessment for CAA diagnosis. MRI scans were centrally rated at Massachusetts General Hospital (Boston, MA, USA) for haemorrhagic and non-haemorrhagic CAA markers, and brain tissue samples were rated by neuropathologists at the contributing sites. We derived the Boston criteria version 2.0 (v2.0) by selecting MRI features to optimise diagnostic specificity and sensitivity in a prespecified derivation cohort (Boston cases 1994-2012, n=159), then externally validated the criteria in a prespecified temporal validation cohort (Boston cases 2012-18, n=59) and a geographical validation cohort (non-Boston cases 2004-18; n=123), comparing accuracy of the new criteria to the currently used modified Boston criteria with histopathological assessment of CAA as the diagnostic standard. We also assessed performance of the v2.0 criteria in patients across all cohorts who had the diagnostic gold standard of brain autopsy. Findings The study protocol was finalised on Jan 15, 2017, patient identification was completed on Dec 31, 2018, and imaging analyses were completed on Sept 30, 2019. Of 401 potentially eligible patients presenting to Massachusetts General Hospital, 218 were eligible to be included in the analysis; of 160 patient datasets from other centres, 123 were included. Using the derivation cohort, we derived provisional criteria for probable CAA requiring the presence of at least two strictly lobar haemorrhagic lesions (ie, intracerebral haemorrhages, cerebral microbleeds, or foci of cortical superficial siderosis) or at least one strictly lobar haemorrhagic lesion and at least one white matter characteristic (ie, severe visible perivascular spaces in centrum semiovale or white matter hyperintensities in a multispot pattern). The sensitivity and specificity of these criteria were 74.8% (95% CI 65.4-82.7) and 84.6% (71.9-93.1) in the derivation cohort, 92.5% (79.6-98.4) and 89.5% (66.9-98.7) in the temporal validation cohort, 80.2% (70.8-87.6) and 81.5% (61.9-93.7) in the geographical validation cohort, and 74.5% (65.4-82.4) and 95.0% (83.1-99.4) in all patients who had autopsy as the diagnostic standard. The area under the receiver operating characteristic curve (AUC) was 0.797 (0.732-0.861) in the derivation cohort, 0.910 (0.828-0.992) in the temporal validation cohort, 0.808 (0.724-0.893) in the geographical validation cohort, and 0.848 (0.794-0.901) in patients who had autopsy as the diagnostic standard. The v2.0 Boston criteria for probable CAA had superior accuracy to the current Boston criteria (sensitivity 64.5% [54.9-73.4]; specificity 95.0% [83.1-99.4]; AUC 0.798 [0.741-0854]; p=0.0005 for comparison of AUC) across all individuals who had autopsy as the diagnostic standard. Interpretation The Boston criteria v2.0 incorporate emerging MRI markers of CAA to enhance sensitivity without compromising their specificity in our cohorts of patients aged 50 years and older presenting with spontaneous intracerebral haemorrhage, cognitive impairment, or transient focal neurological episodes. Future studies will be needed to determine generalisability of the v.2.0 criteria across the full range of patients and clinical presentations.	[Charidimou, Andreas; Boulouis, Gregoire; Pasi, Marco; Gokcal, Elif; Martinez-Ramirez, Sergi; Warren, Andrew; Gurol, M. Edip; Viswanathan, Anand; Greenberg, Steven M.] Massachusetts Gen Hosp, Hemorrhag Stroke Res Program, J Philip Kistler Res Ctr, Dept Neurol, Boston, MA 02139 USA; [Frosch, Matthew P.] Massachusetts Gen Hosp, CS Kub Lab Neuropathol, Dept Pathol, Boston, MA 02139 USA; [Boulouis, Gregoire; Baron, Jean-Claude; Schwall, Corentin; Varlet, Pascale] Univ Paris Cite, Grp Hosp Univ GHU Paris, Inst Psychiat & Neurosci Paris, INSERM,UMR S1266,Psychiat & Neurosci, Paris, France; [Baron, Jean-Claude; Schwall, Corentin; Varlet, Pascale] GHU Psychiat & Neurosci, Site St Anne, Paris, France; [Pasi, Marco; Caparros, Francois; Casolla, Barbara; Cordonnier, Charlotte; Deramecourt, Vincent; Moulin, Solene; Puy, Laurent] Univ Lille, U1172 Lille Neurosci & Cognit, Ctr Hosp Univ CHU Lille, INSERM, Lille, France; [Albucher, Jean Francois; Bonneville, Fabrice; Calviere, Lionel; Delisle, Marie-Bernadette; Olivot, Jean-Marc; Raposo, Nicolas; Viguier, Alain] Univ Toulouse, CHU Toulouse, Dept Neurol,INSERM UPS, Toulouse Neuroimaging Ctr,Hop Pierre Paul Riquet, Toulouse, France; [Albucher, Jean Francois; Bonneville, Fabrice; Calviere, Lionel; Delisle, Marie-Bernadette; Olivot, Jean-Marc; Raposo, Nicolas; Viguier, Alain] Univ Toulouse, CHU Toulouse, Dept Neuroradiol,INSERM UPS, Toulouse Neuroimaging Ctr,Hop Pierre Paul Riquet, Toulouse, France; [Banerjee, Gargi; Barbato, Carmen; Brandner, Sebastian; Jager, Hans Rolf; Jaunmuktane, Zane; Werring, David J.] UCL, Stroke Res Ctr, Dept Brain Repair & Rehabil, Queen Sq Inst Neurol, London, England; [Banerjee, Gargi; Barbato, Carmen; Brandner, Sebastian; Jager, Hans Rolf; Jaunmuktane, Zane; Werring, David J.] Natl Hosp Neurol & Neurosurg, London, England; [Dichgans, Martin; Wollenweber, Frank A.] Ludwig Maximilians Univ Munchen, Inst Stroke & Dementia Res, Munich, Germany; [Herms, Jochen; Roeber, Sigrun] Ludwig Maximilians Univ Munchen, Ctr Neuropathol & Prion Res, Munich, Germany; [Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Dichgans, Martin] German Ctr Neurodegenerat Dis, Munich, Germany; [Hernandez-Guillamon, Mar; Martinez-Saez, Elena; Montaner, Joan] Univ Autonoma Barcelona, Neurovasc Res Lab, Inst Recerca Vall dHebron, Barcelona, Spain; [Montaner, Joan] Univ Seville, Inst Biomed Seville, Hosp Univ Virgen Macarena, Seville, Spain; [Linn, Jennifer] Univ Hosp, Inst Diagnost & Intervent Neuroradiol, Dresden, Germany; [Mawrin, Christian; Schreiber, Stefanie; Schreiber, Frank] Otto von Guericke Univ, Dept Neuropathol, Magdeburg, Germany; [Mawrin, Christian; Schreiber, Stefanie; Schreiber, Frank] Otto von Guericke Univ, Dept Neurosurg, Magdeburg, Germany; [Mawrin, Christian; Schreiber, Stefanie; Schreiber, Frank] Otto von Guericke Univ, Dept Neurol, Magdeburg, Germany; [Piazza, Fabrizio] Univ Milano Bicocca, Sch Med & Surg, CAA & AD Translat Res & Biomarkers Lab, Monza, Italy; [Rodrigues, Mark A.; Samarasekera, Neshika; Smith, Colin; Wardlaw, Joanna M.; Salman, Rustam Al-Shahi] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland; [Wardlaw, Joanna M.; Salman, Rustam Al-Shahi] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Martinez-Ramirez, Sergi; Romero, Jose Rafael] Boston Univ, Sch Med, Framingham Heart Study, Boston, MA 02118 USA; [Martinez-Ramirez, Sergi; Romero, Jose Rafael] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Schneider, Julie A.] Rush Univ, Ruth Alzheimers Dis Ctr, Med Ctr, Chicago, IL 60612 USA; [Szalardy, Levente] Univ Szeged, Fac Med, Albert Szent Gyorgyi Clin Ctr, Dept Neurol, Szeged, Hungary; [Wollenweber, Frank A.] Helios Dr Horst Schmidt Kliniken, Wiesbaden, Germany; [Zedde, Marialuisa] Azienda Unitl Sanitaria Locale IRCCS Reggio Emili, Neurol Unit, Stroke Unit, Reggio Emilia, Italy; [van Buchem, Mark A.] Leiden Univ, Dept Radiol, Med Ctr, Leiden, Netherlands; [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Munich; University of Munich; University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Hospital Universitario Virgen Macarena; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Otto von Guericke University; Otto von Guericke University; Otto von Guericke University; University of Milano-Bicocca; University of Edinburgh; University of Edinburgh; Boston University; Framingham Heart Study; Boston University; Rush University; Szeged University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Calgary; University of Calgary	Charidimou, A (corresponding author), Massachusetts Gen Hosp, J Philip Kistler Res Ctr, Dept Neurol, Stroke Res Ctr,Haemorrhag Stroke Res Program, Boston, MA 02139 USA.	andreas.charidimou.09@ucl.ac.uk; sgreenberg@mgh.harvard.edu	Dichgans, Martin/HCH-3247-2022; Piazza, Fabrizio/L-2094-2016; Jager, Hans Rolf/K-1868-2013	Dichgans, Martin/0000-0002-0654-387X; Piazza, Fabrizio/0000-0002-3385-3224; Samarasekera, Neshika/0000-0001-6840-0199; Rodrigues, Mark/0000-0002-4507-6872; Jager, Hans Rolf/0000-0002-6403-4184; Banerjee, Gargi/0000-0003-0190-7782	US National Institutes of Health [AG26484]; Bodossaki Foundation post-doctoral scholarship; Frechette Family Foundation	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bodossaki Foundation post-doctoral scholarship; Frechette Family Foundation	This work is funded by the US National Institutes of Health (AG26484). AC was supported by a Bodossaki Foundation post-doctoral scholarship and the Frechette Family Foundation.	Auriel E, 2016, JAMA NEUROL, V73, P197, DOI 10.1001/jamaneurol.2015.4078; Banerjee G, 2019, ANN NEUROL, V85, P284, DOI 10.1002/ana.25407; Beitzke M, 2015, STROKE, V46, P1533, DOI 10.1161/STROKEAHA.115.008778; Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1136/bmj.h5527, 10.1148/radiol.2015151516, 10.1373/clinchem.2015.246280]; Boyle PA, 2015, NEUROLOGY, V85, P1930, DOI 10.1212/WNL.0000000000002175; Charidimou A, 2019, INT J STROKE, V14, P956, DOI 10.1177/1747493019855888; Charidimou A, 2018, NEUROLOGY, V90, pE754, DOI 10.1212/WNL.0000000000005030; Charidimou A, 2017, NEUROLOGY, V89, P1490, DOI 10.1212/WNL.0000000000004539; Charidimou A, 2017, BRAIN, V140, P1829, DOI 10.1093/brain/awx047; Charidimou A, 2016, NEUROLOGY, V86, P505, DOI 10.1212/WNL.0000000000002362; Charidimou A, 2015, BRAIN, V138, P2126, DOI 10.1093/brain/awv162; Charidimou A, 2014, NEUROLOGY, V82, P57, DOI 10.1212/01.wnl.0000438225.02729.04; Charidimou A, 2013, J NEUROL NEUROSUR PS, V84, P624, DOI 10.1136/jnnp-2012-304434; Greenberg SM, 1997, STROKE, V28, P1418, DOI 10.1161/01.STR.28.7.1418; Greenberg SM, 2020, NAT REV NEUROL, V16, P30, DOI 10.1038/s41582-019-0281-2; Greenberg SM, 2018, STROKE, V49, P491, DOI 10.1161/STROKEAHA.117.016990; Greenberg SM, 2014, LANCET NEUROL, V13, P419, DOI 10.1016/S1474-4422(14)70003-1; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Knudsen KA, 2001, NEUROLOGY, V56, P537, DOI 10.1212/WNL.56.4.537; Linn J, 2010, NEUROLOGY, V74, P1346, DOI 10.1212/WNL.0b013e3181dad605; Martinez-Ramirez S, 2015, ALZHEIMERS DEMENT, V11, P1480, DOI 10.1016/j.jalz.2015.04.009; Pasi M, 2019, STROKE, V50, P1727, DOI 10.1161/STROKEAHA.119.024843; Pasi M, 2018, NEUROLOGY, V90, pE119, DOI 10.1212/WNL.0000000000004797; Pasi M, 2017, NEUROLOGY, V88, P2162, DOI 10.1212/WNL.0000000000004007; Reijmer YD, 2016, J CEREBR BLOOD F MET, V36, P40, DOI 10.1038/jcbfm.2015.88; Rodrigues MA, 2018, LANCET NEUROL, V17, P232, DOI 10.1016/S1474-4422(18)30006-1; Tsai HH, 2019, NEUROLOGY, V92, pE774, DOI 10.1212/WNL.0000000000006953; van Rooden S, 2016, STROKE, V47, P3041, DOI 10.1161/STROKEAHA.116.014418; van Rooden S, 2009, STROKE, V40, P3022, DOI 10.1161/STROKEAHA.109.554378; VONSATTEL JPG, 1991, ANN NEUROL, V30, P637, DOI 10.1002/ana.410300503; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8; Zhang-Nunes SX, 2006, BRAIN PATHOL, V16, P30, DOI 10.1111/j.1750-3639.2006.tb00559.x	32	7	7	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2022	21	8					714	725		10.1016/S1474-4422(22)00208-3	http://dx.doi.org/10.1016/S1474-4422(22)00208-3			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	4P3VT	35841910	Green Accepted, Green Submitted			2022-12-18	WOS:000855325100018
J	Tabrizi, SJ; Estevez-Fraga, C; van Roon-Mom, WMC; Flower, MD; Scahill, RI; Wild, EJ; Munoz-Sanjuan, I; Sampaio, C; Rosser, AE; Leavitt, BR				Tabrizi, Sarah J.; Estevez-Fraga, Carlos; van Roon-Mom, Willeke M. C.; Flower, Michael D.; Scahill, Rachael I.; Wild, Edward J.; Munoz-Sanjuan, Ignacio; Sampaio, Cristina; Rosser, Anne E.; Leavitt, Blair R.			Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities	LANCET NEUROLOGY			English	Editorial Material							CONVECTION-ENHANCED DELIVERY; MUTANT HUNTINGTIN; TRACK-HD; GENE; PREMANIFEST; ONSET; SUPPRESSION; EXPRESSION; ADULT; BRAIN	Huntington's disease is the most frequent autosomal dominant neurodegenerative disorder; however, no disease-modifying interventions are available for patients with this disease. The molecular pathogenesis of Huntington's disease is complex, with toxicity that arises from full-length expanded huntingtin and N-terminal fragments of huntingtin, which are both prone to misfolding due to proteolysis; aberrant intron-1 splicing of the HTT gene; and somatic expansion of the CAG repeat in the HTT gene. Potential interventions for Huntington's disease include therapies targeting huntingtin DNA and RNA, clearance of huntingtin protein, DNA repair pathways, and other treatment strategies targeting inflammation and cell replacement. The early termination of trials of the antisense oligonucleotide tominersen suggest that it is time to reflect on lessons learned, where the field stands now, and the challenges and opportunities for the future.	[Tabrizi, Sarah J.; Estevez-Fraga, Carlos; Scahill, Rachael I.; Wild, Edward J.] UCL, UCL Queen Sq Inst Neurol, Huntingtons Dis Ctr, London, England; [van Roon-Mom, Willeke M. C.] Leiden Univ, Dept Human Genet, Med Ctr, Leiden, Netherlands; [Munoz-Sanjuan, Ignacio] CHDI Management, Fdn Los Angeles, Los Angeles, CA USA; [Sampaio, Cristina] Lab Clin Pharmacol, Fac Med Lisboa, Lisbon, Portugal; [Rosser, Anne E.] Cardiff Univ, Sch Med, Div Psychol Med & Clin Neurosci, Sampaio BRAIN unit, Cardiff, Wales; [Leavitt, Blair R.] Univ British Columbia, Ctr Huntingtons Dis, Vancouver, BC, Canada	University of London; University College London; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Universidade de Lisboa; Cardiff University; University of British Columbia	Tabrizi, SJ (corresponding author), UCL Queen Sq Inst Neurol, Huntingtons Dis Ctr, London WC1B 5EH, England.	s.tabrizi@ucl.ac.uk		Scahill, Rachael/0000-0002-1832-106X; Flower, Michael/0000-0001-5568-6239; Wild, Edward/0000-0002-6921-7887; Tabrizi, Sarah/0000-0003-2716-2045				Adams Jamie L, 2017, Digit Biomark, V1, P52, DOI 10.1159/000479018; Alterman JF, 2019, NAT BIOTECHNOL, V37, P884, DOI 10.1038/s41587-019-0205-0; Alterman JF, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.38; AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; Bartlett Danielle M., 2019, Neurobiology of Sleep and Circadian Rhythms, V6, P1, DOI 10.1016/j.nbscr.2018.07.001; Bates GP, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.5; Becanovic K, 2015, NAT NEUROSCI, V18, P807, DOI 10.1038/nn.4014; Benraiss A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11758; Bettencourt C, 2016, ANN NEUROL, V79, P983, DOI 10.1002/ana.24656; Bhattacharyya A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27157-z; Biogen, 2018, REACTIONS WEEKLY, V1714, P3, DOI [10.1007/s40278-018-50183-2, DOI 10.1007/S40278-018-50183-2]; Bjorklund A, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00146; Bjorkqvist M, 2008, J EXP MED, V205, P1869, DOI 10.1084/jem.20080178; Boak L, 2022, CHDI FDN ANN THER C; Bocchi VD, 2021, SCIENCE, V372, P591, DOI 10.1126/science.abf5759; Bulaklak K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19505-2; Byrne LM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7108; Byrne LM, 2017, LANCET NEUROL, V16, P601, DOI 10.1016/S1474-4422(17)30124-2; Carrillo-Reid L, 2019, ELIFE, V8, DOI 10.7554/eLife.40818; Ciarmiello A, 2006, J NUCL MED, V47, P215; Ciarmiello A, 2012, EUR J NUCL MED MOL I, V39, P1030, DOI 10.1007/s00259-012-2114-z; Collett J, 2014, GAIT POSTURE, V40, P694, DOI 10.1016/j.gaitpost.2014.08.001; Datson NA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171127; DiFiglia M, 2007, P NATL ACAD SCI USA, V104, P17204, DOI 10.1073/pnas.0708285104; Dinesh K, 2020, J HUNTINGTONS DIS, V9, P69, DOI 10.3233/JHD-190375; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; Drouet V, 2009, ANN NEUROL, V65, P276, DOI 10.1002/ana.21569; Ducray PS, 2019, NEUROLOGY, V92; Dunn B, 2021, JAMA INTERN MED, V181, P1276, DOI 10.1001/jamainternmed.2021.4607; Durr A, 1999, J MED GENET, V36, P172; Eddings CR, 2019, NEUROBIOL DIS, V129, P118, DOI 10.1016/j.nbd.2019.05.009; Evers MM, 2018, MOL THER, V26, P2163, DOI 10.1016/j.ymthe.2018.06.021; Fazio P, 2020, MOVEMENT DISORD, V35, P606, DOI 10.1002/mds.27963; FDA, 2021, HUM GEN THER NEUR DI; Fiandaca MS, 2020, NEUROL NEUROCHIR POL, V54, P220, DOI 10.5603/PJNNS.a2020.0046; Fodale V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78790-5; Grachev ID, 2021, EUR J NUCL MED MOL I, V48, P1103, DOI 10.1007/s00259-020-05030-3; Grondin R, 2012, BRAIN, V135, P1197, DOI 10.1093/brain/awr333; Hagenacker T, 2020, LANCET NEUROL, V19, P317, DOI 10.1016/S1474-4422(20)30037-5; Heman-Ackah SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep28420; High KA, 2019, NEW ENGL J MED, V381, P455, DOI 10.1056/NEJMra1706910; Howland D, 2020, J HUNTINGTONS DIS, V9, P201, DOI 10.3233/JHD-200425; Imbert M, 2019, NUCLEIC ACID THER, V29, P256, DOI 10.1089/nat.2018.0775; Iyer RR, 2021, J HUNTINGTONS DIS, V10, P75, DOI 10.3233/JHD-200438; Keller CG, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28653-6; Killoran A, 2022, NEUROMETHODS, V173, P235, DOI 10.1007/978-1-0716-1712-0_10; Kim J, 2019, NEW ENGL J MED, V381, P1644, DOI 10.1056/NEJMoa1813279; Kingwell K, 2021, NAT REV DRUG DISCOV, V20, P412, DOI 10.1038/d41573-021-00088-6; Kinnunen KM, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.712555; Klug Aaron, 2010, Annu Rev Biochem, V79, P213, DOI 10.1146/annurev-biochem-010909-095056; Kordasiewicz HB, 2012, NEURON, V74, P1031, DOI 10.1016/j.neuron.2012.05.009; Kourkouta E, 2019, MOL THER-NUCL ACIDS, V17, P601, DOI 10.1016/j.omtn.2019.07.004; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI DOI 10.1056/NEJM199405193302001; Lam MF, 2011, J CLIN NEUROSCI, V18, P1163, DOI 10.1016/j.jocn.2011.01.012; Langfelder P, 2016, NAT NEUROSCI, V19, P623, DOI 10.1038/nn.4256; Lau JC, 2019, WORLD NEUROSURG, V122, P404, DOI 10.1016/j.wneu.2018.11.036; Leavitt BR, 2020, JAMA NEUROL, V77, P764, DOI 10.1001/jamaneurol.2020.0299; Lee JM, 2019, CELL, V178, P887, DOI 10.1016/j.cell.2019.06.036; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu LB, 2020, J MED CHEM, V63, P8608, DOI 10.1021/acs.jmedchem.0c00955; Lopes F, 2016, J MED GENET, V53, P190, DOI 10.1136/jmedgenet-2015-103568; Mazur C, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129240; McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI 10.1073/pnas.0801775105; McGarry A, 2020, J HUNTINGTONS DIS, V9, P371, DOI 10.3233/JHD-200440; Miller T, 2020, NEW ENGL J MED, V383, P109, DOI 10.1056/NEJMoa2003715; Miniarikova J, 2018, MOL THER, V26, P947, DOI 10.1016/j.ymthe.2018.02.002; Monteys AM, 2017, MOL THER, V25, P12, DOI 10.1016/j.ymthe.2016.11.010; Moss DJH, 2017, LANCET NEUROL, V16, P701, DOI 10.1016/S1474-4422(17)30161-8; Naia L, 2021, NEUROTHERAPEUTICS, V18, P1017, DOI 10.1007/s13311-021-01022-9; Necking E, 2021, CLIN NEUROL NEUROSUR, V205, DOI 10.1016/j.clineuro.2021.106630; Neueder A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01510-z; Niemela V, 2021, MOVEMENT DISORD, V36, P481, DOI 10.1002/mds.28391; Paulsen JS, 2008, J NEUROL NEUROSUR PS, V79, P874, DOI 10.1136/jnnp.2007.128728; Pfister EL, 2009, CURR BIOL, V19, P774, DOI 10.1016/j.cub.2009.03.030; Pinto RM, 2020, HUM MOL GENET, V29, P2551, DOI 10.1093/hmg/ddaa139; Politis M, 2015, NEUROBIOL DIS, V83, P115, DOI 10.1016/j.nbd.2015.08.011; Politis M, 2011, HUM BRAIN MAPP, V32, P258, DOI 10.1002/hbm.21008; Porro A, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf7906; Potts Matthew B, 2013, Surg Neurol Int, V4, pS22, DOI 10.4103/2152-7806.109190; PTC Therapeutics, 2022, PTC THER ANN IN PIVO; PTC Therapeutics, 2021, PTC518 HUNT DIS PROG; Reilmann R, 2017, HAND CLINIC, V144, P209, DOI 10.1016/B978-0-12-801893-4.00018-3; Rodan LH, 2016, EUR J HUM GENET, V24, P1826, DOI 10.1038/ejhg.2016.74; Rodrigues FB, 2022, J HUNTINGTONS DIS, V11, P59, DOI 10.3233/JHD-210508; Rodrigues FB, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc2888; Rub U, 2015, ADV ANAT EMBRYOL CEL, V217, P1, DOI 10.1007/978-3-319-19285-7_1; Saudou F, 2016, NEURON, V89, P910, DOI 10.1016/j.neuron.2016.02.003; Scahill RI, 2020, LANCET NEUROL, V19, P502, DOI 10.1016/S1474-4422(20)30143-5; Schobel SA, 2020, CHDI FDN ANN THERAPE; Schobel SA, 2021, CHDI FDN ANN THER C; Shaffer JJ, 2017, HUM BRAIN MAPP, V38, P1460, DOI 10.1002/hbm.23465; Shin JW, 2016, HUM MOL GENET, V25, P4566, DOI 10.1093/hmg/ddw286; Skodda S, 2016, NEUROLOGY, V86, P1329, DOI 10.1212/WNL.0000000000002550; Skotte NH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107434; Smith-Dijak AI, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00209; Southwell AL, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar3959; Squitieri F, 2003, CLIN GENET, V64, P524, DOI 10.1046/j.1399-0004.2003.00155.x; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Stiles DK, 2012, EXP NEUROL, V233, P463, DOI 10.1016/j.expneurol.2011.11.020; Stout JC, 2017, HAND CLINIC, V144, P227, DOI 10.1016/B978-0-12-801893-4.00019-5; Tabrizi SJ, 2022, LANCET NEUROL, V21, P632, DOI 10.1016/S1474-4422(22)00120-X; Tabrizi SJ, 2020, NAT REV NEUROL, V16, P529, DOI 10.1038/s41582-020-0389-4; Tabrizi SJ, 2019, NEW ENGL J MED, V380, P2307, DOI 10.1056/NEJMoa1900907; Tabrizi SJ, 2019, NEURON, V101, P801, DOI 10.1016/j.neuron.2019.01.039; Tabrizi SJ, 2013, LANCET NEUROL, V12, P637, DOI 10.1016/S1474-4422(13)70088-7; Tabrizi SJ, 2012, LANCET NEUROL, V11, P42, DOI 10.1016/S1474-4422(11)70263-0; Terstappen GC, 2021, NAT REV DRUG DISCOV, V20, P362, DOI 10.1038/s41573-021-00139-y; Thadke SA, 2018, BIOCHEMISTRY-US, V57, P2094, DOI 10.1021/acs.biochem.8b00062; Tortelli R, 2021, PARKINSONISM RELAT D, V83, P93, DOI 10.1016/j.parkreldis.2021.01.006; Valles A, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb8920; van Vugt JPP, 2001, MOVEMENT DISORD, V16, P481, DOI 10.1002/mds.1097; van Well EM, 2019, EMBO J, V38, DOI 10.15252/embj.2018100730; Vinther-Jensen T, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000287; Vinther-Jensen T, 2014, PARKINSONISM RELAT D, V20, P1301, DOI 10.1016/j.parkreldis.2014.08.011; Wang GH, 2016, P NATL ACAD SCI USA, V113, P3359, DOI 10.1073/pnas.1524575113; Wang N, 2014, NAT MED, V20, P540, DOI 10.1038/nm.3514; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; Wheeler VC, 2021, CHDI FDN ANN THERAPE; Wild EJ, 2017, LANCET NEUROL, V16, P837, DOI 10.1016/S1474-4422(17)30280-6; Wilson H, 2018, INT REV NEUROBIOL, V142, P289, DOI 10.1016/bs.irn.2018.08.007; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zeitler B, 2019, NAT MED, V25, P1131, DOI 10.1038/s41591-019-0478-3; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; Zeun P, 2019, MOL CELL NEUROSCI, V97, P67, DOI 10.1016/j.mcn.2019.02.004; Zhou FF, 2020, VALUE WHOM INCORPORA	125	7	7	11	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2022	21	7					645	658		10.1016/S1474-4422(22)00121-1	http://dx.doi.org/10.1016/S1474-4422(22)00121-1			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3J4YF	35716694				2022-12-18	WOS:000833401200017
J	Mead, S; Khalili-Shirazi, A; Potter, C; Mok, T; Nihat, A; Hyare, H; Canning, S; Schmidt, C; Campbell, T; Darwent, L; Muirhead, N; Ebsworth, N; Hextall, P; Wakeling, M; Linehan, J; Libri, V; Williams, B; Jaunmuktane, Z; Brandner, S; Rudge, P; Collinge, J				Mead, Simon; Khalili-Shirazi, Azadeh; Potter, Caroline; Mok, Tzehow; Nihat, Akin; Hyare, Harpreet; Canning, Stephanie; Schmidt, Christian; Campbell, Tracy; Darwent, Lee; Muirhead, Nicola; Ebsworth, Nicolette; Hextall, Patrick; Wakeling, Madeleine; Linehan, Jacqueline; Libri, Vincenzo; Williams, Bryan; Jaunmuktane, Zane; Brandner, Sebastian; Rudge, Peter; Collinge, John			Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt-Jakob disease: evaluation of a first-in-human treatment treatment programme	LANCET NEUROLOGY			English	Article							OUTCOME MEASURE; DOUBLE-BLIND; PRP; DOXYCYCLINE; QUINACRINE; EFFICACY; CELLS; TRIAL; CJD	Background Human prion diseases, including Creutzfeldt-Jakob disease (CJD), are rapidly progressive, invariably fatal neurodegenerative conditions with no effective therapies. Their pathogenesis involves the obligate recruitment of cellular prion protein (PrPC) into self-propagating multimeric assemblies or prions. Preclinical studies have firmly validated the targeting of PrPC as a therapeutic strategy. We aimed to evaluate a first-in-human treatment programme using an anti-PrPC monoclonal antibody under a Specials Licence. Methods We generated a fully humanised anti-PrPC monoclonal antibody (an IgG4 & UKappa; isotype; PRN100) for human use. We offered treatment with PRN100 to six patients with a clinical diagnosis of probable CJD who were not in the terminal disease stages at the point of first assessment and who were able to readily travel to the University College London Hospital (UCLH) Clinical Research Facility, London, UK, for treatment. After titration (1 mg/kg and 10 mg/kg at 48-h intervals), patients were treated with 80-120 mg/kg of intravenous PRN100 every 2 weeks until death or withdrawal from the programme, or until the supply of PRN100 was exhausted, and closely monitored for evidence of adverse effects. Disease progression was assessed by use of the Medical Research Council (MRC) Prion Disease Rating Scale, Motor Scale, and Cognitive Scale, and compared with that of untreated natural history controls (matched for disease severity, subtype, and PRNP codon 129 genotype) recruited between Oct 1, 2008, and July 31, 2018, from the National Prion Monitoring Cohort study. Autopsies were done in two patients and findings were compared with those from untreated natural history controls. Findings We treated six patients (two men; four women) with CJD for 7-260 days at UCLH between Oct 9, 2018, and July 31, 2019. Repeated intravenous dosing of PRN100 was well tolerated and reached the target CSF drug concentration (50 nM) in four patients after 22-70 days; no clinically significant adverse reactions were seen. All patients showed progressive neurological decline on serial assessments with the MRC Scales. Neuropathological examination was done in two patients (patients 2 and 3) and showed no evidence of cytotoxicity. Patient 2, who was treated for 140 days, had the longest clinical duration we have yet documented for iatrogenic CJD and showed patterns of disease associated PrP that differed from untreated patients with CJD, consistent with drug effects. Patient 3, who had sporadic CJD and only received one therapeutic dose of 80 mg/kg, had weak PrP synaptic labelling in the periventricular regions, which was not a feature of untreated patients with sporadic CJD. Brain tissue-bound drug concentrations across multiple regions in patient 2 ranged from 9middot9 mu g per g of tissue (SD 0middot3) in the thalamus to 27middot4 mu g per g of tissue (1middot5) in the basal ganglia (equivalent to 66-182 nM). Interpretation Our academic-led programme delivered what is, to our knowledge, the first rationally designed experimental treatment for human prion disease to a small number of patients with CJD. The treatment appeared to be safe and reached encouraging CSF and brain tissue concentrations. These findings justify the need for formal efficacy trials in patients with CJD at the earliest possible clinical stages and as prophylaxis in those at risk of prion disease due to PRNP mutations or prion exposure.Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.	[Mead, Simon; Khalili-Shirazi, Azadeh; Potter, Caroline; Mok, Tzehow; Nihat, Akin; Canning, Stephanie; Schmidt, Christian; Campbell, Tracy; Darwent, Lee; Muirhead, Nicola; Ebsworth, Nicolette; Hextall, Patrick; Wakeling, Madeleine; Linehan, Jacqueline; Brandner, Sebastian; Rudge, Peter; Collinge, John] UCL, MRC Prion Unit UCL, UCL Inst Prion Dis, London W1W 7FF, England; [Jaunmuktane, Zane] UCL, Dept Clin & Movement Neurosci, UCL Queen Sq Inst Neurol, London, England; [Brandner, Sebastian] UCL, Dept Neurodegenerat Dis, UCL Queen Sq Inst Neurol, London, England; [Mead, Simon; Khalili-Shirazi, Azadeh; Mok, Tzehow; Nihat, Akin; Rudge, Peter; Collinge, John] Natl Hosp Neurol & Neurosurg, Natl Prion Clin, London, England; [Hyare, Harpreet] Natl Hosp Neurol & Neurosurg, Dept Neuroradiol, London, England; [Jaunmuktane, Zane; Brandner, Sebastian] Natl Hosp Neurol & Neurosurg, Div Neuropathol, London, England; [Libri, Vincenzo; Williams, Bryan] Univ Coll London Hosp, NIHR, Biomed Res Ctr, London, England; [Libri, Vincenzo] Univ Coll London Hosp, Clin Res Facil, London, England	University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University College London Hospitals NHS Foundation Trust; University of London; King's College London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London	Collinge, J (corresponding author), UCL, MRC Prion Unit UCL, UCL Inst Prion Dis, London W1W 7FF, England.	jc@prion.ucl.ac.uk		Williams, Bryan/0000-0002-8094-1841; Mead, Simon/0000-0002-4326-1468; Lim, Yau Mun/0000-0002-8774-9537; Nihat, Akin/0000-0003-2892-1402; Schmidt, Christian/0000-0002-9605-5959	Cure CJD Campaign; National Institute for Health Research UCLH Biomedical Research Centre; Jon Moulton Charitable Trust; UK MRC	Cure CJD Campaign; National Institute for Health Research UCLH Biomedical Research Centre; Jon Moulton Charitable Trust; UK MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The Cure CJD Campaign, the National Institute for Health Research UCLH Biomedical Research Centre, the Jon Moulton Charitable Trust, and the UK MRC.	Antonyuk SV, 2009, P NATL ACAD SCI USA, V106, P2554, DOI 10.1073/pnas.0809170106; Bone I, 2008, EUR J NEUROL, V15, P458, DOI 10.1111/j.1468-1331.2008.02108.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Cohen JIN, 2018, MATTER MENTAL CAPACI; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Collinge J, 2007, SCIENCE, V318, P930, DOI 10.1126/science.1138718; Collinge J, 2016, NATURE, V539, P217, DOI 10.1038/nature20415; Collinge J, 2006, LANCET, V367, P2068, DOI 10.1016/S0140-6736(06)68930-7; Collinge J, 2009, LANCET NEUROL, V8, P334, DOI 10.1016/S1474-4422(09)70049-3; Corbett GT, 2020, ACTA NEUROPATHOL, V139, P503, DOI 10.1007/s00401-019-02114-9; Department of Health and Social Care, 2012, MIN TRANSM RISK CJD; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Geschwind MD, 2013, NEUROLOGY, V81, P2015, DOI 10.1212/WNL.0b013e3182a9f3b4; Ghaemmaghami S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000673; Gill ON, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5675; Haik S, 2014, LANCET NEUROL, V13, P150, DOI 10.1016/S1474-4422(13)70307-7; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; Khalill-Shirazi A, 2007, BBA-PROTEINS PROTEOM, V1774, P1438, DOI 10.1016/j.bbapap.2007.08.028; Klyubin I, 2014, J NEUROSCI, V34, P6140, DOI 10.1523/JNEUROSCI.3526-13.2014; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mallucci GR, 2007, NEURON, V53, P325, DOI 10.1016/j.neuron.2007.01.005; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; Mead S, 2019, ANNU REV GENET, V53, P117, DOI 10.1146/annurev-genet-120213-092352; Mead S, 2016, JAMA NEUROL, V73, P447, DOI 10.1001/jamaneurol.2015.4885; Medicines and Healthcare products Regulatory Agency, 2014, 14 MHRA; Nicoll AJ, 2010, P NATL ACAD SCI USA, V107, P17610, DOI 10.1073/pnas.1009062107; Nihat A, 2020, MEDRXIV; Otto M, 2004, NEUROLOGY, V62, P714, DOI 10.1212/01.WNL.0000113764.35026.EF; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Purro SA, 2018, BIOL PSYCHIAT, V83, P358, DOI 10.1016/j.biopsych.2017.11.020; Skillback T, 2014, JAMA NEUROL, V71, P476, DOI 10.1001/jamaneurol.2013.6455; Song CH, 2008, J GEN VIROL, V89, P1533, DOI 10.1099/vir.0.83578-0; Starke R, 2002, BRIT J HAEMATOL, V119, P863, DOI 10.1046/j.1365-2141.2002.03847.x; Thompson AGB, 2021, MOL PSYCHIATR, V26, P5955, DOI 10.1038/s41380-021-01045-w; Thompson AGB, 2013, BRAIN, V136, P1116, DOI 10.1093/brain/awt048; Varges D, 2017, J NEUROL NEUROSUR PS, V88, P119, DOI 10.1136/jnnp-2016-313541; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Zerr I, 2009, BRAIN, V132, P2659, DOI 10.1093/brain/awp191	39	7	7	8	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2022	21	4					342	354		10.10545.j.LancetNeurol.156877	http://dx.doi.org/10.10545.j.LancetNeurol.156877			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	1Y0JM	35305340				2022-12-18	WOS:000807832700015
J	Bonati, LH; Jansen, O; de Borst, GJ; Brown, MM				Bonati, Leo H.; Jansen, Olav; de Borst, Gert J.; Brown, Martin M.			Management of atherosclerotic extracranial carotid artery stenosis	LANCET NEUROLOGY			English	Review							TRANSIENT ISCHEMIC ATTACK; PROCEDURAL STROKE; CEREBRAL-ISCHEMIA; POOLED ANALYSIS; EARLY RISK; ENDARTERECTOMY; SURGERY; METAANALYSIS; PREVENTION; PREDICTS	Atherosclerosis leading to stenosis of the internal carotid artery is the underlying cause of 8-15% of ischaemic strokes (symptomatic carotid stenosis). 1-2% of the adult population have asymptomatic carotid stenosis. Clinical trials in patients with symptomatic carotid stenosis showed a higher procedural risk of non-disabling stroke with stenting versus endarterectomy, but a higher risk of myocardial infarction, cranial nerve palsy, and access site haematoma with endarterectomy. Apart from procedural complications, both treatments are equally effective in preventing stroke and recurrent severe carotid stenosis in the medium-to-long term. Endarterectomy has a modest effect in preventing stroke among patients with asymptomatic carotid stenosis, whereas the role of stenting remains to be established. With advances in medical therapy against atherosclerosis, benefit from invasive therapy has become uncertain. Risk modelling, with the inclusion of brain and carotid plaque imaging, will become increasingly important in selecting patients for interventions.	[Bonati, Leo H.] Univ Hosp Basel, Dept Neurol & Stroke Ctr, Dept Clin Res, Basel, Switzerland; [Bonati, Leo H.] Univ Basel, Basel, Switzerland; [Jansen, Olav] UKSH Campus Kiel, Clin Radiol & Neuroradiol, Kiel, Germany; [de Borst, Gert J.] Univ Med Ctr, Dept Vasc Surg, Utrecht, Netherlands; [Brown, Martin M.] UCL, Ctr Stroke Res, Dept Brain Repair & Rehabil, UCL Queen Sq Inst Neurol, London, England	University of Basel; University of Basel; University of Kiel; Schleswig Holstein University Hospital; Utrecht University; Utrecht University Medical Center; University of London; University College London	Brown, MM (corresponding author), UCL, Ctr Stroke Res, Dept Brain Repair & Rehabil, UCL Queen Sq Inst Neurol, London, England.	martin.brown@ucl.ac.uk	Jansen, Olav/CAF-4179-2022	Brown, Martin M/0000-0002-3273-1356				Amarenco P, 2020, STROKE, V51, P3504, DOI 10.1161/STROKEAHA.120.032239; Amarenco P, 2016, NEW ENGL J MED, V374, P1533, DOI 10.1056/NEJMoa1412981; Anand SS, 2018, LANCET, V391, P219, DOI 10.1016/S0140-6736(17)32409-1; [Anonymous], 1995, J Neurol Sci, V129, P76; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Bijuklic K, 2012, J AM COLL CARDIOL, V59, P1383, DOI 10.1016/j.jacc.2011.11.035; Blackshear JL, 2011, CIRCULATION, V123, P2571, DOI 10.1161/CIRCULATIONAHA.110.008250; Bonati LH, 2021, EUR STROKE J, V6, pI, DOI 10.1177/23969873211012121; Bonati LH, 2018, LANCET NEUROL, V17, P587, DOI 10.1016/S1474-4422(18)30195-9; Bonati LH, 2015, LANCET, V385, P529, DOI 10.1016/S0140-6736(14)61184-3; Bonati LH, 2010, LANCET, V376, P1062, DOI 10.1016/S0140-6736(10)61009-4; Bonati LH, 2010, LANCET NEUROL, V9, P353, DOI 10.1016/S1474-4422(10)70057-0; Brinster CJ, 2020, J CARDIOVASC SURG, V61, P149, DOI 10.23736/S0021-9509.20.11179-0; Brott TG, 2019, LANCET NEUROL, V18, P348, DOI 10.1016/S1474-4422(19)30028-6; Brott TG, 2016, NEW ENGL J MED, V374, P1021, DOI 10.1056/NEJMoa1505215; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; Broussalis E, 2019, J NEUROINTERV SURG, V11, P62, DOI 10.1136/neurintsurg-2018-013869; Bunch TJ, 2020, HEART RHYTHM, V17, P20, DOI 10.1016/j.hrthm.2019.07.007; Cheng SF, 2019, BRIT J SURG, V106, P872, DOI 10.1002/bjs.11136; Coelho A, 2020, STROKE, V51, P2863, DOI 10.1161/STROKEAHA.120.030283; De Borst GJ, 2012, J CARDIOVASC SURG, V53, P27; Doig D, 2016, EUR J VASC ENDOVASC, V51; Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0; Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5; Eikelboom JW, 2017, NEW ENGL J MED, V377, P1319, DOI 10.1056/NEJMoa1709118; Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; Fokkema M, 2012, STROKE, V43, P793, DOI 10.1161/STROKEAHA.111.633743; Gupta A, 2015, STROKE, V46, P91, DOI 10.1161/STROKEAHA.114.006091; Gurm HS, 2008, NEW ENGL J MED, V358, P1572, DOI 10.1056/NEJMoa0708028; Halliday A, 2004, LANCET, V363, P1491; Halliday A, 2021, LANCET, V398, P1065, DOI 10.1016/S0140-6736(21)01910-3; Hirt LS, 2014, STROKE, V45, P702, DOI 10.1161/STROKEAHA.111.613711; Howard DPJ, 2021, LANCET NEUROL, V20, P193, DOI 10.1016/S1474-4422(20)30484-1; Howard G, 2016, LANCET, V387, P1305, DOI 10.1016/S0140-6736(15)01309-4; Johansson E, 2016, NEUROLOGY, V86, P498, DOI 10.1212/WNL.0000000000002354; Johnston SC, 2020, NEW ENGL J MED, V383, P207, DOI 10.1056/NEJMoa1916870; Johnston SC, 2018, NEW ENGL J MED, V379, P215, DOI 10.1056/NEJMoa1800410; Kakkos SK, 2014, J VASC SURG, V59, P956, DOI 10.1016/j.jvs.2013.10.073; Kakkos SK, 2013, J VASC SURG, V57, P609, DOI 10.1016/j.jvs.2012.09.045; Kelly PJ, 2019, STROKE, V50, P1766, DOI 10.1161/STROKEAHA.119.025422; Keyhani S, 2020, JAMA NEUROL, V77, P1110, DOI 10.1001/jamaneurol.2020.1427; Knappich C, 2017, STROKE, V48, P955, DOI 10.1161/STROKEAHA.116.014869; Kochar A, 2018, CLIN CARDIOL, V41, P39, DOI 10.1002/clc.22846; Koraen-Smith L, 2014, STROKE, V45, P776, DOI 10.1161/STROKEAHA.113.003763; Kuhn AL, 2021, INTERV NEURORADIOL, V27, P241, DOI 10.1177/1591019920959537; Kumar R, 2017, EUR J VASC ENDOVASC, V53, P766, DOI 10.1016/j.ejvs.2017.02.016; Kwolek CJ, 2015, J VASC SURG, V62, P1227, DOI 10.1016/j.jvs.2015.04.460; Lal BK, 2012, LANCET NEUROL, V11, P755, DOI 10.1016/S1474-4422(12)70159-X; Liuzzo G, 2001, Rays, V26, P221; Lovett JK, 2004, NEUROLOGY, V62, P569, DOI 10.1212/01.WNL.0000110311.09970.83; Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]; Malas MB, 2022, J VASC SURG, V75, P213, DOI 10.1016/j.jvs.2021.07.242; Malas MB, 2019, J VASC SURG, V69, P92, DOI 10.1016/j.jvs.2018.05.011; Markus HS, 2010, LANCET NEUROL, V9, P663, DOI 10.1016/S1474-4422(10)70120-4; Marnane M, 2012, ANN NEUROL, V71, P709, DOI 10.1002/ana.23553; Marquardt L, 2010, STROKE, V41, pE11, DOI 10.1161/STROKEAHA.109.561837; Mas JL, 2014, STROKE, V45, P2750, DOI 10.1161/STROKEAHA.114.005671; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; Muller MD, 2020, COCHRANE DB SYST REV, DOI [10.1161/STROKEAHA.120.030521, 10.1002/14651858.CD000515.pub5]; Muller MD, 2019, CIRC-CARDIOVASC INTE, V12, DOI 10.1161/CIRCINTERVENTIONS.119.007870; Muller MD, 2018, STROKE, V49, P2715, DOI 10.1161/STROKEAHA.118.020684; Muller MD, 2017, STROKE, V48, P1285, DOI 10.1161/STROKEAHA.116.014612; Naylor AR, 2018, EUR J VASC ENDOVASC, V55, P3, DOI 10.1016/j.ejvs.2017.06.021; NICE, 2019, HYP AD DIAGN MAN; Nicolaides AN, 2005, EUR J VASC ENDOVASC, V30, P275, DOI 10.1016/j.ejvs.2005.04.031; Nikas D, 2012, CATHETER CARDIO INTE, V80, P1060, DOI 10.1002/ccd.24402; Paraskevas KI, 2020, J VASC SURG, V72, P1489, DOI 10.1016/j.jvs.2020.04.501; Pinter L, 2011, J VASC SURG, V54, P1317, DOI 10.1016/j.jvs.2011.04.040; Plessers M, 2016, J ENDOVASC THER, V23, P249, DOI 10.1177/1526602815626561; Powers WJ, 2011, JAMA-J AM MED ASSOC, V306, P1983, DOI 10.1001/jama.2011.1610; Purroy F, 2007, STROKE, V38, P3225, DOI 10.1161/STROKEAHA.107.488833; Rantner B, 2017, STROKE, V48, P1580, DOI 10.1161/STROKEAHA.116.016233; Reinhard M, 2014, NEUROLOGY, V83, P1424, DOI 10.1212/WNL.0000000000000888; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8; Rosenfield K, 2016, NEW ENGL J MED, V374, P1011, DOI 10.1056/NEJMoa1515706; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Rothwell PM, 2004, STROKE, V35, P2855, DOI 10.1161/01.STR.0000147040.20446.f6; Rothwell PM, 2005, LANCET, V365, P256; Saba L, 2019, LANCET NEUROL, V18, P559, DOI 10.1016/S1474-4422(19)30035-3; Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.1056/NEJMoa1615664, 10.4997/JRCPE.2017.212]; Schindler A, 2020, JACC-CARDIOVASC IMAG, V13, P395, DOI 10.1016/j.jcmg.2019.03.028; Schwartz GG, 2018, NEW ENGL J MED, V379, P2097, DOI 10.1056/NEJMoa1801174; Silvestrini M, 2000, JAMA-J AM MED ASSOC, V283, P2122, DOI 10.1001/jama.283.16.2122; Silvestrini M, 2013, J CEREBR BLOOD F MET, V33, P619, DOI 10.1038/jcbfm.2013.5; Song PG, 2020, LANCET GLOB HEALTH, V8, pE721, DOI 10.1016/S2214-109X(20)30117-0; Speziale F, 2018, EUROINTERVENTION, V13, P1714, DOI 10.4244/EIJ-D-17-00008; Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a; Stromberg S, 2012, STROKE, V43, P1331, DOI 10.1161/STROKEAHA.111.639344; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Traenka C, 2019, EUR STROKE J, V4, P127, DOI 10.1177/2396987318824491; van Lammeren GW, 2011, STROKE, V42, P2550, DOI 10.1161/STROKEAHA.110.607382; Vaniyapong T, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000126.pub4; Wang YJ, 2013, NEW ENGL J MED, V369, P11, DOI 10.1056/NEJMoa1215340; Wodarg F, 2018, J NEUROINTERV SURG, V10, P1149, DOI 10.1136/neurintsurg-2017-013622; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127; Yaghi S, 2021, STROKE, V52, P2414, DOI 10.1161/STROKEAHA.121.034089	96	7	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					273	283		10.1016/S1474-4422(21)00359-8	http://dx.doi.org/10.1016/S1474-4422(21)00359-8			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35182512	Green Submitted			2022-12-18	WOS:000759721800023
J	Galimberti, S; Graziano, F; Maas, AIR; Isernia, G; Lecky, F; Jain, S; Sun, XY; Gardner, RC; Taylor, SR; Markowitz, AJ; Manley, GT; Valsecchi, MG; Bellelli, G; Citerio, G				Galimberti, Stefania; Graziano, Francesca; Maas, Andrew I. R.; Isernia, Giulia; Lecky, Fiona; Jain, Sonia; Sun, Xiaoying; Gardner, Raquel C.; Taylor, Sabrina R.; Markowitz, Amy J.; Manley, Geoffrey; Valsecchi, Maria Grazia; Bellelli, Giuseppe; Citerio, Giuseppe		CENTER-TBI TRACK-TBI Participants	Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation	LANCET NEUROLOGY			English	Article							OLDER-ADULTS; MORTALITY; INDEX; ASSOCIATION; FITNESS; IMPACT; SCALE; AGE	Background Frailty is known to be associated with poorer outcomes in individuals admitted to hospital for medical conditions requiring intensive care. However, little evidence is available for the effect of frailty on patients' outcomes after traumatic brain injury. Many frailty indices have been validated for clinical practice and show good performance to predict clinical outcomes. However, each is specific to a particular clinical context. We aimed to develop a frailty index to predict 6-month outcomes in patients after a traumatic brain injury. Methods A cumulative deficit approach was used to create a novel frailty index based on 30 items dealing with disease states, current medications, and laboratory values derived from data available from CENTER-TBI, a prospective, longitudinal observational study of patients with traumatic brain injury presenting within 24 h of injury and admitted to a ward or an intensive care unit at 65 centres in Europe between Dec 19, 2014, and Dec 17, 2017. From the individual cumulative CENTER-TBI frailty index (range 0-30), we obtained a standardised value (range 0-1), with high scores indicating higher levels of frailty. The effect of frailty on 6-month outcome evaluated with the extended Glasgow Outcome Scale (GOSE) was assessed through a proportional odds logistic model adjusted for known outcome predictors. An unfavourable outcome was defined as death or severe disability (GOSE score <= 4). External validation was performed on data from TRACK-TBI, a prospective observational study co-designed with CENTER-TBI, which enrolled patients with traumatic brain injury at 18 level I trauma centres in the USA from Feb 26, 2014, to July 27, 2018. CENTER-TBI is registered with ClinicalTrials.gov, NCT02210221; TRACK-TBI is registered at ClinicalTrials.gov, NCT02119182. Findings 2993 participants (median age was 51 years [IQR 30-67], 2058 [69%] were men) were included in this analysis. The overall median CENTER-TBI frailty index score was 0.07 (IQR 0.03-0.15), with a median score of 0.17 (0.08-0.27) in older adults (aged >= 65 years). The CENTER-TBI frailty index score was significantly associated with the probability of an increasingly unfavourable outcome (cumulative odds ratio [OR] 1.03, 95% CI 1.02-1.04; p<0.0001), and the association was stronger for participants admitted to hospital wards (1.04, 1.03-1.06, p<0.0001) compared with those admitted to the intensive care unit (1.02, 1.01-1.03 p<0.0001). External validation of the CENTER-TBI frailty index in data from the TRACK-TBI (n=1667) cohort supported the robustness and reliability of these findings. The overall median TRACK-TBI frailty index score was 0.03 (IQR 0-0.10), with the frailty index score significantly associated with the risk of an increasingly unfavourable outcome in patients admitted to hospital wards (cumulative OR 1.05, 95% CI 1.03-1.08; p<0.0001), but not in those admitted to the intensive care unit (1.01, 0.99-1.03; p=0.43). Interpretation We developed and externally validated a frailty index specific to traumatic brain injury. Risk of unfavourable outcome was significantly increased in participants with a higher CENTER-TBI frailty index score, regardless of age. Frailty identification could help to individualise rehabilitation approaches aimed at mitigating effects of frailty in patients with traumatic brain injury. Copyright (C) 2022 Published by Elsevier Ltd. All rights reserved.	[Galimberti, Stefania; Graziano, Francesca; Isernia, Giulia; Valsecchi, Maria Grazia; Bellelli, Giuseppe; Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, I-20100 Milan, Italy; [Galimberti, Stefania; Graziano, Francesca; Valsecchi, Maria Grazia] Univ Milano Bicocca, Bicocca Bioinformat Biostat & Bioimaging B4 Ctr, Milan, Italy; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Lecky, Fiona] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Lecky, Fiona] Salford Royal Hosp, Emergency Dept, Salford, Lancs, England; [Jain, Sonia; Sun, Xiaoying] Univ Calif San Diego, Herbert Wertheim Sch Publ Hlth & Human Longev Sci, La Jolla, CA 92093 USA; [Gardner, Raquel C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Taylor, Sabrina R.; Markowitz, Amy J.; Manley, Geoffrey] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Taylor, Sabrina R.; Markowitz, Amy J.; Manley, Geoffrey] Zuckerberg San Francisco Gen Hosp & Trauma Ctr, Brain & Spinal Injury Ctr, San Francisco, CA USA; [Bellelli, Giuseppe] San Gerardo Hosp, Acute Geriatr Unit, Monza, Italy; [Citerio, Giuseppe] San Gerardo Hosp, Neurointens Care Unit, Monza, Italy	University of Milano-Bicocca; University of Milano-Bicocca; University of Antwerp; University of Antwerp; University of Sheffield; Salford Royal NHS Foundation Trust; Salford Royal Hospital; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Gerardo Hospital; San Gerardo Hospital	Citerio, G (corresponding author), Univ Milano Bicocca, Sch Med & Surg, I-20100 Milan, Italy.	giuseppe.citerio@unimib.it	Gomez, Pedro A./E-2411-2014; Gardner, Raquel/GZM-6396-2022; Posti, Jussi P./Y-2908-2019; Majdan, Marek/K-5017-2012; Sahuquillo, Juan/B-3577-2008; Raj, Rahul/K-7693-2012; Ercole, Ari/B-6288-2009	Gomez, Pedro A./0000-0002-4185-5238; Posti, Jussi P./0000-0002-5925-5193; Sanchez-Porras, Renan/0000-0002-9084-8114; GALIMBERTI, STEFANIA/0000-0003-1504-7242; Schnyer, David/0000-0002-7472-2853; Ragauskas, Arminas/0000-0001-9695-9512; Majdan, Marek/0000-0001-8037-742X; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601; Newcombe, Virginia/0000-0001-6044-9035; Volovici, Victor/0000-0002-5798-5360; Gratz, Johannes/0000-0001-8717-0544; Azzolini, Maria Luisa/0000-0002-3084-7064; Sahuquillo, Juan/0000-0003-0713-5875; Ferguson, Adam/0000-0001-7102-1608; Raj, Rahul/0000-0003-4243-9591; Williams, Guy/0000-0001-5223-6654; Golubovic, Jagos/0000-0001-5524-246X; Zeiler, Frederick/0000-0003-1737-0510; Castano-Leon, Ana M/0000-0002-7918-5049; Ercole, Ari/0000-0001-8350-8093; Kondziella, Daniel/0000-0001-5562-9808; Radoi, Andreea/0000-0002-0677-3544; Dark, Paul/0000-0003-3309-0164				Abdulle AE, 2018, J HEAD TRAUMA REHAB, V33, pE59, DOI 10.1097/HTR.0000000000000368; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Gilbert T, 2018, LANCET, V391, P1775, DOI 10.1016/S0140-6736(18)30668-8; Hoogendijk EO, 2019, LANCET, V394, P1365, DOI 10.1016/S0140-6736(19)31786-6; Joseph B, 2017, J TRAUMA ACUTE CARE, V82, P575, DOI 10.1097/TA.0000000000001329; Joseph B, 2014, JAMA SURG, V149, P766, DOI 10.1001/jamasurg.2014.296; Joseph B, 2014, J AM COLL SURGEONS, V219, P10, DOI 10.1016/j.jamcollsurg.2014.03.020; Khandelwal D, 2012, J NUTR HEALTH AGING, V16, P732, DOI 10.1007/s12603-012-0369-5; Kojima G, 2018, AGE AGEING, V47, P193, DOI 10.1093/ageing/afx162; Kojima G, 2017, DISABIL REHABIL, V39, P1897, DOI 10.1080/09638288.2016.1212282; Logan, 2020, CAN MED ASSOC J, V192, P16; Mitnitski A, 2005, J AM GERIATR SOC, V53, P2184, DOI 10.1111/j.1532-5415.2005.00506.x; Mitnitski A B, 2001, ScientificWorldJournal, V1, P323; Mueller N, 2016, ANN SURG, V264, P1116, DOI 10.1097/SLA.0000000000001546; Muscedere J, 2017, INTENS CARE MED, V43, P1105, DOI 10.1007/s00134-017-4867-0; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Ng TP, 2015, AM J MED, V128, P1225, DOI 10.1016/j.amjmed.2015.06.017; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Rockwood K, 2007, J GERONTOL A-BIOL, V62, P722, DOI 10.1093/gerona/62.7.722; Sablerolles RSG, 2021, LANCET HEALTH LONGEV, V2, pE163, DOI 10.1016/S2666-7568(21)00006-4; Searle Samuel D, 2008, BMC Geriatr, V8, P24, DOI 10.1186/1471-2318-8-24; Smart R, 2017, J FRALITY AGING, V6, P219, DOI 10.14283/jfa.2017.28; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Tracy BM, 2020, AM SURGEON, V86, P1596, DOI 10.1177/0003134820942196; van Buuren S, 2011, J STAT SOFTW, V45, P1; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zeng A, 2015, J GERONTOL A-BIOL, V70, P1586, DOI 10.1093/gerona/glv084	31	7	8	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2022	21	2					153	162		10.1016/S1474-4422(21)00374-4	http://dx.doi.org/10.1016/S1474-4422(21)00374-4			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	ZT4ER	35065038	Green Published			2022-12-18	WOS:000769111800016
J	Huijbers, MG; Marx, A; Plomp, JJ; Le Panse, R; Phillips, WD				Huijbers, Maartje G.; Marx, Alexander; Plomp, Jaap J.; Le Panse, Rozen; Phillips, William			Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders	LANCET NEUROLOGY			English	Article							EATON-MYASTHENIC-SYNDROME; SYNDROME IGG; PROTEIN 4; CLINICAL CHARACTERISTICS; ACETYLCHOLINE-RECEPTOR; TRANSMITTER RELEASE; NERVE-TERMINALS; TYROSINE KINASE; SAFETY FACTOR; END-PLATE	Muscle weakness and fatigue are the hallmarks of autoimmune neuromuscular junction disorders. Although a plethora of immunosuppressive treatments exist, no cure is available to date and many patients are left with debilitating muscle weakness. Recent advances in the understanding of the structure and function of the neuromuscular junction, and the development of novel in vitro and in vivo models, have been instrumental in unravelling the pathophysiology of these autoimmune diseases. These advances are providing the rationale for the development of new therapeutic strategies. Restoration of the immune imbalance in these diseases, in parallel with symptomatic therapeutic approaches at the neuromuscular junction, will be crucial to obtain long-term remission or even cure.	[Huijbers, Maartje G.] Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZC Leiden, Netherlands; [Huijbers, Maartje G.; Plomp, Jaap J.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands; [Marx, Alexander] Heidelberg Univ, Univ Med Ctr Mannheim, Inst Pathol, Mannheim, Germany; [Le Panse, Rozen] Sorbonne Univ, Ctr Res Myol, INSERM, Inst Myol, Paris, France; [Phillips, William] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ruprecht Karls University Heidelberg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Queensland	Huijbers, MG (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, NL-2333 ZC Leiden, Netherlands.	m.g.m.huijbers@lumc.nl	Le Panse, Rozen/B-8945-2013	Le Panse, Rozen/0000-0001-7522-5974				Afshar ME, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62837-8; Altintas A, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420949808; Attia M, 2017, ACTA NEUROPATHOL, V134, P869, DOI 10.1007/s00401-017-1754-2; Benatar M, 2001, J NEUROIMMUNOL, V113, P153, DOI 10.1016/S0165-5728(00)00431-8; Berrih-Aknin S, 2014, J AUTOIMMUN, V52, P90, DOI 10.1016/j.jaut.2013.12.011; Cao M, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00159; Cavalcante P, 2017, ONCOTARGET, V8, P95432, DOI 10.18632/oncotarget.20731; Cebi M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00809; Cetin H, 2020, J NEUROL NEUROSUR PS, V91, P526, DOI 10.1136/jnnp-2019-322640; Clifford KM, 2019, MUSCLE NERVE, V59, P404, DOI 10.1002/mus.26404; Cordiglieri C, 2014, J AUTOIMMUN, V52, P74, DOI 10.1016/j.jaut.2013.12.013; Cossins J, 2012, ANN NY ACAD SCI, V1275, P123, DOI 10.1111/j.1749-6632.2012.06833.x; Cron MA, 2018, AUTOIMMUN REV, V17, P588, DOI 10.1016/j.autrev.2018.01.008; Cron MA, 2018, ANN NY ACAD SCI, V1412, P137, DOI 10.1111/nyas.13519; Cufi P, 2014, J AUTOIMMUN, V52, P44, DOI 10.1016/j.jaut.2013.12.016; CULLCANDY SG, 1980, J PHYSIOL-LONDON, V299, P621, DOI 10.1113/jphysiol.1980.sp013145; DAVID P, 1993, NEUROMUSCULAR DISORD, V3, P451, DOI 10.1016/0960-8966(93)90095-2; de Meel RHP, 2019, NEUROMUSCULAR DISORD, V29, P664, DOI 10.1016/j.nmd.2019.07.006; Dietrich MF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009960; Dos Santos M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18789-8; Dragin N, 2016, J CLIN INVEST, V126, P1525, DOI 10.1172/JCI81894; Eguchi T, 2020, BIOCHEM BIOPH RES CO, V523, P214, DOI 10.1016/j.bbrc.2019.12.011; Eigenmann MJ, 2017, J PHYSIOL-LONDON, V595, P7311, DOI 10.1113/JP274819; ENGEL AG, 1977, MAYO CLIN PROC, V52, P267; Evoli A, 2018, ANN NY ACAD SCI, V1412, P82, DOI 10.1111/nyas.13518; Fichtner ML, 2020, J EXP MED, V217, DOI 10.1084/jem.20200513; Gasperi C, 2014, NEUROLOGY, V82, P1976, DOI 10.1212/WNL.0000000000000478; GRASSI C, 1994, NEUROSCI LETT, V181, P50, DOI 10.1016/0304-3940(94)90558-4; GRAUS YMF, 1993, J IMMUNOL, V150, P4093; Hashimoto S, 2020, ANN THORAC SURG, V109, pE347, DOI 10.1016/j.athoracsur.2019.08.080; HEINEMANN S, 1977, P NATL ACAD SCI USA, V74, P3090, DOI 10.1073/pnas.74.7.3090; Higuchi O, 2011, ANN NEUROL, V69, P418, DOI 10.1002/ana.22312; Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520; Hong Y, 2017, EUR J NEUROL, V24, P844, DOI 10.1111/ene.13300; Howard JF, 2018, ANN NY ACAD SCI, V1412, P113, DOI 10.1111/nyas.13522; Huijbers MG, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000547; Huijbers MG, 2016, J NEUROIMMUNOL, V291, P82, DOI 10.1016/j.jneuroim.2015.12.016; Huijbers MG, 2013, P NATL ACAD SCI USA, V110, P20783, DOI 10.1073/pnas.1313944110; Ingelfinger F, 2021, ACTA NEUROPATHOL, V141, P901, DOI 10.1007/s00401-021-02299-y; Jiang RY, 2020, P NATL ACAD SCI USA, V117, P30649, DOI 10.1073/pnas.2007206117; Jiang RY, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136471; Kawakami Y, 2011, NEUROLOGY, V77, P1819, DOI 10.1212/WNL.0b013e318237f660; Kim N, 2008, NAT NEUROSCI, V11, P19, DOI 10.1038/nn2026; Klooster R, 2012, BRAIN, V135, P1081, DOI 10.1093/brain/aws025; Koneczny I, 2019, AUTOIMMUN REV, V18, P50, DOI 10.1016/j.autrev.2018.07.011; Koneczny I, 2017, J AUTOIMMUN, V77, P104, DOI 10.1016/j.jaut.2016.11.005; Koneczny I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080695; Kusner LL, 2013, MUSCLE NERVE, V47, P33, DOI 10.1002/mus.23448; LAMBERT EH, 1988, MUSCLE NERVE, V11, P1133, DOI 10.1002/mus.880111105; LANG B, 1983, J PHYSIOL-LONDON, V344, P335, DOI 10.1113/jphysiol.1983.sp014943; Lazaridis K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00212; Lefeuvre CMJ, 2020, J AUTOIMMUN, V106, DOI 10.1016/j.jaut.2019.102337; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; Leopardi V, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.618021; Li YK, 2020, J NEUROIMMUNOL, V345, DOI 10.1016/j.jneuroim.2020.577279; Lighaam LC, 2016, SEMIN LIVER DIS, V36, P200, DOI 10.1055/s-0036-1584322; Luttrell SM, 2021, MUSCLE NERVE, V64, P388, DOI 10.1002/mus.27360; Machado CB, 2019, ADV BIOSYST, V3, DOI 10.1002/adbi.201800307; Makarious D, 2017, EUR J CANCER, V82, P128, DOI 10.1016/j.ejca.2017.05.041; Makino T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185976; Manson G, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0821-8; Martins JMF, 2020, CELL STEM CELL, V26, P172, DOI 10.1016/j.stem.2019.12.007; Marx A, 2021, SEMIN IMMUNOPATHOL, V43, P45, DOI 10.1007/s00281-021-00842-3; Meriney SD, 2018, ANN NY ACAD SCI, V1412, P73, DOI 10.1111/nyas.13512; Mori S, 2017, EXP NEUROL, V297, P158, DOI 10.1016/j.expneurol.2017.08.006; Morsch M, 2012, EXP NEUROL, V237, P286, DOI 10.1016/j.expneurol.2012.06.034; Motomura M, 1997, J NEUROL SCI, V147, P35, DOI 10.1016/S0022-510X(96)05303-8; NAGEL A, 1988, ANN NEUROL, V24, P552, DOI 10.1002/ana.410240412; Niks EH, 2008, J NEUROIMMUNOL, V195, P151, DOI 10.1016/j.jneuroim.2008.01.013; Noridomi K, 2017, ELIFE, V6, DOI 10.7554/eLife.23043; Petrany MJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20063-w; Pevzner A, 2012, J NEUROL, V259, P427, DOI 10.1007/s00415-011-6194-7; Pinto A, 2002, MUSCLE NERVE, V25, P715, DOI 10.1002/mus.10087; Plomp JJ, 2017, FRONT BIOSCI-LANDMRK, V22, P1033, DOI 10.2741/4532; Plomp JJ, 2015, EXP NEUROL, V270, P41, DOI 10.1016/j.expneurol.2015.01.007; PLOMP JJ, 1995, ANN NEUROL, V37, P627, DOI 10.1002/ana.410370513; PRIOR C, 1985, ANN NEUROL, V17, P587, DOI 10.1002/ana.410170610; Punga AR, 2022, LANCET NEUROL, V21, P176, DOI 10.1016/S1474-4422(21)00297-0; Reid B, 2003, J NEUROSCI, V23, P9340; Rivner MH, 2020, MUSCLE NERVE, V62, P333, DOI 10.1002/mus.26985; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; Ruff RL, 2008, J NEUROIMMUNOL, V201, P13, DOI 10.1016/j.jneuroim.2008.04.038; Shen CY, 2013, J CLIN INVEST, V123, P5190, DOI 10.1172/JCI66039; Shigemoto K, 2006, J CLIN INVEST, V116, P1016, DOI 10.1172/JCI21545; Song Y, 2016, J THORAC DIS, V8, P314, DOI 10.21037/jtd.2016.03.03; Spillane J, 2015, NEUROLOGY, V84, P575, DOI 10.1212/WNL.0000000000001225; Takamori M, 2008, J NEUROIMMUNOL, V201, P145, DOI 10.1016/j.jneuroim.2008.04.040; Takamori M, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00086; Takamori M, 2013, J NEUROIMMUNOL, V254, P183, DOI 10.1016/j.jneuroim.2012.09.001; Takata K, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127167; Tani T, 2008, J NEUROIMMUNOL, V196, P166, DOI 10.1016/j.jneuroim.2008.03.002; Titulaer MJ, 2011, LANCET NEUROL, V10, P1098, DOI 10.1016/S1474-4422(11)70245-9; Truffault F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00782; Ulusoy C, 2017, IMMUNOL INVEST, V46, P490, DOI 10.1080/08820139.2017.1299754; Uzawa A, 2021, CLIN EXP IMMUNOL, V203, P366, DOI 10.1111/cei.13546; Vergoossen DLE, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020635118; Verschuuren JJ, 2022, LANCET NEUROL, V21, P189, DOI 10.1016/S1474-4422(21)00463-4; Viegas S, 2012, EXP NEUROL, V234, P506, DOI 10.1016/j.expneurol.2012.01.025; VIGLIONE MP, 1995, J PHYSIOL-LONDON, V488, P303, DOI 10.1113/jphysiol.1995.sp020968; Villegas JA, 2019, J AUTOIMMUN, V98, P59, DOI 10.1016/j.jaut.2018.11.005; Vilquin JT, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01343; Wolfe GI, 2019, LANCET NEUROL, V18, P259, DOI 10.1016/S1474-4422(18)30392-2; Wood SJ, 2001, PROG NEUROBIOL, V64, P393, DOI 10.1016/S0301-0082(00)00055-1; Yan M, 2018, NEUROSCIENCE, V373, P113, DOI 10.1016/j.neuroscience.2018.01.015; Yilmaz V, 2018, ANN CLIN TRANSL NEUR, V5, P1408, DOI 10.1002/acn3.645; Yumoto N, 2012, NATURE, V489, P438, DOI 10.1038/nature11348; Zekeridou A, 2019, THORAC CANCER, V10, P1001, DOI 10.1111/1759-7714.13009; Zekeridou A, 2018, MUSCLE NERVE, V58, P600, DOI 10.1002/mus.26166; Zhang B, 2012, ARCH NEUROL-CHICAGO, V69, P445, DOI 10.1001/archneurol.2011.2393; Zhang W, 2011, J BIOL CHEM, V286, P40624, DOI 10.1074/jbc.M111.279307; Zhang XY, 2016, MOL NEUROBIOL, V53, P120, DOI 10.1007/s12035-014-8985-1; Zhong HH, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102349; Zhu HP, 2011, J NEUROSCI, V31, P15269, DOI 10.1523/JNEUROSCI.3766-11.2011; Zisimopoulou P, 2014, J AUTOIMMUN, V52, P139, DOI 10.1016/j.jaut.2013.12.004	114	7	7	10	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2022	21	2					163	175		10.1016/S1474-4422(21)00357-4	http://dx.doi.org/10.1016/S1474-4422(21)00357-4			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZT4ER	35065039				2022-12-18	WOS:000769111800017
J	Dauvilliers, Y; Arnulf, I; Foldvary-Schaefer, N; Morse, AM; Sonka, K; Thorpy, MJ; Mignot, E; Chandler, P; Parvataneni, R; Black, J; Sterkel, A; Chen, D; Skobieranda, F; Bogan, RK				Dauvilliers, Yves; Arnulf, Isabelle; Foldvary-Schaefer, Nancy; Morse, Anne Marie; Sonka, Karel; Thorpy, Michael J.; Mignot, Emmanuel; Chandler, Patricia; Parvataneni, Rupa; Black, Jed; Sterkel, Amanda; Chen, Dan; Skobieranda, Franck; Bogan, Richard K.			Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	LANCET NEUROLOGY			English	Article							LONG-SLEEP TIME; DAYTIME SLEEPINESS; NARCOLEPSY; MULTICENTER; MODAFINIL; VALIDITY; HEALTH	Background Idiopathic hypersomnia is a central hypersomnolence disorder mainly characterised by excessive daytime sleepiness, with prolonged night-time sleep and pronounced sleep inertia. Until August, 2021, no medication had regulatory approval for the treatment of idiopathic hypersomnia. This study aimed to evaluate the safety and efficacy of lower-sodium oxybate in idiopathic hypersomnia. Methods This was a phase 3, multicentre (50 specialist sleep centres; six EU countries and the USA), placebocontrolled, double-blind, randomised withdrawal study. Participants (aged 18-75 years) with idiopathic hypersomnia (meeting criteria from the International Classification of Sleep Disorders, 2nd or 3rd editions) began lower-sodium oxybate treatment (oral solution once or twice nightly) in an open-label titration and optimisation period (10-14 weeks), followed by a 2-week, open-label, stable-dose period. After these open-label periods, participants were randomised (1:1) by means of an interactive web recognition system, stratified by participants' baseline medication use, to either placebo or lower-sodium oxybate (individually optimised dose; range 2.5-9.0 g/night) during a 2-week, double-blind, randomised withdrawal period. To maintain masking of treatment assignment, placebo and lower-sodium oxybate oral solutions were matched in volume, appearance, and taste. During the double-blind, randomised withdrawal period, participants and investigators were unaware of treatment assignments. The primary efficacy endpoint was change in Epworth Sleepiness Scale (ESS) score from the end of the stable-dose period to the end of the double-blind, randomised withdrawal period, which was assessed in the modified intention-to-treat population (defined as all participants who were randomly assigned, took at least one dose of study medication during the double blind, randomised withdrawal period, and had at least one set of post-randomisation assessments for the primary or key secondary endpoints). Adverse events were assessed in the safety population (defined as all participants who took at least one dose of study medication). This study is registered at ClinicalTrials.gov, NCT03533114, and at EU Clinical Trials, 2018-001311-79, and is complete. Findings Between Nov 27, 2018, and March 6, 2020, 154 participants were enrolled and comprised the safety population. ESS scores decreased from a mean of 15.7 (SD 3.8) at baseline to 6.1 (4.0) by the end of the stable-dose period. After the open-label periods, 115 participants were randomly assigned either placebo (n=59) or lower-sodium oxybate (n=56) and comprised the modified intention-to-treat population. During the double-blind, randomised withdrawal period, ESS scores increased (worsened) in participants randomly assigned to placebo but remained stable in those assigned to lower-sodium oxybate (least squares mean difference -6.5; 95% CI -8.0 to -5.0; p<0.0001). Treatment-emergent adverse events included nausea (34 [22%] of 154), headache (27 [18%] of 154), dizziness (19 [12%] of 154), anxiety (17 [11%] 154), and vomiting (17 [11%] 154). No deaths were reported during the study. Interpretation Lower-sodium oxybate treatment resulted in a clinically meaningful improvement in idiopathic hypersomnia symptoms, with an overall safety profile consistent with that reported for narcolepsy. Lower-sodium oxybate was approved in August, 2021, by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults. Copyright (C) 2021 Elsevier Ltd. All rights reserved.	[Dauvilliers, Yves] Gui de Chauliac Hosp, Sleep & Wake Disorders Ctr, Dept Neurol, F-34295 Montpellier, France; [Dauvilliers, Yves] Univ Montpellier, INSERM Inst Neurosci Montpellier, Montpellier, France; [Arnulf, Isabelle] Hop La Pitie Salpetriere, Sleep Disorder Unit, Paris, France; [Arnulf, Isabelle] Sorbonne Univ, Paris, France; [Foldvary-Schaefer, Nancy] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA; [Morse, Anne Marie] Janet Weis Childrens Hosp, Danville, PA USA; [Sonka, Karel] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Sonka, Karel] Gen Univ Hosp, Prague, Czech Republic; [Thorpy, Michael J.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Mignot, Emmanuel] Stanford Univ, Ctr Narcolepsy, Redwood City, CA USA; [Chandler, Patricia; Parvataneni, Rupa; Black, Jed; Sterkel, Amanda; Chen, Dan] Jazz Pharmaceut, Palo Alto, CA USA; [Black, Jed] Stanford Ctr Sleep Sci & Med, Palo Alto, CA USA; [Skobieranda, Franck] Jazz Pharmaceut, Philadelphia, PA USA; [Bogan, Richard K.] Univ South Carolina, Sch Med, Columbia, SC 29208 USA	Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Case Western Reserve University; Cleveland Clinic Foundation; Charles University Prague; General University Hospital Prague; Yeshiva University; Albert Einstein College of Medicine; Stanford University; Jazz Pharmaceuticals; Jazz Pharmaceuticals; University of South Carolina System; University of South Carolina Columbia	Dauvilliers, Y (corresponding author), Gui de Chauliac Hosp, Sleep & Wake Disorders Ctr, Dept Neurol, F-34295 Montpellier, France.	ydauvilliers@yahoo.fr			Jazz Pharmaceuticals	Jazz Pharmaceuticals(Jazz Pharmaceuticals)	Jazz Pharmaceuticals.	Ali M, 2009, J CLIN SLEEP MED, V5, P562; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS; Anderson KN, 2007, SLEEP, V30, P1274, DOI 10.1093/sleep/30.10.1274; [Anonymous], 2021, XYW CALC MAGN POT SO; [Anonymous], 2020, XYREM SOD OX OR SOL; Arnulf I, 2019, SLEEP MED CLIN, V14, P333, DOI 10.1016/j.jsmc.2019.05.007; Bogan RK, 2021, SLEEP, V44, DOI 10.1093/sleep/zsaa206; Cairns Alyssa, 2019, Neurobiology of Sleep and Circadian Rhythms, V6, P62, DOI 10.1016/j.nbscr.2019.02.001; Chasens ER, 2009, SLEEP, V32, P915, DOI 10.1093/sleep/32.7.915; Dauvilliers Y, 2009, J NEUROL NEUROSUR PS, V80, P636, DOI 10.1136/jnnp.2008.161588; Dauvilliers Y, 2019, NEUROLOGY, V92, pE1754, DOI 10.1212/WNL.0000000000007264; Evangelista E, 2021, SLEEP, V44, DOI DOI 10.1093/sleep/zsaa264; Evangelista E, 2018, ANN NEUROL, V83, P235, DOI 10.1002/ana.25141; Evangelista E, 2018, EXPERT OPIN INV DRUG, V27, P187, DOI 10.1080/13543784.2018.1417385; Inoue Y, 2021, SLEEP MED, V80, P315, DOI 10.1016/j.sleep.2021.01.018; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kretzschmar U, 2016, J SLEEP RES, V25, P307, DOI 10.1111/jsr.12383; Lammers GJ, 2020, SLEEP MED REV, V52, DOI 10.1016/j.smrv.2020.101306; Leu-Semenescu S, 2016, SLEEP MED, V17, P38, DOI 10.1016/j.sleep.2015.10.005; Maski K, J CLIN SLEEP MED, V17, P1881; Maski K, 2021, J CLIN SLEEP MED, V17, P1895, DOI 10.5664/jcsm.9326; Mayer G, 2015, J SLEEP RES, V24, P74, DOI 10.1111/jsr.12201; Ozaki A, 2008, J CLIN SLEEP MED, V4, P572; Pardi D, 2006, CNS DRUGS, V20, P993, DOI 10.2165/00023210-200620120-00004; Plante DT, 2018, SLEEP MED, V45, P17, DOI 10.1016/j.sleep.2017.10.005; Plazzi G, 2018, LANCET CHILD ADOLESC, V2, P483, DOI 10.1016/S2352-4642(18)30133-0; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Rassu AL, 2022, J CLIN SLEEP MED, V18, P617, DOI 10.5664/jcsm.9682; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Srivastava B, 2021, ANN NEUROL, V90, pS240; Thorpy M, 2017, DIAGNOSTIC CODING MA, P475; US Food and Drug Administration, 2021, CLIN SUP FIND	32	7	7	8	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					53	65						13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XV0SP	34942138				2022-12-18	WOS:000734663200022
J	Kehoe, PG; Turner, N; Howden, B; Jarutyte, L; Clegg, SL; Malone, IB; Barnes, J; Nielsen, C; Sudre, CH; Wilson, A; Thai, NJ; Blair, PS; Coulthard, E; Lane, JA; Passmore, P; Taylor, J; Mutsaerts, HJ; Thomas, DL; Fox, NC; Wilkinson, I; Ben-Shlomo, Y				Kehoe, Patrick Gavin; Turner, Nicholas; Howden, Beth; Jarutyte, Lina; Clegg, Shona Louise; Malone, Ian Brian; Barnes, Josephine; Nielsen, Casper; Sudre, Carole Helene; Wilson, Aileen; Thai, Ngoc Jade; Blair, Peter Sinclair; Coulthard, Elizabeth; Lane, Janet Athene; Passmore, Peter; Taylor, Jodi; Mutsaerts, Henk-Jan; Thomas, David Lee; Fox, Nick Charles; Wilkinson, Ian; Ben-Shlomo, Yoav		RADAR Investigators	Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	LANCET NEUROLOGY			English	Article							COGNITIVE DECLINE; DEMENTIA; PREVENTION; RATIONALE; PATHOLOGY; DESIGN; MRI	Background Drugs modifying angiotensin II signalling could reduce Alzheimer's disease pathology, thus decreasing the rate of disease progression. We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could reduce brain volume loss, as a measure of disease progression, in clinically diagnosed mild-to-moderate Alzheimer's disease. Methods In this double-blind, multicentre, randomised controlled trial, eligible patients aged 55 years or older, previously untreated with angiotensin II drugs and diagnosed (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria) with mild-to-moderate Alzheimer's disease, and who had capacity to consent, were recruited from 23 UK National Health Service hospital trusts. After undergoing a 4-week, open-label phase of active treatment then washout, participants were randomly assigned (1:1) oral over-encapsulated preparations of either 100 mg losartan (after an initial two-dose titration stage) or matched placebo daily for 12 months. Randomisation, minimised by age and baseline medial temporal lobe atrophy score, was undertaken online or via pin-access service by telephone. Participants, their study companions, and study personnel were masked to group assignment. The primary outcome, analysed by the intention-to-treat principle (ie, participants analysed in the group to which they were randomised, without imputation for missing data), was change in whole brain volume between baseline and 12 months, measured using volumetric MRI and determined by boundary shift interval (BSI) analysis. The trial is registered with the International Standard Randomised Controlled Trial Register (ISRCTN93682878) and the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT 2012-003641-15), and is completed. Findings Between July 22, 2014, and May 17, 2018, 261 participants entered the open-label phase. 211 were randomly assigned losartan (n=105) or placebo (n=106). Of 197 (93%) participants who completed the study, 171 (81%) had complete primary outcome data. The mean brain volume (BSI) reduction was 19.1 mL (SD 10.3) in the losartan group and 20.0 mL (10.8) in the placebo group. The difference in total volume reduction between groups was -2.29 mL (95% CI -6.46 to 0.89; p=0.14). The number of adverse events was low (22 in the losartan group and 20 in the placebo group) with no differences between treatment groups. There was one treatment-related death per treatment group. Interpretation 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease. Further research is needed to assess the potential therapeutic benefit from earlier treatment in patients with milder cognitive impairment or from longer treatment periods. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.	[Kehoe, Patrick Gavin] Univ Bristol, Dementia Res Grp, Bristol, Avon, England; [Jarutyte, Lina; Coulthard, Elizabeth] Univ Bristol, Dementia Neurol Res Grp, Bristol, Avon, England; [Turner, Nicholas; Howden, Beth; Blair, Peter Sinclair; Lane, Janet Athene; Taylor, Jodi; Ben-Shlomo, Yoav] Univ Bristol, Translat Hlth Sci Populat Hlth Sci, Bristol, Avon, England; [Turner, Nicholas; Howden, Beth; Blair, Peter Sinclair; Lane, Janet Athene; Taylor, Jodi; Ben-Shlomo, Yoav] Univ Bristol, Bristol Trials Ctr, Bristol, Avon, England; [Wilson, Aileen; Thai, Ngoc Jade] Univ Bristol, Fac Hlth Sci, Bristol Med Sch, Clin Res Imaging Ctr, Bristol, Avon, England; [Clegg, Shona Louise; Malone, Ian Brian; Barnes, Josephine; Nielsen, Casper; Thomas, David Lee; Fox, Nick Charles] UCL, Dementia Res Ctr, London, England; [Fox, Nick Charles] UCL, UK Dementia Res Inst, London, England; [Clegg, Shona Louise; Malone, Ian Brian; Barnes, Josephine; Nielsen, Casper; Thomas, David Lee; Fox, Nick Charles] UCL, UCL Queen Sq Inst Neurol, London, England; [Sudre, Carole Helene] UCL, MRC Unit Lifelong Hlth & Ageing, London, England; [Sudre, Carole Helene] UCL, Ctr Med Image Comp, London, England; [Sudre, Carole Helene] KingsColl London, Sch Biomed Engn & Imaging Sci, London, England; [Passmore, Peter] Queens Univ Belfast, Royal Victoria Hosp, Inst Clin Sci, Belfast, Antrim, North Ireland; [Mutsaerts, Henk-Jan] Univ Amsterdam, Amsterdam Neurosci, Med Ctr, Amsterdam, Netherlands; [Wilkinson, Ian] Univ Cambridge, Addenbnaokes Hosp, Sch Clin Med, Clin Pharmacol Unit, Cambridge, England	University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; Queens University Belfast; University of Amsterdam; Vrije Universiteit Amsterdam; University of Cambridge	Kehoe, PG (corresponding author), Univ Bristol, Bristol Med Sch, Translat Hlth Sci, Dementia Res Grp, Bristol BS10 5NB, Avon, England.	Patrick.Kehoe@bristol.ac.uk	Fox, Nick C/B-1319-2009; Kehoe, Patrick/P-8760-2018; Pearson, Stephen/J-9257-2018	Fox, Nick C/0000-0002-6660-657X; Kehoe, Patrick/0000-0002-7542-1139; Turner, Nicholas/0000-0003-1591-6997; Malone, Ian/0000-0001-7512-7856; Pearson, Stephen/0000-0002-6935-8698; Sudre, Carole/0000-0001-5753-428X; Blair, Peter/0000-0002-7832-8087; Thomas, David/0000-0003-1491-1641; coulthard, elizabeth/0000-0002-0017-9595	Efficacy and Mechanism Evaluation Programme (UK Medical Research Council); National Institute for Health Research	Efficacy and Mechanism Evaluation Programme (UK Medical Research Council)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research(National Institute for Health Research (NIHR))	Efficacy and Mechanism Evaluation Programme (UK Medical Research Council and National Institute for Health Research).	Bavishi C, 2020, JAMA CARDIOL, V5, P745, DOI 10.1001/jamacardio.2020.1282; Carmichael O, 2010, ARCH NEUROL-CHICAGO, V67, P1370, DOI 10.1001/archneurol.2010.284; Clement C, 2019, J ALZHEIMERS DIS, V69, P1067, DOI 10.3233/JAD-190146; Culman J, 1999, EUR J PHARMACOL, V367, P255, DOI 10.1016/S0014-2999(98)00983-2; Cummings J, 2018, J ALZHEIMERS DIS, V64, pS3, DOI 10.3233/JAD-179901; Danielyan L, 2010, REJUV RES, V13, P195, DOI 10.1089/rej.2009.0944; de Jong DLK, 2019, HYPERTENSION, V74, P413, DOI 10.1161/HYPERTENSIONAHA.119.12892; den Brok MGHE, 2021, J AM MED DIR ASSOC, V22, P1386, DOI 10.1016/j.jamda.2020.12.019; Ding J, 2020, LANCET NEUROL, V19, P61, DOI 10.1016/S1474-4422(19)30393-X; Evans CE, 2020, ACTA NEUROPATHOL, V139, P485, DOI 10.1007/s00401-019-02098-6; Fogari R, 2004, DRUG AGING, V21, P377, DOI 10.2165/00002512-200421060-00003; Fox NC, 1999, NEUROLOGY, V52, P1687, DOI 10.1212/WNL.52.8.1687; Fox NC, 2011, NEUROIMAGE, V57, P15, DOI 10.1016/j.neuroimage.2011.01.077; Gupta A, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-038971; Hajjar I, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.12252; Hong KS, 2010, ACTA NEUROL SCAND, V121, P51, DOI 10.1111/j.1600-0404.2009.01299.x; Iadecola C, 2018, CIRC RES, V123, P406, DOI 10.1161/CIRCRESAHA.118.313400; Iturria-Medina Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11934; Kehoe PG, 2018, J ALZHEIMERS DIS, V61, P803, DOI 10.3233/JAD-170101; Kehoe PG, 2018, J ALZHEIMERS DIS, V62, P1443, DOI 10.3233/JAD-171119; Lee W, 2019, PATIENT PREFER ADHER, V13, P1809, DOI 10.2147/PPA.S216088; Leung KK, 2010, NEUROIMAGE, V51, P1345, DOI 10.1016/j.neuroimage.2010.03.018; Macdonald KE, 2014, NEUROINFORMATICS, V12, P405, DOI 10.1007/s12021-013-9217-y; Peters R, 2020, NEUROLOGY, V94, pE267, DOI 10.1212/WNL.0000000000008732; SCHELTENS P, 1992, J NEUROL NEUROSUR PS, V55, P967, DOI 10.1136/jnnp.55.10.967; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Vemuri P, 2017, JAMA NEUROL, V74, P718, DOI 10.1001/jamaneurol.2017.0244; Wharton W, 2018, J ALZHEIMERS DIS, V61, P815, DOI 10.3233/JAD-161198; Yu JT, 2020, J NEUROL NEUROSUR PS, V91, P1201, DOI 10.1136/jnnp-2019-321913; Zhao Z, 2009, J EXP STROKE TRANSL, V2, P9	30	7	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2021	20	11					895	906		10.1016/S1474-4422(21)00263-5	http://dx.doi.org/10.1016/S1474-4422(21)00263-5			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WL5PY	34687634	Green Published, hybrid			2022-12-18	WOS:000710458300013
J	Palta, P; Albert, MS; Gottesman, RF				Palta, Priya; Albert, Marilyn S.; Gottesman, Rebecca F.			Heart health meets cognitive health: evidence on the role of blood pressure	LANCET NEUROLOGY			English	Review							CARDIOVASCULAR RISK-FACTORS; MINI-MENTAL-STATE; LATE-LIFE; INCIDENT DEMENTIA; ATHEROSCLEROSIS RISK; ALZHEIMERS-DISEASE; YOUNG ADULTHOOD; MIDLIFE; HYPERTENSION; ASSOCIATION	The enormous societal and financial burden of Alzheimer's disease and related dementias requires the identification of risk factors and pathways to reduce dementia risk. Blood pressure (BP) management and control is one promising area, in which data have been inconclusive. Accumulating evidence over the past 5 years shows the effectiveness of BP management interventions among older individuals at risk, most notably from the SPRINT-MIND trial. These findings have been coupled with longitudinal observational data. However, to date, the results do not concur on the optimal timing and target of BP lowering, and further study in diverse populations is needed. Given the long preclinical phase of dementia and data supporting the importance of BP control earlier in the lifecourse, long-term interventional and observational studies in ethnically and racially diverse populations, with novel imaging and blood-based biomarkers of neurodegeneration and vascular cognitive impairment to understand the pathophysiology, are needed to advance the field.	[Palta, Priya] Columbia Univ, Dept Med, Div Gen Med, Irving Med Ctr, New York, NY 10032 USA; [Palta, Priya] Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; [Albert, Marilyn S.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Gottesman, Rebecca F.] NINDS, Stroke Branch, Intramural Program, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA	Columbia University; NewYork-Presbyterian Hospital; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Palta, P (corresponding author), Columbia Univ, Dept Med, Div Gen Med, Irving Med Ctr, New York, NY 10032 USA.	pp2464@cumc.columbia.edu	Gottesman, Rebecca/ABA-8468-2020		National Institutes of Health; National Institute on Aging [R00AG052830, R01AG066134, R01AG067513, R01AG071032, P30AG066507, K24AG052573]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors either are or were recipients of a National Institutes of Health grant. PP is in part supported by grants from the National Institute on Aging (R00AG052830, R01AG066134, R01AG067513, and R01AG071032) . MSA is in part support by a grant from the National Institute on Aging (P30AG066507) . RFG was previously supported by a grant from the National Institute on Aging (K24AG052573) . Funding sources had no part in the preparation of this Review or in the decision to submit for publication. This Review was prepared while RFG was employed at the Johns Hopkins University School of Medicine (Baltimore, MA, USA) . The opinions expressed in this Review are the authors' own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the US Government.	Abell JG, 2018, EUR HEART J, V39, P3119, DOI 10.1093/eurheartj/ehy288; Agency for Healthcare Research and Quality, 2010, DISP HLTH CAR QUAL R; Alzheimer's Association, ACC RISK RED PROM CO; American Association of Retired Persons, GLOB COUNC BRAIN HLT; Arvanitakis Z, 2018, NEUROLOGY, V91, pE517, DOI 10.1212/WNL.0000000000005951; Babulal GM, 2019, ALZHEIMERS DEMENT, V15, P292, DOI 10.1016/j.jalz.2018.09.009; Beason-Held LL, 2013, J NEUROSCI, V33, P18008, DOI 10.1523/JNEUROSCI.1402-13.2013; Bosch J, 2019, NEUROLOGY, V92, pE1435, DOI 10.1212/WNL.0000000000007174; Bress AP, 2017, CIRCULATION, V135, P1617, DOI 10.1161/CIRCULATIONAHA.116.025322; Cedar D, 2018, JAMA PSYCHIAT, V75, P723, DOI 10.1001/jamapsychiatry.2018.1012; Centers for Disease Control and Prevention, HLTH BRAIN IN; Centers for Disease Control and Prevention, GLOB HEARTS IN; Chen Cynthia, 2018, Alzheimers Dement (N Y), V4, P510, DOI 10.1016/j.trci.2018.08.009; Corrada MM, 2017, ALZHEIMERS DEMENT, V13, P103, DOI 10.1016/j.jalz.2016.09.007; de Galan BE, 2009, DIABETOLOGIA, V52, P2328, DOI 10.1007/s00125-009-1484-7; Ding J, 2020, LANCET NEUROL, V19, P61, DOI 10.1016/S1474-4422(19)30393-X; Dorans KS, 2018, J AM HEART ASSOC, V7, DOI [10.1161/JAHA.118.008888, 10.1161/jaha.118.008888]; Elias MF, 2018, AM J HYPERTENS, V31, P631, DOI 10.1093/ajh/hpy033; Euser SM, 2009, J AM GERIATR SOC, V57, P1232, DOI 10.1111/j.1532-5415.2009.02264.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forette F, 2002, ARCH INTERN MED, V162, P2046, DOI 10.1001/archinte.162.18.2046; Frey L, 2019, J HYPERTENS, V37, P2135, DOI 10.1097/HJH.0000000000002176; Gabin JM, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0262-x; Goldstein FC, 2017, J GERONTOL A-BIOL, V72, P121, DOI 10.1093/gerona/glw181; Gottesman RF, 2017, JAMA NEUROL, V74, P1246, DOI 10.1001/jamaneurol.2017.1658; Gottesman RF, 2017, JAMA-J AM MED ASSOC, V317, P1443, DOI 10.1001/jama.2017.3090; Gottesman RF, 2014, JAMA NEUROL, V71, P1218, DOI 10.1001/jamaneurol.2014.1646; Gregson J, 2019, EUR J NEUROL, V26, P1479, DOI 10.1111/ene.14030; Hajjar I, 2017, JAMA NEUROL, V74, P1199, DOI 10.1001/jamaneurol.2017.1863; Hayden KM, 2011, AGE AGEING, V40, P684, DOI 10.1093/ageing/afr101; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Hestad K, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00607; Hughes D, 2020, JAMA-J AM MED ASSOC, V323, P1934, DOI 10.1001/jama.2020.4249; Iadecola C, 2016, HYPERTENSION, V68, pE67, DOI 10.1161/HYP.0000000000000053; Jani B, 2006, POSTGRAD MED J, V82, P357, DOI 10.1136/pgmj.2005.036053; Kario K, 2020, J CLIN HYPERTENS, V22, P321, DOI 10.1111/jch.13750; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Lane CA, 2019, LANCET NEUROL, V18, P942, DOI 10.1016/S1474-4422(19)30228-5; Langbaum JBS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.06.020; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; Levine DA, 2020, JAMA NEUROL, V77, P810, DOI 10.1001/jamaneurol.2020.0568; Levine DA, 2019, HYPERTENSION, V73, P310, DOI 10.1161/HYPERTENSIONAHA.118.12062; Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6; Lu HZ, 2021, ALZHEIMERS DEMENT, V17, P716, DOI 10.1002/alz.12216; Ma Y, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002933; Marcum ZA, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1058-6; McGrath ER, 2017, NEUROLOGY, V89, P2447, DOI 10.1212/WNL.0000000000004741; McGuinness B, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004034.pub3; Mehta KM, 2017, ALZHEIMERS DEMENT, V13, P72, DOI 10.1016/j.jalz.2016.06.2360; Mills KT, 2020, NAT REV NEPHROL, V16, P223, DOI 10.1038/s41581-019-0244-2; Mills KT, 2016, CIRCULATION, V134, P441, DOI 10.1161/CIRCULATIONAHA.115.018912; Muller M, 2014, NEUROLOGY, V82, P2187, DOI 10.1212/WNL.0000000000000517; Murray MD, 2018, J GEN INTERN MED, V33, P455, DOI 10.1007/s11606-017-4281-x; Nasrallah IM, 2019, JAMA-J AM MED ASSOC, V322, P524, DOI 10.1001/jama.2019.10551; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nation DA, 2015, JAMA NEUROL, V72, P546, DOI 10.1001/jamaneurol.2014.4477; National Academies of Sciences Engineering and Medicine, 2017, PREVENTING COGNITIVE; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Olanrewaju Olawale, 2015, Alzheimers Dement (N Y), V1, P151; Patel KK, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.117.003624; Peng MK, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0649-3; Peters R, 2008, LANCET NEUROL, V7, P683, DOI 10.1016/S1474-4422(08)70143-1; Peters R, 2020, NEUROLOGY, V94, pE267, DOI 10.1212/WNL.0000000000008732; Power MC, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005608; Power MC, 2016, ALZHEIMERS DEMENT, V12, P890, DOI 10.1016/j.jalz.2016.03.012; Qiu CX, 2005, LANCET NEUROL, V4, P487, DOI 10.1016/S1474-4422(05)70141-1; Rajan KB, 2021, ALZHEIMERS DEMENT, V17, P1966, DOI 10.1002/alz.12362; Rapp SR, 2020, LANCET NEUROL, V19, P899, DOI 10.1016/S1474-4422(20)30319-7; Reitz C, 2007, ARCH NEUROL-CHICAGO, V64, P1734, DOI 10.1001/archneur.64.12.1734; Rodrigue KM, 2013, JAMA NEUROL, V70, P600, DOI 10.1001/jamaneurol.2013.1342; Rosenberg A, 2020, JPAD-J PREV ALZHEIM, V7, P29, DOI 10.14283/jpad.2019.41; Rovio SP, 2017, J AM COLL CARDIOL, V69, P2279, DOI 10.1016/j.jacc.2017.02.060; Royall DR, 2005, J INT NEUROPSYCH SOC, V11, P899, DOI 10.1017/S135561770505109X; Salthouse T.A., 2010, MAJOR ISSUES COGNITI; Shah NS, 2012, HYPERTENSION, V59, P780, DOI 10.1161/HYPERTENSIONAHA.111.178962; Spencer RJ, 2013, EXP AGING RES, V39, P382, DOI 10.1080/0361073X.2013.808109; Tang MX, 2001, NEUROLOGY, V56, P49, DOI 10.1212/WNL.56.1.49; Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003; Tully PJ, 2016, NEUROLOGY, V87, P601, DOI 10.1212/WNL.0000000000002946; Turana Y, 2019, J CLIN HYPERTENS, V21, P1091, DOI 10.1111/jch.13558; UK Government, 2017, HLTH MATT COMB HIGH; van Charante EPM, 2016, LANCET, V388, P797, DOI 10.1016/S0140-6736(16)30950-3; van Dalen JW, 2019, J AM MED DIR ASSOC, V20, P1091, DOI 10.1016/j.jamda.2018.12.006; Vemuri P, 2017, JAMA NEUROL, V74, P718, DOI 10.1001/jamaneurol.2017.0244; Waldstein SR, 2005, HYPERTENSION, V45, P374, DOI 10.1161/01.HYP.0000156744.44218.74; Walker KA, 2019, JAMA-J AM MED ASSOC, V322, P535, DOI 10.1001/jama.2019.10575; Weuve J, 2015, ALZHEIMERS DEMENT, V11, P1098, DOI 10.1016/j.jalz.2015.06.1885; Weuve J, 2012, EPIDEMIOLOGY, V23, P119, DOI 10.1097/EDE.0b013e318230e861; Whelton Paul K, 2018, J Am Soc Hypertens, V12, DOI [10.1161/HYP.0000000000000065, 10.1016/j.jash.2018.06.010]; White WB, 2019, CIRCULATION, V140, P1626, DOI 10.1161/CIRCULATIONAHA.119.041603; Wilcock D, 2021, ALZHEIMERS DEMENT, V17, P704, DOI 10.1002/alz.12215; Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339; Williamson JD, 2019, JAMA-J AM MED ASSOC, V321, P553, DOI 10.1001/jama.2018.21442; Windham BG, 2019, ANN INTERN MED, V171, P389, DOI 10.7326/M18-0295; Wright JT, 2015, NEW ENGL J MED, V373, P2103, DOI 10.1056/NEJMoa1511939; Wu AZ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3359; Yaffe K, 2020, NEUROLOGY, V95, pE839, DOI 10.1212/WNL.0000000000010078; Yaffe K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7051; Yano Y, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009578; Yano Y, 2017, HYPERTENSION, V70, P1091, DOI 10.1161/HYPERTENSIONAHA.117.10144; Yano Y, 2014, HYPERTENSION, V64, P983, DOI 10.1161/HYPERTENSIONAHA.114.03978; Yassine HN, 2017, LANCET NEUROL, V16, P585, DOI 10.1016/S1474-4422(17)30227-2	102	7	7	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2021	20	10					854	867		10.1016/S1474-4422(21)00248-9	http://dx.doi.org/10.1016/S1474-4422(21)00248-9			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UY8AW	34536406	Green Accepted			2022-12-18	WOS:000701741000020
J	Gusev, EI; Martynov, MY; Nikonov, AA; Shamalov, NA; Semenov, MP; Gerasimets, EA; Yarovaya, EB; Semenov, AM; Archakov, AI; Markin, SS				Gusev, Eugene, I; Martynov, Mikhail Yu; Nikonov, Alexey A.; Shamalov, Nikolay A.; Semenov, Michail P.; Gerasimets, Eugene A.; Yarovaya, Elena B.; Semenov, Andrey M.; Archakov, Alexander, I; Markin, Sergey S.		FRIDA Study Grp	Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial	LANCET NEUROLOGY			English	Article							LARGE VESSEL OCCLUSION; ALTERED IMMUNOREACTIVITY; PLASMINOGEN-ACTIVATOR; STENT RETRIEVER; THROMBOLYSIS; TENECTEPLASE; ASPIRATION; MANAGEMENT; VARIANTS; THERAPY	Background: Non-immunogenic staphylokinase is modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity, and selectivity to fibrin. We aimed to assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with alteplase in patients with acute ischaemic stroke within 4.5 h after symptom onset. Methods: We did a randomised, open-label, multicentre, parallel-group, non-inferiority trial in 18 clinical sites in Russia. We included patients aged 18 years and older with a diagnosis of acute ischaemic stroke (up to 25 points on the National Institutes of Health Stroke Scale). The study drug had to be administered within 4.5 h after the onset of symptoms. Patients were randomly assigned to receive either non-immunogenic staphylokinase (10 mg) or alteplase (0.9 mg/kg, maximum 90 mg), both administered intravenously. The randomisation sequence was created by an independent biostatistician using computer-generated random numbers. 84 blocks (block size of four) of opaque sealed envelopes were numbered sequentially from 1 to 336 and were opened in numerical order. Patients were unaware of their assigned treatment and were assessed by the study investigators who were also unaware of the treatment assignment on all trial days. Emergency department staff, who administered the assigned drug and opened the envelopes, were not masked to treatment. The primary efficacy endpoint was a favourable outcome, defined as a modified Rankin scale (mRS) score of 0-1 on day 90. The margin of non-inferiority was established as 16% for the difference in mRS score of 0-1 on day 90. Non-inferiority was tested using Welch's t-test for the primary outcome only. Endpoints were analysed in the per-protocol population, which comprised all randomly assigned patients who completed treatment without any protocol violations; this population was identical to the intention-to-treat population. This trial is completed and registered at ClinicalTrials.gov, NCT03151993. Findings: Of 385 patients recruited from March 18, 2017, to March 23, 2019, 336 (87%) were included in the trial. 168 (50%) patients were randomly assigned to receive non-immunogenic staphylokinase and 168 (50%) to receive alteplase. The median duration of follow-up was 89 days (IQR 89-89). 84 (50%) of 168 patients in the non-immunogenic staphylokinase group had a favourable outcome at day 90 compared with 68 (40%) of 168 patients in the alteplase group (odds ratio [OR] 1.47, 95% CI 0.93 to 2.32; p=0.10). The difference in the rate of favourable outcome at day 90 was 9.5% (95% CI -1.7 to 20.7) and the lower limit did not cross the margin of non-inferiority (p(non-inferiority) <0.0001). Symptomatic intracranial haemorrhage occurred in five (3%) patients in the non-immunogenic staphylokinase group and in 13 (8%) patients in the alteplase group (p=0.087). On day 90, 17 (10%) patients in the non-immunogenic staphylokinase group and 24 (14%) patients in the alteplase group had died (p=0.32). 22 (13%) patients in the non-immunogenic staphylokinase group had serious adverse events, compared with 37 (22%) patients in the alteplase group (p=0.044). Interpretation Non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Future studies are needed to continue to assess the safety and efficacy of non-immunogenic staphylokinase in patients with acute ischaemic stroke within the 4.5 h time window, and to assess the drug in patients with acute ischaemic stroke outside this time window with reperfusion CT or magnetic resonance angiography followed by thrombectomy if necessary. Copyright (C) Elsevier Ltd. All rights reserved.	[Gusev, Eugene, I; Martynov, Mikhail Yu; Nikonov, Alexey A.] Pirogov Russian Natl Res Med Univ, Dept Neurol, Russian Minist Hlth, Moscow, Russia; [Shamalov, Nikolay A.] Fed Ctr Brain Res & Neurotechnol Fed Med Biol Agc, Fed State Budgetary Inst, Moscow, Russia; [Semenov, Michail P.; Gerasimets, Eugene A.; Semenov, Andrey M.] Peoples Friendship Univ Russia, Med Dept, Moscow, Russia; [Yarovaya, Elena B.] Lomonosov Moscow State Univ, Fac Mech & Math, Moscow, Russia; [Archakov, Alexander, I; Markin, Sergey S.] Inst Biomed Chem, Moscow, Russia; [Semenov, Andrey M.; Markin, Sergey S.] SuperGene, Moscow, Russia	Ministry of Health of the Russian Federation; Pirogov Russian National Research Medical University; Peoples Friendship University of Russia; Lomonosov Moscow State University; Russian Academy of Medical Sciences; Institute of Biomedical Chemistry	Gusev, EI (corresponding author), Pirogov Russian Natl Res Med Univ, Dept Neurol, Russian Minist Hlth, Moscow, Russia.	egusev2339@gmail.com	Kudinov, Vasily/F-9515-2017; Markin, Sergey/ABD-1453-2021; Artyushev, Rafael/ABF-3418-2020; Korobeinikov, Ivan/G-6669-2019; Martynov, Mikhail/K-8390-2018	Kudinov, Vasily/0000-0003-2191-3899; Markin, Sergey/0000-0002-0242-0282; Artyushev, Rafael/0000-0003-0481-2957; Semenov, Andrei/0000-0003-1247-4978; Nikonov, Alexey/0000-0002-7544-5181; Gorbachev, Vladimir/0000-0001-6278-9332; Korobeinikov, Ivan/0000-0003-0361-1512; Martynov, Mikhail/0000-0003-2797-7877	Russian Academy of Sciences	Russian Academy of Sciences(Russian Academy of Sciences)	The Russian Academy of Sciences.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; ARNOLD BC, 1995, AM STAT, V49, P34, DOI 10.2307/2684808; Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Burgos AM, 2019, STROKE, V50, P2156, DOI 10.1161/STROKEAHA.119.025080; Campbell BCV, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0118-8; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Collen D, 1997, CIRCULATION, V95, P463; Collen D, 1996, CIRCULATION, V94, P207, DOI 10.1161/01.CIR.94.2.207; Collen D, 1998, NAT MED, V4, P279, DOI 10.1038/nm0398-279; Committee for Medicinal Products for Human Use European Medicines Agency, 2005, GUID CHOIC NON MARG; Cranston JS, 2017, STROKE, V48, P2946, DOI 10.1161/STROKEAHA.117.017496; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fisher M, 2005, STROKE, V36, P1808, DOI 10.1161/01.STR.0000173403.60553.27; Gusev E I, 2018, Zh Nevrol Psikhiatr Im S S Korsakova, V118, P4, DOI 10.17116/jnevro20181181224; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke Werner, 2008, N Engl J Med, V359, P1317, DOI 10.1056/NEJMoa0804656; Kaul S, 2005, J AM COLL CARDIOL, V46, P1986, DOI 10.1016/j.jacc.2005.07.062; LACK CH, 1948, NATURE, V161, P559, DOI 10.1038/161559b0; Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644; Lin CJ, 2019, STROKE, V50, P3519, DOI 10.1161/STROKEAHA.119.026717; Logallo N, 2017, LANCET NEUROL, V16, P781, DOI 10.1016/S1474-4422(17)30253-3; MAHONEY F I, 1965, Md State Med J, V14, P61; Markin SS, 2012, RUDN J MED, V1, P105; [Марков В.А. Markov V.A.], 2018, [Российский кардиологический журнал, Rossiiskii kardiologicheskii zhurnal], V23, P110, DOI 10.15829/1560-4071-2018-11-110-116; Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158; Turk AS, 2019, LANCET, V393, P998, DOI 10.1016/S0140-6736(19)30297-1; U.S. Food and Drug Administration, 2016, NON CLIN TRIALS EST; Vanderschueren S, 1997, AM HEART J, V134, P213, DOI 10.1016/S0002-8703(97)70127-3; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Vishlov EV, 2017, CARDIOLOGY NEWS OPIN, V2, P57; Wahlgren N, 2008, STROKE, V39, P3316, DOI 10.1161/STROKEAHA.107.510768; Wallin MT, 2019, LANCET NEUROL, V18, P269, DOI 10.1016/S1474-4422(18)30443-5; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213	35	7	7	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2021	20	9					721	728		10.1016/S1474-4422(21)00210-6	http://dx.doi.org/10.1016/S1474-4422(21)00210-6			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UK3MC	34418399				2022-12-18	WOS:000691876000015
J	Rizig, M; Okubadejo, N; Salama, M; Thomas, O; Akpalu, A; Gouider, R				Rizig, Mie; Okubadejo, Njideka; Salama, Mohamed; Thomas, Omotola; Akpalu, Albert; Gouider, Riadh		IPDGC Africa	The International Parkinson Disease Genomics Consortium Africa	LANCET NEUROLOGY			English	Letter									[Rizig, Mie] UCL Queen Sq Inst Neurol, London WC1N 3BG, England; [Okubadejo, Njideka] Univ Lagos, Dept Med, Coll Med, Neurol Unit, Lagos, Nigeria; [Salama, Mohamed] Amer Univ Cairo, Inst Global Hlth & Human Ecol, Cairo, Egypt; [Thomas, Omotola] Parkinsons Africa, London, England; [Akpalu, Albert] Univ Ghana, Dept Med, Sch Med, Accra, Ghana; [Gouider, Riadh] Razi Univ Hosp, Dept Neurol, Clin Invest Ctr Neurosci & Mental Hlth, Tunis, Tunisia; [Gouider, Riadh] Univ Tunis el Manar, Fac Med Tunis, Tunis, Tunisia	University of London; University College London; University of Lagos; Egyptian Knowledge Bank (EKB); American University Cairo; University of Ghana; Universite de Tunis-El-Manar; Hopital Razi; Universite de Tunis-El-Manar; Faculte de Medecine de Tunis (FMT)	Rizig, M (corresponding author), UCL Queen Sq Inst Neurol, London WC1N 3BG, England.	m.rizig@ucl.ac.uk	Rizig, Mie/GNP-2995-2022	Rizig, Mie/0000-0003-2420-4449; Salama, Mohamed/0000-0003-1644-0273	Michael J Fox Program Genetic Diversity in Parkinson's Disease [17483]	Michael J Fox Program Genetic Diversity in Parkinson's Disease	We declare no competing interests.The Consortium is funded by the Michael J Fox Program Genetic Diversity in Parkinson's Disease 2019 (grant number 17483).	CHOUDHURY A, 2020, NATURE; Sherman RM, 2019, NAT GENET, V51, P30, DOI 10.1038/s41588-018-0273-y; Singleton A, 2020, J PARKINSON DIS, V10, P19, DOI 10.3233/JPD-191854; Tan AH, 2021, MOVEMENT DISORD, V36, P842, DOI 10.1002/mds.28494	4	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2021	20	5					335	335		10.1016/S1474-4422(21)00100-9	http://dx.doi.org/10.1016/S1474-4422(21)00100-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WV8FC	33894187	Bronze, Green Accepted			2022-12-18	WOS:000717465200009
J	Benedict, RHB				Benedict, Ralph H. B.			Cognition in multiple sclerosis: Charcot was right	LANCET NEUROLOGY			English	Editorial Material																		Charcot J., 1877, NEW SYDENHAM SOC, V1, P157; Corfield F, 2018, NEUROL THER, V7, P287, DOI 10.1007/s40120-018-0102-3; Landmeyer NC, 2020, NEUROLOGY, V94, pE2373, DOI 10.1212/WNL.0000000000009522; PRATT RTC, 1951, J NEUROL NEUROSUR PS, V14, P326, DOI 10.1136/jnnp.14.4.326	4	7	7	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					810	810		10.1016/S1474-4422(20)30306-9	http://dx.doi.org/10.1016/S1474-4422(20)30306-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3NN	32949540				2022-12-18	WOS:000581119100015
J	Kwakkel, G; Meskers, CGM; Ward, NS				Kwakkel, Gert; Meskers, Carel G. M.; Ward, Nick S.			Time for the next stage of stroke recovery trials	LANCET NEUROLOGY			English	Editorial Material							REHABILITATION		[Kwakkel, Gert; Meskers, Carel G. M.] Vrije Univ Amsterdam, Amsterdam Movement Sci, Amsterdam Neurosci, Dept Rehabil Med,Amsterdam UMC, NL-1081 HV Amsterdam, Netherlands; [Kwakkel, Gert; Meskers, Carel G. M.] Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Ward, Nick S.] UCL, Queen Sq Inst Neurol, Dept Clin & Motor Neurosci, London, England; [Ward, Nick S.] Natl Hosp Neurol & Neurosurg, Dept Neurol, London, England	University of Amsterdam; Vrije Universiteit Amsterdam; Northwestern University; Feinberg School of Medicine; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Kwakkel, G (corresponding author), Vrije Univ Amsterdam, Amsterdam Movement Sci, Amsterdam Neurosci, Dept Rehabil Med,Amsterdam UMC, NL-1081 HV Amsterdam, Netherlands.; Kwakkel, G (corresponding author), Northwestern Univ, Dept Phys Therapy & Human Movement Sci, Feinberg Sch Med, Chicago, IL 60611 USA.	g.kwakkel@amsterdamumc.nl		Ward, Nick/0000-0002-7688-9649				Bernhardt J, 2017, NEUROREHAB NEURAL RE, V31, P694, DOI 10.1177/1545968317724290; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Dennis M, 2019, LANCET, V393, P265, DOI 10.1016/S0140-6736(18)32823-X; Hankey GJ, 2020, LANCET NEUROL, V19, P651, DOI 10.1016/S1474-4422(20)30207-6; Kwakkel G, 2017, NEUROREHAB NEURAL RE, V31, P784, DOI 10.1177/1545968317732662; Lundstrom E, 2020, LANCET NEUROL, V19, P661, DOI 10.1016/S1474-4422(20)30219-2; Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516; Mead GE, 2020, INT J STROKE, V15, P365, DOI 10.1177/1747493019879655; van der Vliet R, 2020, ANN NEUROL, V87, P383, DOI 10.1002/ana.25679; Ward NS, 2017, NAT REV NEUROL, V13, P244, DOI 10.1038/nrneurol.2017.34	10	7	7	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2020	19	8					636	637		10.1016/S1474-4422(20)30218-0	http://dx.doi.org/10.1016/S1474-4422(20)30218-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT8ZY	32702322	Green Submitted			2022-12-18	WOS:000573228000004
J	Cramer, SC				Cramer, Steven C.			Issues important to the design of stroke recovery trials	LANCET NEUROLOGY			English	Editorial Material							ANTAGONIST S44819; BRAIN		[Cramer, Steven C.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA; [Cramer, Steven C.] Calif Rehabil Inst, Los Angeles, CA 90067 USA	University of California System; University of California Los Angeles	Cramer, SC (corresponding author), Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA.; Cramer, SC (corresponding author), Calif Rehabil Inst, Los Angeles, CA 90067 USA.	sccramer@mednet.ucla.edu						Boyd LA, 2017, NEUROREHAB NEURAL RE, V31, P864, DOI 10.1177/1545968317732680; Chabriat H, 2020, LANCET NEUROL, V19, P226, DOI 10.1016/S1474-4422(20)30004-1; Cramer SC, 2006, STROKE, V37, P111, DOI 10.1161/01.STR.0000195135.70379.1f; Darmani G, 2016, J NEUROSCI, V36, P12312, DOI 10.1523/JNEUROSCI.1689-16.2016; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; GROTTA J, 1995, J INTERN MED, V237, P89, DOI 10.1111/j.1365-2796.1995.tb01145.x; Lin DJ, 2018, STROKE, V49, P3107, DOI 10.1161/STROKEAHA.118.021359; Nouri S, 2011, NEUROLOGY, V77, P1076, DOI 10.1212/WNL.0b013e31822e1482; Pace M, 2019, BIORXIV, DOI [10.1101/721282 (preprint), DOI 10.1101/721282]; Wang YC, 2018, STROKE, V49, P2495, DOI 10.1161/STROKEAHA.118.021378	10	7	7	2	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					197	+		10.1016/S1474-4422(20)30030-2	http://dx.doi.org/10.1016/S1474-4422(20)30030-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	32085829				2022-12-18	WOS:000514832700005
J	Winkler, AS				Winkler, Andrea S.			The growing burden of neurological disorders in low-income and middle-income countries: priorities for policy making	LANCET NEUROLOGY			English	Editorial Material									[Winkler, Andrea S.] Tech Univ Munich, Ctr Global Hlth, D-81675 Munich, Germany; [Winkler, Andrea S.] Tech Univ Munich, Dept Neurol, Munich Global Neurol Grp, D-81675 Munich, Germany; [Winkler, Andrea S.] Univ Oslo, Inst Hlth & Soc, Ctr Global Hlth, Oslo, Norway	Technical University of Munich; Technical University of Munich; University of Oslo	Winkler, AS (corresponding author), Tech Univ Munich, Ctr Global Hlth, D-81675 Munich, Germany.; Winkler, AS (corresponding author), Tech Univ Munich, Dept Neurol, Munich Global Neurol Grp, D-81675 Munich, Germany.; Winkler, AS (corresponding author), Univ Oslo, Inst Hlth & Soc, Ctr Global Hlth, Oslo, Norway.	andrea.winkler@tum.de						Feigin VL, 2020, LANCET NEUROL, V19, P255, DOI 10.1016/S1474-4422(19)30411-9; Knauss S, 2019, LANCET NEUROL, V18, P1078, DOI 10.1016/S1474-4422(19)30392-8; Lee KK, 2018, J STROKE, V20, P2, DOI 10.5853/jos.2017.02894; Norwegian Ministry of Foreign Affairs Norwegian Ministry of Health and Care Services, 2019, PNP CHIEF WANTS BETT; Stanaway JD, 2018, LANCET, V392, P1923, DOI [10.1016/S0140-6736(18)32225-6, 10.1016/s0140-6736(18)32225-6]; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; The World Bank Group, 2017, LIF EXP BIRTH TOT YE	7	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2020	19	3					200	202		10.1016/S1474-4422(19)30476-4	http://dx.doi.org/10.1016/S1474-4422(19)30476-4			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KN4TZ	31813849				2022-12-18	WOS:000514832700007
J	Peters, R; Anderson, CS				Peters, Ruth; Anderson, Craig S.			Advancing dementia prevention through effective blood pressure control	LANCET NEUROLOGY			English	Editorial Material							RISK		[Peters, Ruth] Univ New South Wales, NeuRA, Sydney, NSW, Australia; [Peters, Ruth] Imperial Coll London, London, England; [Anderson, Craig S.] Univ New South Wales, Fac Med, George Inst Global Hlth, Sydney, NSW 2050, Australia; [Anderson, Craig S.] Peking Univ, Hlth Sci Ctr, George Inst Global Hlth China, Beijing, Peoples R China	Neuroscience Research Australia; University of New South Wales Sydney; Imperial College London; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; Peking University	Anderson, CS (corresponding author), Univ New South Wales, Fac Med, George Inst Global Hlth, Sydney, NSW 2050, Australia.; Anderson, CS (corresponding author), Peking Univ, Hlth Sci Ctr, George Inst Global Hlth China, Beijing, Peoples R China.	canderson@georgeinstitute.org.au	Peters, Ruth/D-4047-2011	Peters, Ruth/0000-0003-0148-3617				Chow CK, 2013, JAMA-J AM MED ASSOC, V310, P959, DOI 10.1001/jama.2013.184182; Ding J, 2020, LANCET NEUROL, V19, P61, DOI 10.1016/S1474-4422(19)30393-X; Gelber RP, 2013, NEUROLOGY, V81, P888, DOI 10.1212/WNL.0b013e3182a351d4; Marpillat NL, 2013, J HYPERTENS, V31, P1073, DOI 10.1097/HJH.0b013e3283603f53; Peters R, NEUROLOGY; Peters R, 2019, NEUROLOGY, V92, P1017, DOI 10.1212/WNL.0000000000007543; Peters R, 2014, J HYPERTENS, V32, P1945, DOI 10.1097/HJH.0000000000000273; Salam A, 2019, J HYPERTENS, V37, P1567, DOI 10.1097/HJH.0000000000002089; Tully PJ, 2016, J HYPERTENS, V34, P1027, DOI 10.1097/HJH.0000000000000868; World Health Organization, RISK RED COGN DECL D	10	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					25	27		10.1016/S1474-4422(19)30407-7	http://dx.doi.org/10.1016/S1474-4422(19)30407-7			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM	31706888				2022-12-18	WOS:000502286000018
J	Sisodiya, SM				Sisodiya, Sanjay M.			Epilepsy genetics and the precision medicine matrix	LANCET NEUROLOGY			English	Editorial Material									[Sisodiya, Sanjay M.] UCL Queen Sq Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England; [Sisodiya, Sanjay M.] Chalfont Ctr Epilepsy, Gerrards Cross SL9 0RJ, Bucks, England	University of London; University College London	Sisodiya, SM (corresponding author), UCL Queen Sq Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England.; Sisodiya, SM (corresponding author), Chalfont Ctr Epilepsy, Gerrards Cross SL9 0RJ, Bucks, England.	s.sisodiya@ucl.ac.uk						Balestrini S, 2018, NEUROSCI LETT, V667, P27, DOI 10.1016/j.neulet.2017.01.014; Bombard Y, 2019, AM J HUM GENET, V104, P578, DOI 10.1016/j.ajhg.2019.02.025; Ellis CA, 2020, LANCET NEUROL, V19, P93, DOI 10.1016/S1474-4422(19)30269-8; Koch H, 2019, EPILEPSY BEHAV, V91, P90, DOI 10.1016/j.yebeh.2018.06.010; Moller RS, 2019, EXPERT REV MOL DIAGN, V19, P217, DOI 10.1080/14737159.2019.1573144; Phillips M, 2017, GENET MED, V19, P834, DOI [10.1038/gim.2016.199, 10.1038/gim.2017.21]; Savatt JM, 2018, HUM MUTAT, V39, P1668, DOI 10.1002/humu.23633; Wynn J, 2018, CLIN GENET, V93, P1039, DOI 10.1111/cge.13200	8	7	7	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					29	30		10.1016/S1474-4422(19)30331-X	http://dx.doi.org/10.1016/S1474-4422(19)30331-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM	31494010				2022-12-18	WOS:000502286000020
J	Williams, J; McGlasson, S; Irani, S; Duffy, D; Crow, Y; Hunt, D				Williams, Jac; McGlasson, Sarah; Irani, Sarosh; Duffy, Darragh; Crow, Yanick; Hunt, David		Scottish NMOSD Study Grp	Neuromyelitis optica in patients with increased interferon alpha concentrations	LANCET NEUROLOGY			English	Letter							BETA TREATMENT		[Williams, Jac; Hunt, David] Univ Edinburgh, Anne Rowling Clin, Edinburgh EH16 4SB, Midlothian, Scotland; [McGlasson, Sarah; Crow, Yanick; Hunt, David] Univ Edinburgh, Inst Genet & Mol Med, MRC, Edinburgh EH16 4SB, Midlothian, Scotland; [Hunt, David] Univ Edinburgh, UK Dementia Res Inst, Edinburgh EH16 4SB, Midlothian, Scotland; [Irani, Sarosh] Univ Oxford, Oxford Autoimmune Neurol Grp, Oxford, England; [Duffy, Darragh] Inst Pasteur, Lab Dendrit Cell Immunobiol, Paris, France	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Oxford; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Hunt, D (corresponding author), Univ Edinburgh, Anne Rowling Clin, Edinburgh EH16 4SB, Midlothian, Scotland.; Hunt, D (corresponding author), Univ Edinburgh, Inst Genet & Mol Med, MRC, Edinburgh EH16 4SB, Midlothian, Scotland.; Hunt, D (corresponding author), Univ Edinburgh, UK Dementia Res Inst, Edinburgh EH16 4SB, Midlothian, Scotland.	david.hunt@igmm.ed.ac.uk	Irani, Sarosh/AAO-6911-2020; rodero, mathieu/C-8083-2011	Irani, Sarosh/0000-0002-7667-9748; rodero, mathieu/0000-0002-1300-0187; Wilson, Robert/0000-0001-7813-3557	Wellcome Trust [104079/Z/14/Z, 215621/Z/19/Z]; Medical Research Foundation; European Research Council [786142-E-T1IFNs]; Connect Immune research (Multiple Sclerosis Society); Connect Immune research (Juvenile Diabetes Research Foundation); Connect Immune research (Versus Arthritis); UK Medical Research Council; British Medical Association; Epilepsy Research UK [P1201]; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre	Wellcome Trust(Wellcome Trust); Medical Research Foundation(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Research Council(European Research Council (ERC)European Commission); Connect Immune research (Multiple Sclerosis Society); Connect Immune research (Juvenile Diabetes Research Foundation); Connect Immune research (Versus Arthritis); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Medical Association; Epilepsy Research UK; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre(National Institute for Health Research (NIHR))	DH is supported by the Wellcome Trust (215621/Z/19/Z) and the Medical Research Foundation. YC is supported by an European Research Council advanced grant (786142-E-T1IFNs). YC and DH are supported by Connect Immune research (Multiple Sclerosis Society, Juvenile Diabetes Research Foundation, Versus Arthritis). AJ is supported by the UK Medical Research Council. SRI is supported by the Wellcome Trust (104079/Z/14/Z), the British Medical Association's Vera Down (2013) and Margaret Temple (2017) grants, and Epilepsy Research UK (P1201). The research was funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the UK National Health Service (NHS), the NIHR, or the UK Department of Health. We thank the Uppsala Monitoring Centre (Uppsala, Sweden) and the UK Medicines and Healthcare products Regulatory Agency for providing spontaneous reporting data. We thank our patients for willingness and consent to report these cases. Patients 1, 3, and 4 were enrolled in clinical studies approved by: Leeds (East) Research Ethics Committee (10/H1307/132; patient 3) and South-East Scotland Research Ethics Committee 01 (14/SS/0003; patients 1 and 4).The Scottish Neuromyelitis Optica Spectrum Disorder Clinic is part of the NHS NMO UK specialised service.	Asgari N, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/713519; Ciccarelli O, 2019, LANCET NEUROL, V18, P185, DOI 10.1016/S1474-4422(18)30460-5; Domeier PP, 2018, CELL REP, V24, P406, DOI 10.1016/j.celrep.2018.06.046; Feng X, 2012, J NEUROL SCI, V313, P48, DOI 10.1016/j.jns.2011.09.032; Flanagan EP, 2015, JAMA NEUROL, V72, P81, DOI 10.1001/jamaneurol.2014.2137; Hacohen Y, 2015, NEUROLOGY, V85, P381, DOI 10.1212/WNL.0000000000001792; Kim SH, 2012, MULT SCLER J, V18, P1480, DOI 10.1177/1352458512439439; Leussink VI, 2018, NEUROL-NEUROIMMUNOL, V5, DOI [10.1212/NXI.0000000000000504, 10.1212/NXI.0000000000000454]; Palace J, 2010, ARCH NEUROL-CHICAGO, V67, P1016, DOI 10.1001/archneurol.2010.188; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Rodero MP, 2017, J EXP MED, V214, P1547, DOI 10.1084/jem.20161451; Wilson R, 2018, BRAIN, V141, DOI 10.1093/brain/awy010; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729	13	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2020	19	1					31	33		10.1016/S1474-4422(19)30445-4	http://dx.doi.org/10.1016/S1474-4422(19)30445-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JV3SM	31839246	Green Submitted, Bronze			2022-12-18	WOS:000502286000022
J	Andersen, CR; Presseau, J; Saigle, V; Etminan, N; Vergouwen, MDI; English, SW				Andersen, Christopher R.; Presseau, Justin; Saigle, Victoria; Etminan, Nima; Vergouwen, Mervyn D. I.; English, Shane W.		Outcomes Subarachnoid	Core outcomes for subarachnoid haemorrhage	LANCET NEUROLOGY			English	Letter									[Andersen, Christopher R.] Univ Oxford, Nuffield Dept Clin Neurosci, Kadoorie Ctr Crit Care Res, Oxford OX3 9DU, England; [Andersen, Christopher R.] George Inst Global Hlth, Newtown, NSW, Australia; [Presseau, Justin; Saigle, Victoria; English, Shane W.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Presseau, Justin; English, Shane W.] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada; [Etminan, Nima] Heidelberg Univ, Mannheim Univ Hosp, Med Fac Mannheim, Dept Neurosurg, Mannheim, Germany; [Vergouwen, Mervyn D. I.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Neurol & Neurosurg, Utrecht, Netherlands	University of Oxford; George Institute for Global Health; University of Sydney; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ruprecht Karls University Heidelberg; Utrecht University; Utrecht University Medical Center	Andersen, CR (corresponding author), Univ Oxford, Nuffield Dept Clin Neurosci, Kadoorie Ctr Crit Care Res, Oxford OX3 9DU, England.; Andersen, CR (corresponding author), George Inst Global Hlth, Newtown, NSW, Australia.	christopher.andersen@ndcn.ox.ac.uk	Saigle, Victoria/AAT-2846-2020; English, Shane/P-9187-2019	Saigle, Victoria/0000-0002-6797-6732; English, Shane/0000-0002-9477-6146; Andersen, Christopher/0000-0002-9321-8660				Andersen CR, 2019, NEUROCRIT CARE, V30, P534, DOI 10.1007/s12028-018-0566-0; Macdonald RL, 2017, LANCET, V389, P655, DOI 10.1016/S0140-6736(16)30668-7; Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7; Saigle V, 2019, NEUROLOGY, V92, P281, DOI 10.1212/WNL.0000000000006883; Stienen MN, 2019, NEUROCRIT CARE, V30, P102, DOI 10.1007/s12028-019-00737-0; Suarez JI, 2019, NEUROCRIT CARE, V30, P4, DOI 10.1007/s12028-019-00723-6; Williamson PR, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1978-4; Yang M, 2011, CEPHALALGIA, V31, P357, DOI 10.1177/0333102410379890	8	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1075	+		10.1016/S1474-4422(19)30412-0	http://dx.doi.org/10.1016/S1474-4422(19)30412-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	31701889				2022-12-18	WOS:000495892200009
J	Frisoni, GB; Ritchie, C; Carrera, E; Nilsson, P; Ousset, PJ; Molinuevo, JL; Dubois, B; Scheltens, P; Minoshima, S				Frisoni, Giovanni B.; Ritchie, Craig; Carrera, Emmanuel; Nilsson, Peter; Ousset, Pierre-Jean; Molinuevo, Jose Luis; Dubois, Bruno; Scheltens, Philip; Minoshima, Satoshi			Re-aligning scientific and lay narratives of Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material													Frisoni, Giovanni B./K-1360-2016; Scheltens, Philip/AAL-9631-2020; Molinuevo, Jose Luis/HCH-3881-2022	Frisoni, Giovanni B./0000-0002-6419-1753; Scheltens, Philip/0000-0002-1046-6408; Carrera, Emmanuel/0000-0003-0045-5382; Minoshima, Satoshi/0000-0002-0043-3047	The Dunhill Medical Trust [R380R/1114] Funding Source: Medline	The Dunhill Medical Trust(Dunhill Medical Trust)			0	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2019	18	10					918	919		10.1016/S1474-4422(19)30323-0	http://dx.doi.org/10.1016/S1474-4422(19)30323-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IX6HN	31526751				2022-12-18	WOS:000485784000014
J	Casper, ST; Golden, J; Oreskes, N				Casper, S. T.; Golden, J.; Oreskes, N.			First report the findings: genuine balance when reporting CTE (vol 18, pg 522, 2019)	LANCET NEUROLOGY			English	Correction													Callard, Felicity/AEP-9676-2022; Virdi, Jaipreet/AAP-3359-2020; ORTEGA, FRANCISCO/E-9867-2016	Callard, Felicity/0000-0002-5350-1963; ORTEGA, FRANCISCO/0000-0002-5039-9449; Casper, Stephen/0000-0003-2915-8592				Casper ST, 2019, LANCET NEUROL, V18, pE7, DOI 10.1016/S1474-4422(19)30158-9	1	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2019	18	8					E7	E7		10.1016/S1474-4422(19)30158-9	http://dx.doi.org/10.1016/S1474-4422(19)30158-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IH7ZF	31122491	Bronze			2022-12-18	WOS:000474722800002
J	Casper, ST; Golden, J; Oreskes, N; Largent, M; Goldberg, DS; Gillett, G; Philpott-Jones, S; Moreira, T; Virdi, J; Meyers, T; Morrison, D; Rodriguez, JE; Gabriel, JM; Steere-Williams, J; Ross, R; Smith, JM; Ballenger, JF; Bil, G; Kawaguchi, Y; Dyck, E; Callard, F; Ortega, F; Kleinman, S; Brown, M				Casper, Stephen T.; Golden, Janet; Oreskes, Naomi; Largent, Mark; Goldberg, Daniel S.; Gillett, Grant; Philpott-Jones, Sean; Moreira, Tiago; Virdi, Jaipreet; Meyers, Todd; Morrison, Daniel; Rodriguez, Julia E.; Gabriel, Joseph M.; Steere-Williams, Jacob; Ross, Ryan; Smith, Jay M.; Ballenger, Jesse F.; Bil, Geoff; Kawaguchi, Yumiko; Dyck, Erika; Callard, Felicity; Ortega, Francisco; Kleinman, Sherryl; Brown, Michael			First report the findings: genuine balance when reporting CTE	LANCET NEUROLOGY			English	Letter									[Casper, Stephen T.] Clarkson Univ, Clarkson Honors Program, Potsdam, NY 13699 USA; [Philpott-Jones, Sean] Clarkson Univ, Chair Bioeth Program, Potsdam, NY 13699 USA; [Golden, Janet] Rutgers Univ Camden, Dept Hist, Camden, NJ USA; [Oreskes, Naomi] Harvard Univ, Dept Hist Sci, Cambridge, MA 02138 USA; [Largent, Mark] Michigan State Univ, James Madison Coll, E Lansing, MI 48824 USA; [Goldberg, Daniel S.] Univ Colorado, Ctr Bioeth & Humanities, Anschutz Med Campus, Aurora, CO USA; [Gillett, Grant] Univ Otago, Div Hlth Sci, Dunedin, New Zealand; [Moreira, Tiago] Univ Durham, Dept Sociol, Durham, England; [Virdi, Jaipreet] Univ Delaware, Dept Hist, Newark, DE USA; [Meyers, Todd] NYU Shanghai, Ctr Soc Hlth & Med, Shanghai, Peoples R China; [Morrison, Daniel] Abilene Christian Univ, Dept Commun & Sociol, Abilene, TX 79699 USA; [Rodriguez, Julia E.] Univ New Hampshire, Dept Hist, Durham, NH 03824 USA; [Gabriel, Joseph M.] Florida State Univ, Behav Sci & Social Med Dept, Tallahassee, FL 32306 USA; [Steere-Williams, Jacob] Coll Charleston, Dept Hist, Charleston, SC 29401 USA; [Smith, Jay M.] Univ N Carolina, Dept Hist, Chapel Hill, NC USA; [Kleinman, Sherryl] Univ N Carolina, Dept Sociol, Chapel Hill, NC USA; [Ballenger, Jesse F.] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19104 USA; [Bil, Geoff] New York Bot Garden, Luesther T Mertz Lib, New York, NY USA; [Kawaguchi, Yumiko] Ritsumeikan Univ, Grad Sch Core Eth & Frontier, Sci, Kyoto, Japan; [Dyck, Erika] Univ Saskatchewan, Canada Res Chair Hist Med, Saskatoon, SK, Canada; [Callard, Felicity] Birkbeck Univ London, Dept Psychosocial Studies, London, England; [Ortega, Francisco] Univ Estado Rio De Janeiro, Inst Social Med, Rio De Janeiro, Brazil; [Brown, Michael] Univ Roehampton, Dept Humanities, London, England	Clarkson University; Clarkson University; Rutgers State University Camden; Harvard University; Michigan State University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Otago; Durham University; University of Delaware; NYU Shanghai; Abilene Christian University; University System Of New Hampshire; University of New Hampshire; State University System of Florida; Florida State University; College of Charleston; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Drexel University; New York Botanical Garden; Ritsumeikan University; University of Saskatchewan; University of London; Birkbeck University London; Universidade do Estado do Rio de Janeiro; Roehampton University	Casper, ST (corresponding author), Clarkson Univ, Clarkson Honors Program, Potsdam, NY 13699 USA.	scasper@clarkson.edu	Callard, Felicity/AEP-9676-2022; Virdi, Jaipreet/AAP-3359-2020; ORTEGA, FRANCISCO/E-9867-2016	Callard, Felicity/0000-0002-5350-1963; ORTEGA, FRANCISCO/0000-0002-5039-9449; Casper, Stephen/0000-0003-2915-8592				Binney ZO, 2019, NEUROLOGY, V92, P43, DOI 10.1212/WNL.0000000000006699; Brysse K, 2013, GLOBAL ENVIRON CHANG, V23, P327, DOI 10.1016/j.gloenvcha.2012.10.008; Fainaru-Wada M., 2014, LEAGUE DENIAL NFL CO; Gillett G, 2018, CAMB Q HEALTHC ETHIC; Stewart W, 2019, LANCET NEUROL, V18, P231, DOI 10.1016/S1474-4422(19)30020-1	5	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2019	18	6					522	523		10.1016/S1474-4422(19)30158-9	http://dx.doi.org/10.1016/S1474-4422(19)30158-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HY7RQ	31122491	Bronze			2022-12-18	WOS:000468334100009
J	[Anonymous]				[Anonymous]			Complicated decisions on new migraine-prevention therapies	LANCET NEUROLOGY			English	Editorial Material																			0	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2019	18	3					221	221		10.1016/S1474-4422(19)30041-9	http://dx.doi.org/10.1016/S1474-4422(19)30041-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HL2BV	30784544				2022-12-18	WOS:000458509100005
J	Wardlaw, JM; Bath, PM				Wardlaw, Joanna M.; Bath, Philip M.			Stroke research in 2018: extended time windows, refined benefit, and lifestyle prevention targets	LANCET NEUROLOGY			English	Editorial Material							THROMBECTOMY; METAANALYSIS		[Wardlaw, Joanna M.] Univ Edinburgh, UK Dementia Res Inst, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland; [Wardlaw, Joanna M.] Univ Edinburgh, Edinburgh Imaging, Edinburgh EH16 4SB, Midlothian, Scotland; [Bath, Philip M.] Univ Nottingham, City Hosp, Div Clin Neurosci, Stroke Trials Unit, Nottingham, England	University of Edinburgh; University of Edinburgh; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Wardlaw, JM (corresponding author), Univ Edinburgh, UK Dementia Res Inst, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland.; Wardlaw, JM (corresponding author), Univ Edinburgh, Edinburgh Imaging, Edinburgh EH16 4SB, Midlothian, Scotland.	joanna.wardlaw@ed.ac.uk	Wardlaw, Joanna M/Y-3456-2019; Hernandez, María/GYU-3543-2022; Bath, Philip/F-9020-2011	Wardlaw, Joanna M/0000-0002-9812-6642; Bath, Philip/0000-0003-2734-5132	British Heart Foundation; NIHR Health Technology Appraisal programme; UK Medical Research Council; Stroke Association; Fondation Leducq; EU Horizon 2020 programme; Alzheimer's Society; Row Fogo Charitable Trust; Alzheimer's Research UK; Scottish Executive Chief Scientist Office; Wellcome Trust; Dunhill Medical Research Trust; MRC [MC_G1002455, G0501797] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); NIHR Health Technology Appraisal programme; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Stroke Association; Fondation Leducq(Leducq Foundation); EU Horizon 2020 programme; Alzheimer's Society; Row Fogo Charitable Trust; Alzheimer's Research UK(Alzheimer's Research UK (ARUK)); Scottish Executive Chief Scientist Office; Wellcome Trust(Wellcome Trust); Dunhill Medical Research Trust(Dunhill Medical Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	PMB was chief investigator of the TARDIS trial and chaired the PHAST-TRAC trial; has received personal fees from Platelet Solutions Ltd, Diamedica, Nestle, Phagenesis Ltd, ReNeuron Ltd, and Moleac; and grants from the British Heart Foundation and NIHR Health Technology Appraisal programme. JMW reports grants from the UK Medical Research Council, The Stroke Association, The British Heart Foundation, The Fondation Leducq, The EU Horizon 2020 programme, The Alzheimer's Society, The Row Fogo Charitable Trust, Alzheimer's Research UK, Scottish Executive Chief Scientist Office, Wellcome Trust, and Dunhill Medical Research Trust.	Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973; Bath PM, 2018, LANCET, V391, P850, DOI 10.1016/S0140-6736(17)32849-0; Campbell BCV, 2018, LANCET NEUROL, V17, P47, DOI 10.1016/S1474-4422(17)30407-6; Dziewas R, 2018, LANCET NEUROL, V17, P849, DOI 10.1016/S1474-4422(18)30255-2; Gupta A, 2018, LANCET, V392, P1127, DOI 10.1016/S0140-6736(18)31776-8; Hacke W, 2018, INT J STROKE, V13, P175, DOI 10.1177/1747493017744464; Johnston SC, 2018, NEW ENGL J MED, V379, P215, DOI 10.1056/NEJMoa1800410; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; Pandian JD, 2018, LANCET, V392, P1269, DOI 10.1016/S0140-6736(18)31269-8; Rutten-Jacobs LC, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4168; Thomalla G, 2018, NEW ENGL J MED, V379, P611, DOI 10.1056/NEJMoa1804355	11	7	7	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2019	18	1					2	3		10.1016/S1474-4422(18)30457-5	http://dx.doi.org/10.1016/S1474-4422(18)30457-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HE1CJ	30563678	Green Submitted			2022-12-18	WOS:000453007700004
J	Rato, ML; Duarte, GS; Mestre, T; de Carvalho, M; Ferreira, JJ				Rato, Miguel Leal; Duarte, Goncalo S.; Mestre, Tiago; de Carvalho, Mamede; Ferreira, Joaquim J.			Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions	LANCET NEUROLOGY			English	Letter							PLACEBO		[Rato, Miguel Leal] Hosp Prof Doutor Fernando Fonseca, Amadora, Portugal; [Duarte, Goncalo S.; Ferreira, Joaquim J.] Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, P-1649028 Lisbon, Portugal; [Mestre, Tiago] Univ Ottawa, Ottawa Hosp Res Inst, Parkinsons Dis & Movement Disorders Ctr, Brain & Mind Inst,Dept Med,Div Neurol, Ottawa, ON, Canada; [Duarte, Goncalo S.; Ferreira, Joaquim J.] Univ Lisbon, Fac Med, Inst Med Mol, Clin Pharmacol Lab, Lisbon, Portugal; [de Carvalho, Mamede] Univ Lisbon, Fac Med, Inst Med Mol, Inst Physiol, Lisbon, Portugal; [de Carvalho, Mamede] Hosp Santa Maria, Dept Neurosci & Mental Hlth, Neurol, Lisbon, Portugal; [Ferreira, Joaquim J.] Campus Neurol Senior, Torres Vedras, Portugal	Hospital Professor Doutor Fernando Fonseca, EPE; Universidade de Lisboa; University of Ottawa; Ottawa Hospital Research Institute; Universidade de Lisboa; Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria	Ferreira, JJ (corresponding author), Univ Lisbon, Fac Med, Lab Clin Pharmacol & Therapeut, P-1649028 Lisbon, Portugal.; Ferreira, JJ (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol, Clin Pharmacol Lab, Lisbon, Portugal.; Ferreira, JJ (corresponding author), Campus Neurol Senior, Torres Vedras, Portugal.	jferreira@medicina.ulisboa.pt	de Carvalho, Mamede/I-6295-2019; Ferreira, Joaquim/AAA-1837-2020; Duarte, Goncalo/L-4920-2015	de Carvalho, Mamede/0000-0001-7556-0158; Leal Rato, Miguel/0000-0003-2233-0468; Duarte, Goncalo/0000-0001-7802-1897	Novartis; TEVA; Lundbeck; Solvay; Abbott; BIAL; Merck-Serono; Grunenthal; Merck Sharp Dohme; Biogen; Sunovion Pharmaceuticals; Medtronic	Novartis(Novartis); TEVA(Teva Pharmaceutical Industries); Lundbeck(Lundbeck Corporation); Solvay(Solvay SA); Abbott(Abbott Laboratories); BIAL(Bial Group); Merck-Serono(Merck & Company); Grunenthal(HAL Allergy Group); Merck Sharp Dohme(Merck & Company); Biogen(Biogen); Sunovion Pharmaceuticals; Medtronic(Medtronic)	JJF has received speaker and consultant fees from Novartis, TEVA, Lundbeck, Solvay, Abbott, BIAL, Merck-Serono, Grunenthal, Merck Sharp & Dohme, Biogen, Sunovion Pharmaceuticals, and Medtronic. All other authors declare no competing interests.	Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1; European Medicines Agency, 2018, EMEAHC000574N0078; Ludolph AC, 2018, LANCET NEUROL, V17, P681, DOI 10.1016/S1474-4422(18)30176-5; Miller RG, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub3; Silva MA, 2017, NEUROLOGY, V88, P2216, DOI 10.1212/WNL.0000000000004004	5	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2018	17	10					842	842		10.1016/S1474-4422(18)30310-7	http://dx.doi.org/10.1016/S1474-4422(18)30310-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GT9LD	30264722	Bronze			2022-12-18	WOS:000444862200009
J	Rommer, PS; Zettl, UK				Rommer, Paulus S.; Zettl, Uwe K.			Applying the 2017 McDonald diagnostic criteria for multiple sclerosis	LANCET NEUROLOGY			English	Letter									[Rommer, Paulus S.] Med Univ Vienna, Dept Neurol, A-1090 Vienna, Austria; [Zettl, Uwe K.] Univ Rostock, Neuroimmunol Sect, Dept Neurol, Rostock, Germany	Medical University of Vienna; University of Rostock	Rommer, PS (corresponding author), Med Univ Vienna, Dept Neurol, A-1090 Vienna, Austria.	paulus.rommer@meduniwien.ac.at			Biogen; Merck; Shire; Teva; Roche; Almirall; Bayer; Genzyme; Novartis	Biogen(Biogen); Merck(Merck & Company); Shire; Teva(Teva Pharmaceutical Industries); Roche(Roche Holding); Almirall(Almirall); Bayer(Bayer AG); Genzyme(Sanofi-AventisGenzyme Corporation); Novartis(Novartis)	PSR reports grants and personal fees from Biogen; personal fees and non-financial support from Genzyme; grants, personal fees, non-financial support, and other support from Merck; personal fees from Shire and Teva; and grants, personal fees and other from Roche. UKZ reports personal fees from Almirall, Bayer, Biogen; Merck, Roche, and Teva; and grants and personal fees from Genzyme and Novartis.	Brownlee WJ, 2015, J NEUROL NEUROSUR PS, V86, P584, DOI 10.1136/jnnp-2014-308675; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483; Solomon AJ, 2016, NEUROLOGY, V87, P1393, DOI 10.1212/WNL.0000000000003152; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2	5	7	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2018	17	6					497	498		10.1016/S1474-4422(18)30161-3	http://dx.doi.org/10.1016/S1474-4422(18)30161-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GG1RD	29778357	Bronze			2022-12-18	WOS:000432463400016
J	Van Paesschen, W				Van Paesschen, Wim			The future of seizure detection	LANCET NEUROLOGY			English	Editorial Material							EEG; EPILEPSY		[Van Paesschen, Wim] UZ Leuven, Dept Neurol, B-3000 Leuven, Belgium; [Van Paesschen, Wim] Katholieke Univ Leuven, Lab Epilepsy Res, Leuven, Belgium	KU Leuven; University Hospital Leuven; KU Leuven	Van Paesschen, W (corresponding author), UZ Leuven, Dept Neurol, B-3000 Leuven, Belgium.; Van Paesschen, W (corresponding author), Katholieke Univ Leuven, Lab Epilepsy Res, Leuven, Belgium.	wim.vanpaesschen@uzleuven.be	Van Paesschen, Wim/A-4540-2010	Van Paesschen, Wim/0000-0002-8535-1699	Imec; UCB Pharma; Eisai; Novartis; LivaNova; Medtronic	Imec; UCB Pharma(UCB Pharma SA); Eisai(Eisai Co Ltd); Novartis(Novartis); LivaNova; Medtronic(Medtronic)	I report grants from Imec as part of the Seize IT project, which aims to develop a smartphone-based device to detect epileptic seizures and comprises a collaboration of several partners (including Byteflies, UCB Pharma, and PiliPili); and personal fees from UCB Pharma, Eisai, and Novartis, and other fees from UCB Pharma, Novartis, LivaNova, and Medtronic.	Elger CE, 2018, LANCET NEUROL; Gu Y, 2017, SENSORS BASEL, V18; Lam AD, 2017, NAT MED, V23, P678, DOI 10.1038/nm.4330; Lucey BP, 2016, J SLEEP RES, V25, P625, DOI 10.1111/jsr.12417; McKenzie ED, 2017, SCI REP-UK, V7, DOI 10.1038/srep45567; Van de Vel A, 2013, SEIZURE-EUR J EPILEP, V22, P345, DOI 10.1016/j.seizure.2013.02.012; Vandecasteele K, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17102338; Zibrandtsen IC, 2017, CLIN NEUROPHYSIOL, V128, P2454, DOI 10.1016/j.clinph.2017.09.115	8	7	7	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2018	17	3					200	+		10.1016/S1474-4422(18)30034-6	http://dx.doi.org/10.1016/S1474-4422(18)30034-6			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FW1WE	29452676				2022-12-18	WOS:000425090000006
J	Maegele, M				Maegele, Marc			Traumatic brain injury in 2017: exploring the secrets of concussion	LANCET NEUROLOGY			English	Editorial Material									[Maegele, Marc] Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany; [Maegele, Marc] Univ Witten Herdecke, Inst Res Operat Med, Witten, Germany	Witten Herdecke University	Maegele, M (corresponding author), Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany.; Maegele, M (corresponding author), Univ Witten Herdecke, Inst Res Operat Med, Witten, Germany.	marc.maegele@t-online.de						Churchill NW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07742-3; Giza CC, 2017, NEURON, V94, P1051, DOI 10.1016/j.neuron.2017.05.003; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Meng QY, 2017, EBIOMEDICINE, V16, P184, DOI 10.1016/j.ebiom.2017.01.046; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montgomery S, 2017, ANN NEUROL, V82, P554, DOI 10.1002/ana.25036; Schallmo MS, 2017, J BONE JOINT SURG AM, V99, P1314, DOI 10.2106/JBJS.16.01573; Veliz P, 2017, JAMA-J AM MED ASSOC, V318, P1180, DOI 10.1001/jama.2017.9087	8	7	7	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2018	17	1					13	15		10.1016/S1474-4422(17)30419-2	http://dx.doi.org/10.1016/S1474-4422(17)30419-2			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ7VE	29262993				2022-12-18	WOS:000418570500009
J	Sormani, MP; Laroni, A				Sormani, Maria Pia; Laroni, Alice			Approved drugs for multiple sclerosis: the challenge of choice	LANCET NEUROLOGY			English	Editorial Material							ALEMTUZUMAB; DISABILITY		[Sormani, Maria Pia] Univ Genoa, Dept Hlth Sci, Biostat Unit, Genoa, Italy; [Laroni, Alice] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy	University of Genoa; University of Genoa	Sormani, MP (corresponding author), Univ Genoa, Dept Hlth Sci, Biostat Unit, Genoa, Italy.	mariapia.sormani@unige.it	Sormani, Maria Pia/ABH-8756-2020; Laroni, Alice/K-4714-2016	Laroni, Alice/0000-0001-5599-9788; SORMANI, MARIA PIA/0000-0001-6892-104X	Biogen; Novartis; Genzyme; Merck Serono; Roche; GeNeuro; Teva; Merck; Sanofi	Biogen(Biogen); Novartis(Novartis); Genzyme(Sanofi-AventisGenzyme Corporation); Merck Serono(Merck & Company); Roche(Roche Holding); GeNeuro; Teva(Teva Pharmaceutical Industries); Merck(Merck & Company); Sanofi	MPS reports personal fees from Biogen, Novartis, Genzyme, Merck Serono, Roche, GeNeuro, and Teva. AL reports personal fees and non-financial support from Merck, Sanofi, Teva, and Novartis; and grants, personal fees, and non-financial support from Biogen.	Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; Coles AJ, 2012, LANCET, V380, P1829, DOI 10.1016/S0140-6736(12)61768-1; Ford I, 2016, NEW ENGL J MED, V375, P454, DOI 10.1056/NEJMra1510059; Giovannoni G, 2016, NEUROLOGY, V87, P1985, DOI 10.1212/WNL.0000000000003319; Kalincik T, 2017, LANCET NEUROL; Phillips JT, 2011, MULT SCLER J, V17, P970, DOI 10.1177/1352458511399611; Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643; Tramacere I, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011381.pub2; TROJANO M, 2017, NAT REV NEUROL, V13, DOI DOI 10.1038/NRNEUR0L.2016.188	9	7	8	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2017	16	4					252	253		10.1016/S1474-4422(17)30021-2	http://dx.doi.org/10.1016/S1474-4422(17)30021-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EN9RF	28209332				2022-12-18	WOS:000396336600002
J	Attems, J				Attems, Johannes			Alzheimer's disease pathology in synucleinopathies	LANCET NEUROLOGY			English	Editorial Material							LEWY BODIES; DEMENTIA; BRAIN		[Attems, Johannes] Newcastle Univ, Inst Neurosci, Campus Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England	Newcastle University - UK	Attems, J (corresponding author), Newcastle Univ, Inst Neurosci, Campus Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.	j.attems@ncl.ac.uk		Attems, Johannes/0000-0003-1636-1700	Medical Research Council [G1100540, G0400074, G0900652, G0502157] Funding Source: Medline; MRC [G1100540, G0502157, G0400074, G0900652] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Attems J, 2013, CURR ALZHEIMER RES, V10, P569; Clinton LK, 2010, J NEUROSCI, V30, P7281, DOI 10.1523/JNEUROSCI.0490-10.2010; Gomperts SN, 2016, JAMA NEUROL, DOI [10.1001/jamaneuro1.2016.3338, DOI 10.1001/JAMANEURO1.2016.3338.]; Irwin DJ, LANCET NEUROL, V16, P55; Jellinger KA, 2007, J NEUROL SCI, V257, P80, DOI 10.1016/j.jns.2007.01.045; Kovacs GG, 2013, ACTA NEUROPATHOL, V126, P365, DOI 10.1007/s00401-013-1157-y; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; Nedelska Z, 2015, NEUROBIOL AGING, V36, P452, DOI 10.1016/j.neurobiolaging.2014.07.005; Walker L, 2015, ACTA NEUROPATHOL, V129, P729, DOI 10.1007/s00401-015-1406-3	9	7	7	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					22	23		10.1016/S1474-4422(16)30282-4	http://dx.doi.org/10.1016/S1474-4422(16)30282-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27979344				2022-12-18	WOS:000389869200014
J	Brandsma, R; Kremer, HPH; Sival, DA				Brandsma, Rick; Kremer, Hubertus P. H.; Sival, Deborah A.			Riluzole in patients with hereditary cerebellar ataxia	LANCET NEUROLOGY			English	Letter							CHILDREN		[Brandsma, Rick; Kremer, Hubertus P. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Sival, Deborah A.] Univ Groningen, Univ Med Ctr Groningen, Pediat Beatrix Childrens Hosp, NL-9700 RB Groningen, Netherlands	University of Groningen; University of Groningen	Sival, DA (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Pediat Beatrix Childrens Hosp, NL-9700 RB Groningen, Netherlands.	d.a.sival@umcg.nl						Brandsma R, 2014, DEV MED CHILD NEUROL, V56, P556, DOI 10.1111/dmcn.12369; Durr A, 2015, LANCET NEUROL, V14, P968, DOI 10.1016/S1474-4422(15)00217-3; Romano S, 2015, LANCET NEUROL, V14, P985, DOI 10.1016/S1474-4422(15)00201-X; Schmitz-Hubsch T, 2006, NEUROLOGY, V66, P1717, DOI 10.1212/01.wnl.0000219042.60538.92; Sival DA, 2011, DEV MED CHILD NEUROL, V53, P529, DOI 10.1111/j.1469-8749.2011.03931.x	5	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2016	15	8					788	788		10.1016/S1474-4422(16)00131-9	http://dx.doi.org/10.1016/S1474-4422(16)00131-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO1NR	27302351				2022-12-18	WOS:000377545800010
J	Frisoni, GB; Hansson, O				Frisoni, Giovanni B.; Hansson, Oskar			Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?	LANCET NEUROLOGY			English	Editorial Material							DEMENTIA		[Frisoni, Giovanni B.] Univ Hosp Geneva, Geneva, Switzerland; [Frisoni, Giovanni B.] Univ Geneva, Geneva, Switzerland; [Hansson, Oskar] Skane Univ Hosp, Lund, Sweden; [Hansson, Oskar] Lund Univ, Lund, Sweden	University of Geneva; University of Geneva; Lund University; Skane University Hospital; Lund University	Frisoni, GB (corresponding author), Univ Hosp Geneva, Geneva, Switzerland.; Frisoni, GB (corresponding author), Univ Geneva, Geneva, Switzerland.	gfrisoni@fatebenefratelli.it	Frisoni, Giovanni B./K-1360-2016; Hansson, Oskar/A-7134-2013	Frisoni, Giovanni B./0000-0002-6419-1753; Hansson, Oskar/0000-0001-8467-7286				Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bittner T, 2015, ALZHEIMERS DEMENT, DOI [10.1016/j.jalz.2015.09009, DOI 10.1016/J.JALZ.2015.09009]; Blennow K, 2015, TRENDS PHARMACOL SCI, V36, P297, DOI 10.1016/j.tips.2015.03.002; Buchhave P, 2012, ARCH GEN PSYCHIAT, V69, P98, DOI 10.1001/archgenpsychiatry.2011.155; Carrillo MC, 2012, ALZHEIMERS DEMENT, V8, P337, DOI 10.1016/j.jalz.2012.04.007; Detsky AS, 2011, JAMA-J AM MED ASSOC, V306, P2500, DOI 10.1001/jama.2011.1819; Frisoni GB, 2016, NEUROBIOL A IN PRESS; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Mattson N, 2016, NEUROBIOL A IN PRESS; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/S1474-4422(16)00070-3, 10.1016/s1474-4422(16)00070-3]; Scheltens P, 2016, LANCET NEUROL; Schmand B, 2012, J ALZHEIMERS DIS, V29, P641, DOI 10.3233/JAD-2012-111703	12	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2016	15	7					650	651		10.1016/S1474-4422(16)30040-0	http://dx.doi.org/10.1016/S1474-4422(16)30040-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DM7OG	27302222				2022-12-18	WOS:000376549300002
J	Williamson, PR; Nash, TE; Williamson, KC; Nath, A				Williamson, Peter R.; Nash, Theodore E.; Williamson, Kim C.; Nath, Avindra			CNS infections in 2015: emerging catastrophic infections and new insights into neuroimmunological host damage	LANCET NEUROLOGY			English	Editorial Material							CRYPTOCOCCAL MENINGITIS; CEREBROSPINAL-FLUID; ACTIVATION		[Williamson, Peter R.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Nash, Theodore E.] NIAID, Parasit Dis Lab, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Williamson, Kim C.] Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; [Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Williamson, PR (corresponding author), NIAID, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	tnash@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000846, ZIAAI001124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003130] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA NS003130-05, ZIA NS003130-06] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Ayscue P, 2014, MMWR-MORBID MORTAL W, V63, P903; Editorial, 2015, NY TIMES; Hoffmann B, 2015, NEW ENGL J MED, V373, P154, DOI 10.1056/NEJMoa1415627; Jarvis JN, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004754; Li W, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8201; Messacar K, 2015, LANCET, V385, P1662, DOI 10.1016/S0140-6736(14)62457-0; Meya DB, 2015, J INFECT DIS, V211, P1597, DOI 10.1093/infdis/jiu664; Panackal AA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004884; Scriven JE, 2015, J INFECT DIS, V212, P769, DOI 10.1093/infdis/jiv067; Seydel KB, 2015, NEW ENGL J MED, V372, P1126, DOI 10.1056/NEJMoa1400116; Visser DH, 2015, CLIN INFECT DIS, V60, P177, DOI 10.1093/cid/ciu781	11	7	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					17	19		10.1016/S1474-4422(15)00359-2	http://dx.doi.org/10.1016/S1474-4422(15)00359-2			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700901	Green Accepted			2022-12-18	WOS:000366313900010
J	Durr, A				Durr, Alexandra			Rare inherited diseases merit disease-specific trials	LANCET NEUROLOGY			English	Editorial Material							SPINOCEREBELLAR ATAXIA TYPE-1; SCALE		Univ Paris 06, Sorbonne Univ, Univ Hosp Pitie Salpetriere,Inserm,Dept Genet,ICM, APHP,CNRS UMR 7225,UMR S 1127,U1127,Inst Cervau &, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Durr, A (corresponding author), Univ Paris 06, Sorbonne Univ, Univ Hosp Pitie Salpetriere,Inserm,Dept Genet,ICM, APHP,CNRS UMR 7225,UMR S 1127,U1127,Inst Cervau &, Paris, France.	alexandra.durr@upmc.fr						Chan E, 2011, MOVEMENT DISORD, V26, P534, DOI 10.1002/mds.23531; du Montcel ST, 2014, J MED GENET, V51, P479, DOI 10.1136/jmedgenet-2013-102200; du Montcel ST, 2012, ARCH NEUROL-CHICAGO, V69, P500, DOI 10.1001/archneurol.2011.2713; Hobbs NZ, 2015, J NEUROL NEUROSUR PS, V86, P1291, DOI 10.1136/jnnp-2014-309768; Jacobi H, 2011, NEUROLOGY, V77, P1035, DOI 10.1212/WNL.0b013e31822e7ca0; Jacobi H, 2013, LANCET NEUROL, V12, P650, DOI 10.1016/S1474-4422(13)70104-2; Maas RPPWM, 2015, NEUROLOGY, V85, P96, DOI 10.1212/WNL.0000000000001711; Marelli C, 2012, MOVEMENT DISORD, V27, P135, DOI 10.1002/mds.23879; Monin ML, 2015, ANN CLIN TRANSL NEUR, V2, P202, DOI 10.1002/acn3.156; Orr HT, 2012, J CELL BIOL, V197, P167, DOI 10.1083/jcb.201105092; Romano S, 2015, LANCET NEUROL; Schmitz-Hubsch T, 2006, MOVEMENT DISORD, V21, P699, DOI 10.1002/mds.20781	12	7	7	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2015	14	10					968	969		10.1016/S1474-4422(15)00217-3	http://dx.doi.org/10.1016/S1474-4422(15)00217-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CR2VI	26321319				2022-12-18	WOS:000361188400002
J	Keezer, MR; Bell, GS; Duncan, JS; Sander, JW				Keezer, Mark R.; Bell, Gail S.; Duncan, John S.; Sander, Josemir W.			Promise and pitfalls of prognostic models for epilepsy surgery	LANCET NEUROLOGY			English	Letter							NOMOGRAMS		[Keezer, Mark R.; Bell, Gail S.; Duncan, John S.; Sander, Josemir W.] UCL Inst Neurol, Biomed Res Ctr, Univ Coll London Hosp, Natl Inst Hlth Res, London WC1N 3BG, England; [Keezer, Mark R.; Bell, Gail S.; Duncan, John S.; Sander, Josemir W.] Epilepsy Soc, Gerrards Cross, Bucks, England; [Sander, Josemir W.] Stichting Epilepsie Instellingen Nederland, Heemstede, Netherlands	University College London Hospitals NHS Foundation Trust; University of London; University College London	Keezer, MR (corresponding author), UCL Inst Neurol, Biomed Res Ctr, Univ Coll London Hosp, Natl Inst Hlth Res, Box 29, London WC1N 3BG, England.	l.sander@ucl.ac.uk	Sander, Josemir/C-1576-2008	Sander, Josemir/0000-0001-6041-9661; Duncan, John S/0000-0002-1373-0681	National Institute for Health Research [NF-SI-0509-10161] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.3.CO;2-X; Engel J, 2015, LANCET NEUROL, V14, P240, DOI 10.1016/S1474-4422(15)70011-6; Jehi L, 2015, LANCET NEUROL, V14, P283, DOI 10.1016/S1474-4422(14)70325-4	3	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					683	684		10.1016/S1474-4422(15)00100-3	http://dx.doi.org/10.1016/S1474-4422(15)00100-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26067116	Bronze			2022-12-18	WOS:000356195900014
J	McKay, KA; Tremlett, H				McKay, Kyla A.; Tremlett, Helen			The systematic search for risk factors in multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material									[McKay, Kyla A.; Tremlett, Helen] Univ British Columbia, Fac Med Neurol, Vancouver, BC V6T 2B5, Canada	University of British Columbia	McKay, KA (corresponding author), Univ British Columbia, Fac Med Neurol, Vancouver, BC V6T 2B5, Canada.	helen.tremlett@ubc.ca	Tremlett, Helen/AAE-7983-2020	Tremlett, Helen/0000-0001-5804-2535; McKay, Kyla/0000-0002-9081-1522				Belbasis L, 2015, LANCET NEUROL; Cohen JI, 2013, VACCINE, V31, pB194, DOI 10.1016/j.vaccine.2012.09.041; Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707; Duan SR, 2014, NEUROSCI LETT, V570, P108, DOI 10.1016/j.neulet.2014.04.021; Ebers GC, 2008, LANCET NEUROL, V7, P268, DOI 10.1016/S1474-4422(08)70042-5; Killestein J, 2011, LANCET NEUROL, V10, P1026, DOI 10.1016/S1474-4422(11)70228-9; Multiple Sclerosis International Federation, ATL MS 2013 MAPP MUL; Munger KL, 2013, MULT SCLER J, V19, P1323, DOI 10.1177/1352458513483889; Sawcer S, 2014, LANCET NEUROL, V13, P700, DOI 10.1016/S1474-4422(14)70041-9; WARNER KE, 1977, AM J PUBLIC HEALTH, V67, P645, DOI 10.2105/AJPH.67.7.645	10	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2015	14	3					237	238		10.1016/S1474-4422(15)70015-3	http://dx.doi.org/10.1016/S1474-4422(15)70015-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4JM	25662899				2022-12-18	WOS:000349594000003
J	Bennett, DLH				Bennett, David L. H.			Informed drug choices for neuropathic pain	LANCET NEUROLOGY			English	Editorial Material							DOUBLE-BLIND; PHENOTYPE; BURDEN		Univ Oxford, Nuffield Dept Clin Neurosci, Oxford 0X3 9DU, England	University of Oxford	Bennett, DLH (corresponding author), Univ Oxford, Nuffield Dept Clin Neurosci, Oxford 0X3 9DU, England.	david.bennett@ndcn.ox.ac.uk	bennett, david/ABG-1184-2020	Bennett, David/0000-0002-7996-2696	Wellcome Trust [095698] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], [No title captured]; Attal N, 2011, PAIN, V152, P2836, DOI 10.1016/j.pain.2011.09.014; Baron R, 2012, LANCET NEUROL, V11, P999, DOI 10.1016/S1474-4422(12)70189-8; Bouhassira D, 2008, PAIN, V136, P380, DOI 10.1016/j.pain.2007.08.013; Demant DT, 2014, PAIN, V155, P2263, DOI 10.1016/j.pain.2014.08.014; Doth AH, 2010, PAIN, V149, P338, DOI 10.1016/j.pain.2010.02.034; Gilron I, 2013, LANCET NEUROL, V12, P1084, DOI 10.1016/S1474-4422(13)70193-5; Tesfaye S, 2013, PAIN, V154, P2616, DOI 10.1016/j.pain.2013.05.043; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; von Hehn CA, 2012, NEURON, V73, P638, DOI 10.1016/j.neuron.2012.02.008	10	7	9	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2015	14	2					129	130		10.1016/S1474-4422(14)70329-1	http://dx.doi.org/10.1016/S1474-4422(14)70329-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AY9KS	25575709				2022-12-18	WOS:000347869400004
J	Widmann, CN; Schewe, JC; Heneka, MT				Widmann, Catherine N.; Schewe, Jens-Christian; Heneka, Michael T.			Sepsis-associated encephalopathy versus sepsis-induced encephalopathy Reply	LANCET NEUROLOGY			English	Letter							COGNITIVE IMPAIRMENT; SURVIVORS		[Widmann, Catherine N.; Heneka, Michael T.] Univ Bonn, Dept Neurol, Clin Neurosci Unit, D-53127 Bonn, Germany; [Widmann, Catherine N.; Heneka, Michael T.] German Ctr Neurodegenerat Dis, D-53127 Bonn, Germany; [Schewe, Jens-Christian] Univ Bonn, Dept Anaesthesiol & Operat Intens Care Med, D-53127 Bonn, Germany	University of Bonn; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Bonn	Widmann, CN (corresponding author), Univ Bonn, Dept Neurol, Clin Neurosci Unit, D-53127 Bonn, Germany.	michael.heneka@ukb.uni-bonn.de	Heneka, Michael/AAE-8011-2019; Heneka, Michael/E-8072-2015	Heneka, Michael/0000-0003-4996-1630				Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Lindlau A, 2015, EUR J NEUROL, V22, P410, DOI 10.1111/ene.12443; Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883; Widmann CN, 2014, LANCET NEUROL, V13, P630, DOI 10.1016/S1474-4422(14)70017-1	4	7	9	5	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2014	13	10					968	969		10.1016/S1474-4422(14)70204-2	http://dx.doi.org/10.1016/S1474-4422(14)70204-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AP3EZ	25231518	Bronze			2022-12-18	WOS:000341959700008
J	Filippi, M; Rocca, MA; Lassmann, H				Filippi, Massimo; Rocca, Maria A.; Lassmann, Hans			KIR4.1: another misleading expectation in multiple sclerosis?	LANCET NEUROLOGY			English	Editorial Material							CHANNEL		[Filippi, Massimo; Rocca, Maria A.] Inst Sci, Inst Expt Neurol, Div Neurosci, Neuroimaging Res Unit, I-20132 Milan, Italy; [Filippi, Massimo; Rocca, Maria A.] Inst Sci, Dept Neurol, I-20132 Milan, Italy; Univ Osped San Raffaele, I-20132 Milan, Italy; [Lassmann, Hans] Med Univ Vienna, Ctr Brain Res, Vienna, Austria	Vita-Salute San Raffaele University; Medical University of Vienna	Filippi, M (corresponding author), Inst Sci, Inst Expt Neurol, Div Neurosci, Neuroimaging Res Unit, I-20132 Milan, Italy.	m.filippi@hsr.it	Rocca, Maria Assunta/K-1619-2018; Filippi, Massimo/K-1755-2018; Lassmann, Hans/Z-2269-2019	Rocca, Maria Assunta/0000-0003-2358-4320; Filippi, Massimo/0000-0002-5485-0479; Lassmann, Hans/0000-0001-8617-5052				Banati M, 2013, EUR J NEUROL, V20, P1492, DOI 10.1111/ene.12072; Bradl M, 2009, ANN NEUROL, V66, P630, DOI 10.1002/ana.21837; Brickshawana A, 2014, LANCET NEUROL, V13, P795, DOI 10.1016/S1474-4422(14)70141-3; Jin X, 2012, J PHYSIOL-LONDON, V590, P5335, DOI 10.1113/jphysiol.2012.236885; Kraus V, 2014, NEUROLOGY, V82, P470, DOI 10.1212/WNL.0000000000000097; Lennon VA, 2004, LANCET, V364, P2106, DOI 10.1016/S0140-6736(04)17551-X; Lily O, 2004, BRAIN, V127, P269, DOI 10.1093/brain/awh031; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Nerrant E, 2014, MULT SCLER J, V20, P1699, DOI 10.1177/1352458514531086; Schirmer L, 2014, ANN NEUROL, V75, P810, DOI 10.1002/ana.24168; Sharma R, 2010, ACTA NEUROPATHOL, V120, P223, DOI 10.1007/s00401-010-0704-z; Srivastava R, 2012, NEW ENGL J MED, V367, P115, DOI 10.1056/NEJMoa1110740	12	7	7	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2014	13	8					753	755		10.1016/S1474-4422(14)70149-8	http://dx.doi.org/10.1016/S1474-4422(14)70149-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AL9JB	25008547				2022-12-18	WOS:000339456300005
J	Campbell, BCV; Davis, SM; Donnan, GA				Campbell, Bruce C. V.; Davis, Stephen M.; Donnan, Geoffrey A.			Uric acid for stroke: glimmer of hope or false dawn?	LANCET NEUROLOGY			English	Editorial Material							ISCHEMIC BRAIN-INJURY		[Campbell, Bruce C. V.; Davis, Stephen M.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3010, Australia; [Donnan, Geoffrey A.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3010, Australia	Royal Melbourne Hospital; University of Melbourne; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Campbell, BCV (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3010, Australia.	gdonnan@unimelb.edu.au	Campbell, Bruce/J-1220-2019	Campbell, Bruce/0000-0003-3632-9433; Donnan, Geoffrey/0000-0001-6324-3403				Chamorro A, 2014, LANCET NEUROL; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Haberman F, 2007, NEUROMOL MED, V9, P315, DOI 10.1007/s12017-007-8010-1; Macleod MR, 2009, INT J STROKE, V4, P3, DOI 10.1111/j.1747-4949.2009.00241.x; Romanos E, 2007, J CEREBR BLOOD F MET, V27, P14, DOI 10.1038/sj.jcbfm.9600312; Saver JL, 2014, INT J STROKE, V9, P215, DOI 10.1111/ijs.12243; Yu ZF, 1998, J NEUROSCI RES, V53, P613, DOI 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1	7	7	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2014	13	5					440	441		10.1016/S1474-4422(14)70019-5	http://dx.doi.org/10.1016/S1474-4422(14)70019-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AG0LX	24703209				2022-12-18	WOS:000335108100002
J	Dennis, M				Dennis, Martin			Embolic stroke of undetermined source: a therapeutic target?	LANCET NEUROLOGY			English	Editorial Material							PREVENTION; RISK		Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Dennis, M (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	martin.dennis@ed.ac.uk						Amarenco P, 2009, LANCET NEUROL, V8, P453, DOI 10.1016/S1474-4422(09)70058-4; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Franke CL, 1997, ANN NEUROL, V42, P857; Gorter JW, 1999, NEUROLOGY, V53, P1319, DOI 10.1212/WNL.53.6.1319; Hart RG, 2014, LANCET NEUROL, V13, P429, DOI 10.1016/S1474-4422(13)70310-7; Lovett JK, 2004, NEUROLOGY, V62, P569, DOI 10.1212/01.WNL.0000110311.09970.83; Rashid P, 2003, STROKE, V34, P2741, DOI 10.1161/01.STR.0000092488.40085.15; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441	9	7	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2014	13	4					344	346		10.1016/S1474-4422(14)70043-2	http://dx.doi.org/10.1016/S1474-4422(14)70043-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB6NN	24646868				2022-12-18	WOS:000349743800005
J	Sandset, EC				Sandset, Else Charlotte			Blood pressure in acute stroke	LANCET NEUROLOGY			English	Editorial Material							TRIAL; VARIABILITY; OUTCOMES; THERAPY		Oslo Univ Hosp, Dept Neurol, N-0424 Oslo, Norway	University of Oslo	Sandset, EC (corresponding author), Oslo Univ Hosp, Dept Neurol, Postboks 4956, N-0424 Oslo, Norway.	else@sandset.net						Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609; Endo K, 2013, STROKE, V44, P816, DOI 10.1161/STROKEAHA.112.681007; Fischer U, 2014, LANCET; Geeganage C, 2011, STROKE, V42, P491, DOI 10.1161/STROKEAHA.110.596163; He J, 2014, JAMA-J AM MED ASSOC, V311, P479, DOI 10.1001/jama.2013.282543; Leonardi-Bee J, 2002, STROKE, V33, P1315, DOI 10.1161/01.STR.0000014509.11540.66; Manning L, 2014, LANCET NEUROL; Rothwell PM, 2010, LANCET, V375, P895, DOI 10.1016/S0140-6736(10)60308-X; Sandset EC, 2011, LANCET, V377, P741, DOI 10.1016/S0140-6736(11)60104-9; Saver JL, 2014, INT J STROKE, V9, P215, DOI 10.1111/ijs.12243; Thomas D, 2006, INT J STROKE, V1, P245, DOI 10.1111/j.1747-4949.2006.00059.x	11	7	8	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2014	13	4					342	343		10.1016/S1474-4422(14)70042-0	http://dx.doi.org/10.1016/S1474-4422(14)70042-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB6NN	24582531	hybrid			2022-12-18	WOS:000349743800003
J	Lee, BI; Heo, K				Lee, Byung In; Heo, Kyoung			Epilepsy: new genes, new technologies, new insights	LANCET NEUROLOGY			English	Editorial Material									[Lee, Byung In; Heo, Kyoung] Yonsei Univ, Coll Med, Epilepsy Res Inst, Dept Neurol, Seoul 20752, South Korea	Yonsei University; Yonsei University Health System	Lee, BI (corresponding author), Yonsei Univ, Coll Med, Epilepsy Res Inst, Dept Neurol, 50 Yonsei Ro, Seoul 20752, South Korea.	bilee@yuhs.ac						Allen AS, 2013, NATURE, V501, P217, DOI 10.1038/nature12439; Fazel S, 2013, LANCET, V382, P1646, DOI 10.1016/S0140-6736(13)60899-5; Feldmann M, 2013, LANCET NEUROL, V12, P777, DOI 10.1016/S1474-4422(13)70109-1; Krueger DA, 2013, ANN NEUROL, V74, P679, DOI 10.1002/ana.23960; Paz JT, 2013, NAT NEUROSCI, V16, P64, DOI 10.1038/nn.3269	5	7	7	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2014	13	1					7	9		10.1016/S1474-4422(13)70240-0	http://dx.doi.org/10.1016/S1474-4422(13)70240-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	280AL	24331783				2022-12-18	WOS:000329000900005
J	Santamaria, J; Iranzo, A				Santamaria, Joan; Iranzo, Alex			Sleep disorders matter in neurology	LANCET NEUROLOGY			English	Editorial Material							NARCOLEPSY; VACCINATION		[Santamaria, Joan] Univ Barcelona, Sch Med, Neurol Serv, Barcelona, Spain; Univ Barcelona, Sch Med, Hosp Clin Barcelona, Multidisciplinary Sleep Disorders Unit, Barcelona, Spain	University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona	Santamaria, J (corresponding author), Univ Barcelona, Sch Med, Neurol Serv, Barcelona, Spain.	jsantama@clinic.cat						Allen RP, 2013, NEUROLOGY, V80, P2028, DOI 10.1212/WNL.0b013e318294b3f6; Dauvilliers Y, 2013, BRAIN, V136, P2486, DOI 10.1093/brain/awt187; Garcia-Lorenzo D, 2013, BRAIN, V136, P2120, DOI 10.1093/brain/awt152; Han F, 2011, ANN NEUROL, V70, P410, DOI 10.1002/ana.22587; Iranzo A, 2013, LANCET NEUROL, V12, P443, DOI 10.1016/S1474-4422(13)70056-5; John J, 2013, ANN NEUROL, DOI [10.1002/ana23968, DOI 10.1002/ANA]; Schenck CH, 1996, NEUROLOGY, V46, P388, DOI 10.1212/WNL.46.2.388; Valko PO, 2013, ANN NEUROL, V74, P794, DOI 10.1002/ana.24019; Wijnans L, 2013, VACCINE, V31, P1246, DOI 10.1016/j.vaccine.2012.12.015	9	7	7	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2014	13	1					18	20		10.1016/S1474-4422(13)70273-4	http://dx.doi.org/10.1016/S1474-4422(13)70273-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	280AL	24331789				2022-12-18	WOS:000329000900011
J	Gordon, PH				Gordon, Paul H.			The murky path to drug discovery in ALS becomes clearer	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; TRIAL; EFFICIENT; RILUZOLE; DESIGN		Northern Navajo Med Ctr, Shiprock, NM 87420 USA		Gordon, PH (corresponding author), Northern Navajo Med Ctr, Highway 491 North Shiprock, Shiprock, NM 87420 USA.	paul.gordon@psl.aphp.fr		Gordon, Paul/0000-0001-5714-9875				BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Cheung YK, 2006, NEUROLOGY, V67, P1748, DOI 10.1212/01.wnl.0000244464.73221.13; COTZIAS GC, 1967, NEW ENGL J MED, V276, P374, DOI 10.1056/NEJM196702162760703; Cudkowicz M, 2011, NAT MED, V17, P1652, DOI 10.1038/nm.2579; Cudkowicz ME, 2013, LANCET NEUROL, V12, P1059, DOI 10.1016/S1474-4422(13)70221-7; Cudkowicz ME, 2010, AMYOTROPH LATERAL SC, V11, P259, DOI 10.3109/17482960903358865; Gordon PH, 2008, AMYOTROPH LATERAL SC, V9, P212, DOI 10.1080/17482960802195632; Kaufmann P, 2009, ANN NEUROL, V66, P235, DOI 10.1002/ana.21743; Kowal SL, 2013, MOVEMENT DISORD, V28, P311, DOI 10.1002/mds.25292; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Palesch YY, 2004, AMYOTROPH LATERAL SC, V5, P55, DOI 10.1080/17434470410020003; Sacks O, 1983, BMJ-BRIT MED J, V287, P1968; Scott S, 2008, AMYOTROPH LATERAL SC, V9, P4, DOI 10.1080/17482960701856300	13	7	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2013	12	11					1037	1038		10.1016/S1474-4422(13)70224-2	http://dx.doi.org/10.1016/S1474-4422(13)70224-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	239ZC	24067399				2022-12-18	WOS:000326063500003
J	[Anonymous]				[Anonymous]			Brain banking: more effective strategies needed	LANCET NEUROLOGY			English	Editorial Material																			0	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2013	12	11					1035	1035		10.1016/S1474-4422(13)70249-7	http://dx.doi.org/10.1016/S1474-4422(13)70249-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	239ZC	24135204				2022-12-18	WOS:000326063500001
J	Parashos, SA				Parashos, Sotirios A.			Challenges of multidisciplinary care in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							REHABILITATION; PROGRAM; PEOPLE		Pk Nicollet Methodist Hosp, Struthers Parkinsons Ctr, Golden Valley, MN 55427 USA		Parashos, SA (corresponding author), Pk Nicollet Methodist Hosp, Struthers Parkinsons Ctr, Golden Valley, MN 55427 USA.	sotirios.parashos@mpls-clinic.com						Carne W, 2005, NEUROREHABILITATION, V20, P161; Ellis T, 2008, PHYS THER, V88, P812, DOI 10.2522/ptj.20070265; Hely MA, 2005, MOVEMENT DISORD, V20, P190, DOI 10.1002/mds.20324; Parashos SA, 2012, CLIN PRACT, V9, P1; Post B, 2011, POSTGRAD MED J, V87, P575, DOI 10.1136/pgmj.2011.241604rep; Prizer LP, 2012, J PARKINSON DIS, V2, P79, DOI 10.3233/JPD-2012-12075; van der Marck MA, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70196-0; Wade DT, 2003, J NEUROL NEUROSUR PS, V74, P158, DOI 10.1136/jnnp.74.2.158	8	7	7	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2013	12	10					932	933		10.1016/S1474-4422(13)70145-5	http://dx.doi.org/10.1016/S1474-4422(13)70145-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	237XV	23988336				2022-12-18	WOS:000325905800002
J	Petersen, RC				Petersen, Ronald C.			Do preclinical Alzheimer's disease criteria work?	LANCET NEUROLOGY			English	Editorial Material							MILD COGNITIVE IMPAIRMENT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; HYPOTHETICAL MODEL; DYNAMIC BIOMARKERS; RECOMMENDATIONS		Mayo Clin & Mayo Fdn, Alzheimers Dis Res Ctr, Dept Neurol, Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Petersen, RC (corresponding author), Mayo Clin & Mayo Fdn, Alzheimers Dis Res Ctr, Dept Neurol, Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.	peter8@mayo.edu						Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Dubois B, 2010, LANCET NEUROL, V9, P1118, DOI 10.1016/S1474-4422(10)70223-4; Jack CR, 2013, LANCET NEUROL, V12, P207, DOI 10.1016/S1474-4422(12)70291-0; Jack CR, 2012, ANN NEUROL, V71, P765, DOI 10.1002/ana.22628; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Knopman DS, 2012, NEUROLOGY, V78, P1576, DOI 10.1212/WNL.0b013e3182563bbe; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Petersen RC, 2013, ANN NEUROL, V74, P199, DOI 10.1002/ana.23931; Rowe CC, 2010, NEUROBIOL AGING, V31, P1275, DOI 10.1016/j.neurobiolaging.2010.04.007; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Visser PJ, 2009, LANCET NEUROL, V8, P619, DOI 10.1016/S1474-4422(09)70139-5; Vos SJB, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70194-7	14	7	7	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2013	12	10					933	935		10.1016/S1474-4422(13)70217-5	http://dx.doi.org/10.1016/S1474-4422(13)70217-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	237XV	24012373				2022-12-18	WOS:000325905800003
J	[Anonymous]				[Anonymous]			Setting new standards in multiple sclerosis care and research	LANCET NEUROLOGY			English	Editorial Material																			0	7	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2012	11	10					835	835		10.1016/S1474-4422(12)70214-4	http://dx.doi.org/10.1016/S1474-4422(12)70214-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	018BG	22995684	Bronze			2022-12-18	WOS:000309634300001
J	Rothwell, PM				Rothwell, Peter M.			Stroke: more trials, more answers	LANCET NEUROLOGY			English	Editorial Material							WARFARIN		Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX3 9DU, England	University of Oxford	Rothwell, PM (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Stroke Prevent Res Unit, Oxford OX3 9DU, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				Albers GW, 2003, LANCET, V362, P1691; Bousser MG, 2011, LANCET, V377, P2013, DOI 10.1016/S0140-6736(11)60600-4; Chimowitz MI, 2011, NEW ENGL J MED, V365, P993, DOI 10.1056/NEJMoa1105335; Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Sandset EC, 2011, LANCET, V377, P741, DOI 10.1016/S0140-6736(11)60104-9	8	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2012	11	1					2	3		10.1016/S1474-4422(11)70283-6	http://dx.doi.org/10.1016/S1474-4422(11)70283-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	868HG	22172608				2022-12-18	WOS:000298513700002
J	Feigin, A				Feigin, Andrew			Pridopidine in treatment of Huntington's disease: beyond chorea?	LANCET NEUROLOGY			English	Editorial Material							FUNCTIONAL DECLINE		N Shore LIJ Hlth Syst, Feinstein Inst Med Res, Manhasset, NY 11030 USA	Northwell Health	Feigin, A (corresponding author), N Shore LIJ Hlth Syst, Feinstein Inst Med Res, Manhasset, NY 11030 USA.	afeigin@nshs.edu						de Yebenes JG, 2011, LANCET NEUROL, V10, P1049, DOI 10.1016/S1474-4422(11)70233-2; Huntington G., 1872, MED SURGICAL REPORTE, V26, P320; Marder K, 2000, NEUROLOGY, V54, P452, DOI 10.1212/WNL.54.2.452; MCGARRY A, 2011, NEUROTHERAPEUTICS, V8, P135; Peavy GM, 2010, MOVEMENT DISORD, V25, P1163, DOI 10.1002/mds.22953	5	7	7	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2011	10	12					1036	1037		10.1016/S1474-4422(11)70247-2	http://dx.doi.org/10.1016/S1474-4422(11)70247-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	859SH	22071278				2022-12-18	WOS:000297895600002
J	Mangialasche, F; Solomon, A; Winblad, B; Mecocci, P; Kivipelto, M				Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M.			Alzheimer's disease: clinical trials and drug development (vol 9, pg 702, 2010)	LANCET NEUROLOGY			English	Correction													Kivipelto, Miia/AAS-3557-2021					Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8	1	7	7	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2011	10	6					501	501		10.1016/S1474-4422(10)70119-8	http://dx.doi.org/10.1016/S1474-4422(10)70119-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774HK					2022-12-18	WOS:000291376100009
J	Robinson, RG; Adams, HP				Robinson, Robert G.; Adams, Harold P.			Selective serotonin-reuptake inhibitors and recovery after stroke	LANCET NEUROLOGY			English	Editorial Material							POSTSTROKE DEPRESSION; MORTALITY; THERAPY		[Robinson, Robert G.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Robinson, RG (corresponding author), Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA.	robert-robinson@uiowa.edu						Acler M, 2009, J NEUROL, V256, P1152, DOI 10.1007/s00415-009-5093-7; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Dam M, 1996, STROKE, V27, P1211, DOI 10.1161/01.STR.27.7.1211; House A, 2001, STROKE, V32, P696, DOI 10.1161/01.STR.32.3.696; Manganotti P, 2002, CLIN NEUROPHYSIOL, V113, P936, DOI 10.1016/S1388-2457(02)00062-7; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MIKAMI K, AM J GERIAT IN PRESS; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; PARIKH RM, 1990, ARCH NEUROL-CHICAGO, V47, P785, DOI 10.1001/archneur.1990.00530070083014; Pohjasvaara T, 2001, EUR J NEUROL, V8, P315, DOI 10.1046/j.1468-1331.2001.00182.x; Robinson R.G., 2006, CLIN NEUROPSYCHIATRY; Robinson RG, 2008, JAMA-J AM MED ASSOC, V299, P2391, DOI 10.1001/jama.299.20.2391; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SCHUBERT DSP, 1992, GEN HOSP PSYCHIAT, V14, P69, DOI 10.1016/0163-8343(92)90028-9; Zittel S, 2008, NEUROREHAB NEURAL RE, V22, P311, DOI 10.1177/1545968307312173	15	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2011	10	2					110	111		10.1016/S1474-4422(10)70326-4	http://dx.doi.org/10.1016/S1474-4422(10)70326-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	721IT	21216671				2022-12-18	WOS:000287347500002
J	Hankey, GJ				Hankey, Graeme J.			Stroke: fresh insights into causes, prevention, and treatment	LANCET NEUROLOGY			English	Editorial Material							SYMPTOMATIC CAROTID STENOSIS; BLOOD-PRESSURE; ENDARTERECTOMY; METAANALYSIS; RISK		[Hankey, Graeme J.] Royal Perth Hosp, Dept Neurol, Perth, WA, Australia; [Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6001, Australia	Royal Perth Hospital; University of Western Australia; University of Western Australia	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, Perth, WA, Australia.	gjhankey@cyllene.uwa.edu.au	Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				Bonati LH, 2010, LANCET, V376, P1062, DOI 10.1016/S0140-6736(10)61009-4; Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321; Ederle J, 2010, LANCET, V375, P985, DOI 10.1016/S0140-6736(10)60239-5; Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Rothwell PM, 2010, LANCET, V375, P895, DOI 10.1016/S0140-6736(10)60308-X; Rothwell PM, 2009, LANCET NEUROL, V8, P871, DOI 10.1016/S1474-4422(09)70230-3; Shinohara Y, 2010, LANCET NEUROL, V9, P959, DOI 10.1016/S1474-4422(10)70198-8; Webb AJS, 2010, LANCET, V375, P906, DOI 10.1016/S0140-6736(10)60235-8	9	7	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2011	10	1					2	3		10.1016/S1474-4422(10)70279-9	http://dx.doi.org/10.1016/S1474-4422(10)70279-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	701HX	21163433				2022-12-18	WOS:000285810100002
J	Merlini, L				Merlini, Luciano			Measuring muscle strength in clinical trials	LANCET NEUROLOGY			English	Letter									IRCCS, IOR, Lab Musculoskeletal Cell Biol, Bologna, Italy		Merlini, L (corresponding author), IRCCS, IOR, Lab Musculoskeletal Cell Biol, Bologna, Italy.		Merlini, Luciano/N-6478-2019	Merlini, Luciano/0000-0002-1108-1198				BROOKE MH, 1981, MUSCLE NERVE, V4, P186, DOI 10.1002/mus.880040304; COOK JD, 1987, NEUROL CLIN, V5, P101, DOI 10.1016/S0733-8619(18)30937-X; Kirschner J, 2010, LANCET NEUROL, V9, P1053, DOI 10.1016/S1474-4422(10)70196-4	3	7	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2010	9	12					1146	1146		10.1016/S1474-4422(10)70285-4	http://dx.doi.org/10.1016/S1474-4422(10)70285-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	691KG	21087735				2022-12-18	WOS:000285078100006
J	Feigin, VL; Krishnamurthi, R				Feigin, Valery L.; Krishnamurthi, Rita			Public health strategies could reduce the global stroke epidemic	LANCET NEUROLOGY			English	Editorial Material							ISCHEMIC-STROKE; RISK-FACTORS; COUNTRIES; POPULATION		[Feigin, Valery L.; Krishnamurthi, Rita] Auckland Univ Technol, Natl Res Ctr Stroke Appl Neurosci & Neurorehabil, Sch Publ Hlth & Psychosocial Studies, Sch Rehabil & Occupat Studies,Fac Hlth & Environm, Auckland 1142, New Zealand	Auckland University of Technology	Feigin, VL (corresponding author), Auckland Univ Technol, Natl Res Ctr Stroke Appl Neurosci & Neurorehabil, Sch Publ Hlth & Psychosocial Studies, Sch Rehabil & Occupat Studies,Fac Hlth & Environm, Auckland 1142, New Zealand.	valery.feigin@aut.ac.nz	Feigin, Valery/AAF-2313-2019; Krishnamurthi, Rita/AAU-7841-2021	Krishnamurthi, Rita/0000-0003-0869-2083; Feigin, Valery L./0000-0002-6372-1740				Ariesen MJ, 2003, STROKE, V34, P2060, DOI 10.1161/01.STR.0000080678.09344.8D; Feigin VL, 2007, LANCET NEUROL, V6, P94, DOI 10.1016/S1474-4422(07)70007-8; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Goldstein LB, 2001, STROKE, V32, P280, DOI 10.1161/01.STR.32.1.280; Jackson R, 2005, LANCET, V366, P1911, DOI 10.1016/S0140-6736(05)67770-7; McQueen MJ, 2008, LANCET, V372, P224, DOI 10.1016/S0140-6736(08)61076-4; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; Whisnant JP, 1997, STROKE, V28, P1840, DOI 10.1161/01.STR.28.9.1840; Yatsuya H, 2010, STROKE, V41, P417, DOI 10.1161/STROKEAHA.109.566299	10	7	7	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2010	9	9					847	848		10.1016/S1474-4422(10)70190-3	http://dx.doi.org/10.1016/S1474-4422(10)70190-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	645MX	20723839				2022-12-18	WOS:000281465900005
J	Hartung, HP; Aktas, O				Hartung, Hans-Peter; Aktas, Orhan			Oral therapies for multiple sclerosis: are we there yet?	LANCET NEUROLOGY			English	Editorial Material							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PLACEBO-CONTROLLED TRIAL; FINGOLIMOD; NATALIZUMAB; CLADRIBINE; AGENT		[Hartung, Hans-Peter; Aktas, Orhan] Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Hartung, HP (corresponding author), Univ Dusseldorf, Dept Neurol, Moorenstr, D-40225 Dusseldorf, Germany.	hans-peter.hartung@uni-duesseldorf.de	Aktas, Orhan/B-7623-2009	Aktas, Orhan/0000-0002-2020-9210				Aktas O, 2010, TRENDS NEUROSCI, V33, P140, DOI 10.1016/j.tins.2009.12.002; BEUTLER E, 1994, SEMIN HEMATOL, V31, P40; Brinkmann V, 2009, BRIT J PHARMACOL, V158, P1173, DOI 10.1111/j.1476-5381.2009.00451.x; Brousil JA, 2006, ANN PHARMACOTHER, V40, P1814, DOI 10.1345/aph.1H037; Clifford DB, 2010, LANCET NEUROL, V9, P438, DOI 10.1016/S1474-4422(10)70028-4; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Giovannoni G, 2010, NEW ENGL J MED, V362, P416, DOI 10.1056/NEJMoa0902533; Hartung HP, 2009, LANCET NEUROL, V8, P28, DOI 10.1016/S1474-4422(08)70281-3; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Rosen H, 2008, IMMUNOL REV, V223, P221, DOI 10.1111/j.1600-065X.2008.00645.x	10	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2010	9	5					454	457		10.1016/S1474-4422(10)70088-0	http://dx.doi.org/10.1016/S1474-4422(10)70088-0			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	592MY	20398852				2022-12-18	WOS:000277384600006
J	Goadsby, PJ				Goadsby, Peter J.			Cervicogenic headache: a pain in the neck for some neurologists?	LANCET NEUROLOGY			English	Editorial Material							STIMULATION; DIAGNOSIS; MIGRAINE		Univ Calif San Francisco, Dept Neurol, Headache Grp, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	Goadsby, PJ (corresponding author), Univ Calif San Francisco, Dept Neurol, Headache Grp, 1635 Divisadero St, San Francisco, CA 94115 USA.	pgoadsby@headache.ucsf.edu	Goadsby, Peter J/Z-1970-2019	Goadsby, Peter J/0000-0003-3260-5904				Afridi SK, 2006, PAIN, V122, P126, DOI 10.1016/j.pain.2006.01.016; Bartsch T, 2002, BRAIN, V125, P1496, DOI 10.1093/brain/awf166; Bartsch T, 2003, BRAIN, V126, P1801, DOI 10.1093/brain/awg190; Bartsch T, 2005, HEADACHE CURRENTS, V2, P42, DOI DOI 10.1111/J.1743-5013.2005.20201.X; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; DWYER A, 1990, SPINE, V15, P453; FEINSTEIN B, 1954, J BONE JOINT SURG AM, V36-A, P981, DOI 10.2106/00004623-195436050-00007; Giffin NJ, 2003, NEUROLOGY, V60, P935, DOI 10.1212/01.WNL.0000052998.58526.A9; Goadsby PJ, 2008, CEPHALALGIA, V28, P1, DOI 10.1111/j.1468-2982.2008.01606.x; Goadsby PJ, 1997, J ANAT, V190, P367, DOI 10.1046/j.1469-7580.1997.19030367.x; Paemeleire K, 2008, EUR J NEUROL, V15, P10; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; SJAASTAD O, 1983, CEPHALALGIA, V3, P249, DOI 10.1046/j.1468-2982.1983.0304249.x; Sjaastad O, 1998, HEADACHE, V38, P442, DOI 10.1046/j.1526-4610.1998.3806442.x; SJAASTAD O, 1990, HEADACHE, V30, P725, DOI 10.1111/j.1526-4610.1990.hed3011725.x; Tepper SJ, 2004, HEADACHE, V44, P856, DOI 10.1111/j.1526-4610.2004.04167.x	16	7	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2009	8	10					875	877		10.1016/S1474-4422(09)70243-1	http://dx.doi.org/10.1016/S1474-4422(09)70243-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	498BS	19747646				2022-12-18	WOS:000270111200005
J	Ramchandren, S; Shy, ME; Finkel, RS				Ramchandren, Sindhu; Shy, Michael E.; Finkel, Richard S.			Quality of life in children with CMT type 1A	LANCET NEUROLOGY			English	Letter									[Ramchandren, Sindhu; Shy, Michael E.] Wayne State Univ, Med Ctr, Dept Neurol, Detroit, MI 48201 USA; [Finkel, Richard S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA	Detroit Medical Center; Wayne State University; University of Pennsylvania; Childrens Hospital of Philadelphia	Ramchandren, S (corresponding author), Wayne State Univ, Med Ctr, Dept Neurol, Detroit, MI 48201 USA.	sramchan@med.wayne.edu	Ramchandren, Sindhu/D-6942-2012	Ramchandren, Sindhu/0000-0002-5201-9200; Shy, Michael/0000-0001-8460-6971	NINDS NIH HHS [K23 NS072279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS072279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Burns J, 2009, LANCET NEUROL, V8, P537, DOI 10.1016/S1474-4422(09)70108-5; Gutierrez-Suarez R, 2007, RHEUMATOLOGY, V46, P314, DOI 10.1093/rheumatology/kel218; Hays R., 2005, ASSESSING QUALITY LI, P3; Landgraf J.M., 1996, CHILD HLTH QUESTIONN; Padua L, 2005, J PERIPHER NERV SYST, V10, P3, DOI 10.1111/j.1085-9489.2005.10103.x; Vinci P, 2005, NEUROLOGY, V65, P922, DOI 10.1212/01.wnl.0000176062.44360.49; Waters E, 2000, AUST NZ J PUBL HEAL, V24, P207, DOI 10.1111/j.1467-842X.2000.tb00145.x	7	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2009	8	10					880	881		10.1016/S1474-4422(09)70247-9	http://dx.doi.org/10.1016/S1474-4422(09)70247-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	498BS	19747650				2022-12-18	WOS:000270111200009
J	de Ru, JA; van Benthem, PPG; Janssen, LM				de Ru, J. Alexander; van Benthem, Peter Paul G.; Janssen, Luuk M.			Is antiviral medication for severe Bell's palsy still useful?	LANCET NEUROLOGY			English	Letter							PREDNISOLONE; MULTICENTER		[de Ru, J. Alexander; van Benthem, Peter Paul G.; Janssen, Luuk M.] Cent Mil Hosp, Utrecht, Netherlands		de Ru, JA (corresponding author), Cent Mil Hosp, Utrecht, Netherlands.	j.a.deru@umcutrecht.nl	Van Benthem, Peter Paul G/E-5115-2017	Van Benthem, Peter Paul G/0000-0002-7946-1912				Engstrom M, 2008, LANCET NEUROL, V7, P993, DOI 10.1016/S1474-4422(08)70221-7; Gilden D, 2008, LANCET NEUROL, V7, P976, DOI 10.1016/S1474-4422(08)70222-9; Gilden DH, 2007, NEW ENGL J MED, V357, P1653, DOI 10.1056/NEJMe078188; Hato N, 2007, OTOL NEUROTOL, V28, P408, DOI 10.1097/01.mao.0000265190.29969.12; Minnerop M, 2008, J NEUROL, V255, P1726, DOI 10.1007/s00415-008-0008-6; Sullivan FM, 2007, NEW ENGL J MED, V357, P1598, DOI 10.1056/NEJMoa072006	6	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2009	8	6					509	509		10.1016/S1474-4422(09)70114-0	http://dx.doi.org/10.1016/S1474-4422(09)70114-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	448UQ	19446267				2022-12-18	WOS:000266287900006
J	Broderick, J				Broderick, Joseph			Clipping or coiling: the first step for ruptured aneurysms	LANCET NEUROLOGY			English	Editorial Material							SUBARACHNOID HEMORRHAGE; INTRACRANIAL ANEURYSMS; SMOKING; RISK		Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA	University of Cincinnati	Broderick, J (corresponding author), Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA.	joseph.broderick@uc.edu						Anderson CS, 2004, STROKE, V35, P633, DOI 10.1161/01.STR.0000115751.45473.48; Broderick JP, 2009, STROKE, V40, P1952, DOI 10.1161/STROKEAHA.108.542571; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8; Wermer MJH, 2005, STROKE, V36, P2394, DOI 10.1161/01.STR.0000185686.28035.d2; Woo D, 2009, NEUROLOGY, V72, P69, DOI 10.1212/01.wnl.0000338567.90260.46	6	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2009	8	5					414	415		10.1016/S1474-4422(09)70086-9	http://dx.doi.org/10.1016/S1474-4422(09)70086-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	435UE	19329360				2022-12-18	WOS:000265368000002
J	Goldstein, LB				Goldstein, Larry B.			JUPITER and the world of stroke medicine	LANCET NEUROLOGY			English	Editorial Material							C-REACTIVE PROTEIN; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; CHOLESTEROL; ROSUVASTATIN; PRAVASTATIN		Duke Univ, Med Ctr, Durham, NC 27710 USA	Duke University	Goldstein, LB (corresponding author), Duke Univ, Med Ctr, POB 3651, Durham, NC 27710 USA.	golds004@mc.duke.edu		Goldstein, Larry/0000-0001-7747-128X				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Hlatky MA, 2008, NEW ENGL J MED, V359, P2280, DOI 10.1056/NEJMe0808320; ORIORDAN M, 2008, AHA 2008 JUNPITER CA; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2003, CIRCULATION, V108, P2292, DOI 10.1161/01.CIR.0000100688.17280.E6; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Robinson JG, 2005, J AM COLL CARDIOL, V46, P1855, DOI 10.1016/j.jacc.2005.05.085	10	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2009	8	2					129	131		10.1016/S1474-4422(09)70002-X	http://dx.doi.org/10.1016/S1474-4422(09)70002-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	398SO	19161900				2022-12-18	WOS:000262752000004
J	Craven, R				Craven, Rebecca			Building neurological services in Africa	LANCET NEUROLOGY			English	Editorial Material								International institutions will need to work in partnership with Africa to meet the growing burden of neurological disorders across the continent. Many seethe creation of the World Federation of Neurology's Africa Committee as an important step in the right direction. Rebecca Craven reports.				rebecca.craven@zen.co.uk							0	7	7	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2009	8	1					32	33		10.1016/S1474-4422(08)70284-9	http://dx.doi.org/10.1016/S1474-4422(08)70284-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	386CU	19081513				2022-12-18	WOS:000261860700018
J	Hankey, GJ; Eikelboom, JW				Hankey, Graeme J.; Eikelboom, John W.			What do the results of the PRoFESS trial teach us?	LANCET NEUROLOGY			English	Editorial Material							ASPIRIN; STROKE; SYSTEM		[Hankey, Graeme J.] Royal Perth Hosp, Dept Neurol, Perth, WA 6001, Australia; [Eikelboom, John W.] McMaster Univ, Dept Med, Hamilton, ON, Canada	Royal Perth Hospital; University of Western Australia; McMaster University	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, 197 Wellington St, Perth, WA 6001, Australia.	gjhankey@cyllene.uwa.edu.au	Hankey, Graeme J/H-4968-2014; Eikelboom, John/AAG-6117-2019	Hankey, Graeme J/0000-0002-6044-7328; Eikelboom, John/0000-0003-4126-1285				Algra A, 1999, J NEUROL NEUROSUR PS, V66, P255, DOI 10.1136/jnnp.66.2.255; Diener HC, 2008, LANCET NEUROL, V7, P985, DOI 10.1016/S1474-4422(08)70232-1; EIKELBOOM JW, 2008, BMJ IN PRESS; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Krikov M, 2008, J HYPERTENS, V26, P544, DOI 10.1097/HJH.0b013e3282f2dac9; Lawes CMM, 2004, STROKE, V35, P1024, DOI 10.1161/01.STR.0000126208.14181.DD; Paciaroni M, 2006, J THROMB HAEMOST, V4, P1957, DOI 10.1111/j.1538-7836.2006.02095.x; Rother J, 2008, CEREBROVASC DIS, V25, P366, DOI 10.1159/000120687; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Schmieder RE, 2007, LANCET, V369, P1208, DOI 10.1016/S0140-6736(07)60242-6; Verro P, 2008, STROKE, V39, P1358, DOI 10.1161/STROKEAHA.107.496281; Yusuf S, 2008, NEW ENGL J MED, V359, P1225, DOI 10.1056/NEJMoa0804593	13	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2008	7	10					860	862		10.1016/S1474-4422(08)70199-6	http://dx.doi.org/10.1016/S1474-4422(08)70199-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	355RJ	18757237				2022-12-18	WOS:000259725700002
J	Amarenco, P				Amarenco, Pierre			"Telethrombolysis": stroke consultation by telemedicine	LANCET NEUROLOGY			English	Editorial Material							TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; PILOT PROJECT; TELESTROKE NETWORK; CARE TEMPIS; MANAGEMENT; HOSPITALS; BAVARIA		INSERM, U698, F-75654 Paris 13, France; Univ Paris 07, Bichat Stroke Ctr, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Amarenco, P (corresponding author), INSERM, U698, F-75654 Paris 13, France.	pierre.amarenco@bch.aphp.fr						Albers GW, 2008, CHEST, V133, p630S, DOI 10.1378/chest.08-0720; Amarenco P, 2007, INT J STROKE, V2, P47, DOI 10.1111/j.1747-4949.2007.00087.x; Audebert HJ, 2006, LANCET NEUROL, V5, P742, DOI 10.1016/S1474-4422(06)70527-0; Audebert HJ, 2006, STROKE, V37, P1822, DOI 10.1161/01.STR.0000226741.20629.b2; Audebert HJ, 2005, STROKE, V36, P287, DOI 10.1161/01.STR.0000153015.57892.66; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Hess DC, 2005, STROKE, V36, P2018, DOI 10.1161/01.STR.0000177534.02969.e4; Levine SR, 1999, STROKE, V30, P464, DOI 10.1161/01.STR.30.2.464; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Meyer BC, 2008, LANCET NEUROL, V7, P787, DOI 10.1016/S1474-4422(08)70171-6; Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab; Wang S, 2004, STROKE, V35, P1763, DOI 10.1161/01.STR.0000131858.63829.6e; Wiborg A, 2003, STROKE, V34, P2951, DOI 10.1161/01.STR.0000099125.30731.97	13	7	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2008	7	9					763	765		10.1016/S1474-4422(08)70172-8	http://dx.doi.org/10.1016/S1474-4422(08)70172-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345HZ	18676181				2022-12-18	WOS:000258988400003
J	O'Brien, JT				O'Brien, John T.			A promising new treatment for Alzheimer's disease?	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; DEMENTIA; RIVASTIGMINE; MODERATE		Univ Newcastle Upon Tyne, Wolfson Res Ct, Insg Ageing & Hlth, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England	Newcastle University - UK	O'Brien, JT (corresponding author), Univ Newcastle Upon Tyne, Wolfson Res Ct, Insg Ageing & Hlth, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.	j.t.o'brien@ncl.ac.uk		O'Brien, John/0000-0002-0837-5080				Doody RS, 2008, LANCET, V372, P207, DOI 10.1016/S0140-6736(08)61074-0; Emre M, 2004, NEW ENGL J MED, V351, P2509, DOI 10.1056/NEJMoa041470; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; *MYR GEN, 2008, FLUR FAILS ACH SIGN; O'Brien JT, 2006, LANCET NEUROL, V5, P994, DOI 10.1016/S1474-4422(06)70607-X; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Wolfs CAG, 2008, BRIT J PSYCHIAT, V192, P300, DOI 10.1192/bjp.bp.107.035204	8	7	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2008	7	9					768	769		10.1016/S1474-4422(08)70177-7	http://dx.doi.org/10.1016/S1474-4422(08)70177-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345HZ	18702997				2022-12-18	WOS:000258988400006
J	Weiner, HL				Weiner, Howard L.			Oral laquinimod for treatment of relapsing-remitting multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material									Harvard Univ, Sch Med, Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Weiner, HL (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Partners Multiple Sclerosis Ctr, Boston, MA 02115 USA.	hweiner@rics.bwh.harvard.edu						Brunmark C, 2002, J NEUROIMMUNOL, V130, P163, DOI 10.1016/S0165-5728(02)00225-4; Coles AJ, 2007, MULT SCLER, V13, pS166; Comi G, 2008, LANCET, V371, P2085, DOI 10.1016/S0140-6736(08)60918-6; Kappos L, 2007, LANCET NEUROL, V6, P431, DOI 10.1016/S1474-4422(07)70078-9; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Polman C, 2005, NEUROLOGY, V64, P987, DOI 10.1212/01.WNL.0000154520.48391.69	6	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2008	7	8					672	673		10.1016/S1474-4422(08)70148-0	http://dx.doi.org/10.1016/S1474-4422(08)70148-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	330VA	18635014				2022-12-18	WOS:000257969700007
J	Dorr, J; Elitok, S; Dieste, FJ; Vogel, HP; Schneider, W; Wuerfel, J; Zipp, F; Paul, F				Doerr, Jan; Elitok, Saban; Dieste, Franz-Josef; Vogel, Hans-Peter; Schneider, Wolfgang; Wuerfel, Jens; Zipp, Frauke; Paul, Friedemann			Treatment-resistant chronic headaches and focal pachymeningitis in a 46-year-old man: a rare presentation of Wegener's granulomatosis	LANCET NEUROLOGY			English	Article							ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; CHRONIC MENINGITIS; INVOLVEMENT; DIAGNOSIS; ANCA		[Doerr, Jan; Dieste, Franz-Josef; Vogel, Hans-Peter; Wuerfel, Jens; Zipp, Frauke; Paul, Friedemann] Charite Univ Med Berlin, Cecilie Vogt Clin Neurol, HKBB, D-10117 Berlin, Germany; [Elitok, Saban] Charite Univ Med Berlin, HELIOS Hosp Berlin Buch, Franz Volhard Klin, Dept Nephrol, Berlin, Germany; [Schneider, Wolfgang] HELIOS Hosp Berlin Buch, Dept Pathol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Zipp, F (corresponding author), Charite Univ Med Berlin, Cecilie Vogt Clin Neurol, HKBB, Charitepl 1, D-10117 Berlin, Germany.	frauke.zipp@charite.de	Zipp, Frauke/C-9968-2015; Paul, Friedemann/ABF-9415-2020	Zipp, Frauke/0000-0002-1231-1928; Wuerfel, Jens/0000-0002-0034-8053; paul, friedemann/0000-0002-6378-0070				Aouba A, 2008, CLIN REV ALLERG IMMU, V34, P65, DOI 10.1007/s12016-007-8026-1; de Groot K, 2001, ARCH NEUROL-CHICAGO, V58, P1215, DOI 10.1001/archneur.58.8.1215; Di Comite G, 2006, CLIN EXP RHEUMATOL, V24, pS60; DRACHMAN DA, 1963, ARCH NEUROL-CHICAGO, V8, P145, DOI 10.1001/archneur.1963.00460020045003; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; Gleissner B, 2006, LANCET NEUROL, V5, P443, DOI 10.1016/S1474-4422(06)70443-4; Good CD, 2000, NEURORADIOLOGY, V42, P448, DOI 10.1007/s002340000300; Hagen EC, 1998, KIDNEY INT, V53, P743, DOI 10.1046/j.1523-1755.1998.00807.x; Helbok R, 2006, NEUROEPIDEMIOLOGY, V26, P37, DOI 10.1159/000089236; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Jinnah HA, 1997, ARTHRITIS RHEUM, V40, P573, DOI 10.1002/art.1780400326; Kamimura T, 2006, JCR-J CLIN RHEUMATOL, V12, P259, DOI 10.1097/01.rhu.0000239904.62352.5e; Kupersmith MJ, 2004, NEUROLOGY, V62, P686, DOI 10.1212/01.WNL.0000113748.53023.B7; Lim IGS, 2002, ANN RHEUM DIS, V61, P571, DOI 10.1136/ard.61.6.571; NISHINO H, 1993, ANN NEUROL, V33, P4, DOI 10.1002/ana.410330103; Phanthumchinda K, 1997, HEADACHE, V37, P249, DOI 10.1046/j.1526-4610.1997.3704249.x; RAO JK, 1995, ANN INTERN MED, V123, P925, DOI 10.7326/0003-4819-123-12-199512150-00005; Reiber H, 2003, CLIN CHEM LAB MED, V41, P331, DOI 10.1515/CCLM.2003.053; Reinhold-Keller E, 2001, CLIN EXP RHEUMATOL, V19, P541; Schievink WI, 2006, JAMA-J AM MED ASSOC, V295, P2286, DOI 10.1001/jama.295.19.2286; Schluterman KO, 2004, ARCH NEUROL-CHICAGO, V61, P1423, DOI 10.1001/archneur.61.9.1423; Seror R, 2006, MEDICINE, V85, P54, DOI 10.1097/01.md.0000200166.90373.41; Shiotani A, 1997, INTERNAL MED, V36, P514, DOI 10.2169/internalmedicine.36.514; WEINBERGER LM, 1993, NEUROLOGY, V43, P1831, DOI 10.1212/WNL.43.9.1831; WINTERBAUER RH, 1993, CHEST, V104, P352, DOI 10.1378/chest.104.2.352; Wung PK, 2006, NAT CLIN PRACT RHEUM, V2, P192, DOI 10.1038/ncprheum0139; Yasuhara T, 2002, J NEUROSURG, V97, P1229, DOI 10.3171/jns.2002.97.5.1229	27	7	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2008	7	4					368	372		10.1016/S1474-4422(08)70064-4	http://dx.doi.org/10.1016/S1474-4422(08)70064-4			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	285PF	18339352				2022-12-18	WOS:000254788000017
J	Schneider, LS				Schneider, Lon S.			Does donepezil improve executive function inpatients with CADASIL?	LANCET NEUROLOGY			English	Editorial Material							VASCULAR DEMENTIA		Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA	University of Southern California	Schneider, LS (corresponding author), Univ So Calif, Keck Sch Med, 1510 San Pablo St,HCC 600, Los Angeles, CA 90033 USA.	lschneid@usc.edu						Charlton RA, 2006, NEUROLOGY, V66, P1523, DOI 10.1212/01.wnl.0000216270.02610.7e; DICHGANS M, 2008, LANCET NEUROL, V7; Kavirajan H, 2007, LANCET NEUROL, V6, P782, DOI 10.1016/S1474-4422(07)70195-3; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Peters N, 2005, AM J PSYCHIAT, V162, P2078, DOI 10.1176/appi.ajp.162.11.2078; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Royall DR, 1998, J NEUROL NEUROSUR PS, V64, P588, DOI 10.1136/jnnp.64.5.588; ROYALL DR, 1992, J AM GERIATR SOC, V40, P1221, DOI 10.1111/j.1532-5415.1992.tb03646.x	8	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2008	7	4					287	289		10.1016/S1474-4422(08)70047-4	http://dx.doi.org/10.1016/S1474-4422(08)70047-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	285PF	18296122				2022-12-18	WOS:000254788000003
J	Mas, JL; Chatellier, G				Mas, Jean-Louis; Chatellier, Gilles		EVA-3S Investigators	Recent carotid stenting trials	LANCET NEUROLOGY			English	Editorial Material							ENDARTERECTOMY		Univ Paris 05, Hop St Anne, Paris, France; Univ Paris 05, Hop Europeen Georges Pompidou, APHP, Paris, France	GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Mas, JL (corresponding author), Univ Paris 05, Hop St Anne, Paris, France.							Forsting M, 2007, LANCET NEUROL, V6, P101, DOI 10.1016/S1474-4422(07)70010-8; Gray WA, 2007, CATHETER CARDIO INTE, V69, P341, DOI 10.1002/ccd.21050; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Mas JL, 2007, NEW ENGL J MED, V356, P306; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8	6	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2007	6	4					295	296		10.1016/S1474-4422(07)70065-0	http://dx.doi.org/10.1016/S1474-4422(07)70065-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	149KE	17362831				2022-12-18	WOS:000245145000007
J	Maas, AI; Murray, GD				Maas, Andrew I. R.; Murray, Gordon D.			Magnesium for neuroprotection after traumatic brain injury	LANCET NEUROLOGY			English	News Item									Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland	Erasmus University Rotterdam; Erasmus MC; University of Edinburgh	Maas, AI (corresponding author), Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands.	airmaas@erasmusmc.nl	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734	NINDS NIH HHS [R01 NS-426291] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; HEATH DL, 1996, J PHARMACOL EXP THER, V288, P1311; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; MAAS AI, IN PRESS J NEUROTRAU; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5	9	7	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					20	21		10.1016/S1474-4422(06)70668-8	http://dx.doi.org/10.1016/S1474-4422(06)70668-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119UI	17166797				2022-12-18	WOS:000243039000012
J	Spencer, S				Spencer, Susan			Epilepsy: clinical observations and novel mechanisms	LANCET NEUROLOGY			English	News Item							SEIZURES		Yale Univ, Sch Med, New Haven, CT 06520 USA	Yale University	Spencer, S (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.	susan.spencer@yale.edu						Alpherts WCJ, 2006, NEUROLOGY, V67, P626, DOI 10.1212/01.wnl.0000230139.45304.eb; Berkovic SF, 2006, LANCET NEUROL, V5, P488, DOI 10.1016/S1474-4422(06)70446-X; Hermann BP, 2006, ANN NEUROL, V60, P80, DOI 10.1002/ana.20872; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Jirsch JD, 2006, BRAIN, V129, P1593, DOI 10.1093/brain/awl085; Meador KJ, 2006, NEUROLOGY, V67, P407, DOI 10.1212/01.wnl.0000227919.81208.b2	6	7	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					14	16		10.1016/S1474-4422(06)70665-2	http://dx.doi.org/10.1016/S1474-4422(06)70665-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119UI	17166794				2022-12-18	WOS:000243039000009
J	Birkenhager, WH; Staessen, JA				Birkenhager, WH; Staessen, JA			Antihypertensives for prevention of Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							BLOOD-PRESSURE		Univ Louvain, Dept Cardiovasc Dis, Div Hypertens & Cardiovasc Rehabil, Studies Coordinating Ctr, Louvain, Belgium; Erasmus Univ, Rotterdam, Netherlands	Erasmus University Rotterdam	Birkenhager, WH (corresponding author), Univ Louvain, Dept Cardiovasc Dis, Div Hypertens & Cardiovasc Rehabil, Studies Coordinating Ctr, Louvain, Belgium.	w.birkenhager@chello.nl	Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				BIRKENHAGER WH, 2006, IN PRESS PROG CARDIO; Casserly I, 2004, LANCET, V363, P1139, DOI 10.1016/S0140-6736(04)15900-X; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; Elias PK, 2004, HYPERTENSION, V44, P631, DOI 10.1161/01.HYP.0000145858.07252.99; Forette F, 2002, ARCH INTERN MED, V162, P2046, DOI 10.1001/archinte.162.18.2046; KHACHATURIAN AS, 2006, ARCH NEUROL-CHICAGO, V63, pE1; Staessen JA, 2004, HYPERTENSION, V44, P612, DOI 10.1161/01.HYP.0000145864.95630.20; Staessen JA, 2005, HYPERTENS RES, V28, P385, DOI 10.1291/hypres.28.385; WANG JG, 2003, SEMIN CEREBROVASC DI, V3, P155	9	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					466	468		10.1016/S1474-4422(06)70453-7	http://dx.doi.org/10.1016/S1474-4422(06)70453-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16713914	Green Accepted			2022-12-18	WOS:000237906000004
J	Sell, E; Minassian, BA				Sell, Erick; Minassian, Berge A.			Demystifying vaccination-associated encephalopathy	LANCET NEUROLOGY			English	Editorial Material							SEVERE MYOCLONIC EPILEPSY; IMMUNIZATION; PERTUSSIS; VACCINES; INFANCY		Hosp Sick Children, Dept Paediat, Div Neurol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Sell, E (corresponding author), Hosp Sick Children, Dept Paediat, Div Neurol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	bminass@sickkids.ca						*AM AC PED, 2003, 2003 ED BOOK REP COM; BALE LF, 2004, J CHILD NEUROL, V19, P405; Berkovic SF, 2006, LANCET NEUROL, V5, P488, DOI 10.1016/S1474-4422(06)70446-X; Claes L, 2001, AM J HUM GENET, V68, P1327, DOI 10.1086/320609; Dravet C., 1978, VIE ME, V8, P543, DOI DOI 10.1016/S0370-4475(78)80126-9; GALE JL, 1994, JAMA-J AM MED ASSOC, V271, P37, DOI 10.1001/jama.271.1.37; Geier DA, 2004, INT J TOXICOL, V23, P369, DOI 10.1080/10915810490902038; Geier DA, 2004, BRAIN DEV-JPN, V26, P296, DOI 10.1016/S0387-7604(03)00169-4; Nieto-Barrera M, 2000, REV NEUROLOGIA, V30, P620, DOI 10.33588/rn.3007.2000016; Piyasirisilp S, 2002, CURR OPIN NEUROL, V15, P333, DOI 10.1097/00019052-200206000-00018; Stehr-Green P, 2003, AM J PREV MED, V25, P101, DOI 10.1016/S0749-3797(03)00113-2; Tanabe Takuya, 2004, No To Hattatsu, V36, P318; Zhou Weigong, 2003, MMWR Surveill Summ, V52, P1	13	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2006	5	6					465	466		10.1016/S1474-4422(06)70452-5	http://dx.doi.org/10.1016/S1474-4422(06)70452-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	047VE	16713913				2022-12-18	WOS:000237906000003
J	Dietz, V				Dietz, V			Good clinical practice in neurorehabilitation	LANCET NEUROLOGY			English	Editorial Material							LOCOMOTOR-ACTIVITY; TRIAL		Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland	University of Zurich	Dietz, V (corresponding author), Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland.	Volker.Dietz@balgrist.ch						Dietz V, 2004, J APPL PHYSIOL, V96, P1954, DOI 10.1152/japplphysiol.00942.2003; Dietz V, 2002, BRAIN, V125, P2626, DOI 10.1093/brain/awf273; Dietz V, 2002, NAT REV NEUROSCI, V3, P781, DOI 10.1038/nrn939; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004	6	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2006	5	5					377	378		10.1016/S1474-4422(06)70420-3	http://dx.doi.org/10.1016/S1474-4422(06)70420-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	037LF	16632302				2022-12-18	WOS:000237147600004
J	Kastenbauer, S				Kastenbauer, S			Pneumococcal meningitis: a 21st century perspective	LANCET NEUROLOGY			English	Editorial Material							BACTERIAL-MENINGITIS; PROGNOSTIC-FACTORS; ADULTS; DEXAMETHASONE; THERAPY		Univ Munich, Dept Neurol, D-8000 Munich, Germany	University of Munich	Kastenbauer, S (corresponding author), Univ Munich, Dept Neurol, D-8000 Munich, Germany.	stefan@kastenbauer.de						Auer M, 2000, J INFECT DIS, V182, P347, DOI 10.1086/315658; Christen S, 2001, FREE RADICAL BIO MED, V31, P754, DOI 10.1016/S0891-5849(01)00642-6; de Gans J, 2002, NEW ENGL J MED, V347, P1549, DOI 10.1056/NEJMoa021334; Kastenbauer S, 2003, BRAIN, V126, P1015, DOI 10.1093/brain/awg113; Klein M, 2003, ANN NEUROL, V54, P451, DOI 10.1002/ana.10684; Koedel U, 1997, NEUROSCI LETT, V225, P33, DOI 10.1016/S0304-3940(97)00177-8; Koedel U, 2002, LANCET INFECT DIS, V2, P721, DOI 10.1016/S1473-3099(02)00450-4; Leib SL, 2003, PEDIATR RES, V54, P353, DOI 10.1203/01.PDR.0000079185.67878.72; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Swartz MN, 2004, NEW ENGL J MED, V351, P1826, DOI 10.1056/NEJMp048246; Tunkel AR, 2002, NEW ENGL J MED, V347, P1613, DOI 10.1056/NEJMe020131; van de Beek D, 2004, NEW ENGL J MED, V351, P1849, DOI 10.1056/NEJMoa040845; van de Beek D, 2004, LANCET INFECT DIS, V4, P139, DOI 10.1016/S1473-3099(04)00937-5; van de Beek D, 2004, ANN INTERN MED, V141, P327, DOI 10.7326/0003-4819-141-4-200408170-00028; Weisfelt M, 2006, LANCET NEUROL, V5, P123, DOI 10.1016/S1474-4422(05)70288-X	15	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2006	5	2					104	105		10.1016/S1474-4422(06)70329-5	http://dx.doi.org/10.1016/S1474-4422(06)70329-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	006RO	16426981				2022-12-18	WOS:000234914800002
J	Chen, V				Chen, V			Channelopathy linked to epilepsy and paroxysmal dyskinesia	LANCET NEUROLOGY			English	News Item																			0	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2005	4	8					462	462		10.1016/S1474-4422(05)70134-4	http://dx.doi.org/10.1016/S1474-4422(05)70134-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	951EX	16086497				2022-12-18	WOS:000230913000011
J	Nelson, R				Nelson, R			Microtubule-stabilising drugs may be therapeutic in AD	LANCET NEUROLOGY			English	News Item																			0	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2005	4	2					83	84		10.1016/S1474-4422(05)00984-1	http://dx.doi.org/10.1016/S1474-4422(05)00984-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	893IK	15709226				2022-12-18	WOS:000226712300015
J	Ghajar, J; Hesdorffer, DC				Ghajar, J; Hesdorffer, DC			Steroids CRASH out of head-injury treatment	LANCET NEUROLOGY			English	Letter									Cornell Univ, Weill Med Coll, Ithaca, NY 14853 USA; Columbia Univ, GH Sergievsky Ctr, New York, NY USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	Cornell University; Columbia University; Columbia University	Ghajar, J (corresponding author), Cornell Univ, Weill Med Coll, Ithaca, NY 14853 USA.	jam@ghajar.net						Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2	6	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2004	3	12					708	708		10.1016/S1474-4422(04)00932-9	http://dx.doi.org/10.1016/S1474-4422(04)00932-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	873MD	15556802				2022-12-18	WOS:000225283500016
J	McCrory, P; Matser, E; Cantu, R; Ferrigno, M				McCrory, P; Matser, E; Cantu, R; Ferrigno, M			Football Neurology	LANCET NEUROLOGY			English	Editorial Material									Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia; Univ Melbourne, Inst Brain Res, Parkville, Vic 3052, Australia	University of Melbourne; University of Melbourne	McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia.		McCrory, Paul/Q-8688-2019						0	7	7	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2004	3	7					435	436		10.1016/S1474-4422(04)00810-5	http://dx.doi.org/10.1016/S1474-4422(04)00810-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832ZQ	15207801				2022-12-18	WOS:000222306600020
J	Lipton, RB; Dodick, DW				Lipton, RB; Dodick, DW			CGRP antagonists in the acute treatment of migraine	LANCET NEUROLOGY			English	Editorial Material									Albert Einstein Coll Med, Dept Neurol Epidemiol & Populat Hlth, New York, NY USA; Mayo Clin, Coll Med, Scottsdale, AZ USA	Yeshiva University; Mayo Clinic; Mayo Clinic Phoenix	Lipton, RB (corresponding author), Albert Einstein Coll Med, Dept Neurol Epidemiol & Populat Hlth, New York, NY USA.	riipton@aecom.yu.edu	Lipton, Richard B/B-5060-2011; Lipton, Richard Bruce/AAY-2818-2021					DODICK DW, IN PRESS HEADACHE; Ferrari MD, 2001, LANCET, V358, P1668, DOI 10.1016/S0140-6736(01)06711-3; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917; Goldstein DJ, 2001, LANCET, V358, P1230, DOI 10.1016/S0140-6736(01)06347-4; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505	5	7	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					332	332		10.1016/S1474-4422(04)00764-1	http://dx.doi.org/10.1016/S1474-4422(04)00764-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15157847				2022-12-18	WOS:000221663000013
J	Vanmolkot, KRJ; van den Maagdenberg, AMJM; Haan, J; Ferrari, MD				Vanmolkot, KRJ; van den Maagdenberg, AMJM; Haan, J; Ferrari, MD			New discoveries about the second gene for familial hemiplegic migraine, ATP1A2	LANCET NEUROLOGY			English	Editorial Material									Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands; Rijnland Hosp Leiderdorp, Leiderdorp, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Rijnland Hospital	Vanmolkot, KRJ (corresponding author), Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands.		Ferrari, Michel D./ABE-3758-2021; van den Maagdenberg, Arn M.J.M./AAE-9052-2019	Ferrari, Michel D./0000-0001-9691-9449; 				Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; De Fusco M, 2003, NAT GENET, V33, P192, DOI 10.1038/ng1081; HAAN J, 1995, CEPHALALGIA, V15, P477, DOI 10.1046/j.1468-2982.1995.1506477.x; Moseley AE, 2003, J BIOL CHEM, V278, P5317, DOI 10.1074/jbc.M211315200; Vanmolkot KRJ, 2003, ANN NEUROL, V54, P360, DOI 10.1002/ana.10674	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2003	2	12					721	721		10.1016/S1474-4422(03)00591-X	http://dx.doi.org/10.1016/S1474-4422(03)00591-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745AV	14636773				2022-12-18	WOS:000186665800012
J	Sautter, J; Wick, R; Adlkofer, F; Baker, MG				Sautter, J; Wick, R; Adlkofer, F; Baker, MG			Research in the European Union	LANCET NEUROLOGY			English	Article							BURDEN											BAKER M, 2003, PRACTICAL NEUROLOGY, V3, P2; *EUR COMM, BRAIN RES EUR STRUCT; GYORFFI M, 2003, 20591 EUR; Menken M, 2000, ARCH NEUROL-CHICAGO, V57, P418, DOI 10.1001/archneur.57.3.418; Morris Richard G M, 2002, Trends Neurosci, V25, P591, DOI 10.1016/S0166-2236(02)02277-4; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x	6	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2003	2	11					702	706		10.1016/S1474-4422(03)00559-3	http://dx.doi.org/10.1016/S1474-4422(03)00559-3			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	734ZN	14572739				2022-12-18	WOS:000186088000019
J	van de Beek, MT; Taal, W; Veldkamp, RF; Vecht, CJ				van de Beek, MT; Taal, W; Veldkamp, RF; Vecht, CJ			A woman with multiple sclerosis and pink saliva	LANCET NEUROLOGY			English	Editorial Material							NEUROGENIC PULMONARY-EDEMA; PRESENTING SYMPTOM		Med Ctr The Hague, Dept Cardiol, NL-2501 CK The Hague, Netherlands		Vecht, CJ (corresponding author), Med Ctr The Hague, Dept Neurol, POB 432, NL-2501 CK The Hague, Netherlands.	c.vecht@mchaaglanden.nl		Taal, Walter/0000-0002-5530-7259				Crawley F, 2001, MULT SCLER, V7, P71; GENTILONI N, 1992, ITAL J NEUROL SCI, V13, P435, DOI 10.1007/BF02312151; Samuels Martin A., 1993, P103; SIMON RP, 1993, NEUROL CLIN, V11, P309, DOI 10.1016/S0733-8619(18)30155-5; SIMON RP, 1991, ANN NEUROL, V30, P727, DOI 10.1002/ana.410300515	5	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2003	2	4					254	255		10.1016/S1474-4422(03)00354-5	http://dx.doi.org/10.1016/S1474-4422(03)00354-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	658NH	12849214				2022-12-18	WOS:000181726700021
J	Pasinetti, GM; Pompl, PN				Pasinetti, GM; Pompl, PN			Cyclo-oxygenase inhibitors and Alzheimer's: are we well ADAPTed?	LANCET NEUROLOGY			English	Letter							DISEASE; CYCLOOXYGENASE; PROGRESSION		Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.			Pasinetti, Giulio/0000-0002-1524-5196				BRETELER M, ABETA42 PEPTIDE LOWE; CLEMENTS PJ, 1993, TXB RHEUMATOLOGY, P700; Ho L, 2001, ARCH NEUROL-CHICAGO, V58, P487, DOI 10.1001/archneur.58.3.487; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Pasinetti GM, 2001, ARCH GERONTOL GERIAT, V33, P13, DOI 10.1016/S0167-4943(01)00091-7; Raz A, 2002, BIOCHEM PHARMACOL, V63, P343, DOI 10.1016/S0006-2952(01)00857-7; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352; Zandi PP, 2001, NEUROBIOL AGING, V22, P811, DOI 10.1016/S0197-4580(01)00297-4; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880	13	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2002	1	7					403	404		10.1016/S1474-4422(02)00214-4	http://dx.doi.org/10.1016/S1474-4422(02)00214-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	606KC	12849357				2022-12-18	WOS:000178732300012
J	Aurora, SK; Chronicle, EP				Aurora, SK; Chronicle, EP			Migraine's magnetic attraction	LANCET NEUROLOGY			English	Editorial Material									Swedish Neurosci Inst, Seattle, WA USA; Univ Lancaster, Dept Psychol, Lancaster LA1 4YF, England	Swedish Medical Center; Lancaster University	Aurora, SK (corresponding author), Swedish Neurosci Inst, Seattle, WA USA.							Battelli L, 2002, NEUROLOGY, V58, P1066, DOI 10.1212/WNL.58.7.1066; Bohotin V, 2002, BRAIN, V125, P912, DOI 10.1093/brain/awf081; Brighina F, 2002, EXP BRAIN RES, V145, P177, DOI 10.1007/s00221-002-1096-7; Mulleners WM, 2001, HEADACHE, V41, P565, DOI 10.1046/j.1526-4610.2001.041006565.x; Ophoff RA, 1998, TRENDS PHARMACOL SCI, V19, P121, DOI 10.1016/S0165-6147(98)01182-1	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2002	1	4					211	211		10.1016/S1474-4422(02)00097-2	http://dx.doi.org/10.1016/S1474-4422(02)00097-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588KZ	12849451				2022-12-18	WOS:000177701800015
J	Egbebike, J; Shen, Q; Doyle, K; Der-Nigoghossian, CA; Panicker, L; Gonzales, IJ; Grobois, L; Carmona, JC; Vrosgou, A; Kaur, A; Boehme, A; Velazquez, A; Rohaut, B; Roh, D; Agarwal, S; Park, S; Connolly, ES; Claassen, J				Egbebike, Jennifer; Shen, Qi; Doyle, Kevin; Der-Nigoghossian, Caroline A.; Panicker, Lucy; Gonzales, Ian Jerome; Grobois, Lauren; Carmona, Jerina C.; Vrosgou, Athina; Kaur, Arshnell; Boehme, Amelia; Velazquez, Angela; Rohaut, Benjamin; Roh, David; Agarwal, Sachin; Park, Soojin; Connolly, E. Sander; Claassen, Jan			Cognitive-motor dissociation and time to functional recovery in patients with acute brain injury in the USA: a prospective observational cohort study	LANCET NEUROLOGY			English	Article							VEGETATIVE STATE; CONSCIOUSNESS; DISORDERS; REHABILITATION; DIAGNOSIS; ACCURACY; MODEL; COMA	Background Recovery trajectories of clinically unresponsive patients with acute brain injury are largely uncertain. Brain activation in the absence of a behavioural response to spoken motor commands can be detected by EEG, also known as cognitive-motor dissociation. We aimed to explore the role of cognitive-motor dissociation in predicting time to recovery in patients with acute brain injury. Methods In this observational cohort study, we prospectively studied two independent cohorts of clinically unresponsive patients (aged >= 18 years) with acute brain injury. Machine learning was applied to EEG recordings to diagnose cognitive-motor dissociation by detecting brain activation in response to verbal commands. Survival statistics and shift analyses were applied to the data to identify an association between cognitive-motor dissociation and time to and magnitude of recovery. The prediction accuracy of the model that was built using the derivation cohort was assessed using the validation cohort. Functional outcomes of all patients were assessed with the Glasgow Outcome Scale-Extended (GOS-E) at hospital discharge and at 3, 6, and 12 months after injury. Patients who underwent withdrawal of life-sustaining therapies were censored, and death was treated as a competing risk. Findings Between July 1, 2014, and Sept 30, 2021, we screened 598 patients with acute brain injury and included 193 (32%) patients, of whom 100 were in the derivation cohort and 93 were in the validation cohort. At 12 months, 28 (15%) of 193 unresponsive patients had a GOS-E score of 4 or above. Cognitive-motor dissociation was seen in 27 (14%) patients and was an independent predictor of shorter time to good recovery (hazard ratio 5.6 [95% CI 2.5-12.5]), as was underlying traumatic brain injury or subdural haematoma (4.4 [1.4-14.0]), a Glasgow Coma Scale score on admission of greater than or equal to 8 (2.2 [1.0-4.7]), and younger age (1.0 [1.0-1.1]). Among patients discharged home or to a rehabilitation setting, those diagnosed with cognitive-motor dissociation consistently had higher scores on GOS-E indicating better functional recovery compared with those without cognitive-motor dissociation, which was seen as early as 3 months after the injury (odds ratio 4.5 [95% CI 2.0-33.6]). Interpretation Recovery trajectories of clinically unresponsive patients diagnosed with cognitive-motor dissociation early after brain injury are distinctly different from those without cognitive-motor dissociation. A diagnosis of cognitive-motor dissociation could inform the counselling of families of clinically unresponsive patients, and it could help clinicians to identify patients who will benefit from rehabilitation.	[Egbebike, Jennifer; Shen, Qi; Doyle, Kevin; Grobois, Lauren; Carmona, Jerina C.; Vrosgou, Athina; Velazquez, Angela; Rohaut, Benjamin; Agarwal, Sachin; Claassen, Jan] Columbia Univ Irving, Med Ctr, Dept Neurol, New York, MD 10032 USA; [Boehme, Amelia; Connolly, E. Sander] Univ Irving, Med Ctr, Dept Neurosurg, New York, NY USA; [Der-Nigoghossian, Caroline A.; Panicker, Lucy; Gonzales, Ian Jerome; Kaur, Arshnell; Roh, David; Agarwal, Sachin; Park, Soojin; Connolly, E. Sander] New York Presbyterian Hosp, New York, NY USA; [Boehme, Amelia] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	NewYork-Presbyterian Hospital; Columbia University	Claassen, J (corresponding author), Columbia Univ Irving, New York Presbyterian Hosp, Med Ctr, Dept Neurol, New York, NY 10032 USA.	jc1439@columbia.edu	Rohaut, Benjamin/O-9250-2017	Rohaut, Benjamin/0000-0001-6752-8756; Vrosgou, Athina/0000-0002-2040-215X	US National Institutes of Health (NIH) [HL151901]; NIH [NS106014, NS112760, HL153311, NS113055]; McDonnell Foundation	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); McDonnell Foundation	DR is supported by grant funding from the US National Institutes of Health (NIH; HL151901). SA is supported by grant funding from the NIH (HL153311). SP is supported by grant funding from the NIH (NS113055). JC is a minority shareholder at iCE Neurosystems and is supported by grant funding from the NIH (NS106014, NS112760), and the McDonnell Foundation. All other authors declare no competing interests.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Blanche P, 2015, BIOMETRICS, V71, P102, DOI 10.1111/biom.12232; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Claassen J, 2021, NEUROCRIT CARE, V35, P4, DOI 10.1007/s12028-021-01260-x; Claassen J, 2019, NEW ENGL J MED, V380, P2497, DOI 10.1056/NEJMoa1812757; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Edlow BL, 2021, NAT REV NEUROL, V17, P135, DOI 10.1038/s41582-020-00428-x; Edlow BL, 2017, BRAIN, V140, P2399, DOI 10.1093/brain/awx176; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Fernandez-Espejo D, 2015, JAMA NEUROL, V72, P1442, DOI 10.1001/jamaneurol.2015.2614; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Giacino JT, 2018, NEUROLOGY, V91, P450, DOI 10.1212/WNL.0000000000005926; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Greer DM, 2012, CRIT CARE MED, V40, P1150, DOI 10.1097/CCM.0b013e318237bafb; Hammond FM, 2021, NEUROCRIT CARE, V35, P55, DOI 10.1007/s12028-021-01289-y; Hammond FM, 2019, J NEUROTRAUM, V36, P1136, DOI 10.1089/neu.2018.5954; Howard G, 2012, STROKE, V43, P664, DOI 10.1161/STROKEAHA.111.632935; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jourdan C, 2013, NEUROREHAB NEURAL RE, V27, P35, DOI 10.1177/1545968312440744; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kawaguchi A, 2015, J STAT SOFTW, V67, P1; Kondziella D, 2016, J NEUROL NEUROSUR PS, V87, P485, DOI 10.1136/jnnp-2015-310958; Kowalski RG, 2021, JAMA NEUROL, V78, P548, DOI 10.1001/jamaneurol.2021.0084; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lu J, 2010, J NEUROTRAUM, V27, P843, DOI 10.1089/neu.2010.1293; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; O'Donnell JC, 2019, NEUROSCI BIOBEHAV R, V98, P336, DOI 10.1016/j.neubiorev.2018.12.015; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Posner JB, 2007, PLUM POSNERS DIAGNOS; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Tutz G, 1996, COMPUT STAT DATA AN, V22, P537, DOI 10.1016/0167-9473(96)00004-7; von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012; Wannez S, 2017, ANN NEUROL, V81, P883, DOI 10.1002/ana.24962; Zhong Y, 2022, PHARM STAT, V21, P38, DOI 10.1002/pst.2151; Zhou BQ, 2011, BIOMETRICS, V67, P661, DOI 10.1111/j.1541-0420.2010.01493.x	36	6	6	6	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2022	21	8					704	713						10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	4P3VT	35841909				2022-12-18	WOS:000855325100017
J	Ossenkoppele, R; van der Kant, R; Hansson, O				Ossenkoppele, Rik; van der Kant, Rik; Hansson, Oskar			Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials	LANCET NEUROLOGY			English	Review							AMYLOID-BETA; PATHOLOGY; PROTAC; BLOOD	Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease that is closely linked both spatially and temporally to emergence of neurodegeneration and manifestation of clinical symptoms. There is an urgent need for accurate PET, CSF, and plasma biomarkers of tau pathology to improve the diagnostic process in clinical practice and the selection of participants and monitoring of treatment effects in trials. Recent developments Innovative second-generation tau-PET tracers with high affinity and selectivity to tau pathology in Alzheimer's disease have enabled detection of tau pathology in medial temporal lobe subregions that are affected in the earliest disease stages. Furthermore, novel but common tau spreading subtypes have been discovered using tau-PET, suggesting much greater interindividual differences in the distribution of tau pathology across the brain than previously assumed. In the CSF biomarker field, novel phosphorylated tau (p-tau) assays have been introduced that better reflect tau tangle load than established CSF biomarkers of tau pathology. The advent of cost-effective and accessible blood-based biomarkers for tau pathophysiology (ie, p-tau181, p-tau217, and p-tau231) might transform the Alzheimer's disease field, as these biomarkers correlate with post-mortem Alzheimer's disease pathology, differentiate Alzheimer's disease from other types of dementia, and predict future progression from normal cognition and mild cognitive impairment to Alzheimer's disease. In controlled investigational settings, improvements in tau-PET and biofluid p-tau markers have led to earlier disease detection, more accurate diagnostic methods, and refinement of prognosis. The anti-tau therapy landscape is rapidly evolving, with multiple ongoing phase 1 and 2 trials of post-translational modification of tau, tau immunotherapy, tau aggregation inhibitors, and targeting production of tau and reduction of intracellular tau levels. Neuroimaging and biofluid tau markers hold potential for optimising such clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy. Where next? Major challenges to overcome are the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding. Prospective validation studies of biofluid p-tau markers are needed, and assay-related preanalytical and analytical factors need further refinement. Future studies should focus on demonstrating the diagnostic and prognostic accuracy of tau biomarkers-blood-based markers in particular-in non-tertiary settings, such as primary care, which is characterised by a diverse population with medical comorbidities. Large-scale head-to-head studies are needed across different stages of Alzheimer's disease to determine which tau biomarker is optimal in various clinical scenarios, such as early diagnosis, differential diagnosis, and prognosis, and for aspects of clinical trial design, such as proving target engagement, optimising participant selection, and refining monitoring of treatment effects.	[Ossenkoppele, Rik; Hansson, Oskar] Lund Univ, Clin Memory Res Unit, S-20502 Malmo, Sweden; [Ossenkoppele, Rik; van der Kant, Rik] Vrije Univ Amsterdam, Amsterdam Neurosci, Alzheimer Ctr Amsterdam, Dept Neurol, Amsterdam, Netherlands; [van der Kant, Rik] Vrije Univ Amsterdam, Amsterdam Neurosci, Ctr Neurogen & Cognit Res, Amsterdam, Netherlands; [Hansson, Oskar] Skin Univ Hosp, Memory Clin, Malmo, Sweden	Lund University; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Ossenkoppele, R (corresponding author), Lund Univ, Clin Memory Res Unit, S-20502 Malmo, Sweden.	r.ossenkoppele@amsterdamumc.nl	Hansson, Oskar/A-7134-2013	Hansson, Oskar/0000-0001-8467-7286	Lund University from Avid Radiopharmaceuticals; Biogen; Eli Lilly; Eisai; GE Healthcare; Pfizer; Roche	Lund University from Avid Radiopharmaceuticals; Biogen(Biogen); Eli Lilly(Eli Lilly); Eisai(Eisai Co Ltd); GE Healthcare(General ElectricGE Healthcare); Pfizer(Pfizer); Roche(Roche Holding)	OH has acquired research support for Lund University from Avid Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy and speaker fees from Roche, Genentech, Siemens, Biogen, Alzpath, and Cerveau. RO and RVDK declare no competing interests.	AC Immune SA, 2020, AC IMM REP TOP LIN R; AC Immune SA, 2021, AC IMM ANN 1 POS COG; Ashton NJ, 2021, EUR J NUCL MED MOL I, V48, P2140, DOI 10.1007/s00259-021-05253-y; Ashton NJ, 2021, ACTA NEUROPATHOL, V141, P709, DOI 10.1007/s00401-021-02275-6; Barthelemy NR, 2020, J EXP MED, V217, DOI 10.1084/jem.20200861; Barthelemy NR, 2020, NAT MED, V26, P398, DOI 10.1038/s41591-020-0781-z; Bayoumy S, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00939-9; Berron D, 2021, BRAIN, V144, P2771, DOI 10.1093/brain/awab114; Berron D, 2020, BRAIN, V143, P1233, DOI 10.1093/brain/awaa068; Biogen, 2021, BIOG ANN TOPL RES PH; Brickman AM, 2021, ALZHEIMERS DEMENT, V17, P1353, DOI 10.1002/alz.12301; Bridel C, 2022, BRAIN, DOI 10.1093/brain/awac013; Burlot MA, 2015, HUM MOL GENET, V24, P5965, DOI 10.1093/hmg/ddv268; Chang CW, 2021, SCIENCE, V371, P904, DOI 10.1126/science.abb8255; Congdon EE, 2018, NAT REV NEUROL, V14, P399, DOI 10.1038/s41582-018-0013-z; Crooke ST, 2021, NAT REV DRUG DISCOV, V20, P427, DOI 10.1038/s41573-021-00162-z; Cullen NC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23746-0; DeVos SL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0481; Devos SL, 2013, J NEUROSCI, V33, P12887, DOI 10.1523/JNEUROSCI.2107-13.2013; Fleisher AS, 2020, JAMA NEUROL, V77, P829, DOI 10.1001/jamaneurol.2020.0528; Gibbons GS, 2019, JAMA NEUROL, V76, P101, DOI 10.1001/jamaneurol.2018.2505; Hansson O, 2021, NAT MED, V27, P954, DOI 10.1038/s41591-021-01382-x; Horie K, 2021, BRAIN, V144, P515, DOI 10.1093/brain/awaa373; Jack CR, 2019, BRAIN, V142, P3230, DOI 10.1093/brain/awz268; Jack CR, 2018, BRAIN, V141, P1517, DOI 10.1093/brain/awy059; Janelidze S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15436-0; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Karikari TK, 2021, ALZHEIMERS DEMENT, V17, P755, DOI 10.1002/alz.12236; Karikari TK, 2021, MOL PSYCHIATR, V26, P429, DOI 10.1038/s41380-020-00923-z; Karikari TK, 2020, LANCET NEUROL, V19, P422, DOI 10.1016/S1474-4422(20)30071-5; Leuzy A, 2021, EUR J NUCL MED MOL I, V48, P2121, DOI 10.1007/s00259-021-05258-7; Leuzy A, 2022, JAMA NEUROL, V79, P149, DOI 10.1001/jamaneurol.2021.4654; Leuzy A, 2021, NEUROLOGY, V97, pE1681, DOI 10.1212/WNL.0000000000012727; Leuzy A, 2020, JAMA NEUROL, V77, P955, DOI 10.1001/jamaneurol.2020.0989; Lleo A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24319-x; Lu MC, 2018, EUR J MED CHEM, V146, P251, DOI 10.1016/j.ejmech.2018.01.063; Lu M, 2021, JAMA NEUROL, V78, P445, DOI 10.1001/jamaneurol.2020.5505; Mattsson-Carlgren N, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202114022; Mattsson-Carlgren N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19957-6; Mattsson-Carlgren N, 2020, BRAIN, V143, P3234, DOI 10.1093/brain/awaa286; Mattsson-Carlgren N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz2387; Meyer PF, 2022, ANN NEUROL, V91, P548, DOI 10.1002/ana.26308; Mielke MM, 2021, JAMA NEUROL, V78, P1108, DOI 10.1001/jamaneurol.2021.2293; Mintun MA, 2021, NEW ENGL J MED, V384, P1691, DOI 10.1056/NEJMoa2100708; Moloney CM, 2021, ALZHEIMERS DEMENT, V17, P1554, DOI 10.1002/alz.12321; Moscoso A, 2022, ALZHEIMERS DEMENT, DOI 10.1002/alz.12570; Moscoso A, 2021, BRAIN, V144, P325, DOI 10.1093/brain/awaa399; Mullard A, 2021, NAT REV DRUG DISCOV, V20, P888, DOI [10.1038/d41573-021-00188-3, 10.1038/d41573-021-00187-4]; Mummery C, 2021, ALZHEIMERS DEMENT, V17; Myeku N, 2016, NAT MED, V22, P46, DOI 10.1038/nm.4011; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Novak P, 2017, LANCET NEUROL, V16, P123, DOI [10.1016/s1474-4422(16)30331-3, 10.1016/S1474-4422(16)30331-3]; O'Connor A, 2021, MOL PSYCHIATR, V26, P5967, DOI 10.1038/s41380-020-0838-x; Ossenkoppele R, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202114398; Ossenkoppele R, 2021, JAMA NEUROL, V78, P961, DOI 10.1001/jamaneurol.2021.1858; Ossenkoppele R, 2021, ALZHEIMERS DEMENT, V17, P1998, DOI 10.1002/alz.12356; Ossenkoppele R, 2018, JAMA-J AM MED ASSOC, V320, P1151, DOI 10.1001/jama.2018.12917; Ossenkoppele R, 2016, BRAIN, V139, P1551, DOI 10.1093/brain/aww027; Palmqvist S, 2021, NAT MED, V27, P1034, DOI 10.1038/s41591-021-01348-z; Palmqvist S, 2020, JAMA-J AM MED ASSOC, V324, P772, DOI 10.1001/jama.2020.12134; Palmqvist S, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201911170; Pascoal TA, 2020, BRAIN, V143, P2818, DOI 10.1093/brain/awaa180; Pikuleva IA, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.696778; Sanchez JS, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abc0655; Sato C, 2018, NEURON, V98, P861, DOI 10.1016/j.neuron.2018.04.035; Scheltens P, 2021, LANCET, V397, P1577, DOI 10.1016/S0140-6736(20)32205-4; Scholl M, 2016, NEURON, V89, P971, DOI 10.1016/j.neuron.2016.01.028; Smirnov DS, 2022, ACTA NEUROPATHOL, V143, P487, DOI 10.1007/s00401-022-02408-5; Sperling RA, 2019, ANN NEUROL, V85, P181, DOI 10.1002/ana.25395; Spires-Jones TL, 2014, NEURON, V82, P756, DOI 10.1016/j.neuron.2014.05.004; Suarez-Calvet M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012921; Thijssen EH, 2021, LANCET NEUROL, V20, P739, DOI 10.1016/S1474-4422(21)00214-3; Thijssen EH, 2020, NAT MED, V26, P387, DOI 10.1038/s41591-020-0762-2; van der Kant R, 2020, NAT REV NEUROSCI, V21, P21, DOI 10.1038/s41583-019-0240-3; van der Kant R, 2019, CELL STEM CELL, V24, P363, DOI 10.1016/j.stem.2018.12.013; Vogel JW, 2021, NAT MED, V27, P871, DOI 10.1038/s41591-021-01309-6; Wang WJ, 2021, THERANOSTICS, V11, P5279, DOI 10.7150/thno.55680; Wolters EE, 2021, EUR J NUCL MED MOL I, V48, P2097, DOI 10.1007/s00259-020-05118-w; Wu JW, 2016, NAT NEUROSCI, V19, P1085, DOI 10.1038/nn.4328; Yushkevich PA, 2021, BRAIN, V144, P2784, DOI 10.1093/brain/awab262	80	6	6	16	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2022	21	8					726	734		10.1016/S1474-4422(22)00168-5	http://dx.doi.org/10.1016/S1474-4422(22)00168-5			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	4P3VT	35643092				2022-12-18	WOS:000855325100019
J	Francis, A; Palace, J; Fugger, L				Francis, Anna; Palace, Jacqueline; Fugger, Lars			MOG antibody-associated disease after vaccination with ChAdOx1 nCoV-19	LANCET NEUROLOGY			English	Letter									[Fugger, Lars] John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford Ctr Neuroinflammat, Oxford OX3 9DU, England; [Francis, Anna; Palace, Jacqueline] John Radcliffe Hosp, NMO Diagnost & Advisory Serv, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Fugger, L (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford Ctr Neuroinflammat, Oxford OX3 9DU, England.	lars.fugger@ndcn.ox.ac.uk						Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Hennes EM, 2017, NEUROLOGY, V89, P900, DOI 10.1212/WNL.0000000000004312; Jurynczyk M, 2017, BRAIN, V140, P3128, DOI 10.1093/brain/awx276; Maramattom BV, 2021, ANN NEUROL, V90, P312, DOI 10.1002/ana.26143; O'Connell K, 2020, J NEUROL NEUROSUR PS, V91, P1126, DOI 10.1136/jnnp-2020-323158; Pruss H, 2021, NAT REV IMMUNOL, V21, P798, DOI 10.1038/s41577-021-00543-w; Uppsala Monitoring Centre, US WHO UMC SYST STAN; Waters P, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000089	8	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2022	21	3					217	218		10.1016/S1474-4422(22)00043-6	http://dx.doi.org/10.1016/S1474-4422(22)00043-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZF7BZ	35182504				2022-12-18	WOS:000759721800013
J	Baillieul, S; Dekkers, M; Brill, AK; Schmidt, MH; Detante, O; Pepin, JL; Tamisier, R; Bassetti, CLA				Baillieul, Sebastien; Dekkers, Martijn; Brill, Anne-Kathrin; Schmidt, Markus H.; Detante, Olivier; Pepin, Jean-Louis; Tamisier, Renaud; Bassetti, Claudio L. A.			Sleep apnoea and ischaemic stroke: current knowledge and future directions	LANCET NEUROLOGY			English	Review							POSITIVE AIRWAY PRESSURE; CARDIOVASCULAR EVENTS; AMERICAN ACADEMY; CPAP; MANAGEMENT; ADHERENCE; VALIDATION; PREDICTION; GUIDELINE; DIAGNOSIS	Sleep apnoea, one of the most common chronic diseases, is a risk factor for ischaemic stroke, stroke recurrence, and poor functional recovery after stroke. More than half of stroke survivors present with sleep apnoea during the acute phase after stroke, with obstructive sleep apnoea being the most common subtype. Following a stroke, sleep apnoea frequency and severity might decrease over time, but moderate to severe sleep apnoea is nevertheless present in up to a third of patients in the chronic phase after an ischaemic stroke. Over the past few decades evidence suggests that treatment for sleep apnoea is feasible during the acute phase of stroke and might favourably affect recovery and long-term outcomes. Nevertheless, sleep apnoea still remains underdiagnosed and untreated in many cases, due to challenges in the detection and prediction of post-stroke sleep apnoea, uncertainty as to the optimal timing for its diagnosis, and a scarcity of clear treatment guidelines (ie, uncertainty on when to treat and the optimal treatment strategy). Moreover, the pathophysiology of sleep apnoea associated with stroke, the proportion of stroke survivors with obstructive and central sleep apnoea, and the temporal evolution of sleep apnoea subtypes following stroke remain to be clarified. To address these shortcomings, the management of sleep apnoea associated with stroke should be integrated into a multidisciplinary diagnostic, treatment, and follow-up strategy.	[Baillieul, Sebastien; Dekkers, Martijn; Schmidt, Markus H.; Bassetti, Claudio L. A.] Univ Hosp, Inselspital, Dept Neurol, CH-3010 Bern, Switzerland; [Brill, Anne-Kathrin] Univ Hosp, Inselspital, Dept Pulm Med, Bern, Switzerland; [Baillieul, Sebastien; Pepin, Jean-Louis; Tamisier, Renaud] Grenoble Alpes Univ Hosp, Serv Univ Pneumol Physiol, Grenoble, France; [Detante, Olivier] Grenoble Alpes Univ Hosp, Stroke Unit, Neurol Dept, Grenoble, France; [Baillieul, Sebastien; Pepin, Jean-Louis; Tamisier, Renaud] Univ Grenoble Alpes, Grenoble Inst Neurosci, Inserm U1300, Grenoble, France; [Detante, Olivier] Univ Grenoble Alpes, Grenoble Inst Neurosci, Inserm U1216, Grenoble, France; [Schmidt, Markus H.] Ohio Sleep Med Inst, Dublin, OH USA	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Bassetti, CLA (corresponding author), Univ Hosp, Inselspital, Dept Neurol, CH-3010 Bern, Switzerland.	claudio.bassetti@insel.ch	Sébastien, BAILLIEUL/M-7143-2015	Sébastien, BAILLIEUL/0000-0002-2348-6918; Bassetti, Claudio/0000-0002-4535-0245	European Respiratory Society through a Long-Term Research Fellowship [LTRF202001-00711]; Swiss National Foundation [33IC30_166827]	European Respiratory Society through a Long-Term Research Fellowship; Swiss National Foundation(Swiss National Science Foundation (SNSF))	SB received support from the European Respiratory Society through a Long-Term Research Fellowship (fellowship ID number: LTRF202001-00711; host: CLAB) . The work of MD and CLAB is supported by a grant from the Swiss National Foundation (grant number: 33IC30_166827) . The funding sources played no role in the writing of this Review nor the decision to submit the paper for publication. We thank Alison Foote (Grenoble, France) for editing the manuscript.	Aaronson JA, 2016, J CLIN SLEEP MED, V12, P533, DOI 10.5664/jcsm.5684; Alexiev F, 2018, J THORAC DIS, V10, pS4244, DOI 10.21037/jtd.2018.12.66; Baillieul S, 2019, EXPERT REV RESP MED, V13, P545, DOI 10.1080/17476348.2019.1604226; Bailly S, 2020, RESPIROLOGY, V25, P104, DOI 10.1111/resp.13650; Baril AA, 2021, CURR NEUROL NEUROSCI, V21, DOI 10.1007/s11910-021-01094-2; Bassetti CLA, 2020, EUR J NEUROL, V27, P1117, DOI 10.1111/ene.14201; Benjafield AV, 2019, LANCET RESP MED, V7, P687, DOI 10.1016/S2213-2600(19)30198-5; Bernasconi C, 2020, Sleep Med X, V2, P100027, DOI 10.1016/j.sleepx.2020.100027; Berry RB, 2017, J CLIN SLEEP MED, V13, P665, DOI 10.5664/jcsm.6576; Borel AL, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112628; Boulos M, 2020, NEUROLOGY, V94; Boulos MI, 2021, STROKE, V52, P366, DOI 10.1161/STROKEAHA.120.031709; Boulos MI, 2019, SLEEP MED, V56, P177, DOI 10.1016/j.sleep.2018.12.021; Boulos MI, 2017, J STROKE CEREBROVASC, V26, P143, DOI 10.1016/j.jstrokecerebrovasdis.2016.09.001; Boulos MI, 2016, SLEEP MED, V21, P133, DOI 10.1016/j.sleep.2015.12.013; Bravata DM, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008841; Brill AK, 2018, NEUROLOGY, V90, pE1222, DOI 10.1212/WNL.0000000000005262; Brown DL, 2020, SLEEP MED, V75, P1, DOI 10.1016/j.sleep.2020.05.004; Brown DL, 2020, INT J STROKE, V15, P923, DOI 10.1177/1747493020903979; Brown DL, 2019, STROKE, V50, P571, DOI 10.1161/STROKEAHA.118.023807; Brown DL, 2019, SLEEP MED, V59, P90, DOI 10.1016/j.sleep.2018.09.009; Catalan-Serra P, 2019, STROKE, V50, P491, DOI 10.1161/STROKEAHA.118.023353; Chen CY, 2021, NAT SCI SLEEP, V13, P283, DOI 10.2147/NSS.S301668; Chen CY, 2021, J NEUROL, V268, P2951, DOI 10.1007/s00415-021-10480-2; Colelli DR, 2020, SLEEP MED, V66, P243, DOI 10.1016/j.sleep.2018.10.009; Culebras A, 2021, SLEEP MED, V77, P302, DOI 10.1016/j.sleep.2020.10.006; Dong RF, 2018, J STROKE CEREBROVASC, V27, P1471, DOI 10.1016/j.jstrokecerebrovasdis.2017.12.048; Duarte RLM, 2018, J CLIN SLEEP MED, V14, P1097, DOI 10.5664/jcsm.7202; Dunietz GL, 2020, SLEEP HEALTH, V6, P534, DOI 10.1016/j.sleh.2020.01.009; Dunietz GL., 2021, SLEEP, DOI [10.1093/sleep/zsab076, DOI 10.1093/SLEEP/ZSAB076]; Duss SB, 2021, TRIALS, V22, DOI 10.1186/s13063-020-04977-w; Duss Simone B., 2017, Neurobiology of Sleep and Circadian Rhythms, V2, P94, DOI 10.1016/j.nbscr.2016.11.003; Festic N, 2018, J CLIN SLEEP MED, V14, P75, DOI 10.5664/jcsm.6884; Fisse AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171243; Gottlieb DJ, 2020, JAMA-J AM MED ASSOC, V323, P1389, DOI 10.1001/jama.2020.3514; Gunduz C, 2018, RESPIROLOGY, V23, P1180, DOI 10.1111/resp.13372; Gupta A, 2018, J CLIN SLEEP MED, V14, P511, DOI 10.5664/jcsm.7034; Haba-Rubio J, 2019, J CLIN SLEEP MED, V15, P839, DOI 10.5664/jcsm.7832; Hasan F, 2021, STROKE, V52, P655, DOI 10.1161/STROKEAHA.120.029847; Hermann DM, 2016, NEUROLOGY, V87, P1407, DOI 10.1212/WNL.0000000000003037; Javaheri S, 2020, AM J RESP CRIT CARE, V201, P607, DOI 10.1164/rccm.201908-1593LE; Javaheri S, 2017, J AM COLL CARDIOL, V69, P841, DOI 10.1016/j.jacc.2016.11.069; Jian XQ, 2018, STROKE, V49, P1557, DOI 10.1161/STROKEAHA.117.017073; Johnson KG, 2019, SLEEP MED, V59, P94, DOI 10.1016/j.sleep.2018.10.016; Kang DO, 2020, STROKE, V51, P2188, DOI 10.1161/STROKEAHA.119.028730; Kapur VK, 2017, J CLIN SLEEP MED, V13, P479, DOI 10.5664/jcsm.6506; Kendzerska T, 2019, SLEEP BREATH, V23, P1233, DOI 10.1007/s11325-019-01811-9; Khot SP, 2016, J CLIN SLEEP MED, V12, P1019, DOI 10.5664/jcsm.5940; Kleindorfer DO, 2021, STROKE, V52, pE364, DOI 10.1161/STR.0000000000000375; Kotzian ST, 2019, SLEEP MED, V64, P48, DOI 10.1016/j.sleep.2019.06.004; Leino A, 2021, SLEEP MED, V79, P71, DOI 10.1016/j.sleep.2020.12.032; Leino A, 2020, SLEEP BREATH, V24, P1495, DOI 10.1007/s11325-019-02010-2; Leotard A, 2021, ANN PHYS REHABIL MED, V64, DOI 10.1016/j.rehab.2020.04.006; Lin HJ, 2020, SLEEP MED REV, V54, DOI 10.1016/j.smrv.2020.101354; Lisabeth LD, 2019, ANN NEUROL, V86, P241, DOI 10.1002/ana.25515; Liu DQ, 2017, CHEST, V152, P751, DOI 10.1016/j.chest.2017.06.010; Maestri M, 2020, SLEEP BREATH, V24, P413, DOI 10.1007/s11325-019-01921-4; Malhotra A, 2021, SLEEP, V44, DOI 10.1093/sleep/zsab030; Marti-Soler H, 2016, LANCET RESP MED, V4, P742, DOI 10.1016/S2213-2600(16)30075-3; McConnell MV, 2017, JAMA CARDIOL, V2, P67, DOI 10.1001/jamacardio.2016.4395; McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599; Nie S, 2017, SLEEP BREATH, V21, P487, DOI 10.1007/s11325-017-1474-9; Nilius G, 2019, RESPIRATION, V98, P410, DOI 10.1159/000501656; Ott SR, 2020, ERJ OPEN RES, V6, DOI 10.1183/23120541.00334-2019; Pepin JL, 2019, ANN AM THORAC SOC, V16, P1501, DOI 10.1513/AnnalsATS.201909-670ED; Pepin JL, 2019, CHEST, V155, P730, DOI 10.1016/j.chest.2018.11.007; Pepin JLD, 2018, J CLIN SLEEP MED, V14, P57, DOI 10.5664/jcsm.6880; Pevernagie DA, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13066; Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211; Reutrakul S, 2017, CHEST, V152, P1070, DOI 10.1016/j.chest.2017.05.009; Rosen IM, 2017, J CLIN SLEEP MED, V13, P1205, DOI 10.5664/jcsm.6774; Ryan S, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02295-2019; Saletu MT, 2018, J CLIN SLEEP MED, V14, P1495, DOI 10.5664/jcsm.7322; Schutz SG, 2019, SLEEP MED, V60, P178, DOI 10.1016/j.sleep.2019.04.004; Schutz SG, 2021, SLEEP MED, V77, P304, DOI 10.1016/j.sleep.2020.08.025; Seiler A, 2019, NEUROLOGY, V92, pe648, DOI 10.1212/WNL.0000000000006904; Siarnik P, 2020, SLEEP MED, V73, P208, DOI 10.1016/j.sleep.2020.06.035; Sico JJ, 2017, J STROKE CEREBROVASC, V26, P1745, DOI 10.1016/j.jstrokecerebrovasdis.2017.03.042; Sim I, 2019, NEW ENGL J MED, V381, P956, DOI 10.1056/NEJMra1806949; Stepnowsky C, 2019, J CLIN SLEEP MED, V15, P235, DOI 10.5664/jcsm.7624; Takala M, 2018, BRAIN BEHAV, V8, DOI 10.1002/brb3.1146; Tamisier R, 2020, CHEST, V158, P2136, DOI 10.1016/j.chest.2020.05.613; Tsivgoulis G, 2017, STROKE, V48, P2285, DOI 10.1161/STROKEAHA.117.017661; Wallin MT, 2019, LANCET NEUROL, V18, P269, DOI 10.1016/S1474-4422(18)30443-5; Wheeler NC, 2016, J CLIN SLEEP MED, V12, P1233, DOI 10.5664/jcsm.6120; Ye DM, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00912; Yeghiazarians Y, 2021, CIRCULATION, V144, pE56, DOI 10.1161/CIR.0000000000000988; Yu J, 2017, JAMA-J AM MED ASSOC, V318, P156, DOI 10.1001/jama.2017.7967; Zinchuk AV, 2020, AM J RESP CRIT CARE, V201, P1568, DOI 10.1164/rccm.201911-2203LE	89	6	7	4	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2022	21	1					78	88		10.1016/S1474-4422(21)00321-5	http://dx.doi.org/10.1016/S1474-4422(21)00321-5			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XV0SP	34942140				2022-12-18	WOS:000734663200024
J	Schoser, B; Roberts, M; Byrne, BJ; Sitaraman, S; Jiang, H; Laforet, P; Toscano, A; Castelli, J; Diaz-Manera, J; Goldman, M; Van der Ploeg, AT; Bratkovic, D; Kuchipudi, S; Mozaffar, T; Kishnani, PS				Schoser, Benedikt; Roberts, Mark; Byrne, Barry J.; Sitaraman, Sheela; Jiang, Hai; Laforet, Pascal; Toscano, Antonio; Castelli, Jeff; Diaz-Manera, Jordi; Goldman, Mitchell; Van der Ploeg, Ans T.; Bratkovic, Drago; Kuchipudi, Srilakshmi; Mozaffar, Tahseen; Kishnani, Priya S.		Propel Study Grp	Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial	LANCET NEUROLOGY			English	Article							ENZYME REPLACEMENT THERAPY; EMERGING PHENOTYPE; INFANTILE	Background Pompe disease is a rare disorder characterised by progressive loss of muscle and respiratory function due to acid alpha-glucosidase deficiency. Enzyme replacetnent therapy with recombinant human acid alpha-glucosidase, alglucosidase alfa, is the first approved treatment for the disease, but some patients do not respond, and many do not show a sustained benefit. We aimed to assess the safety and efficacy of an investigational two-component therapy (cipaglucosidase alfa, a novel recombinant human acid o-glucosidase, plus miglustat, an enzyme stabiliser) for late-onset Pompe disease. Methods We did a randomised, double-blind, parallel-group, phase 3 trial at 62 neuromuscular and metabolic medical centres in 24 countries in the Americas, Asia -Pacific, and Europe. Eligible participants were aged 18 years or older with late-onset Pompe disease, and had either been receiving alglucosidase alfa for at least 2 years or were enzyme replacement therapy-naive. Participants were randomly assigned (2:1) using interactive response technology software, stratified by 6-min walk distance and previous enzyme replacement therapy status, to intravenous cipaglucosidase alfa (20 mg/kg) plus oral miglustat or to intravenous alglucosidase alfa (20 mg/kg) plus oral placebo once every 2 weeks for 52 weeks. Patients, investigators, and outcome assessors were masked to treatment assignment. The primary endpoint was change from baseline to week 52 in 6 -min walk distance, assessed using a mixed -effect model for repeated measures analysis for comparison of superiority in the intention-to-treat population (all patients who received at least one dose of study drug). This study is now complete and is registered with ClinicalTrials.gov, NCT03729362. Findings Between Dec 3, 2018, and Nov 26, 2019, 130 patients were screened for eligibility and 125 were enrolled and randomly assigned to receive cipaglucosidase alfa plus miglustat (n=85) or alglucosidase alfa plus placebo (n=40). Two patients in the alglucosidase alfa plus placebo group did not receive any dose due to absence of genotype confirmation of late-onset Pompe disease and were excluded from analysis. Six patients discontinued (one in the alglucosidase alfa plus placebo group, five in the cipaglucosidase alfa plus miglustat group), and 117 completed the study. At week 52, mean change from baseline in 6 -min walk distance was 20.8 m (SE 4.6) in the cipaglucosidase alfa plus miglustat group versus 7.2 m (6.6) in the alglucosidase alfa plus placebo group using last observation carried forward (between -group difference 13.6 m [95% CI 2.8 to 29.9]). 118 (96%) of 123 patients experienced at least one treatment-emergent adverse event during the study; the incidence was similar between the cipaglucosidase alfa plus miglustat group (n=81 [95%]) and the alglucosidase alfa plus placebo group (n=37 [97%]). The most frequently reported treatment-emergent adverse events were fall (25 [29%] patients in the cipaglucosidase alfa plus miglustat group vs 15 [39%] in the alglucosidase alfa plus placebo group), headache (20 [24%] vs 9 [24%]), nasopharyngitis (19 [22%] vs 3 [8%]), myalgia (14 [16%] vs 5 [13%]), and arthralgia (13 [15%]) vs 5 [13%]). 12 serious adverse events occurred in eight patients in the cipaglucosidase alfa plus miglustat group; only one event (anaphylaxis) was deemed related to study drug. One serious adverse event (stroke) occurred in the alglucosidase alfa plus placebo group, which was deemed unrelated to study drug. There were no deaths. Interpretation Cipaglucosidase alfa plus miglustat did not achieve statistical superiority to alglucosidase alfa plus placebo for improving 6 -min walk distance in our overall population of patients with late-onset Pompe disease. Further studies should investigate the longer-term safety and efficacy of cipaglucosidase alfa plus miglustat and whether this investigational two-component therapy might provide benefits, particularly in respiratory function and in patients who have been receiving enzyme replacement therapy for snore than 2 years, as suggested by our secondary and subgroup analyses.	[Schoser, Benedikt] Ludwig Maximilians Univ Munchen, Friedrich Baur Inst, Neurol Klin, D-80336 Munich, Germany; [Roberts, Mark] Salford Royal NHS Fdn Trust, Salford, Lancs, England; [Byrne, Barry J.] Univ Florida, Gainesville, FL USA; [Sitaraman, Sheela; Jiang, Hai; Castelli, Jeff; Goldman, Mitchell; Kuchipudi, Srilakshmi] Amicus Therapeut, Philadelphia, PA USA; [Laforet, Pascal] Hop Raymond Poincare, Garches, France; [Toscano, Antonio] Univ Messina, Messina, Italy; [Diaz-Manera, Jordi] Hosp Santa Creu & St Pau Barcelona, Unitat Malalties Neuromusculars Serv Neurol, Barcelona, Spain; [Van der Ploeg, Ans T.] Erasmus MC, Univ Med Ctr, Rotterdam, Netherlands; [Bratkovic, Drago] Royal Adelaide Hosp, PARC Res Clin, Adelaide, SA, Australia; [Mozaffar, Tahseen] Univ Calif Irvine, Irvine, CA USA; [Kishnani, Priya S.] Duke Univ, Med Ctr, Durham, NC USA	University of Munich; Salford Royal NHS Foundation Trust; State University System of Florida; University of Florida; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; University of Messina; Erasmus University Rotterdam; Erasmus MC; Royal Adelaide Hospital; University of California System; University of California Irvine; Duke University	Schoser, B (corresponding author), Ludwig Maximilians Univ Munchen, Friedrich Baur Inst, Neurol Klin, D-80336 Munich, Germany.	benedikt.schoser@med.uni-muenchen.de	Toscano, Antonio/AHE-4657-2022; Shin, Jin-Hong/AAZ-8809-2020; Koritnik, Blaž/N-7487-2019; Kushlaf, Hani/E-9912-2018	Shin, Jin-Hong/0000-0002-5174-286X; Koritnik, Blaž/0000-0002-5083-8261; Schoser, Benedikt/0000-0002-2757-8131; Ruck, Tobias/0000-0001-6332-8650; parenti, giancarlo/0000-0002-6287-5748; Sebok, Agnes/0000-0003-2969-8425; Alonso-Perez, Jorge/0000-0001-8866-5186; SACCONI, Sabrina/0000-0002-0246-1455; Hopkin, Robert/0000-0003-0770-5516; Loscher, Wolfgang/0000-0002-7593-3222; Fecarotta, Simona/0000-0002-8449-361X; Kushlaf, Hani/0000-0002-3786-1133; Kuchipudi, Suresh V./0000-0002-8640-254X; Byrne, Barry J./0000-0002-7302-1756	Amicus Therapeutics	Amicus Therapeutics	Amicus Therapeutics.	An Y, 2005, MOL GENET METAB, V85, P247, DOI 10.1016/j.ymgme.2005.03.010; Angelini C, 2012, J NEUROL, V259, P952, DOI 10.1007/s00415-011-6293-5; Brancaccio P, 2010, CLIN CHEM LAB MED, V48, P757, DOI 10.1515/CCLM.2010.179; Chan J, 2017, MOL GENET METAB, V120, P163, DOI 10.1016/j.ymgme.2016.12.004; Do HV, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.04.15; Genzyme Corporation, 2020, LUM PRESCR INF; Gutschmidt K, 2021, J NEUROL, V268, P2482, DOI 10.1007/s00415-021-10409-9; Hahn A, 2015, JIMD REP, V20, P65, DOI 10.1007/8904_2014_392; Harlaar Laurike, 2019, Neurology, V93, pe1756, DOI 10.1212/WNL.0000000000008441; HERS HG, 1963, BIOCHEM J, V86, P11, DOI 10.1042/bj0860011; Kishnani P, 2019, MOL GENET METAB, V126, pS86, DOI 10.1016/j.ymgme.2018.12.212; Kishnani PS, 2006, GENET MED, V8, P267, DOI 10.1097/01.gim.0000218152.87434.f3; Kishnani PS, 2004, J PEDIATR-US, V144, pS35, DOI 10.1016/j.jpeds.2004.01.053; Kuperus E, 2017, NEUROLOGY, V89, P2365, DOI 10.1212/WNL.0000000000004711; Meena NK, 2020, MOL THER-METH CLIN D, V18, P199, DOI 10.1016/j.omtm.2020.05.026; Montagnese F, 2016, J NEUROL, V263, P631, DOI 10.1007/s00415-015-7926-x; Papadimas GK, 2021, NEUROMUSCULAR DISORD, V31, P91, DOI 10.1016/j.nmd.2020.12.001; Prater SN, 2012, GENET MED, V14, P800, DOI 10.1038/gim.2012.44; Raben N, 1998, J BIOL CHEM, V273, P19086, DOI 10.1074/jbc.273.30.19086; Regnery C, 2012, J INHERIT METAB DIS, V35, P837, DOI 10.1007/s10545-012-9451-8; Schoser B, 2019, NEUROMUSCULAR DISORD, V29, pS122, DOI 10.1016/j.nmd.2019.06.305; Semplicini C, 2020, J INHERIT METAB DIS, V43, P1219, DOI 10.1002/jimd.12272; Stockton DW, 2020, J NEUROL, V267, P3038, DOI 10.1007/s00415-020-09936-8; Strothotte S, 2010, J NEUROL, V257, P91, DOI 10.1007/s00415-009-5275-3; van der Ploeg AT, 2010, NEW ENGL J MED, V362, P1396, DOI 10.1056/NEJMoa0909859; Winkel LPF, 2005, J NEUROL, V252, P875, DOI 10.1007/s00415-005-0922-9; Xu S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125358	27	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2021	20	12					1027	1037		10.1016/S1474-4422(21)00331-8	http://dx.doi.org/10.1016/S1474-4422(21)00331-8			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YZ6RX	34800400				2022-12-18	WOS:000755602800027
J	Cortese, I; Beck, ES; Al-Louzi, O; Ohayon, J; Andrada, F; Osuorah, I; Dwyer, J; Billioux, BJ; Dargah-zada, N; Schindler, MK; Binder, K; Reoma, L; Norato, G; Enose-Akahata, Y; Smith, BR; Monaco, MC; Major, EO; Jacobson, S; Stroncek, D; Highfill, S; Panch, S; Reich, DS; Barrett, J; Nath, A; Muranski, P				Cortese, Irene; Beck, Erin S.; Al-Louzi, Omar; Ohayon, Joan; Andrada, Frances; Osuorah, Ikesinachi; Dwyer, Jenifer; Billioux, B. Jeanne; Dargah-zada, Nigar; Schindler, Matthew K.; Binder, Kyle; Reoma, Lauren; Norato, Gina; Enose-Akahata, Yoshimi; Smith, Bryan R.; Monaco, Maria Chiara; Major, Eugene O.; Jacobson, Steven; Stroncek, David; Highfill, Steven; Panch, Sandhya; Reich, Daniel S.; Barrett, John; Nath, Avindra; Muranski, Pawel			BK virus-specificT cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study	LANCET NEUROLOGY			English	Article							JC-VIRUS; T-CELLS; PML; INFECTIONS; THERAPY	Background Progressive multifocal leukoencephalopathy, a rare disease of the CNS caused by JC virus and occurring in immunosuppressed people, is typically fatal unless adaptive immunity is restored. JC virus is a member of the human polyomavirus family and is closely related to the BK virus. We hypothesised that use of partly HLA-matched donor-derived BK virus-specific T cells for immunotherapy in progressive multifocal leukoencephalopathy would be feasible and safe. Methods We did an open-label, single-cohort pilot study in patients (aged 18 years or older) with clinically definite progressive multifocal leukoencephalopathy and disease progression in the previous month at the National Institutes of Health (NIH) Clinical Center (Bethesda, MD, USA). Overlapping peptide libraries derived from large T antigen and major capsid protein VP1 of BK virus with high sequence homology to JC virus counterparts were used to generate polyomavirus-specific T cells cross-recognising JC virus antigens. Polyomavirus-specific T cells were manufactured from peripheral blood mononuclear cells of first-degree relative donors aged 18 years or older. These cells were administered to patients by intravenous infusion at 1 x 10(6) polyomavirus-specific T cells per kg, followed by up to two additional infusions at 2 x 10(6) polyomavirus-specific T cells per kg. The primary endpoints were feasibility (no manufacturing failure based on meeting release criteria, achieving adequate numbers of cell product for clinical use, and showing measurable antiviral activity) and safety in all patients. The safety monitoring period was 28 days after each infusion. Patients were followed up with serial MRI for up to 12 months after the final infusion. This trial is registered at ClinicalTrials.gov, NCT02694783. Findings Between April 7, 2016, and Oct 19, 2018, 26 patients were screened, of whom 12 were confirmed eligible and received treatment derived from 14 matched donors. All administered polyomavirus-specific T cells met the release criteria and recognised cognate antigens in vitro. 12 patients received at least one infusion, ten received at least two, and seven received a total of three infusions. The median on-study follow-up was 109.5 days (range 23-699). All infusions were tolerated well, and no serious treatment-related adverse events were observed. Seven patients survived progressive multifocal leukoencephalopathy for longer than 1 year after the first infusion, whereas five died of progressive multifocal leukoencephalopathy within 3 months. Interpretation We showed that generation of polyomavirus-specific T cells from healthy related donors is feasible, and these cells can be safely used as an infusion for adoptive immunotherapy of progressive multifocal leukoencephalopathy. Although not powered to assess efficacy, our data provide additional support for this strategy as a potential life-saving therapy for some patients. Copyright Published by Elsevier Ltd.	[Cortese, Irene; Ohayon, Joan; Andrada, Frances; Osuorah, Ikesinachi; Dwyer, Jenifer; Dargah-zada, Nigar] NIH, Neuroimmunol Clin, Bldg 10, Bethesda, MD 20892 USA; [Beck, Erin S.; Al-Louzi, Omar; Schindler, Matthew K.; Reich, Daniel S.] NIH, Translat Neuroradiol Sect, Bldg 10, Bethesda, MD 20892 USA; [Billioux, B. Jeanne; Enose-Akahata, Yoshimi; Jacobson, Steven] NIH, Viral Immunol Sect, Bldg 10, Bethesda, MD 20892 USA; [Reoma, Lauren; Norato, Gina] NIH, Clin Trials Unit, Bldg 10, Bethesda, MD 20892 USA; [Smith, Bryan R.; Nath, Avindra] NIH, Sect Infect Nervous Syst, Bldg 10, Bethesda, MD 20892 USA; [Monaco, Maria Chiara; Major, Eugene O.] NIH, Lab Mol Med & Neurosci, Bldg 10, Bethesda, MD 20892 USA; [Monaco, Maria Chiara; Major, Eugene O.] NINDS, Lab Mol Med & Neurosci, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA; [Binder, Kyle] NIAID, Mol Dev Immune Syst Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Stroncek, David; Highfill, Steven; Panch, Sandhya] NIH, Ctr Cellular Engn, Dept Transfus Med, Bldg 10, Bethesda, MD 20892 USA; [Barrett, John; Muranski, Pawel] NIH, Hematol Branch, HLBI, Bldg 10, Bethesda, MD 20892 USA; [Barrett, John] George Washington Univ, Ctr Canc, Washington, DC USA; [Muranski, Pawel] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; George Washington University; Columbia University	Cortese, I (corresponding author), NINDS, Neuroimmunol Clin, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.	corteseir@ninds.nih.gov	Beck, Erin/AAA-8399-2022; Reich, Daniel S./E-5701-2010; Enose-Akahata, Yoshimi/AAY-2327-2021	Reich, Daniel S./0000-0002-2628-4334; Al-Louzi, Omar/0000-0003-2260-5660	Intramural Research Program of the National Institute of Neurological Disorders and Stroke of the NIH	Intramural Research Program of the National Institute of Neurological Disorders and Stroke of the NIH	Intramural Research Program of the National Institute of Neurological Disorders and Stroke of the NIH.	Alstadhaug KB, 2014, JAMA NEUROL, V71, P1030, DOI 10.1001/jamaneurol.2014.825; Anand P, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000618; Balduzzi A, 2011, BONE MARROW TRANSPL, V46, P987, DOI 10.1038/bmt.2010.221; Beck ES, 2020, CURR OPIN VIROL, V40, P19, DOI 10.1016/j.coviro.2020.02.005; Berger JR, 2013, NEUROLOGY, V80, P1430, DOI 10.1212/WNL.0b013e31828c2fa1; Berger JR, 2003, J NEUROVIROL, V9, P38, DOI 10.1080/13550280390195261; Berzero G, 2021, ANN NEUROL, V89, P769, DOI 10.1002/ana.26020; Bossolasco S, 2005, CLIN INFECT DIS, V40, P738, DOI 10.1086/427698; Carson KR, 2009, BLOOD, V113, P4834, DOI 10.1182/blood-2008-10-186999; Clifford DB, 2010, LANCET NEUROL, V9, P438, DOI 10.1016/S1474-4422(10)70028-4; Cortese I, 2019, NEW ENGL J MED, V380, P1597, DOI 10.1056/NEJMoa1815039; Du Pasquier RA, 2004, BRAIN, V127, P1970, DOI 10.1093/brain/awh215; Dunham SR, 2020, NEUROTHERAPEUTICS, V17, P955, DOI 10.1007/s13311-020-00848-z; Egli A, 2009, J INFECT DIS, V199, P837, DOI 10.1086/597126; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Gheuens S, 2011, J VIROL, V85, P7256, DOI 10.1128/JVI.02506-10; Harel A, 2018, J NEUROVIROL, V24, P652, DOI 10.1007/s13365-018-0657-x; Jelcic I, 2016, ANN NEUROL, V79, P404, DOI 10.1002/ana.24574; Johnson EM, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/197807; Kean JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000363; Knowles WA, 2003, J MED VIROL, V71, P115, DOI 10.1002/jmv.10450; Leen AM, 2013, BLOOD, V121, P5113, DOI 10.1182/blood-2013-02-486324; Major E, 2018, LANCET NEUROL, V17, P467, DOI 10.1016/S1474-4422(18)30040-1; Migliori E, 2018, CURR OPIN HEMATOL, V25, P486, DOI 10.1097/MOH.0000000000000461; Miskin DP, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000213; Muftuoglu M, 2018, NEW ENGL J MED, V379, P1443, DOI 10.1056/NEJMoa1801540; Naik S, 2016, J ALLERGY CLIN IMMUN, V137, P1498, DOI 10.1016/j.jaci.2015.12.1311; Papadopoulou A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008825; Stefoski D, 2019, ANN CLIN TRANSL NEUR, V6, P923, DOI 10.1002/acn3.776; Tuan DS, 2015, J NEUROVIROL, V21, P637, DOI [10.1007/s13365-015-0316-4, 10.1007/s13365-015]; Tzannou I, 2017, J CLIN ONCOL, V35, P3547, DOI [10.1200/JCO.2017.73.0655, 10.1200/jco.2017.73.0655]; US Department of Health and Human Services, COMMON TERMINOLOGY C	32	6	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2021	20	8					639	652		10.1016/S1474-4422(21)00174-5	http://dx.doi.org/10.1016/S1474-4422(21)00174-5			14	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP6CG	34302788	Green Accepted			2022-12-18	WOS:000677684700017
J	Frank, S				Frank, Stephan			Catch me if you can: SARS-CoV-2 detection in brains of deceased patients with COVID-19	LANCET NEUROLOGY			English	Editorial Material							HETEROGENEITY		[Frank, Stephan] Univ Basel, Univ Basel Hosp, Inst Med Genet & Pathol, Div Neuropathol, CH-4031 Basel, Switzerland	University of Basel	Frank, S (corresponding author), Univ Basel, Univ Basel Hosp, Inst Med Genet & Pathol, Div Neuropathol, CH-4031 Basel, Switzerland.	stephan.frank@usb.ch						Bottcher C, 2019, NAT NEUROSCI, V22, P78, DOI 10.1038/s41593-018-0290-2; Deigendesch N, 2020, ACTA NEUROPATHOL, V140, P583, DOI 10.1007/s00401-020-02213-y; Edler C, 2020, INT J LEGAL MED, V134, P1275, DOI 10.1007/s00414-020-02317-w; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669; Masuda T, 2020, CELL REP, V30, P1271, DOI 10.1016/j.celrep.2020.01.010; Matschke J, 2020, LANCET NEUROL, V19, P919, DOI 10.1016/S1474-4422(20)30308-2; Ramani A, 2020, EMBO J, V39, DOI 10.15252/embj.2020106230; Schaefer IM, 2020, MODERN PATHOL, V33, P2104, DOI 10.1038/s41379-020-0595-z; Solomon IH, 2020, NEW ENGL J MED, V383, P989, DOI 10.1056/NEJMc2019373	10	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2020	19	11					883	884		10.1016/S1474-4422(20)30371-9	http://dx.doi.org/10.1016/S1474-4422(20)30371-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3OI	33031734	Bronze, Green Published			2022-12-18	WOS:000581121200006
J	Al-Hassany, L; MaassenVanDenBrink, A				Al-Hassany, Linda; MaassenVanDenBrink, Antoinette			Targeting CGRP in migraine: a matter of choice and dose	LANCET NEUROLOGY			English	Editorial Material							ATOGEPANT; HEADACHE; DISEASE; BURDEN		[Al-Hassany, Linda; MaassenVanDenBrink, Antoinette] Erasmus MC, Dept Internal Med, Div Vasc Med & Pharmacol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	MaassenVanDenBrink, A (corresponding author), Erasmus MC, Dept Internal Med, Div Vasc Med & Pharmacol, Rotterdam, Netherlands.	a.vanharen-maassenvandenbrink@erasmusmc.nl	Al-Hassany, Linda/AAE-5528-2022	Maassen van den Brink, Antoinette/0000-0001-7176-126X				Allergan USA, 2019, UBR UBR US PRESCR IN; Amgen Inc, 2018, ER AIM US PRESCR INF; Ankrom W, 2020, J CLIN PHARMACOL, V60, P1157, DOI 10.1002/jcph.1610; Biohaven Pharmaceuticals, 2020, RIM NURT ODT US PRES; Edvinsson L, 2018, NAT REV NEUROL, V14, P338, DOI 10.1038/s41582-018-0003-1; Eli Lilly and Company, 2018, GALC EMG US PRESCR I; Goadsby PJ, 2020, LANCET NEUROL, V19, P727, DOI 10.1016/S1474-4422(20)30234-9; Kielbasa W, 2019, CEPHALALGIA, V39, P1284, DOI 10.1177/0333102419840780; Kristoffersen ES, 2014, THER ADV DRUG SAF, V5, P87, DOI 10.1177/2042098614522683; Lipton RB, 2007, NEUROLOGY, V68, P343, DOI 10.1212/01.wnl.0000252808.97649.21; Lundbeck Seattle BioPharmaceuticals Inc, 2020, EPT VYEPT US PRESCR; Negro A, 2019, EXPERT OPIN INV DRUG, V28, P555, DOI 10.1080/13543784.2019.1618830; Rubio-Beltran E, 2020, CEPHALALGIA, V40, P357, DOI 10.1177/0333102419884943; Silberstein SD, 2013, CLIN PHARMACOL THER, V93, P78, DOI 10.1038/clpt.2012.198; Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI [10.1016/S1474-4422(18)30322-3, 10.1016/S1474-4422(18)30499-X]; Teva Pharmaceuticals USA Inc, 2018, FREM AJ US PRESCR IN	16	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2020	19	9					712	713		10.1016/S1474-4422(20)30282-9	http://dx.doi.org/10.1016/S1474-4422(20)30282-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NE4GY	32822621				2022-12-18	WOS:000562556500004
J	Turnbull, J				Turnbull, John			Reappraisal of an ALS trial: unaccounted procedural risk	LANCET NEUROLOGY			English	Letter							AMYOTROPHIC-LATERAL-SCLEROSIS		[Turnbull, John] McMaster Univ, Fac Hlth Sci, Hamilton, ON L8N 3Z5, Canada	McMaster University	Turnbull, J (corresponding author), McMaster Univ, Fac Hlth Sci, Hamilton, ON L8N 3Z5, Canada.	turnbull@mcmaster.ca						Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1; Atassi N, 2014, NEUROLOGY, V83, P1719, DOI 10.1212/WNL.0000000000000951; European Medicines Agency, 2019, RAD WITHDR MARK AUTH; Proudfoot M, 2016, AMYOTROPH LAT SCL FR, V17, P414, DOI 10.3109/21678421.2016.1140786; Takei K, 2017, AMYOTROPH LAT SCL FR, V18, P88, DOI 10.1080/21678421.2017.1361445; Turnbull J, 2018, AMYOTROPH LAT SCL FR, V19, P477, DOI 10.1080/21678421.2018.1517179; US Food and Drug Administration, RAD ED INJ	7	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2020	19	9					717	718		10.1016/S1474-4422(20)30265-9	http://dx.doi.org/10.1016/S1474-4422(20)30265-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NE4GY	32822626	Bronze			2022-12-18	WOS:000562556500023
J	Vazquez-Costa, JF				Vazquez-Costa, Juan F.			Natural history data in adults with SMA	LANCET NEUROLOGY			English	Letter									[Vazquez-Costa, Juan F.] Hosp Univ & Politecn La Fe, Motor Neuron Unit, Dept Neurol, Valencia 46026, Spain; [Vazquez-Costa, Juan F.] Ctr Invest Biomed Red Enfermedades Raras, Valencia, Spain; [Vazquez-Costa, Juan F.] Univ Valencia, Dept Med, Valencia, Spain	Hospital Universitari i Politecnic La Fe; CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Valencia	Vazquez-Costa, JF (corresponding author), Hosp Univ & Politecn La Fe, Motor Neuron Unit, Dept Neurol, Valencia 46026, Spain.; Vazquez-Costa, JF (corresponding author), Ctr Invest Biomed Red Enfermedades Raras, Valencia, Spain.; Vazquez-Costa, JF (corresponding author), Univ Valencia, Dept Med, Valencia, Spain.	vazquez_juacos@gva.es	Vazquez Costa, Juan Francisco/D-4393-2015	Vazquez Costa, Juan Francisco/0000-0002-3043-7938					0	6	6	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2020	19	7					564	565		10.1016/S1474-4422(20)30183-6	http://dx.doi.org/10.1016/S1474-4422(20)30183-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MF5BW	32562673	Bronze			2022-12-18	WOS:000545358600023
J	McManus, RM; Heneka, MT				McManus, Roisin M.; Heneka, Michael T.			T cells in Alzheimer's disease: space invaders	LANCET NEUROLOGY			English	Editorial Material							INFECTION		[McManus, Roisin M.; Heneka, Michael T.] Univ Hosp Bonn, Dept Neurodegenerat Dis & Geriatr Psychiat, Bonn, Germany; [McManus, Roisin M.; Heneka, Michael T.] German Ctr Neurodegenerat Dis, D-53127 Bonn, Germany; [Heneka, Michael T.] Univ Massachusetts, Sch Med, Dept Infect Dis & Immunol, Worcester, MA 01655 USA	University of Bonn; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Massachusetts System; University of Massachusetts Worcester	Heneka, MT (corresponding author), Univ Hosp Bonn, Dept Neurodegenerat Dis & Geriatr Psychiat, Bonn, Germany.; Heneka, MT (corresponding author), German Ctr Neurodegenerat Dis, D-53127 Bonn, Germany.; Heneka, MT (corresponding author), Univ Massachusetts, Sch Med, Dept Infect Dis & Immunol, Worcester, MA 01655 USA.	michael.heneka@dzne.de	McManus, Róisín/AAD-6153-2021; Heneka, Michael/E-8072-2015	McManus, Róisín/0000-0002-6896-0302; Heneka, Michael/0000-0003-4996-1630				Gate D, 2020, NATURE, V577, P399, DOI 10.1038/s41586-019-1895-7; Holmes C, 2003, J NEUROL NEUROSUR PS, V74, P788, DOI 10.1136/jnnp.74.6.788; Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95; Labzin LI, 2018, ANNU REV MED, V69, P437, DOI 10.1146/annurev-med-050715-104343; Larbi A, 2014, CYTOM PART A, V85A, P25, DOI 10.1002/cyto.a.22351; McManus RM, 2014, NEUROBIOL AGING, V35, P109, DOI 10.1016/j.neurobiolaging.2013.07.025; Natalwala A, 2008, DEMENT GERIATR COGN, V26, P499, DOI 10.1159/000171044; Smatti MK, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00211; Togo T, 2002, J NEUROIMMUNOL, V124, P83, DOI 10.1016/S0165-5728(01)00496-9; Tu WJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02111	10	6	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2020	19	4					285	+		10.1016/S1474-4422(20)30076-4	http://dx.doi.org/10.1016/S1474-4422(20)30076-4			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KW1GS	32199089				2022-12-18	WOS:000520920500008
J	Parnetti, L; Gaetani, L; Di Filippo, M				Parnetti, Lucilla; Gaetani, Lorenzo; Di Filippo, Massimiliano			Serum neurofilament light chain as a preclinical marker of neurodegeneration	LANCET NEUROLOGY			English	Editorial Material							DEMENTIA		[Parnetti, Lucilla] Univ Perugia, Sect Neurol, Dept Med, Lab Clin Neurochem, I-06132 Perugia, Italy; [Gaetani, Lorenzo; Di Filippo, Massimiliano] Univ Perugia, Sect Neurol, Dept Med, Perugia, Italy	University of Perugia; University of Perugia	Parnetti, L (corresponding author), Univ Perugia, Sect Neurol, Dept Med, Lab Clin Neurochem, I-06132 Perugia, Italy.	lucilla.parnetti@unipg.it	Parnetti, Lucilla/K-8258-2016; Gaetani, Lorenzo/ABA-8769-2021	Parnetti, Lucilla/0000-0001-5722-3967; 				Bjornevik K, 2020, JAMA NEUROL, V77, P58, DOI 10.1001/jamaneurol.2019.3238; Gaetani L, 2019, J NEUROL NEUROSUR PS, V90, P870, DOI 10.1136/jnnp-2018-320106; Honig LS, 2018, NEW ENGL J MED, V378, P321, DOI 10.1056/NEJMoa1705971; Jiskoot LC, 2019, BRAIN, V142, P193, DOI 10.1093/brain/awy288; van der Ende EL, 2019, LANCET NEUROL, V18, P1103, DOI 10.1016/S1474-4422(19)30354-0; Weston PSJ, 2017, NEUROLOGY, V89, P2167, DOI 10.1212/WNL.0000000000004667; Weydt P, 2016, ANN NEUROL, V79, P152, DOI 10.1002/ana.24552	7	6	6	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1070	+		10.1016/S1474-4422(19)30405-3	http://dx.doi.org/10.1016/S1474-4422(19)30405-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	31701888				2022-12-18	WOS:000495892200005
J	[Anonymous]				[Anonymous]			Essential medicines for patients with multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material																			0	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2019	18	12					1067	1067		10.1016/S1474-4422(19)30390-4	http://dx.doi.org/10.1016/S1474-4422(19)30390-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JM0CO	31701885	Bronze			2022-12-18	WOS:000495892200002
J	Stinear, CM				Stinear, Cathy M.			Dopamine for motor recovery after stroke: where to from here?	LANCET NEUROLOGY			English	Editorial Material							LEVODOPA; DRUGS		[Stinear, Cathy M.] Univ Auckland, Dept Med, Auckland 1142, New Zealand	University of Auckland	Stinear, CM (corresponding author), Univ Auckland, Dept Med, Auckland 1142, New Zealand.	c.stinear@auckland.ac.nz						Berends HI, 2009, EUR J PHYS REHAB MED, V45, P621; Bradley CL, 2019, NEUROREHAB NEURAL RE, V33, P331, DOI 10.1177/1545968319837289; Cramer SC, 2015, STROKE, V46, P2998, DOI 10.1161/STROKEAHA.115.007433; Ford GA, 2019, LANCET NEUROL, V18, P530, DOI 10.1016/S1474-4422(19)30147-4; Resterneyer C, 2007, RESTOR NEUROL NEUROS, V25, P143; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Stinear CM, 2017, LANCET NEUROL, V16, P826, DOI 10.1016/S1474-4422(17)30283-1; Viale L, 2018, EXPERT REV NEUROTHER, V18, P65, DOI 10.1080/14737175.2018.1400910	8	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2019	18	6					514	515		10.1016/S1474-4422(19)30162-0	http://dx.doi.org/10.1016/S1474-4422(19)30162-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HY7RQ	31122485	hybrid			2022-12-18	WOS:000468334100003
J	[Anonymous]				[Anonymous]			The risks of ignoring scientific evidence	LANCET NEUROLOGY			English	Editorial Material																			0	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2019	18	5					415	415		10.1016/S1474-4422(19)30089-4	http://dx.doi.org/10.1016/S1474-4422(19)30089-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HS8SW	30981315	Bronze			2022-12-18	WOS:000464140400003
J	Berrih-Aknin, S; Le Panse, R				Berrih-Aknin, Sonia; Le Panse, Rozen			Thymectomy in myasthenia gravis: when, why, and how?	LANCET NEUROLOGY			English	Editorial Material									[Berrih-Aknin, Sonia; Le Panse, Rozen] UPMC Univ Paris 6, Sorbonne Univ, Paris, France; [Berrih-Aknin, Sonia; Le Panse, Rozen] INSERM, U974, Paris, France; GH Pitie Salpetriere, Inst Myol, AIM, Paris, France	UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Berrih-Aknin, S (corresponding author), UPMC Univ Paris 6, Sorbonne Univ, Paris, France.; Berrih-Aknin, S (corresponding author), INSERM, U974, Paris, France.	sonia.berrih-aknin@upmc.fr	Berrih‐Aknin, Sonia/F-8025-2013; Le Panse, Rozen/B-8945-2013	Berrih‐Aknin, Sonia/0000-0001-9199-4175; Le Panse, Rozen/0000-0001-7522-5974				Berrih-Aknin S, 2014, J AUTOIMMUN, V52, P90, DOI 10.1016/j.jaut.2013.12.011; Cataneo AJM, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0837-z; Diaz A, 2014, INTERACT CARDIOV TH, V18, P381, DOI 10.1093/icvts/ivt510; Gradolatto A, 2014, J AUTOIMMUN, V52, P53, DOI 10.1016/j.jaut.2013.12.015; Molin CJ, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000450; Poea-Guyon S, 2005, J IMMUNOL, V174, P5941, DOI 10.4049/jimmunol.174.10.5941; Sudres M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89665; Truffault F, 2017, CLIN REV ALLERG IMMU, V52, P108, DOI 10.1007/s12016-016-8558-3; Wolfe GI, 2016, NEW ENGL J MED, V375, P511, DOI 10.1056/NEJMoa1602489; Wolfe GI, 2019, LANCET NEUROL, V18, P259, DOI 10.1016/S1474-4422(18)30392-2	10	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2019	18	3					225	226		10.1016/S1474-4422(18)30467-8	http://dx.doi.org/10.1016/S1474-4422(18)30467-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HL2BV	30692053				2022-12-18	WOS:000458509100008
J	Charlier, P; Lippi, D; Perciaccante, A; Appenzeller, O; Bianucci, R				Charlier, Philippe; Lippi, Donatella; Perciaccante, Antonio; Appenzeller, Otto; Bianucci, Raffaella			Neurological disorder? No, Mannerism	LANCET NEUROLOGY			English	Letter							HAND		[Charlier, Philippe] Musee Quai Brainly Jacques Chirach, Dept Rech & Enseignement, Paris, France; [Charlier, Philippe] UVSQ, Lab DANTE, EA4498, Montigny Le Bretonneux, France; [Lippi, Donatella] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Perciaccante, Antonio] San Giovanni Dio Hosp, Dept Med, I-34170 Gorizia, Italy; [Appenzeller, Otto] New Mexico Hlth Enhancement & Marathon Clin Res F, Albuquerque, NM USA; [Appenzeller, Otto] New Mexico Museum Nat Hist & Sci, Albuquerque, NM USA; [Bianucci, Raffaella] Univ Turin, Dept Publ Hlth & Paediat Sci, Legal Med Sect, Turin, Italy; [Bianucci, Raffaella] Univ Warwick, Microbiol & Infect Div, Warwick Med Sch, Coventry, W Midlands, England; [Bianucci, Raffaella] Fac Med Marseille, Lab Anthropol Bioculturelle Droit Et & Sante Ades, UMR 7268, Marseille, France	UDICE-French Research Universities; Universite Paris Saclay; University of Florence; University of Turin; University of Warwick; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Aix-Marseille Universite	Perciaccante, A (corresponding author), San Giovanni Dio Hosp, Dept Med, I-34170 Gorizia, Italy.	antonioperciaccante@libero.it	Bianucci, Raffaella/AAW-1433-2020					Falciani Carlo, 2010, BRONZINO PITTORE POE; Karenberg A, 2009, Prague Med Rep, V110, P140; Vein AA, 2018, LANCET NEUROL, V17, P742, DOI 10.1016/S1474-4422(18)30282-5; Weisz GM, 2013, RHEUMATOL INT, V33, P2177, DOI 10.1007/s00296-012-2422-4	4	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2019	18	2					135	135		10.1016/S1474-4422(18)30447-2	http://dx.doi.org/10.1016/S1474-4422(18)30447-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HI0TY	30663602	Bronze			2022-12-18	WOS:000456158200006
J	Meier, B				Meier, Bernhard			Optimal stroke prevention in patients with patent foramen ovale	LANCET NEUROLOGY			English	Editorial Material							MEDICAL THERAPY; CRYPTOGENIC STROKE; CLOSURE; EMBOLISM		[Meier, Bernhard] Univ Hosp, Dept Cardiol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Meier, B (corresponding author), Univ Hosp, Dept Cardiol, CH-3010 Bern, Switzerland.	bernhard.meier@insel.ch						Agarwal S, 2012, JACC-CARDIOVASC INTE, V5, P777, DOI 10.1016/j.jcin.2012.02.021; Carroll JD, 2013, NEW ENGL J MED, V368, P1092, DOI 10.1056/NEJMoa1301440; Hart RG, 2018, NEW ENGL J MED, V378, P2191, DOI 10.1056/NEJMoa1802686; Hart RG, 2014, LANCET NEUROL, V13, P429, DOI 10.1016/S1474-4422(13)70310-7; Homma S, 2002, CIRCULATION, V105, P2625, DOI 10.1161/01.CIR.0000017498.88393.44; Kasner SE, 2018, LANCET NEUROL, V17, P1053, DOI 10.1016/S1474-4422(18)30319-3; Mas JL, 2017, NEW ENGL J MED, V377, P1011, DOI 10.1056/NEJMoa1705915; Meier B, 2013, NEW ENGL J MED, V368, P1083, DOI 10.1056/NEJMoa1211716; Saver JL, 2017, NEW ENGL J MED, V377, P1022, DOI 10.1056/NEJMoa1610057	9	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2018	17	12					1027	1028		10.1016/S1474-4422(18)30369-7	http://dx.doi.org/10.1016/S1474-4422(18)30369-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HA3AA	30340930				2022-12-18	WOS:000450119300005
J	Gagnon, C; Gallais, B; Laberge, L				Gagnon, Cynthia; Gallais, Benjamin; Laberge, Luc			Myotonic dystrophy type 1: reasons to be OPTIMISTIC	LANCET NEUROLOGY			English	Editorial Material							APATHY; DISEASE		[Gagnon, Cynthia] Univ Sherbrooke, Fac Med & Sci Sante, Ecole Readaptat, Sherbrooke, PQ, Canada; [Gagnon, Cynthia; Gallais, Benjamin; Laberge, Luc] Ctr Sante & Serv Sociaux Saguenay Lac St Jean, Grp Rech Interdisciplinaire Malad Neuromusculaire, Jonquiere, PQ, Canada; [Gagnon, Cynthia] Ctr Rech Charles Le Moyne Saguenay Lac St Jean In, Jonquiere, PQ, Canada; [Gallais, Benjamin; Laberge, Luc] Cegep Jonquiere, Ecobes Rech & Transfert, Jonquiere, PQ G7X 7W2, Canada; [Laberge, Luc] Univ Quebec Chicoutimi, Dept Sci Sante, Chicoutimi, PQ, Canada	University of Sherbrooke; University of Quebec; University of Quebec Chicoutimi	Laberge, L (corresponding author), Ctr Sante & Serv Sociaux Saguenay Lac St Jean, Grp Rech Interdisciplinaire Malad Neuromusculaire, Jonquiere, PQ, Canada.; Laberge, L (corresponding author), Cegep Jonquiere, Ecobes Rech & Transfert, Jonquiere, PQ G7X 7W2, Canada.; Laberge, L (corresponding author), Univ Quebec Chicoutimi, Dept Sci Sante, Chicoutimi, PQ, Canada.	luclaberge@cegepjonquiere.ca	gagnon, cynthia/AAM-7292-2021	gagnon, cynthia/0000-0003-2829-8470				Baldanzi S, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0417-z; Boyle PA, 2003, AM J GERIAT PSYCHIAT, V11, P214, DOI 10.1176/appi.ajgp.11.2.214; Heatwole C, 2012, NEUROLOGY, V79, P348, DOI 10.1212/WNL.0b013e318260cbe6; Hermans MCE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139944; Hillman D, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy083; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; Okkersen K, 2018, LANCET NEUROL, V17, P671, DOI 10.1016/S1474-4422(18)30203-5; Okkersen K, 2017, CORTEX, V95, P143, DOI 10.1016/j.cortex.2017.08.008; Padala PR, 2018, AM J PSYCHIAT, V175, P159, DOI 10.1176/appi.ajp.2017.17030316; Peric S, 2015, J NEUROL, V262, P142, DOI 10.1007/s00415-014-7545-y	11	6	6	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2018	17	8					652	U1		10.1016/S1474-4422(18)30240-0	http://dx.doi.org/10.1016/S1474-4422(18)30240-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN5BH	29934200				2022-12-18	WOS:000439057500002
J	Woo, D; Anderson, CD; Maguire, J; Fornage, M; Lee, JM; Seshadri, S; Markus, HS; Majersik, JJ; Jimenez-Conde, J; Crawford, K; Lindgren, AG; Debette, S				Woo, Daniel; Anderson, Christopher D.; Maguire, Jane; Fornage, Myriam; Lee, Jin-Moo; Seshadri, Sudha; Markus, Hugh S.; Majersik, Jennifer J.; Jimenez-Conde, Jordi; Crawford, Katherine; Lindgren, Arne G.; Debette, Stephanie			Top research priorities for stroke genetics	LANCET NEUROLOGY			English	Letter							GENOME-WIDE ASSOCIATION		[Woo, Daniel] Univ Cincinnati, Coll Med, Dept Neurol & Rehabil Med, Cincinnati, OH 45267 USA; [Anderson, Christopher D.; Crawford, Katherine] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA; [Maguire, Jane] Univ Technol Sydney, Sydney, NSW, Australia; [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, McGovern Med Sch, Houston, TX 77030 USA; [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA; [Lee, Jin-Moo] Washington Univ, Sch Med, Dept Neurol Radiol & Biomed Engn, St Louis, MO USA; [Seshadri, Sudha] Univ Texas Hlth Sci Ctr San Antonio, Glenn Biggs Inst Alzheimers & Neurodegenerat Dis, San Antonio, TX 78229 USA; [Seshadri, Sudha] Boston Univ, Sch Med, Framingham Heart Study, Boston, MA 02118 USA; [Seshadri, Sudha] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Markus, Hugh S.] Univ Cambridge, Dept Neurosci, Stroke Res Grp, Cambridge, England; [Majersik, Jennifer J.] Univ Utah, Dept Neurol, Salt Lake City, UT USA; [Jimenez-Conde, Jordi] Univ Autonoma Barcelona, IMIM Inst Hosp del Mar Invest Med, Neurovasc Res Grp, Dept Neurol, Barcelona, Spain; [Crawford, Katherine] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA; [Lindgren, Arne G.] Lund Univ, Dept Clin Sci Lund, Neurol, Lund, Sweden; [Lindgren, Arne G.] Skane Univ Hosp, Dept Neurol & Rehabil Med, Lund, Sweden; [Debette, Stephanie] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, UMR 1219, Bordeaux, France; [Debette, Stephanie] CHU Bordeaux, Dept Neurol, Bordeaux, France	University System of Ohio; University of Cincinnati; Harvard University; Massachusetts General Hospital; University of Technology Sydney; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Washington University (WUSTL); University of Texas System; University of Texas Health San Antonio; Boston University; Framingham Heart Study; Boston University; University of Cambridge; Utah System of Higher Education; University of Utah; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Lund University; Lund University; Skane University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux	Woo, D (corresponding author), Univ Cincinnati, Coll Med, Dept Neurol & Rehabil Med, Cincinnati, OH 45267 USA.	Daniel.woo@uc.edu	JIMENEZ-CONDE, JORDI/C-1941-2012; Debette, Stephanie/T-4946-2019; Maguire, Jane M.M./D-8427-2017; Majersik, Jennifer Juhl/J-4236-2019; Lee, Jin-Moo/K-2024-2015	Debette, Stephanie/0000-0001-8675-7968; Maguire, Jane M.M./0000-0001-5722-8311; Lee, Jin-Moo/0000-0002-3979-0906; Seshadri, Sudha/0000-0001-6135-2622; Anderson, Christopher/0000-0002-0053-2002	NIH [U10NS077311, U01NS036695, R01NS093870, R01NS100417, R01AG033193, U01AG049505, R01AG049607, R01AG033040, U01AG52409, R01AG054076, R01NS017950, UH2NS100605]; NIH/NINDS [K23NS086873, R01NS103924, R01NS087541, R21AG055333, R01NS084028, R01NS085419, R01NS094692, U10NS086606]; NIHR; Swedish Heart Lung Foundation, Lund University, Region Skane; Freemasons Lodge of Instruction EOS in Lund; Foundation of Fars & Frosta-Sparbanken Skane; Swedish Stroke Association; Agence Nationale de la Recherche; Joint Programme on Neurodegenerative Disease research; European Research Council; Initiative of Excellence of University of Bordeaux; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950, U01NS036695, U10NS086606, R01NS093870, UH2NS100605, R01NS087541, R01NS100417, R01NS103924, U10NS077311, R01NS094692, R01NS085419, K23NS086873, R01NS084028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG054076, R01AG049607, U01AG052409, R21AG055333, U01AG049505, R01AG033193, R01AG033040] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIHR(National Institute for Health Research (NIHR)); Swedish Heart Lung Foundation, Lund University, Region Skane; Freemasons Lodge of Instruction EOS in Lund; Foundation of Fars & Frosta-Sparbanken Skane; Swedish Stroke Association; Agence Nationale de la Recherche(French National Research Agency (ANR)); Joint Programme on Neurodegenerative Disease research; European Research Council(European Research Council (ERC)European Commission); Initiative of Excellence of University of Bordeaux; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	DW is supported by NIH U10NS077311, U01NS036695, R01NS093870, and R01NS100417 funding. CDA is supported by NIH/NINDS K23NS086873, R01NS103924, and has consulted for ApoPharma Inc. MF is supported by NIH/NINDS R01NS087541 funding. J-ML is supported by NIH/NINDS R21AG055333, R01NS084028, R01NS085419, and R01NS094692 funding. SS is supported by NIH R01AG033193, U01AG049505, R01AG049607, R01AG033040, U01AG52409, R01AG054076, R01NS017950, and UH2NS100605 funding. HSM is supported by an NIHR Senior Investigator award and his work is supported by infrastructural support by the Cambridge University NHS Trust NIHR Biomedical Research Centre. JM is supported by NIH/NINDS U10NS086606 funding. AGL is supported by the Swedish Heart Lung Foundation, Lund University, Region Skane, the Freemasons Lodge of Instruction EOS in Lund, the Foundation of Fars & Frosta-Sparbanken Skane, and the Swedish Stroke Association. SD is supported by grants from the Agence Nationale de la Recherche, the Joint Programme on Neurodegenerative Disease research, the European Research Council, and the Initiative of Excellence of University of Bordeaux. JM, JJ-C, and KC declare no competing interests.	DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458; Debette S, 2015, NAT GENET, V47, P78, DOI 10.1038/ng.3154; Feigin VL, 2016, LANCET NEUROL, V15, P913, DOI 10.1016/S1474-4422(16)30073-4; Foroud T, 2014, STROKE, V45, P3194, DOI 10.1161/STROKEAHA.114.006096; Jonathan C, 2005, NAT GENET, V37, P161, DOI 10.1038/ng1509; Maguire JM, 2017, EUR STROKE J, V2, P229, DOI 10.1177/2396987317704547; Malik R, 2018, NAT GENET, V50, P524, DOI 10.1038/s41588-018-0058-3; Partridge N, 2004, LANCET, V364, P1923, DOI 10.1016/S0140-6736(04)17494-1; Verhaaren BFJ, 2015, CIRC-CARDIOVASC GENE, V8, P398, DOI 10.1161/CIRCGENETICS.114.000858; Woo D, 2014, AM J HUM GENET, V94, P511, DOI 10.1016/j.ajhg.2014.02.012	10	6	6	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2018	17	8					663	U5		10.1016/S1474-4422(18)30243-6	http://dx.doi.org/10.1016/S1474-4422(18)30243-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN5BH	30033056	Bronze			2022-12-18	WOS:000439057500009
J	Finsterer, J				Finsterer, Josef			The SeLECT score is inappropriate to predict post-stroke epilepsy	LANCET NEUROLOGY			English	Editorial Material									[Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria	Rudolfstiftung Hospital	Finsterer, J (corresponding author), Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.	fifigs1@yahoo.de						Galovic M, 2018, LANCET NEUROL, V17, P143, DOI 10.1016/S1474-4422(17)30404-0; Hatzinger Martin, 2009, Ther Umsch, V66, P413, DOI 10.1024/0040-5930.66.6.413; Learoyd AE, 2017, TRANSL STROKE RES, V8, P541, DOI 10.1007/s12975-017-0553-3; Nabbout R, 2013, HAND CLINIC, V111, P567, DOI 10.1016/B978-0-444-52891-9.00059-2; Vinik AI, 2015, ENDOTEXT; Viramontes Terry S, 2016, Consult Pharm, V31, P139, DOI 10.4140/TCP.n.2016.139	6	6	6	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2018	17	2					106	107		10.1016/S1474-4422(17)30460-X	http://dx.doi.org/10.1016/S1474-4422(17)30460-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT0PA	29413306				2022-12-18	WOS:000422828500004
J	Dinsmore, J				Dinsmore, Judith			HERMES: a helpful messenger in the anaesthesia for thrombectomy debate?	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; CONSCIOUS SEDATION; GENERAL-ANESTHESIA; TRIAL		[Dinsmore, Judith] St George Hosp, Dept Anaesthesia, London SW17 0QT, England	St Georges University London	Dinsmore, J (corresponding author), St George Hosp, Dept Anaesthesia, London SW17 0QT, England.	judith.dinsmore@nhs.net						Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Bracard S, 2016, LANCET NEUROL, V15, P1138, DOI 10.1016/S1474-4422(16)30177-6; Brinjikji W, 2015, AM J NEURORADIOL, V36, P525, DOI 10.3174/ajnr.A4159; Campbell BCV, 2018, LANCET NEUROL, V17, P47, DOI 10.1016/S1474-4422(17)30407-6; Henden PL, 2017, STROKE, V48, P1601, DOI 10.1161/STROKEAHA.117.016554; Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780; Schonenberger S, 2016, JAMA-J AM MED ASSOC, V316, P1986, DOI 10.1001/jama.2016.16623; Simonsen CZ, 2017, EUR STROKE J, V2, P477; Soriano SG, 2017, BRIT J ANAESTH, V119, P443, DOI 10.1093/bja/aex238	9	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2018	17	1					21	23		10.1016/S1474-4422(17)30412-X	http://dx.doi.org/10.1016/S1474-4422(17)30412-X			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ7VE	29262998				2022-12-18	WOS:000418570500014
J	Sejvar, JJ				Sejvar, James J.			Global burden of neurological disease: what's in a name?	LANCET NEUROLOGY			English	Editorial Material									[Sejvar, James J.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Sejvar, JJ (corresponding author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA.	zea3@cdc.gov						GBD 2015 Neurological Disorders Collaborator Group, 2015, GLOB REG NAT BURD NE	1	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2017	16	11					858	859		10.1016/S1474-4422(17)30333-2	http://dx.doi.org/10.1016/S1474-4422(17)30333-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FJ3WM	28931492	hybrid			2022-12-18	WOS:000412663200002
J	Akimoto, M; Nakamura, K				Akimoto, Makoto; Nakamura, Kazue		Edaravone MCI-186 ALS Study Grp	Edaravone for treatment of early-stage ALS Reply	LANCET NEUROLOGY			English	Letter									[Akimoto, Makoto; Nakamura, Kazue; Edaravone MCI-186 ALS Study Grp] Mitsubishi Tanabe Pharma Corp, Ikuyaku Integrated Value Dev Div, Clin Planning Dept 1, Tokyo 1038405, Japan	Mitsubishi Tanabe Pharma Corporation	Akimoto, M (corresponding author), Mitsubishi Tanabe Pharma Corp, Ikuyaku Integrated Value Dev Div, Clin Planning Dept 1, Tokyo 1038405, Japan.	akimoto.makoto@mc.mt-pharma.co.jp						Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1; Fournier C, 2015, NAT BIOTECHNOL, V33, P45, DOI 10.1038/nbt.3118; Mitsubishi Tanabe Pharma Corporation, CLIN TRIAL PROT MCI1	3	6	7	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2017	16	10					772	772		10.1016/S1474-4422(17)30290-9	http://dx.doi.org/10.1016/S1474-4422(17)30290-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5PI	28920878				2022-12-18	WOS:000410379900010
J	Rothwell, PM				Rothwell, Peter M.			Stroke research in 2016: when more medicine is better, and when it isn't	LANCET NEUROLOGY			English	Editorial Material							TRANSIENT ISCHEMIC ATTACK; INTRACEREBRAL HEMORRHAGE; PLATELET TRANSFUSION; CEREBRAL-HEMORRHAGE; ASPIRIN; RISK		[Rothwell, Peter M.] Univ Oxford, John Radcliffe Hosp, Ctr Prevent Stroke & Dementia, Oxford OX3 9DU, England	University of Oxford	Rothwell, PM (corresponding author), Univ Oxford, John Radcliffe Hosp, Ctr Prevent Stroke & Dementia, Oxford OX3 9DU, England.	peter.rothwell@clneuro.ox.ac.uk	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211	National Institute for Health Research [NF-SI-0514-10168] Funding Source: researchfish; Wellcome Trust Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome TrustEuropean Commission)		Amarenco P, 2016, NEW ENGL J MED, V374, P1533, DOI 10.1056/NEJMoa1412981; Anderson CS, 2016, NEW ENGL J MED, V374, P2313, DOI 10.1056/NEJMoa1515510; Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609; Baharoglu MI, 2016, LANCET, V387, P2605, DOI 10.1016/S0140-6736(16)30392-0; Hughes S, MEDSCAPE MED NEWS CO; Johnston SC, 2016, NEW ENGL J MED, V375, P35, DOI 10.1056/NEJMoa1603060; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Qureshi AI, 2016, NEW ENGL J MED, V375, P1033, DOI 10.1056/NEJMoa1603460; Rothwell PM, 2016, LANCET, V388, P365, DOI 10.1016/S0140-6736(16)30468-8	9	6	7	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					2	3		10.1016/S1474-4422(16)30332-5	http://dx.doi.org/10.1016/S1474-4422(16)30332-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27979343				2022-12-18	WOS:000389869200002
J	Dyer, SM; Flicker, L; Laver, K; Whitehead, C; Cumming, R				Dyer, Suzanne M.; Flicker, Leon; Laver, Kate; Whitehead, Craig; Cumming, Robert			The clinical value of fluid biomarkers for dementia diagnosis	LANCET NEUROLOGY			English	Letter							ALZHEIMERS-DISEASE		[Dyer, Suzanne M.; Laver, Kate; Whitehead, Craig] Flinders Univ S Australia, Sch Hlth Sci, Dept Rehabil Aged & Extended Care, Adelaide, SA, Australia; [Dyer, Suzanne M.; Laver, Kate; Whitehead, Craig] Univ Sydney, NHMRC Partnership Ctr Cognit & Funct Decline, Sydney, NSW, Australia; [Cumming, Robert] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia; [Flicker, Leon] Univ Western Australia, Med Res Ctr, Crawley, WA, Australia	Flinders University South Australia; University of Sydney; University of Sydney; University of Western Australia	Dyer, SM (corresponding author), Flinders Univ S Australia, Sch Hlth Sci, Dept Rehabil Aged & Extended Care, Adelaide, SA, Australia.; Dyer, SM (corresponding author), Univ Sydney, NHMRC Partnership Ctr Cognit & Funct Decline, Sydney, NSW, Australia.	suzanne.dyer@sa.gov.au	Flicker, Leon/AAE-1530-2022; Laver, Kate/AFM-0623-2022	Flicker, Leon/0000-0002-3650-0475; Laver, Kate/0000-0003-0259-2209; Dyer, Suzanne M/0000-0003-2748-8547				Brayne C, 2014, LANCET NEUROL, V13, P532, DOI 10.1016/S1474-4422(14)70098-5; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/S1474-4422(16)00070-3, 10.1016/s1474-4422(16)00070-3]; Ritchie C, 2014, COCHRANE DB SYST REV, V10; Sackett DL, 2002, BRIT MED J, V324, P539, DOI 10.1136/bmj.324.7336.539; Zhang S, 2014, COCHRANE DB SYST REV, V23	5	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2016	15	12					1204	1204		10.1016/S1474-4422(16)30238-1	http://dx.doi.org/10.1016/S1474-4422(16)30238-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EA0YO	27751543	Bronze			2022-12-18	WOS:000386315700011
J	Jaccard, A; Magy, L				Jaccard, Arnaud; Magy, Laurent			Thalidomide and POEMS syndrome: a cautious step forward	LANCET NEUROLOGY			English	Editorial Material									[Jaccard, Arnaud] Univ Hosp Limoges, Dept Hematol, F-870000 Limoges, France; [Magy, Laurent] Univ Hosp Limoges, Dept Neurol, F-870000 Limoges, France; [Jaccard, Arnaud] Univ Hosp Limoges, Ctr Reference Amylose AL & Autres Malad Depots Im, F-870000 Limoges, France; [Magy, Laurent] Univ Hosp Limoges, Ctr Reference Neuropathies Peripher Rares, FILNEMUS, F-870000 Limoges, France	CHU Limoges; CHU Limoges; CHU Limoges; CHU Limoges	Jaccard, A (corresponding author), Univ Hosp Limoges, Dept Hematol, F-870000 Limoges, France.; Jaccard, A (corresponding author), Univ Hosp Limoges, Ctr Reference Amylose AL & Autres Malad Depots Im, F-870000 Limoges, France.	arnaud.jaccard@chu-limoges.fr						Abe D, 2008, BLOOD, V112, P836, DOI 10.1182/blood-2007-12-126979; Dispenzieri A, 2003, BLOOD, V101, P2496, DOI 10.1182/blood-2002-07-2299; Dispenzieri A, 2012, BLOOD, V119, P5650, DOI 10.1182/blood-2012-03-378992; Fermand JP, 2016, 2 WORLD C CONTR MULT; Li J, 2011, BLOOD, V117, P6445, DOI 10.1182/blood-2010-12-328112; Merlini G, 2006, BLOOD, V108, P2520, DOI 10.1182/blood-2006-03-001164; Misawa S, 2016, LANCET NEUROL; Royer B, 2013, AM J HEMATOL, V88, P207, DOI 10.1002/ajh.23374; Watanabe O, 1996, LANCET, V347, P702, DOI 10.1016/S0140-6736(96)91261-1	9	6	7	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2016	15	11					1104	1105		10.1016/S1474-4422(16)30176-4	http://dx.doi.org/10.1016/S1474-4422(16)30176-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DX3MJ	27496679				2022-12-18	WOS:000384276900002
J	Fraser, JF				Fraser, Justin F.			Standardisation of research strategies in acute ischaemic stroke	LANCET NEUROLOGY			English	Editorial Material							URIC-ACID; IMPROVES		[Fraser, Justin F.] Univ Kentucky, Ctr Adv Translat Stroke Sci, Dept Neurol Surg, 800 Rose St,Room MS108A, Lexington, KY 40536 USA; [Fraser, Justin F.] Univ Kentucky, Ctr Adv Translat Stroke Sci, Dept Neurol, 800 Rose St,Room MS108A, Lexington, KY 40536 USA; [Fraser, Justin F.] Univ Kentucky, Ctr Adv Translat Stroke Sci, Dept Radiol, 800 Rose St,Room MS108A, Lexington, KY 40536 USA; [Fraser, Justin F.] Univ Kentucky, Ctr Adv Translat Stroke Sci, Dept Anat & Neurobiol, 800 Rose St,Room MS108A, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Fraser, JF (corresponding author), Univ Kentucky, Ctr Adv Translat Stroke Sci, Dept Neurol Surg, 800 Rose St,Room MS108A, Lexington, KY 40536 USA.; Fraser, JF (corresponding author), Univ Kentucky, Ctr Adv Translat Stroke Sci, Dept Neurol, 800 Rose St,Room MS108A, Lexington, KY 40536 USA.; Fraser, JF (corresponding author), Univ Kentucky, Ctr Adv Translat Stroke Sci, Dept Radiol, 800 Rose St,Room MS108A, Lexington, KY 40536 USA.; Fraser, JF (corresponding author), Univ Kentucky, Ctr Adv Translat Stroke Sci, Dept Anat & Neurobiol, 800 Rose St,Room MS108A, Lexington, KY 40536 USA.	jfr235@uky.edu						Chamorro A, 2016, LANCET NEUROL, V15, P869, DOI 10.1016/S1474-4422(16)00114-9; Chamorro A, 2014, LANCET NEUROL, V13, P453, DOI 10.1016/S1474-4422(14)70054-7; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Grupke S, 2015, CLIN NEUROL NEUROSUR, V129, P1, DOI 10.1016/j.clineuro.2014.11.013; Llull L, 2015, STROKE, V46, P2162, DOI 10.1161/STROKEAHA.115.009960; Romanos E, 2007, J CEREBR BLOOD F MET, V27, P14, DOI 10.1038/sj.jcbfm.9600312	6	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2016	15	8					784	785		10.1016/S1474-4422(16)30080-1	http://dx.doi.org/10.1016/S1474-4422(16)30080-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO1NR	27302347				2022-12-18	WOS:000377545800007
J	Mandelbaum, DE				Mandelbaum, David E.			Cannabidiol in patients with treatment-resistant epilepsy	LANCET NEUROLOGY			English	Letter									[Mandelbaum, David E.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA	Brown University	Mandelbaum, DE (corresponding author), Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.	david_mandelbaum@brown.edu						Brecht B., 1966, GALILEO; Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8; Friedman D, 2014, EFFECT EPIDIOLEX CAN; Ng YT, 2011, NEUROLOGY, V77, P1473, DOI 10.1212/WNL.0b013e318232de76	4	6	6	1	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2016	15	6					544	545		10.1016/S1474-4422(16)00122-8	http://dx.doi.org/10.1016/S1474-4422(16)00122-8			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI9PW	27302117	Bronze			2022-12-18	WOS:000373835900011
J	Li, HF; Xie, YC; Yue, YX				Li, Hai-Feng; Xie, Yanchen; Yue, Yao-Xian			Myasthenia gravis: subgroup classifications	LANCET NEUROLOGY			English	Letter									[Li, Hai-Feng; Yue, Yao-Xian] Shandong Univ, Qilu Hosp, Dept Neurol, Jinan 250012, Shandong, Peoples R China; [Xie, Yanchen] George Washington Univ, Dept Neurol, Washington, DC USA	Shandong University; George Washington University	Li, HF (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurol, Jinan 250012, Shandong, Peoples R China.	drlhf@163.com	Xie, Yanchen/GXM-9448-2022	Xie, Yanchen/0000-0002-7879-0554				Akaishi T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106757; Della Marina A, 2014, NEUROPEDIATRICS, V45, P75, DOI 10.1055/s-0033-1364181; Gilhus NE, 2015, LANCET NEUROL, V14, P1023, DOI 10.1016/S1474-4422(15)00145-3; Li H, 2012, EUR J NEUROL, V19, P386; Meriggioli MN, 2009, LANCET NEUROL, V8, P475, DOI 10.1016/S1474-4422(09)70063-8; Romi F, 2011, AUTOIMMUN DIS, V2011, DOI 10.4061/2011/474512; VINCENT A, 1985, J NEUROL NEUROSUR PS, V48, P1246, DOI 10.1136/jnnp.48.12.1246; Zisimopoulou P, 2014, J AUTOIMMUN, V52, P139, DOI 10.1016/j.jaut.2013.12.004	8	6	10	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					355	356		10.1016/S1474-4422(16)00032-6	http://dx.doi.org/10.1016/S1474-4422(16)00032-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP	26971654	Bronze			2022-12-18	WOS:000371974000013
J	Hattori, N				Hattori, Nobutaka			Movement disorders: advances in 2015	LANCET NEUROLOGY			English	Editorial Material							PARKINSONS-DISEASE; BRAIN		[Hattori, Nobutaka] Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Hattori, N (corresponding author), Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	nhattori@juntendo.ac.jp	Hattori, Nobutaka/ACR-0069-2022					Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2; Holmqvist S, 2014, ACTA NEUROPATHOL, V128, P805, DOI 10.1007/s00401-014-1343-6; Odekerken VJJ, 2015, NEUROLOGY, V84, P1355, DOI 10.1212/WNL.0000000000001419; Ogaki K, 2015, NEUROLOGY, V85, P2016, DOI 10.1212/WNL.0000000000002170; Peelaerts W, 2015, NATURE, V522, P340, DOI 10.1038/nature14547; Steinbeck JA, 2015, NAT BIOTECHNOL, V33, P204, DOI 10.1038/nbt.3124; Svensson E, 2015, ANN NEUROL, V78, P522, DOI 10.1002/ana.24448; Tysnes OB, 2015, ANN NEUROL, V78, P1011, DOI 10.1002/ana.24531	8	6	6	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					8	9		10.1016/S1474-4422(15)00362-2	http://dx.doi.org/10.1016/S1474-4422(15)00362-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26700896				2022-12-18	WOS:000366313900005
J	Langer-Gould, A				Langer-Gould, Annette			Sex hormones and multiple sclerosis: another informative failure	LANCET NEUROLOGY			English	Editorial Material									[Langer-Gould, Annette] Kaiser Permanente, Res & Evaluat, Pasadena, CA 91101 USA	Kaiser Permanente	Langer-Gould, A (corresponding author), Kaiser Permanente, Res & Evaluat, 100 S Los Robles Ave, Pasadena, CA 91101 USA.	Annette.M.Langer-Gould@kp.org						Arnold AP, 2009, FRONT NEUROENDOCRIN, V30, P1, DOI 10.1016/j.yfrne.2008.11.001; Clark GF, 2001, CELLS TISSUES ORGANS, V168, P113, DOI 10.1159/000016812; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Gammill HS, 2010, INT J DEV BIOL, V54, P531, DOI 10.1387/ijdb.082767hg; Sicotte NL, 2002, ANN NEUROL, V52, P421, DOI 10.1002/ana.10301; Smith-Bouvier DL, 2008, J EXP MED, V205, P1099, DOI 10.1084/jem.20070850; Voskuhl RR, 2012, NAT REV NEUROL, V8, P255, DOI 10.1038/nrneurol.2012.43; Voskuhl RR, 2015, LANCET NEUROL; Vukusic S, 2012, ECTRIMS 2012; Williams JL, 2013, CLIN IMMUNOL, V149, P236, DOI 10.1016/j.clim.2013.04.005	10	6	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2016	15	1					22	23		10.1016/S1474-4422(15)00348-8	http://dx.doi.org/10.1016/S1474-4422(15)00348-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY3MM	26621681				2022-12-18	WOS:000366313900012
J	Funayama, M; Hattori, N				Funayama, Manabu; Hattori, Nobutaka			CHCHD2 and Parkinson's disease Reply	LANCET NEUROLOGY			English	Letter							MUTATIONS		[Funayama, Manabu; Hattori, Nobutaka] Juntendo Univ, Grad Sch Med, Ctr Genom & Regenerat Med, Res Inst Dis Old Age, Tokyo, Japan; [Funayama, Manabu; Hattori, Nobutaka] Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University; Juntendo University	Funayama, M (corresponding author), Juntendo Univ, Grad Sch Med, Ctr Genom & Regenerat Med, Res Inst Dis Old Age, Tokyo, Japan.	nhattori@juntendo.ac.jp	Hattori, Nobutaka/ACR-0069-2022; Funayama, Manabu/E-6485-2013	Funayama, Manabu/0000-0002-7412-3631				Feyeux M, 2012, HUM MOL GENET, V21, P3883, DOI 10.1093/hmg/dds216; Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2; Kumari U, 2009, FEBS J, V276, P6455, DOI 10.1111/j.1742-4658.2009.07344.x; Satake W, 2009, NAT GENET, V41, P1303, DOI 10.1038/ng.485; Singleton AB, 2013, MOVEMENT DISORD, V28, P14, DOI 10.1002/mds.25249; Song R, 2015, MOL MED REP, V11, P4053, DOI 10.3892/mmr.2015.3256	6	6	6	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2015	14	7					682	683		10.1016/S1474-4422(15)00097-6	http://dx.doi.org/10.1016/S1474-4422(15)00097-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK4LS	26067115	Bronze			2022-12-18	WOS:000356195900013
J	[Anonymous]				[Anonymous]			WHO takes up the baton on dementia	LANCET NEUROLOGY			English	Editorial Material																			0	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2015	14	5					455	455		10.1016/S1474-4422(15)00022-8	http://dx.doi.org/10.1016/S1474-4422(15)00022-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG6SY	25895925	Bronze			2022-12-18	WOS:000353433900001
J	Lynn, RC; Guskiewicz, KM				Lynn, Robert C.; Guskiewicz, Kevin M.			Concussion research: new horizons	LANCET NEUROLOGY			English	Editorial Material									[Lynn, Robert C.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related TBI Res Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Lynn, RC (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related TBI Res Ctr, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Lynall, Robert/M-2888-2014	Lynall, Robert/0000-0002-0785-6640; Guskiewicz, Kevin/0000-0002-8682-2130				Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Kroshus E, 2015, HEALTH EDUC BEHAV, V42, P153, DOI 10.1177/1090198114543011; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367	6	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					14	16		10.1016/S1474-4422(14)70308-4	http://dx.doi.org/10.1016/S1474-4422(14)70308-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25496886				2022-12-18	WOS:000346885300009
J	Milani, D; Pezzani, L; Tadini, G; Menni, F; Esposito, S				Milani, Donatella; Pezzani, Lidia; Tadini, Gianluca; Menni, Francesca; Esposito, Susanna			A multidisciplinary approach in neurofibromatosis 1	LANCET NEUROLOGY			English	Letter							TYPE-1		[Milani, Donatella; Pezzani, Lidia; Tadini, Gianluca; Menni, Francesca; Esposito, Susanna] Univ Milan, Dept Pathophysiol & Transplantat, Pediat Highly Intens Care Unit, I-20122 Milan, Italy; [Tadini, Gianluca] Univ Milan, Dept Pathophysiol & Transplantat, Unit Dermatol, I-20122 Milan, Italy	University of Milan; University of Milan	Milani, D (corresponding author), Univ Milan, Dept Pathophysiol & Transplantat, Pediat Highly Intens Care Unit, I-20122 Milan, Italy.	susanna.esposito@unimi.it	Milani, Donatella/AAC-8430-2019; Pezzani, Lidia/AAA-5742-2019; Pezzani, Lidia/AAB-7524-2019; Esposito, Susanna/K-3475-2016	Milani, Donatella/0000-0002-3087-8514; Pezzani, Lidia/0000-0002-4601-2985; Esposito, Susanna/0000-0003-4103-2837				DeBella K, 2000, NEUROLOGY, V54, P1646, DOI 10.1212/WNL.54.8.1646; Hirbe AC, 2014, LANCET NEUROL, V13, P834, DOI 10.1016/S1474-4422(14)70063-8; Tadini G, 2013, DERMATOLOGY, V226, P115, DOI 10.1159/000346643; Tadini G, 2014, EUR J INTERN MED, V25, P506, DOI 10.1016/j.ejim.2014.04.004; Viola F, 2012, OPHTHALMOLOGY, V119, P369, DOI 10.1016/j.ophtha.2011.07.046	5	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					29	30		10.1016/S1474-4422(14)70255-8	http://dx.doi.org/10.1016/S1474-4422(14)70255-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25496892	Green Submitted, Bronze			2022-12-18	WOS:000346885300019
J	Tfelt-Hansen, P				Tfelt-Hansen, Peer			Site of effect of LY2951742 for migraine prophylaxis	LANCET NEUROLOGY			English	Letter							ANTIBODIES; PREVENTION		Univ Copenhagen, Danish Headache Ctr, Dept Neurol, Glostrup Hosp, DK-2600 Glostrup, Denmark	University of Copenhagen	Tfelt-Hansen, P (corresponding author), Univ Copenhagen, Danish Headache Ctr, Dept Neurol, Glostrup Hosp, DK-2600 Glostrup, Denmark.	ptha@regionh.dk						del Rio MS, 1999, CEPHALALGIA, V19, P701, DOI 10.1046/j.1468-2982.1999.019008701.x; Dodick DW, 2014, LANCET NEUROL, V13, P885, DOI 10.1016/S1474-4422(14)70128-0; Edvinsson L, 2008, CEPHALALGIA, V28, P1245, DOI 10.1111/j.1468-2982.2008.01675.x; Reuter U, 2014, LANCET NEUROL, V13, P857, DOI 10.1016/S1474-4422(14)70126-7; Yu YJ, 2013, NEUROTHERAPEUTICS, V10, P459, DOI 10.1007/s13311-013-0187-4	5	6	12	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					31	32		10.1016/S1474-4422(14)70306-0	http://dx.doi.org/10.1016/S1474-4422(14)70306-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25496894				2022-12-18	WOS:000346885300021
J	van den Berg, LH				van den Berg, Leonard H.			Therapy of amyotrophic lateral sclerosis remains a challenge	LANCET NEUROLOGY			English	Editorial Material							ALS; DEXPRAMIPEXOLE; EMPOWER; TRIAL		Univ Med Ctr Utrecht, Dept Neurol, Brain Ctr Rudolf Magnus, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	van den Berg, LH (corresponding author), Univ Med Ctr Utrecht, Dept Neurol, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.	l.h.vandenberg@umcutrecht.nl						Berry JD, PLOS ONE, V8; Bozik ME, 2014, AMYOTROPH LAT SCL FR, V15, P406, DOI 10.3109/21678421.2014.943672; Chio A, 2011, NEUROLOGY, V77, P1432, DOI 10.1212/WNL.0b013e318232ab9b; Cudkowicz ME, 2014, LANCET NEUROL; Cudkowicz ME, 2013, LANCET NEUROL, V12, P1059, DOI 10.1016/S1474-4422(13)70221-7; Ravits J, 2013, AMYOTROPH LAT SCL FR, V14, P5, DOI 10.3109/21678421.2013.778548; van den Berg LH, 2011, J NEUROL NEUROSUR PS, V82, P711, DOI 10.1136/jnnp.2011.241513	7	6	6	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2014	13	11					1062	1063		10.1016/S1474-4422(14)70179-6	http://dx.doi.org/10.1016/S1474-4422(14)70179-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR7TZ	25297014				2022-12-18	WOS:000343783900002
J	[Anonymous]				[Anonymous]			Bringing forward the diagnosis of Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material																			0	6	6	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2014	13	10					961	961		10.1016/S1474-4422(14)70211-X	http://dx.doi.org/10.1016/S1474-4422(14)70211-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AP3EZ	25231514				2022-12-18	WOS:000341959700001
J	Grandjean, P; Landrigan, PJ				Grandjean, Philippe; Landrigan, Philip J.			Neurodevelopmental toxicity: still more questions than answers Response	LANCET NEUROLOGY			English	Letter							NEUROTOXICITY		[Grandjean, Philippe] Univ Southern Denmark, Dept Environm Med, Odense, Denmark; [Grandjean, Philippe] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02215 USA; [Landrigan, Philip J.] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA	University of Southern Denmark; Harvard University; Harvard T.H. Chan School of Public Health; Icahn School of Medicine at Mount Sinai	Grandjean, P (corresponding author), Univ Southern Denmark, Dept Environm Med, Odense, Denmark.	pgrand@hsph.harvard.edu	Grandjean, Philippe/I-2962-2014	Grandjean, Philippe/0000-0003-4046-9658	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011681, R01ES009797] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Cattani D, 2014, TOXICOLOGY, V320, P34, DOI 10.1016/j.tox.2014.03.001; Choi AL, 2012, ENVIRON HEALTH PERSP, V120, P1362, DOI 10.1289/ehp.1104912; Grandjean P, 2014, LANCET NEUROL, V13, P330, DOI 10.1016/S1474-4422(13)70278-3; National Research Council (NRC), 2006, FLUOR DRINK WAT SCI; United States Environmental Protection Agency website, EPA HHS ANN NEW SCI	5	6	6	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2014	13	7					648	649		10.1016/S1474-4422(14)70121-8	http://dx.doi.org/10.1016/S1474-4422(14)70121-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK5RI	24943339				2022-12-18	WOS:000338483600010
J	Macdonald, RL				Macdonald, R. Loch			Are statins to be STASHed in subarachnoid haemorrhage?	LANCET NEUROLOGY			English	Editorial Material							TRIALS; STROKE		[Macdonald, R. Loch] Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Div Neurosurg,Labatt Family Ctr Excellence Brain, Toronto, ON M5B 1W8, Canada; [Macdonald, R. Loch] Univ Toronto, St Michaels Hosp, Dept Surg, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto	Macdonald, RL (corresponding author), Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Div Neurosurg,Labatt Family Ctr Excellence Brain, Toronto, ON M5B 1W8, Canada.	macdonaldlo@smh.ca			Canadian Institutes of Health Research Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Eisa-Beygi S, 2013, DEV BIOL, V373, P258, DOI 10.1016/j.ydbio.2012.11.024; Flaster M, 2011, EXPERT REV NEUROTHER, V11, P1141, DOI [10.1586/ern.11.101, 10.1586/ERN.11.101]; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Kirkpatrick PJ, 2014, LANCET NEUROL; Landis S, 2013, STROKE, V44, P1217, DOI 10.1161/STROKEAHA.113.001534; Macdonald RL, 2014, NAT REV NEUROL, V10, P44, DOI 10.1038/nrneurol.2013.246; Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386; Sabri M, 2010, WORLD NEUROSURG, V73, P646, DOI 10.1016/j.wneu.2010.03.032; Tseng MY, 2007, STROKE, V38, P1545, DOI 10.1161/STROKEAHA.106.475905; Wong GKC, 2013, NEUROSURGERY, V72, P840, DOI 10.1227/NEU.0b013e31828ab413	11	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2014	13	7					639	641		10.1016/S1474-4422(14)70095-X	http://dx.doi.org/10.1016/S1474-4422(14)70095-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK5RI	24837689				2022-12-18	WOS:000338483600003
J	[Anonymous]				[Anonymous]			Sex differences and stroke prevention	LANCET NEUROLOGY			English	Editorial Material																			0	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2014	13	4					339	339		10.1016/S1474-4422(14)70057-2	http://dx.doi.org/10.1016/S1474-4422(14)70057-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB6NN	24646867	Bronze			2022-12-18	WOS:000349743800001
J	Kochanek, PM; Bell, MJ				Kochanek, Patrick M.; Bell, Michael J.			Making an IMPACT in traumatic brain injury research	LANCET NEUROLOGY			English	Editorial Material							AMANTADINE; TRIAL		[Kochanek, Patrick M.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X				Bell MJ, 2013, PEDIATR CRIT CARE ME, V14, P811, DOI 10.1097/PCC.0b013e3182975e2f; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Maas AIR, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70234-5	11	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2013	12	12					1132	1133		10.1016/S1474-4422(13)70245-X	http://dx.doi.org/10.1016/S1474-4422(13)70245-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	265BG	24139679				2022-12-18	WOS:000327924100005
J	Andersen, PM				Andersen, Peter M.			ALS and FTD: two sides of the same coin?	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; REPEAT EXPANSION; CAG REPEAT; MOSAICISM; DISEASE; COHORT		Umea Univ, Dept Clin Neurosci, SE-90185 Umea, Sweden	Umea University	Andersen, PM (corresponding author), Umea Univ, Dept Clin Neurosci, SE-90185 Umea, Sweden.	peter.andersen@neuro.umu.se						Andersen PM, 2011, NAT REV NEUROL, V7, P603, DOI 10.1038/nrneurol.2011.150; Brettschneider J, 2012, ACTA NEUROPATHOL, V123, P825, DOI 10.1007/s00401-012-0970-z; Byrne S, 2012, LANCET NEUROL, V11, P232, DOI 10.1016/S1474-4422(12)70014-5; Cancel G, 1998, HUM MUTAT, V11, P23, DOI 10.1002/(SICI)1098-1004(1998)11:1<23::AID-HUMU4>3.0.CO;2-M; Charcot JM, 1881, LECT DIS NERVOUS S 2, V2; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Gijselinck I, 2012, LANCET NEUROL, V11, P54, DOI 10.1016/S1474-4422(11)70261-7; TELENIUS H, 1994, NAT GENET, V6, P409, DOI 10.1038/ng0494-409; van Blitterswijk M, 2013, LANCET NEUROL, DOI DOI 10.1016/51474-4422(13)70210-2	9	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2013	12	10					937	938		10.1016/S1474-4422(13)70218-7	http://dx.doi.org/10.1016/S1474-4422(13)70218-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	237XV	24011654				2022-12-18	WOS:000325905800005
J	Walker, FO				Walker, Francis O.			Huntington's disease: the road to progress	LANCET NEUROLOGY			English	Editorial Material							TRACK-HD		Wake Forest Med Sch, Dept Neurol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center	Walker, FO (corresponding author), Wake Forest Med Sch, Dept Neurol, Winston Salem, NC 27157 USA.	fwalker@wakehealth.edu		Walker, Francis/0000-0002-7817-9421				Biglan KM, 2010, MOVEMENT DISORD, V25, pS269; Kieburtz K, 2012, LANCET NEUROL, V11, P24, DOI 10.1016/S1474-4422(11)70285-X; Tabrizi SJ, 2012, LANCET NEUROL, V11, P42, DOI 10.1016/S1474-4422(11)70263-0; Tabrizi SJ, 2009, LANCET NEUROL, V8, P791, DOI 10.1016/S1474-4422(09)70170-X; Tabrizi SJ, 2013, LANCET NEUROL; Walker FO, 2007, LANCET, V369, P218, DOI 10.1016/S0140-6736(07)60111-1	6	6	7	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2013	12	7					624	625		10.1016/S1474-4422(13)70105-4	http://dx.doi.org/10.1016/S1474-4422(13)70105-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	172CH	23664845				2022-12-18	WOS:000320977100002
J	Rascol, O				Rascol, Olivier			Extended-release carbidopa-levodopa in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							THERAPY		Univ UPS Toulouse III, Dept Clin Pharmacol & Neurosci, CIC INSERM UMR825 9302, F-31062 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Rascol, O (corresponding author), Univ UPS Toulouse III, Dept Clin Pharmacol & Neurosci, CIC INSERM UMR825 9302, F-31062 Toulouse, France.	olivier.rascol@univ-tlse3.fr						Coelho M, 2012, NAT REV NEUROL, V8, P435, DOI 10.1038/nrneurol.2012.126; Hauser RA, 2013, LANCET NEUROL, V12, P346, DOI 10.1016/S1474-4422(13)70025-5; Hauser RA, 2011, MOVEMENT DISORD, V26, P2246, DOI 10.1002/mds.23861; Nutt JG, 2007, MOVEMENT DISORD, V22, P1, DOI 10.1002/mds.21060; Olanow CW, 2009, NEUROLOGY, V72, pS1, DOI 10.1212/WNL.0b013e3181a1d44c; Rascol O, 2005, LANCET, V365, P947, DOI 10.1016/S0140-6736(05)71083-7; Rascol O, 2000, NEW ENGL J MED, V342, P1484, DOI 10.1056/NEJM200005183422004; Rascol O, LANCET, V359, P1589; Seeberger LC, 2009, EXPERT REV NEUROTHER, V9, P929, DOI [10.1586/ern.09.64, 10.1586/ERN.09.64]; Stocchi F, 2010, ANN NEUROL, V68, P18, DOI 10.1002/ana.22060; Weintraub D, 2010, ARCH NEUROL-CHICAGO, V67, P589, DOI 10.1001/archneurol.2010.65	11	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2013	12	4					325	326		10.1016/S1474-4422(13)70039-5	http://dx.doi.org/10.1016/S1474-4422(13)70039-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138SZ	23485609				2022-12-18	WOS:000318531600003
J	Dirks, M; Dippel, DWJ				Dirks, Maaike; Dippel, Diederik W. J.			Implementation of thrombolysis for ischaemic stroke	LANCET NEUROLOGY			English	Editorial Material							IMPROVEMENT		[Dirks, Maaike; Dippel, Diederik W. J.] Erasmus MC, Univ Med Ctr, Dept Neurol, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Dirks, M (corresponding author), Erasmus MC, Univ Med Ctr, Dept Neurol, NL-3000 CA Rotterdam, Netherlands.	d.dippel@erasmusmc.nl	Dippel, Diederik/AAJ-2192-2020	Dippel, Diederik/0000-0002-9234-3515				Boode B, 2007, CEREBROVASC DIS, V23, P294, DOI 10.1159/000098330; Dirks M, 2012, NEUROLOGY, V79, P508, DOI 10.1212/WNL.0b013e31826356bf; Dirks M, 2011, STROKE, V42, P1325, DOI 10.1161/STROKEAHA.110.596940; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Moynihan B, 2010, J ROY SOC MED, V103, P363, DOI 10.1258/jrsm.2010.090434; Schouten LMT, 2008, BMJ-BRIT MED J, V336, P1491, DOI 10.1136/bmj.39570.749884.BE; Schwamm LH, 2009, CIRCULATION, V119, P107, DOI 10.1161/CIRCULATIONAHA.108.783688; Scott PA, 2012, LANCET NEUROL; Van Wijngaarden JDH, 2011, QJM-INT J MED, V104, P785, DOI 10.1093/qjmed/hcr075; van Wijngaarden JDH, 2009, STROKE, V40, P3390, DOI 10.1161/STROKEAHA.109.559492; Wardlaw JM, 2012, LANCET, V379, P2364, DOI 10.1016/S0140-6736(12)60738-7	11	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2013	12	2					120	121		10.1016/S1474-4422(12)70304-6	http://dx.doi.org/10.1016/S1474-4422(12)70304-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	081NZ	23260190				2022-12-18	WOS:000314330200002
J	Ferrari, MD				Ferrari, Michel D.			Headache: the changing migraine brain	LANCET NEUROLOGY			English	Editorial Material							GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; STROKE		Leiden Univ, Med Ctr, Dept Neurol, Chair Leiden Ctr Translat Neurosci, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Ferrari, MD (corresponding author), Leiden Univ, Med Ctr, Dept Neurol, Chair Leiden Ctr Translat Neurosci, NL-2300 RC Leiden, Netherlands.	m.d.ferrari@lumc.nl	Ferrari, Michel D./ABE-3758-2021	Ferrari, Michel D./0000-0001-9691-9449				Anttila V, 2010, NAT GENET, V42, P869, DOI 10.1038/ng.652; Borsook D, 2012, NEURON, V73, P219, DOI 10.1016/j.neuron.2012.01.001; Chasman DI, 2011, NAT GENET, V43, P695, DOI 10.1038/ng.856; Diener HC, 2012, NAT REV NEUROL, V8, P162, DOI 10.1038/nrneurol.2012.13; Eikermann-Haerter K, 2012, CIRCULATION, V125, P335, DOI 10.1161/CIRCULATIONAHA.111.045096; Freilinger T, 2012, NAT GENET, V44, P777, DOI 10.1038/ng.2307; Jackson JL, 2012, JAMA-J AM MED ASSOC, V307, P1736, DOI 10.1001/jama.2012.505; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Kurth T, 2012, LANCET NEUROL, V11, P92, DOI 10.1016/S1474-4422(11)70266-6; Maleki N, 2012, BRAIN, V135, P2546, DOI 10.1093/brain/aws175; Palm-Meinders IH, 2012, JAMA-J AM MED ASSOC, V308, P1889, DOI 10.1001/jama.2012.14276	11	6	8	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2013	12	1					6	8		10.1016/S1474-4422(12)70290-9	http://dx.doi.org/10.1016/S1474-4422(12)70290-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	055PR	23237889				2022-12-18	WOS:000312429400004
J	Okun, MS; Foote, KD				Okun, Michael S.; Foote, Kelly D.			Setting realistic expectations for DBS in dystonia	LANCET NEUROLOGY			English	Editorial Material							DEEP-BRAIN-STIMULATION; PRIMARY GENERALIZED DYSTONIA; DISEASE		[Okun, Michael S.] Univ Florida, Dept Neurol, Ctr Movement Disorders & Neurorestorat, Gainesville, FL 32607 USA; Univ Florida, Dept Neurosurg, Ctr Movement Disorders & Neurorestorat, Gainesville, FL 32607 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Okun, MS (corresponding author), Univ Florida, Dept Neurol, Ctr Movement Disorders & Neurorestorat, Gainesville, FL 32607 USA.	okun@neurology.ufl.edu		Foote, Kelly/0000-0002-2436-4138; Okun, Michael/0000-0002-6247-9358				BENABID AL, 1987, APPL NEUROPHYSIOL, V50, P344; Benabid AL., 2001, J NEUROL S3, V248, P37, DOI DOI 10.1007/PL00007825; Benabid AL, 2007, EXPERT REV MED DEVIC, V4, P895, DOI 10.1586/17434440.4.6.895; Berman BD, 2009, STEREOT FUNCT NEUROS, V87, P37, DOI 10.1159/000195718; Isaias IU, 2008, BRAIN, V131, P1895, DOI 10.1093/brain/awn120; Isaias IU, 2011, J NEUROL, V258, P1469, DOI 10.1007/s00415-011-5961-9; Isaias IU, 2009, ARCH NEUROL-CHICAGO, V66, P465, DOI 10.1001/archneurol.2009.20; Kupsch A, 2006, NEW ENGL J MED, V355, P1978, DOI 10.1056/NEJMoa063618; Susatia F, 2010, J NEUROL, V257, P44, DOI 10.1007/s00415-009-5261-9; Vidailhet M, 2005, NEW ENGL J MED, V352, P459, DOI 10.1056/NEJMoa042187; Volkmann J, 2002, MOVEMENT DISORD, V17, pS181, DOI 10.1002/mds.10162; Volkmann J, 2012, LANCET NEUROL	12	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2012	11	12					1014	1015		10.1016/S1474-4422(12)70263-6	http://dx.doi.org/10.1016/S1474-4422(12)70263-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044CX	23123072				2022-12-18	WOS:000311598100002
J	Jolobe, OMP				Jolobe, Oscar M. P.			Stroke and familial hemiplegic migraine	LANCET NEUROLOGY			English	Letter									John Rylands Univ Lib, Manchester Med Soc, Manchester M13 9PP, Lancs, England	University of Manchester	Jolobe, OMP (corresponding author), John Rylands Univ Lib, Manchester Med Soc, Manchester M13 9PP, Lancs, England.	oscarjolobe@yahoo.co.uk						Eikermann-Haerter K, 2012, CIRCULATION, V125, P335, DOI 10.1161/CIRCULATIONAHA.111.045096; Kurth T, 2012, LANCET NEUROL, V11, P92, DOI 10.1016/S1474-4422(11)70266-6	2	6	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2012	11	6					484	484		10.1016/S1474-4422(12)70123-0	http://dx.doi.org/10.1016/S1474-4422(12)70123-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	952JW	22608661	Bronze			2022-12-18	WOS:000304789800007
J	Rothwell, PM; Buchan, AM				Rothwell, Peter M.; Buchan, Alastair M.			Mobile acute stroke units: bringing the hospital to the patient	LANCET NEUROLOGY			English	Editorial Material									[Rothwell, Peter M.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England; [Buchan, Alastair M.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Rothwell, PM (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England.	peter.rothwell@clneuro.ox.ac.uk	Buchan, Alastair M/B-9095-2009; Rothwell, Peter/ABE-5913-2020	Buchan, Alastair M/0000-0002-2918-5200; Rothwell, Peter/0000-0001-9739-9211	Wellcome Trust [095626] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; Walter S, 2012, LANCET NEUROL, DOI [10.1016/S1474-4422(12)200524, DOI 10.1016/S1474-4422(12)700571]	2	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2012	11	5					382	383		10.1016/S1474-4422(12)70069-8	http://dx.doi.org/10.1016/S1474-4422(12)70069-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	930KM	22497930				2022-12-18	WOS:000303138300002
J	Kieburtz, K; Venuto, C				Kieburtz, Karl; Venuto, Charles			TRACK-HD: both promise and disappointment	LANCET NEUROLOGY			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; HUNTINGTON-DISEASE		[Kieburtz, Karl; Venuto, Charles] Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, Rochester, NY 14642 USA	University of Rochester	Kieburtz, K (corresponding author), Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, Rochester, NY 14642 USA.	karl.kieburtz@chet.rochester.edu						Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Dorsey ER, 2008, ARCH NEUROL-CHICAGO, V65, P1582, DOI 10.1001/archneur.65.12.1582; de Yebenes JG, 2011, LANCET NEUROL, V10, P1049, DOI 10.1016/S1474-4422(11)70233-2; Marshall FJ, 2006, NEUROLOGY, V66, P366, DOI 10.1212/01.wnl.0000198586.85250.13; Paulsen JS, 2008, J NEUROL NEUROSUR PS, V79, P874, DOI 10.1136/jnnp.2007.128728; Shoulson I, 2006, ARCH NEUROL-CHICAGO, V63, P991; Tabrizi SJ, 2012, LANCET NEUROL, V11, P42, DOI 10.1016/S1474-4422(11)70263-0; Tabrizi SJ, 2011, LANCET NEUROL, V10, P31, DOI 10.1016/S1474-4422(10)70276-3; Tilley BC, 2006, NEUROLOGY, V66, P628, DOI 10.1212/01.wnl.0000201251.33253.fb	9	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2012	11	1					24	25		10.1016/S1474-4422(11)70285-X	http://dx.doi.org/10.1016/S1474-4422(11)70285-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	868HG	22137355				2022-12-18	WOS:000298513700014
J	Gaillard, R; Mir, O				Gaillard, Raphael; Mir, Olivier			Fluoxetine and motor recovery after ischaemic stroke	LANCET NEUROLOGY			English	Letter							NEUROGENESIS; ANGIOGENESIS		[Gaillard, Raphael] Ctr Psychiat & Neurosci, Lab Physiopathol Malad Psychiat, INSERM U894, Paris, France; [Gaillard, Raphael] Univ Paris 05, Ctr Hosp St Anne, Paris, France; [Mir, Olivier] Univ Paris 05, Cochin Teaching Hosp, AP HP, Ctr Res Angiogenesis Inhibitors CERIA, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Gaillard, R (corresponding author), Ctr Psychiat & Neurosci, Lab Physiopathol Malad Psychiat, INSERM U894, Paris, France.	olivier.mir@cch.aphp.fr	Mir, Olivier/GNP-7828-2022; Gaillard, Raphael/J-6527-2015	Mir, Olivier/0000-0002-6761-4002; Gaillard, Raphael/0000-0002-1297-4369				Allaman I, 2011, PSYCHOPHARMACOLOGY, V216, P75, DOI 10.1007/s00213-011-2190-y; Boldrini M, 2009, NEUROPSYCHOPHARMACOL, V34, P2376, DOI 10.1038/npp.2009.75; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Greene J, 2009, NEUROPSYCHOPHARMACOL, V34, P2459, DOI 10.1038/npp.2009.68; Kubera M, 2009, PHARMACOL REP, V61, P1113, DOI 10.1016/S1734-1140(09)70174-4; Lee JS, 2009, J NEUROSCI, V29, P8493, DOI 10.1523/JNEUROSCI.1321-09.2009; Lee SC, 2010, EUR J NEUROL, V17, P45, DOI 10.1111/j.1468-1331.2009.02731.x; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Takebayashi M, 2010, J NEURAL TRANSM, V117, P1119, DOI 10.1007/s00702-010-0452-1; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	11	6	6	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2011	10	6					499	499		10.1016/S1474-4422(11)70111-9	http://dx.doi.org/10.1016/S1474-4422(11)70111-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774HK	21601157	Bronze			2022-12-18	WOS:000291376100006
J	Odili, AN; Richart, T; Staessen, JA				Odili, Augustine N.; Richart, Tom; Staessen, Jan A.			Methodological issues in the assessment of cognitive decline in ONTARGET and TRANSCEND	LANCET NEUROLOGY			English	Editorial Material							BLOOD-PRESSURE; SECONDARY PREVENTION; STROKE PREVENTION; DOUBLE-BLIND; DEMENTIA; TRIAL; HYPERTENSION; DISEASE		[Odili, Augustine N.; Richart, Tom; Staessen, Jan A.] Univ Leuven, Div Hypertens & Cardiovasc Rehabil, Dept Cardiovasc Dis, BE-3000 Louvain, Belgium; [Odili, Augustine N.] Univ Abuja, Dept Internal Med, Coll Hlth Sci, Abuja, Nigeria; [Richart, Tom; Staessen, Jan A.] Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands	KU Leuven; Maastricht University	Odili, AN (corresponding author), Univ Leuven, Div Hypertens & Cardiovasc Rehabil, Dept Cardiovasc Dis, Campus Sint Rafael, BE-3000 Louvain, Belgium.	jan.staessen@med.kuleuven.be	Staessen, Jan A/A-1065-2011; Odili, Augustine/O-2612-2019	Staessen, Jan A/0000-0002-3026-1637; Odili, Augustine/0000-0002-4564-1587				Anderson C, 2011, LANCET NEUROL, V10, P43, DOI 10.1016/S1474-4422(10)70250-7; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; FARMER ME, 1987, AM J EPIDEMIOL, V126, P1103, DOI 10.1093/oxfordjournals.aje.a114749; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Fournier A, 2002, STROKE, V33, P881; Hanon O, 2005, J NUTR HEALTH AGING, V9, P106; Liu LS, 2009, HYPERTENS RES, V32, P1032, DOI 10.1038/hr.2009.139; Messerli FH, 2003, ARCH INTERN MED, V163, P2557, DOI 10.1001/archinte.163.21.2557; Peters R, 2008, LANCET NEUROL, V7, P683, DOI 10.1016/S1474-4422(08)70143-1; Staessen JA, 2007, HYPERTENSION, V49, P389, DOI 10.1161/01.HYP.0000258151.00728.d8; Turnbull F, 2003, LANCET, V362, P1527; Verdecchia P, 2005, HYPERTENSION, V46, P386, DOI 10.1161/01.HYP.0000174591.42889.a2; Zhang HF, 2006, HYPERTENSION, V48, P187, DOI 10.1161/01.HYP.0000231939.40959.60	14	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2011	10	1					22	24		10.1016/S1474-4422(10)70272-6	http://dx.doi.org/10.1016/S1474-4422(10)70272-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	701HX	21067977	Green Accepted			2022-12-18	WOS:000285810100013
J	[Anonymous]				[Anonymous]			Biomarker promise for Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material																			0	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2010	9	12					1139	1139		10.1016/S1474-4422(10)70284-2	http://dx.doi.org/10.1016/S1474-4422(10)70284-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	691KG	21087732	Bronze			2022-12-18	WOS:000285078100001
J	Truelsen, T				Truelsen, Thomas			Stroke incidence studies in Africa	LANCET NEUROLOGY			English	Editorial Material							VERBAL AUTOPSY PROCEDURES; ADULT DEATHS; VALIDATION; TANZANIA		Univ Copenhagen Hosp, Dept Neurol, DK-2100 Copenhagen, Denmark	University of Copenhagen	Truelsen, T (corresponding author), Univ Copenhagen Hosp, Dept Neurol, DK-2100 Copenhagen, Denmark.	truelsen@heh.regionh.dk	Truelsen, Thomas/AAY-1549-2020					Addo J, 2007, HYPERTENSION, V50, P1012, DOI 10.1161/HYPERTENSIONAHA.107.093336; CHANDRAMOHAN D, 1994, INT J EPIDEMIOL, V23, P213, DOI 10.1093/ije/23.2.213; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Gajalakshmi V, 2006, INT J EPIDEMIOL, V35, P748, DOI 10.1093/ije/dyl112; Joshi R, 2009, B WORLD HEALTH ORGAN, V87, P678, DOI 10.2471/BLT.07.049288; Kahn K, 2000, TROP MED INT HEALTH, V5, P824, DOI 10.1046/j.1365-3156.2000.00638.x; Setel PW, 2006, TROP MED INT HEALTH, V11, P681, DOI 10.1111/j.1365-3156.2006.01603.x; Walker R, 2010, LANCET NEUROL, V9, P786, DOI 10.1016/S1474-4422(10)70144-7; Walker RW, 2000, J NEUROL NEUROSUR PS, V68, P744, DOI 10.1136/jnnp.68.6.744; Walker RW, 2000, LANCET, V355, P1684, DOI 10.1016/S0140-6736(00)02240-6; *WHO, DIS INJ REG EST 2004; Yang GH, 2006, INT J EPIDEMIOL, V35, P741, DOI 10.1093/ije/dyi181	12	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2010	9	8					755	757		10.1016/S1474-4422(10)70161-7	http://dx.doi.org/10.1016/S1474-4422(10)70161-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	635LS	20609628				2022-12-18	WOS:000280657800004
J	Salinas, AM				Morales Salinas, Alberto			Atenolol in uncomplicated hypertension: time for changes	LANCET NEUROLOGY			English	Letter									Cardioctr Ernesto Che Guevara, Santa Clara, Villa Clara, Cuba		Salinas, AM (corresponding author), Cardioctr Ernesto Che Guevara, Santa Clara, Villa Clara, Cuba.	cardioams@yahoo.es	Salinas, Alberto Morales/I-2778-2019	Salinas, Alberto Morales/0000-0003-4706-2041				Joshi R, 2008, J AM COLL CARDIOL, V52, P1817, DOI 10.1016/j.jacc.2008.08.049; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Mancia G, 2009, J HYPERTENS, V27, P2121, DOI 10.1097/HJH.0b013e328333146d; NEUTEL JM, 1990, AM HEART J, V120, P166, DOI 10.1016/0002-8703(90)90174-V; Rothwell PM, 2010, LANCET NEUROL, V9, P469, DOI 10.1016/S1474-4422(10)70066-1	5	6	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2010	9	7					652	652		10.1016/S1474-4422(10)70146-0	http://dx.doi.org/10.1016/S1474-4422(10)70146-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	617NF	20610338	Bronze			2022-12-18	WOS:000279286900006
J	Etienne, M; Powell, C; Faux, B				Etienne, Mill; Powell, Clydette; Faux, Brian			Disaster relief in Haiti: a perspective from the neurologists on the USNS COMFORT	LANCET NEUROLOGY			English	Editorial Material									[Etienne, Mill] Natl Naval Med Ctr, Dept Neurol, Bethesda, MD USA; [Powell, Clydette] US Agcy Int Dev, Bur Global Hlth, Washington, DC 20523 USA; [Faux, Brian] San Antonio Mil Med Complex, Dept Pediat, Div Child Neurol, Lackland AFB, TX USA	Walter Reed National Military Medical Center; United States Agency for International Development (USAID)	Etienne, M (corresponding author), Natl Naval Med Ctr, Dept Neurol, Bethesda, MD USA.	mill.etienne@med.navy.mil							0	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2010	9	5					461	463		10.1016/S1474-4422(10)70091-0	http://dx.doi.org/10.1016/S1474-4422(10)70091-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	592MY	20398854				2022-12-18	WOS:000277384600009
J	Gorelick, PB				Gorelick, Philip B.			Reducing blood pressure variability to prevent stroke?	LANCET NEUROLOGY			English	Editorial Material							ATENOLOL		Univ Illinois, Coll Med, Ctr Stroke Res, Dept Neurol & Rehabil, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gorelick, PB (corresponding author), Univ Illinois, Coll Med, Ctr Stroke Res, Dept Neurol & Rehabil, Chicago, IL 60612 USA.	pgorelic@uic.edu						Aiyagari V, 2009, STROKE, V40, P2251, DOI 10.1161/STROKEAHA.108.531574; Carlberg B, 2004, LANCET, V364, P1684, DOI 10.1016/S0140-6736(04)17355-8; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; Goldstein IB, 2005, NEUROLOGY, V64, P1846, DOI 10.1212/01.WNL.0000164712.24389.BB; Gorelick PB, 2002, LANCET NEUROL, V1, P149, DOI 10.1016/S1474-4422(02)00070-4; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MOSER M, 2004, CLIN MANAGEMENT HYPE; Poulter NR, 2005, LANCET, V366, P907, DOI 10.1016/S0140-6736(05)67186-3; Rothwell PM, 2010, LANCET, V375, P938, DOI 10.1016/S0140-6736(10)60309-1; Rothwell PM, 2010, LANCET NEUROL, V9, P469, DOI 10.1016/S1474-4422(10)70066-1; Williams B, 2006, LANCET, V368, P6, DOI 10.1016/S0140-6736(06)68943-5; Zuccala G, 2001, NEUROLOGY, V57, P1986, DOI 10.1212/WNL.57.11.1986	13	6	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2010	9	5					448	449		10.1016/S1474-4422(10)70067-3	http://dx.doi.org/10.1016/S1474-4422(10)70067-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	592MY	20227348				2022-12-18	WOS:000277384600002
J	Berweck, S				Berweck, Steffen			BP-DBS for dystonia-choreoathetosis cerebral palsy	LANCET NEUROLOGY			English	Editorial Material									Univ Munich, Dept Paediat Neurol, Dr von Hauners Childrens Hosp, Munich, Germany	University of Munich	Berweck, S (corresponding author), Univ Munich, Dept Paediat Neurol, Dr von Hauners Childrens Hosp, Munich, Germany.	steffen.berweck@med.uni-muenchen.de	Berweck, Steffen/N-1422-2013					Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; Rosenbaum P, 2007, DEV MED CHILD NEUROL, V49, P8, DOI 10.1111/j.1469-8749.2007.tb12610.x; Sanger TD, 2007, J CHILD NEUROL, V22, P530, DOI 10.1177/0883073807302601; Vidailhet M, 2009, LANCET NEUROL, V8, P709, DOI 10.1016/S1474-4422(09)70151-6	4	6	7	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2009	8	8					692	693		10.1016/S1474-4422(09)70172-3	http://dx.doi.org/10.1016/S1474-4422(09)70172-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	477YV	19576853				2022-12-18	WOS:000268555800002
J	Dodick, DW				Dodick, David W.			Tonabersat for migraine prevention: new life or last gasp?	LANCET NEUROLOGY			English	Editorial Material							CORTICAL SPREADING DEPRESSION; BRAIN; AURA; RISK		Mayo Clin Arizona, Dept Neurol, Phoenix, AZ 85054 USA	Mayo Clinic; Mayo Clinic Phoenix	Dodick, DW (corresponding author), Mayo Clin Arizona, Dept Neurol, Phoenix, AZ 85054 USA.	dodick.david@mayo.edu						Ayata C, 2006, ANN NEUROL, V59, P652, DOI 10.1002/ana.20778; Bolay H, 2002, NAT MED, V8, P136, DOI 10.1038/nm0202-136; Durham PL, 2008, HEADACHE, V48, pS5, DOI 10.1111/j.1526-4610.2008.01262.x; Goadsby PJ, 2009, CEPHALALGIA, V29, P7, DOI 10.1111/j.1468-2982.2008.01804.x; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; HAGUE AW, 2009, LANCET NEUROL, DOI DOI 10.1016/S1474-4422(09)70135-8; Kruit MC, 2004, JAMA-J AM MED ASSOC, V291, P427, DOI 10.1001/jama.291.4.427; Kurth T, 2009, NEUROLOGY, V73, P581, DOI 10.1212/WNL.0b013e3181ab2c20; MacClellan LR, 2007, STROKE, V38, P2438, DOI 10.1161/STROKEAHA.107.488395; Schmitz N, 2008, HEADACHE, V48, P1044, DOI 10.1111/j.1526-4610.2008.01133.x; Schwedt TJ, 2009, LANCET NEUROL, V8, P560, DOI 10.1016/S1474-4422(09)70107-3; Smith MI, 2000, CEPHALALGIA, V20, P546, DOI 10.1046/j.1468-2982.2000.00092.x	12	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2009	8	8					693	695		10.1016/S1474-4422(09)70174-7	http://dx.doi.org/10.1016/S1474-4422(09)70174-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	477YV	19570718				2022-12-18	WOS:000268555800003
J	Salman, RAS; Sudlow, CLM				Salman, Rustam Al-Shahi; Sudlow, Cathie L. M.			Case fatality after subarachnoid haemorrhage: declining, but why?	LANCET NEUROLOGY			English	Editorial Material							STROKE INCIDENCE; WORLDWIDE		[Salman, Rustam Al-Shahi; Sudlow, Cathie L. M.] Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Salman, RAS (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland.	rustam.al-shahi@ed.ac.uk	Sudlow, Cathie LM/F-3420-2010	Al-Shahi Salman, Rustam/0000-0002-2108-9222; Sudlow, Cathie/0000-0002-7725-7520				Al-Shahi R, 2006, BMJ-BRIT MED J, V333, P235, DOI 10.1136/bmj.333.7561.235; Anderson C, 2000, STROKE, V31, P1843; Feigin VL, 2009, LANCET NEUROL, V8, P355, DOI 10.1016/S1474-4422(09)70025-0; Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8; Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7; Sudlow CLM, 1996, STROKE, V27, P550, DOI 10.1161/01.STR.27.3.550; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Truelsen T, 1998, STROKE, V29, P2298, DOI 10.1161/01.STR.29.11.2298	8	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2009	8	7					598	599		10.1016/S1474-4422(09)70143-7	http://dx.doi.org/10.1016/S1474-4422(09)70143-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466EN	19501023				2022-12-18	WOS:000267643700005
J	Ballard, C; Aarsland, D				Ballard, Clive; Aarsland, Dag			Person-centred care and care mapping in dementia	LANCET NEUROLOGY			English	Editorial Material							TRIAL		[Ballard, Clive; Aarsland, Dag] Kings Coll London, Wolfson Ctr Age Related Dis, London WC2R 2LS, England	University of London; King's College London	Ballard, C (corresponding author), Kings Coll London, Wolfson Ctr Age Related Dis, London WC2R 2LS, England.	clive.ballard@kcl.ac.uk		Aarsland, Dag/0000-0001-6314-216X; Ballard, Clive/0000-0003-0022-5632				Brooker D, 1998, AGING MENT HEALTH, V2, P60, DOI 10.1080/13607869856957; CHENOWETH L, 2009, LANCET NEUROL; Fossey J, 2006, BMJ-BRIT MED J, V332, P756, DOI 10.1136/bmj.38782.575868.7C; Teri L, 2003, JAMA-J AM MED ASSOC, V290, P2015, DOI 10.1001/jama.290.15.2015; TERI L, 1997, J GERONTOL B-PSYCHOL, V52, P159, DOI DOI 10.1093/GER0NB/52B.4.P159	5	6	7	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2009	8	4					302	303		10.1016/S1474-4422(09)70046-8	http://dx.doi.org/10.1016/S1474-4422(09)70046-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	425CH	19282245				2022-12-18	WOS:000264614100002
J	Hill, MD				Hill, Michael D.			Desmoteplase and imaging science	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; PERFUSION-DIFFUSION MISMATCH; THROMBOLYSIS; ALTEPLASE; PENUMBRA; TRIAL; SIZE		Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary Stroke Program, Calgary, AB T2N 1N4, Canada	University of Calgary	Hill, MD (corresponding author), Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary Stroke Program, Calgary, AB T2N 1N4, Canada.	michael.Hill@albertahealthservices.ca	Hill, Michael D/C-9073-2012	Hill, Michael D/0000-0002-6269-1543				Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Butcher K, 2008, STROKE, V39, P75, DOI 10.1161/STROKEAHA.107.490524; Butcher KS, 2005, STROKE, V36, P1153, DOI 10.1161/01.STR.0000166181.86928.8b; Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Furlan AJ, 2006, STROKE, V37, P1227, DOI 10.1161/01.STR.0000217403.66996.6d; Guadagno JV, 2004, J CEREBR BLOOD F MET, V24, P1249, DOI 10.1097/01.WCB.0000141557.32867.6B; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; HACKE W, 2008, LANCET NEUROL, DOI DOI 10.1016/S1474-4422(08)70267-0; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Heiss WD, 2004, STROKE, V35, P2671, DOI 10.1161/01.STR.0000143329.81997.8a; Kane I, 2007, STROKE, V38, P3158, DOI 10.1161/STROKEAHA.107.483842; Puetz V, 2008, INT J STROKE, V3, P230, DOI 10.1111/j.1747-4949.2008.00221.x	12	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2009	8	2					126	128		10.1016/S1474-4422(08)70268-0	http://dx.doi.org/10.1016/S1474-4422(08)70268-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	398SO	19097941				2022-12-18	WOS:000262752000002
J	Naylor, AR				Naylor, A. Ross			Stenting versus endarterectomy : the debate continues	LANCET NEUROLOGY			English	Editorial Material							ANGIOPLASTY		Leicester Royal Infirm, Dept Vasc Surg, Leicester, Leics, England	University of Leicester	Naylor, AR (corresponding author), Leicester Royal Infirm, Dept Vasc Surg, Clin Sci Bldg, Leicester, Leics, England.	ross.naylor@uhl-tr.nhs.uk						Brown MM, 2001, LANCET, V357, P1729; Eckstein HH, 2008, LANCET NEUROL, V7, P893, DOI 10.1016/S1474-4422(08)70196-0; Ederle J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000515.pub3; Gray WA, 2007, CATHETER CARDIO INTE, V70, P1025, DOI 10.1002/ccd.21359; Hobson RW, 2004, J VASC SURG, V40, P1106, DOI 10.1016/j.jvs.2004.10.022; Mas JL, 2008, LANCET NEUROL, V7, P885, DOI 10.1016/S1474-4422(08)70195-9; Mas J, 2006, NEW ENGL J MED, V355, P1660, DOI 10.1056/NEJMoa061752; Ringleb PA, 2006, LANCET, V368, P1239, DOI 10.1016/S0140-6736(06)69122-8; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	10	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2008	7	10					862	864		10.1016/S1474-4422(08)70197-2	http://dx.doi.org/10.1016/S1474-4422(08)70197-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	355RJ	18774744				2022-12-18	WOS:000259725700003
J	Benamer, HTS				Benamer, Hani T. S.			The ancestry of LRRK2 Gly2019Ser parkinsonism	LANCET NEUROLOGY			English	Editorial Material							TUNISIAN BERBERS; ARAB		New Cross Hosp, Dept Neurol, Wolverhampton WV10 0QP, England	New Cross Hospital	Benamer, HTS (corresponding author), New Cross Hosp, Dept Neurol, Wolverhampton WV10 0QP, England.	benamer@doctors.org.uk	Benamer, Hani T/B-9780-2009	Benamer, Hani T/0000-0003-1369-8746				ABDENNAJI GB, 2006, INT J IMMUNOGENET, V33, P93; BENAMER HT, 2008, MOV DISORD; CHAABANI H, 1984, J IMMUNOGENET, V11, P107; CHAABANI H, 1988, HUM HERED, V38, P308, DOI 10.1159/000153804; Ennafaa H, 2006, ANN HUM BIOL, V33, P634, DOI 10.1080/03014460600931087; Hulihan MM, 2008, LANCET NEUROL, V7, P591, DOI 10.1016/S1474-4422(08)70116-9	6	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2008	7	9					769	770		10.1016/S1474-4422(08)70178-9	http://dx.doi.org/10.1016/S1474-4422(08)70178-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345HZ	18702998				2022-12-18	WOS:000258988400007
J	Sandercock, P; Wardlaw, J; Dennis, M; Lindley, R; Hankey, G; Matz, K; Peeters, A; Phillips, S; Gubitz, G; Prasad, K; Ricci, S; Celani, MG; Righetti, E; Cantisani, T; Arauz, A; Berge, E; Slot, KB; Kobayashi, A; Czlonkowska, A; Correia, M; Murray, V; Lyrer, P; Venables, G				Sandercock, Peter; Wardlaw, Joanna; Dennis, Martin; Lindley, Richard; Hankey, Graeme; Matz, Karl; Peeters, Andre; Phillips, Stephen; Gubitz, Gord; Prasad, Kameshwar; Ricci, Stefano; Celani, Maria Grazia; Righetti, Enrico; Cantisani, Theresa; Arauz, Antonio; Berge, Eivind; Slot, Karsten Bruins; Kobayashi, Adam; Czlonkowska, Anna; Correia, Manuel; Murray, Veronica; Lyrer, Philippe; Venables, Graham		IST-3 Collaborative Grp	EPITHET - where next?	LANCET NEUROLOGY			English	Editorial Material							STROKE; TRIAL		[Sandercock, Peter; Wardlaw, Joanna; Dennis, Martin] IST 3 Corrdinating Off, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland; [Lindley, Richard] Univ Sydney, Dept Geriatr Med, Sydney, NSW, Australia; [Matz, Karl] Landesklinikum Donauregion Tulln, Dept Neurol, Tulln, Austria; [Peeters, Andre] Univ Catholique Louvain, Dept Neurol, Louvain, Belgium; [Phillips, Stephen; Gubitz, Gord] QE II Hlth Sci, Dept Neurol, Halifax, NS, Canada; [Prasad, Kameshwar] All India Inst Med Sci, Delhi, India; [Ricci, Stefano; Celani, Maria Grazia; Righetti, Enrico; Cantisani, Theresa] USL2, Servizio Malattie Cerebrovascolari, Perugia, Italy; [Arauz, Antonio] Natl Inst Neurol & Neurosurg, Stroke Clin, Mexico City, DF, Mexico; [Berge, Eivind; Slot, Karsten Bruins] Ulleval Hosp, Dept Med, Oslo, Norway; [Kobayashi, Adam; Czlonkowska, Anna] Univ Warsaw, Dept Neurol, Warsaw, Poland; [Correia, Manuel] Hosp Geral De Santo Antonio, Dept Neurol, Oporto, Portugal; [Murray, Veronica] Karolinska Inst, Dept Med, Stockholm, Sweden; [Lyrer, Philippe] Univ Basel, Dept Neurol, Basel, Switzerland; [Venables, Graham] Univ Sheffield, Dept Neurol, Sheffield, S Yorkshire, England	University of Edinburgh; University of Sydney; Universite Catholique Louvain; All India Institute of Medical Sciences (AIIMS) New Delhi; University of Oslo; University of Warsaw; Karolinska Institutet; University of Basel; University of Sheffield	Sandercock, P (corresponding author), IST 3 Corrdinating Off, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland.	peter.sandercock@ed.ac.uk	Hankey, Graeme J/H-4968-2014; Hernandez, María/GYU-3543-2022; Lindley, Richard/B-8148-2013; Wardlaw, Joanna M/Y-3456-2019; Lueck, Christian Joseph/O-4031-2016; Zini, Andrea/K-1136-2014; celani, maria grazia/AAF-4143-2020	Hankey, Graeme J/0000-0002-6044-7328; Lindley, Richard/0000-0002-0104-5679; Wardlaw, Joanna M/0000-0002-9812-6642; Lueck, Christian Joseph/0000-0003-1537-7612; Zini, Andrea/0000-0003-1486-4507; Czlonkowska, Anna/0000-0002-1956-1866; Sandercock, Peter/0000-0001-8484-0135; , M. Grazia/0000-0003-1480-263X; celani, maria grazia/0000-0002-0739-4140; dennis, martin/0000-0003-1148-8972; Matz, Karl/0000-0002-2851-9897	MRC [G0400069] Funding Source: UKRI; Medical Research Council [G0400069] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Davis SM, 2008, LANCET NEUROL, V7, P299, DOI 10.1016/S1474-4422(08)70044-9; Schellinger PD, 2008, LANCET NEUROL, V7, P286, DOI 10.1016/S1474-4422(08)70045-0; Warach S, 2006, CEREBROVASC DIS, V21, P106, DOI 10.1159/000090208; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213	4	6	6	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2008	7	7					570	571		10.1016/S1474-4422(08)70123-6	http://dx.doi.org/10.1016/S1474-4422(08)70123-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	320DJ	18565447				2022-12-18	WOS:000257213600006
J	Sethi, KD				Sethi, Kapil D.			Restless legs syndrome sees the light of day	LANCET NEUROLOGY			English	Editorial Material							EPIDEMIOLOGY; ASSOCIATION; DISEASE; SLEEP; AUGMENTATION; HEALTH		Med Coll Georgia, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Sethi, KD (corresponding author), Med Coll Georgia, 1429 Harper St,Room 1121HB, Augusta, GA 30912 USA.	ksethi@mcg.edu						AKPINAR S, 1987, CLIN NEUROPHARMACOL, V10, P69; Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Allen RP, 1996, SLEEP, V19, P205, DOI 10.1093/sleep/19.3.205; Garcia LA, 2006, J ENDOVASC THER, V13, P3, DOI 10.1583/05-1751.1; Garcia-Borreguero D, 2007, SLEEP MED, V8, P520, DOI 10.1016/j.sleep.2007.03.022; Olanow CW, 2006, LANCET NEUROL, V5, P677, DOI 10.1016/S1474-4422(06)70521-X; Stefansson H, 2007, NEW ENGL J MED, V357, P639, DOI 10.1056/NEJMoa072743; Tison F, 2005, NEUROLOGY, V65, P239, DOI 10.1212/01.wnl.0000168910.48309.4a; Trenkwalder C, 2005, LANCET NEUROL, V4, P465, DOI 10.1016/S1474-4422(05)70139-3; TRENKWALDER C, 2008, LANCET NEUROL; Walters AS, 2004, MOVEMENT DISORD, V19, P1414, DOI 10.1002/mds.20257; Winkelman JW, 2006, NEUROLOGY, V67, P1034, DOI 10.1212/01.wnl.0000231513.23919.a1; Winkelman JW, 2008, NEUROLOGY, V70, P35, DOI 10.1212/01.wnl.0000287072.93277.c9; Winkelmann J, 2007, NAT GENET, V39, P1000, DOI 10.1038/ng2099	14	6	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2008	7	7					564	565		10.1016/S1474-4422(08)70113-3	http://dx.doi.org/10.1016/S1474-4422(08)70113-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	320DJ	18515184				2022-12-18	WOS:000257213600003
J	Troster, AI				Troster, Alexander I.			Short-term cognitive and affective outcomes after subthalamic deep brain stimulation for Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							QUALITY-OF-LIFE; NUCLEUS		Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Troster, AI (corresponding author), Univ N Carolina, Dept Neurol, CB 7025, Chapel Hill, NC 27599 USA.	trostera@neurology.unc.edu						Derost PP, 2007, NEUROLOGY, V68, P1345, DOI 10.1212/01.wnl.0000260059.77107.c2; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Houeto JL, 2006, ARCH NEUROL-CHICAGO, V63, P1090, DOI 10.1001/archneur.63.8.1090; Lezcano E, 2004, EUR J NEUROL, V11, P451, DOI 10.1111/j.1468-1331.2004.00804.x; Parsons TD, 2006, LANCET NEUROL, V5, P578, DOI 10.1016/S1474-4422(06)70475-6; Schupbach M, 2006, NEUROLOGY, V66, P1811, DOI 10.1212/01.wnl.0000234880.51322.16; Siderowf A, 2006, MOVEMENT DISORD, V21, P746, DOI 10.1002/mds.20786; Smeding HMM, 2006, NEUROLOGY, V66, P1830, DOI 10.1212/01.wnl.0000234881.77830.66; Voon V, 2006, MOVEMENT DISORD, V21, pS305, DOI 10.1002/mds.20963; Witt K, 2008, LANCET NEUROL, V7, P605, DOI 10.1016/S1474-4422(08)70114-5	10	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2008	7	7					565	567		10.1016/S1474-4422(08)70115-7	http://dx.doi.org/10.1016/S1474-4422(08)70115-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	320DJ	18538635				2022-12-18	WOS:000257213600004
J	Goodman, BP; Driver-Dunckley, ED; Leslie, KO; Patel, AC; Wesselius, L				Goodman, Brent P.; Driver-Dunckley, Erika D.; Leslie, Kevin O.; Patel, Ameet C.; Wesselius, Lewisj			A case of gait unsteadiness - an atypical manifestation of an unusual disease	LANCET NEUROLOGY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; CAUDA-EQUINA; NEUROLOGIC MANIFESTATIONS; CEREBROSPINAL-FLUID; CONUS MEDULLARIS; SARCOIDOSIS; POLYRADICULOPATHY; DIAGNOSIS; MR		Mayo Clin, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix	Goodman, BP (corresponding author), Mayo Clin, 13600 E Shea Blvd, Scottsdale, AZ 85259 USA.	goodman.brent@mayo.edu						Abrey LE, 1998, J NEURO-ONCOL, V39, P261, DOI 10.1023/A:1005958205591; BARON B, 1989, J COMPUT ASSIST TOMO, V13, P364, DOI 10.1097/00004728-198903000-00041; Bassam BA, 1998, SOUTHERN MED J, V91, P870, DOI 10.1097/00007611-199809000-00015; CAMPBELL JN, 1977, J NEUROSURG, V47, P109, DOI 10.3171/jns.1977.47.1.0109; Crystal RG, 2005, HARRISONS PRINCIPLES, P2022; Dale JC, 1999, MAYO CLIN PROC, V74, P535; DELANEY P, 1977, ANN INTERN MED, V87, P336, DOI 10.7326/0003-4819-87-3-336; Frey I, 1998, EUR RADIOL, V8, P1187, DOI 10.1007/s003300050532; JAMES DG, 1967, P ROY SOC MED, V60, P1169, DOI 10.1177/003591576706011P145; Kaiboriboon K, 2005, NEUROLOGIST, V11, P179, DOI 10.1097/01.nrl.0000159983.19068.21; Koffman B, 1999, MUSCLE NERVE, V22, P608, DOI 10.1002/(SICI)1097-4598(199905)22:5<608::AID-MUS9>3.3.CO;2-C; Ku A, 1996, PARAPLEGIA, V34, P116, DOI 10.1038/sc.1996.21; LEXA FJ, 1994, AM J NEURORADIOL, V15, P973; Martin AJ, 2001, ACTA NEUROCHIR, V143, P739, DOI 10.1007/s007010170056; Moghtaderi A, 2003, INT J TUBERC LUNG D, V7, P1186; OKSANEN V, 1985, NEUROLOGY, V35, P1220, DOI 10.1212/WNL.35.8.1220; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; Sinnreich M, 2004, NEUROLOGY, V63, P1662, DOI 10.1212/01.WNL.0000142507.12763.58; STERN BJ, 1985, ARCH NEUROL-CHICAGO, V42, P909, DOI 10.1001/archneur.1985.04060080095022; VANDELLEN JR, 1980, S AFR MED J, V58, P137; Verma KK, 2000, J NEUROL, V247, P573, DOI 10.1007/s004150070163; Weissman NM, 1996, NEUROSURGERY, V39, P179, DOI 10.1097/00006123-199607000-00041; WIEDERHOLT WC, 1965, NEUROLOGY, V15, P1147, DOI 10.1212/WNL.15.12.1147; WOOD EH, 1959, RADIOLOGY, V73, P226, DOI 10.1148/73.2.226; ZAJICEK J, 1990, J NEUROL, V237, P424, DOI 10.1007/BF00314734; Zajicek JP, 1999, QJM-INT J MED, V92, P103, DOI 10.1093/qjmed/92.2.103	26	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2007	6	11					1029	1032		10.1016/S1474-4422(07)70268-5	http://dx.doi.org/10.1016/S1474-4422(07)70268-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	226VX	17945156				2022-12-18	WOS:000250617700017
J	Feldman, HH; Ferris, S; Winblad, B				Feldman, H. H.; Ferris, S.; Winblad, B.			Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment. the InDDEx study (vol 6, pg 501, 2007)	LANCET NEUROLOGY			English	Correction																		Feldman HH, 2007, LANCET NEUROL, V6, P501, DOI 10.1016/S1474-4422(07)70109-6	1	6	6	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2007	6	10					849	849		10.1016/S1474-4422(07)70233-8	http://dx.doi.org/10.1016/S1474-4422(07)70233-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218SQ					2022-12-18	WOS:000250035600011
J	Korczyn, AD				Korczyn, Amos D.			Drugs for vascular dementia	LANCET NEUROLOGY			English	Editorial Material							RIVASTIGMINE		Tel Aviv Univ, Sch Med, Sieratzki Chair Neurol, IL-69978 Ramat Aviv, Israel	Tel Aviv University	Korczyn, AD (corresponding author), Tel Aviv Univ, Sch Med, Sieratzki Chair Neurol, IL-69978 Ramat Aviv, Israel.	neurol3@post.tau.ac.il	Korczyn, Amos D/C-3461-2017	Korczyn, Amos D/0000-0003-0125-2579				Auchus AP, 2007, NEUROLOGY, V69, P448, DOI 10.1212/01.wnl.0000266625.31615.f6; Bentham P, 2004, LANCET, V363, P2105; Emre M, 2004, NEW ENGL J MED, V351, P2509, DOI 10.1056/NEJMoa041470; Giladi N, 2003, ACTA NEUROL SCAND, V108, P368, DOI 10.1034/j.1600-0404.2003.00211.x; Kavirajan H, 2007, LANCET NEUROL, V6, P782, DOI 10.1016/S1474-4422(07)70195-3; KORCZYN AD, 2002, ANN NY ACAD SCI, V977, P127; Mendez MF, 2007, AM J GERIAT PSYCHIAT, V15, P84, DOI 10.1097/01.JGP.0000231744.69631.33; Mesulam M, 2003, NEUROLOGY, V60, P1183, DOI 10.1212/01.WNL.0000055927.22611.EB	8	6	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2007	6	9					749	751		10.1016/S1474-4422(07)70199-0	http://dx.doi.org/10.1016/S1474-4422(07)70199-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	204SV	17706553				2022-12-18	WOS:000249065200003
J	Svendsen, C				Svendsen, Clive			The first steps towards gene therapy for Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material									Univ Wisconsin, Waisman Ctr, Dept Anat, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Dept Neurol, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Svendsen, C (corresponding author), Univ Wisconsin, Waisman Ctr, Dept Anat, 1500 Highland Ave, Madison, WI 53705 USA.	svendsen@waisman.wisc.edu						Bankiewicz KS, 2006, MOL THER, V14, P564, DOI 10.1016/j.ymthe.2006.05.005; Emborg ME, 2007, J CEREBR BLOOD F MET, V27, P501, DOI 10.1038/sj.jcbfm.9600364; Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140-6736(07)60982-9; Kordower JH, 2006, ANN NEUROL, V60, P706, DOI 10.1002/ana.21032; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846	5	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2007	6	9					754	756		10.1016/S1474-4422(07)70202-8	http://dx.doi.org/10.1016/S1474-4422(07)70202-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	204SV	17706556				2022-12-18	WOS:000249065200006
J	Bell, GS; Sander, JW				Bell, Gail S.; Sander, Josemir W.			Suicide risk in epilepsy: where do we stand?	LANCET NEUROLOGY			English	Editorial Material							MORTALITY; COHORT		UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London W1N 3BG, England; Epiliepsy Inst Netherlands Fdn, SEIN, NL-2103 SW Heemstede, Netherlands	University of London; University College London	Sander, JW (corresponding author), UCL, Inst Neurol, Dept Clin & Expt Epilepsy, Queen Square, London W1N 3BG, England.	lsander@ion.ucl.ac.uk	Sander, Josemir/C-1576-2008	Sander, Josemir/0000-0001-6041-9661				Blumer D, 2002, EPILEPSY BEHAV, V3, P232, DOI 10.1016/S1525-5050(02)00006-9; Christensen J, 2007, LANCET NEUROL, V6, P693, DOI 10.1016/S1474-4422(07)70175-8; Day SM, 2005, NEUROLOGY, V65, P216, DOI 10.1212/01.wnl.0000169018.44950.68; Jones JE, 2003, EPILEPSY BEHAV, V4, pS31, DOI 10.1016/j.yebeh.2003.08.019; MAZZA M, 2007, J NEUROL SCI, DOI DOI 10.1016/J.JNS.2007.04.007; Mohanraj R, 2006, LANCET NEUROL, V5, P481, DOI 10.1016/S1474-4422(06)70448-3; Murray C.J., 2000, GLOBAL BURDEN DIS; Nilsson L, 1997, EPILEPSIA, V38, P1062, DOI 10.1111/j.1528-1157.1997.tb01194.x; Nilsson L, 2002, EPILEPSIA, V43, P644, DOI 10.1046/j.1528-1157.2002.40001.x; Shackleton DP, 1999, J NEUROL NEUROSUR PS, V66, P636, DOI 10.1136/jnnp.66.5.636	10	6	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2007	6	8					666	667		10.1016/S1474-4422(07)70182-5	http://dx.doi.org/10.1016/S1474-4422(07)70182-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	193HJ	17638606				2022-12-18	WOS:000248264800003
J	Dickerson, BC				Dickerson, Bradford C.			The entorhinal cortex: an anatomical mediator of genetic vulnerability to Alzheimer's disease?	LANCET NEUROLOGY			English	Editorial Material							MEMORY PERFORMANCE		Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University	Dickerson, BC (corresponding author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.	bradd@nmr.mgh.harvard.edu						Bathum L, 2006, J AM GERIATR SOC, V54, P654, DOI 10.1111/j.1532-5415.2005.53554.x; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Dickerson Bradford C, 2005, NeuroRx, V2, P348, DOI 10.1007/BF03206676; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Jorm AF, 2007, NEUROPSYCHOLOGY, V21, P1, DOI 10.1037/0894-4105.21.1.1; Lee JH, 2004, NEUROLOGY, V62, P414, DOI 10.1212/01.WNL.0000106461.96637.AC; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Papassotiropoulos A, 2006, SCIENCE, V314, P475, DOI 10.1126/science.1129837; Reiman EM, 2007, ANN NY ACAD SCI, V1097, P94, DOI 10.1196/annals.1379.011; Scarmeas Nikolaos, 2006, Curr Psychiatry Rep, V8, P11, DOI 10.1007/s11920-006-0076-1; Shaw P, 2007, LANCET NEUROL, V6, P494, DOI 10.1016/S1474-4422(07)70106-0; Van Hoesen GW, 2000, ANN NY ACAD SCI, V911, P254	12	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2007	6	6					471	473		10.1016/S1474-4422(07)70112-6	http://dx.doi.org/10.1016/S1474-4422(07)70112-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	175WO	17509474				2022-12-18	WOS:000247044900003
J	Berge, E				Berge, Eivind			Decompressive surgery for cerebral oedema after stroke: evidence at last	LANCET NEUROLOGY			English	Editorial Material							INFARCTION; CRANIECTOMY		Ullevaal Univ Hosp, Oslo, Norway	University of Oslo	Berge, E (corresponding author), Ullevaal Univ Hosp, Oslo, Norway.	eivind.berge@medisin.uio.no						Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Hacke W., 2002, PRACTICAL NEUROL, V2, P144; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; MORLEY NC, 2002, COCHRANE DB SYST REV, V3; Post PN, 2001, STROKE, V32, P1425, DOI 10.1161/01.STR.32.6.1425; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4	8	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2007	6	3					200	201		10.1016/S1474-4422(07)70039-X	http://dx.doi.org/10.1016/S1474-4422(07)70039-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138BU	17303520				2022-12-18	WOS:000244338400002
J	Miller, D				Miller, David			Multiple sclerosis: new insights and therapeutic progress	LANCET NEUROLOGY			English	News Item									UCL, Inst Neurol, London, England	University of London; University College London	Miller, D (corresponding author), UCL, Inst Neurol, London, England.	d.miller@ion.ucl.ac.uk						Gutcher I, 2006, NAT IMMUNOL, V7, P946, DOI 10.1038/ni1377; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; PATRIKIOS P, 2006, BRAIN           0818, DOI DOI 10.1093/BRAIN/AWL217; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397	5	6	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					5	6		10.1016/S1474-4422(06)70660-3	http://dx.doi.org/10.1016/S1474-4422(06)70660-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119UI	17166789				2022-12-18	WOS:000243039000004
J	Stupp, R; Hegi, ME				Stupp, Roger; Hegi, Monika E.			Neuro-oncology: oligodendroglioma and molecular markers	LANCET NEUROLOGY			English	News Item							PHASE-III TRIAL; INHIBITORS; 19Q; 1P		Univ Lausanne Hosp, Dept Neurosurg, Multidisciplinary Oncol Ctr, CH-1011 Lausanne, Switzerland; Univ Lausanne Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Stupp, R (corresponding author), Univ Lausanne Hosp, Dept Neurosurg, Multidisciplinary Oncol Ctr, CH-1011 Lausanne, Switzerland.	roger.stupp@chuv.ch	Stupp, Roger/L-3303-2019; Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495				BAO S, 2006, NATURE          1018, DOI DOI 10.1038/NATURE05236; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Lassman AB, 2005, CLIN CANCER RES, V11, P7841, DOI 10.1158/1078-0432.CCR-05-0421; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; van den Bent MJ, 2006, J CLIN ONCOL, V24, P2715, DOI 10.1200/JCO.2005.04.6078	7	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					10	12		10.1016/S1474-4422(06)70663-9	http://dx.doi.org/10.1016/S1474-4422(06)70663-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	119UI	17166792				2022-12-18	WOS:000243039000007
J	Oprisiu, R; Serot, JM; Godefroy, O; Black, SE; Fournier, A				Oprisiu, Roxana; Serot, Jean-Marie; Godefroy, Olivier; Black, Sandra E.; Fournier, Albert			Plasma amyloid-beta concentrations in Alzheimer's disease: an alternative hypothesis	LANCET NEUROLOGY			English	Editorial Material							ANGIOTENSIN-CONVERTING ENZYME; DEMENTIA		Amiens Univ Hosp, Dept Geriatr, Amiens, France; Amiens Univ Hosp, Dept Neurol, Amiens, France; Amiens Univ Hosp, Nephrol Internal Med Dept, Amiens, France; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Oprisiu, R (corresponding author), Amiens Univ Hosp, Dept Geriatr, Amiens, France.	fournier.albert@chu-amiens.fr		Godefroy, Olivier/0000-0001-6789-6620; Black, Sandra/0000-0001-7093-8289				Eckman EA, 2006, J BIOL CHEM, V281, P30471, DOI 10.1074/jbc.M605827200; Hemming ML, 2005, J BIOL CHEM, V280, P37644, DOI 10.1074/jbc.M508460200; Khachaturian AS, 2006, ARCH NEUROL-CHICAGO, V63, P686, DOI 10.1001/archneur.63.5.noc60013; Tzourio C, 2003, ARCH INTERN MED, V163, P1069; van Oijen M, 2006, LANCET NEUROL, V5, P655, DOI 10.1016/S1474-4422(06)70501-4	5	6	6	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	DEC	2006	5	12					1001	1002		10.1016/S1474-4422(06)70612-3	http://dx.doi.org/10.1016/S1474-4422(06)70612-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	108VA	17110279				2022-12-18	WOS:000242266100010
J	Tomson, T				Tomson, Torbjorn			Excess mortality in epilepsy in developing countries	LANCET NEUROLOGY			English	Editorial Material							ILAE/IBE/WHO; CHINA		Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Tomson, T (corresponding author), Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden.	torbjorn.tomson@karolinska.se						Ding D, 2006, LANCET NEUROL, V5, P823, DOI 10.1016/S1474-4422(06)70528-2; Dua T, 2006, EPILEPSIA, V47, P1225, DOI 10.1111/j.1528-1167.2006.00595.x; Forsgren L, 2005, EPILEPSIA, V46, P18, DOI 10.1111/j.1528-1167.2005.00403.x; Hauser WA, 2005, EPILEPSIA, V46, P62, DOI 10.1111/j.1528-1167.2005.00412.x; Logroscino G, 2005, EPILEPSIA, V46, P3, DOI 10.1111/j.1528-1167.2005.00399.x; Scott RA, 2001, B WORLD HEALTH ORGAN, V79, P344; Wang WZ, 2006, LANCET NEUROL, V5, P46, DOI 10.1016/S1474-4422(05)70254-4; Wang WZ, 2003, NEUROLOGY, V60, P1544, DOI 10.1212/01.WNL.0000059867.35547.DE; WHO, 2000, GLOB CAMP EP OUT SHA	9	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2006	5	10					804	805		10.1016/S1474-4422(06)70555-5	http://dx.doi.org/10.1016/S1474-4422(06)70555-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	087YD	16987722				2022-12-18	WOS:000240777800002
J	Squire, LR; Bayley, PJ				Squire, LR; Bayley, PJ			The neuroanatomy of very remote memory	LANCET NEUROLOGY			English	Editorial Material							AMNESIA		Univ Calif San Diego, San Diego, CA 92103 USA	University of California System; University of California San Diego	Squire, LR (corresponding author), Univ Calif San Diego, San Diego, CA 92103 USA.	lsquire@ucsd.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH024600] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH024600-32, R01 MH024600] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bayley PJ, 2005, NEURON, V46, P799, DOI 10.1016/j.neuron.2005.04.034; Bayley PJ, 2003, NEURON, V38, P135, DOI 10.1016/S0896-6273(03)00156-9; Bayley PJ, 2005, NATURE, V436, P550, DOI 10.1038/nature03857; Cipolotti L, 2005, LANCET NEUROL, V4, P792, DOI 10.1016/S1474-4422(05)70232-5; Cipolotti L, 2001, NEUROPSYCHOLOGIA, V39, P151, DOI 10.1016/S0028-3932(00)00103-2; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Thomas L, 2005, LANCET NEUROL, V4, P460, DOI 10.1016/S1474-4422(05)70132-0; WARRINGTON EK, 1992, NEUROPSYCHOLOGIA, V30, P437, DOI 10.1016/0028-3932(92)90091-Y	8	6	8	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2006	5	2					112	113		10.1016/S1474-4422(06)70335-0	http://dx.doi.org/10.1016/S1474-4422(06)70335-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	006RO	16426987	Green Accepted			2022-12-18	WOS:000234914800008
J	Chatterjee, P				Chatterjee, P			Japanese encephalitis outbreak in India	LANCET NEUROLOGY			English	News Item																			0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2005	4	11					700	700		10.1016/S1474-4422(05)70211-8	http://dx.doi.org/10.1016/S1474-4422(05)70211-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980GK	16265791				2022-12-18	WOS:000233002400009
J	Petrovitch, H; White, L				Petrovitch, H; White, L			Exercise and cognitive function	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMERS-DISEASE; PHYSICAL-ACTIVITY; RISK-FACTORS; DEMENTIA; ASSOCIATION; OCCUPATION; EDUCATION; FITNESS; MIDLIFE		Honolulu Asia Aging Study, Pacific Hlth Res Inst, Honolulu, HI USA; Kuakini Med Ctr, Honolulu, HI USA	Pacific Health Research & Education Institute	Petrovitch, H (corresponding author), Honolulu Asia Aging Study, Pacific Hlth Res Inst, Honolulu, HI USA.	Hpetrovitch@phrihawaii.org						Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; Andel R, 2005, J GERONTOL B-PSYCHOL, V60, pP251, DOI 10.1093/geronb/60.5.P251; BONAIUTO S, 1995, NEUROEPIDEMIOLOGY, V14, P101, DOI 10.1159/000109785; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Hatta A, 2005, JPN J PHYSIOL, V55, P29, DOI 10.2170/jjphysiol.R2068; Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019; Landi F, 2004, ARCH GERONTOL GERIAT, P235; Mancuso M, 2003, EXP NEUROL, V182, P421, DOI 10.1016/S0014-4886(03)00092-X; McCurry SM, 2005, J AM GERIATR SOC, V53, P793, DOI 10.1111/j.1532-5415.2005.53252.x; Podewils LJ, 2005, AM J EPIDEMIOL, V161, P639, DOI 10.1093/aje/kwi092; Qiu CX, 2003, AM J IND MED, V43, P204, DOI 10.1002/ajim.10159; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; Scarmeas N, 2003, ARCH NEUROL-CHICAGO, V60, P359, DOI 10.1001/archneur.60.3.359; Van de Winckel A, 2004, CLIN REHABIL, V18, P253, DOI 10.1191/0269215504cr750oa; Yamada M, 2003, J AM GERIATR SOC, V51, P410, DOI 10.1046/j.1532-5415.2003.51117.x	16	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2005	4	11					690	691		10.1016/S1474-4422(05)70203-9	http://dx.doi.org/10.1016/S1474-4422(05)70203-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	980GK	16239172				2022-12-18	WOS:000233002400002
J	Love, R				Love, R			Two hit hypothesis for temporal lobe epilepsy	LANCET NEUROLOGY			English	News Item																			0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2005	4	8					458	458		10.1016/S1474-4422(05)70128-9	http://dx.doi.org/10.1016/S1474-4422(05)70128-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	951EX	16086491				2022-12-18	WOS:000230913000005
J	Bradbury, J				Bradbury, J			Canine epilepsy gene mutation identified	LANCET NEUROLOGY			English	News Item																			0	6	6	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2005	4	3					143	143		10.1016/S1474-4422(05)01004-5	http://dx.doi.org/10.1016/S1474-4422(05)01004-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	901QT	15744941				2022-12-18	WOS:000227297700009
J	Fine, PEM				Fine, PEM			Poliomyelitis: very small risks and very large risks	LANCET NEUROLOGY			English	Letter									London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Fine, PEM (corresponding author), London Sch Hyg & Trop Med, London WC1, England.	Paul.Fine@lshtm.ac.uk						Alexander LN, 2004, JAMA-J AM MED ASSOC, V292, P1696, DOI 10.1001/jama.292.14.1696; Dowdle WR, 2004, B WORLD HEALTH ORGAN, V82, P59; Kew OM, 2004, B WORLD HEALTH ORGAN, V82, P16; *WHO, 2003, GLOB POL ER IN STRAT; *WHO POL UN, 2004, 1 MILL VACC 80 MILL	5	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2004	3	12					703	703		10.1016/S1474-4422(04)00928-7	http://dx.doi.org/10.1016/S1474-4422(04)00928-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	873MD	15556798				2022-12-18	WOS:000225283500012
J	Wildasin, K				Wildasin, K			Role of reticulon proteins in Alzheimer's disease	LANCET NEUROLOGY			English	News Item																			0	6	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2004	3	10					576	576		10.1016/S1474-4422(04)00874-9	http://dx.doi.org/10.1016/S1474-4422(04)00874-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	857SC	15461990				2022-12-18	WOS:000224137600007
J	Butcher, J				Butcher, J			Mutations in ROBO3 cause HGPPS	LANCET NEUROLOGY			English	News Item														Butcher, James/0000-0001-8546-6093					0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					328	328		10.1016/S1474-4422(04)00786-0	http://dx.doi.org/10.1016/S1474-4422(04)00786-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15176408				2022-12-18	WOS:000221663000009
J	Hayward, P				Hayward, P			Viral proteins cause cell death in HIV-associated dementia	LANCET NEUROLOGY			English	News Item																			0	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2004	3	6					325	325		10.1016/S1474-4422(04)00780-X	http://dx.doi.org/10.1016/S1474-4422(04)00780-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	824CZ	15176402				2022-12-18	WOS:000221663000003
J	McCrone, J				McCrone, J			Freud's neurology	LANCET NEUROLOGY			English	Editorial Material																			0	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2004	3	5					320	320		10.1016/S1474-4422(04)00747-1	http://dx.doi.org/10.1016/S1474-4422(04)00747-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	817EL	15099547				2022-12-18	WOS:000221160700026
J	Burton, A				Burton, A			NSAIDS and Alzheimer's disease: it's only Rock and Rho	LANCET NEUROLOGY			English	News Item																			0	6	6	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2004	3	1					6	6		10.1016/S1474-4422(03)00637-9	http://dx.doi.org/10.1016/S1474-4422(03)00637-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756BZ	14700055				2022-12-18	WOS:000187447100007
J	Grosse, P; Schulz, J; Schmierer, K				Grosse, P; Schulz, J; Schmierer, K			Diagnostic pitfalls in eosinophilic cryptococcal meningoencephalitis	LANCET NEUROLOGY			English	Editorial Material							MENINGITIS		Humboldt Univ, Campus Virchow Klinikum, Charite, Dept Neurol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Grosse, P (corresponding author), UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, Box 146,8-11 Queens Sq, London WC1N 3BG, England.		Schulz, Joachim/H-2430-2011; Schmierer, Klaus/W-3253-2019; Schmierer, Klaus/C-1712-2008	Grosse, Pascal/0000-0002-0114-0430				ANDERSON P, 1985, ANN INTERN MED, V103, P306, DOI 10.7326/0003-4819-103-2-306_2; MARWAHA RK, 1995, PEDIATR INFECT DIS J, V4, P102; MULLER W, 1978, ACTA NEUROCHIR, V44, P223, DOI 10.1007/BF01402064; SCHMIDT S, 1995, CLIN NEUROL NEUROSUR, V97, P23, DOI 10.1016/0303-8467(94)00063-C; WELLER PF, 1993, SEMIN NEUROL, V13, P61	5	6	7	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2003	2	8					512	512		10.1016/S1474-4422(03)00488-5	http://dx.doi.org/10.1016/S1474-4422(03)00488-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	704AC	12878440				2022-12-18	WOS:000184314700021
J	Camino, R; Arjona, A				Camino, R; Arjona, A			Septo-optic dysplasia plus	LANCET NEUROLOGY			English	Editorial Material							CORTICAL DEVELOPMENT; MALFORMATIONS		Hosp Infarta Margarita, Cordoba, Spain; Hosp Torrecardenas, Secc Neurol, Almeria, Spain	Hospital Torrecardenas	Arjona, A (corresponding author), C Violeta 70, E-04720 Aquadulce, Almeria, Spain.							Barkovich AJ, 2001, NEUROLOGY, V57, P2168, DOI 10.1212/WNL.57.12.2168; Miller SP, 2000, NEUROLOGY, V54, P1701, DOI 10.1212/WNL.54.8.1701	2	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2003	2	7					436	436		10.1016/S1474-4422(03)00441-1	http://dx.doi.org/10.1016/S1474-4422(03)00441-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	694GF	12849124				2022-12-18	WOS:000183765300020
J	Pantoni, L				Pantoni, L			Not-so-silent infarcts	LANCET NEUROLOGY			English	Editorial Material							DEMENTIA		Univ Florence, Dept Neurol & Psychiat Sci, I-50134 Florence, Italy	University of Florence	Pantoni, L (corresponding author), Univ Florence, Dept Neurol & Psychiat Sci, Viale Morgagni 85, I-50134 Florence, Italy.							Erkinjuntti T, 2000, J NEURAL TRANSM-SUPP, P23; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; UEDA K, 1992, STROKE, V23, P798, DOI 10.1161/01.STR.23.6.798; Vermeer SE, 2003, NEW ENGL J MED, V348, P1215, DOI 10.1056/NEJMoa022066	5	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2003	2	6					335	335		10.1016/S1474-4422(03)00406-X	http://dx.doi.org/10.1016/S1474-4422(03)00406-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	682WH	12849148				2022-12-18	WOS:000183115000015
J	Bogousslavsky, J; Aarli, J; Kimura, J				Bogousslavsky, J; Aarli, J; Kimura, J		Board Trustees; World Fed Neurology	Stroke and neurology: a plea from the WFN	LANCET NEUROLOGY			English	Editorial Material							MYOCARDIAL-INFARCTION; COST-EFFECTIVENESS; SMOKING CESSATION; HEALTH		Univ Lausanne, Dept Neurol, Stroke Affairs & Liaison Comm WFN, CH-1011 Lausanne, Switzerland; Univ Bergen, Haukeland Hosp, Dept Neurol, WHO Liaison Comm WFN, N-5021 Bergen, Norway; Kyoto Univ, Kyoto, Japan; Univ Iowa, Iowa City, IA 52242 USA	University of Lausanne; University of Bergen; Haukeland University Hospital; Kyoto University; University of Iowa	Bogousslavsky, J (corresponding author), Univ Lausanne, Dept Neurol, Stroke Affairs & Liaison Comm WFN, CH-1011 Lausanne, Switzerland.	julien.bogousslavsky@chuv.hospvd.ch						Asplund K., 1998, CEREBROVASC DIS, P901; Bergen DC, 2002, ARCH NEUROL-CHICAGO, V59, P1194, DOI 10.1001/archneur.59.7.1194; Brott T, 2000, NEW ENGL J MED, V343, P710, DOI 10.1056/NEJM200009073431007; Ebrahim S, 2000, BRIT MED BULL, V56, P557, DOI 10.1258/0007142001903201; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; KRUMHOLZ HM, 1993, J AM COLL CARDIOL, V22, P1697, DOI 10.1016/0735-1097(93)90598-U; LEE JW, 2003, LANCET NEUROL, V2, P133; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089	8	6	9	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2003	2	4					212	213		10.1016/S1474-4422(03)00347-8	http://dx.doi.org/10.1016/S1474-4422(03)00347-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	658NH	12849207				2022-12-18	WOS:000181726700015
J	Collinge, J; Brandner, S; Kennedy, A; Rossor, M; Smith, P; Stevens, J; Rudge, P				Collinge, J; Brandner, S; Kennedy, A; Rossor, M; Smith, P; Stevens, J; Rudge, P			A 38-year-old man with a 9 month history of neurological and cognitive impairment	LANCET NEUROLOGY			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRION-PROTEIN; STRAIN VARIATION; MOLECULAR-BASIS; TONSIL BIOPSY; CONFORMATION; DIAGNOSIS; DEMENTIA; GENOTYPE; APPENDIX		UCL Natl Hosp Neurol & Neurosurg, Dept Neurol, London WC1N 3BG, England; UCL Natl Hosp Neurol & Neurosurg, Dept Radiol, London WC1N 3BG, England; St Marys Hosp, Natl Prion Clin, London, England; UCL Natl Hosp Neurol & Neurosurg, Dementia Res Grp, London WC1N 3BG, England; Inst Neurol, Dept Neurodegenerat Dis, MRC, Prion Unit, London WC1N 3BG, England; London Sch Hyg & Trop Med, London WC1, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Rudge, P (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Neurol, Queen Sq, London WC1N 3BG, England.	peter.rudge@uclh.org	smith, peter/ABH-9627-2020; Brandner, Sebastian/J-4562-2014; Rossor, Martin/C-1598-2008	smith, peter/0000-0003-0080-7560; Brandner, Sebastian/0000-0002-9821-0342; Rossor, Martin/0000-0001-8215-3120				BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; Blattler T, 2002, NEUROSURG REV, V25, P195, DOI 10.1007/s101430100170; BRUCE ME, 1997, NATURE, V389, P489; Cervenakova L, 1998, P NATL ACAD SCI USA, V95, P13239, DOI 10.1073/pnas.95.22.13239; COLLINGE J, 1989, LANCET, V2, P15, DOI 10.1016/S0140-6736(89)90256-0; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; d'Aignaux JH, 1999, NEUROLOGY, V53, P1197, DOI 10.1212/WNL.53.6.1197; Flechsig E, 2001, MOL MED, V7, P679, DOI 10.1007/BF03401958; FRASER H, 1992, PRION DIS HUMANS ANI; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hilton DA, 2002, BRIT MED J, V325, P633, DOI 10.1136/bmj.325.7365.633; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Joiner S, 2002, J NEUROL NEUROSUR PS, V73, P597, DOI 10.1136/jnnp.73.5.597; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PARCHI P, 1996, ANN NEUROL, V39, P669; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Sellars RJ, 2002, AM J NEURORADIOL, V23, P1070; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; WEEKS GAH, 1997, VET REC, V121, P41; Zeidler M, 1999, BRIT MED J, V318, P538, DOI 10.1136/bmj.318.7182.538a	28	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2003	2	3					189	194		10.1016/S1474-4422(03)00325-9	http://dx.doi.org/10.1016/S1474-4422(03)00325-9			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	648NV	12849240				2022-12-18	WOS:000181158200017
J	Sano, M				Sano, M			Do dietary antioxidants prevent Alzheimer's disease?	LANCET NEUROLOGY			English	Editorial Material									Columbia Univ, Coll Phys & Surg, Taub Inst Alzheimers Dis Res, New York, NY 10027 USA; Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, Dept Neurol, New York, NY USA	Columbia University; Columbia University	Sano, M (corresponding author), Columbia Univ, Coll Phys & Surg, Taub Inst Alzheimers Dis Res, New York, NY 10027 USA.							Engelhart MJ, 2002, JAMA-J AM MED ASSOC, V287, P3223, DOI 10.1001/jama.287.24.3223; Kontush A, 2001, FREE RADICAL BIO MED, V31, P345, DOI 10.1016/S0891-5849(01)00595-0; Logroscino G, 1996, ANN NEUROL, V39, P89, DOI 10.1002/ana.410390113; Morris MC, 2002, JAMA-J AM MED ASSOC, V287, P3230, DOI 10.1001/jama.287.24.3230; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704	5	6	8	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2002	1	6					342	342		10.1016/S1474-4422(02)00158-8	http://dx.doi.org/10.1016/S1474-4422(02)00158-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	599PB	12849394				2022-12-18	WOS:000178343200017
J	Shelton, RC				Shelton, RC			St John's wort for the treatment of depression	LANCET NEUROLOGY			English	Editorial Material									Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37212 USA	Vanderbilt University	Shelton, RC (corresponding author), Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37212 USA.							Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; Gaster B, 2000, ARCH INTERN MED, V160, P152, DOI 10.1001/archinte.160.2.152; Kasper S, 2001, PHARMACOPSYCHIATRY, V34, pS51, DOI 10.1055/s-2001-15467; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978	5	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2002	1	5					275	275		10.1016/S1474-4422(02)00129-1	http://dx.doi.org/10.1016/S1474-4422(02)00129-1			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588LB	12849421				2022-12-18	WOS:000177702000012
J	Wallace, R				Wallace, R			Mutations in GABA-receptor genes cause human epilepsy	LANCET NEUROLOGY			English	Editorial Material							GAMMA-2-SUBUNIT		Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center	Wallace, R (corresponding author), Univ Tennessee, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38103 USA.							Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Harkin LA, 2002, AM J HUM GENET, V70, P530, DOI 10.1086/338710; Treiman DM, 2001, EPILEPSIA, V42, P8, DOI 10.1046/j.1528-1157.2001.042suppl.3008.x; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/88259	5	6	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2002	1	4					212	212		10.1016/S1474-4422(02)00098-4	http://dx.doi.org/10.1016/S1474-4422(02)00098-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588KZ	12849452				2022-12-18	WOS:000177701800016
J	Gilden, DH				Gilden, DH			Multiple sclerosis exacerbations and infection	LANCET NEUROLOGY			English	Article									Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gilden, DH (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, 4200 E 9th Ave, Denver, CO 80262 USA.	don.gilden@uchsc.edu						Buljevac D, 2002, BRAIN, V125, P952, DOI 10.1093/brain/awf098; Gilden D H, 1996, Mult Scler, V2, P179; GLYNN P, 1982, J NEUROL SCI, V57, P369, DOI 10.1016/0022-510X(82)90042-9; Owens GP, 1998, ANN NEUROL, V43, P236, DOI 10.1002/ana.410430214; Smith-Jensen T, 2000, NEUROLOGY, V54, P1227, DOI 10.1212/WNL.54.6.1227	5	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2002	1	3					145	145		10.1016/S1474-4422(02)00066-2	http://dx.doi.org/10.1016/S1474-4422(02)00066-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HB	12849479				2022-12-18	WOS:000177695100013
J	Lacoux, P; Ford, N				Lacoux, P; Ford, N			Treatment of neuropathic pain in Sierra Leone	LANCET NEUROLOGY			English	Editorial Material								During Sierra Leone's violent decade-long war, the warring parties used amputation, especially of arms, as a means of terror. In a camp for amputees in the capital city Freetown, Medecins Sans Frontibres established a clinic and a treatment programme for neuropathic pain. Insecurity and cultural and language barriers have complicated this work, but medical and humanitarian benefits have been demonstrated. Pain services are virtually non-existent in less-developed countries. There have recently been no major treatment advances for neuropathic or phantom pain; however, the general body of knowledge about amputation pain can be increased by observations from these difficult settings.	Med Sans Frontieres, London EC1 5DJ, England; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland	Doctors Without Borders; University of Dundee	Lacoux, P (corresponding author), Med Sans Frontieres, 124-132 Clerkenwell Rd, London EC1 5DJ, England.							AMOWITZ L, 2002, JAMA-J AM MED ASSOC, V287, P4; BENATAR S, 2002, JUSTICE MSF OPERATIO, P5; de Jong K, 2000, LANCET, V355, P2067, DOI 10.1016/S0140-6736(00)02364-3; DESMET J, 1998, PAIN CLIN UPDATES, V6, P1; FORD N, 1999, INTENTIONS CONSEQUEN; Griekspoor A, 2001, BRIT MED J, V323, P740, DOI 10.1136/bmj.323.7315.740; *HUM RIGHTS WATCH, 1999, SIER LEON GETT AW MU, V11, P3; Isaakidis P, 2002, BRIT MED J, V324, P702, DOI 10.1136/bmj.324.7339.702; LACOUX PA, IN PRESS PAIN; MCQUAY H, 1995, BRIT MED J, V311, P1047, DOI 10.1136/bmj.311.7012.1047; McQuay HJ, 1996, PAIN, V68, P217, DOI 10.1016/S0304-3959(96)03140-5; Mwafongo V, 2001, TROP DOCT, V31, P227, DOI 10.1177/004947550103100421; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; Richards P., 1996, FIGHTING RAINFOREST; *ROYAL COLL SURG E, 1990, COMM PROV SURG SERV; *UN, 2001, UN DEV PROGR; 2000, DRUG THER B, V38, P89	17	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2002	1	3					190	195		10.1016/S1474-4422(02)00075-3	http://dx.doi.org/10.1016/S1474-4422(02)00075-3			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	588HB	12849488				2022-12-18	WOS:000177695100021
J	Zipser, CM; Cragg, JJ; Guest, JD; Fehlings, MG; Jutzeler, CR; Anderson, AJ; Curt, A				Zipser, Carl M.; Cragg, Jacquelyn J.; Guest, James D.; Fehlings, Michael G.; Jutzeler, Catherine R.; Anderson, Aileen J.; Curt, Armin			Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials	LANCET NEUROLOGY			English	Review							INTERNATIONAL STANDARDS; MOTOR RECOVERY; SCHWANN-CELLS; BONE-MARROW; TRANSPLANTATION; THERAPY; GROWTH; RAT; RECOMMENDATIONS; CLASSIFICATION	Spinal cord injury is a severely disabling neurological condition leading to impaired mobility, pain, and autonomic dysfunction. Most often, a single traumatic event, such as a traffic or recreational accident, leads to primary spinal cord damage through compression and laceration, followed by secondary damage consisting of inflammation and ischaemia, and culminating in substantial tissue loss. Patients need appropriate timely surgical and critical care, followed by neurorehabilitation to facilitate neuronal reorganisation and functional compensation. Although some neurological function might be regained, most patients with initially complete lesions have severe, irreversible neurological impairment. Cell-based and stem-cell-based therapies are recognised as promising candidates to promote functional recovery. However, no trials of these therapies in patients have yet provided reproducible evidence for clinical efficacy, challenged by small effect sizes, low immune suppression, and low sensitivity study designs. Nevertheless, in the past decade, clinical trials have shown the feasibility and long-term safety of cell transplantation into the injured spinal cord. This crucial milestone has paved the way to consider refinements and combined therapies, such as the use of biomaterials to augment the effects of cell transplantation. In the future, emerging cell types, scaffolding, and cell engineering might improve cell survival, integration, and therapeutic efficiency.	[Zipser, Carl M.; Curt, Armin] Univ Zurich, Balgrist Univ Hosp, Spinal Cord Injury Ctr, CH-8008 Zurich, Switzerland; [Cragg, Jacquelyn J.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Cragg, Jacquelyn J.] Int Collaborat Repair Discoveries ICORD, Vancouver, BC, Canada; [Guest, James D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Fehlings, Michael G.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Fehlings, Michael G.] Univ Toronto, Dept Surg, Spinal Program, Toronto, ON, Canada; [Jutzeler, Catherine R.] Swiss Fed Inst Technol, Dept Hlth Sci AndTechnol, Basel, Switzerland; [Anderson, Aileen J.] Univ Calif Irvine, Dept Phys Med, Irvine, CA USA; [Anderson, Aileen J.] Univ Calif Irvine, Bill Gross Stem Cell Res Ctr, Irvine, CA USA	University of Zurich; University of British Columbia; University of Miami; University of Toronto; University of Toronto; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of California System; University of California Irvine; University of California System; University of California Irvine	Curt, A (corresponding author), Univ Zurich, Balgrist Univ Hosp, Spinal Cord Injury Ctr, CH-8008 Zurich, Switzerland.	armin.curt@balgrist.ch	Zipser, Carl Moritz/ACR-8199-2022	Zipser, Carl Moritz/0000-0002-4396-4796; Jutzeler, Catherine/0000-0001-7167-8271				Ahuja CS, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.18; Aimetti AA, 2019, SPINAL CORD, V57, P753, DOI 10.1038/s41393-019-0299-8; Alizadeh A, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00282; Anderson KD, 2017, J NEUROTRAUM, V34, P2950, DOI 10.1089/neu.2016.4895; Assinck P, 2017, NAT NEUROSCI, V20, P637, DOI 10.1038/nn.4541; Badhiwala JH, 2021, LANCET NEUROL, V20, P117, DOI 10.1016/S1474-4422(20)30406-3; Benavente F, 2020, ELIFE, V9, DOI 10.7554/eLife.55732; Boyd J G, 2003, Anat Rec B New Anat, V271, P49, DOI 10.1002/ar.b.10011; Bunge MB, 2017, PROG BRAIN RES, V231, P107, DOI 10.1016/bs.pbr.2016.12.012; Buri M, 2022, J NEUROTRAUM, V39, P266, DOI 10.1089/neu.2020.7407; Catz A, 2007, J REHABIL RES DEV, V44, P65, DOI 10.1682/JRRD.2005.07.0123; Chen YY, 2016, ARCH PHYS MED REHAB, V97, P1610, DOI 10.1016/j.apmr.2016.03.017; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Ciciriello AJ, 2020, ACS BIOMATER SCI ENG, V6, P5771, DOI 10.1021/acsbiomaterials.0c00844; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Curt A, 2020, NEUROREHAB NEURAL RE, V34, P758, DOI 10.1177/1545968320935815; Curt A, 2017, JAMA NEUROL, V74, P635, DOI 10.1001/jamaneurol.2017.0318; Curtis E, 2018, CELL STEM CELL, V22, P941, DOI 10.1016/j.stem.2018.05.014; Deng LX, 2011, EXP NEUROL, V229, P238, DOI 10.1016/j.expneurol.2011.02.001; Deuse T, 2019, NAT BIOTECHNOL, V37, P252, DOI 10.1038/s41587-019-0016-3; Dumont CM, 2018, TISSUE ENG PT A, V24, P1588, DOI [10.1089/ten.tea.2018.0053, 10.1089/ten.TEA.2018.0053]; DYCK PJ, 1972, BRAIN, V95, P223, DOI 10.1093/brain/95.2.223; Fehlings MG, 2017, GLOB SPINE J, V7, p195S, DOI 10.1177/2192568217706367; Freund P, 2019, LANCET NEUROL, V18, P1123, DOI 10.1016/S1474-4422(19)30138-3; FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Gant KL, 2022, J NEUROTRAUM, V39, P285, DOI 10.1089/neu.2020.7590; Ghobrial GM, 2017, NEUROSURGERY, V64, P87, DOI 10.1093/neuros/nyx242; Guest J, 2011, BRAIN RES BULL, V84, P267, DOI 10.1016/j.brainresbull.2010.11.007; Han X, 2019, P NATL ACAD SCI USA, V116, P10441, DOI 10.1073/pnas.1902566116; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hupp M, 2018, J NEUROTRAUM, V35, P2916, DOI 10.1089/neu.2017.5576; Hwang DH, 2014, J NEUROSCI, V34, P12788, DOI 10.1523/JNEUROSCI.5359-13.2014; Jaja BNR, 2021, NEUROLOGY, V96, pE2736, DOI 10.1212/WNL.0000000000012028; Jiang F, 2019, CRIT CARE MED, V47, pE854, DOI 10.1097/CCM.0000000000003937; Katoh H, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00248; Khazaei M, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aau3538; Kirshblum S, 2021, J NEUROTRAUM, V38, P1267, DOI 10.1089/neu.2020.7473; Kirshblum S, 2020, PHYS MED REH CLIN N, V31, P319, DOI 10.1016/j.pmr.2020.03.005; Koffler J, 2019, NAT MED, V25, P263, DOI 10.1038/s41591-018-0296-z; Krassioukov A, 2012, J SPINAL CORD MED, V35, P201, DOI 10.1179/1079026812Z.00000000053; Krause JS, 1997, ARCH PHYS MED REHAB, V78, P815, DOI 10.1016/S0003-9993(97)90193-3; Kutikov AB, 2019, NEUROSURGERY, V85, P560, DOI 10.1093/neuros/nyy379; Lammertse DP, 2012, SPINAL CORD, V50, P661, DOI 10.1038/sc.2012.39; Levi AD, 2019, J NEUROTRAUM, V36, P891, DOI 10.1089/neu.2018.5843; Levi AD, 2018, NEUROSURGERY, V82, P562, DOI 10.1093/neuros/nyx250; Li G, 2021, BIOACT MATER, V6, P3766, DOI 10.1016/j.bioactmat.2021.03.036; Li J, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/786475; Lu P, 2012, CELL, V150, P1264, DOI 10.1016/j.cell.2012.08.020; Mackay-Sim A, 2008, BRAIN, V131, P2376, DOI 10.1093/brain/awn173; Macklin RA, 2016, SPINAL CORD, V54, P16, DOI 10.1038/sc.2015.104; Malik NN, 2019, REGEN MED, V14, P983, DOI 10.2217/rme-2019-0117; Marino RJ, 2008, J SPINAL CORD MED, V31, P166, DOI 10.1080/10790268.2008.11760707; McDaid D, 2019, SPINAL CORD, V57, P778, DOI 10.1038/s41393-019-0285-1; Oh SK, 2016, NEUROSURGERY, V78, P436, DOI 10.1227/NEU.0000000000001056; Pearse DD, 2021, NEUROSCI LETT, V748, DOI 10.1016/j.neulet.2021.135690; Ramer LM, 2014, LANCET NEUROL, V13, P1241, DOI 10.1016/S1474-4422(14)70144-9; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; Rivers CS, 2018, ARCH PHYS MED REHAB, V99, P443, DOI 10.1016/j.apmr.2017.06.012; Saadeh YS, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.8.FOCUS17428; Salado-Manzano C, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00250; Salewski RP, 2015, STEM CELL TRANSL MED, V4, P743, DOI 10.5966/sctm.2014-0236; Santamaria AJ, 2021, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.514181; Santamaria AJ, 2018, METHODS MOL BIOL, V1739, P467, DOI 10.1007/978-1-4939-7649-2_31; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Shi L, 2020, STEM CELLS, V38, P1423, DOI 10.1002/stem.3269; Steeves JD, 2011, SPINAL CORD, V49, P257, DOI 10.1038/sc.2010.99; Sugai K, 2021, REGEN THER, V18, P321, DOI 10.1016/j.reth.2021.08.005; Svaren J, 2008, GLIA, V56, P1541, DOI 10.1002/glia.20767; Tai WJ, 2021, CELL STEM CELL, V28, P923, DOI 10.1016/j.stem.2021.02.009; Tate DG, 2020, J SPINAL CORD MED, V43, P141, DOI 10.1080/10790268.2019.1706033; Tetzlaff W, 2011, J NEUROTRAUM, V28, P1611, DOI 10.1089/neu.2009.1177; Tuszynski MH, 2002, J COMP NEUROL, V449, P88, DOI 10.1002/cne.10266; Vallotton K, 2019, NEUROLOGY, V92, pE2793, DOI 10.1212/WNL.0000000000007642; van Hedelt HJA, 2008, NEUROL RES, V30, P61, DOI 10.1179/016164107X230775; Wang ZZ, 2019, EXP NEUROL, V319, DOI 10.1016/j.expneurol.2018.09.020; Warner FM, 2019, J NEUROTRAUM, V36, P1461, DOI 10.1089/neu.2018.5960; Warner FM, 2017, CELL REP, V18, P1614, DOI 10.1016/j.celrep.2017.01.048; Williamson TL, 2021, J NEUROSURG-SPINE, V34, P254, DOI 10.3171/2020.6.SPINE20251; Woodworth CF, 2019, CAN MED ASSOC J, V191, pE761, DOI 10.1503/cmaj.181696; Wu X, 2015, SPINAL CORD, V53, P84, DOI 10.1038/sc.2014.232; Ye QS, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12946; Zweckberger K, 2016, ACTA BIOMATER, V42, P77, DOI 10.1016/j.actbio.2016.06.016	86	5	5	6	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2022	21	7					659	670		10.1016/S1474-4422(21)00464-6	http://dx.doi.org/10.1016/S1474-4422(21)00464-6			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	3J4YF	35569486				2022-12-18	WOS:000833401200018
J	Mehta, AR; Chataway, J; Pal, S; Parmar, MKB; Chandran, S				Mehta, Arpan R.; Chataway, Jeremy; Pal, Suvankar; Parmar, Mahesh K. B.; Chandran, Siddharthan			Trials for neurodegenerative diseases: time to innovate	LANCET NEUROLOGY			English	Editorial Material																			0	5	5	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2021	20	12					984	984		10.1016/S1474-4422(21)00388-4	http://dx.doi.org/10.1016/S1474-4422(21)00388-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YZ6RX	34800413	Green Accepted			2022-12-18	WOS:000755602800019
J	Cudkowicz, M; Genge, A; Maragakis, N; Petri, S; van den Berg, L; Aho, VV; Sarapohja, T; Kuoppamaki, M; Garratt, C; Al-Chalabi, A				Cudkowicz, Merit; Genge, Angela; Maragakis, Nicholas; Petri, Susanne; van den Berg, Leonard; Aho, Valtteri V.; Sarapohja, Toni; Kuoppamaki, Mikko; Garratt, Chris; Al-Chalabi, Ammar		REFALS Investigators	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study) : a randomised, double-blind, placebo-controlled phase 3 trial	LANCET NEUROLOGY			English	Article							TIRASEMTIV; MUSCLE	Background There is an urgent unmet need for new therapies in amyotrophic lateral sclerosis. In a clinical study with healthy volunteers, levosimendan, a calcium sensitiser, was shown to improve neuromechanical efficiency and contractile function of the human diaphragm. We aimed to evaluate the safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis, with a focus on respiratory function. Methods The REFALS study is a randomised, double-blind, placebo-controlled phase 3 trial at 99 amyotrophic lateral sclerosis specialist centres in 14 countries worldwide. People with amyotrophic lateral sclerosis were eligible for participation if they were at least 18 years of age and had a sitting slow vital capacity (SVC) of 60-90% predicted. Participants were randomly assigned (2:1) by interactive web-response system to receive either levosimendan or placebo. The capsules for oral administration were identical in appearance to maintain blinding of participants and investigators. The primary endpoint was the change from baseline in supine SVC at 12 weeks, assessed as the percentage of predicted normal sitting SVC. The key secondary endpoint was the combined assessment of function and survival (CAFS) up to 48 weeks. Analyses were done in the intention-to-treat population, comprising all participants who were randomly assigned. This trial is registered at ClinicalTrials.gov (NCT03505021) and has been completed. An extension study (REFALS-ES; NCT03948178) has also been completed, but will be reported separately. Findings Between June 21, 2018, and June 28, 2019, 871 people were screened for the study, of whom 496 were randomly assigned either levosimendan (n=329) or placebo (n=167). Participants were followed up between June 27, 2018 and June 26, 2020, for a median duration of 50.1 (IQR 37.5-51.1) weeks. The median duration of treatment was 47.9 (IQR 26.4-48.1) weeks. Change from baseline in supine SVC at 12 weeks was -6.73% with levosimendan and -6.99% with placebo, with no significant difference between the treatments (estimated treatment difference 0.26%, 95% CI -2.03 to 2.55, p=0.83). Similarly, at week 48, CAFS did not differ between treatment groups (least squares mean change from baseline 10.69, 95% CI -15.74 to 37.12; nominal p value=0.43). The most frequent adverse events were increased heart rate (106 [33%] of 326 receiving levosimendan vs 12 [7%] of 166 receiving placebo), fall (85 [26%] vs 48 [29%]), headache (93 [29%] vs 36 [22%]), and dyspnoea (59 [18%] vs 32 [19%]). 33 (10%) participants allocated levosimendan and 20 (12%) assigned placebo died during the trial, mainly due to respiratory failure or progression of amyotrophic lateral sclerosis. Interpretation Levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis. Although levosimendan was generally well tolerated, increased heart rate and headache occurred more frequently with levosimendan than with placebo. The possibility of a clinically relevant subgroup of responsive individuals requires further evaluation.	[Cudkowicz, Merit] Massachusetts Gen Hosp, Healey & AMG Ctr ALS, Boston, MA 02114 USA; [Genge, Angela] Montreal Neurol Hosp & Inst, Clin Res Unit, Montreal, PQ, Canada; [Genge, Angela] Montreal Neurol Hosp & Inst, ALS Clin, Montreal, PQ, Canada; [Maragakis, Nicholas] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA; [Petri, Susanne] Hannover Med Sch, Hannover, Germany; [van den Berg, Leonard] Univ Med Ctr Utrecht, Dept Neurol, Utrecht, Netherlands; [Aho, Valtteri V.; Sarapohja, Toni; Kuoppamaki, Mikko; Garratt, Chris] Orion Corp, Espoo, Finland; [Al-Chalabi, Ammar] Kings Coll London, Kings Coll Hosp, Maurice Wohl Clin Neurosci Inst, Dept Basic & Clin Neurosci, London, England; [Al-Chalabi, Ammar] Kings Coll London, Kings Coll Hosp, Dept Neurol, London, England	Harvard University; Massachusetts General Hospital; McGill University; McGill University; Johns Hopkins University; Hannover Medical School; Utrecht University; Utrecht University Medical Center; Orion Corporation; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Cudkowicz, M (corresponding author), Massachusetts Gen Hosp, Healey & AMG Ctr ALS, Boston, MA 02114 USA.	cudkowicz.merit@mgh.harvard.edu	CUDKOWICZ, MERIT/GWM-6585-2022; Petri, Susanne/AID-7665-2022; Aguera-Morales, Eduardo/Q-7167-2018; Vazquez Costa, Juan Francisco/D-4393-2015; Grosskreutz, Julian/G-2293-2010	CUDKOWICZ, MERIT/0000-0002-7075-1681; Schultz, David/0000-0001-6319-7574; Bedlack, Richard/0000-0003-4666-7495; Aguera-Morales, Eduardo/0000-0002-8604-2054; Vazquez Costa, Juan Francisco/0000-0002-3043-7938; Grosskreutz, Julian/0000-0001-9525-1424; Loscher, Wolfgang/0000-0002-7593-3222; Rath, Jakob/0000-0001-6581-4572; Goutman, Stephen/0000-0001-8780-6637	Orion Corporation - (Orion Corporation)	Orion Corporation - (Orion Corporation)	This study was funded by Orion Corporation. We thank all participants, investigators, and study centre personnel involved in this trial; and Aura Kaunisto for medical writing and editing support (funded by Orion Corporation).	Abe K, 2017, LANCET NEUROL, V16, P505, DOI 10.1016/S1474-4422(17)30115-1; Al-Chalabi A, 2019, J CARDIOVASC PHARM, V74, P389, DOI 10.1097/FJC.0000000000000728; Al-Chalabi A, 2019, J NEUROL NEUROSUR PS, V90, P1165, DOI 10.1136/jnnp-2018-320288; Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x; Berry JD, 2013, AMYOTROPH LAT SCL FR, V14, P162, DOI 10.3109/21678421.2012.762930; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Brown RH, 2017, NEW ENGL J MED, V377, P162, DOI [10.1038/nrdp.2017.85, 10.1016/S0140-6736(10)61156-7, 10.1016/S0140-6736(17)31287-4, 10.1056/NEJMra1603471, 10.1038/nrdp.2017.71, 10.1056/NEJMc1710379]; Doorduin J, 2012, AM J RESP CRIT CARE, V185, P90, DOI 10.1164/rccm.201107-1268OC; Fang T, 2018, LANCET NEUROL, V17, P416, DOI 10.1016/S1474-4422(18)30054-1; Genge A, 2019, 18 ANN NE AM LAT SCL; Just N, 2010, EUR RESPIR J, V35, P353, DOI 10.1183/09031936.00184908; Morelot-Panzini C, 2019, RESPIROLOGY, V24, P521, DOI 10.1111/resp.13525; Packer, 2005, REVIVE 2 MULTICENTER; Paganoni S, 2020, NEW ENGL J MED, V383, P919, DOI 10.1056/NEJMoa1916945; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Rudnicki SA, 2019, 30 S ALS MND PERTH W; Shefner JM, 2019, AMYOTROPH LAT SCL FR, V20, P630, DOI 10.1080/21678421.2019.1639381; Shefner JM, 2021, AMYOTROPH LAT SCL FR, V22, P287, DOI 10.1080/21678421.2020.1822410; Shefner JM, 2016, AMYOTROPH LAT SCL FR, V17, P426, DOI 10.3109/21678421.2016.1148169; van Hees HWH, 2009, AM J RESP CRIT CARE, V179, P41, DOI 10.1164/rccm.200805-732OC	20	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2021	20	10					821	831		10.1016/S1474-4422(21)00242-8	http://dx.doi.org/10.1016/S1474-4422(21)00242-8			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UY8AW	34536404				2022-12-18	WOS:000701741000017
J	Correale, J				Correale, Jorge			BTK inhibitors as potential therapies for multiple sclerosis	LANCET NEUROLOGY			English	Editorial Material							SAFETY		[Correale, Jorge] Inst Neurol Res FLENI, Dept Neurol, Montaneses 2325, RA-1428 Buenos Aires, DF, Argentina		Correale, J (corresponding author), Inst Neurol Res FLENI, Dept Neurol, Montaneses 2325, RA-1428 Buenos Aires, DF, Argentina.	jcorreale@fleni.org.ar						Baecher-Allan C, 2018, NEURON, V97, P742, DOI 10.1016/j.neuron.2018.01.021; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Contentti EC, 2020, EXPERT OPIN EMERG DR, V25, P377, DOI 10.1080/14728214.2020.1822817; Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Liang CY, 2018, EUR J MED CHEM, V151, P315, DOI 10.1016/j.ejmech.2018.03.062; MONTALBAN X, 2019, NEW ENGL J MED; Reich DS, 2021, LANCET NEUROL, V20, P729, DOI 10.1016/S1474-4422(21)00237-4; Smith PF, 2019, MULT SCLER J, V25, P52; Zarrin AA, 2021, NAT REV DRUG DISCOV, V20, P39, DOI 10.1038/s41573-020-0082-8	10	5	5	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2021	20	9					689	691		10.1016/S1474-4422(21)00250-7	http://dx.doi.org/10.1016/S1474-4422(21)00250-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UK3MC	34418385				2022-12-18	WOS:000691876000003
J	Greenberg, SM; Cordonnier, C; Schneider, JA; Smith, EE; Van Buchem, MA; Van Veluw, SJ; Verbeek, MM; Viswanathan, A; Werring, DJ				Greenberg, Steven M.; Cordonnier, Charlotte; Schneider, Julie A.; Smith, Eric E.; Van Buchem, Mark A.; Van Veluw, Susanne J.; Verbeek, Marcel M.; Viswanathan, Anand; Werring, David J.			Off-label use of aducanumab for cerebral amyloid angiopathy	LANCET NEUROLOGY			English	Letter									[Greenberg, Steven M.; Van Veluw, Susanne J.; Viswanathan, Anand] Harvard Med Sch, Massachusetts Gen Hosp, Haemorrhag Stroke Res Program, J Philip Kistler Stroke Res Ctr,Dept Neurol, Boston, MA 02114 USA; [Cordonnier, Charlotte] Univ Lille, CHU Lille, INSERM, LilNCog,Lille Neurosci & Cognit,U 1172, F-59000 Lille, France; [Schneider, Julie A.] Rush Univ, Med Ctr, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA; [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Van Buchem, Mark A.; Van Veluw, Susanne J.] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands; [Verbeek, Marcel M.] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Radboud Alzheimer Ctr, Dept Neurol, Nijmegen, Netherlands; [Verbeek, Marcel M.] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Radboud Alzheimer Ctr, Lab Med, Nijmegen, Netherlands; [Werring, David J.] UCL, Queen Sq Inst Neurol, Ctr Stroke Res, Dept Brain Repair & Rehabil, London, England; [Werring, David J.] Natl Hosp Neurol & Neurosurg, London, England	Harvard University; Harvard Medical School; Massachusetts General Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Rush University; University of Calgary; University of Calgary; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen; Radboud University Nijmegen; University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Greenberg, SM (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Haemorrhag Stroke Res Program, J Philip Kistler Stroke Res Ctr,Dept Neurol, Boston, MA 02114 USA.	sgreenberg@mgh.harvard.edu	Verbeek, Marcel M/D-1971-2010; Werring, David/Q-8435-2019; van Buchem, Mark/AAC-9843-2022	Verbeek, Marcel M/0000-0003-4635-7876; Werring, David/0000-0003-2074-1861; van Buchem, Mark/0000-0003-1881-1998				Biogen. Aduhelm (aducanumab-avwa), HIGHL PRESCR INF, P2021; FDA, 2021, FDA GRANTS ACC APPR; Greenberg SM, 2020, NAT REV NEUROL, V16, P30, DOI 10.1038/s41582-019-0281-2; Greenberg SM, 2018, STROKE, V49, P491, DOI 10.1161/STROKEAHA.117.016990; Leurent C, 2019, ANN CLIN TRANSL NEUR, V6, P795, DOI 10.1002/acn3.761	5	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2021	20	8					596	597		10.1016/S1474-4422(21)00213-1	http://dx.doi.org/10.1016/S1474-4422(21)00213-1		JUL 2021	2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP6CG	34237272	Green Submitted, Bronze			2022-12-18	WOS:000677684700022
J	[Anonymous]				[Anonymous]			A contentious FDA ruling for Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material																			0	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2021	20	8					585	585		10.1016/S1474-4422(21)00215-5	http://dx.doi.org/10.1016/S1474-4422(21)00215-5		JUL 2021	1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	TP6CG	34237273	Bronze			2022-12-18	WOS:000677684700002
J	Pratt, J; Lester, E; Parker, R				Pratt, James; Lester, Evan; Parker, Roy			Could SARS-CoV-2 cause tauopathy?	LANCET NEUROLOGY			English	Letter									[Pratt, James; Lester, Evan; Parker, Roy] Univ Colorado, Dept Biochem, Boulder, CO 80303 USA; [Parker, Roy] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80303 USA; [Parker, Roy] Univ Colorado, BioFrontiers Inst, Boulder, CO 80303 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Parker, R (corresponding author), Univ Colorado, Dept Biochem, Boulder, CO 80303 USA.; Parker, R (corresponding author), Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80303 USA.; Parker, R (corresponding author), Univ Colorado, BioFrontiers Inst, Boulder, CO 80303 USA.	roy.parker@colorado.edu		Lester, Evan/0000-0002-0486-0361				Garg RK, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2058; Heneka MT, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00640-3; Hoffman LA, 2017, BRAIN, V140, P2246, DOI 10.1093/brain/awx177; Jiao L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00591-7; Ramani A, 2020, EMBO J, V39, DOI 10.15252/embj.2020106230; Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065	6	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2021	20	7					506	506		10.1016/S1474-4422(21)00168-X	http://dx.doi.org/10.1016/S1474-4422(21)00168-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UD5TG	34146504	Bronze, Green Published			2022-12-18	WOS:000687268300004
J	Maas, AIR; Peul, W; Thome, C				Maas, Andrew I. R.; Peul, Wilco; Thome, Claudius			Surgical decompression in acute spinal cord injury: earlier is better	LANCET NEUROLOGY			English	Editorial Material									[Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, B-2650 Edegem, Belgium; [Peul, Wilco] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands; [Peul, Wilco] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands; [Thome, Claudius] Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria	University of Antwerp; University of Antwerp; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Haaglanden Medical Center; Medical University of Innsbruck	Maas, AIR (corresponding author), Antwerp Univ Hosp, Dept Neurosurg, B-2650 Edegem, Belgium.; Maas, AIR (corresponding author), Univ Antwerp, B-2650 Edegem, Belgium.	andrew.maas@uza.be			EU Framework 7 programme; BITPharma; BrainLab; DePuySynthes; Icotec; Intrinsic Therapeutics; Pfizer; Signus Medical; Tissue Engineering Technologies	EU Framework 7 programme; BITPharma; BrainLab; DePuySynthes; Icotec; Intrinsic Therapeutics; Pfizer(Pfizer); Signus Medical; Tissue Engineering Technologies	AIRM reports grants from the EU Framework 7 programme, and personal fees from PesSura Neuro, NeuroTrauma Sciences, and Wings for Life, outside the submitted work. CT reports grants from BITPharma, BrainLab, DePuySynthes, Icotec, Intrinsic Therapeutics, Pfizer, Signus Medical, and Tissue Engineering Technologies, and personal fees from BrainLab, DePuySynthes, Icotec, Intrinsic Therapeutics, Medtronic, Nuvasive, Signus Medical, Wings for Life, and Zeiss, outside the submitted work. WP reports being a Board Member of ZonMW (the Netherlands Organisation for Health Research and Development) and declares no influence of ZonMW on the submitted work.	Aarabi B, 2019, J NEUROTRAUM, V36, P862, DOI 10.1089/neu.2018.5834; Badhiwala JH, 2021, LANCET NEUROL, V20, P117, DOI 10.1016/S1474-4422(20)30406-3; Burke JF, 2019, NEUROSURGERY, V85, P199, DOI 10.1093/neuros/nyy537; Chari A, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7020018; Fehlings MG, 2017, GLOB SPINE J, V7, p195S, DOI 10.1177/2192568217706367; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Fouad K, 2020, J NEUROTRAUM, V37, P831, DOI 10.1089/neu.2019.6674; Jaja BNR, 2014, NEUROCRIT CARE, V21, P551, DOI 10.1007/s12028-014-9990-y; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; ter Wengel PV, 2018, EUR SPINE J, V27, P1831, DOI 10.1007/s00586-018-5551-y	10	5	5	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2021	20	2					84	86		10.1016/S1474-4422(20)30478-6	http://dx.doi.org/10.1016/S1474-4422(20)30478-6		JAN 2021	3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV7ZK	33357515				2022-12-18	WOS:000610201500006
J	Bourdette, D				Bourdette, Dennis			Are drugs for multiple sclerosis fatigue just placebos?	LANCET NEUROLOGY			English	Editorial Material									[Bourdette, Dennis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA	Oregon Health & Science University	Bourdette, D (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.	bourdett@ohsu.edu						Asano M, 2014, MULT SCLER INT, V2014, DOI 10.1155/2014/798285; Brown JN, 2010, ANN PHARMACOTHER, V44, P1098, DOI 10.1345/aph.1M705; Hugos CL, 2019, MULT SCLER J, V25, P275, DOI 10.1177/1352458517745723; Krupp L, 2006, MULT SCLER J, V12, P367, DOI 10.1191/135248506ms1373ed; Krupp LB, 2010, EXPERT REV NEUROTHER, V10, P1437, DOI 10.1586/ERN.10.99; Nourbakhsh B, 2021, LANCET NEUROL, V20, P38, DOI 10.1016/S1474-4422(20)30354-9; Oken BS, 2008, BRAIN, V131, P2812, DOI 10.1093/brain/awn116; Pucci E, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002818.pub2; Rottoli M, 2017, EXPERT REV NEUROTHER, V17, P373, DOI 10.1080/14737175.2017.1247695; Yadav V, 2016, MULT SCLER RELAT DIS, V9, P80, DOI 10.1016/j.msard.2016.07.001	10	5	5	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					20	21		10.1016/S1474-4422(20)30415-4	http://dx.doi.org/10.1016/S1474-4422(20)30415-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33242420				2022-12-18	WOS:000600831400014
J	Sandsmark, DK; Diaz-Arrastia, R				Sandsmark, Danielle K.; Diaz-Arrastia, Ramon			Advances in traumatic brain injury research in 2020	LANCET NEUROLOGY			English	Editorial Material									[Sandsmark, Danielle K.; Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania	Diaz-Arrastia, R (corresponding author), Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.	ramon.diaz-arrastia@uphs.upenn.edu						Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Czeiter E, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102785; Hartings JA, 2020, JAMA NEUROL, V77, P489, DOI 10.1001/jamaneurol.2019.4476; Jolly AE, 2020, BRAIN, V143, P1158, DOI 10.1093/brain/awaa067; Sharma S, 2020, ANN NEUROL, V87, P442, DOI 10.1002/ana.25675; Veksler R, 2020, BRAIN, V143, P1826, DOI 10.1093/brain/awaa140; Willis EF, 2020, CELL, V180, P833, DOI 10.1016/j.cell.2020.02.013	7	5	5	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2021	20	1					5	+		10.1016/S1474-4422(20)30455-5	http://dx.doi.org/10.1016/S1474-4422(20)30455-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PI1AM	33340484				2022-12-18	WOS:000600831400005
J	Li, HF; Hao, HJ; Chen, XJ				Li, Hai-Feng; Hao, Hong-Jun; Chen, Xiang-Jun			Provisional case definitions for COVID-19-associated neurological disease	LANCET NEUROLOGY			English	Letter									[Li, Hai-Feng] Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing 100053, Peoples R China; [Hao, Hong-Jun] Peking Univ, Hosp 1, Dept Neurol, Beijing, Peoples R China; [Chen, Xiang-Jun] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai, Peoples R China	Capital Medical University; Peking University; Fudan University	Li, HF (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Neurol, Beijing 100053, Peoples R China.	drlhf@163.com						Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; Kong WH, 2020, NAT MICROBIOL, V5, P675, DOI 10.1038/s41564-020-0713-1; Lucchese G, 2020, CELL STRESS CHAPERON, V25, P731, DOI 10.1007/s12192-020-01145-6; Petras M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020150; Yue HH, 2020, J MED VIROL, V92, P2870, DOI 10.1002/jmv.26163	5	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2020	19	11					890	+		10.1016/S1474-4422(20)30373-2	http://dx.doi.org/10.1016/S1474-4422(20)30373-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3OI	33098793	Bronze, Green Published			2022-12-18	WOS:000581121200013
J	Condello, C; DeGrado, WF; Prusiner, SB				Condello, Carlo; DeGrado, William F.; Prusiner, Stanley B.			Prion biology: implications for Alzheimer's disease therapeutics Comment	LANCET NEUROLOGY			English	Editorial Material							PROTEIN		[Condello, Carlo; DeGrado, William F.; Prusiner, Stanley B.] Univ Calif San Francisco, UCSF Weill Inst Neurosci, Inst Neurodegenerat Dis, San Francisco, CA 94158 USA; [Condello, Carlo; Prusiner, Stanley B.] Univ Calif San Francisco, UCSF Weill Inst Neurosci, Dept Neurol, San Francisco, CA 94158 USA; [DeGrado, William F.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; [Prusiner, Stanley B.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Prusiner, SB (corresponding author), Univ Calif San Francisco, UCSF Weill Inst Neurosci, Inst Neurodegenerat Dis, San Francisco, CA 94158 USA.; Prusiner, SB (corresponding author), Univ Calif San Francisco, UCSF Weill Inst Neurosci, Dept Neurol, San Francisco, CA 94158 USA.; Prusiner, SB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA.	stanley.prusiner@ucsf.edu			National Institutes of Health [P01 AG002132, RF1 AG061874, R35 GM122603]; Brockman Foundation; Sherman Fairchild Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Brockman Foundation; Sherman Fairchild Foundation	SBP is a member of the scientific advisory board of ViewPointTherapeutics and a member of the board of directors of Trizell, neither of which have contributed financial or any other support to this Comment. All other authors declare no competing interests. We acknowledge support from the National Institutes of Health (P01 AG002132, RF1 AG061874, and R35 GM122603), the Brockman Foundation, and the Sherman Fairchild Foundation.	Aoyagi A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat8462; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; Kollmer M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12683-8; Lauwers E, 2020, LANCET NEUROL; Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Purro SA, 2018, NATURE, V564, P415, DOI 10.1038/s41586-018-0790-y; Sanders DW, 2014, NEURON, V82, P1271, DOI 10.1016/j.neuron.2014.04.047; Stohr J, 2012, P NATL ACAD SCI USA, V109, P11025, DOI 10.1073/pnas.1206555109; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	10	5	5	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2020	19	10					802	+		10.1016/S1474-4422(20)30274-X	http://dx.doi.org/10.1016/S1474-4422(20)30274-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OF3NN	32949533	Green Submitted			2022-12-18	WOS:000581119100007
J	Demetriades, AK; Duran, SH; Aldea, CC; Gandia-Gonzalez, ML; Broekman, MLD; Schaller, K				Demetriades, Andreas K.; Duran, Silvia Hernandez; Aldea, Cristina C.; Gandia-Gonzalez, Maria L.; Broekman, Marike L. D.; Schaller, Karl			Diversity and equality in neurosurgery	LANCET NEUROLOGY			English	Letter									[Demetriades, Andreas K.] Western Gen Hosp, Dept Neurosurg, Edinburgh EH4 2XU, Midlothian, Scotland; [Duran, Silvia Hernandez] Univ Med Gottingen, Klin Neurochirurg, Gottingen, Germany; [Aldea, Cristina C.] Iuliu Hatieganu Univ Med & Pharm Cluj Napoca, Cluj Napoca, Romania; [Aldea, Cristina C.] Cluj Cty Emergency Hosp, Dept Neurosurg, Cluj Napoca, Romania; [Gandia-Gonzalez, Maria L.] Hosp Univ La Paz, Dept Neurosurg, Madrid, Spain; [Broekman, Marike L. D.] Haaglanden Med Ctr, Dept Neurosurg, The Hague, Netherlands; [Broekman, Marike L. D.] Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands; [Broekman, Marike L. D.] Harvard Med Sch, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Schaller, Karl] Univ Geneva, Med Ctr, Dept Neurosurg, CH-1205 Geneva, Switzerland; [Schaller, Karl] Univ Geneva, Fac Med, CH-1205 Geneva, Switzerland	University of Edinburgh; University of Gottingen; Iuliu Hatieganu University of Medicine & Pharmacy; Hospital Universitario La Paz; Haaglanden Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Geneva; University of Geneva	Demetriades, AK (corresponding author), Western Gen Hosp, Dept Neurosurg, Edinburgh EH4 2XU, Midlothian, Scotland.	andreas.demetriades@gmail.com	gandia, marisa/AAC-1941-2022; DEMETRIADES, Andreas K/P-5806-2019	DEMETRIADES, Andreas K/0000-0002-2004-9448; GANDIA GONZALEZ, MARIA LUISA/0000-0002-5683-1300				Norton EJ, 2020, LANCET NEUROL, V19, P382, DOI 10.1016/S1474-4422(20)30080-6; Schaller K, 2020, ACTA NEUROCHIR, V162, P239, DOI 10.1007/s00701-019-04165-z; Skarparis Y, 2016, ACTA NEUROCHIR, V158, P27, DOI 10.1007/s00701-015-2651-x; Stienen MN, 2016, J NEUROSURG, V125, P1317, DOI 10.3171/2016.4.JNS16788	4	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2020	19	8					645	646		10.1016/S1474-4422(20)30226-X	http://dx.doi.org/10.1016/S1474-4422(20)30226-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT8ZY	32702328	Bronze			2022-12-18	WOS:000573228000021
J	Hermann, DM; Bassetti, CL; Marx, U; Audoli-Inthavong, ML; Chabriat, H				Hermann, Dirk M.; Bassetti, Claudio L.; Marx, Ute; Audoli-Inthavong, Marie-Laure; Chabriat, Hugues			Refining endpoints for stroke recovery trials	LANCET NEUROLOGY			English	Letter									[Hermann, Dirk M.] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, D-45122 Essen, Germany; [Bassetti, Claudio L.] Univ Hosp Berne, Dept Neurol, Bern, Switzerland; [Marx, Ute; Audoli-Inthavong, Marie-Laure] Inst Rech Int Servier IRIS, Suresnes, France; [Chabriat, Hugues] Paris Diderot Univ, Lariboisiere Hosp, Dept Neurol, Paris, France; [Chabriat, Hugues] INSERM, U1141, Paris, France	University of Duisburg Essen; University of Bern; University Hospital of Bern; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Hermann, DM (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, D-45122 Essen, Germany.	dirk.hermann@uk-essen.de	Hermann, Dirk/GZB-9350-2022; Hermann, Dirk M./AAT-3652-2021; Chabriat, Hugues/G-5699-2010	Hermann, Dirk M./0000-0003-0198-3152; Bassetti, Claudio/0000-0002-4535-0245; Chabriat, Hugues/0000-0001-8436-6074				Chabriat H, 2020, LANCET NEUROL, V19, P226, DOI 10.1016/S1474-4422(20)30004-1; Cramer SC, 2020, LANCET NEUROL, V19, P197, DOI 10.1016/S1474-4422(20)30030-2; European Agency for the Evaluation of Medicinal Products, 2001, CPMPEWP56098 EUR AG; FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79; Pace M, 2019, BIORXIV, DOI [10.1101/721282 (preprint), DOI 10.1101/721282]; Wang YC, 2018, STROKE, V49, P2495, DOI 10.1161/STROKEAHA.118.021378	6	5	5	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					381	382		10.1016/S1474-4422(20)30101-0	http://dx.doi.org/10.1016/S1474-4422(20)30101-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32333891	Bronze			2022-12-18	WOS:000573045100023
J	Hudry, K; Pellicano, E; Uljarevic, M; Whitehouse, AJO				Hudry, Kristelle; Pellicano, Elizabeth; Uljarevic, Mirko; Whitehouse, Andrew J. O.			Setting the research agenda to secure the wellbeing of autistic people	LANCET NEUROLOGY			English	Editorial Material							CHILDREN		[Hudry, Kristelle] La Trobe Univ, Sch Psychol & Publ Hlth, Melbourne, Vic 3086, Australia; [Pellicano, Elizabeth] Macquarie Univ, Macquarie Sch Educ, Sydney, NSW, Australia; [Uljarevic, Mirko] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Uljarevic, Mirko] Stanford Univ, Sch Med, Child & Adolescent Psychiat, Stanford, CA 94305 USA; [Whitehouse, Andrew J. O.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia	La Trobe University; Macquarie University; University of Melbourne; Stanford University; Telethon Kids Institute; University of Western Australia	Hudry, K (corresponding author), La Trobe Univ, Sch Psychol & Publ Hlth, Melbourne, Vic 3086, Australia.	k.hudry@latrobe.edu.au	Whitehouse, Andrew J.O./AGJ-2519-2022	Whitehouse, Andrew J.O./0000-0001-8722-1575; Hudry, Kristelle/0000-0002-2752-8345				Chetcuti L, 2019, J CHILD PSYCHOL PSYC, V60, P225, DOI 10.1111/jcpp.12957; Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-126; den Houting J, 2019, J AUTISM DEV DISORD, V49, P4400, DOI 10.1007/s10803-019-04155-1; Lai MC, 2020, LANCET NEUROL, V19, P434, DOI 10.1016/S1474-4422(20)30034-X; McConachie H, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19410; Uljarevic M, 2020, J AM ACAD CHILD PSY, V59, P1252, DOI 10.1016/j.jaac.2019.07.938; Vivanti G, 2018, AUTISM RES, V11, P16, DOI 10.1002/aur.1900; Whitehouse AJO, 2019, LANCET CHILD ADOLESC, V3, P605, DOI 10.1016/S2352-4642(19)30184-1; Whitehouse AJO, 2017, INT J SPEECH-LANG PA, V19, P208, DOI 10.1080/17549507.2016.1276963; Wray J., 2018, NATL GUIDELINE ASSES	10	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					374	376		10.1016/S1474-4422(20)30031-4	http://dx.doi.org/10.1016/S1474-4422(20)30031-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	NT6JQ	32142627				2022-12-18	WOS:000573045100006
J	Schapira, AHV				Schapira, Anthony H., V			A pragmatic, personalised approach to treatment initiation in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							LEVODOPA		[Schapira, Anthony H., V] UCL, Queen Sq Inst Neurol, Dept Clin & Movement Neurosci, Royal Free Campus, London NW3 2PF, England	University of London; University College London	Schapira, AHV (corresponding author), UCL, Queen Sq Inst Neurol, Dept Clin & Movement Neurosci, Royal Free Campus, London NW3 2PF, England.	a.schapira@ucl.ac.uk	Schapira, Anthony/A-1245-2010	Schapira, Anthony/0000-0002-3018-3966				Barone P, 2010, LANCET NEUROL, V9, P573, DOI 10.1016/S1474-4422(10)70106-X; de Bie RMA, 2020, LANCET NEUROL, V19, P452, DOI 10.1016/S1474-4422(20)30036-3; Fahn S, 2004, NEW ENGL J MED, V351, P2498; Olanow CW, 2013, MOVEMENT DISORD, V28, P1064, DOI 10.1002/mds.25364; Schapira AHV, 2013, EUR J NEUROL, V20, P50, DOI 10.1111/j.1468-1331.2012.03712.x; Schapira AHV, 2006, ANN NEUROL, V59, P559, DOI 10.1002/ana.20789; Schapira AHV, 2017, NAT REV NEUROSCI, V18, P435, DOI 10.1038/nrn.2017.62; Schapira AHV, 2008, ANN NEUROL, V64, pS47, DOI 10.1002/ana.21460; Stocchi F, 2010, ANN NEUROL, V68, P18, DOI 10.1002/ana.22060	9	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2020	19	5					376	378		10.1016/S1474-4422(20)30065-X	http://dx.doi.org/10.1016/S1474-4422(20)30065-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NT6JQ	32171386	Green Submitted			2022-12-18	WOS:000573045100007
J	Schonewille, WJ				Schonewille, Wouter J.			BEST evidence on mechanical thrombectomy for patients with vertebrobasilar occlusion	LANCET NEUROLOGY			English	Editorial Material							BASILAR ARTERY-OCCLUSION; OUTCOMES		[Schonewille, Wouter J.] St Antonius Hosp, Dept Neurol, NL-3435 CM Nieuwegein, Netherlands	St. Antonius Hospital Utrecht	Schonewille, WJ (corresponding author), St Antonius Hosp, Dept Neurol, NL-3435 CM Nieuwegein, Netherlands.	w.schonewille@antoniusziekenhuis.nl						Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587; Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X; Kumar G, 2015, J NEUROINTERV SURG, V7, P868, DOI 10.1136/neurintsurg-2014-011418; Liu XF, 2020, LANCET NEUROL, V19, P115, DOI 10.1016/S1474-4422(19)30395-3; Macleod MR, 2005, CEREBROVASC DIS, V20, P12, DOI 10.1159/000086121; Meinel TR, 2019, J NEUROINTERV SURG, V11, P1174, DOI 10.1136/neurintsurg-2018-014516; Schonewille WJ, 2009, LANCET NEUROL, V8, P724, DOI 10.1016/S1474-4422(09)70173-5; van der Hoeven EJRJ, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-200; ZEUMER H, 1983, AM J NEURORADIOL, V4, P401	9	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2020	19	2					102	103		10.1016/S1474-4422(19)30477-6	http://dx.doi.org/10.1016/S1474-4422(19)30477-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KE1XC	31831389				2022-12-18	WOS:000508351900007
J	Adams, HHH; Evans, TE; Terzikhan, N				Adams, Hieab H. H.; Evans, Tavia E.; Terzikhan, Natalie			The Uncovering Neurodegenerative Insights Through Ethnic Diversity consortium	LANCET NEUROLOGY			English	Letter									[Adams, Hieab H. H.; Evans, Tavia E.; Terzikhan, Natalie] Erasmus MC, Dept Epidemiol, NL-3015 CE Rotterdam, Netherlands; [Adams, Hieab H. H.; Evans, Tavia E.] Erasmus MC, Dept Radiol & Nucl Med, NL-3015 CE Rotterdam, Netherlands; [Adams, Hieab H. H.] Erasmus MC, Dept Clin Genet, NL-3015 CE Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Adams, HHH (corresponding author), Erasmus MC, Dept Epidemiol, NL-3015 CE Rotterdam, Netherlands.; Adams, HHH (corresponding author), Erasmus MC, Dept Radiol & Nucl Med, NL-3015 CE Rotterdam, Netherlands.; Adams, HHH (corresponding author), Erasmus MC, Dept Clin Genet, NL-3015 CE Rotterdam, Netherlands.	h.adams@erasmusmc.nl	Adams, Hieab/GLN-6421-2022		Netherlands Organization for Health Research and Development (ZonMW) [916.19.151]	Netherlands Organization for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development)	We declare no competing interests. This project is supported by the Netherlands Organization for Health Research and Development (ZonMW, grant 916.19.151).	Adams HHH, 2016, NAT NEUROSCI, V19, P1569, DOI 10.1038/nn.4398; Bertram L, 2019, NAT REV NEUROL, V15, P191, DOI 10.1038/s41582-019-0158-4; Hendrix JA, 2015, ALZHEIMERS DEMENT, V11, P850, DOI 10.1016/j.jalz.2015.05.008; Mills MC, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-018-0261-x; Thompson PM, 2014, BRAIN IMAGING BEHAV, V8, P153, DOI 10.1007/s11682-013-9269-5; Toga AW, 2016, ALZHEIMERS DEMENT, V12, P49, DOI 10.1016/j.jalz.2015.06.1896; Wyss AB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05369-0	7	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2019	18	10					915	915		10.1016/S1474-4422(19)30324-2	http://dx.doi.org/10.1016/S1474-4422(19)30324-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IX6HN	31526750				2022-12-18	WOS:000485784000011
J	Launer, LJ				Launer, Lenore J.			Blood pressure control as an intervention to prevent dementia	LANCET NEUROLOGY			English	Editorial Material									[Launer, Lenore J.] NIA, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Launer, LJ (corresponding author), NIA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.	launerl@nia.nih.gov			Intramural NIH HHS [ZIA AG007280] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Iadecola C, 2016, HYPERTENSION, V68, pE67, DOI 10.1161/HYP.0000000000000053; Lane CA, 2019, LANCET NEUROL, V18, P942, DOI 10.1016/S1474-4422(19)30228-5; Launer LJ, 2005, NEUROBIOL AGING, V26, P335, DOI 10.1016/j.neurobiolaging.2004.03.016; Olsen MH, 2016, LANCET, V388, P2665, DOI 10.1016/S0140-6736(16)31134-5; Richards M, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024404; Williamson JD, 2019, JAMA-J AM MED ASSOC, V321, P553, DOI 10.1001/jama.2018.21442	6	5	5	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2019	18	10					906	908		10.1016/S1474-4422(19)30288-1	http://dx.doi.org/10.1016/S1474-4422(19)30288-1			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IX6HN	31444143	Green Accepted, hybrid			2022-12-18	WOS:000485784000004
J	[Anonymous]				[Anonymous]			A spotlight on sex differences in neurological disorders	LANCET NEUROLOGY			English	Editorial Material																			0	5	5	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2019	18	4					319	319		10.1016/S1474-4422(19)30001-8	http://dx.doi.org/10.1016/S1474-4422(19)30001-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HO7ZR	30878094	Bronze			2022-12-18	WOS:000461169400002
J	Ashina, M				Ashina, Messoud			The most important advances in headache research in 2018	LANCET NEUROLOGY			English	Editorial Material									[Ashina, Messoud] Univ Copenhagen, Fac Hlth & Med Sci, Rigshosp Glostrup, Dept Neurol,Danish Headache Ctr, DK-2600 Glostrup, Denmark	University of Copenhagen	Ashina, M (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Rigshosp Glostrup, Dept Neurol,Danish Headache Ctr, DK-2600 Glostrup, Denmark.	ashina@dadlnet.dk	Ashina, Messoud/AFU-1246-2022	Ashina, Messoud/0000-0003-0951-5804				Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Dodick DW, 2018, JAMA-J AM MED ASSOC, V319, P1999, DOI 10.1001/jama.2018.4853; Reuter U, 2018, LANCET, V392, P2280, DOI 10.1016/S0140-6736(18)32534-0; Schain AJ, 2018, ANN NEUROL, V83, P508, DOI 10.1002/ana.25169; Stauffer VL, 2018, JAMA NEUROL, V75, P1080, DOI 10.1001/jamaneurol.2018.1212	5	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2019	18	1					5	+		10.1016/S1474-4422(18)30434-4	http://dx.doi.org/10.1016/S1474-4422(18)30434-4			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HE1CJ	30563683				2022-12-18	WOS:000453007700006
J	Beghi, E; Giussani, G				Beghi, Ettore; Giussani, Giorgia			Treatment of epilepsy in light of the most recent advances	LANCET NEUROLOGY			English	Editorial Material							CANNABIDIOL; SEIZURES; OUTCOMES		[Beghi, Ettore; Giussani, Giorgia] IRCCS, Ist Ric Farmacol Mario Negri, Dept Neurosci, Lab Neurol Disorders, Via Giuseppe La Masa 19, I-20156 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Beghi, E (corresponding author), IRCCS, Ist Ric Farmacol Mario Negri, Dept Neurosci, Lab Neurol Disorders, Via Giuseppe La Masa 19, I-20156 Milan, Italy.	ettore.beghi@marionegri.it	Giussani, Giorgia/AAA-8029-2020; Giussani, Giorgia/E-8057-2017; Beghi, Ettore/AAA-7426-2020	Giussani, Giorgia/0000-0003-2460-3095; Giussani, Giorgia/0000-0003-2460-3095; Beghi, Ettore/0000-0003-2542-0469	Italian Ministry of Health; UCB-Pharma	Italian Ministry of Health(Ministry of Health, Italy); UCB-Pharma(UCB Pharma SA)	EB has received grants from UCB-Pharma and from the Italian Ministry of Health. GG declares no competing interests.	Brodie MJ, 2018, EPILEPSIA, V59, P291, DOI 10.1111/epi.13973; Chen ZB, 2018, JAMA NEUROL, V75, P279, DOI 10.1001/jamaneurol.2017.3949; Cooper MS, 2016, EPILEPSY RES, V128, P43, DOI 10.1016/j.eplepsyres.2016.10.006; Devinsky O, 2018, NEUROLOGY, V90, pE1204, DOI 10.1212/WNL.0000000000005254; Devinsky O, 2018, NEW ENGL J MED, V378, P1888, DOI 10.1056/NEJMoa1714631; Meador KJ, 2013, LANCET NEUROL, V12, P244, DOI 10.1016/S1474-4422(12)70323-X; Myers KA, 2018, EPILEPSIA, V59, P1372, DOI 10.1111/epi.14438; Thiele EA, 2018, LANCET, V391, P1085, DOI 10.1016/S0140-6736(18)30136-3; Tomson T, 2018, LANCET NEUROL, V17, P530, DOI 10.1016/S1474-4422(18)30107-8; Tomson T, 2016, LANCET NEUROL, V15, P210, DOI [10.1016/S1474-4422(15)00314-2, 10.1016/S1474-4422(15)00398-1]	10	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2019	18	1					7	8		10.1016/S1474-4422(18)30412-5	http://dx.doi.org/10.1016/S1474-4422(18)30412-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HE1CJ	30563684				2022-12-18	WOS:000453007700007
J	Vein, AA; Mouret, A				Vein, Alla A.; Mouret, Alexander			Claw hand in a Renaissance portrait	LANCET NEUROLOGY			English	Letter									[Vein, Alla A.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands; [Mouret, Alexander] Leiden Univ, Luris Knowledge Exchange Off, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Vein, AA (corresponding author), Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands.	A.A.Vein@lumc.nl						Laurenza Domenico, 2012, METROPOLITAN MUSEUM, V69, P4; Moore K, 2014, CLIN ORIENTED ANATOM, P768; Vasari Giorgio, 2006, LIVES MOST EXCELLENT	3	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2018	17	9					742	742		10.1016/S1474-4422(18)30282-5	http://dx.doi.org/10.1016/S1474-4422(18)30282-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GQ3AO	30129472	Bronze			2022-12-18	WOS:000441532100009
J	Striano, P; Nobile, C				Striano, Pasquale; Nobile, Carlo			The genetic basis of juvenile myoclonic epilepsy	LANCET NEUROLOGY			English	Editorial Material							INTESTINAL-CELL KINASE; EFHC1; MUTATIONS		[Striano, Pasquale] Univ Genoa, Inst Giannina Gaslini, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Pediat Neurol & Muscular Dis Unit, I-16148 Genoa, Italy; [Nobile, Carlo] Univ Padua, Consiglio Nazl Ric, Neurosci Inst, Padua, Italy; [Nobile, Carlo] Univ Padua, Dept Biomed Sci, Padua, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Striano, P (corresponding author), Univ Genoa, Inst Giannina Gaslini, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Pediat Neurol & Muscular Dis Unit, I-16148 Genoa, Italy.	pstriano@unige.it	Striano, Pasquale/F-9117-2014	Striano, Pasquale/0000-0002-6065-1476; Nobile, Carlo/0000-0002-0634-2218	Italian Ministry of Health; Telethon Foundation [GGP15229]; Genetics Commission of the Italian League Against Epilepsy	Italian Ministry of Health(Ministry of Health, Italy); Telethon Foundation(Fondazione Telethon); Genetics Commission of the Italian League Against Epilepsy	PS received honoraria from Kolfarma, UCB pharma, Eisai, and research support from the Italian Ministry of Health. CN received research support from the Telethon Foundation (grant number GGP15229) and the Genetics Commission of the Italian League Against Epilepsy.	Annesi F, 2007, EPILEPSIA, V48, P1686, DOI 10.1111/j.1528-1167.2007.01173.x; Bailey JN, 2018, NEW ENGL J MED, V378, P1018, DOI 10.1056/NEJMoa1700175; de Nijs L, 2012, HUM MOL GENET, V21, P5106, DOI 10.1093/hmg/dds356; Gelfman S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00141-2; Jeong A, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0708-8; Kim Ji Hyun, 2017, J Epilepsy Res, V7, P77, DOI 10.14581/jer.17013; Pedley, 1997, EPILEPSY COMPREHENSI, P2389; Santos BR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173695; Striano P, 2017, EXPERT OPIN PHARMACO, V18, P187, DOI 10.1080/14656566.2017.1280459; Suzuki T, 2004, NAT GENET, V36, P842, DOI 10.1038/ng1393; Syvertsen M, 2017, EPILEPSIA, V58, P105, DOI 10.1111/epi.13613; Wu D, 2012, J BIOL CHEM, V287, P12510, DOI 10.1074/jbc.M111.302117	12	5	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2018	17	6					493	495		10.1016/S1474-4422(18)30173-X	http://dx.doi.org/10.1016/S1474-4422(18)30173-X			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GG1RD	29778354				2022-12-18	WOS:000432463400009
J	Najm, IM				Najm, Imad M.			Mapping brain networks in patients with focal epilepsy	LANCET NEUROLOGY			English	Editorial Material							SURGERY		[Najm, Imad M.] Cleveland Clin, Neurol Inst, Epilepsy Ctr, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Najm, IM (corresponding author), Cleveland Clin, Neurol Inst, Epilepsy Ctr, Cleveland, OH 44195 USA.	najmi@ccf.org	Najm, Imad/R-2143-2019		US National Institutes of Health; Department of Defense; Eisai; Sunovion	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Eisai(Eisai Co Ltd); Sunovion	I have received grants from the US National Institutes of Health and Department of Defense and personal fees from Eisai and Sunovion.	Grinenko O, 2018, BRAIN, V141, P117, DOI 10.1093/brain/awx306; Jehi L, 2015, LANCET NEUROL, V14, P283, DOI 10.1016/S1474-4422(14)70325-4; Lim JS, 2015, NAT MED, V21, P395, DOI 10.1038/nm.3824; McIntosh AM, 2012, EPILEPSIA, V53, P970, DOI 10.1111/j.1528-1167.2012.03430.x; Najm I, 2013, EPILEPSIA, V54, P772, DOI 10.1111/epi.12152; Spencer DD, 2018, LANCET NEUROL, V17, P373, DOI 10.1016/S1474-4422(18)30031-0; WHO, 2005, ATL EP CAR WORLD 200; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501	8	5	5	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2018	17	4					295	297		10.1016/S1474-4422(18)30090-5	http://dx.doi.org/10.1016/S1474-4422(18)30090-5			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FZ3AO	29553374				2022-12-18	WOS:000427458000006
J	Edvinsson, L				Edvinsson, Lars			Headache advances in 2017: a new horizon in migraine therapy	LANCET NEUROLOGY			English	Editorial Material							ERENUMAB		[Edvinsson, Lars] Lund Univ, Expt Vasc Res, Div Med, S-22184 Lund, Sweden	Lund University	Edvinsson, L (corresponding author), Lund Univ, Expt Vasc Res, Div Med, S-22184 Lund, Sweden.	lars.edvinsson@med.lu.se		Edvinsson, Lars/0000-0002-1805-1346	Lundbeck Foundation [R59-2010-5404] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		Ashina M, 2017, NEUROLOGY, V89, P1237, DOI 10.1212/WNL.0000000000004391; Cohen JM, 2017, HEADACHE, V57, P1375, DOI 10.1111/head.13156; Edvinsson L, 2019, CEPHALALGIA, V39, P366, DOI 10.1177/0333102417736900; Goadsby PJ, 2017, PHYSIOL REV, V97, P553, DOI 10.1152/physrev.00034.2015; Tepper S, 2017, LANCET NEUROL, V16, P425, DOI 10.1016/S1474-4422(17)30083-2; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2	6	5	6	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2018	17	1					5	6		10.1016/S1474-4422(17)30415-5	http://dx.doi.org/10.1016/S1474-4422(17)30415-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ7VE	29263007				2022-12-18	WOS:000418570500004
J	Hardy, J				Hardy, John			Neurodegeneration: the first mechanistic therapy and other progress in 2017	LANCET NEUROLOGY			English	Editorial Material							SPINAL MUSCULAR-ATROPHY; ALZHEIMERS-DISEASE; ONSET		[Hardy, John] UCL Inst Neurol, Reta Lila Weston Res Labs, London WC1N 3BG, England; [Hardy, John] UCL Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Hardy, J (corresponding author), UCL Inst Neurol, Reta Lila Weston Res Labs, London WC1N 3BG, England.; Hardy, J (corresponding author), UCL Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England.	j.hardy@ucl.ac.uk	Hardy, John/C-2451-2009	Hardy, John/0000-0002-3122-0423				Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277; Byrne LM, 2017, LANCET NEUROL, V16, P601, DOI 10.1016/S1474-4422(17)30124-2; Finkel RS, 2017, NEW ENGL J MED, V377, P1723, DOI 10.1056/NEJMoa1702752; Fitzpatrick AWP, 2017, NATURE, V547, P185, DOI 10.1038/nature23002; Gremer L, 2017, SCIENCE, V358, P116, DOI 10.1126/science.aao2825; Huang KL, 2017, NAT NEUROSCI, V20, P1052, DOI 10.1038/nn.4587; Liscovitch-Brauer N, 2017, CELL, V169, P191, DOI 10.1016/j.cell.2017.03.025; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Qiang W, 2017, NATURE, V541, P217, DOI 10.1038/nature20814; Rasmussen J, 2017, PRION, V11, P215, DOI 10.1080/19336896.2017.1334029; Weston PSJ, 2017, NEUROLOGY, V89, P2167, DOI 10.1212/WNL.0000000000004667	11	5	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2018	17	1					3	5		10.1016/S1474-4422(17)30414-3	http://dx.doi.org/10.1016/S1474-4422(17)30414-3			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ7VE	29263004	Green Submitted			2022-12-18	WOS:000418570500003
J	Wang, YL; Wang, YJ				Wang, Yilong; Wang, Yongjun			Stroke research in 2017: surgical progress and stem-cell advances	LANCET NEUROLOGY			English	Editorial Material							ACUTE ISCHEMIC-STROKE; FORAMEN OVALE CLOSURE; TRIAL; EFFICACY; THERAPY; SAFETY		[Wang, Yongjun] Capital Med Univ, Beijing TianTan Hosp, Dept Neurol, Beijing 100050, Peoples R China; China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China; Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China	Capital Medical University	Wang, YJ (corresponding author), Capital Med Univ, Beijing TianTan Hosp, Dept Neurol, Beijing 100050, Peoples R China.	yongjunwang1962@gmail.com	wangwangwang, yuanyaun/HHN-6432-2022					Davalos A, 2017, LANCET NEUROL, V16, P369, DOI 10.1016/S1474-4422(17)30047-9; Hanley DF, 2017, LANCET, V389, P603, DOI 10.1016/S0140-6736(16)32410-2; Hess DC, 2017, LANCET NEUROL, V16, P360, DOI 10.1016/S1474-4422(17)30046-7; Jovin TG, 2017, 3 EUR STROK ORG C PR; Lansberg MG, 2017, ANN NEUROL, V81, P849, DOI 10.1002/ana.24953; Mas JL, 2017, N ENGL J MED; Saver JL, 2017, NEW ENGL J MED, V377, P1022, DOI 10.1056/NEJMoa1610057; Sondergaard L, 2017, NEW ENGL J MED, V377, P1033, DOI 10.1056/NEJMoa1707404; van den Berg LA, 2017, NEW ENGL J MED, V376, P1341, DOI 10.1056/NEJMoa1612136	9	5	5	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2018	17	1					2	3		10.1016/S1474-4422(17)30421-0	http://dx.doi.org/10.1016/S1474-4422(17)30421-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FQ7VE	29262997				2022-12-18	WOS:000418570500002
J	Blauwendraat, C; Bandres-Ciga, S; Singleton, AB				Blauwendraat, Cornelis; Bandres-Ciga, Sara; Singleton, Andrew B.			Predicting progression in patients with Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							INITIATIVE PPMI		[Blauwendraat, Cornelis; Bandres-Ciga, Sara; Singleton, Andrew B.] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; [Blauwendraat, Cornelis] NINDS, Neurodegenerat Dis Res Unit, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Singleton, AB (corresponding author), NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA.	singleta@mail.nih.gov	Singleton, Andrew B/C-3010-2009; Ciga, Sara Bandres/AAA-5036-2020	Bandres Ciga, Sara/0000-0003-0056-1361	Intramural Research Program of the National Institute on Aging, National Institutes of Health, US Department of Health and Human Services [ZO1 AG000949]; NATIONAL INSTITUTE ON AGING [Z01AG000949] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute on Aging, National Institutes of Health, US Department of Health and Human Services; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We declare no competing interests. Our work is supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, which is part of the US Department of Health and Human Services (project number ZO1 AG000949).	Davis MY, 2016, JAMA NEUROL, V73, P1217, DOI 10.1001/jamaneurol.2016.2245; Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340; Kim M, 2017, SCI REP-UK, V7, DOI 10.1038/srep46700; Latourelle JC, 2017, LANCET NEUROL; Marek K, 2011, PROG NEUROBIOL, V95, P629, DOI 10.1016/j.pneurobio.2011.09.005; Nalls MA, 2016, MOVEMENT DISORD, V31, P79, DOI 10.1002/mds.26374; Nalls MA, 2015, LANCET NEUROL, V14, P1002, DOI 10.1016/S1474-4422(15)00178-7; Ravina B, 2012, MOVEMENT DISORD, V27, P1392, DOI 10.1002/mds.25157; Ravina B, 2009, MOVEMENT DISORD, V24, P2081, DOI 10.1002/mds.22690	9	5	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2017	16	11					860	862		10.1016/S1474-4422(17)30331-9	http://dx.doi.org/10.1016/S1474-4422(17)30331-9			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FJ3WM	28958800	Green Accepted			2022-12-18	WOS:000412663200004
J	Minguez-Olaondo, A; Irimia, P; Fruhbeck, G				Minguez-Olaondo, Ane; Irimia, Pablo; Fruhbeck, Gema			Obesity and the nervous system: more questions	LANCET NEUROLOGY			English	Letter							MIGRAINE		[Minguez-Olaondo, Ane; Irimia, Pablo] Clin Univ Navarra, Dept Neurol, Pamplona 31008, Spain; [Fruhbeck, Gema] Clin Univ Navarra, Dept Endocrinol, Pamplona 31008, Spain; [Fruhbeck, Gema] Clin Univ Navarra, Metab Res Lab, Pamplona 31008, Spain; [Fruhbeck, Gema] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBERobn, Madrid, Spain	University of Navarra; University of Navarra; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Instituto de Salud Carlos III	Minguez-Olaondo, A (corresponding author), Clin Univ Navarra, Dept Neurol, Pamplona 31008, Spain.	aneminola@gmail.com		Minguez-Olaondo, Ane/0000-0002-7742-3920	Allergan; Teva Pharmaceuticals	Allergan(AbbVieAllergan); Teva Pharmaceuticals(Teva Pharmaceutical Industries)	Pablo Irimia has received personal fees from Allergan and Teva Pharmaceuticals. The other authors declare no competing interests.	Gelaye B, 2017, NEUROLOGY, V88, P1795, DOI [10.1212/WNL.0000000000003919, 10.1212/wnl.0000000000003919]; Novack V, 2011, CEPHALALGIA, V31, P1336, DOI 10.1177/0333102411413162; O'Brien PD, 2017, LANCET NEUROL, V16, P465, DOI 10.1016/S1474-4422(17)30084-4; Peterlin BL, 2016, HEADACHE, V56, P622, DOI 10.1111/head.12788; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31678-6, 10.1016/S0140-6736(16)31012-1]	5	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2017	16	10					773	773		10.1016/S1474-4422(17)30292-2	http://dx.doi.org/10.1016/S1474-4422(17)30292-2			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FG5PI	28920881	Bronze			2022-12-18	WOS:000410379900012
J	Aarsland, D; Creese, B; Chaudhuri, KR				Aarsland, Dag; Creese, Byron; Chaudhuri, K. Ray			A new tool to identify patients with Parkinson's disease at increased risk of dementia	LANCET NEUROLOGY			English	Editorial Material							COHORT		[Aarsland, Dag] Stavanger Univ Hosp, Dept Old Age Psychiat, Inst Psychiat Psychol & Neurosci, Stavanger, Norway; [Creese, Byron; Chaudhuri, K. Ray] Kings Coll London, Maurice Wohl Clin Neurosci Inst, Dept Basic & Clin Neurosci, London, England	Stavanger University Hospital; University of London; King's College London	Aarsland, D (corresponding author), Stavanger Univ Hosp, Dept Old Age Psychiat, Inst Psychiat Psychol & Neurosci, Stavanger, Norway.	dag.aarsland@kcl.ac.uk	Creese, Byron/AAF-6745-2020	Aarsland, Dag/0000-0001-6314-216X; Ray Chaudhuri, K/0000-0003-2815-0505	Astra-Zeneca; H Lundbeck; Novartis Pharmaceuticals; GE Health; Eisai; Axovant; Wolfson Foundation; Royal Society; National Institute for Health Research (NIHR) Biomedical Research Centre; Maudsley NHS Foundation Trust; King's College London	Astra-Zeneca(AstraZeneca); H Lundbeck(Lundbeck Corporation); Novartis Pharmaceuticals(Novartis); GE Health(General ElectricGE Healthcare); Eisai(Eisai Co Ltd); Axovant; Wolfson Foundation; Royal Society(Royal Society of London); National Institute for Health Research (NIHR) Biomedical Research Centre(National Institute for Health Research (NIHR)); Maudsley NHS Foundation Trust; King's College London(General Electric)	DA has received research support or honoraria from Astra-Zeneca, H Lundbeck, Novartis Pharmaceuticals, and GE Health, and is a paid consultant for H Lundbeck, Eisai, and Axovant. DA is a Royal Society Wolfson Research Merit Award Holder and thanks the Wolfson Foundation and the Royal Society for their support. This Comment represents independent research [part] funded by the National Institute for Health Research (NIHR) Biomedical Research Centre, Maudsley NHS Foundation Trust, and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. BC and KRC declare no competing interests.	Aarsland D, 2017, NAT REV NEUROL, V13, P217, DOI 10.1038/nrneurol.2017.27; Desikan RS, 2015, MOL PSYCHIATR, V20, P1588, DOI 10.1038/mp.2015.6; Evans JR, 2011, J NEUROL NEUROSUR PS, V82, P1112, DOI 10.1136/jnnp.2011.240366; Ffytche DH, 2017, NAT REV NEUROL, V13, P81, DOI 10.1038/nrneurol.2016.200; Liu G, 2017, LANCET NEUROL; Titova N, MOV DISORD IN PRESS; Williams-Gray CH, 2009, BRAIN, V132, P2958, DOI 10.1093/brain/awp245; Williams-Gray CH, 2009, J NEUROL, V256, P493, DOI 10.1007/s00415-009-0119-8	8	5	6	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2017	16	8					576	578		10.1016/S1474-4422(17)30170-9	http://dx.doi.org/10.1016/S1474-4422(17)30170-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FA1LP	28629880				2022-12-18	WOS:000405201300005
J	Lingsma, HF; Cnossen, MC				Lingsma, Hester F.; Cnossen, Maryse C.			Identification of patients at risk for poor outcome after mTBI	LANCET NEUROLOGY			English	Editorial Material							POST-CONCUSSION SYNDROME; TRAUMATIC BRAIN-INJURY; MILD		[Lingsma, Hester F.; Cnossen, Maryse C.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Lingsma, HF (corresponding author), Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, NL-3000 CA Rotterdam, Netherlands.	h.lingsma@erasmusmc.nl						Carroll L, 2014, BRAIN INJURY, V28, P729; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cnossen MC, 2017, J NEUROTRAUM, V34, P2396, DOI 10.1089/neu.2016.4819; Foks KA, 2017, J NEUROTRAUM, V34, P2529, DOI 10.1089/neu.2016.4919; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Marshall CM, 2015, PHYSICIAN SPORTSMED, V43, P274, DOI 10.1080/00913847.2015.1064301; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5	9	5	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2017	16	7					494	495		10.1016/S1474-4422(17)30171-0	http://dx.doi.org/10.1016/S1474-4422(17)30171-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EX4MH	28653640				2022-12-18	WOS:000403208400005
J	George, S; Brundin, P				George, Sonia; Brundin, Patrik			Solving the conundrum of insoluble protein aggregates	LANCET NEUROLOGY			English	Editorial Material							DISEASES		[George, Sonia; Brundin, Patrik] Van Andel Res Inst, Ctr Neurodegenerat Sci, Grand Rapids, MI 49503 USA	Van Andel Institute	Brundin, P (corresponding author), Van Andel Res Inst, Ctr Neurodegenerat Sci, Grand Rapids, MI 49503 USA.	patrik.brundin@vai.org			Capital Technologies Inc; Roche; H Lundbeck A/S; AbbVie Inc; NeuroDerm; Appollo Biologics LP; Renovo Neural Inc; Teva Pharmaceuticals; ParkCell AB; AcouSort AB	Capital Technologies Inc; Roche(Roche Holding); H Lundbeck A/S; AbbVie Inc(AbbVie); NeuroDerm; Appollo Biologics LP; Renovo Neural Inc; Teva Pharmaceuticals(Teva Pharmaceutical Industries); ParkCell AB(HOGANAS ABStatisticon AB); AcouSort AB(HOGANAS ABStatisticon AB)	PD reports personal fees from Capital Technologies Inc, personal fees and non-financial support from Roche, H Lundbeck A/S, AbbVie Inc, NeuroDerm, and Appollo Biologics LP, personal fees and other from Renovo Neural Inc, and other from Teva Pharmaceuticals, ParkCell AB, and AcouSort AB, outside the submitted work. SG declares no competing interests.	Bliederhaeuser C, 2016, ACTA NEUROPATHOL, V131, P379, DOI 10.1007/s00401-015-1504-2; Chin-Chan M, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00124; Ciechanover A, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.117; Goedert M, 2010, TRENDS NEUROSCI, V33, P317, DOI 10.1016/j.tins.2010.04.003; Jin SG, 2016, CELL REP, V14, P493, DOI 10.1016/j.celrep.2015.12.044; Kalinderi K, 2016, ACTA NEUROL SCAND, V134, P314, DOI 10.1111/ane.12563; Kaufman SK, 2016, NEURON, V92, P796, DOI 10.1016/j.neuron.2016.09.055; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Soreq L, 2017, CELL REP, V18, P557, DOI 10.1016/j.celrep.2016.12.011; Stopschinski BE, 2017, LANCET NEUROLOGY; Valastyan JS, 2014, DIS MODEL MECH, V7, P9, DOI 10.1242/dmm.013474	11	5	6	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2017	16	4					258	259		10.1016/S1474-4422(17)30045-5	http://dx.doi.org/10.1016/S1474-4422(17)30045-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EN9RF	28238710				2022-12-18	WOS:000396336600006
J	Padua, L; Coraci, D; Erra, C; Pazzaglia, C; Paolasso, I; Loreti, C; Caliandro, P; Hobson-Webb, LD				Padua, Luca; Coraci, Daniele; Erra, Carmen; Pazzaglia, Costanza; Paolasso, Ilaria; Loreti, Claudia; Caliandro, Pietro; Hobson-Webb, Lisa D.			Diagnosis and treatment of carpal tunnel syndrome Response	LANCET NEUROLOGY			English	Letter									[Padua, Luca; Erra, Carmen] Univ Cattolica Sacro Cuore, Dept Geriatr Neurosci & Orthopaed, Rome, Italy; [Padua, Luca; Coraci, Daniele; Pazzaglia, Costanza; Paolasso, Ilaria; Loreti, Claudia] Don Carlo Gnocchi Onlus Fdn, Milan, Italy; [Coraci, Daniele] Sapienza Univ, Board Phys Med & Rehabil, Dept Orthopaed Sci, Rome, Italy; [Caliandro, Pietro] Policlin A Gemelli Fdn Univ Hosp, Inst Neurol, Rome, Italy; [Hobson-Webb, Lisa D.] Duke Univ, Dept Neurol, Durham, NC USA	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Fondazione Don Carlo Gnocchi Onlus; Sapienza University Rome; Catholic University of the Sacred Heart; Duke University	Padua, L (corresponding author), Univ Cattolica Sacro Cuore, Dept Geriatr Neurosci & Orthopaed, Rome, Italy.; Padua, L (corresponding author), Don Carlo Gnocchi Onlus Fdn, Milan, Italy.	luca.padua@unicatt.it	Loreti, Claudia/AAZ-3089-2020; Padua, Luca/K-5398-2016; Loreti, Claudia/N-9236-2017; Caliandro, Pietro/AAC-5096-2022	Loreti, Claudia/0000-0002-0835-4079; Padua, Luca/0000-0003-2570-9326; Loreti, Claudia/0000-0002-0835-4079; Caliandro, Pietro/0000-0002-1190-4879				American Academy of Orthopaedic Surgeons, 2016, MAN CARP TUNN SYNDR; Maslow AH, 1966, PSYCHOL SCI RECONNAI; Padua L, 2016, LANCET NEUROL, V15, P1271, DOI 10.1016/S1474-4422(16)30231-9	3	5	5	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2017	16	4					263	264		10.1016/S1474-4422(17)30058-3	http://dx.doi.org/10.1016/S1474-4422(17)30058-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EN9RF	28327333	Bronze			2022-12-18	WOS:000396336600014
J	Thomson, JG				Thomson, J. Grant			Diagnosis and treatment of carpal tunnel syndrome	LANCET NEUROLOGY			English	Letter									[Thomson, J. Grant] Yale Sch Med, Sect Plast Surg, New Haven, CT 06520 USA	Yale University	Thomson, JG (corresponding author), Yale Sch Med, Sect Plast Surg, New Haven, CT 06520 USA.	grant.thomson@yale.edu						American Academy of Orthopaedic Surgeons, 2016, MAN CARP TUNN SYNDR; Lane LB, 2014, J HAND SURG-AM, V39, P2181, DOI 10.1016/j.jhsa.2014.07.019; Padua L, 2016, LANCET NEUROL, V15, P1271, DOI 10.1016/S1474-4422(16)30231-9; Roberts Charles Stewart, 2010, Proc (Bayl Univ Med Cent), V23, P377; Sears ED, 2016, J HAND SURG-AM, V41, P665, DOI 10.1016/j.jhsa.2016.03.002	5	5	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2017	16	4					263	263		10.1016/S1474-4422(17)30059-5	http://dx.doi.org/10.1016/S1474-4422(17)30059-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EN9RF	28327334	Bronze			2022-12-18	WOS:000396336600013
J	Morelli, N; Rota, E; Michieletti, E; Guidetti, D				Morelli, Nicola; Rota, Eugenia; Michieletti, Emanuele; Guidetti, Donata			Mechanical thrombectomy after intravenous thrombolysis for acute ischaemic stroke	LANCET NEUROLOGY			English	Letter									[Morelli, Nicola; Rota, Eugenia; Guidetti, Donata] Guglielmo da Saliceto Hosp, Neurol Unit, Piacenza, Italy; [Morelli, Nicola; Michieletti, Emanuele] Guglielmo da Saliceto Hosp, Radiol Unit, Via Taverna 49, I-29121 Piacenza, Italy	Guglielmo da Saliceto Hospital; Guglielmo da Saliceto Hospital	Morelli, N (corresponding author), Guglielmo da Saliceto Hosp, Neurol Unit, Piacenza, Italy.; Morelli, N (corresponding author), Guglielmo da Saliceto Hosp, Radiol Unit, Via Taverna 49, I-29121 Piacenza, Italy.	nicola.morelli.md@gmail.com	Morelli, Nicola/AAN-7876-2020	Morelli, Nicola/0000-0003-3787-2243				Badhiwala JH, 2015, JAMA-J AM MED ASSOC, V314, P1832, DOI 10.1001/jama.2015.13767; Bracard S, 2016, LANCET NEUROL, V15, P1138, DOI 10.1016/S1474-4422(16)30177-6; Demchuk AM, 2012, ANN NY ACAD SCI, V1268, P63, DOI 10.1111/j.1749-6632.2012.06732.x; Jia BX, 2016, EXPERT REV NEUROTHER, V16, P515, DOI 10.1586/14737175.2016.1165094; Whitesell RT, 2014, EMERG RADIOL, V21, P271, DOI 10.1007/s10140-014-1210-8	5	5	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2017	16	2					103	104		10.1016/S1474-4422(16)30379-9	http://dx.doi.org/10.1016/S1474-4422(16)30379-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EH6VA	28102144	Bronze			2022-12-18	WOS:000391910800007
J	Majbour, N; El-Agnaf, O				Majbour, Nour; El-Agnaf, Omar			Cognitive impairment in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							ALPHA-SYNUCLEIN; PROGRESSION		[Majbour, Nour; El-Agnaf, Omar] Hamad Bin Khalifa Univ, Qatar Fdn, Neurol Disorders Res Ctr, Qatar Biomed Res Inst, POB 5825, Doha, Qatar; [El-Agnaf, Omar] Hamad Bin Khalifa Univ, Qatar Fdn, Div Life Sci, Coll Sci & Engn, POB 5825, Doha, Qatar	Qatar Foundation (QF); Hamad Bin Khalifa University-Qatar; Qatar Biomedical Research Institute (QBRI); Qatar Foundation (QF); Hamad Bin Khalifa University-Qatar	El-Agnaf, O (corresponding author), Hamad Bin Khalifa Univ, Qatar Fdn, Neurol Disorders Res Ctr, Qatar Biomed Res Inst, POB 5825, Doha, Qatar.; El-Agnaf, O (corresponding author), Hamad Bin Khalifa Univ, Qatar Fdn, Div Life Sci, Coll Sci & Engn, POB 5825, Doha, Qatar.	oelagnaf@qf.org.qa		Majbour, Nour/0000-0002-7544-8497				Goldman JG, 2011, MINERVA MED, V102, P441; Hu MTM, 2014, MOVEMENT DISORD, V29, P351, DOI 10.1002/mds.25748; Janvin CC, 2006, MOVEMENT DISORD, V21, P1343, DOI 10.1002/mds.20974; Majbour NK, 2016, MOVEMENT DISORD, V31, P1535, DOI 10.1002/mds.26754; Majbour NK, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0072-9; Parnetti L, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00053; Pigott K, 2015, NEUROLOGY, V85, P1276, DOI 10.1212/WNL.0000000000002001; Schrag A, 2000, J NEUROL NEUROSUR PS, V69, P308, DOI 10.1136/jnnp.69.3.308; Schrag A., 2016, LANCET NEUROL	9	5	6	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2017	16	1					23	24		10.1016/s1474-4422(16)30329-5	http://dx.doi.org/10.1016/s1474-4422(16)30329-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EE8IP	27866857				2022-12-18	WOS:000389869200015
J	Olsson, B; Blennow, K; Zetterberg, H				Olsson, Bob; Blennow, Kaj; Zetterberg, Henrik			The clinical value of fluid biomarkers for dementia diagnosis reply	LANCET NEUROLOGY			English	Letter							ALZHEIMERS-DISEASE; CSF		[Olsson, Bob; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Dept Psychiat & Neurochem, Sahlgrenska Acad, Molndal, Sweden	University of Gothenburg	Olsson, B (corresponding author), Univ Gothenburg, Dept Psychiat & Neurochem, Sahlgrenska Acad, Molndal, Sweden.	bob.olsson@neuro.gu.se		Olsson, Bob/0000-0002-6368-6172				Blennow K, 2015, TRENDS PHARMACOL SCI, V36, P297, DOI 10.1016/j.tips.2015.03.002; Bocchetta M, 2015, ALZHEIMERS DEMENT, V11, P195, DOI 10.1016/j.jalz.2014.06.006; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Lehmann S, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt267; Mattsson N, 2013, ALZHEIMERS DEMENT, V9, P251, DOI 10.1016/j.jalz.2013.01.010; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/S1474-4422(16)00070-3, 10.1016/s1474-4422(16)00070-3]; Palmqvist S, 2015, NEUROLOGY, V85, P1240, DOI 10.1212/WNL.0000000000001991; Ritchie C, 2014, COCHRANE DB SYST REV, V10	8	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2016	15	12					1204	1205		10.1016/S1474-4422(16)30247-2	http://dx.doi.org/10.1016/S1474-4422(16)30247-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EA0YO	27751544				2022-12-18	WOS:000386315700012
J	Di Perri, C; Thibaut, A; Heine, L; Annen, J; Laureys, S				Di Perri, Carol; Thibaut, Aurore; Heine, Lizette; Annen, Jitka; Laureys, Steven			Towards new methods of diagnosis in disorders of consciousness reply	LANCET NEUROLOGY			English	Letter									[Di Perri, Carol; Thibaut, Aurore; Heine, Lizette; Annen, Jitka; Laureys, Steven] Quartier Hop, GIGA ULg B34, Coma Sci Grp, Sart Tilman Par Liege, Belgium		Di Perri, C (corresponding author), Quartier Hop, GIGA ULg B34, Coma Sci Grp, Sart Tilman Par Liege, Belgium.	diperric@gmail.com; steven.laureys@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011; Annen, Jitka/ABH-5297-2020; Thibaut, Aurore/U-8101-2019	Laureys, Steven/0000-0002-3096-3807; Annen, Jitka/0000-0002-7459-4345; Di Perri, Carol/0000-0003-0284-770X; Heine, Lizette/0000-0003-1369-8199				Bruno MA, 2011, J NEUROL, V258, P1373, DOI 10.1007/s00415-011-6114-x; Di Perri C, 2016, LANCET NEUROL, V15, P830, DOI 10.1016/S1474-4422(16)00111-3; Di Perri C, 2014, EPILEPSY BEHAV, V30, P28, DOI 10.1016/j.yebeh.2013.09.014; Gosseries O, 2014, BRAIN INJURY, V28, P1141, DOI 10.3109/02699052.2014.920522	4	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2016	15	11					1115	1116		10.1016/S1474-4422(16)30205-8	http://dx.doi.org/10.1016/S1474-4422(16)30205-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DX3MJ	27647636	Bronze			2022-12-18	WOS:000384276900010
J	[Anonymous]				[Anonymous]			Worldwide collaboration in the Microbleeds International Collaborative Network	LANCET NEUROLOGY			English	Letter															Grants-in-Aid for Scientific Research [15K10364] Funding Source: KAKEN; Stroke Association [TSABHF2009/01] Funding Source: researchfish	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Stroke Association		Charidimou A, LANCET NEUROL; De Guio F, 2016, J CEREBR BLOOD F MET, V36, P1319, DOI 10.1177/0271678X16647396; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8; Werring DJ, 2016, STROKE, V47, pE176, DOI 10.1161/STROKEAHA.116.013530; Wilson DCA, 2016, NEUROLOGY IN PRESS	6	5	5	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2016	15	11					1113	1114		10.1016/S1474-4422(16)30213-7	http://dx.doi.org/10.1016/S1474-4422(16)30213-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DX3MJ	27647634	Bronze, Green Submitted			2022-12-18	WOS:000384276900008
J	Silver, B				Silver, Brian			Virtual reality versus reality in post-stroke rehabilitation	LANCET NEUROLOGY			English	Editorial Material							CONSTRAINT-INDUCED MOVEMENT; STROKE; THERAPY; TRIAL		[Silver, Brian] Rhode Isl Hosp, Providence, RI 02903 USA	Lifespan Health Rhode Island; Rhode Island Hospital	Silver, B (corresponding author), Rhode Isl Hosp, Providence, RI 02903 USA.	Brian_Silver@brown.edu	Silver, Brian/A-2204-2010					Bernhardt J, 2015, LANCET, V386, P46, DOI 10.1016/S0140-6736(15)60690-0; Dromerick AW, 2009, NEUROLOGY, V73, P195, DOI 10.1212/WNL.0b013e3181ab2b27; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Lo AC, 2010, NEW ENGL J MED, V362, P1772, DOI 10.1056/NEJMoa0911341; Lohse KR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093318; Saposnik G, 2016, LANCET NEUROL; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	7	5	5	1	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2016	15	10					996	997		10.1016/S1474-4422(16)30126-0	http://dx.doi.org/10.1016/S1474-4422(16)30126-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1ZJ	27365260				2022-12-18	WOS:000381280300002
J	Nelson, PT				Nelson, Peter T.			Cerebrovascular pathology and Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material							RECOMMENDATIONS; BRAIN		[Nelson, Peter T.] Univ Kentucky, Lexington, KY 40536 USA	University of Kentucky	Nelson, PT (corresponding author), Univ Kentucky, Lexington, KY 40536 USA.	pnels2@email.uky.edu			NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR014189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG042419, P30AG028383] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG042419, P30 AG028383] Funding Source: Medline; NINR NIH HHS [R01 NR014189] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Abner E.L, 2016, ALZHEIMERS DEMENT; Arvanitakis Z, 2016, LANCET NEUROL; Ighodaro ET, 2016, J CEREB BLOOD FLOW M; Jack CR, 2016, NAT REV NEUROL, V12, P117, DOI 10.1038/nrneurol.2015.251; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Knopman DS, 2013, ANN NEUROL, V73, P472, DOI 10.1002/ana.23816; Marchant NL, 2013, JAMA NEUROL, V70, P488, DOI 10.1001/2013.jamaneurol.405; Naylor MD, 2012, ALZHEIMERS DEMENT, V8, P445, DOI 10.1016/j.jalz.2012.08.001; Nelson PT, 2007, J NEUROPATH EXP NEUR, V66, P1136, DOI 10.1097/nen.0b013e31815c5efb; Nelson PT, 2011, ACTA NEUROPATHOL, V121, P571, DOI 10.1007/s00401-011-0826-y; Schneider JA, 2009, J ALZHEIMERS DIS, V18, P691, DOI 10.3233/JAD-2009-1227	11	5	5	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2016	15	9					895	896		10.1016/S1474-4422(16)30038-2	http://dx.doi.org/10.1016/S1474-4422(16)30038-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT1YY	27312739	Green Accepted			2022-12-18	WOS:000381279200004
J	Fernandez, F; Edgin, JO				Fernandez, Fabian; Edgin, Jamie O.			Pharmacotherapy in Down's syndrome: which way forward?	LANCET NEUROLOGY			English	Editorial Material							BEHAVIOR; ADULTS		[Fernandez, Fabian] Univ Arizona, Life Sci North, Dept Psychol, Room 349,1501 N Campbell Ave, Tucson, AZ 85724 USA; [Fernandez, Fabian] Univ Arizona, Life Sci North, Dept Neurol, Room 349,1501 N Campbell Ave, Tucson, AZ 85724 USA; [Fernandez, Fabian] Univ Arizona, Life Sci North, Inst BIO5, Room 349,1501 N Campbell Ave, Tucson, AZ 85724 USA; [Fernandez, Fabian] Univ Arizona, Life Sci North, Evelyn F McKnight Brain Inst, Room 349,1501 N Campbell Ave, Tucson, AZ 85724 USA; [Edgin, Jamie O.] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA; [Edgin, Jamie O.] Univ Arizona, Sonoran Univ Ctr Excellence Dev Disabil, Tucson, AZ USA	University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Fernandez, F (corresponding author), Univ Arizona, Life Sci North, Dept Psychol, Room 349,1501 N Campbell Ave, Tucson, AZ 85724 USA.; Fernandez, F (corresponding author), Univ Arizona, Life Sci North, Dept Neurol, Room 349,1501 N Campbell Ave, Tucson, AZ 85724 USA.; Fernandez, F (corresponding author), Univ Arizona, Life Sci North, Inst BIO5, Room 349,1501 N Campbell Ave, Tucson, AZ 85724 USA.; Fernandez, F (corresponding author), Univ Arizona, Life Sci North, Evelyn F McKnight Brain Inst, Room 349,1501 N Campbell Ave, Tucson, AZ 85724 USA.	FabianF@email.arizona.edu		Fernandez, Fabian-Xose/0000-0002-4288-5383	Bill & Melinda Gates Foundation � Grand Challenges Explorations Initiative [OPP1119381] Funding Source: researchfish	Bill & Melinda Gates Foundation � Grand Challenges Explorations Initiative		Ball SL, 2008, BRIT J CLIN PSYCHOL, V47, P1, DOI 10.1348/014466507X230967; Boada R, 2012, TRANSL PSYCHIAT, V2012, P2; Breslin J, 2014, DEV MED CHILD NEUROL, V56, P657, DOI 10.1111/dmcn.12376; Catuara-Solarz S, 2015, FRONT BEHAV NEUROSCI, V9, DOI [10.3389/fnbeh.7015.00330, 10.3389/fnbeh.2015.00330]; De la Torre R, 2014, MOL NUTR FOOD RES, V58, P278, DOI 10.1002/mnfr.201300325; de Sola S, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00708; Delabar Jean-Maurice, 1993, European Journal of Human Genetics, V1, P114; Devenny DA, 2002, J INTELL DISABIL RES, V46, P472, DOI 10.1046/j.1365-2788.2002.00417.x; Farre M, 2016, LANCET NEUROL; Fernandez F, 2015, HANDB EXP PHARMACOL, V228, P335, DOI 10.1007/978-3-319-16522-6_12; Karmiloff-Smith Annette, 2016, F1000Res, V5, DOI 10.12688/f1000research.7506.1; Pujol J, 2015, CORTEX, V64, P148, DOI 10.1016/j.cortex.2014.10.012	12	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2016	15	8					776	777		10.1016/S1474-4422(16)30056-4	http://dx.doi.org/10.1016/S1474-4422(16)30056-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DO1NR	27302343				2022-12-18	WOS:000377545800002
J	[Anonymous]				[Anonymous]			Finding a cure for Alzheimer's disease starts with prevention	LANCET NEUROLOGY			English	Editorial Material																			0	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2016	15	7					649	649		10.1016/S1474-4422(16)30047-3	http://dx.doi.org/10.1016/S1474-4422(16)30047-3			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DM7OG	27302221	Bronze			2022-12-18	WOS:000376549300001
J	Baron, R; Binder, A				Baron, Ralf; Binder, Andreas			Fighting neuropathic pain with botulinum toxin A	LANCET NEUROLOGY			English	Editorial Material									[Baron, Ralf; Binder, Andreas] Univ Kiel, Dept Neurol, Div Neurol Pain Res & Therapy, D-24105 Kiel, Germany	University of Kiel	Baron, R (corresponding author), Univ Kiel, Dept Neurol, Div Neurol Pain Res & Therapy, D-24105 Kiel, Germany.	r.baron@neurologie.uni-kiel.de						Attal N, 2016, LANCET NEUROL, V15, P555, DOI 10.1016/S1474-4422(16)00017-X; Baron R, 2012, LANCET NEUROL, V11, P999, DOI 10.1016/S1474-4422(12)70189-8; Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5; BRIN MF, 1987, MOVEMENT DISORD, V2, P237, DOI 10.1002/mds.870020402; Carmichael NME, 2010, PAIN, V149, P316, DOI 10.1016/j.pain.2010.02.024; Carroll I, 2011, PAIN MED, V12, P1094, DOI 10.1111/j.1526-4637.2011.01135.x; Demant DT, 2014, PAIN, V155, P2263, DOI 10.1016/j.pain.2014.08.014; Maier C, 2010, PAIN, V150, P439, DOI 10.1016/j.pain.2010.05.002; Marinelli S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047977; Pellett S, 2015, TOXINS, V7, P4519, DOI 10.3390/toxins7114519; Verderio C, 2012, BIOL CELL, V104, P213, DOI 10.1111/boc.201100070	11	5	8	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2016	15	6					534	+		10.1016/S1474-4422(16)00056-9	http://dx.doi.org/10.1016/S1474-4422(16)00056-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI9PW	26947718				2022-12-18	WOS:000373835900002
J	Kieburtz, K				Kieburtz, Karl			Treating neurodegenerative disease before illness: a challenge for the 21st century	LANCET NEUROLOGY			English	Editorial Material									[Kieburtz, Karl] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Kieburtz, K (corresponding author), Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA.	karl.kieburtz@chet.rochester.edu						Biglan KM, 2016, JAMA NEUROL, V73, P102, DOI 10.1001/jamaneurol.2015.2736; Salat D., 2016, LANCET NEUROL	2	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2016	15	6					540	541		10.1016/S1474-4422(16)30001-1	http://dx.doi.org/10.1016/S1474-4422(16)30001-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI9PW	27013350				2022-12-18	WOS:000373835900006
J	Gorelick, PB				Gorelick, Philip B.			Adaptation of neurological practice and policy to a changing US health-care landscape	LANCET NEUROLOGY			English	Review							EVIDENCE-BASED MEDICINE; COST-CONSCIOUS CARE; ACADEMIC NEUROLOGY; PATIENT EXPERIENCE; POPULATION HEALTH; ISCHEMIC-STROKE; ASSOCIATION; PHYSICIANS; MEDICARE; QUALITY	Health care in the USA is undergoing a drastic transformation under the Patient Protection and Affordable Care Act. The Patient Protection and Affordable Care Act is driving major health-care policy changes by connecting payment for traditional health-care services to value-based care initiatives and emphasising population health and innovative mechanisms to deliver care. Under the Patient Protection and Affordable Care Act, neurological practice will need to adapt and transform. Therefore, neurological policy should consider employing a new framework for neurological residency training, developing interdisciplinary team approaches to neurological subspecialty care, and strengthening the primary care-neurological specialty care interface to avoid redundancies and other medical waste. Additionally, neurological policy will need to support a more robust review of diagnostic and care pathway use to reduce avoidable expenditures, and test and implement bundled payments for key neurological diagnoses. In view of an anticipated 19% shortage of US neurologists in the next 10 years, development of new neurological policy under the Patient Protection and Affordable Care Act is paramount.	[Gorelick, Philip B.] Michigan State Univ, Translat Sci & Mol Med, Coll Human Med, Mercy Hlth Hauenstein Neurosci Ctr, Grand Rapids, MI 49503 USA	Michigan State University; Michigan State University College of Human Medicine	Gorelick, PB (corresponding author), Michigan State Univ, Translat Sci & Mol Med, Coll Human Med, Mercy Hlth Hauenstein Neurosci Ctr, Grand Rapids, MI 49503 USA.	pgorelic@mercyhealth.com						ABIM Foundation, CHOOS WIS; Adornato BT, 2011, NEUROLOGY, V77, P1921, DOI 10.1212/WNL.0b013e318238ee13; Agrawal S, 2013, JAMA-J AM MED ASSOC, V309, P1115, DOI 10.1001/jama.2013.1013; Aronson L, 2015, JAMA-J AM MED ASSOC, V313, P797, DOI 10.1001/jama.2014.18174; Baicker K, 2013, NEW ENGL J MED, V368, P1713, DOI 10.1056/NEJMsa1212321; BAILEY P, 1951, NEUROLOGY, V1, P1; Baker DW, 2013, ANN INTERN MED, V158, P55, DOI 10.7326/0003-4819-158-1-201301010-00560; Barnes KA, 2012, NEW ENGL J MED, V367, P891, DOI 10.1056/NEJMp1204487; Bettger JP, 2012, ANN INTERN MED, V157, P407, DOI 10.7326/0003-4819-157-6-201209180-00004; Blue Ridge Institute for Medical Research, TOP 10 NIH FUND CLIN; Blumenthal D, 2015, NEW ENGL J MED, V372, P2451, DOI 10.1056/NEJMhpr1503614; Blumenthal D, 2015, NEW ENGL J MED, V372, P671, DOI 10.1056/NEJMhpr1414856; Braithwaite RS, 2013, JAMA-J AM MED ASSOC, V310, P2149, DOI 10.1001/jama.2013.281996; Brock J, 2013, JAMA-J AM MED ASSOC, V309, P381, DOI 10.1001/jama.2012.216607; Brotherton Sarah E, 2015, JAMA, V314, P2436, DOI 10.1001/jama.2015.10473; Burke JF, 2014, NEUROLOGY, V82, P2196, DOI 10.1212/WNL.0000000000000514; Burke JF, 2013, ANN NEUROL, V73, P679, DOI 10.1002/ana.23865; Burke JF, 2012, ANN NEUROL, V71, P179, DOI 10.1002/ana.22698; Burwell SM, 2015, NEW ENGL J MED, V372, P897, DOI 10.1056/NEJMp1500445; Caplan LR, 2001, J NEUROL NEUROSUR PS, V71, P569, DOI 10.1136/jnnp.71.5.569; Colla CH, 2012, JAMA-J AM MED ASSOC, V308, P1015, DOI 10.1001/2012.jama.10812; Dall TM, 2013, NEUROLOGY, V81, P470, DOI 10.1212/WNL.0b013e318294b1cf; Detsky AS, 2012, JAMA-J AM MED ASSOC, V307, P464; Eggleston EM, 2014, JAMA-J AM MED ASSOC, V311, P797, DOI 10.1001/jama.2014.163; Emanuel E, 2012, NEW ENGL J MED, V367, P949, DOI 10.1056/NEJMsb1205901; Faulkner LR, 2010, NEUROLOGY, V75, P1110, DOI 10.1212/WNL.0b013e3181f39a41; Freeman WD, 2013, NEUROLOGY, V81, P479, DOI 10.1212/WNL.0b013e31829d8783; Friedberg MW, 2014, JAMA-J AM MED ASSOC, V311, P815, DOI 10.1001/jama.2014.353; Fuchs VR, 2014, JAMA-J AM MED ASSOC, V312, P2095, DOI 10.1001/jama.2014.14114; Ganguli I, 2015, JAMA-J AM MED ASSOC, V313, P1905, DOI 10.1001/jama.2015.3356; Gold D, 2015, JAMA NEUROL, V72, P623, DOI 10.1001/jamaneurol.2015.0083; Gorelick PB, 2015, EXPERT REV CARDIOVAS, V13, P49, DOI 10.1586/14779072.2015.987128; Gorelick PB, 2013, NEUROHOSPITALIST, V3, P117, DOI 10.1177/1941874413482132; Graber ML, 2012, JAMA-J AM MED ASSOC, V308, P1211, DOI 10.1001/2012.jama.11913; Grumbach K, 2014, JAMA-J AM MED ASSOC, V311, P1109, DOI 10.1001/jama.2014.705; Halfon N, 2013, NEW ENGL J MED, V368, P1569, DOI 10.1056/NEJMp1215897; Holloway RG, 2011, ANN NEUROL, V69, P909, DOI 10.1002/ana.22439; Hong CS, 2014, NEW ENGL J MED, V371, P491, DOI 10.1056/NEJMp1401755; Hussey PS, 2013, ANN INTERN MED, V158, P27, DOI 10.7326/0003-4819-158-1-201301010-00006; Jones EC, 2010, NEUROLOGY, V75, pS52, DOI 10.1212/WNL.0b013e3181fc2861; Judson TJ, 2013, JAMA-J AM MED ASSOC, V309, P2325, DOI 10.1001/jama.2013.5797; Kassler WJ, 2015, NEW ENGL J MED, V372, P109, DOI 10.1056/NEJMp1406838; Korenstein D, 2012, ARCH INTERN MED, V172, P171, DOI 10.1001/archinternmed.2011.772; Lakhan SE, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00171; Lee GM, 2012, NEW ENGL J MED, V367, P1428, DOI 10.1056/NEJMsa1202419; Lee TH, 2012, NEW ENGL J MED, V367, P466, DOI 10.1056/NEJMhpr1204386; Manary MP, 2013, NEW ENGL J MED, V368, P201, DOI 10.1056/NEJMp1211775; Marvasti FF, 2012, NEW ENGL J MED, V367, P889, DOI 10.1056/NEJMp1206230; Matchar DB, 2015, STROKE, V46, P1414, DOI 10.1161/STROKEAHA.115.009089; McWilliams JM, 2015, NEW ENGL J MED, V372, P1927, DOI 10.1056/NEJMsa1414929; Mehrotra A, 2015, JAMA-J AM MED ASSOC, V313, P1907, DOI 10.1001/jama.2015.3359; Miyata H, 2015, LANCET, V385, P2549, DOI 10.1016/S0140-6736(15)61135-7; Mobley W, 2012, ARCH NEUROL-CHICAGO, V69, P308, DOI 10.1001/archneurol.2011.1858; Montori VM, 2013, JAMA-J AM MED ASSOC, V310, P2503, DOI 10.1001/jama.2013.281422; Noble DJ, 2013, JAMA-J AM MED ASSOC, V309, P1119, DOI 10.1001/jama.2013.592; Novelli WD, 2012, JAMA-J AM MED ASSOC, V308, P1531, DOI 10.1001/jama.2012.13369; Nyweide DJ, 2015, JAMA-J AM MED ASSOC, V313, P2152, DOI 10.1001/jama.2015.4930; Palen TE, 2012, JAMA-J AM MED ASSOC, V308, P2012, DOI 10.1001/jama.2012.14126; Porter ME, 2015, NEW ENGL J MED, V372, P1681, DOI 10.1056/NEJMp1502419; Powers BW, 2015, JAMA-J AM MED ASSOC, V313, P795, DOI 10.1001/jama.2014.18171; Pronovost PJ, 2013, JAMA-J AM MED ASSOC, V310, P2501, DOI 10.1001/jama.2013.281334; Pronovost PJ, 2012, JAMA-J AM MED ASSOC, V308, P769, DOI 10.1001/jama.2012.9537; Rajkumar R, 2015, NEW ENGL J MED, V372, P1981, DOI 10.1056/NEJMp1501951; Ringel SP, 2015, NEUROLOGY, V84, P2086, DOI 10.1212/WNL.0000000000001589; Rosenwald G., 1992, STORIED LIVES CULTUR, P1; Shortell SM, 2013, JAMA-J AM MED ASSOC, V309, P1121, DOI 10.1001/jama.2013.887; Smith CD, 2012, ANN INTERN MED, V157, P284, DOI 10.7326/0003-4819-157-4-201208210-00496; Sniderman AD, 2013, MAYO CLIN PROC, V88, P1108, DOI 10.1016/j.mayocp.2013.07.012; Taksler GB, 2013, ANN INTERN MED, V159, P161, DOI 10.7326/0003-4819-159-3-201308060-00005; Turner M, 2015, STROKE, V46, P1065, DOI 10.1161/STROKEAHA.114.007608; Verma AA, 2014, JAMA-J AM MED ASSOC, V311, P571, DOI 10.1001/jama.2013.285245; Vespa PM, 2011, NEUROLOGY, V77, P1702, DOI 10.1212/WNL.0b013e3182364918; Wartman Steven A, 2015, Pharos Alpha Omega Alpha Honor Med Soc, V78, P2; White A, 2013, JAMA-J AM MED ASSOC, V309, P2327, DOI 10.1001/jama.2013.6030	74	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	4					444	450		10.1016/S1474-4422(16)00020-X	http://dx.doi.org/10.1016/S1474-4422(16)00020-X			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG3MP	26971663				2022-12-18	WOS:000371974000023
J	Quaglio, G; Brand, H; Dario, C				Quaglio, Gianluca; Brand, Helmut; Dario, Claudio			Fighting dementia in Europe: the time to act is now	LANCET NEUROLOGY			English	Editorial Material									[Quaglio, Gianluca] European Parliament, European Parliamentary Res Serv, Sci Foresight Unit, Rue Wiertz 60, B-1047 Brussels, Belgium; [Brand, Helmut] Maastricht Univ, Dept Int Hlth, NL-6200 MD Maastricht, Netherlands; [Brand, Helmut] Maastricht Univ, CAPHRI, Sch Publ Hlth & Primary Care, NL-6200 MD Maastricht, Netherlands; [Dario, Claudio] Local Hlth Author 16, Padua, Italy	Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC)	Quaglio, G (corresponding author), European Parliament, European Parliamentary Res Serv, Sci Foresight Unit, Rue Wiertz 60, B-1047 Brussels, Belgium.	gianluca.quaglio@europarl.europa.eu	Brand, Helmut/F-6368-2013	Brand, Helmut/0000-0002-2755-0673				[Anonymous], 1978, Br Med J, V1, P1; Brownson RC, 2006, AM J PREV MED, V30, P164, DOI 10.1016/j.amepre.2005.10.004; Davis P, 1996, SOC SCI MED, V43, P865, DOI 10.1016/0277-9536(96)00130-X; European Commission, DG RES INN RES FIN R; O'Connor C, 2012, NEURON, V74, P220, DOI 10.1016/j.neuron.2012.04.004; Oliver TR, 2006, ANNU REV PUBL HEALTH, V27, P195, DOI 10.1146/annurev.publhealth.25.101802.123126; Quaglio G, 2015, LANCET NEUROL, V14, P243, DOI 10.1016/S1474-4422(15)70014-1; Rabesandratana T., 2013, MANIFESTO URGES BREA; Winblad B, 2016, LANCET NEUROL, V15, P455, DOI 10.1016/S1474-4422(16)00062-4	9	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2016	15	5					452	454		10.1016/S1474-4422(16)00079-X	http://dx.doi.org/10.1016/S1474-4422(16)00079-X			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG8IU	26987700				2022-12-18	WOS:000372328100002
J	Saidha, S; Calabresi, PA				Saidha, Shiv; Calabresi, Peter A.			Phenytoin in acute optic neuritis: neuroprotective or not?	LANCET NEUROLOGY			English	Editorial Material							MULTIPLE-SCLEROSIS; PATHOLOGY		[Saidha, Shiv; Calabresi, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurol, Div Neuroimmunol & Neurol Infect, Baltimore, MD 21287 USA	Johns Hopkins University	Saidha, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Div Neuroimmunol & Neurol Infect, Baltimore, MD 21287 USA.	ssaidha2@jhmi.edu	Calabresi, Peter A./AAF-2288-2019; Saidha, Shiv/S-1771-2019	Saidha, Shiv/0000-0001-6387-0714; Calabresi, Peter/0000-0002-7776-6472				Balcer LJ, 2006, NEW ENGL J MED, V354, P1273, DOI 10.1056/NEJMcp053247; Bhargava P, 2015, MULT SCLER INT, V2015, DOI 10.1155/2015/136295; IKUTA F, 1976, NEUROLOGY, V26, P26, DOI 10.1212/WNL.26.6_Part_2.26; Raftopoulos R, 2016, LANCET NEURAL; Saidha S, 2011, MULT SCLER J, V17, P1449, DOI 10.1177/1352458511418630; Saidha S, 2011, BRAIN, V134, P518, DOI 10.1093/brain/awq346; Syc SB, 2012, BRAIN, V135, P521, DOI 10.1093/brain/awr264	7	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2016	15	3					233	235		10.1016/S1474-4422(16)00024-7	http://dx.doi.org/10.1016/S1474-4422(16)00024-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DE1ON	26822743				2022-12-18	WOS:000370396400003
J	Ng, YS; Gorman, GS; Turnbull, DM; Martikainen, MH				Ng, Yi Shiau; Gorman, Grainne S.; Turnbull, Doug M.; Martikainen, Mika H.			The diagnosis of posterior reversible encephalopathy syndrome	LANCET NEUROLOGY			English	Letter							MITOCHONDRIAL DISEASE		[Ng, Yi Shiau; Gorman, Grainne S.; Turnbull, Doug M.; Martikainen, Mika H.] Newcastle Univ, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Ng, YS (corresponding author), Newcastle Univ, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	mika.martikainen@ncl.ac.uk	Ng, Yi Shiau/AFF-1445-2022	Ng, Yi Shiau/0000-0002-7591-2034; Turnbull, Doug/0000-0002-8878-9901; Gorman, Grainne/0000-0002-7585-3409	MRC [MR/L016354/1] Funding Source: UKRI; Medical Research Council [MR/L016354/1] Funding Source: Medline; Wellcome Trust [096919] Funding Source: Medline; National Institute for Health Research [NF-SI-0510-10187] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); National Institute for Health Research(National Institute for Health Research (NIHR))		Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007; Fugate JE, 2015, LANCET NEUROL, V14, P914, DOI 10.1016/S1474-4422(15)00111-8; Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362; Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3; McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2; Rabinstein AA, 2012, J STROKE CEREBROVASC, V21, P254, DOI 10.1016/j.jstrokecerebrovasdis.2011.03.011	6	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2015	14	11					1073	1073		10.1016/S1474-4422(15)00253-7	http://dx.doi.org/10.1016/S1474-4422(15)00253-7			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT7DY	26466774	Bronze			2022-12-18	WOS:000362975200007
J	Hauser, RA				Hauser, Robert A.			alpha-Synuclein in Parkinson's disease: getting to the core of the matter	LANCET NEUROLOGY			English	Editorial Material							PATHOLOGY		[Hauser, Robert A.] Univ S Florida, Parkinsons Dis & Movement Disorders Ctr, Natl Parkinson Fdn Ctr Excellence, Dept Neurol, Tampa, FL 33613 USA; [Hauser, Robert A.] Univ S Florida, Parkinsons Dis & Movement Disorders Ctr, Natl Parkinson Fdn Ctr Excellence, Dept Mol Pharmacol, Tampa, FL 33613 USA; [Hauser, Robert A.] Univ S Florida, Parkinsons Dis & Movement Disorders Ctr, Natl Parkinson Fdn Ctr Excellence, Dept Physiol, Tampa, FL 33613 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Hauser, RA (corresponding author), Univ S Florida, Parkinsons Dis & Movement Disorders Ctr, Natl Parkinson Fdn Ctr Excellence, Dept Neurol, Tampa, FL 33613 USA.	rhauser@health.usf.edu						Bekris LM, 2010, J GERIATR PSYCH NEUR, V23, P228, DOI 10.1177/0891988710383572; Berg D, 2012, MOVEMENT DISORD, V27, P656, DOI 10.1002/mds.24985; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; DEHAY B, 2015, LANCET NEUROL; Kordower JH, 2008, NAT MED, V14, P504, DOI 10.1038/nm1747; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Recasens A, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00159; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166	9	5	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2015	14	8					785	786		10.1016/S1474-4422(15)00136-2	http://dx.doi.org/10.1016/S1474-4422(15)00136-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CM7MZ	26116313				2022-12-18	WOS:000357879200005
J	Bruce, DG				Bruce, David G.			Type 2 diabetes and cognitive function: many questions, few answers	LANCET NEUROLOGY			English	Editorial Material									Univ Western Australia, Fremantle Hosp, Sch Med & Pharmacol, Fremantle, WA 6959, Australia	University of Western Australia	Bruce, DG (corresponding author), Univ Western Australia, Fremantle Hosp, Sch Med & Pharmacol, Fremantle, WA 6959, Australia.	David.bruce@uwa.edu.au	Bruce, David G/H-8900-2014	Bruce, David/0000-0002-9979-6867				Akbaraly TN, 2010, DIABETES CARE, V33, P84, DOI 10.2337/dc09-1218; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Bruce DG, 2009, DIABETOLOGIA, V52, P1808, DOI 10.1007/s00125-009-1437-1; Bruce DG, 2014, AM J GERIAT PSYCHIAT, DOI [10.1016/i.jagp.2014.09.010, DOI 10.1016/I.JAGP.2014.09.010]; Davis WA, 2010, EUR J ENDOCRINOL, V163, P559, DOI 10.1530/EJE-10-0474; Gow AJ, 2011, PSYCHOL AGING, V26, P232, DOI 10.1037/a0021072; Koekkoek PS, 2015, LANCET NEUROL, V14, P329, DOI 10.1016/S1474-4422(14)70249-2; Lindenberger U, 2014, SCIENCE, V346, P572, DOI 10.1126/science.1254403; Paradise MB, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-108; Sjoblom P, 2008, DIABETES RES CLIN PR, V82, P197, DOI 10.1016/j.diabres.2008.08.014; Twig G, 2014, DIABETES CARE, V37, P2982, DOI 10.2337/dc14-0715	11	5	7	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2015	14	3					241	243		10.1016/S1474-4422(14)70299-6	http://dx.doi.org/10.1016/S1474-4422(14)70299-6			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4JM	25728433				2022-12-18	WOS:000349594000006
J	Singleton, A				Singleton, Andrew			A new gene for Parkinson's disease: should we care?	LANCET NEUROLOGY			English	Editorial Material							DROSOPHILA-PINK1; INTERACTS		NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Singleton, A (corresponding author), NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA.	singleta@mail.nih.gov	Singleton, Andrew B/C-3010-2009					Beilina A, 2014, P NATL ACAD SCI USA, V111, P2626, DOI 10.1073/pnas.1318306111; Burchell VS, 2013, NAT NEUROSCI, V16, P1257, DOI 10.1038/nn.3489; Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779; Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2; MacLeod DA, 2013, NEURON, V77, P425, DOI 10.1016/j.neuron.2012.11.033; Nalls MA, 2014, NAT GENET, V46, P989, DOI 10.1038/ng.3043; Novarino G, 2014, SCIENCE, V343, P506, DOI 10.1126/science.1247363; Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788	8	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2015	14	3					239	240		10.1016/S1474-4422(14)70270-4	http://dx.doi.org/10.1016/S1474-4422(14)70270-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4JM	25728432				2022-12-18	WOS:000349594000004
J	Levine, SR				Levine, Steven R.			Covering all the bases to improve acute stroke care	LANCET NEUROLOGY			English	Editorial Material									[Levine, Steven R.] Suny Downstate Med Ctr, Dept Neurol, Coll Med, Stroke Ctr, Brooklyn, NY 11203 USA; [Levine, Steven R.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Levine, SR (corresponding author), Suny Downstate Med Ctr, Dept Neurol, Coll Med, Stroke Ctr, 450 Clarkson Ave,MSC 1213, Brooklyn, NY 11203 USA.	steven.levine@downstate.edu						Brott T, 1997, STROKE, V28, P1530, DOI 10.1161/01.STR.28.8.1530; Emberson J, 2014, LANCET; Fonarow GC, 2010, CIRC-CARDIOVASC QUAL, V3, P291, DOI 10.1161/CIRCOUTCOMES.109.921858; Grossman AW, 2013, ANN NEUROL, V74, P363, DOI 10.1002/ana.23993; Kleindorfer DO, 2013, STROKE, V44, P949, DOI 10.1161/STROKEAHA.111.000560; Schwamm LH, 2009, CIRCULATION, V119, P107, DOI 10.1161/CIRCULATIONAHA.108.783688; Tilley BC, 1997, ARCH NEUROL-CHICAGO, V54, P1466, DOI 10.1001/archneur.1997.00550240020008; Willeit J, 2014, LANCET NEUROL	8	5	5	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2015	14	1					25	27		10.1016/S1474-4422(14)70302-3	http://dx.doi.org/10.1016/S1474-4422(14)70302-3			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AX4DZ	25435130				2022-12-18	WOS:000346885300015
J	Hoffman, E				Hoffman, Eric			A rebirth for drisapersen in Duchenne muscular dystrophy?	LANCET NEUROLOGY			English	Editorial Material							MDX MICE; MORPHOLINO; RESTORATION; EXPRESSION; DOGS		Childrens Natl Med Ctr, Med Genet Res Ctr, Washington, DC 20010 USA	Children's National Health System	Hoffman, E (corresponding author), Childrens Natl Med Ctr, Med Genet Res Ctr, 111 Michigan Ave NW, Washington, DC 20010 USA.	ehoffman@cnmcresearch.org		Hoffman, Eric/0000-0001-6470-5139				Cirak S, 2011, LANCET, V378, P595, DOI 10.1016/S0140-6736(11)60756-3; Garralda ME, 2013, CHILD CARE HLTH DEV, V39, P449, DOI 10.1111/j.1365-2214.2012.01387.x; Goemans N, 2013, WORLD MUSCL SOC C AS; Goemans NM, 2011, N ENGL J MED; Goyenvalle A, 2010, MOL THER, V18, P198, DOI 10.1038/mt.2009.248; Jirka SMG, 2014, NUCLEIC ACID THER, V24, P25, DOI 10.1089/nat.2013.0448; Kinali M, 2009, LANCET NEUROL, V8, P918, DOI 10.1016/S1474-4422(09)70211-X; Mendell JR, 2013, ANN NEUROL, V74, P637, DOI 10.1002/ana.23982; Voit T, 2014, LANCET NEUROL; Wu B, 2012, AM J PATHOL, V181, P392, DOI 10.1016/j.ajpath.2012.04.006; Yokota T, 2012, NUCLEIC ACID THER, V22, P306, DOI 10.1089/nat.2012.0368; Yokota T, 2009, ANN NEUROL, V65, P667, DOI 10.1002/ana.21627	12	5	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2014	13	10					963	965		10.1016/S1474-4422(14)70158-9	http://dx.doi.org/10.1016/S1474-4422(14)70158-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AP3EZ	25209737				2022-12-18	WOS:000341959700003
J	Pearce, N; Gallo, V; McElvenny, D				Pearce, Neil; Gallo, Valentina; McElvenny, Damien			Sports-related head trauma and neurodegenerative disease	LANCET NEUROLOGY			English	Letter									[Pearce, Neil] London Sch Hyg & Trop Med, Ctr Global NCDs, London WC1E 7HT, England; [Pearce, Neil] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; [Gallo, Valentina] Queen Mary Univ London, London, England; [McElvenny, Damien] Inst Occupat Med, Edinburgh EH8 9SV, Midlothian, Scotland	University of London; London School of Hygiene & Tropical Medicine; Massey University; University of London; Queen Mary University London	Pearce, N (corresponding author), London Sch Hyg & Trop Med, Ctr Global NCDs, London WC1E 7HT, England.	neil.pearce@lshtm.ac.uk	Gallo, Valentina/X-1139-2018	Gallo, Valentina/0000-0002-1268-8629; Pearce, Neil/0000-0002-9938-7852				Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Harris MA, 2013, OCCUP ENVIRON MED, V70, P839, DOI 10.1136/oemed-2013-101444; Jones SAV, 2014, BRIT J SPORT MED, V48, P159, DOI 10.1136/bjsports-2013-092758; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mielke MM, 2014, NEUROLOGY, V82, P70, DOI 10.1212/01.wnl.0000438229.56094.54	6	5	5	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2014	13	10					969	970		10.1016/S1474-4422(14)70146-2	http://dx.doi.org/10.1016/S1474-4422(14)70146-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AP3EZ	25231519				2022-12-18	WOS:000341959700009
J	Albanese, A				Albanese, Alberto			Deep brain stimulation for cervical dystonia	LANCET NEUROLOGY			English	Editorial Material							TRIAL		Univ Cattolica Sacro Cuore, Ist Neurol Carlo Besta, I-20133 Milan, Italy	Catholic University of the Sacred Heart; IRCCS Istituto Neurologico Besta	Albanese, A (corresponding author), Univ Cattolica Sacro Cuore, Ist Neurol Carlo Besta, I-20133 Milan, Italy.	alberto.albanese@unicatt.it	Albanese, Alberto/K-7396-2016	Albanese, Alberto/0000-0002-5864-0006				Albanese A, 2011, EUR J NEUROL, V18, P5, DOI 10.1111/j.1468-1331.2010.03042.x; Albanese A, 2013, MOVEMENT DISORD, V28, P863, DOI 10.1002/mds.25475; Camfield L, 2002, MOVEMENT DISORD, V17, P838, DOI 10.1002/mds.10127; Chou KL, 2005, MOVEMENT DISORD, V20, P377, DOI 10.1002/mds.20341; Coubes P, 2000, LANCET, V355, P2220, DOI 10.1016/S0140-6736(00)02410-7; Defazio Giovanni, 2013, Tremor Other Hyperkinet Mov (N Y), V3, DOI 10.7916/D80C4TGJ; Hung SW, 2007, NEUROLOGY, V68, P457, DOI 10.1212/01.wnl.0000252932.71306.89; Kiss ZHT, 2007, BRAIN, V130, P2879, DOI 10.1093/brain/awm229; Misra VP, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000881; Pollak Pierre, 2013, Handb Clin Neurol, V116, P97, DOI 10.1016/B978-0-444-53497-2.00009-7; Quartarone A, 2013, MOVEMENT DISORD, V28, P958, DOI 10.1002/mds.25532; Schjerling L, 2013, J NEUROSURG, V119, P1537, DOI 10.3171/2013.8.JNS13844; Vidailhet M, 2013, J NEUROL NEUROSUR PS, V84, P1029, DOI 10.1136/jnnp-2011-301714; Volkmann J, 2014, LANCET NEUROL, V13, P875, DOI 10.1016/S1474-4422(14)70143-7; Walsh RA, 2013, BRAIN, V136, P761, DOI 10.1093/brain/awt009	15	5	9	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2014	13	9					856	857		10.1016/S1474-4422(14)70178-4	http://dx.doi.org/10.1016/S1474-4422(14)70178-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AO5SK	25127234				2022-12-18	WOS:000341405400002
J	Bloem, BR; Munneke, M				Bloem, Bastiaan R.; Munneke, Marten			Evidence or clinical implementation: which should come first?	LANCET NEUROLOGY			English	Letter							RANDOMIZED CONTROLLED-TRIAL; PARKINSONS-DISEASE		[Bloem, Bastiaan R.; Munneke, Marten] Radboud Univ Nijmegen, Med Ctr, Dept Neurol 935, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Bloem, BR (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol 935, POB 9101, NL-6500 HB Nijmegen, Netherlands.	bas.bloem@radboudumc.nl	Munneke, Marten/N-3583-2014; Bloem, Bastiaan/H-8013-2014	Bloem, Bastiaan/0000-0002-6371-3337				[Anonymous], 2014, LANCET NEUROL, V13, P525; Bloem BR, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1838; Munneke M, 2010, LANCET NEUROL, V9, P46, DOI 10.1016/S1474-4422(09)70327-8; Sturkenboom IHWM, 2014, LANCET NEUROL, V13, P557, DOI 10.1016/S1474-4422(14)70055-9; van der Marck MA, 2013, LANCET NEUROL, V12, P947, DOI 10.1016/S1474-4422(13)70196-0; van Nimwegen M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f576	6	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2014	13	7					649	649		10.1016/S1474-4422(14)70118-8	http://dx.doi.org/10.1016/S1474-4422(14)70118-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AK5RI	24943340				2022-12-18	WOS:000338483600011
J	Sorensen, PS				Sorensen, Per Soelberg			Effects of fingolimod in relapsing-remitting multiple sclerosis Comment	LANCET NEUROLOGY			English	Editorial Material							PLACEBO-CONTROLLED PHASE-3; ORAL FINGOLIMOD; TRIAL; INTERFERON; BG-12		Rigshosp, Dept Neurol, Danish Multiple Sclerosis Ctr, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Sorensen, PS (corresponding author), Rigshosp, Dept Neurol, Danish Multiple Sclerosis Ctr, DK-2100 Copenhagen, Denmark.	pss@rh.dk		Sorensen, Per Soelberg/0000-0002-2818-3780				Calabresi PA, 2014, LANCET NEUROLOGY; Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Sorensen PS, 2012, MULT SCLER J, V18, P143, DOI 10.1177/1352458511435105; Uitdehaag BMJ, 2011, CURR MED RES OPIN, V27, P1529, DOI 10.1185/03007995.2011.591370	8	5	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2014	13	6					526	527		10.1016/S1474-4422(14)70067-5	http://dx.doi.org/10.1016/S1474-4422(14)70067-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI8YK	24685277				2022-12-18	WOS:000337212700002
J	Arnold, C				Arnold, Carrie			Concussions in women	LANCET NEUROLOGY			English	Editorial Material												carrierobin@gmail.com							0	5	6	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2014	13	2					136	137		10.1016/S1474-4422(13)70287-4	http://dx.doi.org/10.1016/S1474-4422(13)70287-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	301QE	24332917	Bronze			2022-12-18	WOS:000330546200008
J	Kiernan, MC				Kiernan, Matthew C.			ALS and neuromuscular disease: in search of the Holy Grail	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS		Univ Sydney, Brain & Mind Res Inst, Sydney, NSW 2050, Australia	University of Sydney	Kiernan, MC (corresponding author), Univ Sydney, Brain & Mind Res Inst, Sydney, NSW 2050, Australia.	matthew.kiernan@sydney.edu.au	Kiernan, Matthew C/E-4460-2011	Kiernan, Matthew/0000-0001-9054-026X				Cudkowicz ME, 2013, LANCET NEUROL, V12, P1059, DOI 10.1016/S1474-4422(13)70221-7; Donnelly CJ, 2013, NEURON, V80, P415, DOI 10.1016/j.neuron.2013.10.015; Huisman MHB, 2013, J NEUROL NEUROSUR PS, V84, P976, DOI 10.1136/jnnp-2012-304724; Ricotti V, 2013, J NEUROL NEUROSUR PS, V84, P698, DOI 10.1136/jnnp-2012-303902; Stagg CJ, 2013, NEUROLOGY, V80, P610, DOI 10.1212/WNL.0b013e318281ccec; Turner MR, 2013, LANCET NEUROL, V12, P310, DOI 10.1016/S1474-4422(13)70036-X	6	5	5	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2014	13	1					13	14		10.1016/S1474-4422(13)70226-6	http://dx.doi.org/10.1016/S1474-4422(13)70226-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	280AL	24331786				2022-12-18	WOS:000329000900008
J	Waubant, E; Cross, A				Waubant, Emmanuelle; Cross, Anne			MS and related disorders: groundbreaking news	LANCET NEUROLOGY			English	Editorial Material							OLIGODENDROCYTE PROGENITOR CELLS		[Waubant, Emmanuelle] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Cross, Anne] Washington Univ, St Louis, MO USA	University of California System; University of California San Francisco; Washington University (WUSTL)	Waubant, E (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	emmanuelle.waubant@ucsf.edu		Cross, Anne/0000-0003-0829-7569				Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770; Chataway J, 2012, MULT SCLER J, V18, P509; Kleinewietfeld M, 2013, NATURE, V496, P518, DOI 10.1038/nature11868; Najm FJ, 2013, NAT BIOTECHNOL, V31, P426, DOI 10.1038/nbt.2561; Pittock SJ, 2013, LANCET NEUROL, V12, P554, DOI 10.1016/S1474-4422(13)70076-0; Wang S, 2013, CELL STEM CELL, V12, P252, DOI 10.1016/j.stem.2012.12.002; Yosef N, 2013, NATURE, V496, P461, DOI 10.1038/nature11981	7	5	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2014	13	1					11	13		10.1016/S1474-4422(13)70284-9	http://dx.doi.org/10.1016/S1474-4422(13)70284-9			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	280AL	24331785				2022-12-18	WOS:000329000900007
J	Fagan, AM; Vos, SJB				Fagan, Anne M.; Vos, Stephanie J. B.			Preclinical Alzheimer's disease criteria	LANCET NEUROLOGY			English	Letter									[Fagan, Anne M.] Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, Dept Neurol, St Louis, MO 63110 USA; [Vos, Stephanie J. B.] Maastricht Univ, Sch Mental Hlth & Neurosci, Alzheimer Ctr Limburg, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands	Washington University (WUSTL); Maastricht University	Fagan, AM (corresponding author), Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, Dept Neurol, St Louis, MO 63110 USA.	fagana@neuro.wustl.edu; s.vos@maastrichtuniversity.nl			NIA NIH HHS [P01 AG026276, P50 AG005681] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG005681, P01AG026276] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Knopman DS, 2012, NEUROLOGY, V78, P1576, DOI 10.1212/WNL.0b013e3182563bbe; Petersen RC, 2013, LANCET NEUROL, V12, P933, DOI 10.1016/S1474-4422(13)70217-5; Vos SJB, 2013, LANCET NEUROL, V12, P957, DOI 10.1016/S1474-4422(13)70194-7	3	5	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2013	12	12					1134	1134		10.1016/S1474-4422(13)70222-9	http://dx.doi.org/10.1016/S1474-4422(13)70222-9			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	265BG	24025450	Green Accepted			2022-12-18	WOS:000327924100008
J	Acosta, MT				Acosta, Maria T.			Challenges of cognitive research in neurofibromatosis type 1	LANCET NEUROLOGY			English	Editorial Material							MOUSE MODEL; LOVASTATIN; DEFICITS		George Washington Univ, Childrens Natl Med Ctr, Dept Neurol & Pediat, Neurofibromatosis Inst, Washington, DC 20052 USA	Children's National Health System; George Washington University	Acosta, MT (corresponding author), George Washington Univ, Childrens Natl Med Ctr, Dept Neurol & Pediat, Neurofibromatosis Inst, Washington, DC 20052 USA.	macosta@childrensnational.org						Acosta MT, 2011, PEDIATR NEUROL, V45, P241, DOI 10.1016/j.pediatrneurol.2011.06.016; Chabernaud C, 2012, NEUROSCI LETT, V515, P28, DOI 10.1016/j.neulet.2012.03.009; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; Krab LC, 2008, JAMA-J AM MED ASSOC, V300, P287, DOI 10.1001/jama.300.3.287; Li WD, 2005, CURR BIOL, V15, P1961, DOI 10.1016/j.cub.2005.09.043; van der Vaart T, 2013, LANCET NEUROL, V12, P1076, DOI 10.1016/S1474-4422(13)70227-8	6	5	5	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2013	12	11					1040	1041		10.1016/S1474-4422(13)70179-0	http://dx.doi.org/10.1016/S1474-4422(13)70179-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	239ZC	24107290				2022-12-18	WOS:000326063500005
J	Wexler, NS				Wexler, Nancy S.			Three decades of caring for the Venezuelan Huntington's disease families	LANCET NEUROLOGY			English	Letter									[Wexler, Nancy S.] Hereditary Dis Fdn, New York, NY 10032 USA; [Wexler, Nancy S.] Columbia Univ, Dept Neurol, New York State Psychiat Inst, New York, NY USA; [Wexler, Nancy S.] Columbia Univ, Dept Psychiat, New York State Psychiat Inst, New York, NY USA	Columbia University; New York State Psychiatry Institute; Columbia University; New York State Psychiatry Institute	Wexler, NS (corresponding author), Hereditary Dis Fdn, New York, NY 10032 USA.	wexlern@nyspi.columbia.edu							0	5	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2013	12	8					738	738		10.1016/S1474-4422(13)70170-4	http://dx.doi.org/10.1016/S1474-4422(13)70170-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	195GP	23867196				2022-12-18	WOS:000322690600012
J	Rudick, RA; Cutter, G				Rudick, Richard A.; Cutter, Gary			MRI lesions: a surrogate for relapses in multiple sclerosis?	LANCET NEUROLOGY			English	Editorial Material									[Rudick, Richard A.] Cleveland Clin, Neurol Inst, Mellen Ctr, Cleveland, OH 44195 USA; [Cutter, Gary] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA	Cleveland Clinic Foundation; University of Alabama System; University of Alabama Birmingham	Rudick, RA (corresponding author), Cleveland Clin, Neurol Inst, Mellen Ctr, Cleveland, OH 44195 USA.	rubickr@ccf.org	Cutter, Gary/AAY-5392-2021	Cutter, Gary/0000-0002-8455-980X				Fisher E, 2008, ANN NEUROL, V64, P255, DOI 10.1002/ana.21436; Hauser SL, 2012, ANN NEUROL, V71, pA5, DOI 10.1002/ana.23608; Lublin FD, 2001, ANN NEUROL, V49, P677, DOI 10.1002/ana.1025; Petkau J, 2008, MULT SCLER J, V14, P770, DOI 10.1177/1352458507088104; Sormani MP, 2009, ANN NEUROL, V65, P268, DOI 10.1002/ana.21606; Sormani MP, 2013, LANCET NEUROL	6	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2013	12	7					628	630		10.1016/S1474-4422(13)70108-X	http://dx.doi.org/10.1016/S1474-4422(13)70108-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	172CH	23743083				2022-12-18	WOS:000320977100005
J	[Anonymous]				[Anonymous]			Disparities in stroke: not just black and white	LANCET NEUROLOGY			English	Editorial Material																			0	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2013	12	7					623	623		10.1016/S1474-4422(13)70137-6	http://dx.doi.org/10.1016/S1474-4422(13)70137-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	172CH	23769593				2022-12-18	WOS:000320977100001
J	Deuschl, G				Deuschl, Guenther			New hope for severe essential tremor?	LANCET NEUROLOGY			English	Editorial Material							GAMMA-KNIFE THALAMOTOMY		Univ Kiel, Dept Neurol, Univ Hosp Schleswig Holstein, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Deuschl, G (corresponding author), Univ Kiel, Dept Neurol, Univ Hosp Schleswig Holstein, Kiel Campus, D-24105 Kiel, Germany.	g.deuschl@neurologie.uni-kiel.de	Deuschl, Gunther/A-7986-2010	Deuschl, Gunther/0000-0002-4176-9196				Alvarez L, 2001, MOVEMENT DISORD, V16, P72, DOI 10.1002/1531-8257(200101)16:1<72::AID-MDS1019>3.0.CO;2-6; Deuschl G, 2011, LANCET NEUROL, V10, P148, DOI 10.1016/S1474-4422(10)70322-7; Hassler R., 1979, STEREOTAXIS PARKINSO; Jeanmonod D, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2011.10.FOCUS11248; Lipsman N, 2013, LANCET NEUROL, V12, P462, DOI 10.1016/S1474-4422(13)70048-6; Lorenz D, 2011, EUR J NEUROL, V18, P972, DOI 10.1111/j.1468-1331.2010.03295.x; Louis ED, 2005, LANCET NEUROL, V4, P100, DOI 10.1016/S1474-4422(05)00991-9; Louis ED, 2010, MOVEMENT DISORD, V25, P534, DOI 10.1002/mds.22838; Ohye C, 2005, J NEUROSURG, V102, P234, DOI 10.3171/jns.2005.102.s_supplement.0234; Tufail Y, 2010, NEURON, V66, P681, DOI 10.1016/j.neuron.2010.05.008; Young RF, 2010, J NEUROSURG, V112, P1311, DOI 10.3171/2009.10.JNS09332	11	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2013	12	5					420	422		10.1016/S1474-4422(13)70062-0	http://dx.doi.org/10.1016/S1474-4422(13)70062-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	142ZS	23523143				2022-12-18	WOS:000318836700005
J	Holmes, C				Holmes, Clive			Intravenous immunoglobulin for Alzheimer's disease	LANCET NEUROLOGY			English	Editorial Material									Univ Southampton, Moorgreen Hosp, Memory Assessment & Res Ctr, Southampton S030 3JB, Hants, England	University of Southampton	Holmes, C (corresponding author), Univ Southampton, Moorgreen Hosp, Memory Assessment & Res Ctr, Southampton S030 3JB, Hants, England.	ch4@soton.ac.uk						Dodel RC, 2004, J NEUROL NEUROSUR PS, V75, P1472, DOI 10.1136/jnnp.2003.033399; Dodel R, 2013, LANCET NEUROL, V12, P233, DOI 10.1016/S1474-4422(13)70014-0; Farlow M, 2012, ALZHEIMERS DEMENT, V8, P261, DOI 10.1016/j.jalz.2011.09.224; Relkin NR, 2009, NEUROBIOL AGING, V30, P1728, DOI 10.1016/j.neurobiolaging.2007.12.021; Solomon B, 2007, CURR OPIN MOL THER, V9, P79; Vellas B, 2009, CURR ALZHEIMER RES, V6, P144, DOI 10.2174/156720509787602852	6	5	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2013	12	3					218	219		10.1016/S1474-4422(13)70015-2	http://dx.doi.org/10.1016/S1474-4422(13)70015-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	138SW	23375966				2022-12-18	WOS:000318531300002
J	Ratsimbazafy, V; Rakotovao, T; Marin, B; Javerliat, M; Preux, PM				Ratsimbazafy, Voa; Rakotovao, Tanamasoandro; Marin, Benoit; Javerliat, Madeleine; Preux, Pierre-Marie			The dangers of inadequate understanding of epilepsy in Madagascar	LANCET NEUROLOGY			English	Letter							TREATMENT GAP		[Ratsimbazafy, Voa; Rakotovao, Tanamasoandro; Marin, Benoit; Preux, Pierre-Marie] INSERM, UMR1094, Limoges, France; [Ratsimbazafy, Voa; Marin, Benoit; Preux, Pierre-Marie] Univ Limoges, Inst Neuroepidemiol & Trop Neurol, Sch Med, CNRS,FR 3503,GEIST, Limoges, France; [Ratsimbazafy, Voa; Javerliat, Madeleine] Ctr Hosp & Univ Limoges, Federat Plateau Medicotech, Dept Pharm, Limoges, France; [Marin, Benoit; Preux, Pierre-Marie] Ctr Hosp & Univ Limoges, Federat Publ Hlth, Dept Clin Res & Biostat, Limoges, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Franche-Comte; Universite de Limoges; CHU Limoges; CHU Limoges	Ratsimbazafy, V (corresponding author), INSERM, UMR1094, Limoges, France.	voa_ratsimbazafy@yahoo.fr	PREUX, Pierre-Marie/B-8393-2014; Preux, Pierre-Marie/N-3538-2019; MARIN, Benoit/E-2356-2015	PREUX, Pierre-Marie/0000-0002-2171-2977; Preux, Pierre-Marie/0000-0002-2171-2977; MARIN, Benoit/0000-0001-8857-0910				Fallon A, 2012, INDEPENDENT     0611; Mbuba CK, 2008, EPILEPSIA, V49, P1491, DOI 10.1111/j.1528-1167.2008.01693.x; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Preux PM, 2005, LANCET NEUROL, V4, P21, DOI 10.1016/S1474-4422(04)00963-9; Ratsimbazafy V, 2011, TROP DOCT, V41, P38, DOI 10.1258/td.2010.100254	5	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2012	11	9					748	749		10.1016/S1474-4422(12)70186-2	http://dx.doi.org/10.1016/S1474-4422(12)70186-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	994DS	22898731				2022-12-18	WOS:000307911700009
J	Wijdicks, EFM				Wijdicks, Eelco F. M.			Being comatose: why definition matters	LANCET NEUROLOGY			English	Editorial Material									Mayo Clin, Div Crit Care Neurol, Rochester, MN 55905 USA	Mayo Clinic	Wijdicks, EFM (corresponding author), Mayo Clin, Div Crit Care Neurol, Rochester, MN 55905 USA.	wijde@mayo.edu						JENNETT B, 1972, LANCET, V1, P734; Jox RJ, 2012, LANCET NEUROL, V11, P732, DOI 10.1016/S1474-4422(12)70154-0; Wijdicks EFM, 2007, NEUROLOGY, V68, P1092, DOI 10.1212/01.wnl.0000259401.36220.1a; Wijdicks EF, 2008, COMATOSE PATIENT	4	5	5	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	AUG	2012	11	8					657	658		10.1016/S1474-4422(12)70161-8	http://dx.doi.org/10.1016/S1474-4422(12)70161-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	983AX	22814535				2022-12-18	WOS:000307089700005
J	[Anonymous]				[Anonymous]			Colombia at the centre of preclinical AD research	LANCET NEUROLOGY			English	Editorial Material																			0	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2012	11	7					567	567		10.1016/S1474-4422(12)70144-8	http://dx.doi.org/10.1016/S1474-4422(12)70144-8			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	969YN	22710749				2022-12-18	WOS:000306095400001
J	van Schaik, IN				van Schaik, Ivo N.			First-line treatment for CIDP: a new piece of the puzzle	LANCET NEUROLOGY			English	Editorial Material							INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY; INTRAVENOUS IMMUNOGLOBULIN; CONTROLLED TRIAL; POLYNEUROPATHY		Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DD Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	van Schaik, IN (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, POB 22660, NL-1100 DD Amsterdam, Netherlands.	i.n.vanschaik@amc.uva.nl						DYCK PJ, 1982, ANN NEUROL, V11, P136, DOI 10.1002/ana.410110205; Eftimov F, 2009, COCHRANE DB SYST REV, V1; Hughes R, 2001, ANN NEUROL, V50, P195, DOI 10.1002/ana.1088; Hughes RAC, 2008, LANCET NEUROL, V7, P136, DOI 10.1016/S1474-4422(07)70329-0; Latov N, 2010, ARCH NEUROL-CHICAGO, V67, P802, DOI 10.1001/archneurol.2010.105; Lopate G, 2005, ARCH NEUROL-CHICAGO, V62, P249, DOI 10.1001/archneur.62.2.249; Lunn MPT, 1999, J NEUROL NEUROSUR PS, V66, P677, DOI 10.1136/jnnp.66.5.677; Mehndiratta MM, 2002, COCHRANE DB SYST REV, V1; Muley SA, 2008, ARCH NEUROL-CHICAGO, V65, P1460, DOI 10.1001/archneur.65.11.1460; Nobile-Orazio E, 2012, LANCET NEUROL, V11, P493, DOI 10.1016/S1474-4422(12)70093-5; van Schaik IN, 2010, LANCET NEUROL, V9, P245, DOI 10.1016/S1474-4422(10)70021-1	11	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2012	11	6					478	479		10.1016/S1474-4422(12)70101-1	http://dx.doi.org/10.1016/S1474-4422(12)70101-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	952JW	22578913				2022-12-18	WOS:000304789800002
J	[Anonymous]				[Anonymous]			Public health planning for dementia must start now	LANCET NEUROLOGY			English	Editorial Material																			0	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2012	11	6					477	477		10.1016/S1474-4422(12)70120-5	http://dx.doi.org/10.1016/S1474-4422(12)70120-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	952JW	22608659				2022-12-18	WOS:000304789800001
J	Hartings, JA; Strong, AJ; Okonkwo, DO; Bullock, MR				Hartings, Jed A.; Strong, Anthony J.; Okonkwo, David O.; Bullock, M. Ross			Spreading depolarisations and traumatic brain injury: time course and mechanisms Reply	LANCET NEUROLOGY			English	Letter									[Hartings, Jed A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH 45221 USA; [Strong, Anthony J.] Kings Coll London, Dept Clin Neurosci, London WC2R 2LS, England; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA; [Bullock, M. Ross] Univ Miami, Dept Neurol Surg, Miami, FL USA	University System of Ohio; University of Cincinnati; University of London; King's College London; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Miami	Hartings, JA (corresponding author), Univ Cincinnati, Dept Neurosurg, Cincinnati, OH 45221 USA.							Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428	9	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2012	11	5					389	390		10.1016/S1474-4422(12)70085-6	http://dx.doi.org/10.1016/S1474-4422(12)70085-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	930KM					2022-12-18	WOS:000303138300008
J	Tasker, RC				Tasker, Robert C.			Spreading depolarisations and traumatic brain injury: time course and mechanisms	LANCET NEUROLOGY			English	Letter							RECEPTOR ANTAGONIST; DEPRESSION		[Tasker, Robert C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Tasker, Robert C.] Harvard Univ, Sch Med, Dept Anesthesiol Pediat, Boston, MA USA; [Tasker, Robert C.] Childrens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Tasker, RC (corresponding author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.	Robert.tasker@childrens.harvard.edu	Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113				Bakiri Y, 2008, GLIA, V56, P233, DOI 10.1002/glia.20608; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; MCLACHLAN RS, 1992, CAN J NEUROL SCI, V19, P487, DOI 10.1017/S0317167100041688; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; NELLGARD B, 1992, ACTA PHYSIOL SCAND, V146, P497, DOI 10.1111/j.1748-1716.1992.tb09451.x; Obrenovitch TP, 1996, BRIT J PHARMACOL, V117, P931, DOI 10.1111/j.1476-5381.1996.tb15283.x; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806	10	5	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2012	11	5					389	389		10.1016/S1474-4422(12)70084-4	http://dx.doi.org/10.1016/S1474-4422(12)70084-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	930KM	22516073	Bronze			2022-12-18	WOS:000303138300007
J	Andersen, PM				Andersen, Peter M.			Mutation in C9orf72 changes the boundaries of ALS and FTD	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; HEXANUCLEOTIDE REPEAT; EXPANSION		Umea Univ, Dept Clin Neurosci, Umea, Sweden	Umea University	Andersen, PM (corresponding author), Umea Univ, Dept Clin Neurosci, Umea, Sweden.	peter.andersen@neuro.umu.se						Andersen PM, 2011, NAT REV NEUROL, V7, P603, DOI 10.1038/nrneurol.2011.150; Andersen PM, 2011, EUR J NEUROL, DOI [10.1111/j.1468-1331.2011.03501.x, DOI 10.1111/0468-1331.2011.03501.X]; Byrne S, 2012, LANCET NEUROL, V11, P232, DOI 10.1016/S1474-4422(12)70014-5; Charcot JM, 1881, LECT DIS NERVOUS S 2, V2, P163; De Carvalho M, 2009, AMYOTROPH LATERAL SC, V10, P53, DOI 10.1080/17482960802521126; DeJesus-Hernandez M, 2011, NEURON, V72, P245, DOI 10.1016/j.neuron.2011.09.011; Dornbluth O., 1889, NEUROLOGISCHES CENTR, V13, P24; Gijselinck I, 2012, LANCET NEUROL, V11, P54, DOI 10.1016/S1474-4422(11)70261-7; GUNNARSSON LG, 1991, ACTA NEUROL SCAND, V84, P429, DOI 10.1111/j.1600-0404.1991.tb04983.x; HOFFMANN J, 1895, DTSCH Z NERVENHEILK, V6, P150; Morita M, 2006, NEUROLOGY, V66, P839, DOI 10.1212/01.wnl.0000200048.53766.b4; Renton AE, 2011, NEURON, V72, P257, DOI 10.1016/j.neuron.2011.09.010; Turner MR, 2005, BRAIN, V128, P1323, DOI 10.1093/brain/awh509	13	5	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2012	11	3					205	207		10.1016/S1474-4422(12)70020-0	http://dx.doi.org/10.1016/S1474-4422(12)70020-0			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	902BZ	22305803				2022-12-18	WOS:000301014900004
J	Hesdorffer, DC; Tomson, T				Hesdorffer, Dale C.; Tomson, Torbjorn			Adjunctive antiepileptic drug therapy and prevention of SUDEP	LANCET NEUROLOGY			English	Editorial Material							SUDDEN UNEXPECTED DEATH; RISK-FACTORS; EPILEPSY		[Hesdorffer, Dale C.] Columbia Univ, GH Sergievsky Ctr, New York, NY 10027 USA; [Tomson, Torbjorn] Karolinska Inst, Stockholm, Sweden	Columbia University; Karolinska Institutet	Hesdorffer, DC (corresponding author), Columbia Univ, GH Sergievsky Ctr, New York, NY 10027 USA.	dch5@columbia.edu						Ficker DM, 1998, NEUROLOGY, V51, P1270, DOI 10.1212/WNL.51.5.1270; Hesdorffer DC, 2011, EPILEPSIA, V52, P1150, DOI 10.1111/j.1528-1167.2010.02952.x; Nilsson L, 1999, LANCET, V353, P888, DOI 10.1016/S0140-6736(98)05114-9; Perucca E, 1999, EPILEPSY RES, V33, P247, DOI 10.1016/S0920-1211(98)00095-3; RYVLIN P, 2011, LANCET NEUROL, DOI DOI 10.1016/S1424-4422(11)20193-4; Sillanpaa M, 2010, NEW ENGL J MED, V363, P2522, DOI 10.1056/NEJMoa0911610; Tellez-Zenteno JF, 2005, EPILEPSY RES, V65, P101, DOI 10.1016/j.eplepsyres.2005.05.004; Tomson T, 2008, LANCET NEUROL, V7, P1021, DOI 10.1016/S1474-4422(08)70202-3; Walczak TS, 2001, NEUROLOGY, V56, P519, DOI 10.1212/WNL.56.4.519	9	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2011	10	11					948	949		10.1016/S1474-4422(11)70194-6	http://dx.doi.org/10.1016/S1474-4422(11)70194-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	839WJ	21937279				2022-12-18	WOS:000296399900002
J	Tan, EK				Tan, Eng-King			Rare and common LRRK2 exonic variants in Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							MUTATIONS		Duke Natl Univ Singapore, Grad Sch Med, Singapore Gen Hosp, Dept Neurol,Natl Neurosci Inst, Singapore 169108, Singapore	National Neuroscience Institute (NNI); National University of Singapore; Singapore General Hospital	Tan, EK (corresponding author), Duke Natl Univ Singapore, Grad Sch Med, Singapore Gen Hosp, Dept Neurol,Natl Neurosci Inst, Singapore 169108, Singapore.	gnrtek@sgh.com.sg						Healy DG, 2008, LANCET NEUROL, V7, P583, DOI 10.1016/S1474-4422(08)70117-0; Lee BD, 2010, NAT MED, V16, P998, DOI 10.1038/nm.2199; Ng CH, 2009, J NEUROSCI, V29, P11257, DOI 10.1523/JNEUROSCI.2375-09.2009; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Ross OA, 2011, LANCET NEUROL, DOI [10. 1016/S1474-4422(11)70175-2, DOI 10.1016/S1474-4422(11)70175-2]; Sheng DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000914; Tan EK, 2007, HUM MUTAT, V28, P641, DOI 10.1002/humu.20507; Tan EK, 2010, HUM MUTAT, V31, P561, DOI 10.1002/humu.21225; Webber PJ, 2009, FEBS J, V276, P6436, DOI 10.1111/j.1742-4658.2009.07342.x; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	10	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2011	10	10					869	870		10.1016/S1474-4422(11)70185-5	http://dx.doi.org/10.1016/S1474-4422(11)70185-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	832OP	21885346				2022-12-18	WOS:000295814600004
J	Berg, D				Berg, Daniela			Tracking of striatal degeneration in prediagnostic Parkinson's disease: first steps into a promising future	LANCET NEUROLOGY			English	Editorial Material							SLEEP BEHAVIOR DISORDER; RISK		[Berg, Daniela] Hertie Inst Clin Brain Res, Dept Neurodegenerat, Tubingen, Germany; [Berg, Daniela] German Ctr Neurodegenerat Dis, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE)	Berg, D (corresponding author), Hertie Inst Clin Brain Res, Dept Neurodegenerat, Tubingen, Germany.	daniela.berg@uni-tuebingen.de	Berg, Daniela/A-8728-2019	Berg, Daniela/0000-0001-5796-5442				Berg D, 2010, MOVEMENT DISORD, V25, P1464, DOI 10.1002/mds.23114; Iranzo A, 2011, LANCET NEUROL, V10, P797, DOI 10.1016/S1474-4422(11)70152-1; Marion MH, 2008, J NEUROL, V255, P192, DOI 10.1007/s00415-008-0629-9; Postuma RB, 2010, J NEUROL NEUROSUR PS, V81, P1008, DOI 10.1136/jnnp.2009.174748; Postuma RB, 2009, NEUROLOGY, V72, P1296, DOI 10.1212/01.wnl.0000340980.19702.6e; Stephenson R, 2009, MOVEMENT DISORD, V24, pS665, DOI 10.1002/mds.22403; Stern MB, 2010, MOVEMENT DISORD, V25, pS89, DOI 10.1002/mds.22719	7	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2011	10	9					775	776		10.1016/S1474-4422(11)70174-0	http://dx.doi.org/10.1016/S1474-4422(11)70174-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	815NM	21802992				2022-12-18	WOS:000294532300003
J	Keegan, BM				Keegan, B. Mark			Natalizumab for multiple sclerosis: a complicated treatment	LANCET NEUROLOGY			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; PATIENT SELECTION; RECOMMENDATIONS		Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic	Keegan, BM (corresponding author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.	keegan.bmark@mayo.edu						Clifford D, 2011, NEUROLOGY, V76, pA28; Kappos L, 2007, LANCET NEUROL, V6, P431, DOI 10.1016/S1474-4422(07)70078-9; Kappos L, 2011, LANCET NEUROL, V10, P745, DOI 10.1016/S1474-4422(11)70149-1; Khatri BO, 2009, NEUROLOGY, V72, P402, DOI 10.1212/01.wnl.0000341766.59028.9d; Killestein J, 2010, ANN NEUROL, V68, P392, DOI 10.1002/ana.22074; Lenhard T, 2010, NEUROLOGY, V75, P831, DOI 10.1212/WNL.0b013e3181f07362; Miller DH, 2007, NEUROLOGY, V68, P1390, DOI 10.1212/01.wnl.0000260064.77700.fd; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397	8	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	AUG	2011	10	8					677	678		10.1016/S1474-4422(11)70150-8	http://dx.doi.org/10.1016/S1474-4422(11)70150-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	803WJ	21777819				2022-12-18	WOS:000293612600005
J	Gonzenbach, RR; Taegtmeyer, AB; Luft, A; Russmann, S				Gonzenbach, Roman R.; Taegtmeyer, Anne B.; Luft, Andreas; Russmann, Stefan			Fluoxetine and motor recovery after ischaemic stroke	LANCET NEUROLOGY			English	Letter							CLOPIDOGREL; CITALOPRAM; CYP2C19		[Gonzenbach, Roman R.; Luft, Andreas] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Taegtmeyer, Anne B.; Russmann, Stefan] Univ Zurich Hosp, Dept Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Gonzenbach, RR (corresponding author), Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland.	roman.gonzenbach@usz.ch						Bhatt DL, 2010, NEW ENGL J MED, V363, P1909, DOI 10.1056/NEJMoa1007964; Bouman HJ, 2011, NAT MED, V17, P110, DOI 10.1038/nm.2281; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Harvey AT, 2001, J CLIN PSYCHOPHARM, V21, P161, DOI 10.1097/00004714-200104000-00007; Ho PM, 2009, JAMA-J AM MED ASSOC, V301, P937, DOI 10.1001/jama.2009.261; Jeppesen U, 1996, EUR J CLIN PHARMACOL, V51, P73, DOI 10.1007/s002280050163; Juurlink DN, 2009, CAN MED ASSOC J, V180, P713, DOI 10.1503/cmaj.082001; Von Moltke LL, 2001, DRUG METAB DISPOS, V29, P1102; Zittel S, 2008, NEUROREHAB NEURAL RE, V22, P311, DOI 10.1177/1545968307312173	9	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2011	10	6					499	500		10.1016/S1474-4422(11)70112-0	http://dx.doi.org/10.1016/S1474-4422(11)70112-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774HK	21601158	Bronze			2022-12-18	WOS:000291376100007
J	[Anonymous]				[Anonymous]			Tuberculosis of the CNS remains a lethal threat	LANCET NEUROLOGY			English	Editorial Material																			0	5	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2011	10	5					395	395		10.1016/S1474-4422(11)70082-5	http://dx.doi.org/10.1016/S1474-4422(11)70082-5			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	761TV	21511188	Bronze			2022-12-18	WOS:000290424800001
J	Ballard, C; Corbett, A; Jones, EL				Ballard, Clive; Corbett, Anne; Jones, Emma L.			Dementia: challenges and promising developments	LANCET NEUROLOGY			English	Editorial Material							ALZHEIMER-DISEASE; ASSOCIATION		[Ballard, Clive; Jones, Emma L.] Kings Coll London, Wolfson Ctr Age Related Dis, London SE1 1UL, England; [Corbett, Anne] Alzheimers Soc, London, England	University of London; King's College London	Ballard, C (corresponding author), Kings Coll London, Wolfson Ctr Age Related Dis, Hodgkin Bldg, London SE1 1UL, England.	clive.ballard@kcl.ac.uk	Corbett, Anne/B-3223-2014	Corbett, Anne/0000-0003-2015-0316; Ballard, Clive/0000-0003-0022-5632				*ALZH RES FOR, 2010, DIM DIS PHAS 3 TRIAL; Ballard CG, 2009, NAT REV NEUROL, V5, P245, DOI 10.1038/nrneurol.2009.39; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; Ritchie K, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3885; Rosenberg PB, 2010, AM J GERIAT PSYCHIAT, V18, P136, DOI 10.1097/JGP.0b013e3181c796eb; Smith AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012244; Stott DJ, 2010, ARTERIOSCL THROM VAS, V30, P605, DOI 10.1161/ATVBAHA.109.199448; Thambisetty M, 2010, ARCH GEN PSYCHIAT, V67, P739, DOI 10.1001/archgenpsychiatry.2010.78	10	5	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2011	10	1					7	9		10.1016/S1474-4422(10)70304-5	http://dx.doi.org/10.1016/S1474-4422(10)70304-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	701HX	21163436				2022-12-18	WOS:000285810100005
J	Diener, HC; Connolly, SJ; Ezekowitz, MD				Diener, H. C.; Connolly, S. J.; Ezekowitz, M. D.		RE-LY Study Grp	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial (vol 9, pg 1157, 2010)	LANCET NEUROLOGY			English	Correction													Ezekowitz, Michael/AAJ-2543-2021					DIENER HC, 2010, EPILEPSIA, V9, P1157	1	5	5	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2011	10	1					27	27		10.1016/S1474-4422(10)70274-X	http://dx.doi.org/10.1016/S1474-4422(10)70274-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	701HX					2022-12-18	WOS:000285810100016
J	Zhang, HL; Yang, Y; Zhou, HW; Wu, JA				Zhang, Hong-Liang; Yang, Yi; Zhou, Hong-Wei; Wu, Jiang			Diagnosis of posterior reversible encephalopathy syndrome: does DWI help?	LANCET NEUROLOGY			English	Letter									[Zhang, Hong-Liang; Yang, Yi; Wu, Jiang] Jilin Univ, Hosp 1, Dept Neurol, Changchun 130021, Peoples R China; [Zhou, Hong-Wei] Jilin Univ, Hosp 1, Dept Radiol, Changchun 130021, Peoples R China	Jilin University; Jilin University	Zhang, HL (corresponding author), Jilin Univ, Hosp 1, Dept Neurol, Changchun 130021, Peoples R China.	drzhl@hotmail.com	Zhang, Hongliang/AAN-3077-2020	Zhang, Hongliang/0000-0001-9205-5559				Bartynski WS, 2008, AM J NEURORADIOL, V29, P1043, DOI 10.3174/ajnr.A0929; Doelken M, 2007, DIAGN INTERV RADIOL, V13, P125; Lee VH, 2008, ARCH NEUROL-CHICAGO, V65, P205, DOI 10.1001/archneurol.2007.46; Pula JH, 2008, CURR OPIN OPHTHALMOL, V19, P479, DOI 10.1097/ICU.0b013e3283129746; Sharma M, 2010, LANCET NEUROL, V9, P933, DOI 10.1016/S1474-4422(10)70167-8	5	5	6	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	NOV	2010	9	11					1046	1047		10.1016/S1474-4422(10)70262-3	http://dx.doi.org/10.1016/S1474-4422(10)70262-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	680PL	20965431	Bronze			2022-12-18	WOS:000284246800011
J	Kumbhani, DJ; Bhatt, DL				Kumbhani, Dharam J.; Bhatt, Deepak L.			Secondary prevention of stroke: can we do better than aspirin?	LANCET NEUROLOGY			English	Editorial Material							ANTIPLATELET THERAPY; ISCHEMIC-STROKE; METAANALYSIS; RISK		[Kumbhani, Dharam J.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System; Harvard University; Harvard Medical School	Kumbhani, DJ (corresponding author), Brigham & Womens Hosp, VA Boston Healthcare Syst, 75 Francis St, Boston, MA 02115 USA.	dlbhattmd@post.harvard.edu						Algra A, 1999, J NEUROL NEUROSUR PS, V66, P255, DOI 10.1136/jnnp.66.2.255; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bhatt DL, 2007, NEW ENGL J MED, V357, P2078, DOI 10.1056/NEJMe0706859; Gotoh F, 2000, J Stroke Cerebrovasc Dis, V9, P147, DOI 10.1053/jscd.2000.7216; Guo H, 2009, J MATER SCI TECHNOL, V25, P383, DOI 10.1179/174328408X262409; Huang YI, 2008, LANCET NEUROL, V7, P494, DOI 10.1016/S1474-4422(08)70094-2; Mak KH, 2009, AM HEART J, V157, P658, DOI 10.1016/j.ahj.2008.08.031; Meadows TA, 2007, CIRC RES, V100, P1261, DOI 10.1161/01.RES.0000264509.36234.51; O'Donnell MJ, 2008, STROKE, V39, P1638, DOI 10.1161/STROKEAHA.107.497271; SHINOHARA Y, 2010, LANCET, DOI DOI 10.1016/S1474-4422(10)70198-8	11	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2010	9	10					942	943		10.1016/S1474-4422(10)70217-9	http://dx.doi.org/10.1016/S1474-4422(10)70217-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	672WC	20833590				2022-12-18	WOS:000283616700002
J	[Anonymous]				[Anonymous]			Epilepsy must become a higher priority in Europe	LANCET NEUROLOGY			English	Editorial Material																			0	5	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2010	9	10					941	941		10.1016/S1474-4422(10)70226-X	http://dx.doi.org/10.1016/S1474-4422(10)70226-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	672WC	20864043				2022-12-18	WOS:000283616700001
J	Hernandez-Lahoz, C; Rodrigo, L				Hernandez-Lahoz, Carlos; Rodrigo, Luis			Gluten sensitivity and the CNS: diagnosis and treatment	LANCET NEUROLOGY			English	Letter							MULTIPLE-SCLEROSIS		[Hernandez-Lahoz, Carlos] Hosp Univ Cent Asturias, Dept Neurol, Oviedo, Spain; [Rodrigo, Luis] Hosp Univ Cent Asturias, Dept Gastroenterol, Oviedo, Spain	Central University Hospital Asturias; Central University Hospital Asturias	Hernandez-Lahoz, C (corresponding author), Hosp Univ Cent Asturias, Dept Neurol, Oviedo, Spain.	carloshlahoz@gmail.com	Bianchi, Paola Ilaria/AAC-5385-2022; Rodrigo, Luis/A-6278-2010	Bianchi, Paola Ilaria/0000-0002-0606-6807; Rodrigo, Luis/0000-0003-1717-9345				Davidson A, 2001, NEW ENGL J MED, V345, P340, DOI 10.1056/NEJM200108023450506; Hadjivassiliou M, 2010, LANCET NEUROL, V9, P318, DOI 10.1016/S1474-4422(09)70290-X; Hernandez-Lahoz C, 2009, NEUROLOGIA, V24, P213; Shor DBA, 2009, ANN NY ACAD SCI, V1173, P343, DOI 10.1111/j.1749-6632.2009.04620.x	4	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2010	9	7					653	654		10.1016/S1474-4422(10)70149-6	http://dx.doi.org/10.1016/S1474-4422(10)70149-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	617NF	20610339				2022-12-18	WOS:000279286900009
J	Arzimanoglou, A; Ryvlin, P; Perucca, E				Arzimanoglou, Alexis; Ryvlin, Philippe; Perucca, Emilio			When the past challenges the present: are older antiepileptic drugs still the best choice in childhood absence epilepsy?	LANCET NEUROLOGY			English	Editorial Material							PEDIATRIC EPILEPSY; EXPERT OPINION; VALPROIC ACID; LAMOTRIGINE; SEIZURES; ETHOSUXIMIDE; MONOTHERAPY		[Arzimanoglou, Alexis; Ryvlin, Philippe] Univ Hosp Lyon, Inst Children & Adolescents Epilepsy DEE, Lyon, France; [Arzimanoglou, Alexis; Ryvlin, Philippe] INSERM, U821, F-69008 Lyon, France; [Ryvlin, Philippe] Univ Hosp Lyon, Dept Neurol, Lyon, France; [Perucca, Emilio] Fdn Lyon 1 Clin Pharmacol, Inst Children & Adolescents Epilepsy IDEE, Lyon, France; [Perucca, Emilio] IRCCS C Mondino Fdn, Inst Neurol, Pavia, Italy; [Perucca, Emilio] Univ Pavia, I-27100 Pavia, Italy	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; IRCCS Fondazione Casimiro Mondino; University of Pavia	Arzimanoglou, A (corresponding author), Univ Hosp Lyon, Inst Children & Adolescents Epilepsy DEE, Lyon, France.	alexis.arzimanoglou@chu-lyon.fr	Ryvlin, Philippe/K-7402-2019; Ryvlin, Philippe/O-5214-2016; Perucca, Emilio/Q-7308-2019	Ryvlin, Philippe/0000-0001-7775-6576; Ryvlin, Philippe/0000-0001-7775-6576; Arzimanoglou, Alexis/0000-0002-7233-2771; Perucca, Emilio/0000-0001-8703-223X				Coppola G, 2004, EPILEPSIA, V45, P1049, DOI 10.1111/j.0013-9580.2004.40903.x; GIANNAKODIMOS S, 1995, CLIN ELECTROENCEPHAL, V26, P200, DOI 10.1177/155005949502600405; Glauser T, 2006, EPILEPSIA, V47, P1094, DOI 10.1111/j.1528-1167.2006.00585.x; Glauser TA, 2010, NEW ENGL J MED, V362, P790, DOI 10.1056/NEJMoa0902014; Hughes JR, 2009, EPILEPSY BEHAV, V15, P404, DOI 10.1016/j.yebeh.2009.06.007; Perucca E, 2005, EPILEPSIA, V46, P31, DOI 10.1111/j.1528-1167.2005.463007.x; Posner EB, 2005, SEIZURE-EUR J EPILEP, V14, P117, DOI 10.1016/j.seizure.2004.12.003; Tomson T, 2009, NEUROL CLIN, V27, P993, DOI 10.1016/j.ncl.2009.06.006; Wheless JW, 2007, EPILEPTIC DISORD, V9, P353; Wheless JW, 2005, J CHILD NEUROL, V20, pS1, DOI 10.1177/088307380502000101	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2010	9	5					457	459		10.1016/S1474-4422(10)70089-2	http://dx.doi.org/10.1016/S1474-4422(10)70089-2			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	592MY	20398853				2022-12-18	WOS:000277384600007
J	Clifford, DB; De Luca, A; Simpson, DM; Arendt, G; Giovannoni, G; Nath, A				Clifford, D. B.; De Luca, A.; Simpson, D. M.; Arendt, G.; Giovannoni, G.; Nath, A.			Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases (vol 9, pg 438, 2010)	LANCET NEUROLOGY			English	Correction																		Clifford DB, 2010, LANCET NEUROL, V9, P438, DOI 10.1016/S1474-4422(10)70028-4	1	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2010	9	5					463	463		10.1016/S1474-4422(10)70028-4	http://dx.doi.org/10.1016/S1474-4422(10)70028-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	592MY					2022-12-18	WOS:000277384600010
J	Swash, M				Swash, Michael			Lithium time-to-event trial in amyotrophic lateral sclerosis stops early for futility	LANCET NEUROLOGY			English	Editorial Material							ALS; PROGRESSION; MOUSE; MODEL		Queen Mary Univ London, Royal London Hosp, Barts & London Sch Med & Dent, London, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Swash, M (corresponding author), Queen Mary Univ London, Royal London Hosp, Barts & London Sch Med & Dent, London, England.	mswash@btinternet.com		Swash, Michael/0000-0002-8717-8914				Aggarwal SP, 2010, LANCET NEUROL, V9, P481, DOI 10.1016/S1474-4422(10)70068-5; Benatar M, 2007, NEUROBIOL DIS, V26, P1, DOI 10.1016/j.nbd.2006.12.015; Fornai F, 2008, AUTOPHAGY, V4, P527, DOI 10.4161/auto.5923; Fornai F, 2008, P NATL ACAD SCI USA, V105, P2052, DOI 10.1073/pnas.0708022105; Gill A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006489; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Pizzasegola C, 2009, AMYOTROPH LATERAL SC, V10, P221, DOI 10.1080/17482960902803440; Scott S, 2008, AMYOTROPH LATERAL SC, V9, P4, DOI 10.1080/17482960701856300; Zoccolella S, 2009, NEUROPSYCH DIS TREAT, V5, P577	9	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAY	2010	9	5					449	451		10.1016/S1474-4422(10)70085-5	http://dx.doi.org/10.1016/S1474-4422(10)70085-5			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	592MY	20363191				2022-12-18	WOS:000277384600003
J	[Anonymous]				[Anonymous]			Antiepileptic drugs: the drawbacks of generic substitution	LANCET NEUROLOGY			English	Editorial Material																			0	5	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2010	9	3					227	227						1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	565BL	20170834	Bronze			2022-12-18	WOS:000275263400001
J	Bonifati, V				Bonifati, Vincenzo			Shaking the genome: new studies reveal genetic risk for Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							ASSOCIATION; MUTATIONS		Erasmus MC, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Bonifati, V (corresponding author), Erasmus MC, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands.	v.bonifati@erasmusmc.nl						Bonifati V, 2007, NEUROCHEM RES, V32, P1700, DOI 10.1007/s11064-007-9324-y; Fung HC, 2006, LANCET NEUROL, V5, P911, DOI 10.1016/S1474-4422(06)70578-6; Galpern WR, 2006, ANN NEUROL, V59, P449, DOI 10.1002/ana.20819; Gasser T, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001148; Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902; Pankratz N, 2009, HUM GENET, V124, P593, DOI 10.1007/s00439-008-0582-9; Satake W, 2009, NAT GENET, V41, P1303, DOI 10.1038/ng.485; Sidransky E, 2009, NEW ENGL J MED, V361, P1651, DOI 10.1056/NEJMoa0901281; Simon-Sanchez J, 2009, NAT GENET, V41, P1308, DOI 10.1038/ng.487; Tucker T, 2009, AM J HUM GENET, V85, P142, DOI 10.1016/j.ajhg.2009.06.022	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	FEB	2010	9	2					136	138		10.1016/S1474-4422(09)70363-1	http://dx.doi.org/10.1016/S1474-4422(09)70363-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	547XB	20129160				2022-12-18	WOS:000273922000006
J	Hass, CJ; Okun, MS				Hass, Chris J.; Okun, Michael S.			Time for comprehensive care networks for Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							ALLIED HEALTH-CARE; PHYSICAL-THERAPY		[Hass, Chris J.] Univ Florida, Dept Appl Physiol & Kinesiol, Movement Disorders Ctr, McKnight Brain Inst, Gainesville, FL 32611 USA; [Okun, Michael S.] Univ Florida, Dept Neurol, Movement Disorders Ctr, McKnight Brain Inst, Gainesville, FL USA; [Okun, Michael S.] Univ Florida, Dept Neurosurg, Movement Disorders Ctr, McKnight Brain Inst, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Hass, CJ (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, Movement Disorders Ctr, McKnight Brain Inst, Gainesville, FL 32611 USA.	okun@neurology.ufl.edu		Okun, Michael/0000-0002-6247-9358				Hirsch MA, 2009, EUR J PHYS REHAB MED, V45, P215; Keus SHJ, 2007, MOVEMENT DISORD, V22, P451, DOI 10.1002/mds.21244; Keus SHJ, 2009, MOVEMENT DISORD, V24, P1, DOI 10.1002/mds.22141; Keus SHJ, 2004, J NEUROL, V251, P680, DOI 10.1007/s00415-004-0402-7; King LA, 2009, PHYS THER, V89, P384, DOI 10.2522/ptj.20080214; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Morris ME, 2000, PHYS THER, V80, P578, DOI 10.1093/ptj/80.6.578; Munneke M, 2010, LANCET NEUROL, V9, P46, DOI 10.1016/S1474-4422(09)70327-8; Nijkrake M, 2006, MOVEMENT DISORD, V21, pS131; Nijkrake MJ, 2009, MOVEMENT DISORD, V24, P282, DOI 10.1002/mds.22377; NIJKRAKE MJ, EUR J PHYS IN PRESS	11	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2010	9	1					20	22		10.1016/S1474-4422(09)70331-X	http://dx.doi.org/10.1016/S1474-4422(09)70331-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	538QS	19959399				2022-12-18	WOS:000273199700012
J	Lyden, PD				Lyden, Patrick D.			Extending the time window for thrombolytic therapy-primum non tardare	LANCET NEUROLOGY			English	Editorial Material							EARLY STROKE TREATMENT		Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Lyden, PD (corresponding author), Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA.	lydenp@cshs.org						Bluhmki E, 2009, LANCET NEUROL, V8, P1095, DOI 10.1016/S1474-4422(09)70264-9; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Hacke W, 2004, LANCET, V363, P768; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Lyden P.D., 2005, THROMBOLYTIC THERAPY; Lyden P, 2008, NEW ENGL J MED, V359, P1393, DOI 10.1056/NEJMe0806335; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Ovbiagele B, 2006, CEREBROVASC DIS, V21, P260, DOI 10.1159/000091224; Wahlgren N, 2008, LANCET, V372, P1303, DOI 10.1016/S0140-6736(08)61339-2; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	14	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2009	8	12					1074	1075		10.1016/S1474-4422(09)70274-1	http://dx.doi.org/10.1016/S1474-4422(09)70274-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	523WS	19850526				2022-12-18	WOS:000272106100002
J	Pittock, SJ				Pittock, Sean J.			Uncertain BENEFIT of early interferon beta-1b treatment	LANCET NEUROLOGY			English	Editorial Material							CLINICALLY ISOLATED SYNDROME; MULTIPLE-SCLEROSIS; FOLLOW-UP; CONVERSION; DEFINITE; EVENT		[Pittock, Sean J.] Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55905 USA; [Pittock, Sean J.] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Pittock, SJ (corresponding author), Mayo Clin, Coll Med, Dept Neurol, Rochester, MN 55905 USA.	pittock.sean@mayo.edu						Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Comi G, 2008, NAT CLIN PRACT NEURO, V4, P234, DOI 10.1038/ncpneuro0772; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Kappos L, 2006, NEUROLOGY, V67, P1242, DOI 10.1212/01.wnl.0000237641.33768.8d; Kappos L, 2007, LANCET, V370, P389, DOI 10.1016/S0140-6736(07)61194-5; Kappos L, 2009, LANCET NEUROL, V8, P987, DOI 10.1016/S1474-4422(09)70237-6; Kinkel R, 2009, NEUROLOGY, V72, pA315; Miller D, 2005, LANCET NEUROL, V4, P281, DOI 10.1016/S1474-4422(05)70071-5; Pittock SJ, 2007, LANCET, V370, P363, DOI 10.1016/S0140-6736(07)61170-2; Siva A, 2008, NAT CLIN PRACT NEURO, V4, P236, DOI 10.1038/ncpneuro0774	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2009	8	11					970	971		10.1016/S1474-4422(09)70258-3	http://dx.doi.org/10.1016/S1474-4422(09)70258-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	513GC	19748320				2022-12-18	WOS:000271309600002
J	[Anonymous]				[Anonymous]			Neurology in the elderly: more trials urgently needed	LANCET NEUROLOGY			English	Editorial Material																			0	5	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	NOV	2009	8	11					969	969		10.1016/S1474-4422(09)70265-0	http://dx.doi.org/10.1016/S1474-4422(09)70265-0			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	513GC	19800849	Bronze			2022-12-18	WOS:000271309600001
J	Bottino, D				Bottino, Dina			Cognitive outcome after exposure to antiepileptic drugs in utero	LANCET NEUROLOGY			English	Editorial Material							EPILEPSY; FETAL		Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurophysiol, Epilepsy Ctr, I-20133 Milan, Italy	IRCCS Istituto Neurologico Besta	Bottino, D (corresponding author), Fdn IRCCS Ist Neurol Carlo Besta, Dept Neurophysiol, Epilepsy Ctr, Via Celoria 11, I-20133 Milan, Italy.	dbattino@istituto-besta.it	Battino, Dina/J-9215-2016	Battino, Dina/0000-0001-5784-9986				Adab N, 2004, J NEUROL NEUROSUR PS, V75, P1575, DOI 10.1136/jnnp.2003.029132; ADAB N, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004848; Meador KJ, 2009, NEW ENGL J MED, V360, P1597, DOI 10.1056/NEJMoa0803531; *SCOTT INT GUID NE, 2003, DIAGN MAN EP AD NAT; Tomson T, 2004, EPILEPSIA, V45, P1171, DOI 10.1111/j.0013-9580.2004.15104.x	5	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2009	8	7					600	601		10.1016/S1474-4422(09)70154-1	http://dx.doi.org/10.1016/S1474-4422(09)70154-1			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466EN	19539227				2022-12-18	WOS:000267643700006
J	Burtscher, M				Burtscher, Martin			High-altitude cerebral effects: risks and mechanisms	LANCET NEUROLOGY			English	Letter							HEADACHE		Univ Innsbruck, A-6020 Innsbruck, Austria	University of Innsbruck	Burtscher, M (corresponding author), Univ Innsbruck, Furstenweg 185, A-6020 Innsbruck, Austria.	martin.burtscher@uibk.ac.at		Burtscher, Martin/0000-0002-5232-3632				Burtscher M, 1998, BRIT MED J, V316, P1057; Ray CJ, 2002, J PHYSIOL-LONDON, V544, P195, DOI 10.1113/jphysiol.2002.023440; Wienecke T, 2009, CEPHALALGIA, V29, P509, DOI 10.1111/j.1468-2982.2008.01748.x; Wilson MH, 2009, LANCET NEUROL, V8, P175, DOI 10.1016/S1474-4422(09)70014-6	4	5	5	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2009	8	7					604	605		10.1016/S1474-4422(09)70160-7	http://dx.doi.org/10.1016/S1474-4422(09)70160-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	466EN	19539232	Bronze			2022-12-18	WOS:000267643700012
J	Engstrom, M; Berg, T; Stjernquist-Desatnik, A; Axelsson, S; Pitkaranta, A; Huitcrantz, M; Kanerva, M; Hanner, P; Jonsson, L				Engstrom, Mats; Berg, Thomas; Stjernquist-Desatnik, Anna; Axelsson, Sara; Pitkaranta, Anne; Huitcrantz, Malou; Kanerva, Mervi; Hanner, Per; Jonsson, Lars			Is antiviral medication for severe Bell's palsy still useful? Reply	LANCET NEUROLOGY			English	Letter									[Engstrom, Mats; Berg, Thomas; Stjernquist-Desatnik, Anna; Axelsson, Sara; Pitkaranta, Anne; Huitcrantz, Malou; Kanerva, Mervi; Hanner, Per; Jonsson, Lars] Dept Otorhinolaryngol Head & Neck Surg, Uppsala, Sweden		Engstrom, M (corresponding author), Dept Otorhinolaryngol Head & Neck Surg, Uppsala, Sweden.	mats.engstrom@akademiska.se						Engstrom M, 2008, LANCET NEUROL, V7, P993, DOI 10.1016/S1474-4422(08)70221-7; Minnerop M, 2008, J NEUROL, V255, P1726, DOI 10.1007/s00415-008-0008-6	2	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2009	8	6					509	510		10.1016/S1474-4422(09)70115-2	http://dx.doi.org/10.1016/S1474-4422(09)70115-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	448UQ					2022-12-18	WOS:000266287900007
J	Shy, M				Shy, Michael			Ascorbic acid for treatment of CMT1A: the jury is still out	LANCET NEUROLOGY			English	Editorial Material							MARIE-TOOTH-DISEASE; SPINAL MUSCULAR-ATROPHY; FUNCTIONAL MOTOR SCALE; OUTCOME MEASURES; MOUSE MODEL; NEUROPATHY; 1A; RELIABILITY; DUPLICATION; DNA		Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA	Wayne State University	Shy, M (corresponding author), Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48202 USA.	m.shy@wayne.edu		Shy, Michael/0000-0001-8460-6971				BURNS J, 2009, LANCET NEUROL; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; Huxley C, 1996, HUM MOL GENET, V5, P563, DOI 10.1093/hmg/5.5.563; Iannaccone ST, 2003, ARCH NEUROL-CHICAGO, V60, P1130, DOI 10.1001/archneur.60.8.1130; Krajewski KM, 2000, BRAIN, V123, P1516, DOI 10.1093/brain/123.7.1516; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; Main M, 2003, EUR J PAEDIATR NEURO, V7, P155, DOI 10.1016/S1090-3798(03)00060-6; Mayhew JE, 2007, MUSCLE NERVE, V35, P36, DOI 10.1002/mus.20654; Nelis E, 1996, EUR J HUM GENET, V4, P25; O'Hagen JM, 2007, NEUROMUSCULAR DISORD, V17, P693, DOI 10.1016/j.nmd.2007.05.009; Passage E, 2004, NAT MED, V10, P396, DOI 10.1038/nm1023; Raeymaekers P, 1991, Neuromuscul Disord, V1, P93, DOI 10.1016/0960-8966(91)90055-W; Sahenk Z, 1999, ANN NEUROL, V45, P16, DOI 10.1002/1531-8249(199901)45:1<16::AID-ART5>3.0.CO;2-F; Sancho S, 1999, BRAIN, V122, P1563, DOI 10.1093/brain/122.8.1563; Sereda M, 1996, NEURON, V16, P1049, DOI 10.1016/S0896-6273(00)80128-2; Shy ME, 2008, NEUROLOGY, V70, P378, DOI 10.1212/01.wnl.0000297553.36441.ce; Shy ME, 2005, NEUROLOGY, V64, P1209, DOI 10.1212/01.WNL.0000156517.00615.A3; SKRE H, 1974, CLIN GENET, V6, P98	18	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2009	8	6					505	507		10.1016/S1474-4422(09)70112-7	http://dx.doi.org/10.1016/S1474-4422(09)70112-7			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	448UQ	19427270				2022-12-18	WOS:000266287900004
J	Traynor, BJ; Singleton, AB				Traynor, Bryan J.; Singleton, Andrew B.			What's the FUS!	LANCET NEUROLOGY			English	Editorial Material							AMYOTROPHIC-LATERAL-SCLEROSIS; MUTATIONS; TDP-43		[Traynor, Bryan J.] NIA, Neuromuscular Dis Res Grp, Neurogenet Lab, Bethesda, MD 20892 USA; [Singleton, Andrew B.] NIA, Mol Genet Sect, Neurogenet Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Traynor, BJ (corresponding author), NIA, Neuromuscular Dis Res Grp, Neurogenet Lab, Bethesda, MD 20892 USA.	singleta@mail.nih.gov	Singleton, Andrew B/C-3010-2009; Traynor, Bryan J/G-5690-2010		Intramural NIH HHS Funding Source: Medline; NIA NIH HHS [Z01 AG000958-05] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000958, ZIAAG000958, ZIAAG000957, ZIAAG000933] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Chio A, 2008, NEUROLOGY, V70, P533, DOI 10.1212/01.wnl.0000299187.90432.3f; Garber K, 2008, SCIENCE, V319, P20, DOI 10.1126/science.319.5859.20; Guerreiro RJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002450; Kwiatkowski TJ, 2009, SCIENCE, V323, P1205, DOI 10.1126/science.1166066; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; Rothstein JD, 2009, ANN NEUROL, V65, pS3, DOI 10.1002/ana.21543; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Van Deerlin VM, 2008, LANCET NEUROL, V7, P409, DOI 10.1016/S1474-4422(08)70071-1; Vance C, 2009, SCIENCE, V323, P1208, DOI 10.1126/science.1165942	9	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAY	2009	8	5					418	419		10.1016/S1474-4422(09)70088-2	http://dx.doi.org/10.1016/S1474-4422(09)70088-2			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	435UE	19375659				2022-12-18	WOS:000265368000005
J	Hariz, M				Hariz, Marwan			Deep brain stimulation versus best medical therapy for advanced Parkinson's disease	LANCET NEUROLOGY			English	Editorial Material							5-YEAR FOLLOW-UP; SUBTHALAMIC NUCLEUS; RANDOMIZED-TRIAL; MULTICENTER; PALLIDOTOMY		Inst Neurol, Unit Funct Neurosurg, London WC1N 3BG, England	University of London; University College London	Hariz, M (corresponding author), Inst Neurol, Unit Funct Neurosurg, Queen Sq, London WC1N 3BG, England.	m.hariz@ion.ucl.ac.uk						de Bie RMA, 1999, LANCET, V354, P1665, DOI 10.1016/S0140-6736(99)03556-4; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; Ostergaard K, 2006, MOVEMENT DISORD, V21, P624, DOI 10.1002/mds.20776; Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571; Schupbach WMM, 2007, NEUROLOGY, V68, P267, DOI 10.1212/01.wnl.0000250253.03919.fb; Schupbach WMM, 2005, J NEUROL NEUROSUR PS, V76, P1640, DOI 10.1136/jnnp.2005.063206; Vitek JL, 2003, ANN NEUROL, V53, P558, DOI 10.1002/ana.10517; Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929; Wider C, 2008, PARKINSONISM RELAT D, V14, P114, DOI 10.1016/j.parkreldis.2007.06.012	10	5	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	MAR	2009	8	3					223	224		10.1016/S1474-4422(09)70027-4	http://dx.doi.org/10.1016/S1474-4422(09)70027-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	412FZ	19233027				2022-12-18	WOS:000263711200005
J	MacReady, N				MacReady, Norra			Neurological deficits in the homeless: a downward spiral	LANCET NEUROLOGY			English	Editorial Material												medrite@aol.com							0	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	MAR	2009	8	3					228	229		10.1016/S1474-4422(09)70033-X	http://dx.doi.org/10.1016/S1474-4422(09)70033-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	412FZ	19233033				2022-12-18	WOS:000263711200011
J	Backonja, M; Wallace, MS; Blonsky, ER				Backonja, M.; Wallace, M. S.; Blonsky, E. R.			NGX-4010, a high concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study (vol 7, pg 1106, 2008)	LANCET NEUROLOGY			English	Correction																		Backonja M, 2008, LANCET NEUROL, V7, P1106, DOI 10.1016/S1474-4422(08)70228-X	1	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2009	8	1					31	31		10.1016/S1474-4422(08)70228-X	http://dx.doi.org/10.1016/S1474-4422(08)70228-X			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	386CU					2022-12-18	WOS:000261860700017
J	Martin-Schild, S				Martin-Schild, Sheryl			Blood pressure in acute stroke: lower it or let the CHHIPS fall where they will	LANCET NEUROLOGY			English	Editorial Material							QUALITY-OF-CARE; ISCHEMIC-STROKE; GUIDELINES; MANAGEMENT; OUTCOMES; COUNCIL; ADULTS		Tulane Univ, Hosp & Clin, New Orleans, LA 70112 USA	Tulane University	Martin-Schild, S (corresponding author), Tulane Univ, Hosp & Clin, New Orleans, LA 70112 USA.	smartin2@tulane.edu						Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Castillo J, 2004, STROKE, V35, P520, DOI 10.1161/01.STR.0000109769.22917.B0; Chamorro A, 1998, STROKE, V29, P1850, DOI 10.1161/01.STR.29.9.1850; Okumura K, 2005, J HYPERTENS, V23, P1217, DOI 10.1097/01.hjh.0000170385.76826.4a; Oliveira J, 2003, NEUROLOGY, V61, P1047, DOI 10.1212/01.WNL.0000092498.75010.57; Potter JF, 2009, LANCET NEUROL, V8, P48, DOI 10.1016/S1474-4422(08)70263-1; Vemmos KN, 2004, J INTERN MED, V255, P257, DOI 10.1046/j.1365-2796.2003.01291.x	8	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2009	8	1					23	24		10.1016/S1474-4422(08)70264-3	http://dx.doi.org/10.1016/S1474-4422(08)70264-3			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	386CU	19058761				2022-12-18	WOS:000261860700013
J	Binder, A; Baron, R				Binder, Andreas; Baron, Ralf			Postherpetic neuralgia-fighting pain with fire	LANCET NEUROLOGY			English	Editorial Material							NEUROPATHIC PAIN		[Binder, Andreas; Baron, Ralf] Univ Kiel, Neurol Klin, Sekt Neurol Schmerzforsch & Therapie, D-24105 Kiel, Germany	University of Kiel	Binder, A (corresponding author), Univ Kiel, Neurol Klin, Sekt Neurol Schmerzforsch & Therapie, Schittenhelmstr 10, D-24105 Kiel, Germany.	r.baron@neurologie.uni-kiel.de	Baron, Ralf/E-4298-2010					Backonja M, 2008, LANCET NEUROL, V7, P1106, DOI 10.1016/S1474-4422(08)70228-X; Baron R, 2006, NAT CLIN PRACT NEURO, V2, P95, DOI 10.1038/ncpneuro0113; Dworkin RH, 2007, PAIN, V132, P237, DOI 10.1016/j.pain.2007.08.033; Fields HL, 1998, NEUROBIOL DIS, V5, P209, DOI 10.1006/nbdi.1998.0204; Hong SS, 2005, J BIOL CHEM, V280, P618, DOI 10.1074/jbc.M408500200; Hudson LJ, 2001, EUR J NEUROSCI, V13, P2105, DOI 10.1046/j.0953-816x.2001.01591.x; Johnson Robert W, 2007, Expert Rev Neurother, V7, P1581, DOI 10.1586/14737175.7.11.1581; Polydefkis M, 2004, BRAIN, V127, P1606, DOI 10.1093/brain/awh175; Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041; Schmader KE, 2002, CLIN J PAIN, V18, P350, DOI 10.1097/00002508-200211000-00002; Tominaga M, 2004, J NEUROBIOL, V61, P3, DOI 10.1002/neu.20079	11	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2008	7	12					1077	1078		10.1016/S1474-4422(08)70242-4	http://dx.doi.org/10.1016/S1474-4422(08)70242-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	379KV	18977179				2022-12-18	WOS:000261396000004
J	Stuve, O; Eagar, TN				Stuve, Olaf; Eagar, Todd N.			B cells, antibodies, and tertiary lymphoid tissue in MS brains	LANCET NEUROLOGY			English	Editorial Material							MULTIPLE-SCLEROSIS		[Stuve, Olaf; Eagar, Todd N.] VA N Texas Hlth Care Syst, Dallas, TX 75216 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Stuve, O (corresponding author), VA N Texas Hlth Care Syst, Dallas, TX 75216 USA.	olaf.stuve@utsouthwestern.edu						BERGER JR, 1989, NEUROLOGY, V39, P324, DOI 10.1212/WNL.39.3.324; FAGRAEUS A, 1948, J IMMUNOL, V58, P1; Franciotta D, 2008, LANCET NEUROL, V7, P852, DOI 10.1016/S1474-4422(08)70192-3; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Kabat EA, 1942, J CLIN INVEST, V21, P571, DOI 10.1172/JCI101335; PATERSON PY, 1960, J EXP MED, V111, P119, DOI 10.1084/jem.111.1.119; PRINEAS JW, 1979, SCIENCE, V203, P1123, DOI 10.1126/science.424741; Simpson JA, 1960, SCOT MED J, V5, P419, DOI [10.1177/003693306000501001, DOI 10.1177/003693306000501001]; vanOosten BW, 1997, NEUROLOGY, V49, P351, DOI 10.1212/WNL.49.2.351	9	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2008	7	9					766	767		10.1016/S1474-4422(08)70176-5	http://dx.doi.org/10.1016/S1474-4422(08)70176-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	345HZ	18702996				2022-12-18	WOS:000258988400005
J	Hankey, GJ				Hankey, Graeme J.			Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke	LANCET NEUROLOGY			English	Editorial Material							DIABETIC-PATIENTS; DOUBLE-BLIND; TRIAL; CLOPIDOGREL; DESIGN		Royal Perth Hosp, Dept Neurol, Perth, WA 6001, Australia	Royal Perth Hospital; University of Western Australia	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, 197 Wellington St, Perth, WA 6001, Australia.	gjhankey@cyllene.uwa.edu.au	Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				Ahn Y, 2008, CIRC J, V72, P35, DOI 10.1253/circj.72.35; Cordonnier C, 2007, BRAIN, V130, P1988, DOI 10.1093/brain/awl387; Diener HC, 2007, CEREBROVASC DIS, V23, P368, DOI 10.1159/000100105; Falconer TM, 2008, CLIN INTERV AGING, V3, P17; Gotoh F, 2000, J Stroke Cerebrovasc Dis, V9, P147, DOI 10.1053/jscd.2000.7216; Huang YI, 2008, LANCET NEUROL, V7, P494, DOI 10.1016/S1474-4422(08)70094-2; Lee SW, 2008, J AM COLL CARDIOL, V51, P1181, DOI 10.1016/j.jacc.2007.11.049; Liu M, 2007, LANCET NEUROL, V6, P456, DOI 10.1016/S1474-4422(07)70004-2; ODONNELL MJ, 2008, STROKE          0327, DOI DOI 10.1161/STROKEAHA.107.497271; Rother J, 2008, CEREBROVASC DIS, V25, P366, DOI 10.1159/000120687	10	5	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	JUN	2008	7	6					469	470		10.1016/S1474-4422(08)70095-4	http://dx.doi.org/10.1016/S1474-4422(08)70095-4			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	305WF	18456559				2022-12-18	WOS:000256207800003
J	Butcher, J				Butcher, James			Polio eradication nears the end game	LANCET NEUROLOGY			English	Editorial Material												james@two-cultures.com		Butcher, James/0000-0001-8546-6093					0	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	APR	2008	7	4					292	293		10.1016/S1474-4422(08)70053-X	http://dx.doi.org/10.1016/S1474-4422(08)70053-X			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	285PF	18339344	hybrid			2022-12-18	WOS:000254788000007
J	[Anonymous]				[Anonymous]			Guidance for off-label use of drugs	LANCET NEUROLOGY			English	Editorial Material																			0	5	5	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2008	7	4					285	285		10.1016/S1474-4422(08)70050-4	http://dx.doi.org/10.1016/S1474-4422(08)70050-4			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	285PF	18339342				2022-12-18	WOS:000254788000001
J	Brodie, MJ				Brodie, Martin J.			Epilepsy: randomised trials and genetic tribulations	LANCET NEUROLOGY			English	Editorial Material							LAMOTRIGINE; TOPIRAMATE; SANAD		Western Infirm & Associated Hosp, Glasgow G11 6NT, Lanark, Scotland		Brodie, MJ (corresponding author), Western Infirm & Associated Hosp, Glasgow G11 6NT, Lanark, Scotland.	mjb2k@clinmed.gla.ac.uk						Brodie MJ, 2007, NEUROLOGY, V68, P402, DOI 10.1212/01.wnl.0000252941.50833.4a; Harkin LA, 2007, BRAIN, V130, P843, DOI 10.1093/brain/awm002; Marson AG, 2007, LANCET, V369, P1016, DOI 10.1016/S0140-6736(07)60461-9; Marson AG, 2007, LANCET, V369, P1000, DOI 10.1016/S0140-6736(07)60460-7; Scheffer IE, 2007, BRAIN, V130, P100, DOI 10.1093/brain/awl272	5	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2008	7	1					7	8		10.1016/S1474-4422(07)70301-0	http://dx.doi.org/10.1016/S1474-4422(07)70301-0			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	247FO	18093548				2022-12-18	WOS:000252063300005
J	Hesdorffer, DC; Hauser, WA; Olafsson, E; Ludvigsson, P; Kjartansson, O				Hesdorffer, Dale C.; Hauser, W. Allen; Olafsson, Elias; Ludvigsson, Petur; Kjartansson, Olafur			Epilepsy and suicide risk	LANCET NEUROLOGY			English	Editorial Material							DEPRESSION		Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA	Columbia University	Hesdorffer, DC (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA.	dch5@columbia.ac.edu	Hauser, W Allen/AAB-5277-2020; Olafsson, Elias/R-8517-2019					Bradvik L, 2003, SUICIDE LIFE-THREAT, V33, P381, DOI 10.1521/suli.33.4.381.25234; Christensen J, 2007, LANCET NEUROL, V6, P693, DOI 10.1016/S1474-4422(07)70175-8; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Suominen K, 2004, AM J PSYCHIAT, V161, P562, DOI 10.1176/appi.ajp.161.3.562	4	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	OCT	2007	6	10					847	847		10.1016/S1474-4422(07)70229-6	http://dx.doi.org/10.1016/S1474-4422(07)70229-6			1	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218SQ	17884671				2022-12-18	WOS:000250035600007
J	van Swieten, JC				van Swieten, John C.			Genetic basis of frontotemporal dementia	LANCET NEUROLOGY			English	Editorial Material							LOBAR DEGENERATION; PROGRANULIN GENE; NULL MUTATIONS; TAU		Erasmus MC, Dept Neurol, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	van Swieten, JC (corresponding author), Erasmus MC, Dept Neurol, NL-3015 GD Rotterdam, Netherlands.	j.c.vanswieten@erasmusmc.nl		van Swieten, John/0000-0001-6278-6844				Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Bronner IF, 2007, EUR J HUM GENET, V15, P369, DOI 10.1038/sj.ejhg.5201772; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Josephs KA, 2007, J NEUROPATH EXP NEUR, V66, P142, DOI 10.1097/nen.0b013e31803020cf; Le Ber I, 2007, HUM MUTAT, V28, P846, DOI 10.1002/humu.20520; Mackenzie IRA, 2006, BRAIN, V129, P3081, DOI 10.1093/brain/awl271; McKhann GM, 2001, ARCH NEUROL-CHICAGO, V58, P1803, DOI 10.1001/archneur.58.11.1803; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Rademakers R, 2007, LANCET NEUROL, V6, P857, DOI 10.1016/S1474-4422(07)70221-1; Snowden JS, 2006, BRAIN, V129, P3091, DOI 10.1093/brain/awl267; van Swieten J, 2007, BRAIN PATHOL, V17, P63, DOI 10.1111/j.1750-3639.2007.00052.x	12	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422			LANCET NEUROL	Lancet Neurol.	OCT	2007	6	10					840	841		10.1016/S1474-4422(07)70224-7	http://dx.doi.org/10.1016/S1474-4422(07)70224-7			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218SQ	17884666				2022-12-18	WOS:000250035600002
J	Coles, A				Coles, Alasdair			The fragile benefit of BENEFIT	LANCET NEUROLOGY			English	Editorial Material							CLINICALLY ISOLATED SYNDROMES; MULTIPLE-SCLEROSIS; DELAYS CONVERSION; MCDONALD MS; DEFINITE; EVENT		Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Coles, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Cambridge CB2 2QQ, England.	ajc1020@medschl.cam.ac.uk		Coles, Alasdair/0000-0003-4738-0760				Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Kappos L, 2006, NEUROLOGY, V67, P1242, DOI 10.1212/01.wnl.0000237641.33768.8d; Kappos L, 2007, LANCET, V370, P389, DOI 10.1016/S0140-6736(07)61194-5; Koch MW, 2007, NEUROLOGY, V68, P1163, DOI 10.1212/01.wnl.0000261131.23708.1c	5	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	SEP	2007	6	9					753	754		10.1016/S1474-4422(07)70201-6	http://dx.doi.org/10.1016/S1474-4422(07)70201-6			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	204SV	17706555				2022-12-18	WOS:000249065200005
J	Erickson, RP				Erickson, Robert P.			A first therapy for Niemann-pick C	LANCET NEUROLOGY			English	Editorial Material							CHOLESTEROL; DISEASE; TRANSPORT; STORAGE; MOUSE; MICE; GENE		Univ Arizona, Tucson, AZ 85724 USA	University of Arizona	Erickson, RP (corresponding author), Univ Arizona, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.	erickson@peds.arizona.edu						Camargo F, 2001, LIFE SCI, V70, P131, DOI 10.1016/S0024-3205(01)01384-4; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Erickson RP, 2000, J INHERIT METAB DIS, V23, P54, DOI 10.1023/A:1005650930330; Garver William S., 2002, Current Molecular Medicine (Hilversum), V2, P485, DOI 10.2174/1566524023362375; Garver WS, 2002, J LIPID RES, V43, P579; Gondre-Lewis MC, 2003, CURR BIOL, V13, P1324, DOI 10.1016/S0960-9822(03)00531-1; Liu YJ, 2000, HUM MOL GENET, V9, P1087, DOI 10.1093/hmg/9.7.1087; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Patterson MC, 2007, LANCET NEUROL, V6, P765, DOI 10.1016/S1474-4422(07)70194-1; PENTCHEV PG, 1984, J BIOL CHEM, V259, P5784; Sleat DE, 2004, P NATL ACAD SCI USA, V101, P5886, DOI 10.1073/pnas.0308456101	11	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	SEP	2007	6	9					748	749		10.1016/S1474-4422(07)70198-9	http://dx.doi.org/10.1016/S1474-4422(07)70198-9			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	204SV	17706552				2022-12-18	WOS:000249065200002
J	Vahedi, K; Hofmeijer, J; Juettler, E; Vicaut, E; George, B; Algra, A; Amelink, GJ; Schmiedeck, P; Schwab, S; Rothwell, PM				Vahedi, Katayoun; Hofmeijer, Jeannette; Juettler, Eric; Vicaut, Eric; George, Bernard; Algra, Ale; Amelink, G. Johan; Schmiedeck, Peter; Schwab, Stefan; Rothwell, Peter M.		DECIMAL; DESTINY; Hamlet Investigators	Assessing the benefits of hemicraniectomy: what is a favourable outcome? Reply	LANCET NEUROLOGY			English	Letter									Hop Lariboisiere, AP HP, F-75475 Paris, France; Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Neurol, Utrecht, Netherlands; Univ Heidelberg Hosp, Heidelberg, Germany; Univ Oxford, Oxford, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Utrecht University; Utrecht University Medical Center; Ruprecht Karls University Heidelberg; University of Oxford	Vahedi, K (corresponding author), Hop Lariboisiere, AP HP, F-75475 Paris, France.	werner_hacke@med.uni-heidelberg.de	Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4	2	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUL	2007	6	7					580	581		10.1016/S1474-4422(07)70161-8	http://dx.doi.org/10.1016/S1474-4422(07)70161-8			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	184WJ					2022-12-18	WOS:000247673000008
J	Valente, EM; Ferraris, A				Valente, Enza Maria; Ferraris, Alessandro			Heterozygous mutations in genes causing parkinsonism: monogenic disorders go complex	LANCET NEUROLOGY			English	Editorial Material							LRRK2 G2019S; DISEASE		CSS Mendel Inst, Rome, Italy; Univ Messina, Dept Med & Surg Pediat Sci, Messina, Italy	IRCCS Casa Sollievo Della Sofferenza; Istituto CSS Mendel; University of Messina	Valente, EM (corresponding author), CSS Mendel Inst, Rome, Italy.	e.valente@css-mendel.it	Valente, Enza Maria/G-2942-2017; Ferraris, Alessandro/E-4392-2013; Ferraris, Alessandro/AHC-2875-2022	Valente, Enza Maria/0000-0002-0600-6820; Ferraris, Alessandro/0000-0003-2947-9572				Badano JL, 2002, NAT REV GENET, V3, P779, DOI 10.1038/nrg910; Goldwurm S, 2007, NEUROLOGY, V68, P1141, DOI 10.1212/01.wnl.0000254483.19854.ef; Klein C, 2006, NAT CLIN PRACT NEURO, V2, P136, DOI 10.1038/ncpneuro0126; Klein C, 2007, LANCET NEUROL, V6, P652, DOI 10.1016/S1474-4422(07)70174-6; Lesage S, 2006, NEW ENGL J MED, V354, P422, DOI 10.1056/NEJMc055540	5	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JUL	2007	6	7					576	578		10.1016/S1474-4422(07)70158-8	http://dx.doi.org/10.1016/S1474-4422(07)70158-8			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	184WJ	17582354				2022-12-18	WOS:000247673000005
J	Faught, E				Faught, Edward			Epilepsy drugs: getting it right the first time	LANCET NEUROLOGY			English	Editorial Material							LAMOTRIGINE; TOPIRAMATE; CARBAMAZEPINE; GABAPENTIN; VALPROATE; SANAD		Univ Alabama Birmingham, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham	Faught, E (corresponding author), Univ Alabama Birmingham, Birmingham, AL 35233 USA.	faught@uab.edu	Faught, Raymond Edward/F-7767-2010					BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Marson AG, 2007, LANCET, V369, P1016, DOI 10.1016/S0140-6736(07)60461-9; Marson AG, 2007, LANCET, V369, P1000, DOI 10.1016/S0140-6736(07)60460-7; Meador KJ, 2006, NEUROLOGY, V67, P407, DOI 10.1212/01.wnl.0000227919.81208.b2; *NAT I CLIN EXC, 2004, TA76 NAT I CLIN EXC; Nicolson A, 2004, J NEUROL NEUROSUR PS, V75, P75; Rowan AJ, 2005, NEUROLOGY, V64, P1868, DOI 10.1212/01.WNL.0000167384.68207.3E; Sheth RD, 2004, LANCET NEUROL, V3, P516, DOI 10.1016/S1474-4422(04)00848-8	8	5	5	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JUN	2007	6	6					476	478		10.1016/S1474-4422(07)70115-1	http://dx.doi.org/10.1016/S1474-4422(07)70115-1			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	175WO	17509477				2022-12-18	WOS:000247044900006
J	Hardiman, O; Greenway, M				Hardiman, Orla; Greenway, Matthew			The complex genetics of amyotrophic lateral sclerosis	LANCET NEUROLOGY			English	Editorial Material							SUSCEPTIBILITY		Beaumont Hosp, Natl Ctr Neurosci, Dept Neurol, Dublin 9, Ireland; Royal Coll Surgeons Ireland, Dept Neurosci, Dublin 2, Ireland; Our Ladys Hosp Sick Children, Natl Ctr Med Genet, Dublin, Ireland	Royal College of Surgeons - Ireland; Our Ladys Children Hospital Crumlin	Hardiman, O (corresponding author), Beaumont Hosp, Natl Ctr Neurosci, Dept Neurol, Dublin 9, Ireland.	ohard@iol.ie	Hardiman, Orla/Y-3441-2019	Hardiman, Orla/0000-0003-2610-1291				Corcia P, 2006, NEUROLOGY, V67, P1147, DOI 10.1212/01.wnl.0000233830.85206.1e; Goodall EF, 2005, NEUROLOGY, V65, P934, DOI 10.1212/01.wnl.0000176032.94434.d4; Greenway MJ, 2006, NAT GENET, V38, P411, DOI 10.1038/ng1742; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Schymick JC, 2007, LANCET NEUROL, V6, P322, DOI 10.1016/S1474-4422(07)70037-6; Shaw CE, 2006, NEUROLOGY, V67, P738, DOI 10.1212/01.wnl.0000238979.73142.cd; Slowik A, 2006, NEUROLOGY, V67, P766, DOI 10.1212/01.wnl.0000219565.32247.11; Van den Bosch L, 2006, CURR NEUROL NEUROSCI, V6, P423, DOI 10.1007/s11910-996-0024-9; Veldink JH, 2005, NEUROLOGY, V65, P820, DOI 10.1212/01.wnl.0000174472.03292.dd	11	5	6	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	APR	2007	6	4					291	292		10.1016/S1474-4422(07)70062-5	http://dx.doi.org/10.1016/S1474-4422(07)70062-5			2	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	149KE	17362828				2022-12-18	WOS:000245145000004
J	Elkind, MSV				Elkind, Mitchell S. V.			Anticoagulation for secondary stroke prevention: another nail in the coffin?	LANCET NEUROLOGY			English	Editorial Material							WARFARIN; ASPIRIN		Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Elkind, MSV (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	mse13@columbia.edu						Chimowitz MI, 1998, STROKE, V29, P1389, DOI 10.1161/01.str.29.7.1389; Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033; Elkind MSV, 2005, NEUROLOGY, V65, P17, DOI 10.1212/01.WNL.0000171745.13592.cb; Franke CL, 1997, ANN NEUROL, V42, P857; Gage BF, 2004, CIRCULATION, V110, P2287, DOI 10.1161/01.CIR.0000145172.55640.93; Halkes PHA, 2007, LANCET NEUROL, V6, P115, DOI 10.1016/S1474-4422(06)70685-8; Halkes PHA, 2006, LANCET, V367, P1665; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Pullicino P, 2006, J CARD FAIL, V12, P39, DOI 10.1016/j.cardfail.2005.07.007; Sacco RL, 2006, CEREBROVASC DIS, V22, P4, DOI 10.1159/000092331	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2007	6	2					97	99		10.1016/S1474-4422(07)70008-X	http://dx.doi.org/10.1016/S1474-4422(07)70008-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	130JG	17239790				2022-12-18	WOS:000243795300003
J	Schwab, M; Fitzek, C; Witte, OW; Isenmann, S				Schwab, Matthias; Fitzek, Clemens; Witte, Otto W.; Isenmann, Stefan			Extending the potential of perfusion imaging with MRI to prevent major stroke	LANCET NEUROLOGY			English	Editorial Material							TISSUE-PLASMINOGEN ACTIVATOR; OUTCOMES; MILD		Univ Jena, Dept Neurol, D-6900 Jena, Germany	Friedrich Schiller University of Jena	Schwab, M (corresponding author), Univ Jena, Dept Neurol, D-6900 Jena, Germany.	stefan.isenmann@med.uni-jena.de	Schwab, Matthias/ABH-7449-2020; Witte, Otto/P-4127-2018; Isenmann, Stefan/AAJ-3788-2020	Witte, Otto/0000-0003-2101-4105; 				Berrouschot J, 2005, STROKE, V36, P2421, DOI 10.1161/01.STR.0000185696.73938.e0; Fink JN, 2001, NEUROLOGY, V57, P1739, DOI 10.1212/WNL.57.9.1739; Grau AJ, 2001, STROKE, V32, P2559, DOI 10.1161/hs1101.098524; Kammersgaard LP, 2004, AGE AGEING, V33, P149, DOI 10.1093/ageing/afh052; Muir KW, 2006, LANCET NEUROL, V5, P755, DOI 10.1016/S1474-4422(06)70545-2; Rajajee V, 2006, NEUROLOGY, V67, P980, DOI 10.1212/01.wnl.0000237520.88777.71; Smith EE, 2005, STROKE, V36, P2497, DOI 10.1161/01.STR.0000185798.78817.f3	7	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	FEB	2007	6	2					102	104		10.1016/S1474-4422(07)70011-X	http://dx.doi.org/10.1016/S1474-4422(07)70011-X			3	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	130JG	17239793				2022-12-18	WOS:000243795300006
